<SEC-DOCUMENT>0001485003-21-000221.txt : 20211108
<SEC-HEADER>0001485003-21-000221.hdr.sgml : 20211108
<ACCEPTANCE-DATETIME>20211108080053
ACCESSION NUMBER:		0001485003-21-000221
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211108
DATE AS OF CHANGE:		20211108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sesen Bio, Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		211386565

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-444-8550

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sesn-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:43f34410-0797-4c9d-95d4-0172445a49a1,g:6be5cc14-c349-4e45-a047-13acab623f46,d:0b6b8a80699f4ebca69187de21a4e617--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:sesn="http://www.sesenbio.com/20210930" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sesn-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl80LTEtMS0xLTkwMTI_e09d608e-6e23-4cfc-9949-e601ee4832b6">0001485003</ix:nonNumeric><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl81LTEtMS0xLTkwMTI_3075cd22-4486-4601-acc7-1f23686cabdf">12/31</ix:nonNumeric><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl83LTEtMS0xLTkwMTI_573f1815-62a5-4d98-a867-795a8ef00227">2021</ix:nonNumeric><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl84LTEtMS0xLTkwMTI_574c5619-2549-4a47-9370-f6ea39691363">Q3</ix:nonNumeric><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl85LTEtMS0xLTkwMTI_fe79f694-51ea-46ef-8e76-639154bcab3e">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sesn-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia74a1039ca8c4ff2869659d992be7a2e_I20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i342f8c81e3cd4634b8691627803c791d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94658670cd664227afb5198f212af78d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id546f5275111478eae55ae8b7ddd61d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1bdbafc64bc4e6f927a8c8b89d17e1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb42dcf497cf4db4bb42c8d89c51f961_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41f4d8f7f114855a616af3e79f0b5f1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f203500303a43978dd153bf5525882b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia736239317b24101bef5d62a00a3d7c9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac80310a46fa497792ae2b23f361970b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3172bc731cc8465ca35ef631d4862d13_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d261af049ab482490810fd8b8e53435_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504486b9de8f4cd5ab2cc5ddda4d7df6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb4562dea9ab4a92a5891acdb449c85e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac6b4e3f3ab049039f1f5a6789966e1c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dbf1c141a0c4eb483ea692aec134f4b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45ac0ee18ade4af8b7b471481a04a2c3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd658161e2c94d2a852bd1a21e30693d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2075535641a548e287b521ae3d4bbb18_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c7eda9e3954ea795f7fc70c0134b09_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba9eed293fb489583e83d76334fb473_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e794ca5abe9423b8fcb06f2a3b212a6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9e1dcf0f804b12800ee77146e934bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia345782a36b04632a22dcefbffbf2122_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6721966bda4737b5d6c09a51510e67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30cab611aee04f429c25aa68fcb3a66d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746ad97c6cd749bea3090dff8cc5d3c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0f30e637a74e7bbfde72ce37739632_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95480a6da5214cc3867f93de1459e972_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieafcf2967a0e4400ba5e2ef91b2c4e95_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153d728efff347759e0394fab9944503_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8a154a5219c4779983d780486eecb41_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if14f953deda7433f98e5de86c3866f7a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64611da1b2004612b9b69bfe30c13dc8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7e08a33ca6d4f589a32a804b0218dab_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4502189f31a9474283888eeb7a770696_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002e2f171b10423aa884ac9b368e3eb8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54dfac6708f940ae8d7d54eb45c4cdf6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i069fefbb34c949ec9377080da376e4fb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe33102ebcf8432bb484924b03e689bd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf4b71ad2308422da8c65596d76c09fd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fee51ba1523446dac271d22281350e4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf3a7c87f6d1422aa77aa5b7f9f2ecb0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5245ae5196f44ba6949d51a19c7f5a0f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief9d18a3e43644049cf7c9dd882573e0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i255ec6c67daf44f3b60c0bef3b4adc4d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f99021539f4ebcb94f4695fa55a58b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4cdeca849b4134b8aa1380f258de14_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i566ffe1fbdb6406dbcda243abb86908b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>sesn:segment</xbrli:measure></xbrli:unit><xbrli:context id="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="idc9920534e564063b17cf3276820d0f3_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d84ce34ad9409399002fee7af82ae3_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07f5c65b436140d38150a47e9b6c1c36_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5b45b654db4116bd06d251988b14f4_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia797d1ca4fc645e8b395e6d9263565df_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bcc2b9836694810a0403c78508eec6f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia45b2253ea0241f883b480c50a91e7ee_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8cfcaa24fb4ed5a8ee17f30da2aecb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ad64fc04cf04fd8be661f0721499ef2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b740de8bf63490bb488468c1c7ef16b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e931e5abe8401e88a126d64a293b20_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i956068aabeb24f898f4ef28b58b5d3e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4934a8dc9143cca95a8e41327cd312_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54798f9a263e4006acf115b512314f6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c50f17d10a14d9eabcc22c8f3758312_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084a1ef5b7d84536a0488186c21a7485_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ac34a0eb6d444668cb6a7cfe8729dcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41191996f8d5431abab1f677026cf472_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic84c83bbc78b4c12a4fe38ef570304f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ed5df0fffaa498399f610dcc2d9649d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e86bda1e5244696a1806edda33f2bfb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1415d97efbe429391dd2e7d1b088f99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6825967355184d4db34915ea37cd569f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i555450de9c964d30965deb1462b538f4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d44b389ccbd43a2bbfcdc75634eaab2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09310b7c37a84f11878085deb559133d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7b6d5d2caa648dcb555f0031c4766b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib081c37a1b7148fabc6bbbdd4c81cd6d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9a1851f4b84938b499fb6f2ec592fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3daf5ae769a4d4691f5323122b152a4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3748dd3582454f23a8200a59516d8d6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1c35ca8bc59451b99b15883438c09e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7692a883ce45169ba52f34b1597844_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>sesn:term</xbrli:measure></xbrli:unit><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i52acd18eaeab4bbeb00da4524f747aa3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ebb0e11dab4338ba1489efd21f78a5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bd4a05fa0ad4322ae22d1c69ac3251a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a7fddfe10f34cafa6c5a4a5879fe96b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68276962a8f74cf19dd3fffa8b75f81a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f8f4fa4924486482fcd1b7ca9c6d9d_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5ea54630c14b3b8074d7e574a485d1_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67a67d24259846938c78c4e27aa8ba68_D20201001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5526ac0da03b4995acfde7f67df66fdc_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14f2b1575414e92a7e8692a1656ed6e_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib12fdfe409da499985845294be59cd32_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23e8f40d129643c4955e53934f43c919_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if89a1bed4d6e4801a7b55c57bb01b6a0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id978bed0cf5c4d5fbab94cd056d775b8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7579e0e22c047768232e96e33209c00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d4b935d6b414f729cd483380a572798_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8591390616e24942a1790a6fef158000_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fcaf5bf73c144fb87d727c536f11433_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9742c1fa4df446ea92bcdc4006e5dac4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980c30d4b2e5432f83166c9129e01ffa_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i716f44ff8fdb4ed68f03fe519e006002_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d9dcbb55e2474ea2ed0ba322bad3ac_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e070c6f5694cc184d3ff043754818a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6379246986547cc9a88c6f8b29535d6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd1ce8b4f094a86aaf1094f5ade0c3a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e16f0e7c69a48b793e80ba1cbd35337_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a98b848353a4028b0c3659a7cc0fc8d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30380f6c6c241cca4d331347c506d7b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e50b89a5f094c2485a5ef23806abe14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ac338c8a528448585157860bb14aae6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideefad39445444f5978ed30df0f8d67d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1595e3478bb64207a037de6271baebed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044c60384a9e4cc8afe4aaa8645c9ef6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia92cad4084294782890738c13756e328_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib500bf44eae5476d9fdf2b96b6e0d1d7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87670fceac7f42239018c3f8b55269ad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23062afacb1848248023392b8378bd19_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079b1e485a6a4b42a083e958ffce61c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c43cdc3ac654396a4484ffac139d4b2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb6380fa09c4290abc4c61a23509a0c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f2a7e233df4d15a0180432313c57a9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7ed6768ea3b4560b2c82d895f9ea130_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e8e8e954db04e80ad3a16adadbfc86f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic81f556c7f3c49bd8d272a05a36ddb60_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d48ee562070454db26870e4c0814801_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8f1e5ffe2b4317a81ef1b3efe55cdb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c2750e9d614718ab26e1de3cd36e4b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac03a2fc4741476e8ed3f485593ae492_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12438f69900b46c898f17d03af72571f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f44079082f4029859d1879bcb92442_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib66fca9e5de8456b900bc5c4eff17509_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ccec642f85408396200523b237087c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a6396e7d05347c98d3c1b2c891d6ee3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4abb48a5d14a81b4f1e923deb97260_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide409042192a4d70ab470516112033d4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c7f2bf3ddf5406f8bc9acdceac07628_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4063b8153be44ce181d918f92b6ef50e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d3a64a89d7413aa462e07545736067_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac93b032a464cdd8545afbe5796bd81_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb66b6b5cfd47af8f6c6a3efea03f81_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fffc682fabb44acb6f7a3985fe6f99d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4100955bccbe4c1ca4b78e3cf52bfe56_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc91c1e2691446ca8ae6ebaf034e2270_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b253e391e304883b5148ddaac3a9fd8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e23dc0be574c6988f056e62ef032cd_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9fbfe5c81f499888ab93c21e589337_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6eb0c1e7e34af989c1740d371026c8_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf84269345dc45a9bd019d1e9ba53cbf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42971e76e3e4c0d9a0e368891e0d42c_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d3fa03486b42c3b433ce8bdf6e4808_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ed448b11a8424c96a6b8d0eb2a1783_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30b08122198e489bbce9b4354ecc6c61_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb8cc9e9e234566a44813522f65ed55_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0859c061dad4634bd9bf31be447575b_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc6ff2c6504a4ed1b6cfa6a5cbdb6eb9_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b167efec9143cf989e99b7088a541a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045d66e15494473e88b935c50abb8750_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e6b449973d4c2792e479ee587c6018_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7693b351b0846618d4fcdce51f3fe9e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:IL6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>sesn:option</xbrli:measure></xbrli:unit><xbrli:context id="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7df092ca1e64946a1a0ac3ea4c32c84_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife38f0f87de845fe90d0a4d078d250cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe2301ff7fd49808ebec14107299e1c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610ca7a4385742b085d50632419fb7f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78e2ef0bd77468a99078bdc44ca15ac_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc185febf435474dabf49a740bcc7f59_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4a691bd7f24cc8a757bf6eb9a87a8e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6554c571ca414ea564532ae47c5f15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia96662f1953a42bc873ffe3a7870d8b6_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i136787f1fdff4cf289282d421587f27f_D20210805-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23457221904940608ad590d221ec55f2_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>sesn:position</xbrli:measure></xbrli:unit><xbrli:context id="i3294967843ca408b88c9279ce575d789_D20210830-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0910e0e2e544c658b3c5f01387c4bf7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31980ac255374540a2c360974effe9e9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb45047e6e3464eb0f8a32d0685227a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07777b364f564270bb6efdada23c4efe_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0b6b8a80699f4ebca69187de21a4e617_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY184Ng_1586bc7a-df49-4637-9c9b-e188ca359c93">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MTY4N2Y0NjNiNTk4NDEzZTg4ZTI1M2I1MjE0MjU1MmMvdGFibGVyYW5nZToxNjg3ZjQ2M2I1OTg0MTNlODhlMjUzYjUyMTQyNTUyY18wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpmMjgzZmMwYTNmZDE0YTMxYWYyNzRhNDllMzBhZTY2M180_a876f458-0b12-459f-9122-e55354c2f849">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18xMzQ_376060f4-0cce-4543-9d2d-44fc5fb72508">September&#160;30, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6ZDZkZmQzYWMxMTNjNDcwOWE0ZDc5MmNjZjBjMmI1ZmMvdGFibGVyYW5nZTpkNmRmZDNhYzExM2M0NzA5YTRkNzkyY2NmMGMyYjVmY18wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpkYThmMmFkMmZkMTE0NDIyYjI3NGEyMGNkY2Q4MzNlZV80_b9d0c27a-e056-4bc8-a207-ded5eb2efc01">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18yMTY_4348198b-849f-42d5-b7eb-4aa583e5d321">001-36296</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18yMjE_29cfb2c6-0f57-4875-bde1-c09a7b880a3d">Sesen Bio, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MmQ2ZjNkNmMyZDNiNDYxMzkxNTZkMDMzOGQyZWY1YzkvdGFibGVyYW5nZToyZDZmM2Q2YzJkM2I0NjEzOTE1NmQwMzM4ZDJlZjVjOV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjo1M2E3MjYwYTg5MzE0ZDRiOTQ1ZTFhMGZiOTRkZGY1Zl80_38914a6e-dca5-4072-aa94-664e23c32b6d">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MmQ2ZjNkNmMyZDNiNDYxMzkxNTZkMDMzOGQyZWY1YzkvdGFibGVyYW5nZToyZDZmM2Q2YzJkM2I0NjEzOTE1NmQwMzM4ZDJlZjVjOV8wLTEtMS0xLTkwMTIvdGV4dHJlZ2lvbjo2NmFhZWE2NGY3NDI0ODg2OWZiZjg1NTJmMGVmMjEzNV80_fb202a54-a5a3-45bc-86bd-287769d1fbbb">26-2025616</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpiNDczZTc2Yjk4NjI0OTBmOWY4ODlkZGNmN2Y2NTI2Nl80_f683634a-9509-42ce-82c0-dceaa1eb72a8">245 First Street</ix:nonNumeric>, <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpiNDczZTc2Yjk4NjI0OTBmOWY4ODlkZGNmN2Y2NTI2Nl84_3ac032d1-cf87-44f1-8c72-903f21a16696">Suite 1800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpiNDczZTc2Yjk4NjI0OTBmOWY4ODlkZGNmN2Y2NTI2Nl8xMQ_b3d25e9b-acbd-4eb8-8083-77d20935af66">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpiNDczZTc2Yjk4NjI0OTBmOWY4ODlkZGNmN2Y2NTI2Nl8xNQ_efeb908c-0b69-4d9f-93c7-8d4eb1e8e263">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTEtMS0xLTkwMTIvdGV4dHJlZ2lvbjo5ZmRhM2VlNzEyMGE0NzQzYjg4YzdmNWVhMDU0ODA2OV80_60c4600b-8e1e-4336-97a3-49ed2002527f">02142</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18yODY_40189021-0a10-4429-a4b8-17b0f3e93419">617</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18yOTA_e676d7af-b1ed-407d-9094-8e2acaa7e7a6">444-8550</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"></td><td style="width:43.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6YTdlMWRkYjMwZTRjNDI1MGE5MGUzMmU5ZDE2NGRjMzUvdGFibGVyYW5nZTphN2UxZGRiMzBlNGM0MjUwYTkwZTMyZTlkMTY0ZGMzNV8xLTAtMS0xLTkwMTI_c48600f1-15e9-43a5-8f8c-f7bd6d796e18">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6YTdlMWRkYjMwZTRjNDI1MGE5MGUzMmU5ZDE2NGRjMzUvdGFibGVyYW5nZTphN2UxZGRiMzBlNGM0MjUwYTkwZTMyZTlkMTY0ZGMzNV8xLTEtMS0xLTkwMTI_46f36cad-60a6-41f8-8fd0-ce4a36d4f160">SESN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6YTdlMWRkYjMwZTRjNDI1MGE5MGUzMmU5ZDE2NGRjMzUvdGFibGVyYW5nZTphN2UxZGRiMzBlNGM0MjUwYTkwZTMyZTlkMTY0ZGMzNV8xLTItMS0xLTkwMTI_392c6783-e14d-4f69-9f55-ed840242f430">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.   <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY184NTg_f644ac4a-2c0c-4567-846f-936c7504f77d">Yes</ix:nonNumeric> &#9746;   No &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to&#160;Rule 405 of Regulation S-T&#160;during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18xMTU1_d2c9adbd-5a9a-4971-855e-3c09138ce87c">Yes</ix:nonNumeric> &#9746;   No &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.280%"><tr><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6NDJkMmNmYWZhMTU5NGVlNmFhYjYwNjYyOWM4YzBiNzEvdGFibGVyYW5nZTo0MmQyY2ZhZmExNTk0ZWU2YWFiNjA2NjI5YzhjMGI3MV8wLTMtMS0xLTkwMTIvdGV4dHJlZ2lvbjo5MzcwM2VlZjNhYzg0NWZiODBiYmJlNWZhMmJmOTdhYl80_e308816d-6b57-41be-bab1-73d0c269a9d8">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6NDJkMmNmYWZhMTU5NGVlNmFhYjYwNjYyOWM4YzBiNzEvdGFibGVyYW5nZTo0MmQyY2ZhZmExNTk0ZWU2YWFiNjA2NjI5YzhjMGI3MV8xLTMtMS0xLTkwMTIvdGV4dHJlZ2lvbjo2NjlkMWI4YzRjMWU0MzA1YjYzODJlYmJmMDI4NzBjYV80_35a0b04e-2221-40f1-b2ee-b752174f3a47">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6NDJkMmNmYWZhMTU5NGVlNmFhYjYwNjYyOWM4YzBiNzEvdGFibGVyYW5nZTo0MmQyY2ZhZmExNTk0ZWU2YWFiNjA2NjI5YzhjMGI3MV8yLTAtMS0xLTkwMTI_dbfaba67-6325-43ae-95e0-cbfe1e9e3d01">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18xODg3_b51f89a5-cf78-427f-a63f-10349c7ed312">&#9744;</ix:nonNumeric> No &#9746;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia74a1039ca8c4ff2869659d992be7a2e_I20211101" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18xOTEw_416a7e0e-079b-4ea0-8112-754db0770ba5">199,463,645</ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the registrant's common stock outstanding as of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;1, 2021</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Report on Form 10-Q for the Quarterly Period ended September&#160;30, 2021 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I - FINANCIAL INFORMATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Income (Operations) and Comprehensive  Income (Loss) for the Three and Nine Months ended September 30, 2021 and 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the Three and Nine Months ended September 30, 2021 and 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the Nine Months ended </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021 and 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_76">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_97">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_100">45</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II - OTHER INFORMATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_106">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_106">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities and Use of Proceeds.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_1153">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_1153">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_1153">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_1153">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_109">50</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0b6b8a80699f4ebca69187de21a4e617_115">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_13"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements.</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_16"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMy0xLTEtMS05MDEy_df006554-39fc-48b4-a608-eba3b24704ca">175,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMy0zLTEtMS05MDEy_85c751ea-ef18-4490-bbe4-e66150a30a30">52,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNC0xLTEtMS05MDEy_cb6ffd7f-3025-4bc0-8aad-96576a7a73ec">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNC0zLTEtMS05MDEy_7fe90166-dfff-4739-8299-7ad02f1c1ac4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNS0xLTEtMS05MDEy_60d9b9b1-4f53-4f6c-8290-b793908373dd">24,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNS0zLTEtMS05MDEy_3aa18e09-eca0-41e8-9926-3334a79c8935">7,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNi0xLTEtMS05MDEy_a779a811-f19a-47a6-904f-77d21eb6ecc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNi0zLTEtMS05MDEy_bce1c45b-96dc-487c-bc78-5a7a9d0ee122">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNy0xLTEtMS05MDEy_18da26f9-7a25-4a8d-a243-9d5f5212acfc">200,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNy0zLTEtMS05MDEy_28e89c49-d6bf-48c4-9249-f1ee0b48d088">62,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTAtMS0xLTEtOTAxMg_81ebb001-dfba-43f7-9ec6-adc2c70b823c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTAtMy0xLTEtOTAxMg_e6951901-a26b-4f55-aee0-88ccd58a0a78">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTEtMS0xLTEtOTAxMg_c1b747a3-6baa-49d8-b8eb-f84dc76f3718">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTEtMy0xLTEtOTAxMg_99722407-d852-4b3f-be8d-c62a98ebf864">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTItMS0xLTEtOTAxMg_1ecb79aa-23f9-417b-ae16-ca50e2616a5b">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTItMy0xLTEtOTAxMg_33acb1b5-922c-45e1-bae0-565917ad2d31">46,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTMtMS0xLTEtOTAxMg_c825e174-2d6b-4782-afb7-67b918e73938">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTMtMy0xLTEtOTAxMg_069a0782-dcb0-4759-8682-7dc6b24c8542">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTQtMS0xLTEtOTAxMg_055c33e1-048f-415f-8054-7faea3aff142">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTQtMy0xLTEtOTAxMg_2fe2f63a-4ecc-4d76-98b8-1c2734efc178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTUtMS0xLTEtOTAxMg_19bf954f-6f82-4355-a00c-8106212d0e94">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTUtMy0xLTEtOTAxMg_440d155c-3113-4a62-a554-285da6bda0c1">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTYtMS0xLTEtOTAxMg_f503b61f-ef92-422e-bad3-22008a6bc6e9">35,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTYtMy0xLTEtOTAxMg_86b0c38a-6ff8-40d6-b825-06a9788a1ad9">59,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTctMS0xLTEtOTAxMg_ee42bae3-2c97-4a40-8322-de71a9c10fd7">235,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTctMy0xLTEtOTAxMg_76f9fc8d-8f83-495b-a838-0ef24758830a">122,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjEtMS0xLTEtOTAxMg_8bc6f263-e12b-4cc1-b214-09c5c5779c47">3,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjEtMy0xLTEtOTAxMg_b2caa210-260c-442a-b53c-8f1ae4e0a260">3,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjItMS0xLTEtOTAxMg_0cf0adf1-59d6-44a8-89e8-a76a20f4672d">8,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjItMy0xLTEtOTAxMg_62ddddfd-a729-457d-9212-c97ea2d41e87">3,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjMtMS0xLTEtOTAxMg_f6c09103-baeb-4f22-86f3-0c9ac9a4c8c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjMtMy0xLTEtOTAxMg_c3836784-9ee9-4a34-a944-37d8eb3aab21">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjQtMS0xLTEtOTAxMg_0f5767ad-c681-4472-beef-6332f69dd45f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjQtMy0xLTEtOTAxMg_53205f28-98be-4c9b-90ad-047d02f156d1">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjUtMS0xLTEtOTAxMg_d36a7e41-353a-4fde-8f67-ef7f37fbfe4d">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjUtMy0xLTEtOTAxMg_f37ab62c-3bea-45bd-ae37-5077a3366486">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjYtMS0xLTEtOTAxMg_b84b56a9-d156-44e2-b854-bde87835aafa">12,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjYtMy0xLTEtOTAxMg_32594926-5775-4486-bc0f-ec359e36fe71">18,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjktMS0xLTEtOTAxMg_fce812ac-548b-42d1-8d5d-1b5804284bec">56,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjktMy0xLTEtOTAxMg_18a12625-c7f1-4248-9432-c23b1b7f60e3">99,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzAtMS0xLTEtOTAxMg_2850e566-682e-4bbf-8cea-2d2087efea28">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzAtMy0xLTEtOTAxMg_7c8ec831-93f9-432d-943a-0e2f62bdee55">12,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzEtMS0xLTEtOTAxMg_0597326e-d958-4cda-a1c1-009bd4750d91">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzEtMy0xLTEtOTAxMg_a239f186-7f2d-4d60-bf72-66fed5bbfd0d">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzItMS0xLTEtOTAxMg_607fb631-475d-441d-a6fb-0665ac533fbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzItMy0xLTEtOTAxMg_e4a1ceb3-cb03-4792-8df1-dcac611b2554">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzMtMS0xLTEtOTAxMg_dcc6fd05-a518-4680-ab41-73d58eea5ec7">62,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzMtMy0xLTEtOTAxMg_dcdb29ba-3876-4967-a2cb-3627c5a072b2">114,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzQtMS0xLTEtOTAxMg_29bdd823-4624-4d95-be20-23375e6fdc7c">74,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzQtMy0xLTEtOTAxMg_2c4e7321-4a0d-4525-a0d7-47f977f7cc22">132,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity (Deficit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzIx_120ac6c1-0b66-4f93-8c97-4d68225ec2d7"><ix:nonFraction unitRef="usdPerShare" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzIx_b7358a26-9532-437b-aa83-e1b213b2e226">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzQ1_bc576579-6e75-4ffe-bcf7-ce921032cd6c"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzQ1_d25bad4e-3d06-46a3-a52e-d330a8bd9fd2">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2021 and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzEwNg_006793d7-1abb-42bf-8bdf-c8bab813b78a"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzEwNg_0d03d9b1-1aee-449e-ae97-57ac598d0b5c"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzEwNg_40fdbfe9-e1b6-4609-91f6-2128e9cced92"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzEwNg_77692980-2470-4176-9f7b-357b5e5dc765">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMS0xLTEtOTAxMg_66c1ec53-c194-4b57-bebc-be58a3d05b7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMy0xLTEtOTAxMg_174624c3-da58-404d-b234-7a9c60a31fcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzE4_6a73a4f1-f446-4b69-864f-8decb5523923"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzE4_e5ee92cd-77c7-41d7-bd85-e4bcbb5be003">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzQy_709eecbe-9f28-4356-bd53-52c0a4859d0a">400,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzQ5_afbb4c46-b7b5-4e0a-892a-0936e2adb9d0">200,000,000</ix:nonFraction> shares authorized at September&#160;30, 2021 and December&#160;31, 2020, respectively; <ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzEyNA_9d4a88a4-55a5-4548-a09a-f249a9ce2f86"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzEyNA_c3d78f1f-3e56-4f00-b990-184ec215f932">199,463,645</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzEzMQ_6c520777-a6ed-4080-b8f5-58360afb5400"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzEzMQ_ef91ad3d-eaae-4771-82f4-71c06f55e746">140,449,647</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMS0xLTEtOTAxMg_3e133af7-562e-497a-8ab2-d735062db4dc">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMy0xLTEtOTAxMg_3ef025fe-29d6-4171-9508-d3a7ab7b14f1">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDAtMS0xLTEtOTAxMg_d6cdb563-cd68-4f37-bece-76faf7a52d09">486,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDAtMy0xLTEtOTAxMg_e34dd971-2863-41ee-b26e-4f80e1d496cc">306,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDEtMS0xLTEtOTAxMg_c6c3a9df-989f-4e3d-8772-36a78bd99db6">325,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDEtMy0xLTEtOTAxMg_3533fba3-14bf-4501-a516-cbc99f736a14">315,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Stockholders&#8217; Equity (Deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDItMS0xLTEtOTAxMg_857645b4-cfbb-4d38-be12-ca20a454599d">161,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDItMy0xLTEtOTAxMg_4c8a6ef8-1543-456c-b01c-cbb56624a7e3">9,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDMtMS0xLTEtOTAxMg_e9689010-33be-4e3d-a231-56356fa4826a">235,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDMtMy0xLTEtOTAxMg_63e00a4c-3c94-4f70-b9c0-0efe67ff7157">122,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:55.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.902%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi0xLTEtMS05MDEy_16b8e6c9-893c-45dd-8d15-8b313987704c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi0zLTEtMS05MDEy_7dad26a6-9566-46e4-a1f0-eeb3cdf67645">11,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi01LTEtMS05MDEy_848a5c50-13f4-4407-8df7-802a5005740b"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi01LTEtMS05MDEy_e66a903f-68ac-47b9-af46-4bc215b8b85b">6,544</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi03LTEtMS05MDEy_354ff255-2f3f-400b-9fd4-aac7e0e1582f"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi03LTEtMS05MDEy_7fb951d5-b424-43c3-b1ea-27ed11ff956d">11,236</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNS0xLTEtMS05MDEy_8b86c125-30ca-4000-8022-946103af8fc7">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNS0zLTEtMS05MDEy_764fea54-c5e2-410c-a419-6b5e09908161">10,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNS01LTEtMS05MDEy_7c35c8ba-5ae1-4444-abb5-a99ae384cb69">18,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNS03LTEtMS05MDEy_c5dba97f-2578-45d7-930b-0af54d6aebed">23,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNi0xLTEtMS05MDEy_276044d4-45d5-47e7-b336-f73cd3cf4e51">8,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNi0zLTEtMS05MDEy_8df6f61e-d81f-4d4d-a48e-5591d00474f1">4,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNi01LTEtMS05MDEy_110f9e8e-a29d-4969-864e-31be4f6c4ea7">20,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNi03LTEtMS05MDEy_fd6d993c-9621-4f17-b1c1-c123bc805642">10,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy0xLTEtMS0yMDM3Mw_e96e3f93-97d0-438d-a7a9-1bfbf49b7c63">5,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy0zLTEtMS0yMDM4Mw_bcb64857-d9fe-4fd5-8498-7e4205de058d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy01LTEtMS0yMDM5MA_6f46690c-d1e9-4aab-bfec-4626bf41f9f2">5,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy03LTEtMS0yMDM5Nw_19e8ff22-c86b-41dc-a096-10a8856b7a15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC0xLTEtMS0yMDM3Mw_3c65ddb9-5362-482e-a3a0-5acad000eda9">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC0zLTEtMS0yMDM4Mw_27c251b5-cf36-4bd0-873a-fc27fbbc02e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC01LTEtMS0yMDM5MA_fc16b759-753a-4105-8973-c51f7e0d725c">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC03LTEtMS0yMDM5Nw_90cd370e-08c0-4005-8dee-6201043e8af8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy0xLTEtMS05MDEy_97c1ab7e-6b6f-4cb0-ab2f-af1099ced6fb">114,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy0zLTEtMS05MDEy_4197a5b1-fef0-47fd-944c-ba70516ef57f">18,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy01LTEtMS05MDEy_cd9199b3-a347-4665-81b6-15ed83cccaa6">52,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy03LTEtMS05MDEy_16df4903-3883-4252-a1a1-e6bcf5ead42a">16,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC0xLTEtMS05MDEy_638fe0f0-5058-4c08-a496-d3c127546395">63,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC0zLTEtMS05MDEy_9f54c8d5-9b35-48b5-a6fd-2c983bd1c17f">32,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC01LTEtMS05MDEy_085e4d02-29bf-4048-98c4-9d2de6995c97"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC01LTEtMS05MDEy_55e9a84b-977a-4455-8fc6-d264b93be1e3">24,052</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC03LTEtMS05MDEy_09a9ca57-38e5-4f66-a375-16eb0a2171ad"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC03LTEtMS05MDEy_248881b8-cc85-4d13-82fb-c078276a02c0">17,687</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Loss) from Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTAtMS0xLTEtOTAxMg_1458cc70-6932-43a1-a377-bf51b45c96b4">63,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTAtMy0xLTEtOTAxMg_62b58c8c-98f9-4e8c-8840-c48ed8e64bff">21,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTAtNS0xLTEtOTAxMg_0bba6a75-c595-4ed9-a4f0-d8af8a562a48">17,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTAtNy0xLTEtOTAxMg_01c85714-7fd2-45d4-a82f-84d6f5ab6951">6,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTEtMS0xLTEtOTAxMg_94b4d3c5-4b65-4200-9948-035d1235a4c6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTEtMy0xLTEtOTAxMg_09a4632f-1695-428b-ae3b-961e8e8a2c08">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTEtNS0xLTEtOTAxMg_9cf03b19-6788-4977-b4f1-5eaef78d1bb3">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTEtNy0xLTEtOTAxMg_05104e8c-151d-4d16-a5fc-cdfcf0779646">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Loss) Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTItMS0xLTEtOTAxMg_780db623-8f65-4b61-8c42-15b894acf042">63,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTItMy0xLTEtOTAxMg_cbc7e897-be88-462b-aa21-59925b1fe181">21,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTItNS0xLTEtOTAxMg_bf8cc452-3939-45ad-9dfd-9cc65842bb20">17,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTItNy0xLTEtOTAxMg_96920a7e-e8d7-4c22-9929-ba63f6257c2f">6,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTMtMS0xLTEtOTAxMg_08c5e228-3d07-4714-8a94-1c915e74037f">8,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTMtMy0xLTEtOTAxMg_7771854a-da8d-46f3-a0c8-2a08401424e7">1,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTMtNS0xLTEtOTAxMg_9022cab7-9bb7-48ac-b56d-27e752261e83">8,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTMtNy0xLTEtOTAxMg_8416f036-37dd-4984-99b2-90973adee74f">1,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (Loss) and Comprehensive Income (Loss) After Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTQtMS0xLTEtOTAxMg_6b5e45b6-344c-4ba6-b618-c2b2b6df2261">71,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTQtMy0xLTEtOTAxMg_769123d9-f212-4041-ab32-513bf244e20e">22,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTQtNS0xLTEtOTAxMg_9fb15208-20f9-4d7e-8e11-409feec84b43">9,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTQtNy0xLTEtOTAxMg_590175f4-6957-4a60-ab34-4bcb44e1cb76">7,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTgtMS0xLTEtOTAxMg_0cabd591-a301-4b4a-89bc-322810ace8b4">71,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTgtMy0xLTEtOTAxMg_79e9941d-624c-408e-b6f0-d94aa8780171">22,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTgtNS0xLTEtOTAxMg_69747083-2be7-45e7-a5ac-f964f385e6ae">9,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTgtNy0xLTEtOTAxMg_bc286e27-04a0-40eb-8a8f-9ff423ca7599">7,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders - diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTktMS0xLTEtOTAxMg_a7fc125b-acfa-4092-aa0f-72496c375bd1">71,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTktMy0xLTEtOTAxMg_50534143-b78f-47f5-b759-576de9b914cd">22,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTktNS0xLTEtOTAxMg_56607b45-db50-48f3-95ad-77817378238d">9,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTktNy0xLTEtOTAxMg_e69b3128-91ee-46f5-bd97-4672f2858dec">7,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtMS0xLTEtMjU3MzI_170d987f-3a59-4d2e-b885-ab52c4da81c9">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtMy0xLTEtMjU3MzI_d8b24b25-ebbe-4161-a200-39f95cbdbf4f">0.19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtNS0xLTEtMjU3MzI_63ca0587-c9eb-49cc-9d89-f38bfc89e589">0.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtNy0xLTEtMjU3MzI_20494a06-c8ba-42d7-b7fa-97d2e9d6c518">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtMS0xLTEtOTAxMg_b67d7d02-510e-4862-80e6-f0bf9f19a231">196,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtMy0xLTEtOTAxMg_51c9e48f-4e07-499d-8f80-da43c76f395c">117,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtNS0xLTEtOTAxMg_10b11a01-a77e-49e7-be1a-0311ad0c339c">176,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtNy0xLTEtOTAxMg_04a88dea-581e-4058-8594-7e5666f5acf2">113,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share - diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjItMS0xLTEtOTAxMg_55303c59-49fe-45f8-b7ef-5650c65f5862">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjItMy0xLTEtOTAxMg_e08eb5d1-5a08-4373-8d95-6fe7d49a26b8">0.19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjItNS0xLTEtOTAxMg_38859e16-f59a-4bff-83ad-8bedac2ab8fe">0.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjItNy0xLTEtOTAxMg_c9d170ec-7cec-4332-accb-364debff9652">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjUtMS0xLTEtMjU3MzI_19852ea4-d591-4bd4-8072-cb7d75ef7384">201,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjUtMy0xLTEtMjU3MzI_bf733197-552f-46cf-96e2-fb3bedeb6380">117,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjUtNS0xLTEtMjU3MzI_5552b0c9-ce89-4ef5-9efb-c73e0e4d6de6">176,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjUtNy0xLTEtMjU3MzI_759381d0-5fb0-4e6b-a628-cce1a71b4025">113,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.940%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id546f5275111478eae55ae8b7ddd61d8_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi0xLTEtMS05MDEy_bd0dd0f7-8762-4166-8499-843aaf1ea9e7">140,449,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id546f5275111478eae55ae8b7ddd61d8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi0zLTEtMS05MDEy_6090e364-c4a9-4a61-9ea4-fad0531fe180">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1bdbafc64bc4e6f927a8c8b89d17e1f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi01LTEtMS05MDEy_09d40c2b-193b-4538-bf17-b01dbe6ece4b">306,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb42dcf497cf4db4bb42c8d89c51f961_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi03LTEtMS05MDEy_8bdd4b43-ec03-4279-87d3-53c851d37858">315,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi05LTEtMS05MDEy_1a45aa5d-4afb-46c5-9672-5f724384d585">9,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic41f4d8f7f114855a616af3e79f0b5f1_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMy03LTEtMS05MDEy_70cfeaba-a4d6-4dfd-ad48-01cb8ef4e14d">55,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMy05LTEtMS05MDEy_7c7e5728-f6f6-4b57-b491-77a7cc73b35c">55,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f203500303a43978dd153bf5525882b_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNC01LTEtMS05MDEy_37afb932-8e8c-4a58-8e64-f31f8bb84669">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNC05LTEtMS05MDEy_b57a55d4-e644-4625-a052-13388e1ff8b0">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNS0xLTEtMS05MDEy_66cbe24a-b6f4-4bc7-8743-cd1380aa064e">30,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f203500303a43978dd153bf5525882b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNS01LTEtMS05MDEy_27095072-ebfa-40aa-b349-c7bfe7285c4d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNS05LTEtMS05MDEy_521120df-3d63-4217-ad8c-9cea6a0f36df">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNi0xLTEtMS05MDEy_77a3f5ba-f1c8-48e8-b228-318eadc315f6">852,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNi0zLTEtMS05MDEy_a3f7523c-1b41-47ca-bfa8-6e205783a2f7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f203500303a43978dd153bf5525882b_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNi01LTEtMS05MDEy_75629a31-5f4d-4e84-bb12-07a106ed2a12">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNi05LTEtMS05MDEy_48cb91cd-4c54-478b-9f38-7b2f397b573e">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy0wLTEtMS05MDEyL3RleHRyZWdpb246YTI1ZDNmYmFhMmU2NDA1Y2I0NTIzNzhjOTk0MjVlNjZfNzQ_572ad8d6-14d5-4901-a7f7-ce6be6035027">2.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy0xLTEtMS05MDEy_d2c97003-8e36-4b6d-9914-84acf1af7543">30,645,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy0zLTEtMS05MDEy_bd075b4b-402d-4b36-b2dc-14558724d402">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f203500303a43978dd153bf5525882b_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy01LTEtMS05MDEy_75b1f0b0-2592-4b71-975a-ca08b473b873">72,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy05LTEtMS05MDEy_c0e325cf-340e-4588-aa94-dd756af0fb92">72,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia736239317b24101bef5d62a00a3d7c9_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC0xLTEtMS05MDEy_0a1647e3-220f-457a-b4cf-2eb1fbe519d8">171,978,799</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia736239317b24101bef5d62a00a3d7c9_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC0zLTEtMS05MDEy_83b88357-7ac6-4b9a-a66a-1e01e181b619">172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac80310a46fa497792ae2b23f361970b_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC01LTEtMS05MDEy_f12b2c0a-6f21-4892-899d-edc350d4042a">380,531</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3172bc731cc8465ca35ef631d4862d13_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC03LTEtMS05MDEy_e4ff2044-1c97-48bb-85e9-a693fdc49cf8">371,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d261af049ab482490810fd8b8e53435_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC05LTEtMS05MDEy_775010e0-a52c-40ea-b0a1-bfe137070599">9,270</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i504486b9de8f4cd5ab2cc5ddda4d7df6_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTAtNy0xLTEtOTAxMg_256bab5a-3c5e-4079-b723-d40340f85f0e">25,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTAtOS0xLTEtOTAxMg_9fccd568-122f-457c-94ad-afcce2ac22c5">25,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4562dea9ab4a92a5891acdb449c85e_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTEtNS0xLTEtOTAxMg_52872494-c80f-4af9-b801-8c2267d1231c">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTEtOS0xLTEtOTAxMg_96272cf6-3f8c-431d-84d8-dfc0c3375ef3">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmQ4OGFkZTkxZTM1NDQ5ZThhOTUyZGJkNWI4ZTU0NGFkXzc1_6a5cc844-bc7e-414a-bd95-aa1bdc0e6f1a">2.0</ix:nonFraction>&#160;million </span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac6b4e3f3ab049039f1f5a6789966e1c_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtMS0xLTEtOTAxMg_669170fa-7df7-438d-8668-e132283185fa">16,482,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6b4e3f3ab049039f1f5a6789966e1c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtMy0xLTEtOTAxMg_d9b41ede-f2b9-459e-87e7-f5083e06cc6b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4562dea9ab4a92a5891acdb449c85e_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtNS0xLTEtOTAxMg_b8702bbf-68ee-44b9-aa85-4020b0c1390c">64,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtOS0xLTEtOTAxMg_4253ba3e-c046-41a6-b4d1-ffe3b15d7735">64,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dbf1c141a0c4eb483ea692aec134f4b_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtMS0xLTEtOTAxMg_d3744109-2faa-411f-aea8-6b4fd34fbded">188,460,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dbf1c141a0c4eb483ea692aec134f4b_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtMy0xLTEtOTAxMg_1fb8d183-2c4a-4aa1-97fd-6f852ca98473">188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ac0ee18ade4af8b7b471481a04a2c3_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtNS0xLTEtOTAxMg_7e0c9ea4-d5e9-4a5a-a63f-c97b75815907">446,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd658161e2c94d2a852bd1a21e30693d_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtNy0xLTEtOTAxMg_fa6ee3d4-3a38-4059-92eb-afff8e1da6a1">396,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2075535641a548e287b521ae3d4bbb18_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtOS0xLTEtOTAxMg_2de72a3f-ddd8-45e7-a9e4-a2702402456f">49,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c7eda9e3954ea795f7fc70c0134b09_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTctNy0xLTEtOTQzNQ_63bd3922-e3dc-4965-bc77-aabeae83c5d8">71,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTctOS0xLTEtOTQzNQ_3e534b2e-631c-4322-b712-aa9b10726f32">71,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTgtNS0xLTEtOTQzNQ_edac3937-f5b5-4921-a249-5d2379053156">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTgtOS0xLTEtOTQzNQ_24ec20ff-47cd-4e17-8304-652999400668">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTktMS0xLTEtOTQzNQ_9be4ecd2-3161-402b-b1ba-55ce91755635">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTktNS0xLTEtOTQzNQ_dd3799e5-90f1-466b-9726-3c90c2ccc580">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTktOS0xLTEtOTQzNQ_9deb6022-8400-4842-87e0-2f157627f89f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjAtMS0xLTEtOTQzNQ_e831799b-3d1a-484d-b369-9220b91744ac">1,195,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjAtMy0xLTEtOTQzNQ_43abc68a-aefc-48cf-bc38-9a30ee7f0084">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjAtNS0xLTEtOTQzNQ_1d6ab790-bddf-4dc0-bb10-3384b6418e01">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjAtOS0xLTEtOTQzNQ_dd918873-c3ba-47e9-ad8b-b18582aa2841">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtMC0xLTEtOTM0Ny90ZXh0cmVnaW9uOmNlYWI3NDZmMjI0YTQzZGZiYTUwMWIxOGU0NjM4YzFjXzQzOTgwNDY1MTEyMDM_21cd5a79-f8dc-4701-9728-4be19b4f76a7">1.2</ix:nonFraction> million </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtMS0xLTEtOTQzNQ_ca0faa23-52b1-4a0c-b183-5de98f67a6ee">9,804,475</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtMy0xLTEtOTQzNQ_e5b3fe51-45a0-4675-b6cf-d9569d1ebccf">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtNS0xLTEtOTQzNQ_831e4f58-48e0-4284-82f6-60545e7b1f04">38,147</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtOS0xLTEtOTQzNQ_8270d9f1-57bb-49bb-817b-724184e925e3">38,157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ba9eed293fb489583e83d76334fb473_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItMS0xLTEtMTk5Mjc_8aa33315-6e98-4217-88a3-5ca9d8c943fb">199,463,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba9eed293fb489583e83d76334fb473_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItMy0xLTEtMTk5Mjc_091b03a4-3ca0-479b-8343-a164723caa1d">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e794ca5abe9423b8fcb06f2a3b212a6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItNS0xLTEtMTk5Mjc_41c6ab20-ed48-4cc2-88ea-dc1b42d00d59">486,010</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d9e1dcf0f804b12800ee77146e934bb_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItNy0xLTEtMTk5Mjc_cd861de7-11a3-4c8b-b462-81e164bf80e4">325,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItOS0xLTEtMTk5Mjc_69113b2d-58d9-4f7f-b082-12ce5d16ce9e">161,008</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.940%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia345782a36b04632a22dcefbffbf2122_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi0xLTEtMS05MDEy_1ead621f-0535-42bc-8f8b-842f0ba07c4b">106,801,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia345782a36b04632a22dcefbffbf2122_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi0zLTEtMS05MDEy_25a89862-c345-462e-920e-1e477287a016">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6721966bda4737b5d6c09a51510e67_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi01LTEtMS05MDEy_815a5948-a16c-41d1-8afb-df16c02cb056">266,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30cab611aee04f429c25aa68fcb3a66d_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi03LTEtMS05MDEy_a5064421-6755-4395-8896-86efcdb0cd26">293,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i746ad97c6cd749bea3090dff8cc5d3c8_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi05LTEtMS05MDEy_1823f9fa-1a48-4e31-b562-dc8614585d05">26,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0f30e637a74e7bbfde72ce37739632_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMy03LTEtMS05MDEy_4639690a-abf1-4ccf-9272-1f40164afa85">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMy05LTEtMS05MDEy_3a99c3f2-f1c2-4b4b-97fd-13781ad6f37d">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95480a6da5214cc3867f93de1459e972_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNC01LTEtMS05MDEy_c0677471-0592-49b5-aa89-0765711c678a">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNC05LTEtMS05MDEy_350d736c-53b5-45a7-9e2a-5dd2f75c697c">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of common stock under 2014 ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieafcf2967a0e4400ba5e2ef91b2c4e95_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNS0xLTEtMS05MDEy_0dabba62-6371-4f25-b669-805d227b96a8">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95480a6da5214cc3867f93de1459e972_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNS01LTEtMS05MDEy_bf602756-8f35-4f86-901a-63e9186b98a5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNS05LTEtMS05MDEy_24d22ff2-cf31-4f08-a32e-6bc67ffa4c6e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi0wLTEtMS05MDEyL3RleHRyZWdpb246MDBmMDk4OTQ2OTljNDEzMDhkMWM2NDI2NDFhYzc1ZTBfNzQ_6b3f921c-c73c-4c56-a840-9929b9af3ffa">0.1</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieafcf2967a0e4400ba5e2ef91b2c4e95_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi0xLTEtMS05MDEy_08aff9b9-44d8-4689-b0ff-4b1494e45055">3,187,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafcf2967a0e4400ba5e2ef91b2c4e95_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi0zLTEtMS05MDEy_745d2229-94d9-4b12-a05d-8f0f72f8be97">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95480a6da5214cc3867f93de1459e972_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi01LTEtMS05MDEy_433a8387-d4e1-4db2-8ee7-5a0d61fc6654">3,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi05LTEtMS05MDEy_f2fa35d1-507d-43a2-8f17-ac6db7ca5024">3,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153d728efff347759e0394fab9944503_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy0xLTEtMS05MDEy_78dbe9d3-27eb-432c-a664-44dc22971f2e">109,991,553</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153d728efff347759e0394fab9944503_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy0zLTEtMS05MDEy_b241df34-3cb9-470a-8563-928dfc58f52b">110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a154a5219c4779983d780486eecb41_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy01LTEtMS05MDEy_6b997623-5611-4747-8613-1576b3d99c36">270,301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if14f953deda7433f98e5de86c3866f7a_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy03LTEtMS05MDEy_7913dd55-22cc-4bcd-9827-43d66ad19b29">251,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64611da1b2004612b9b69bfe30c13dc8_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy05LTEtMS05MDEy_f54981e7-7355-4704-9b64-c349de436bcb">18,451</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7e08a33ca6d4f589a32a804b0218dab_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfOS03LTEtMS05MDEy_a6ac1532-5694-4050-9ab4-1fd693c938ce">26,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4502189f31a9474283888eeb7a770696_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfOS05LTEtMS05MDEy_c6683111-06fc-4e0a-8ef8-de8fb4e9abc6">26,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002e2f171b10423aa884ac9b368e3eb8_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTAtNS0xLTEtOTAxMg_5411ff6d-3ce9-45bd-a25c-6ad9a93c7ea8">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4502189f31a9474283888eeb7a770696_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTAtOS0xLTEtOTAxMg_1bf5ad96-a5b0-4afe-84e0-24ae57f1baf3">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i4502189f31a9474283888eeb7a770696_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjg2MTM5MWZkMjlmODQ3ZDI4NmI3NTYzNjk0YjU4YjBlXzgx_22e2dcfa-3a17-44bc-ac1b-4cd394cd6a04">0.1</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54dfac6708f940ae8d7d54eb45c4cdf6_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtMS0xLTEtOTAxMg_3963cca8-2ca1-4850-a874-eead81e6f8b5">6,636,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54dfac6708f940ae8d7d54eb45c4cdf6_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtMy0xLTEtOTAxMg_5202ce60-fb36-483d-9d3d-b0df1b0827e4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002e2f171b10423aa884ac9b368e3eb8_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtNS0xLTEtOTAxMg_12860074-bc35-4825-bfe8-bab0b25d3ee4">4,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4502189f31a9474283888eeb7a770696_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtOS0xLTEtOTAxMg_5e900866-5813-40c1-9f24-5217b82d01e2">4,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i069fefbb34c949ec9377080da376e4fb_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItMS0xLTEtOTAxMg_e0f9ae60-5124-498f-8583-c7dab3900397">116,627,653</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069fefbb34c949ec9377080da376e4fb_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItMy0xLTEtOTAxMg_78e01faa-4277-4651-9089-e2da8a86c0d1">116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe33102ebcf8432bb484924b03e689bd_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItNS0xLTEtOTAxMg_d2e596f5-72cf-483d-8c54-b3db00df683e">275,560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf4b71ad2308422da8c65596d76c09fd_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItNy0xLTEtOTAxMg_8a80d3c9-3a0b-40c6-b8a2-ca0d9a3cdf4c">278,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fee51ba1523446dac271d22281350e4_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItOS0xLTEtOTAxMg_bba69e89-1a27-4d28-adf0-ff292248ffdc">2,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf3a7c87f6d1422aa77aa5b7f9f2ecb0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTQtNy0xLTEtOTgwMg_6fed6bb5-4db2-4d9b-a556-cbdccc8fc84e">22,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTQtOS0xLTEtOTgwMg_ce2b5961-2daa-4dc9-96f3-9c502688810d">22,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5245ae5196f44ba6949d51a19c7f5a0f_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTUtNS0xLTEtOTgwMg_f3ddb0ce-85f4-444c-9ac2-b6851422f3a8">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTUtOS0xLTEtOTgwMg_4fedc4d0-6c03-4e12-af2f-726eea388dd7">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of common stock under 2014 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief9d18a3e43644049cf7c9dd882573e0_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTYtMS0xLTEtOTgwMg_12efb218-befd-4a60-b668-1e025634a5a6">25,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5245ae5196f44ba6949d51a19c7f5a0f_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTYtNS0xLTEtOTgwMg_5ebd0b4f-4003-45d3-b3a1-65eb29944143">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTYtOS0xLTEtOTgwMg_db6ccec4-8be3-4e1d-a1d2-7c49d334b86b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctMC0xLTEtOTc1NC90ZXh0cmVnaW9uOjYwOGI5ZTM1ZDI0ODQyODA5NTA1MTk5N2VlMDNjODE2XzQzOTgwNDY1MTEyMDI_ef31f59d-ac7c-4b26-8aca-4bd7c7f95bdc">0.3</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief9d18a3e43644049cf7c9dd882573e0_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctMS0xLTEtOTgwMg_33ddd41a-91e5-42a7-98fa-fd562b8040a2">6,991,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9d18a3e43644049cf7c9dd882573e0_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctMy0xLTEtOTgwMg_9b92b167-b1c9-41dd-b966-d49648485b94">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5245ae5196f44ba6949d51a19c7f5a0f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctNS0xLTEtOTgwMg_414ae9b8-e1f7-4c3f-8cf2-57568805cbb4">8,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctOS0xLTEtOTgwMg_ed0447e1-9871-4c60-8c55-eba60ddb488c">8,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i255ec6c67daf44f3b60c0bef3b4adc4d_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtMS0xLTEtMTk5NDE_5185d158-0d49-4bc4-a0c5-e39f41861123">123,645,007</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i255ec6c67daf44f3b60c0bef3b4adc4d_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtMy0xLTEtMTk5NDE_345fec8f-e9dc-4c79-91df-6f618fb16ba9">123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f99021539f4ebcb94f4695fa55a58b_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtNS0xLTEtMTk5NDE_d769b947-6da2-4703-a85f-3d5528ab0030">284,236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad4cdeca849b4134b8aa1380f258de14_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtNy0xLTEtMTk5NDE_0b9ae290-730c-4291-84bd-ba8eb29da00a">300,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtOS0xLTEtMTk5NDE_18c24c45-4573-4ec9-aaf2-d930ec6f797e">16,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:74.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMy0xLTEtMS05MDEy_9fb15208-20f9-4d7e-8e11-409feec84b43">9,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMy0zLTEtMS05MDEy_590175f4-6957-4a60-ab34-4bcb44e1cb76">7,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNS0xLTEtMS05MDEy_b58f348f-437b-4e86-b1ed-6945a4ccf40c">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNS0zLTEtMS05MDEy_1f3073de-d7c0-48a9-94d1-e507049d9829">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNi0xLTEtMS05MDEy_12c2a7fd-260b-4dc6-b292-9c8eda720e28">3,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNi0zLTEtMS05MDEy_880ce9f0-1a50-4c31-a5e1-423685345576">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNy0xLTEtMS05MDEy_cd9199b3-a347-4665-81b6-15ed83cccaa6">52,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNy0zLTEtMS05MDEy_16df4903-3883-4252-a1a1-e6bcf5ead42a">16,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfOC0xLTEtMS0yMjIzNg_7b70c202-6815-4cc6-a0ae-457931367c72">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfOC0zLTEtMS0yMjIyOQ_af934467-5152-4d9b-8c91-6bfa81cb5b4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable (net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfOS0xLTEtMS05MDEy_0f070e35-50af-4739-a978-f9a28352bcb6">1,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfOS0zLTEtMS05MDEy_352d822e-0742-4d5f-ac5d-a6ced93ccdaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTAtMS0xLTEtOTAxMg_fcd3aaf2-4644-4a83-8fa3-590ac3b0bc66">23,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTAtMy0xLTEtOTAxMg_de2838c8-bb88-404f-add3-e87e6e28646c">899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTEtMS0xLTEtOTAxMg_671243cc-4153-4ee1-93ef-eefa051f2a10">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTEtMy0xLTEtOTAxMg_60c05ac1-d18d-4fc9-9dc5-02af4c69c4fc">378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTItMS0xLTEtOTAxMg_e58370bc-0dd2-4133-afea-18b6ef138148">4,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTItMy0xLTEtOTAxMg_0f181cdd-bd24-4887-a1e4-97ae8fc3d907">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTMtMS0xLTEtOTAxMg_f0441605-4bcb-4400-9a93-ecd355a347ce">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTMtMy0xLTEtOTAxMg_ef6e1bc8-441a-49a3-acc3-f68220f1b0f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTQtMS0xLTEtOTAxMg_5624ed41-bfdc-4c01-80d4-96b4d918eb63">56,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTQtMy0xLTEtOTAxMg_c9230a91-ffe8-4fb2-9b03-f1eee560c5a2">22,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTYtMS0xLTEtOTAxMg_88c95616-4490-446f-a6f2-f824c3aa93b4">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTYtMy0xLTEtOTAxMg_09fcb2b7-34c4-44e2-b4ab-cc32c1f075e7">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTctMS0xLTEtOTAxMg_b8469b8e-3bd2-4fa9-86fc-2466d528865e">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTctMy0xLTEtOTAxMg_b481b4fc-6086-4622-b926-64fc33a7f542">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM Offering, net of<br/>issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTktMS0xLTEtOTAxMg_6aef8029-cfd4-4383-a3e7-f1c17c030994">174,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTktMy0xLTEtOTAxMg_c3ec0a3f-c4b8-4b31-84b2-b6e8bc51458a">16,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjAtMS0xLTEtOTAxMg_50d20518-35d5-487f-ad6d-658e45ec36d8">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjAtMy0xLTEtOTAxMg_36df4ea3-d326-4a4a-a0ea-24d7037cb4ca">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjEtMS0xLTEtOTAxMg_4984ecc0-01ef-4093-bac7-0b62449136ca">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjEtMy0xLTEtOTAxMg_b1bdc33d-7a47-47bc-b6f5-10223979c28a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjQtMS0xLTEtOTAxMg_4dc19f98-44de-4ad0-abc7-77efca51fc47">176,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjQtMy0xLTEtOTAxMg_b9b9cac0-d22d-4264-b528-3254c91657be">16,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjUtMS0xLTEtOTAxMg_50225eb1-7dcb-4319-b024-d0ca884a70b6">119,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjUtMy0xLTEtOTAxMg_2eb6bf7f-278d-4c92-bd58-49a52200ac2a">6,152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjYtMS0xLTEtOTAxMg_ae25cca5-eb6f-448c-a7af-c50fc9d51231">55,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746ad97c6cd749bea3090dff8cc5d3c8_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjYtMy0xLTEtOTAxMg_e020044e-7848-4064-99c6-80ae135d688a">48,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjctMS0xLTEtOTAxMg_54e1fbad-5095-4909-b8f6-09201df89c81">175,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjctMy0xLTEtOTAxMg_741a5539-a50e-4ca0-bca2-b243afa2e15d">41,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzAtMS0xLTEtMjAwMTk_e041a4ca-0c80-435e-9933-b2192f58e1d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzAtMy0xLTEtMTk5ODk_78eeff60-aa0f-4135-b12e-6481f237475e">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzAtMS0xLTEtOTAxMg_3b10d3c9-3a28-4c82-b2fd-982364968c9b">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzAtMy0xLTEtOTAxMg_65c49cb8-317b-4357-8b0b-753187a5d041">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed Dividend on adjustment of exercise price on certain warrants </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:OtherDividendAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzQtMS0xLTEtOTAxMg_72965146-943d-46b3-8c5e-aab1fd21e9e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="sesn:OtherDividendAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzQtMy0xLTEtOTAxMg_41874779-f7c5-46c3-9eea-48900168b86e">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_31"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfMTIxNTE_ba7304e4-e3df-403d-b26f-7ed1954c12a5" continuedAt="idb5f977b0c73408ba3c788eef30235c1" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="idb5f977b0c73408ba3c788eef30235c1" continuedAt="i8e76304f2d9e44829eb00ea92d6978d1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, VicineumTM, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus Calmette-Gu&#233;rin ("BCG")-unresponsive non-muscle invasive bladder cancer ("NMIBC"). The Company has an ongoing single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On July 13, 2021, the Company participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, the Company and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to chemistry, manufacturing and controls (&#8220;CMC&#8221;), and a timeline to submit additional supporting information was agreed upon. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On October 29, 2021, the Company participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL (the "CMC Type A Meeting"). During the CMC Type A Meeting, the Company and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any potential future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. The Company is preparing for a separate Type A Meeting to discuss the recommendations specific to additional clinical/statistical data and analyses that the FDA raised in the CRL (the &#8220;Clinical Type A Meeting&#8221;), which the Company expects to occur later this year. The Company operates in <ix:nonFraction unitRef="segment" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfMjQxOA_a752229e-f6c6-4b5f-a141-4f5a0044f5c0">one</ix:nonFraction> segment under the direction of its Chief Executive Officer (chief operating decision maker). The Company was formerly known as Eleven Biotherapeutics, Inc. until its name changed in May 2018.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued <ix:nonFraction unitRef="shares" contextRef="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930" decimals="INF" format="ixt:num-dot-decimal" name="sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfMzM3Nw_e654b78e-ca60-49af-b5a8-92d383a30a3b">4.0</ix:nonFraction>&#160;million shares of its common stock to the Selling Shareholders, which at that time represented approximately <ix:nonFraction unitRef="number" contextRef="idc9920534e564063b17cf3276820d0f3_I20160930" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfMzQ4MQ_2bac8133-4aec-42e2-af49-773fed1d8c09">19.9</ix:nonFraction>% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, who served as a director of the Company until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDA1OQ_9a617dad-c388-4d10-99d4-6737860cb698">12.5</ix:nonFraction>&#160;million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;) in the United States; (ii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i04d84ce34ad9409399002fee7af82ae3_D20160901-20160930" decimals="-6" format="ixt:num-dot-decimal" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDE4Nw_f57626b1-e731-470c-962a-94cbe23efb36">7</ix:nonFraction>&#160;million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i07f5c65b436140d38150a47e9b6c1c36_D20160901-20160930" decimals="-6" format="ixt:num-dot-decimal" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDMzMw_24eeca64-6c8b-4354-bc0b-48df18af0cf6">3</ix:nonFraction>&#160;million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to <ix:nonFraction unitRef="number" contextRef="icd5b45b654db4116bd06d251988b14f4_D20160901-20160930" decimals="2" name="sesn:SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDQ0NQ_860b1dfd-4223-4d20-9657-2ec78b0ad63c">2</ix:nonFraction>% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033 and (ii) <ix:nonNumeric contextRef="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930" format="ixt-sec:durwordsen" name="sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDcxMQ_cf62a3f9-fb78-4d88-869b-d2bea4f884bd">fifteen years</ix:nonNumeric> after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country (collectively, the "Contingent Consideration"). Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts for the first <ix:nonNumeric contextRef="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930" format="ixt-sec:durwordsen" name="sesn:SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNTA3Mg_d8f22075-2ac8-4b3a-8342-82726ec49331">seven years</ix:nonNumeric> following the closing of the Viventia Acquisition, to achieve marketing </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e76304f2d9e44829eb00ea92d6978d1">authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors, however as of September&#160;30, 2021, none of these individuals are employees or members of the Company's board of directors.</ix:continuation></span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_34"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2NA_78fd89a5-fc33-4e93-b2d0-c7a5aa896ef3" continuedAt="i36314b347e2c4e519ad01103764f449e" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i36314b347e2c4e519ad01103764f449e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASUs&#8221;), promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2NQ_0e2441f5-acc8-4f99-89b1-f42343013808" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on March 15, 2021, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2Ng_7deea7dc-47c3-4597-8faf-7db2303a7071" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; revenue recognition and going concern considerations.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2Nw_b5ea9c49-be56-4f1b-a6ae-cb99176a31a8" continuedAt="i2185cb19b9bb45df9e6361cfa5304d55" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2185cb19b9bb45df9e6361cfa5304d55">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2OA_67f0ff54-9a14-4bbb-9cfb-369c16b29ac2" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the U.S. dollar.</span></div></ix:nonNumeric></ix:continuation><div id="i0b6b8a80699f4ebca69187de21a4e617_37"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNy9mcmFnOjdkMjhlMDc2ZTkyYzQxZGJhNTY4MzQyMTc1ZTczZGZmL3RleHRyZWdpb246N2QyOGUwNzZlOTJjNDFkYmE1NjgzNDIxNzVlNzNkZmZfMzY4_de370e33-0525-473d-9196-a4c6428b7f83" continuedAt="i7c8d2b2d9602407eaea7c7a805aacc2b" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7c8d2b2d9602407eaea7c7a805aacc2b">The Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2020.</ix:continuation></span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_40"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180MC9mcmFnOjE4MjUyYjRhYzhkYjRiMzRiODgyOWQ4ZmM2ZTg3NzFiL3RleHRyZWdpb246MTgyNTJiNGFjOGRiNGIzNGI4ODI5ZDhmYzZlODc3MWJfOTM2_efd1a5d1-3b31-4418-831c-3a91e5fc6a72" continuedAt="i4a3ab126e3f24e48b145e7eb67252402" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="i4a3ab126e3f24e48b145e7eb67252402" continuedAt="i74e71004aa354520969858961629779c"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180MC9mcmFnOjE4MjUyYjRhYzhkYjRiMzRiODgyOWQ4ZmM2ZTg3NzFiL3RleHRyZWdpb246MTgyNTJiNGFjOGRiNGIzNGI4ODI5ZDhmYzZlODc3MWJfOTM3_34130b83-d43f-4438-b898-f13f42156ca7" continuedAt="id050bf6d5cbd47a9973ade3dc2a31ce2" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2021</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i74e71004aa354520969858961629779c"><ix:continuation id="id050bf6d5cbd47a9973ade3dc2a31ce2">for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.</ix:continuation></ix:continuation></span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_43"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNTI5MA_3765bd69-5c86-40d0-8143-7b87f760d293" continuedAt="ifd26b1122f124cebb20e1c405e6cb1ab" escape="true">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ifd26b1122f124cebb20e1c405e6cb1ab" continuedAt="i8a79f51c612f43f5aa829f04d9b25926"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNTI4Nw_a54599c4-25b9-44c3-bb73-bcb44540412b" continuedAt="i99c0d9a59f364428bae90f1b7a1adb7c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September&#160;30, 2021 and December&#160;31, 2020 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs.  The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:continuation id="i99c0d9a59f364428bae90f1b7a1adb7c" continuedAt="ifc32fda78764493681ca782388e2caf4">Level 3</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc32fda78764493681ca782388e2caf4">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.</ix:continuation> </span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNTI3Mw_b9282bfa-ba7a-4b2f-a905-cd97a32f0e36" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:35.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia797d1ca4fc645e8b395e6d9263565df_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC0xLTEtMS05MDEy_0a5d5bca-dc00-4cd9-8e03-c47213a2c7ba">16,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc2b9836694810a0403c78508eec6f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC0zLTEtMS05MDEy_048ba4d6-9104-41a6-a63b-a6984965da28">16,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45b2253ea0241f883b480c50a91e7ee_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC01LTEtMS05MDEy_829f73f1-efaf-448c-9331-ae55588ad9ba">16,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8cfcaa24fb4ed5a8ee17f30da2aecb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC03LTEtMS05MDEy_0be23201-5fb2-4030-923e-33f9c5a3dd58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad64fc04cf04fd8be661f0721499ef2_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC05LTEtMS05MDEy_b97f964c-ea4f-47bd-ab39-47ef4f9a8348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia797d1ca4fc645e8b395e6d9263565df_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi0xLTEtMS05MDEy_2990c186-8bcb-40c5-9238-8d495822926f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc2b9836694810a0403c78508eec6f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi0zLTEtMS05MDEy_2a20a632-f7d1-4837-8573-2eb1191254ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45b2253ea0241f883b480c50a91e7ee_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi01LTEtMS05MDEy_dd43f09c-2933-47a8-86fc-aedb41d570f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8cfcaa24fb4ed5a8ee17f30da2aecb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi03LTEtMS05MDEy_d389fd0a-99f3-417a-9439-744851f05f16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad64fc04cf04fd8be661f0721499ef2_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi05LTEtMS05MDEy_89252b17-f2c0-46e3-8376-b15878590979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia797d1ca4fc645e8b395e6d9263565df_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy0xLTEtMS05MDEy_d4c368b8-d89b-459c-9abc-9b04f4fb7550">56,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc2b9836694810a0403c78508eec6f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy0zLTEtMS05MDEy_8147c9ef-2c1c-4808-b345-b85525aeca02">56,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45b2253ea0241f883b480c50a91e7ee_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy01LTEtMS05MDEy_0b550ca0-5e83-40da-8ee2-f83f412e9d27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8cfcaa24fb4ed5a8ee17f30da2aecb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy03LTEtMS05MDEy_28e1cb81-f21e-44ec-b460-863b56aedf91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad64fc04cf04fd8be661f0721499ef2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy05LTEtMS05MDEy_16c3be8e-e905-47af-b57a-787f1dd62db1">56,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:35.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b740de8bf63490bb488468c1c7ef16b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC0xLTEtMS05MDEy_2150906d-7456-4636-8f93-01b362f495c6">16,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e931e5abe8401e88a126d64a293b20_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC0zLTEtMS05MDEy_8f555c9e-ac41-4465-a8d7-5768fcdd121f">16,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i956068aabeb24f898f4ef28b58b5d3e3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC01LTEtMS05MDEy_d443559e-92c1-47bd-8473-0f887da8e4e0">16,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4934a8dc9143cca95a8e41327cd312_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC03LTEtMS05MDEy_fe3e1a6a-8d88-436f-b441-82c54beabd9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54798f9a263e4006acf115b512314f6d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC05LTEtMS05MDEy_f5419af1-a2f1-41f2-a09a-20b411bcf472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b740de8bf63490bb488468c1c7ef16b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi0xLTEtMS05MDEy_e6f6eacd-3bac-4d9f-b010-15da9191844d">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e931e5abe8401e88a126d64a293b20_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi0zLTEtMS05MDEy_7031942f-e118-42bb-98d5-8ae30a4e64c4">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i956068aabeb24f898f4ef28b58b5d3e3_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi01LTEtMS05MDEy_b1713848-4005-476b-8609-7ba992bb893e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4934a8dc9143cca95a8e41327cd312_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi03LTEtMS05MDEy_2ad1b067-4e5c-4895-8f51-9806063938c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54798f9a263e4006acf115b512314f6d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi05LTEtMS05MDEy_35ce1c82-14a0-4c68-a236-ab16dc010d29">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b740de8bf63490bb488468c1c7ef16b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy0xLTEtMS05MDEy_42a5d091-57e3-4cee-893b-73cafd4f6a5c">99,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e931e5abe8401e88a126d64a293b20_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy0zLTEtMS05MDEy_c07bd829-90f4-4086-98d3-498cb1949418">99,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i956068aabeb24f898f4ef28b58b5d3e3_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy01LTEtMS05MDEy_d6511a2d-b783-4730-9a49-cb1cd386f6ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4934a8dc9143cca95a8e41327cd312_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy03LTEtMS05MDEy_acb9b006-8e55-4027-b60d-8e8a9f2b07db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54798f9a263e4006acf115b512314f6d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy05LTEtMS05MDEy_96a8cdde-3a58-4f43-8c22-acd2b9ea000c">99,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i8a79f51c612f43f5aa829f04d9b25926"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of clinical and regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2024 to 2033, the level of commercial sales of Vicineum forecasted for the United States, Europe, Japan, China and other potential markets and discount rates ranging from <ix:nonFraction unitRef="number" contextRef="i6c50f17d10a14d9eabcc22c8f3758312_I20210930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDM5ODA0NjUxOTYyNQ_0136e45f-c501-4b97-8e12-bb6458ffadbe">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i084a1ef5b7d84536a0488186c21a7485_I20210930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMjc0ODc3OTA4NDYyMA_c4ad2738-4eee-45b8-ac75-36bbd1de1a0c">8.6</ix:nonFraction>%  as of September&#160;30, 2021 and <ix:nonFraction unitRef="number" contextRef="i4ac34a0eb6d444668cb6a7cfe8729dcc_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMzU5NA_181dc2c2-1157-4a12-8ca5-bd9cef9a6cf6">8.4</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i41191996f8d5431abab1f677026cf472_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMzYwMA_74e37d53-f769-47e6-b8be-8ba2b9e2e59d">8.8</ix:nonFraction>% as of December 31, 2020. There have been no changes to the valuation methods utilized during the nine months ended September 30, 2021.</span></div><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNTI4MA_1534c68d-626c-4288-8d1a-86fb72aa1f3e" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the nine months ended September 30, 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.643%"><tr><td style="width:1.0%"></td><td style="width:78.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.613%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ic84c83bbc78b4c12a4fe38ef570304f9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOmJlYWQxNWYyOTg1MzQ1YWU4YTE3NjAzYjM3ODA4M2IxL3RhYmxlcmFuZ2U6YmVhZDE1ZjI5ODUzNDVhZThhMTc2MDNiMzc4MDgzYjFfMC0xLTEtMS05MDEy_5284ec9a-f17c-417b-989f-707b462fa169">108,840</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - short term </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ed5df0fffaa498399f610dcc2d9649d_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOmJlYWQxNWYyOTg1MzQ1YWU4YTE3NjAzYjM3ODA4M2IxL3RhYmxlcmFuZ2U6YmVhZDE1ZjI5ODUzNDVhZThhMTc2MDNiMzc4MDgzYjFfMS0xLTEtMS05MDEy_59f348f1-0605-4740-968b-4ea4a95c9e68">8,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ed5df0fffaa498399f610dcc2d9649d_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOmJlYWQxNWYyOTg1MzQ1YWU4YTE3NjAzYjM3ODA4M2IxL3RhYmxlcmFuZ2U6YmVhZDE1ZjI5ODUzNDVhZThhMTc2MDNiMzc4MDgzYjFfMi0xLTEtMS05MDEy_aa326154-e286-4043-85d9-8d15c4d4d4b8">43,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e86bda1e5244696a1806edda33f2bfb_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOmJlYWQxNWYyOTg1MzQ1YWU4YTE3NjAzYjM3ODA4M2IxL3RhYmxlcmFuZ2U6YmVhZDE1ZjI5ODUzNDVhZThhMTc2MDNiMzc4MDgzYjFfMy0xLTEtMS05MDEy_d2e02c83-06d0-437b-a73d-4ab379231a85">56,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDI2Mg_968458d3-0516-4d29-9b25-d7e7c2460baf">2</ix:nonFraction>%</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDM2MQ_2c2523f5-7369-4988-8120-e70473b85abb">2</ix:nonFraction>% earnout is derived from the Company&#8217;s estimated weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from <ix:nonFraction unitRef="number" contextRef="ib1415d97efbe429391dd2e7d1b088f99_I20201231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDQ4MQ_7bf88e50-b45d-4418-a16c-3746e25a94da">8.8</ix:nonFraction>% as of December 31, 2020 to <ix:nonFraction unitRef="number" contextRef="i6825967355184d4db34915ea37cd569f_I20210930" decimals="3" format="ixt:num-dot-decimal" name="sesn:WeightedAverageCostOfCapital" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDM5ODA0NjUxODM2MA_bca8da15-c0c2-4281-b067-b2f75eafffed">8.6</ix:nonFraction>% as of September&#160;30, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from <ix:nonFraction unitRef="number" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDcyNg_69ce82b1-d4f0-4f48-8fa2-e74121707e9a">8.4</ix:nonFraction>% as of December 31, 2020 to  <ix:nonFraction unitRef="number" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDM5ODA0NjUxODM2Ng_0a94000f-34ee-4fdb-b266-d1ec61263432">7.5</ix:nonFraction>% as of September&#160;30, 2021. The decrease in the fair value of contingent consideration of  $<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMTY0OTI2NzQ0OTEyMw_cdced075-0aee-411b-ab05-379bc1cb1dce">52.2</ix:nonFraction> million for the nine months ended September 30, 2021 was driven by the receipt of the CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form. Due to the inherent uncertainty in the path forward for Vicineum at this time, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success (POS); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company anticipates needing to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately <ix:nonFraction unitRef="number" contextRef="i555450de9c964d30965deb1462b538f4_I20210930" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMjE5OTAyMzI2ODc5OQ_849e4b15-ffdb-49ac-af82-abb0eb04c8a4">45</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1d44b389ccbd43a2bbfcdc75634eaab2_I20210930" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMTY0OTI2NzQ1NTAwMw_bc9fa622-90a3-4240-a458-939d29b516a5">55</ix:nonFraction>% globally. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA later this year to discuss questions related to clinical matters raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates as a result of these meetings, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.</span></div></ix:continuation><div id="i0b6b8a80699f4ebca69187de21a4e617_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.<ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDc5_9fa5dc01-0927-4007-95f4-c861340fd7e7" continuedAt="if7a8e5b543a248aab0d7b96b9c3959ae" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="if7a8e5b543a248aab0d7b96b9c3959ae" continuedAt="i3f0aafa577154805bd10d03fc098e8c7">Intangible Assets </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i3f0aafa577154805bd10d03fc098e8c7" continuedAt="i21709d029c4c49c0a9e6adbb8c0017fc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDgw_606ebb5a-c531-4dd9-ab52-c3258f5fb1cf" continuedAt="if3cae06e37154d51afe53f18cd255220" escape="true">The following table sets forth the composition of intangible assets as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</ix:nonNumeric></span><ix:continuation id="if3cae06e37154d51afe53f18cd255220"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09310b7c37a84f11878085deb559133d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IntangibleAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfMi0xLTEtMS05MDEy_ea2d633b-ac40-44b4-9859-986f16053795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b6d5d2caa648dcb555f0031c4766b6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfMi0zLTEtMS05MDEy_5de45dbd-07fc-4986-ac8d-6e4ea00a4f6b">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib081c37a1b7148fabc6bbbdd4c81cd6d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfMy0xLTEtMS05MDEy_ec2fab0f-1389-4bca-98fa-f928a7737be1">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9a1851f4b84938b499fb6f2ec592fc_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfMy0zLTEtMS05MDEy_d76e50af-e6e4-4175-a287-2204f68c9975">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3daf5ae769a4d4691f5323122b152a4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfNC0xLTEtMS05MDEy_ecf86472-c18e-4c5f-9ce8-87c82dcccabd">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3748dd3582454f23a8200a59516d8d6f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfNC0zLTEtMS05MDEy_22b08188-825c-4324-a4a6-dba56dee5b17">46,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The fair value of the acquired intangible asset for the U.S. and E.U. rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, the Company&#8217;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss the clinical issues raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, an impairment analysis was conducted, which concluded that the carrying value of our intangible assets of Vicineum United States rights was fully impaired as of September 30, 2021. However, while similar delays in timelines and reduced probabilities of success also affected the carrying value of our intangible assets of Vicineum E.U. rights, this asset was not impaired as of September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="id1c35ca8bc59451b99b15883438c09e9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfMjc0ODc3OTA3NzU4OQ_d118f3a5-1d6d-4772-9ff7-c27378682d3d">31.7</ix:nonFraction> million of impairment charges for the period ended September&#160;30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market as of September 30, 2021. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of our intangible assets of Vicineum E.U. rights, this asset was not impaired as of September 30, 2021. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the EU asset is burdened with significantly less expense than the US asset, as our strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with the Company earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i21709d029c4c49c0a9e6adbb8c0017fc">Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDYw_4d38d096-6b32-48c4-bfc5-c97ac2d5f200"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDYw_ec6b4bde-3b22-49c2-a2cb-ecef409e7259">13.1</ix:nonFraction></ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, a quantitative impairment analysis was conducted during the quarter, in advance of the Company's typical annual assessment date of October 1. While an impairment was recognized in one of its intangible assets, Vicineum U.S. Rights, the Company concluded that the carrying value of its goodwill of $<ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDM5ODA0NjUyOTQ1Ng_8c5db6e0-9d9d-4590-8eb5-2d36f258942e">13.1</ix:nonFraction>&#160;million was not impaired as of September 30, 2021, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately <ix:nonFraction unitRef="number" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfMTY0OTI2NzQ3NDEyOQ_acb0a40d-0e03-4860-9f3a-e3bc4df34c55">45</ix:nonFraction>%. The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in our current development profile (ranging from <ix:nonFraction unitRef="number" contextRef="i555450de9c964d30965deb1462b538f4_I20210930" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfMTY0OTI2NzQ3NDExOQ_f5a3deef-b03c-4fc3-b1e2-07fd67280ce0">45</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1d44b389ccbd43a2bbfcdc75634eaab2_I20210930" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDM5ODA0NjU1NTQ3MQ_24533f43-0611-4ec2-9b37-200897f7baa9">55</ix:nonFraction>% globally) also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of BCG-unresponsive NMIBC. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss questions related to clinical matters raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum, and will assess the outcome of those meetings, and other information obtained, to determine if further impairment testing is required. Further reductions to probabilities of success, additional development and commercial launch delays, or increases in underlying discount rates have the potential to result in future goodwill impairment.</ix:continuation> </span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMjE4Ng_b3c7b457-b180-4b3d-8771-8b316009e322" continuedAt="i4359c6e3125b4c96bec4bc8fef948c80" escape="true">LEASES</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i4359c6e3125b4c96bec4bc8fef948c80"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its <ix:nonFraction unitRef="sqft" contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930" decimals="-2" format="ixt:num-dot-decimal" name="sesn:OperatingLeasesAreaOfOfficeSpace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTEz_83106b93-a4a4-4c08-8c51-1831497dc5cb">31,100</ix:nonFraction> square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional <ix:nonNumeric contextRef="ifd7692a883ce45169ba52f34b1597844_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMjE4OA_dec24413-2169-4743-8181-c244c6445d9d">two years</ix:nonNumeric>, through September 2022, with a right to extend the lease for <ix:nonFraction unitRef="term" contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMzky_f33ea8c1-c19c-425b-bb38-df9ce99421fe">one</ix:nonFraction> subsequent <ix:nonNumeric contextRef="ifd7692a883ce45169ba52f34b1597844_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMjE4NQ_5ea273b0-5c07-44b8-a610-12696850e29f">three year</ix:nonNumeric> term. The minimum monthly rent under this lease is CAD $<ix:nonFraction unitRef="cad" contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930" decimals="-2" format="ixt:num-dot-decimal" name="sesn:OperatingLeaseMonthlyRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfNDY5_9d32420b-1c70-4d0d-ab38-4e403acb6eac">18,100</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930" decimals="-2" format="ixt:num-dot-decimal" name="sesn:OperatingLeaseMonthlyRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfNDk3_07781f4f-f820-4a7e-93bb-171b30437c1f">14,300</ix:nonFraction> at exchange rates in effect on September 30, 2021). In addition to rent expense, the Company expects to incur CAD $<ix:nonFraction unitRef="cad" contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930" decimals="-2" format="ixt:num-dot-decimal" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfNjA5_d5f20611-a43f-43c1-b5e9-d4598cac5700">18,200</ix:nonFraction> per month related to operating expenses (approximately $<ix:nonFraction unitRef="usd" contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930" decimals="-2" format="ixt:num-dot-decimal" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfNjY3_aa9d5288-747e-418a-b6c1-6c01c1498371">14,300</ix:nonFraction> at exchange rates in effect on September 30, 2021). Operating lease cost under this lease, including the related operating costs, were $<ix:nonFraction unitRef="usd" contextRef="i52acd18eaeab4bbeb00da4524f747aa3_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfODAw_83efc213-3d42-4166-b711-8a6935eb5b0b">79,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfODA3_28680885-1489-41aa-b349-9dd5be67128e">245,000</ix:nonFraction> for the three and nine months ended September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i18ebb0e11dab4338ba1489efd21f78a5_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfODI1_128d74eb-c595-4a46-99e4-aaaf6a91f096">75,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2bd4a05fa0ad4322ae22d1c69ac3251a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfODMy_475c5f27-6381-48ac-8682-dfa0110ff4d7">223,000</ix:nonFraction> for the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within other assets on the Company's condensed consolidated balance sheets. The short-term lease liability is recorded in other current liabilities and the long-term lease liability is recorded in other liabilities on the Company&#8217;s condensed consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every three months to six months and currently extend through June 2022 and November 2021, respectively. The minimum monthly rent for these office spaces is $<ix:nonFraction unitRef="usd" contextRef="i5a7fddfe10f34cafa6c5a4a5879fe96b_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="sesn:OperatingLeaseMonthlyRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTA5OTUxMTYzMDIwMQ_fabd13e2-38ff-4751-9b02-0236a902cd3f">2,100</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i68276962a8f74cf19dd3fffa8b75f81a_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="sesn:OperatingLeaseMonthlyRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTY5NQ_194a707e-7782-48c7-9191-4227005106e3">18,000</ix:nonFraction>, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTgyNw_32803834-80d8-4e63-b22c-c8f9233a568b">63,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTgzNA_898c6307-02d4-49a6-8859-ce536991436e">201,000</ix:nonFraction> in rent expense for the three and nine months ended September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTg2OA_4d005c47-e868-4917-8329-efa71ed7a28f">64,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTg3NQ_5a0f8757-522b-4a13-89ae-0d6e7dfdae92">195,000</ix:nonFraction> for the three and nine months ended September 30, 2020, respectively. The Company's accounting policy election was disclosed in "Item 15. Exhibits and Financial Statement Schedules - Note. 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div></ix:continuation><div id="i0b6b8a80699f4ebca69187de21a4e617_55"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RleHRyZWdpb246ZTBlM2Q4OTZjZTVkNGYyODgyOWZmYTJmNDgxNzkyYzhfMTMw_90168b0f-577a-4595-9437-ce903bada001" continuedAt="i822140ebf59841e591a24da996bd7549" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i822140ebf59841e591a24da996bd7549"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RleHRyZWdpb246ZTBlM2Q4OTZjZTVkNGYyODgyOWZmYTJmNDgxNzkyYzhfMTMz_1c6b0888-8495-40cb-8300-0a829a282d83" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands): </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"></td><td style="width:59.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.066%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfMS0xLTEtMS05MDEy_59fc32cc-1063-4c56-997b-d16e62c79ebe">2,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfMS0zLTEtMS05MDEy_e223e342-e1a8-40e8-bab9-044fcc18c4e9">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfMi0xLTEtMS05MDEy_3cdb04c5-3e17-4fb1-a013-c963cf94b683">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfMi0zLTEtMS05MDEy_d874025e-ffe3-4a71-8110-a45dadeab8b9">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNC0xLTEtMS05MDEy_afa64678-98a7-4123-b2c0-beee5d4bd373">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNC0zLTEtMS05MDEy_fdbd51a1-c110-4d78-88a2-b3bdb7d4590b">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="sesn:AccruedRestructuringChargesRelatedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNS0xLTEtMS05MDEy_94624a5d-3d57-4366-b534-7b110c0de49e">2,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:fixed-zero" name="sesn:AccruedRestructuringChargesRelatedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNS0zLTEtMS05MDEy_9b79eeea-b141-4f40-be62-d8d6ab39cb51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNi0xLTEtMS05MDEy_1f64eadb-2258-40fc-9499-39c48f088ede">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNi0zLTEtMS05MDEy_9e58f2e2-4600-4d1b-a7d7-cb7139a205e9">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNy0xLTEtMS05MDEy_8740d818-0ae0-4351-8fcf-003eb303afc1">8,186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNy0zLTEtMS05MDEy_f7f12a37-37e9-4f76-9c8b-d96082a2f2cb">3,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0b6b8a80699f4ebca69187de21a4e617_58"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNjEyMg_fa11db4c-abd0-440f-b673-45368b71654a" continuedAt="i4667ef426bd840feafc6bc3235c6b1bb" escape="true">STOCKHOLDERS' EQUITY (DEFICIT)</ix:nonNumeric></span></div><ix:continuation id="i4667ef426bd840feafc6bc3235c6b1bb" continuedAt="icf907775bbd0479db85bc47da524294e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i39f8f4fa4924486482fcd1b7ca9c6d9d_I20191130" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjg0_20e7f3b3-37a7-4482-a7de-c8ebf362cf04">0.001</ix:nonFraction> per share, from time to time for an aggregate sales price of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="idd5ea54630c14b3b8074d7e574a485d1_D20191101-20191130" decimals="-6" format="ixt:num-dot-decimal" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzU0_9c312feb-81dc-4cd0-b2b6-9101f4089285">35</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through Jefferies (the "ATM Offering"). In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively.  Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $<ix:nonFraction unitRef="usd" contextRef="i67a67d24259846938c78c4e27aa8ba68_D20201001-20211031" decimals="-6" format="ixt:num-dot-decimal" name="sesn:SaleOfStockAdditionalSharesAuthorizedForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNzIx_df5cad38-4e4f-4330-b75d-e75de10b9e7f">50</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5526ac0da03b4995acfde7f67df66fdc_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="sesn:SaleOfStockAdditionalSharesAuthorizedForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNzI4_07ca67e1-dddd-47aa-98b7-be3a78554099">34.5</ix:nonFraction>&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia14f2b1575414e92a7e8692a1656ed6e_D20210601-20210601" decimals="-6" format="ixt:num-dot-decimal" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA2Mg_3a8b8f01-cd81-4690-aa85-5d4ce6ee2601">200</ix:nonFraction>&#160;million of common stock pursuant to the Sale Agreement.  Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. The Company may sell shares of its common stock efficiently from time to time, but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="icf907775bbd0479db85bc47da524294e" continuedAt="i7d92d698d04e412c87e873944a3059c0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to <ix:nonFraction unitRef="number" contextRef="idd5ea54630c14b3b8074d7e574a485d1_D20191101-20191130" decimals="INF" name="sesn:SaleOfStockCommissionFixedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjA5OQ_ba3eac08-2fa3-4160-9a30-02af757a7688">3.0</ix:nonFraction>% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $<ix:nonFraction unitRef="usd" contextRef="ib12fdfe409da499985845294be59cd32_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjQ3NA_cffd002c-716c-44a9-929d-b38520eafa4c">38.2</ix:nonFraction>&#160;million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="ib12fdfe409da499985845294be59cd32_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjUxMA_2ebf1950-0e67-49d7-855f-6db52e2e5932">9.8</ix:nonFraction>&#160;million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib12fdfe409da499985845294be59cd32_D20210701-20210930" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjU2Nw_28b10857-f220-4b94-b8ed-6ad1e1c66ea5">4.01</ix:nonFraction> per share during the three months ended September 30, 2021, compared to $<ix:nonFraction unitRef="usd" contextRef="i23e8f40d129643c4955e53934f43c919_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzMzk1MA_c4e12246-ff29-4e98-876e-25ac3985bebe">8.2</ix:nonFraction> million of net proceeds from the sale of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i23e8f40d129643c4955e53934f43c919_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzMzk1NQ_809c2980-0976-4716-a47e-26a709014482">7.0</ix:nonFraction> million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i23e8f40d129643c4955e53934f43c919_D20200701-20200930" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzMzk2MQ_b57d4b31-1aa6-45b2-bdb3-fc344c76d60b">1.21</ix:nonFraction> per share during the three months ended September 30, 2020. The Company raised $<ix:nonFraction unitRef="usd" contextRef="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDM3Mg_84c05c40-ecd2-44b2-8ad4-2168d16ef5ee">175.0</ix:nonFraction>&#160;million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDQwOQ_d90ea873-2134-46a8-acf4-35c647e5b02c">56.9</ix:nonFraction>&#160;million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDQ2OA_a90985c9-3adb-4d48-ad76-0009d6d061af">3.17</ix:nonFraction> per share during the nine months ended September 30, 2021, compared to $<ix:nonFraction unitRef="usd" contextRef="if89a1bed4d6e4801a7b55c57bb01b6a0_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDUxMA_4b958da0-dccf-4ada-afb4-8c89197fcc03">16.2</ix:nonFraction> million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="if89a1bed4d6e4801a7b55c57bb01b6a0_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDU0Nw_a4d3b533-a0c4-455a-a0aa-c2f869387e2d">16.8</ix:nonFraction> million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if89a1bed4d6e4801a7b55c57bb01b6a0_D20200101-20200930" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDYzOA_7228b135-7b4b-4cf3-b74b-3b9ee115eccf">0.99</ix:nonFraction> per share during the nine months ended September 30, 2020. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $<ix:nonFraction unitRef="usd" contextRef="ib12fdfe409da499985845294be59cd32_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjgxOA_9e7caae2-5c09-4469-8014-fe99c6fa0cac">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjgyNQ_b55d1b9c-db8a-4e04-bf49-f50ce80df904">5.4</ix:nonFraction>&#160;million during the three and nine months ended September 30, 2021, respectively. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzAyNg_bc576579-6e75-4ffe-bcf7-ce921032cd6c"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzAyNg_d25bad4e-3d06-46a3-a52e-d330a8bd9fd2">5.0</ix:nonFraction></ix:nonFraction> million shares of "blank check" preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzA3MA_120ac6c1-0b66-4f93-8c97-4d68225ec2d7"><ix:nonFraction unitRef="usdPerShare" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzA3MA_b7358a26-9532-437b-aa83-e1b213b2e226">0.001</ix:nonFraction></ix:nonFraction> par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had <ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzUxNA_2cb99a36-97f7-41f5-9d13-8f60ae654b5c"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzUxNA_38d87f44-06f9-4fe3-89db-7a053c33571f"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzUxNA_80684d5d-88f6-4983-ba89-d266ae6ff7ef"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzUxNA_8c5c3e40-4003-4b2b-8f70-3e91b2500040">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred stock issued and outstanding as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjE5OTAyMzI2MzQ5MQ_afbb4c46-b7b5-4e0a-892a-0936e2adb9d0">200</ix:nonFraction> million to <ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzY2Nw_709eecbe-9f28-4356-bd53-52c0a4859d0a">400</ix:nonFraction> million, of which <ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzcxMA_7a8e0f7b-742a-49e7-86a5-f0fda7a1e569"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzcxMA_97be4b97-3d06-44c2-97d3-f71269c04263">199</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzcxNw_4e65743a-0a3d-43f5-bbc8-48c651dcbd2a"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzcxNw_6ed12997-f41e-4803-8937-1b205b99ddb8">140</ix:nonFraction></ix:nonFraction> million shares were issued and outstanding as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September&#160;30, 2021 and December&#160;31, 2020, respectively. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNjExNg_f38e3bf8-7981-40d8-b941-6a9493314d60" continuedAt="i6de103f16f89496c9e385095c77dfc02" escape="true">In addition, the Company had reserved for issuance the following number of shares of common stock for the purposes described below as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i6de103f16f89496c9e385095c77dfc02"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfMS0xLTEtMS05MDEy_e9d914a8-6bd9-42a4-9650-4ff3fc032d6a">199,464</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfMS0zLTEtMS05MDEy_ecd0cc19-49c9-476e-979d-eefd9d4ee605">140,450</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id978bed0cf5c4d5fbab94cd056d775b8_I20210930" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfMy0xLTEtMS05MDEy_eea58201-3598-423d-acea-bc9141e9bb84">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7579e0e22c047768232e96e33209c00_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfMy0zLTEtMS05MDEy_c47900cb-7909-480a-b174-62ada3d6995b">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d4b935d6b414f729cd483380a572798_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNC0xLTEtMS05MDEy_b6f46fe8-93c8-4c4a-866f-36504926384f">15,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8591390616e24942a1790a6fef158000_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNC0zLTEtMS05MDEy_e2d50a73-bc1b-4d16-874a-b8e077b6e8d1">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fcaf5bf73c144fb87d727c536f11433_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNS0xLTEtMS05MDEy_5243a917-d16a-4861-8b11-4713c224303f">11,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9742c1fa4df446ea92bcdc4006e5dac4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNS0zLTEtMS05MDEy_8079278f-ee05-4d17-96a1-d05068c77d48">4,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i980c30d4b2e5432f83166c9129e01ffa_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNi0xLTEtMS05MDEy_af6bf17e-3633-4c85-bfe2-bd853846be39">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716f44ff8fdb4ed68f03fe519e006002_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNi0zLTEtMS05MDEy_14e56ddb-93c2-4750-add2-c497c21aaa3b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="sesn:CommonStockSharesIssuedAndReservedForFuture" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNy0xLTEtMS05MDEy_82962f50-dba7-406f-88e0-529edbfc8d30">229,457</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="sesn:CommonStockSharesIssuedAndReservedForFuture" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNy0zLTEtMS05MDEy_b71924c8-793d-4895-8d0c-620325f9ecaf">157,707</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i7d92d698d04e412c87e873944a3059c0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and permanently classified as equity because they meet the derivative scope exception under ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 815-40")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNjEyNA_5c477d2e-2a31-43dd-aac9-d14c6757daf9" continuedAt="i22defac7671541dcbe18ef84d3750039" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's warrant activity for the nine months ended September 30, 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year-to-Date Warrant Activity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Expired)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i52d9dcbb55e2474ea2ed0ba322bad3ac_I20210930" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy0yLTEtMS05MDEy_e2a22303-4d17-488f-b9a0-70987d3c12d9">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57e070c6f5694cc184d3ff043754818a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy02LTEtMS05MDEy_872670d0-343f-4433-b657-63fdcabb2c6b">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6379246986547cc9a88c6f8b29535d6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy04LTEtMS05MDEy_c2f7f656-596e-45fa-b7f8-bc626218dbdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic6379246986547cc9a88c6f8b29535d6_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy0xMC0xLTEtOTAxMg_354a47b0-3858-407c-8ddb-0275431d5ded">1,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6379246986547cc9a88c6f8b29535d6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy0xMi0xLTEtOTAxMg_e602dd8a-4f12-4d73-a1c4-dc27e8b453a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52d9dcbb55e2474ea2ed0ba322bad3ac_I20210930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy0xNC0xLTEtOTAxMg_32818989-7ee5-4194-8818-756ba8c999df">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idcd1ce8b4f094a86aaf1094f5ade0c3a_I20210930" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC0yLTEtMS05MDEy_04139728-38a7-4dc7-bb12-d967e75aecb7">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e16f0e7c69a48b793e80ba1cbd35337_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC02LTEtMS05MDEy_d4180d10-472c-4b86-9fea-12382428a180">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a98b848353a4028b0c3659a7cc0fc8d_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC04LTEtMS05MDEy_bd4ca023-c234-4897-987b-2e33b768d404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7a98b848353a4028b0c3659a7cc0fc8d_D20210101-20210930" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC0xMC0xLTEtOTAxMg_878dcc13-0bf9-4d63-a962-c728c16b5d69">475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a98b848353a4028b0c3659a7cc0fc8d_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC0xMi0xLTEtOTAxMg_c1a03426-c579-4347-b497-dffbb0cad755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd1ce8b4f094a86aaf1094f5ade0c3a_I20210930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC0xNC0xLTEtOTAxMg_ac520164-f102-4a7c-861f-1580667a9eeb">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if30380f6c6c241cca4d331347c506d7b_I20210930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS0yLTEtMS05MDEy_cf8a943e-1f95-420e-84bc-d4a5b8d7ecd1">11.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e50b89a5f094c2485a5ef23806abe14_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS02LTEtMS05MDEy_2d0381b8-0d99-4f7a-9df5-275cce90b2c5">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ac338c8a528448585157860bb14aae6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS04LTEtMS05MDEy_8ab83454-cb1a-4fe9-b2bb-0456af4e8f54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ac338c8a528448585157860bb14aae6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS0xMC0xLTEtOTAxMg_4f16ab42-d4f2-478c-9bb3-6a65cb441cc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ac338c8a528448585157860bb14aae6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS0xMi0xLTEtOTAxMg_60f82121-d1c8-4dca-ba4b-d75eb7434b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if30380f6c6c241cca4d331347c506d7b_I20210930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS0xNC0xLTEtOTAxMg_f203ca26-8a2f-4dfb-8cf6-952e332e918d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ideefad39445444f5978ed30df0f8d67d_I20210930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi0yLTEtMS05MDEy_ba28c8ac-c5eb-4016-8f58-d025bb6d0934">11.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1595e3478bb64207a037de6271baebed_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi02LTEtMS05MDEy_fe2358aa-345a-4dee-94d0-a3fe4264132f">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i044c60384a9e4cc8afe4aaa8645c9ef6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi04LTEtMS05MDEy_8f1be93a-8533-4f80-bc0a-fad370438c1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i044c60384a9e4cc8afe4aaa8645c9ef6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi0xMC0xLTEtOTAxMg_e1fa335e-c797-43e7-a82f-2c76a4f27a67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i044c60384a9e4cc8afe4aaa8645c9ef6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi0xMi0xLTEtOTAxMg_1c23b19c-0212-4e39-ada7-a8b87740898e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ideefad39445444f5978ed30df0f8d67d_I20210930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi0xNC0xLTEtOTAxMg_a70c56a8-2ed7-475e-8b79-2d1e51831185">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy02LTEtMS05MDEy_daa11037-493c-48a5-bcbd-99eb13d4b168">2,247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy04LTEtMS05MDEy_969bbe84-602e-4831-98d4-eace817b8d7c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy0xMC0xLTEtOTAxMg_34fc7823-973d-4931-925b-f369f2309381">2,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy0xMi0xLTEtOTAxMg_f071429f-5d1a-4487-aee6-bc6167fe24de">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy0xNC0xLTEtOTAxMg_b6922ab2-a82e-4669-8fc3-96f653c86355">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><ix:continuation id="i22defac7671541dcbe18ef84d3750039"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification (ii) subject to further adjustment based on down round provision added by amendment described in "Item 15. Exhibits and Financial Statement Schedules - Note. 10 Stockholders' (Deficit) Equity" in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></ix:continuation></div></ix:continuation><div id="i0b6b8a80699f4ebca69187de21a4e617_61"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RleHRyZWdpb246NzBhNzkwM2E2ODVhNGM4NTk3ZjA5NmVjMDFiZDgzZmJfMjg0NA_9e57437e-0b0a-4a4e-9edc-5eceaae6c31e" continuedAt="ic774e869e22d4a3a94f2ee7862d5f168" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ic774e869e22d4a3a94f2ee7862d5f168" continuedAt="i466dae2ab6c64b8caed8e0ecdc824b41"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted.  Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income.  During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Company applied the two-class method to calculate basic and diluted net earnings per share of common stock for the three months ended September 30, 2021. The two-class method was not applied for the nine months ended September 30, 2021 and for the three and nine months ended September 30, 2020 as the Company&#8217;s participating securities do not have any obligation to absorb net losses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RleHRyZWdpb246NzBhNzkwM2E2ODVhNGM4NTk3ZjA5NmVjMDFiZDgzZmJfNDM5ODA0NjUxNTQxMw_64397b1a-2296-49cd-ab4e-161f09c0b5bc" continuedAt="i621ed97aa0244eac83f843a0e9235ad5" escape="true">The following table illustrates the determination of earnings (loss) per share for each period presented:</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i466dae2ab6c64b8caed8e0ecdc824b41"><div><ix:continuation id="i621ed97aa0244eac83f843a0e9235ad5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic Earnings (Loss) Per Share:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNS0xLTEtMS0yNTU4MA_6b5e45b6-344c-4ba6-b618-c2b2b6df2261">71,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNS0zLTEtMS0yNTU4MA_ed406716-c5ce-4215-8de7-8fc47fbef877">22,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNS01LTEtMS0yNTU4MA_9fb15208-20f9-4d7e-8e11-409feec84b43">9,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNS03LTEtMS0yNTU4MA_d1055552-0618-46c6-a553-d32dc9a63a5c">7,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Deemed Dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNi0xLTEtMS0yNTU4MA_1d1c87ee-d1f5-4e12-b8a2-5b6ead0b2445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNi0zLTEtMS0yNTU4MA_9411a073-5f32-4554-b26d-bf2987ad5c49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNi01LTEtMS0yNTU4MA_bbdcc0dc-6a1d-4971-a918-b6e3caad3c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNi03LTEtMS0yNTU4MA_8f1a2721-57d4-4b15-9f8c-eaa58a21590d">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income attributable to participating securities - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNy0xLTEtMS0yNTU4MA_48abda6a-f91e-4974-a85c-bb380ee9ac85">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNy0zLTEtMS0yNTU4MA_83c4976c-367e-47d0-93c3-83a095fcfbc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNy01LTEtMS0yNTU4MA_ea1089e8-d6ad-4d98-9f39-c20459281f08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNy03LTEtMS0yNTU4MA_c688cd9b-c752-4572-a30d-41aac849088c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders - basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfOC0xLTEtMS0yNjAyMA_50b572ec-ab7d-4b5e-adb6-c8adb13f4936">71,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfOC0zLTEtMS0yNjAyMA_2de1c770-f62e-4ef6-a85d-2f628607ef15">22,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfOC01LTEtMS0yNjAyMA_a2f4e613-a2be-473c-8515-53dfaf707642">9,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfOC03LTEtMS0yNjAyMA_3ad098a9-74cb-4149-b3bf-f612ac60fce3">7,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTEtMS0xLTEtMjU1ODY_f5eb7ac4-9239-41c3-a0a9-9623646e6cdf">196,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTEtMy0xLTEtMjU1ODY_61523968-dae8-4e1e-b98f-983ef033538b">117,886</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTEtNS0xLTEtMjU1ODY_46d791d0-3ee7-448d-829d-93519627a9f7">176,547</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTEtNy0xLTEtMjU1ODY_70158be9-2a36-4732-889e-dfb10ab9b66d">113,437</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share applicable to common stockholders - basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTItMS0xLTEtMjYwMjA_0491aa71-54bc-4b66-9bec-f2b64c2840ba">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTItMy0xLTEtMjYwMjA_83142186-22ee-4fcb-a4dc-07ccfe713c47">0.19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTItNS0xLTEtMjYwMjA_d690b649-b547-45ab-94b9-8802576ec7b5">0.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTItNy0xLTEtMjYwMjA_77f19f48-27e6-44b5-8fcc-1562367a81e2">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dilutive Earnings (Loss) Per Share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTYtMS0xLTEtMjU1OTE_28ec05a8-089a-40de-b321-eb1587af3d66">71,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTYtMy0xLTEtMjU1OTE_d140548e-96b9-43cb-bfcc-76b3f452821e">22,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTYtNS0xLTEtMjU1OTE_e80dcbff-66c7-475d-b405-e827d9b90771">9,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTYtNy0xLTEtMjU1OTE_980e528e-ca88-439f-abdd-ae19ecf55ea2">7,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Deemed Dividend</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTctMS0xLTEtMjU1OTE_1ac000c4-a5bb-468f-80bb-145313086f51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTctMy0xLTEtMjU1OTE_0de94fb5-157d-454e-bf6b-fccf79a7a63b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTctNS0xLTEtMjU1OTE_6e11f28a-de1e-4544-8779-9b9d609fbb9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTctNy0xLTEtMjU1OTE_eb5815bb-d833-48cc-9da8-8fb8c1ad9168">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income attributable to participating securities - diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTgtMS0xLTEtMjU1OTE_a57413fa-88af-446c-8b45-ac79d64526ae">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTgtMy0xLTEtMjU1OTE_9c60bb4e-cb83-4a62-a756-74bfef371894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTgtNS0xLTEtMjU1OTE_cad5cc6c-2167-4239-9e28-062e2dbbd888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTgtNy0xLTEtMjYwMjA_e119ba09-1316-4674-b2ce-4bcc08abdeec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)  attributable to common stockholders - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTktMS0xLTEtMjYwMjA_45c8ce52-a5b6-45d2-a22d-f0f0bfb0a329">71,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTktMy0xLTEtMjYwMjA_bd083888-02c1-45e6-b900-c79eb823337d">22,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTktNS0xLTEtMjYwMjA_72769564-f19c-43cf-bfb2-ffe6e385ddc9">9,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTktNy0xLTEtMjYwMjA_95d5d59c-c08f-4aed-8ebb-ab9b136d8cd3">7,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjItMS0xLTEtMjU2MDI_48178140-134b-4351-b024-7a5aa8403c67">196,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjItMy0xLTEtMjU2MDI_370bc635-e711-4dce-bf5d-f1b983b748b4">117,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjItNS0xLTEtMjU2MDI_bd49ee3d-c84a-4259-8173-87fcbd235a75">176,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjItNy0xLTEtMjU2MDI_05ef5c81-1e7f-44b7-a1bb-e4f01b6a8a44">113,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive impact from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjUtMS0xLTEtMjU3NjA_1d42b603-ba84-4e9d-bd80-8609af65c245">4,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjUtMy0xLTEtMjU3NjA_76f92937-76e2-42c2-b684-b546068821c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjUtNS0xLTEtMjU3NjA_acbfad74-bd76-4d39-b8d4-ae82ef4f0710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjUtNy0xLTEtMjU3NjA_cbfb22de-950f-4789-8a57-45d692e2abb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding <br/>- diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjYtMS0xLTEtMjYwMjA_391a675f-c148-446a-b8d6-c19f37b24f25">201,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjYtMy0xLTEtMjYwMjA_46262594-4aad-44bf-abfe-022b5a90846d">117,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjYtNS0xLTEtMjYwMjA_931d1137-120a-4253-826e-bfdc68e75a8c">176,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjYtNy0xLTEtMjYwMjA_11ea2f15-6a73-437c-9dc8-1fd4e8f53563">113,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share applicable to common stockholders - diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjctMS0xLTEtMjYwMjA_a33f4001-1930-4af7-b501-a747c211a654">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjctMy0xLTEtMjYwMjA_b204da15-7d4b-4f43-a18b-df9561472bd3">0.19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjctNS0xLTEtMjYwMjA_c3583037-be32-4f39-bebe-64df042d8cde">0.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjctNy0xLTEtMjYwMjA_d0d9d805-ee30-4278-bf39-3dacb989b069">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RleHRyZWdpb246NzBhNzkwM2E2ODVhNGM4NTk3ZjA5NmVjMDFiZDgzZmJfMjg0Mw_617baf07-fd44-49a5-b4b7-ecda497c95a7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of September&#160;30, 2021 and 2020 have been excluded from the denominator of the diluted income (loss) per share of common stock outstanding calculation as their effect is anti-dilutive.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92cad4084294782890738c13756e328_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMi0xLTEtMS05MDEy_d77f9ece-dc21-4adc-8c80-b20d1c50b9d7">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib500bf44eae5476d9fdf2b96b6e0d1d7_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMi0zLTEtMS05MDEy_205ac309-3248-4855-a80f-58662a9ef91e">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87670fceac7f42239018c3f8b55269ad_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMi01LTEtMS05MDEy_95dd5bbc-b942-41ef-a5fb-f9f1cde0cda0">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23062afacb1848248023392b8378bd19_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMi03LTEtMS05MDEy_194d9312-bd54-4ae4-bcf1-206e94ed85df">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i079b1e485a6a4b42a083e958ffce61c2_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMy0xLTEtMS05MDEy_39515396-b843-497e-b632-39b384d45f6d">11,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c43cdc3ac654396a4484ffac139d4b2_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMy0zLTEtMS05MDEy_a46f9128-e8fc-412d-862d-cfaae09c39ec">10,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fb6380fa09c4290abc4c61a23509a0c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMy01LTEtMS05MDEy_1b51aa5c-58f0-49e6-a18b-a79531299782">15,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23f2a7e233df4d15a0180432313c57a9_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMy03LTEtMS05MDEy_2cb76f46-221c-4050-898d-cfae441de306">10,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfNC0xLTEtMS05MDEy_c700f073-c46d-4373-ba48-fb22903707bd">11,328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfNC0zLTEtMS05MDEy_4bd413ac-e39a-4390-a56c-bfc2cddc7d1e">12,712</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfNC01LTEtMS05MDEy_31afb673-d5f3-409c-9729-b7eac4779681">15,710</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfNC03LTEtMS05MDEy_15d30504-18d3-491a-8f65-72cf64c417f5">12,712</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_64"></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDgxNg_d7e7d33b-8b88-4752-af33-8de33f44f54f" continuedAt="iafc6f5194c46467dacbfa8834b56ba21" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="iafc6f5194c46467dacbfa8834b56ba21" continuedAt="i3b047a20597a488ba651f7ef0a59a760"><div style="margin-top:6pt"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDgxOA_10c7b3b2-6467-4c64-9132-d62aa68129b1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its condensed consolidated statements of income (operations) and comprehensive income (loss) for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ed6768ea3b4560b2c82d895f9ea130_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMi0xLTEtMS05MDEy_5a434e1c-28ab-471e-a003-73e7b7c5fe4c">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e8e8e954db04e80ad3a16adadbfc86f_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMi0zLTEtMS05MDEy_19fdb9b1-351a-4db8-9321-82cce3e7f4ef">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81f556c7f3c49bd8d272a05a36ddb60_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMi01LTEtMS05MDEy_404e2d05-0a0c-43cb-888e-15bd516d3a59">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d48ee562070454db26870e4c0814801_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMi03LTEtMS05MDEy_d4497392-97c7-4751-99bd-eb8877923e94">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8f1e5ffe2b4317a81ef1b3efe55cdb_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMy0xLTEtMS05MDEy_161ab03f-0999-45da-b1a2-48f0455cd43e">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c2750e9d614718ab26e1de3cd36e4b_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMy0zLTEtMS05MDEy_d32dc1c9-1e20-457a-a6dc-758a80345f55">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac03a2fc4741476e8ed3f485593ae492_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMy01LTEtMS05MDEy_abd5d39a-00cc-47a0-8b46-2b24da89d00e">2,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12438f69900b46c898f17d03af72571f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMy03LTEtMS05MDEy_3e15d7c1-91e5-4391-b157-2f354e729865">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfNC0xLTEtMS05MDEy_d0f38a63-f571-4ff1-aa98-9b3a09f12780">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfNC0zLTEtMS05MDEy_9f4af30e-6a5e-4348-96c2-f97a015bc50b">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfNC01LTEtMS05MDEy_5d3546db-3bb7-4b22-8bee-6de1f66a20ce">3,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfNC03LTEtMS05MDEy_91688025-841e-4cf3-9dcf-2a13385afa86">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended ("2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by <ix:nonFraction unitRef="shares" contextRef="i99f44079082f4029859d1879bcb92442_D20190601-20190630" decimals="-3" format="ixt:num-dot-decimal" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTU4Mw_e61dcd1c-cdb0-44a1-9c36-ba9e39b76af2">7.9</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by <ix:nonFraction unitRef="shares" contextRef="ib66fca9e5de8456b900bc5c4eff17509_D20210501-20210531" decimals="-3" format="ixt:num-dot-decimal" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMjA1Mg_3e39e358-6c80-4e63-a7d5-f53ffe882c03">12</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately <ix:nonFraction unitRef="shares" contextRef="if6ccec642f85408396200523b237087c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMjE2MA_4b58f7c4-24f6-434e-93e4-1f15d2bb7d6a">12.0</ix:nonFraction>&#160;million shares of common stock available for issuance under the 2014 Plan as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a <ix:nonNumeric contextRef="i3a6396e7d05347c98d3c1b2c891d6ee3_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDM5ODA0NjU1MDU5Ng_8f1ba1d8-2273-4c8a-9bef-dcff562bf580">four-year</ix:nonNumeric> period at the rate of <ix:nonFraction unitRef="number" contextRef="i3c4abb48a5d14a81b4f1e923deb97260_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NDU2MQ_c6b8e37e-87a0-4e03-8884-e0212e06b8c7">25</ix:nonFraction>% of the grant vesting on the first anniversary of the date of grant and <ix:nonFraction unitRef="number" contextRef="ide409042192a4d70ab470516112033d4_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NzI1OA_4ed6d963-7808-4c5c-b1a0-0e730c02cdb1">6.25</ix:nonFraction>% of the grant vesting at the end of each successive three month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of <ix:nonNumeric contextRef="i3a6396e7d05347c98d3c1b2c891d6ee3_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NDYyMg_2991dba5-06f2-4213-ba99-930345db1d59">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="if6ccec642f85408396200523b237087c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NDU4Nw_710284d9-a301-4e06-88aa-3bb07176c222">12.7</ix:nonFraction> million stock options outstanding under the 2014 Plan as of September&#160;30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated ("2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i3b047a20597a488ba651f7ef0a59a760"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercisable for a period of <ix:nonNumeric contextRef="i2c7f2bf3ddf5406f8bc9acdceac07628_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMzE2OA_5d85fe3e-4aee-468c-9aa7-44b292d69976">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i2c7f2bf3ddf5406f8bc9acdceac07628_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMzIyMA_7f9b31d3-8a53-480a-af15-b94f3ebe4842">0.1</ix:nonFraction> million fully vested stock options outstanding under the 2009 Plan as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately <ix:nonFraction unitRef="shares" contextRef="i4063b8153be44ce181d918f92b6ef50e_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMzcyNw_f973dbf7-c9aa-4e21-a8c9-4b04886fe46a">2.6</ix:nonFraction> million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDgyMw_1ab7dcf4-5ac8-49d5-8b5f-daa0c271847c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the nine months ended September 30, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Exercise Price per Option</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Remaining Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMS0xLTEtMS05MDEy_628fba90-f178-4d5f-9b5e-68700b1f258f">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMS0zLTEtMS05MDEy_3a199556-d015-494b-ac2e-381db5e122c6">1.26</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8d3a64a89d7413aa462e07545736067_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMS01LTEtMS05MDEy_120e68c6-8905-4466-8b21-f8e68a6a2f24">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMS03LTEtMS05MDEy_eb614063-6d2e-4405-a9a5-66205f77777f">3,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMi0xLTEtMS05MDEy_bf4c2a4e-526d-45ec-b0bd-a6c318db7240">8,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMi0zLTEtMS05MDEy_e63bdd43-ffb3-40e9-ad97-f1dde22a22a5">3.40</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMy0xLTEtMS05MDEy_c4ae705a-c31d-448d-af31-de2703948c90">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMy0zLTEtMS05MDEy_b0def66e-2b7c-4f5d-897b-7c35908bc351">1.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNC0xLTEtMS05MDEy_25fecbd7-be45-4ec7-a7f1-f81cbd8de554">2,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNC0zLTEtMS05MDEy_7a583e50-faae-4a78-93a1-7a11e4378456">3.75</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNS0xLTEtMS05MDEy_76c8eef8-4bf9-427b-a002-ae08fd6f7ebe">15,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNS0zLTEtMS05MDEy_db073b9d-52aa-4aaa-a9e8-ef62b56b9206">1.95</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNS01LTEtMS05MDEy_a68cd6e0-c9de-4962-9420-ab6221a3cfc2">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNS03LTEtMS05MDEy_ad71ae70-4a80-4cab-b73d-dc8d159af003">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNi0xLTEtMS05MDEy_90739fa7-2178-4eaa-8513-43a4dd80f383">6,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNi0zLTEtMS05MDEy_c2f820bc-66e5-4ddd-ad01-e1ac17f1ae11">1.61</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNi01LTEtMS05MDEy_d4bca69a-450b-4a1b-b5d7-0e5b9c0c0a75">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNi03LTEtMS05MDEy_5ae2b426-3a4b-4f60-b509-759bd5722f3c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense related to stock options of $<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDE2Nw_ad2d6fd3-943c-4a6e-a8fb-0ba817ae4a14">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDE3NA_1fadff09-a28c-4ac1-b7d1-e81486f386e4">3.4</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2021, respectively and $<ix:nonFraction unitRef="usd" contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDIwNg_6cadb380-87b2-4eb3-95a1-fe4f5d21ec94">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDIxMw_8dddc798-3660-4eae-ae53-c6bc4d8242bb">1.4</ix:nonFraction>&#160;million for the</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2020, respectively. As of September&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDI2Mg_b4089faa-75ab-4ef3-8307-ccb88a495cd8">11.5</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDQxNA_a1207ade-e482-4e0f-a1a0-4c452487087f">2.83</ix:nonNumeric> years. The weighted-average grant-date fair value of stock options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDQ5Ng_2682ad9c-f7f6-4b7a-8234-782708896bc5">2.20</ix:nonFraction> per option for the nine months ended September 30, 2021 and $<ix:nonFraction unitRef="usdPerShare" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NzI2Mg_2950f479-ebc3-4acf-b03b-a00f8d0ec22f">0.56</ix:nonFraction> per option for the nine months ended September 30, 2020. The total intrinsic value of stock options exercised during the nine months ended September 30, 2021 was de minimis.</span></div><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDgxOQ_52f54050-127a-4094-a117-07361fcca52e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMS0xLTEtMS05MDEy_df187fb6-1400-452f-82e4-85da4dc9e479">3.40</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMS0yLTEtMS05MDEy_c0487f3d-ed53-42b1-aa15-14c6f249cc92">0.87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMi0xLTEtMS05MDEy_d89fce2d-fde3-49b7-a2bf-ab11d599d321">3.40</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMi0yLTEtMS05MDEy_09ede7c3-c1c0-4a81-90c8-5afc313ddd58">0.87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMy0xLTEtMS05MDEy_0e86cb95-8643-4f36-85b4-fad41d7e0227">6.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMy0yLTEtMS05MDEy_863c2eb9-ac9e-4693-9fc4-78abc3b55c34">6.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNC0xLTEtMS05MDEy_ffea81f8-b161-4123-b019-3c9151c8cad2">0.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNC0yLTEtMS05MDEy_8ae47c6d-0b4d-4926-9bd6-6df7104e982f">1.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNS0xLTEtMS05MDEy_b862b9d3-3a8c-43d3-bba3-d17fa3d597c6">74.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNS0yLTEtMS05MDEy_5f516acb-f925-4386-bce3-44ccba74f959">71.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNi0xLTEtMS05MDEy_10984c1f-0f0a-47a6-9fec-471cc077fa08">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNi0yLTEtMS05MDEy_02b9df70-9975-4b40-b3e0-b064f7bc4352">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0b6b8a80699f4ebca69187de21a4e617_67"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMjQ0MA_cb730b22-dd48-4f8f-bd78-40556fa7cd24" continuedAt="i88ad7344ae45473a8991a6b072f8ce34" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i88ad7344ae45473a8991a6b072f8ce34" continuedAt="i2f9b57bc1a8e4fb2b706e2572f2c22fa"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of <ix:nonFraction unitRef="shares" contextRef="i8ac93b032a464cdd8545afbe5796bd81_I20140228" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMzg2_eecaa350-e088-468e-a171-b39246dc3b6d">0.2</ix:nonFraction> million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by <ix:nonFraction unitRef="shares" contextRef="i4cb66b6b5cfd47af8f6c6a3efea03f81_D20210501-20210531" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfNjE2_93090480-c7e3-424b-aab3-5b52d81a7a18">2.3</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i2f9b57bc1a8e4fb2b706e2572f2c22fa"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="i3fffc682fabb44acb6f7a3985fe6f99d_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfOTYz_82c68667-70ce-4c22-a09a-5d1ece01ce15">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of September&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i4100955bccbe4c1ca4b78e3cf52bfe56_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMTM3Ng_9e63cd70-bda6-4f38-a8c2-5e802d2143ed">2.3</ix:nonFraction>&#160;million shares of common stock available for sale under the 2014 ESPP. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its U.S. employees. Employees are eligible to participate immediately upon their date of hire. Under the 401(k) plan, participating employees may defer up to <ix:nonFraction unitRef="number" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMTc0Ng_f02a0a07-8916-4ef8-8919-f7169d3966a2">100</ix:nonFraction>% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum $<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMTk0Mg_55e7038a-c5b5-4119-99be-179fcea3947a">4,000</ix:nonFraction> per year. The expenses incurred for the periods presented were de minimis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first <ix:nonFraction unitRef="number" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMjI5MQ_e066478d-444d-4d9f-b939-04419e8cf433">4</ix:nonFraction>% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis.</span></div></ix:continuation><div id="i0b6b8a80699f4ebca69187de21a4e617_1137"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl80Mzk4MDQ2NTE0NDYw_b724ef26-2f1b-4d42-9ae2-a5954733dead" continuedAt="i5f06bdd4ec624abd8f948be0305f988a" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i5f06bdd4ec624abd8f948be0305f988a" continuedAt="i45043dc67f87407381fc50e4da279062"><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl80Mzk4MDQ2NTE1MTA1_260f0b37-25fb-4ca2-9111-609c5a45c3d4" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:63.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl8zLTEtMS0xLTI0NjQ5_953896b8-6e3d-4fb3-9b7e-a867b5cebc4d">38,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl8zLTMtMS0xLTI0NjQ5_a711bcbb-d8c4-4276-b5e3-4339c415fc53">18,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl80LTEtMS0xLTI0NjQ5_5349558d-65ee-4a76-8446-3fbc4b9d84e0">21,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl80LTMtMS0xLTI0NjQ5_fac3d362-d2ea-46a0-8c7a-660e9071e5fd">12,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl81LTEtMS0xLTI1NDI5_0bdc7881-7b7b-43b0-8d46-e7fdd6f260b9">17,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl81LTMtMS0xLTI1NDI5_0c748119-c6ab-43c3-9b28-0c3ed2d5dc9f">6,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl80Mzk4MDQ2NTE1MTA4_0b87aa4c-defb-4310-b0d2-2bac9c470690" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:63.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Benefit (Provision):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV8zLTEtMS0xLTI1MDU5_b2e2d84b-d568-4a9d-abdd-7b90f3692ad1">8,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV8zLTMtMS0xLTI1MDU5_47299229-1f01-4bc7-99d8-4efe2e7da9fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV80LTEtMS0xLTI1MDU5_59af3eda-0666-4f12-9e1b-7ec0fd5c970e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV80LTMtMS0xLTI1MDU5_90edf4b0-94b6-48fb-874d-d59472257354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV81LTEtMS0xLTI1MDU5_8a298082-5c8d-4966-8bc6-64388ab0104d">286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV81LTMtMS0xLTI1MDU5_36d5de92-35e3-4e72-96a6-9f4020f2d518">1,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Benefit (Provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV82LTEtMS0xLTI1MDU5_d42248c9-e6ca-4de3-a38b-d51aeb53e2cf">8,273</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV82LTMtMS0xLTI1MDU5_0e7a81ba-0100-496c-9af6-6593703c847b">1,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl80Mzk4MDQ2NTE1MTA5_ed2794af-085f-4703-8e70-5632b219112b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:63.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="sesn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8zLTEtMS0xLTI0OTAy_55bb7240-13dd-486c-9a6b-cf3d1fd303e2">3,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="sesn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8xMC0zLTEtMS0yNDgwOQ_3bd56da5-6687-4ec7-bf10-1fc2a90cc9cf">12,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8zLTEtMS0xLTI1NDQy_e1dc4790-b402-41a2-944d-66ef1882f5e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8xMS0zLTEtMS0yNDgwOQ_fab3c77a-2855-4b67-b82b-dae5f1b45f76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Deferred Tax Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF80LTEtMS0xLTI1NDQy_43a9e9f9-a4ef-4348-8ab9-5f407a065506">3,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8xMi0zLTEtMS0yNDgwOQ_24f9d774-c522-4a80-ac7d-16b5a73f8031">12,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, the Company recorded a benefit from income taxes of $<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl8xNjQ5MjY3NDQ2OTQ2_43bc89a7-1857-41e2-a501-e9d2b36a329a">8.3</ix:nonFraction>&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021, the Company determined that the fair value of the Vicineum United States rights was zero, which resulted in an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl8xNjQ5MjY3NDQ3MDQ2_6fd529e8-d144-4c78-aca9-17023216b167">31.7</ix:nonFraction>&#160;million. In connection with this impairment charge, in the third quarter of 2021, the Company wrote-down the associated deferred tax liability by $<ix:nonFraction unitRef="usd" contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:DeferredTaxLiabilityImpairmentWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl8xNjQ5MjY3NDQ3MDMy_6dd8e36a-78ef-4643-b8e3-48a821496c6c">8.6</ix:nonFraction>&#160;million as a benefit. Please refer to Note 6, "Intangible Assets and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i45043dc67f87407381fc50e4da279062">Goodwill," for further information regarding the impairment charge. For the nine months ended September 30, 2020, the Company recorded a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl8xNjQ5MjY3NDQ2OTU0_15216db2-eaf0-40d4-af49-7bea1aa7255e">1.1</ix:nonFraction>&#160;million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the License Agreement with Qilu.</ix:continuation> </span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_70"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="sesn:LicenseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTgzNjY_69acee52-4ce8-49a0-815f-dbdadbcf047e" continuedAt="i4401f7e83d3b4f3a980c16eb862f730b" escape="true">LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i4401f7e83d3b4f3a980c16eb862f730b" continuedAt="i4c1b50f3b5df45f8bf15598d3ce74f39"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a License Agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same. These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $<ix:nonFraction unitRef="usd" contextRef="ibc91c1e2691446ca8ae6ebaf034e2270_D20210101-20210930" decimals="-4" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNTM2_bf467bf8-43f3-4390-89b0-d35c5b5ceb56">0.5</ix:nonFraction>&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a <ix:nonFraction unitRef="number" contextRef="i6b253e391e304883b5148ddaac3a9fd8_D20210101-20210930" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODU4_a1624b8a-0a0e-48f7-87d6-3fa59cf51f75">4</ix:nonFraction>% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is <ix:nonFraction unitRef="number" contextRef="i6b253e391e304883b5148ddaac3a9fd8_D20210101-20210930" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTEyOQ_3db67aeb-04cf-41e3-9df7-9db6e0f60201">10</ix:nonFraction>% or greater, provided that the royalty rate to Zurich may not be less than <ix:nonFraction unitRef="number" contextRef="i6b253e391e304883b5148ddaac3a9fd8_D20210101-20210930" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTIwNg_25331ca7-3838-459a-8689-58415a096ecd">2</ix:nonFraction>% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="i16e23dc0be574c6988f056e62ef032cd_D20201001-20201231" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementMilestoneAchievementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTU5OA_30d5bac9-010c-42a0-8524-4ba19d530f65">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9b9fbfe5c81f499888ab93c21e589337_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementMilestoneAchievementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTA5OTUxMTY0NjU3NQ_82a08939-7cb5-47fb-ab9f-5a0f7b4459e7">0.5</ix:nonFraction>&#160;million related to achievement of a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the three months ended December 31, 2020 and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the three months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents cover some key aspects of Vicineum. Under the terms of the License Agreement with Micromet, as of September&#160;30, 2021, the Company may be obligated to pay up to &#8364;<ix:nonFraction unitRef="eur" contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMjIyMw_caf986e6-519e-4575-b8f5-115e0d447f89">2.4</ix:nonFraction>&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $<ix:nonFraction unitRef="usd" contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMjM3MA_433274e9-c145-4dad-9f65-6839adf11534">2.8</ix:nonFraction>&#160;million at exchange rates in effect on September 30, 2021). The Company is also required to pay up to a <ix:nonFraction unitRef="number" contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMjYxNQ_604798b4-2f98-48be-bfba-a55bdbfc9e57">3.5</ix:nonFraction>% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to <ix:nonFraction unitRef="number" contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930" decimals="INF" name="sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMjc4NA_3977103f-792d-4529-a7b7-3b8f3cf5a238">1.5</ix:nonFraction>% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;<ix:nonFraction unitRef="eur" contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="sesn:LicenseMaintenanceFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzE3Nw_d56373ca-76e8-4753-8ab0-6a9b8492c426">50,000</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="sesn:LicenseMaintenanceFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzE5NQ_c1f8c839-8c90-4832-84d1-3eb77440948d">57,965</ix:nonFraction> at exchange rates in effect as of September 30, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of  &#8364;<ix:nonFraction unitRef="eur" contextRef="idd6eb0c1e7e34af989c1740d371026c8_D20201001-20201231" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementMilestoneAchievementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzM2NA_b55a4131-a61a-4899-a732-eaa6a07dff49">0.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="idd6eb0c1e7e34af989c1740d371026c8_D20201001-20201231" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementMilestoneAchievementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzM2OA_506b0981-ffae-4169-b51a-1e6a253a7f29">0.9</ix:nonFraction>&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ecember 2020. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="idf84269345dc45a9bd019d1e9ba53cbf_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementMilestoneAchievementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzU4OA_e0a39b8e-3a06-4ad4-a14a-a9667c7541c4">0.5</ix:nonFraction>&#160;million (approximately $<ix:nonFraction unitRef="usd" contextRef="idf84269345dc45a9bd019d1e9ba53cbf_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementMilestoneAchievementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzYwNg_43f69617-d745-4f7f-b698-a760705b4b62">0.6</ix:nonFraction>&#160;million) related to the submission of the Marketing Authorization Application ("MAA") to the European Medicines Agency (&#8220;EMA&#8221;) for Vysyneum&#8482; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. Under the terms of the License Agreement with XOMA, the Company is required to pay up to $<ix:nonFraction unitRef="usd" contextRef="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930" decimals="-4" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDIzMw_6f82d11a-9743-4bad-88e9-a0b22de82a6f">0.25</ix:nonFraction>&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#8217;s clinical development pathway. The Company is also required to pay a <ix:nonFraction unitRef="number" contextRef="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDU2Mw_5ff7a0e6-20c6-4dd8-8416-7869bccb60b2">2.5</ix:nonFraction>% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than <ix:nonFraction unitRef="number" contextRef="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDg4MQ_6bd1c7bb-efde-4df1-9807-e7d1b7bdcaa1">1.75</ix:nonFraction>% of net sales. In addition, the foregoing royalty rates are reduced by <ix:nonFraction unitRef="number" contextRef="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDk1NA_3243ed0a-da3d-4d90-9876-feb4c95f515e">50</ix:nonFraction>% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i4c1b50f3b5df45f8bf15598d3ce74f39" continuedAt="i10af07d963f849e7a014570da01bdd21"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the License Agreement with F. Hoffmann-LA Roche Ltd and Hoffman-La Roche Inc. (collectively, "Roche"), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal&#160;antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the License Agreement with Roche, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ic42971e76e3e4c0d9a0e368891e0d42c_D20160801-20160831" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjIxNg_9054da59-a266-4ba1-a4d2-e053e9c16469">7.5</ix:nonFraction> million in August 2016 upon the effectiveness of the License Agreement with Roche following approval by the Company's stockholders, and Roche agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="ic42971e76e3e4c0d9a0e368891e0d42c_D20160801-20160831" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAdditionalUpFrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjM4Nw_cb402c49-aa8e-45db-baae-572a0845fb00">262.5</ix:nonFraction>&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="id1d3fa03486b42c3b433ce8bdf6e4808_D20160801-20160831" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjU3Mw_de03c635-8b3e-4917-b9f6-b5b9cfaa76c0">197.5</ix:nonFraction> million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="id3ed448b11a8424c96a6b8d0eb2a1783_D20160801-20160831" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjcwMg_af4e5ac5-beb1-451c-8f02-e919a282a702">72.5</ix:nonFraction> million in development milestones, the next of which is $<ix:nonFraction unitRef="usd" contextRef="i30b08122198e489bbce9b4354ecc6c61_D20160801-20160831" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjc1Mw_db250387-eb77-45e6-8249-f13cee6194c2">20.0</ix:nonFraction>&#160;million for initiation of the first Phase II study, (ii) $<ix:nonFraction unitRef="usd" contextRef="i0fb8cc9e9e234566a44813522f65ed55_D20160801-20160831" decimals="-6" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjgwNQ_9c6c3118-a94b-4499-ab10-384ed2249c9f">50</ix:nonFraction> million in regulatory milestones and (iii) $<ix:nonFraction unitRef="usd" contextRef="ie0859c061dad4634bd9bf31be447575b_D20160801-20160831" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjg0Mw_ab6eaaa2-259c-449b-955f-eb7beec405d4">75</ix:nonFraction> million in commercialization milestones. In September 2016, Roche paid the Company the first development milestone of $<ix:nonFraction unitRef="usd" contextRef="ibc6ff2c6504a4ed1b6cfa6a5cbdb6eb9_D20160901-20160930" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjk1Ng_bbe35f89-b9e1-4059-a318-7d5853967d9a">22.5</ix:nonFraction>&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. Additional amounts of up to $<ix:nonFraction unitRef="usd" contextRef="i15b167efec9143cf989e99b7088a541a_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzEwNw_134653e4-e9ae-46cd-9340-696088be02b3">65</ix:nonFraction> million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from <ix:nonFraction unitRef="number" contextRef="i045d66e15494473e88b935c50abb8750_I20210930" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzM1Ng_4739cd77-6a82-45ab-92be-66bcc4703781">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i63e6b449973d4c2792e479ee587c6018_I20210930" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzM2Mg_cbfdafbd-bc22-4b21-ac18-605817fb9ccc">15</ix:nonFraction>% of net sales of potential future products containing EBI-031 and up to <ix:nonFraction unitRef="number" contextRef="ia7693b351b0846618d4fcdce51f3fe9e_I20210930" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzQzNg_7b00978d-783d-420a-a0b7-904758faeee4">50</ix:nonFraction>% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement with Roche provides for <ix:nonFraction unitRef="option" contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630" decimals="INF" format="ixt-sec:numwordsen" name="sesn:LicenseAgreementOptionPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzcwNQ_bbe3288c-70d8-404d-9fba-f753203ca87e">two</ix:nonFraction> &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $<ix:nonFraction unitRef="usd" contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630" decimals="-6" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODE5OA_3c572e6c-c887-4313-bf7c-9e902d468136">135</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630" format="ixt-sec:durday" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODIwOA_47f520dd-784e-4d51-b5ae-32e8c47f7dc2">30</ix:nonNumeric> days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a  Roche Licensed Product in either the United States or in the E.U., in which case Roche is required to pay the Company, within <ix:nonNumeric contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630" format="ixt-sec:durday" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODcxMg_13fd7a3b-ce8a-4906-bb4e-af6130895231">30</ix:nonNumeric> days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $<ix:nonFraction unitRef="usd" contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630" decimals="-6" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODgwNQ_48c5c88d-b2e0-4874-bb52-56d2c9bd1182">265</ix:nonFraction>&#160;million, which amount would be reduced to $<ix:nonFraction unitRef="usd" contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630" decimals="-6" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODg0Mg_0c846f2a-b5b9-43ce-908b-32efa3eb8ae1">220</ix:nonFraction>&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the E.U.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the License Agreement with Roche if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the License Agreement with Roche following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the License Agreement with Roche if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Licensed Product in the Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i10af07d963f849e7a014570da01bdd21" continuedAt="id554f8e275a749988c342e22a7872517"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="id7df092ca1e64946a1a0ac3ea4c32c84_D20200730-20200730" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTExMTI_89858895-07f0-411d-a1f1-a40d81230a63">12</ix:nonFraction>&#160;million, and milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="id7df092ca1e64946a1a0ac3ea4c32c84_D20200730-20200730" decimals="-6" format="ixt:num-dot-decimal" name="sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTExNTQ_979d846d-2dcc-421d-ab2a-10a0ebd53f1b">23</ix:nonFraction>&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Qilu also agreed to pay the Company a <ix:nonFraction unitRef="number" contextRef="id7df092ca1e64946a1a0ac3ea4c32c84_D20200730-20200730" decimals="2" name="sesn:BusinessCombinationRoyaltyPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTE0NTc_3ee0e869-2892-4a20-a457-7977546b89d6">12</ix:nonFraction>% royalty based upon annual net sales of Licensed Products in Greater China. The royalties are payable on a Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Licensed Product in a particular region or no data or regulatory exclusivity of a Licensed Product in a particular region.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Licensed Product necessary for Qilu to develop and commercialize the Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Licensed Product has been obtained.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement with Qilu will expire on a Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the License Agreement with Qilu for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the License Agreement with Qilu is terminated under certain circumstances.  The License Agreement with Qilu includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The License Agreement with Qilu is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606"), which was adopted effective January 1, 2018. In 2020, the initial transaction price was estimated to be $<ix:nonFraction unitRef="usd" contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ0NTY_b4a1e2a1-202d-4ca5-bfb0-00f1ee5eebc9">11.2</ix:nonFraction>&#160;million and was based on the up-front fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="ife38f0f87de845fe90d0a4d078d250cd_D20200101-20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ1MTI_92dbdb8b-4877-4341-8dfb-226a79c76819">12</ix:nonFraction>&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the License Agreement with Qilu represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $<ix:nonFraction unitRef="usd" contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ3MzA_25ef3b34-4ba9-46fa-aa7b-0cd59f12d309">11.2</ix:nonFraction>&#160;million of the total $<ix:nonFraction unitRef="usd" contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ3NDY_80165365-a409-4b08-bf3f-6f2f30b6975e">11.2</ix:nonFraction>&#160;million transaction price was considered earned and the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i3fe2301ff7fd49808ebec14107299e1c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ4MTQ_fa49730e-1ff5-4af5-b70f-658754151291">11.2</ix:nonFraction>&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i610ca7a4385742b085d50632419fb7f8_D20210101-20210331" decimals="-6" format="ixt:num-dot-decimal" name="sesn:BusinessCombinationMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTUwODc_82ffc158-d507-43d9-8926-49de1da79947">3</ix:nonFraction>&#160;million dollar milestone payment from Qilu, the first milestone payment out of the $<ix:nonFraction unitRef="usd" contextRef="i610ca7a4385742b085d50632419fb7f8_D20210101-20210331" decimals="-6" format="ixt:num-dot-decimal" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTUxNjU_b63d8070-66a9-49c5-bd1e-19a9099c7b3b">23</ix:nonFraction>&#160;million in potential milestone payments. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i610ca7a4385742b085d50632419fb7f8_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTUyMjI_db47d39f-ec44-4e50-b5df-37b3e76f05a2">2.8</ix:nonFraction>&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company recorded the outstanding $<ix:nonFraction unitRef="usd" contextRef="ib78e2ef0bd77468a99078bdc44ca15ac_I20210331" decimals="-5" format="ixt:num-dot-decimal" name="sesn:LicenseAgreementAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTUzNDY_e9d2a27b-89e0-40f9-95a3-56e40e33b772">2.8</ix:nonFraction>&#160;million to accounts receivables as of March 31, 2021 and received the payment as of June 30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ibc185febf435474dabf49a740bcc7f59_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTU3MjE_b6dfeec6-d3c1-46a9-950b-d3a1632c489f">0.9</ix:nonFraction>&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("the MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i7e4a691bd7f24cc8a757bf6eb9a87a8e_D20210101-20210331" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTY2NDc_ceafb377-28ef-4720-856b-13efc0a9f3ee">3</ix:nonFraction>&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $<ix:nonFraction unitRef="usd" contextRef="i4a6554c571ca414ea564532ae47c5f15_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTcwODQ_665fb962-3856-4f6f-82ae-bc7927fc888b">1.5</ix:nonFraction>&#160;million as of December 31, 2020 and was based on <ix:nonFraction unitRef="number" contextRef="i4a6554c571ca414ea564532ae47c5f15_I20201231" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTcxMjg_caa50bb3-a7bf-46d9-a1bd-79daee52df0a">50</ix:nonFraction>% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The Company also concluded that its agreements under </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="id554f8e275a749988c342e22a7872517" continuedAt="id91a3195a0b646bb8e184a8157968312"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $<ix:nonFraction unitRef="usd" contextRef="i7e4a691bd7f24cc8a757bf6eb9a87a8e_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTc3ODQ_a5e7464c-8ee0-4d23-8229-2fc66d92c5fe">1.5</ix:nonFraction>&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered.  As of September&#160;30, 2021,</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div></ix:continuation><div style="text-align:justify"><ix:continuation id="id91a3195a0b646bb8e184a8157968312" continuedAt="ic5e222adabc24dcb82db6e585ea8ed78"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 5, 2021, we entered into an exclusive license agreement with Eczacibasi Pharmaceuticals Marketing (&#8220;EIP&#8221;) pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the licensing agreement, we are entitled to receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia96662f1953a42bc873ffe3a7870d8b6_I20210805" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDM5ODA0NjUzMTUxMg_0615a3c8-1f39-48c0-9c62-03e281b41e5b">1.5</ix:nonFraction>&#160;million, are eligible to receive additional regulatory and commercial milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i136787f1fdff4cf289282d421587f27f_D20210805-20210805" decimals="-5" format="ixt:num-dot-decimal" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDM5ODA0NjUzNjA2Mw_18f47ebe-a294-40ba-a019-bec350fd8263">2.0</ix:nonFraction>&#160;million and are also entitled to receive a <ix:nonFraction unitRef="number" contextRef="i23457221904940608ad590d221ec55f2_I20210805" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDM5ODA0NjUzMTUyNg_a68a7b18-245e-48cb-a463-823d7825e6b6">30</ix:nonFraction>% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The EIP License Agreement is subject to the provisions of ASC 606 and as of September&#160;30, 2021, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No initial transaction price was estimated by management as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as the upfront payment is subject to a refund if certain regulatory approvals in the US are not obtained. The Company also concluded that its promises under this license agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2021,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ic5e222adabc24dcb82db6e585ea8ed78"> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</ix:continuation> </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_1118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGV4dHJlZ2lvbjpjNzYwZTYwMjg2YTM0MGYzYWJlZTcyZjRjZjdhYjdmY180Mzk4MDQ2NTEzNTg0_541e6947-f291-40c0-90a2-b9f5d330875b" continuedAt="ib1fd413535fd4fdca1634baf24fcd079" escape="true">RESTRUCTURING AND RELATED ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="ib1fd413535fd4fdca1634baf24fcd079"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Restructuring Plan included a reduction in the Company&#8217;s workforce by <ix:nonFraction unitRef="position" contextRef="i3294967843ca408b88c9279ce575d789_D20210830-20210930" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGV4dHJlZ2lvbjpjNzYwZTYwMjg2YTM0MGYzYWJlZTcyZjRjZjdhYjdmY180Mzk4MDQ2NTEzODMz_19382e21-99a2-4eaa-88fa-a12a6b403cf3">18</ix:nonFraction> positions (or approximately <ix:nonFraction unitRef="number" contextRef="i3294967843ca408b88c9279ce575d789_D20210830-20210930" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGV4dHJlZ2lvbjpjNzYwZTYwMjg2YTM0MGYzYWJlZTcyZjRjZjdhYjdmY180Mzk4MDQ2NTEzODM3_cc2370aa-0def-4fea-9d70-a250a7d2cf13">35</ix:nonFraction>% of the Company&#8217;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGV4dHJlZ2lvbjpjNzYwZTYwMjg2YTM0MGYzYWJlZTcyZjRjZjdhYjdmY180Mzk4MDQ2NTEzNTg1_6543dccb-046b-4f23-b802-0d9b0b8f3fa6" continuedAt="i24c17f1630854029a6d2300069494e5b" escape="true">The following is a summary of accrued restructuring costs related to the Restructuring Plan:</ix:nonNumeric></span></div><div><ix:continuation id="i24c17f1630854029a6d2300069494e5b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.130%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0910e0e2e544c658b3c5f01387c4bf7_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml8yLTEtMS0xLTIwMDM3_0a13cd4e-ddf0-431d-8a00-6cb21f1af522">2,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31980ac255374540a2c360974effe9e9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml8zLTEtMS0xLTIwMDM3_886e7c16-3a80-41f7-bcb7-7ab53db61109">2,730</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb45047e6e3464eb0f8a32d0685227a_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml80LTEtMS0xLTIwMDM3_b839e3f4-835b-4e3d-8e0f-e0d3688cb542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml81LTEtMS0xLTIwMDM3_7b162756-1a59-486d-8f90-82b69e2904ab">5,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml82LTEtMS0xLTIwMDQz_deb1cc10-1825-4d70-aeca-460c8b8dbc67">856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml83LTEtMS0xLTIwMDQ3_bc7d9aff-ba52-45d8-bedd-9fc22594ec4a">4,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company&#8217;s Condensed Consolidated Statements of Income (Operations) and Comprehensive Income (Loss) in the three months ended September 30, 2021. The Company expects that substantially all of the accrued restructuring costs as of September 30, 2021 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> of September 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_1124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTI0L2ZyYWc6NzBiNmEwNWYyMDVjNGFiMmJmNjJmODNiZTczMDZjYzQvdGV4dHJlZ2lvbjo3MGI2YTA1ZjIwNWM0YWIyYmY2MmY4M2JlNzMwNmNjNF80Mzk4MDQ2NTMzMzg3_a9f5ff65-fd04-4d2a-a083-bacf06b26c87" continuedAt="ifbe4a826a89840559e75a6e7537bfeb4" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ifbe4a826a89840559e75a6e7537bfeb4" continuedAt="i3bb46a498d6a4f2483c31c9f3c5f93fe"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Legal Proceedings </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 19, 2021, August 31, 2021 and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the U.S. District Court for the Southern District of New York.  The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH, and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dresaj collectively as the &#8220;lead plaintiff&#8221; under the Private Securities Litigation Reform Act.  On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff.  The court has not ruled on those motions at this time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the U.S. District Court for the District of Massachusetts, with the Company named as a nominal defendant. The two derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The two derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i3bb46a498d6a4f2483c31c9f3c5f93fe">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company.</ix:continuation> </span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_73"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183My9mcmFnOjAzMGU1Y2MxMWRlNDQzMWViNWNlNmQ4Nzg5NGJiZWJmL3RleHRyZWdpb246MDMwZTVjYzExZGU0NDMxZWI1Y2U2ZDg3ODk0YmJlYmZfMjEzMQ_d6c7c933-be07-4e8a-bfc3-18272d044267" continuedAt="i3abae96eb3de4f56b7fa9ebe563c2e83" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i3abae96eb3de4f56b7fa9ebe563c2e83"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Retention Program described in Note 11 above, and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately <ix:nonFraction unitRef="number" contextRef="i07777b364f564270bb6efdada23c4efe_I20211001" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183My9mcmFnOjAzMGU1Y2MxMWRlNDQzMWViNWNlNmQ4Nzg5NGJiZWJmL3RleHRyZWdpb246MDMwZTVjYzExZGU0NDMxZWI1Y2U2ZDg3ODk0YmJlYmZfNDM5ODA0NjUyMzcxNA_fe183808-192f-4293-859e-518dcbf813c6">50</ix:nonFraction>% of current base salary. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 29, 2021, the Company participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL. During the CMC Type A Meeting, the Company and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any potential future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. The Company is preparing for a separate Clinical Type A Meeting, which the Company expects to occur later this year.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form 10-Q, should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes thereto appearing elsewhere herein and our audited annual consolidated financial statements and related notes thereto and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) on March 15, 2021. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, the impact of the COVID-19 pandemic, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">our plans and ability to resolve the issues identified in the complete response letter (&#8220;CRL&#8221;) we received from the US Food and Drug Administration (&#8220;FDA&#8221;) regarding our Biologics License Application (&#8220;BLA&#8221;) for Vicineum&#8482; for the treatment of bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;)-unresponsive non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">our plans and ability to resolve the concerns identified in the European Medicines Agency&#8217;s (&#8220;EMA&#8221;) Withdrawal Assessment Report related to our marketing authorization application (&#8220;MAA&#8221;) for Vysyneum&#8482; (the &#8220;EMA Withdrawal Report&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">the Company&#8217;s belief that it has a clear understanding of what additional information regarding CMC is required for potential resubmission of the BLA for Vicineum;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">the Company&#8217;s ability to utilize Vicineum manufactured during process validation for any potential clinical trials needed to address issues raised in the CRL, and that any such potential clinical trials can proceed while addressing CMC issues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the Type A meeting to discuss the recommendations specific to additional clinical/statistical data and analyses that the FDA raised in the CRL to discuss next steps for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Clinical Type A Meeting&#8221;) and the anticipated timing of any such meeting; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our expectation that we will need to conduct an additional clinical trial for Vicineum for the treatment of BCG-unresponsive NMIBC to address questions related to clinical matters raised in the CRL;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">our intentions to use the information from the CMC Type A Meeting and the Clinical Type A Meeting to determine the appropriate path forward with regulators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">our plans and ability to resubmit the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA following the issuance of the CRL by the FDA, and if approved by the FDA, our ability to commercialize Vicineum for the treatment of BCG unresponsive NMIBC in the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">our plans and ability to resume pursuing regulatory approval of Vysyneum for the treatment of BCG-unresponsive NMIBC in the European Union when there is more clarity from the FDA on next steps for Vicineum in the US;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">our intentions to work closely with the FDA to understand next steps for Vicineum for the treatment of BCG-unresponsive NMIBC in the US;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our intentions to work closely with the EMA to understand next steps for Vysyneum for the treatment of BCG-unresponsive NMIBC in the European Union;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">our ongoing voluntary internal review by outside counsel and other experts on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety and effectiveness of Vicineum;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expected future loss and accumulated deficit levels;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulties and expenses associated with obtaining and maintaining regulatory approval of Vicineum for the</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of BCG-unresponsive NMIBC in the United States, the European Union and other foreign jurisdictions, and the labeling under any approval we may obtain;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectation that the first wave of potential country approvals for Vicineum for the treatment of BCG-unresponsive NMIBC in the MENA region may occur as early as 2025;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected financial position and estimated cash burn rate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our belief that we have sufficient future cash flows from additional geographic regions outside the US to support the value of our goodwill and EU IPR&amp;D;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our plans to continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of BCG-unresponsive NMIBC;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our estimations regarding any remeasurement of contingent consideration liability in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our estimations regarding any potential impairment to our goodwill and indefinite lived intangible assets in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for, and ability to obtain, additional</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to raise substantial additional capital to fund our operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost and timing of our pre-clinical studies and clinical trials in the United States and other foreign</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on third parties, including contract research organizations (&#8220;CROs&#8221;) in the conduct of our pre-clinical</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs associated with our manufacturing process and technology transfer to FUJIFILM Diosynth</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnologies U.S.A., Inc. (&#8220;Fujifilm&#8221;) for the production of Vicineum drug substance, and our reliance on Fujifilm</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to perform under our agreement with Fujifilm; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs associated with our manufacturing process and technology transfer to Baxter Oncology GmbH</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;Baxter&#8221;) for the production of Vicineum drug product, and our reliance on Baxter to perform under our agreement</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with Baxter; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs associated with our manufacturing process and technology transfer to Qilu Pharmaceutical Co.,</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ltd. (&#8220;Qilu&#8221;) for the production of Vicineum drug substance and drug product, and our reliance on Qilu to perform</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our agreement with Qilu;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our product candidates, including Vicineum for the treatment of BCG-unresponsive NMIBC, the</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">size and growth of the potential markets for our product candidates, and our ability to serve those markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategic operating plan to sublicense Vicineum for the treatment of BCG-unresponsive NMIBC to business development partners in all regions outside the US, including the EU, to earn a potential combination of upfront, milestone, and royalty payments, and the business development partner to bear the majority of regulatory and commercialization costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the amount and timing of milestone and royalty payments pursuant to our out-license</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements and business development partnership agreements, including our license agreement with F. Hoffmann-La</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) and our exclusive license agreement with Qilu for the</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development, manufacture and commercialization of Vicineum in Greater China;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to seek additional business development partnerships; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies and products that are or become available.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, among others, the following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to resolve the issues raised in the CRL we received from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to resolve the concerns identified in the EMA Withdrawal Assessment Report;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">after the CMC Type A Meeting and the Clinical Type A Meeting with the FDA to discuss our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, we may not have a viable path forward for continued clinical development of Vicineum, which would prevent us from resubmitting our BLA for Vicineum;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not achieve profitable operations or access needed capital;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, or any of our other product candidates, may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other foreign regulatory authorities or otherwise produce favorable results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not obtain marketing approval of Vicineum for the treatment of BCG-unresponsive NMIBC in the United</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States, the European Union, or other foreign jurisdictions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vicineum may not gain market acceptance for the treatment of BCG-unresponsive NMIBC in the United States, the European Union or other foreign jurisdictions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market opportunity for Vicineum may be limited to those patients who are ineligible for established therapies or for</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whom prior therapies have failed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience issues or delays with implementation of commercial-scale manufacturing of Vicineum;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to establish sales, marketing and distribution capabilities or scale up and validate external</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing capabilities of Vicineum (including completing the manufacturing process and technology transfer to</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any third-party manufacturers) for the treatment of BCG-unresponsive NMIBC in the United States, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors may discover, develop or commercialize products before, or more successfully than, we do;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to obtain, maintain, defend and enforce patent claims and other intellectual property rights; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to defend against pending or threatened litigation, which may be costly and time-consuming;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ongoing voluntary internal review by outside counsel and other experts on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety and effectiveness of Vicineum could result in significant expenses and other harm to our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to comply with all regulatory requirements or experience unanticipated problems with our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may recognize impairment of our goodwill and indefinite lived intangible assets; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such other factors described in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K and in Item 1A. Risk Factors in this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;Sesen,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Sesen Bio, Inc. and its subsidiaries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically fuse the targeting antibody fragment and the cytotoxic protein payload into a single molecule that is produced through our proprietary one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell.&#160;We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates ("ADCs") where a payload is chemically attached to a targeting antibody.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of BCG-unresponsive NMIBC. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 18, 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA. On February 12, 2021, the FDA notified us that it had accepted our BLA filing. The FDA also granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form, and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. On October 20, 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of Quality, Good Clinical Practice, Efficacy and Safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained. On</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 29, 2021, we participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL. During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any potential future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. We are preparing for a separate Type A Meeting to discuss the recommendations specific to additional clinical/statistical data and analyses that the FDA raised in the CRL, which we expect to occur later this year. We intend to use information from the CMC Type A Meeting and the Clinical Type A Meeting to determine the appropriate path forward with regulators.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we reported updated preliminary efficacy data from our ongoing single-arm, multi-center, open-label Phase&#160;3 clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). As of the May 29, 2019 data cutoff date, the preliminary complete response rates ("CRRs") in evaluable carcinoma </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in situ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("CIS") patients following three, six, nine and 12 months of treatment in the clinical trial were consistent with those observed in the previously completed Phase 1 and Phase 2 Vicineum clinical trials for the treatment of  NMIBC. The VISTA Trial completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment (under 2018 FDA guidance on treatment of NMIBC, adequate BCG is defined as at least two courses of BCG with at least five doses in an initial induction course of treatment, plus at least two doses in a second course of treatment): </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with or without papillary disease that were determined to be refractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that was determined to be refractory or recurred within six months of their last course of adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of the VISTA Trial were CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive and duration of response ("DoR") for BCG-unresponsive CIS patients who experience a complete response ("CR").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.158%"><tr><td style="width:1.0%"></td><td style="width:19.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Time Point</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evaluable Patients*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Complete Response Rate<br/>(95% Confidence Interval)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=82</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39% (28%-50%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=82</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26% (17%-36%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=82</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20% (12%-30%)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-months</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=82</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17% (10%-27%)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* Response-evaluable population includes any modified intention-to-treat ("mITT") patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.158%"><tr><td style="width:1.0%"></td><td style="width:19.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Time Point</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evaluable Patients*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Complete Response Rate<br/>(95% Confidence Interval)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=7</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57% (18%-90%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=7</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57% (18%-90%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=7</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43% (10%-82%)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-months</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=7</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% (0%-58%)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.158%"><tr><td style="width:1.0%"></td><td style="width:19.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Time Point</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evaluable Patients*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Complete Response Rate</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=89</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40% (30%-51%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=89</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28% (19%-39%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=89</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21% (13%-31%)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-months</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=89</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17% (10%-26%)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.000%"><tr><td style="width:1.0%"></td><td style="width:17.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Time Point</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preliminary Phase 3 Pooled CRR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2 Pooled CRR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40% (30%-51%)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40% (26%-56%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28% (19%-39%)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27% (15%-42%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21% (13%-31%)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18% (8%-32%)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-months</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17% (10%-26%)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16% (7%-30%)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate&#8224;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.158%"><tr><td style="width:1.0%"></td><td style="width:19.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Time Point</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evaluable Patients*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurrence-Free Rate</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=38</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71% (54%-85%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=38</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58% (41%-74%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-months</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=38</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45% (29%-62%)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-months</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n=38</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42% (26%-59%)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8224; Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) is 287 days (lower 95% confidence interval ("CI") = 154 days, upper 95% confidence interval is not estimable ("NE") due to the limited number of events occurring beyond the median), using the Kaplan-Meier method. The Kaplan-Meier method is a </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-parametric statistical analysis used to estimate survival times and times to event when incomplete observations in data exist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) shows that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted additional analyses for secondary endpoints based on the May 29, 2019 data cutoff date. These additional preliminary data include the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis shows that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy is a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with higher rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) is 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g. T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of May 29, 2019 data cut from the Phase III VISTA trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. Final numbers are pending. On August 13, 2021, the FDA issued a CRL for the BLA, which included requests for additional clinical and statistical data. We intend to discuss these topics with the FDA at a Type A meeting we expect to occur later this year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary Safety Results </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of  adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%) - all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5). There were no age-related increases in adverse events observed in the VISTA Trial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Vicineum Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, we submitted the completed BLA, including Module 3 (CMC), to the FDA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, the FDA notified us that it had accepted our BLA filing. The FDA also granted Priority Review for the BLA and a target PDUFA date for a decision on the BLA of August 18, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, we submitted our MAA to the EMA for Vicineum (oportuzumab monatox) for the treatment of BCG-unresponsive NMIBC under the EMA&#8217;s centralized procedure. We received notice on March 25, 2021 from the EMA that our MAA for Vicineum was found to be valid and that the review procedure had officially started.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 31, 2021, we were informed that the Committee for Medicinal Products for Human Use of the EMA had conditionally accepted the proprietary brand name Vysyneum for our product candidate, oportuzumab monatox, in the European Union. The name Vysyneum has identical pronunciation to the U.S. proprietary brand name Vicineum and was developed in accordance with the criteria outlined in the EMA&#8217;s Guideline on the acceptability of names for human medicinal products. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On July 13, 2021, we participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, we and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to CMC, and a timeline to submit additional supporting information was agreed upon.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve our BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on the next steps for Vicineum in the United States.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On September 17, 2021, we disclosed that we have voluntarily engaged outside counsel and other experts to conduct a review focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety and effectiveness of Vicineum. We expect to incur substantial costs in conducting this internal review, but because the internal review is ongoing, we cannot predict the duration, scope, or result of the review.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On October 20, 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of Quality, Good Clinical Practice, Efficacy and Safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained. We intend to use information from the CMC Type A Meeting and the Clinical Type A Meeting to determine the appropriate path forward with regulators.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 27, 2021, the FDA published a Warning Letter (the &#8220;FDA Warning Letter&#8221;) issued to a former study investigator in our VISTA trial for Vicineum arising from a 2021 FDA inspection related to the review of our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. We discontinued use of the clinical site and the study investigator over four years ago when we learned of professional misconduct by the study investigator that was unrelated to the VISTA trial. The FDA Warning Letter indicates that the study investigator did not comply with applicable statutory requirements and applicable regulations regarding conduct of clinical investigations. The study investigator operated a clinical site that was previously part of the VISTA trial, which was closed by us on May 26, 2017. The study investigator's medical license was temporarily suspended on May 29, 2017 due to inaccurate recordkeeping, which was unassociated with Sesen Bio and the patients in the VISTA trial. We notified the FDA of the misconduct at that time. When the clinical site was closed, five patients had completed treatment and were in post-treatment follow-up. There was no evidence found that patients were harmed by the study investigator&#8217;s actions. We included the corresponding patient data from the clinical site in its BLA submission to the FDA, which were thoroughly analyzed and discussed during the BLA review.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 29, 2021, we participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL. During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. We are preparing for a separate Type A Meeting to discuss the recommendations specific to additional clinical/statistical data and analyses that the FDA raised in the CRL, which we expect to occur later this year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2018, we entered into a Master Bioprocessing Services Agreement with Fujifilm (the "Fujifilm MSA") for the manufacturing process and technology transfer of Vicineum drug substance production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2019, the first full, commercial-scale current Good Manufacturing Practice (&#8220;cGMP&#8221;) run was completed at Fujifilm. Full quality release testing was completed and all Phase 3 release specifications were met, supporting Fujifilm&#8217;s ability to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">produce the bulk drug substance form of Vicineum for commercial purposes if we receive regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter for the manufacturing process and technology transfer of Vicineum drug product production.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2020, manufacturing of the pre-process performance qualification ("pre-PPQ") cGMP batch was completed at Fujifilm. Full quality release testing of the drug substance was completed and all quality acceptance criteria were met.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, we completed manufacturing of the drug substance PPQ batches at Fujifilm and in September 2020, we successfully completed the final of three drug product PPQ batches at Baxter. All of the completed drug substance PPQ batches and drug product PPQ batches met all quality acceptance criteria.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we received and analyzed all of the analytical comparability test results from the drug substance and drug product PPQ batches. For analytical comparability, we conducted testing across four categories: release testing, biophysical characterization, forced degradation studies, and stability studies. This approach is in alignment with requirements of the FDA, the EMA and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The test results for product intended for commercial use were found to be highly comparable to our clinical supply of Vicineum.  The comparability data from the PPQ campaigns for both drug substance and drug product were the final material components of our completed BLA, which was submitted to the FDA on December 18, 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2020, we entered into a commercial manufacturing and supply framework agreement with Qilu (the "Qilu Framework Agreement") for Qilu to be a contract manufacturer for the global commercial supply of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, we signed a Scope of Work (" SOW #10") with Fujifilm under the Fujifilm MSA for the manufacturing of commercial batches of Vicineum in 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2021, we amended and replaced the Qilu Framework Agreement and entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for global commercial supply of Vicineum drug substance and drug product. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 29, 2021, at the CMC Type A Meeting, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any potential future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Outside of United States ("OUS") Business Development Partnering</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. ("Qilu") pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan ("Greater China"). We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retain (i) development and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received a total of $10 million in net proceeds associated with the Qilu License Agreement. We are also entitled to receive up to an additional $23 million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i) twelve years after the first commercial sale of Vicineum in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii) the expiration of regulatory or data exclusivity for Vicineum in such region. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Investigational New Drug application ("IND") for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. We recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of value-added tax ("VAT") recovery. As such, we recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. We will not be subject to VAT on future potential milestone payments. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we entered into an exclusive license agreement with Hikma Pharmaceuticals LLC ("Hikma") (the &#8220;Hikma License Agreement&#8221;) pursuant to which we granted Hikma an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, to commercialize Vicineum in the MENA region. We retain development and commercialization rights in the rest of the world excluding Greater China and MENA. In consideration for the rights granted by us, Hikma agreed to pay to us an upfront payment, sales related milestones payments, and royalties and on net sales in the MENA region for the term of the Hikma License Agreement. We continue to work closely with our partner, Hikma Pharmaceuticals, to submit marketing authorization applications for Vicineum in 2021 in seven key markets in the region: the Kingdom of Saudi Arabia, Jordan, Morocco, Egypt, Lebanon, Kuwait and Algeria. These seven markets represent a significant opportunity in the MENA region, as Saudi Arabia, Jordan and Morocco have some of the most advanced healthcare systems in the region while Egypt is the second largest economy in Africa. We anticipate the first wave of potential country approvals for Vicineum in the MENA region as early as 2025.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 5, 2021, we entered into an exclusive license agreement with Eczacibasi Pharmaceuticals Marketing (&#8220;EIP&#8221;) pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the licensing agreement, we are entitled to receive an upfront payment of $1.5 million, which we agreed to defer the payment of this amount until the conclusion of our Type A meetings with the FDA. We are also eligible to receive additional regulatory and commercial milestone payments of $2.0 million and are entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. We have deferred the upfront payment due from EIP until conclusion of the Type A meetings with the FDA which are expected to be completed by the end of 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">National Cancer Institute </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2017, we entered into a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with the National Cancer Institute (&#8220;NCI&#8221;) for the development of Vicineum in combination with AstraZeneca&#8217;s immune checkpoint inhibitor durvalumab for the treatment of BCG-unresponsive NMIBC. Vicineum is believed to work via a dual mechanism of action to directly kill cancer cells and activate a local inflammatory process that stimulates T-cells, which then proliferate and destroy the cancer cells. Because of this second mechanism, there may be potential for a synergistic effect when given in combination with checkpoint inhibitors. This hypothesis is being tested by the NCI in a Phase 1 clinical trial in patients with BCG-unresponsive NMIBC to evaluate the safety, efficacy and biological correlates of Vicineum in combination with durvalumab (&#8220;NCI Trial&#8221;). This Phase 1 clinical trial is open and actively recruiting patients.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Related Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue consists of revenue recognized pursuant to our OUS business development partnership agreements which is assessed under ASC 606. In the future, we may generate revenue from a combination of up-front payments, milestone payments and royalties in connection with our OUS business development partnership agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of Vicineum for the treatment of BCG-unresponsive NMIBC, which include:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the nature and scope of activities required to resolve the CRL issued by the FDA in response to our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, which we expect will include the completion of an additional clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and share-based compensation expense;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations ("CROs") and investigative sites that conduct our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with transferring manufacturing capabilities to contract manufacturing organizations ("CMOs") for commercial-scale production;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with regulatory activities; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with license milestone fees</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of Vicineum for the treatment of BCG-unresponsive NMIBC is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, outcome and costs of our clinical trials and other research and development activities, including future clinical trials for Vicineum for the treatment of BCG-unresponsive NMIBC;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages of Vicineum for the treatment of BCG-unresponsive NMIBC compared to alternative treatments, including any standard of care;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market acceptance of Vicineum for the treatment of BCG-unresponsive NMIBC;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of the implementation of commercial-scale manufacturing of Vicineum;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant and changing government regulation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and terms of any marketing approvals.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A change in the outcome of any of these variables with respect to the development of Vicineum for the treatment of BCG-unresponsive NMIBC could mean a significant change in the costs and timing associated with the development of Vicineum for the treatment of BCG-unresponsive NMIBC. For example, we expect needing to conduct an additional clinical trial to address clinical issues raised in the CRL from the FDA. If the FDA, EMA or another regulatory authority were to require us to conduct clinical trials or other testing to complete the clinical development of Vicineum for the treatment of BCG-unresponsive NMIBC, we could be required to expend significant additional financial resources and time on the completion of clinical development of Vicineum for the treatment of BCG-unresponsive NMIBC. We expect our research and development costs to relate to Vicineum for the foreseeable future as we seek to resolve the CRL issued by the FDA with regard to our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the EMA Withdrawal Assessment Report, and obtain regulatory approval for Vicineum in the US and the European Union, and if successful in obtaining such regulatory approvals, advance Vicineum through the commercialization scale-up, clinical and other activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, costs related to manufacturing or purchasing clinical trial materials and technology transfer and license milestone fees, to specific product programs. We do not allocate employee and contractor-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product programs because these costs may be deployed across multiple product programs under research and development and, as such, are separately classified. The table below provides research and development expenses incurred for Vicineum for the treatment of BCG-unresponsive NMIBC and other expenses by category. We have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deferred further development of Vicineum for the treatment of squamous cell carcinoma of the head and neck and VB6-845d in order to focus our efforts and our resources on our ongoing development and, if approved, commercialization of Vicineum for the treatment of BCG-unresponsive NMIBC. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not allocate research and development expenses to any other specific product program during the periods presented (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Programs:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum for the treatment of BCG-unresponsive NMIBC </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct program expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,888&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,005&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel and other expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and contractor-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform-related lab expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total personnel and other expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 68.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Research and Development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation and benefits, in executive, operational, finance, business development and human resource functions. Other general and administrative expenses include facility-related costs, professional fees for legal, insurance, investment banking fees, patent, consulting and accounting services, pre-commercial United States market research and pre-launch market readiness for the potential launch of Vicineum. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Restructuring Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). The Restructuring Plan includes a reduction in our workforce by 18 positions (or approximately 35% of our workforce) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum. Restructuring costs related to the Restructuring Plan were recorded in operating expenses in our Condensed Consolidated Statements of Income (Operations) and Comprehensive Income (Loss) in the three months ended September 30, 2021. We expect that substantially all of the accrued restructuring costs as of September 30, 2021 will be paid in cash by the end of September 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Intangibles Impairment Charge</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed. The fair value of the acquired intangible asset for the U.S. and E.U. rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. . In August 2021, we received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, our lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. We participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expect to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss the clinical issues raised in the CRL. Both meetings are intended to help us determine the appropriate path forward for Vicineum. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, an impairment analysis was conducted, which concluded that the carrying value of our intangible assets of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges for the period ended September 30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">expected future cash flows estimated in the US market as of September 30, 2021. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of our intangible assets of Vicineum E.U. rights, this asset was not impaired as of September 30, 2021. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the EU asset is burdened with significantly less expense than the US asset, as our strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with the Company earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Viventia Bio, Inc. ("Viventia") in September 2016, we recorded contingent consideration pertaining to the amounts potentially payable to the former shareholders of Viventia pursuant to the terms of the Share Purchase Agreement among us, Viventia and the other signatories thereto (the "Share Purchase Agreement") and are based on launch timing in certain markets, probabilities of clinical and regulatory success, which are used to estimate future revenue levels. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized in earnings (or loss) for the period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists primarily of interest income earned on cash and cash equivalents and, to a lesser extent, any gains or losses on foreign exchange.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit (Provision) from Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit for income taxes is driven by the intangible impairment charge, changing the value of deferred tax liabilities. Provision for income taxes consists of income taxes incurred to foreign jurisdictions pursuant to our OUS business development partnership agreements, including the Qilu License Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months ended September&#160;30, 2021 and 2020 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,823)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Loss) from Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,475)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21,476)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,561&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,693&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(856)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income (Loss) and Comprehensive Income (Loss) After Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71,674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,608)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Related Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We had no revenue for the three months ended September 30, 2021.</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue for the three months ended September 30, 2020 was $11.2 million, which was due to the recognition of revenue pursuant to the license agreement with our OUS business development partner for Greater China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Research and development expenses were $5.0 million for the three months ended September&#160;30, 2021 compared to $10.2 million for the three months ended September&#160;30, 2020. The decrease of $5.2 million was due primarily to lower costs associated with technology transfer and manufacturing ($6.3 million), partially offset by increased license fees related to a milestone payment to the University of Zurich triggered by the receipt of the CRL ($0.5 million), regulatory fees triggered by withdrawal of our MAA to the EMA for Vysyneum ($0.3 million) and regulatory consultant fees ($0.2 million). We anticipate that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">R&amp;D expenses may increase beginning in 2022 due to additional clinical trial activity costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">General and administrative expenses were $8.7 million for the three months ended September&#160;30, 2021 compared to $4.1 million for the three months ended September&#160;30, 2020. The increase of $4.6 million was due primarily to increases in sales and marketing expense for Vicineum pre-commercial launch planning ($2.4 million), employee-related compensation driven by increased headcount as part of the commercial build ($1.3 million) and professional fees for accounting services ($0.2 million). The majority of these expenses were incurred prior to receipt of the CRL in August 2021. Additionally, legal fees increased due to legal proceedings and the on-going independent review related to Vicineum ($0.9 million). Such increase was partially offset by certain other decreases in G&amp;A expenses, none of which were individually material ($0.2 million)</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charge</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring ex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">penses were $5.5 million for the three months ended September&#160;30, 2021 compared to no restructuring expenses for the three months ended September&#160;30, 2020. The increase of $5.5 million was due to one-time costs associated with the Restructuring Plan of approximately $2.7 million associated with the termination of certain contracts and severance and other employee-related costs of approximately $2.8 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles Impairment Charge</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Intangibles impairment charge for three months ended September&#160;30, 2021 was $31.7 million compared to no impairment in the three month ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2021, we received a CRL from the FDA regarding our BLA for Vicineum for the treatment of NMIBC, our lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. We participated in a Type A meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expect to engage in a Type A meeting to discuss clinical issues raised in the CRL later this year. Both meetings are intended to help us determine the appropriate path forward for Vicineum. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, an impairment analysis was conducted, which concluded that the carrying value of our intangible assets of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges for the period ended September&#160;30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market at this time.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The non-cash change in fair value of contingent consideration was income of $114.0 million for the three months ended September&#160;30, 2021 compared to an $18.4 million loss for the three months ended September&#160;30, 2020. The decrease in the fair value of contingent consideration of $114.0 million for the three months ended September&#160;30, 2021 was driven by the receipt of a CRL from the FDA, in which the FDA determined that it cannot approve the BLA for Vicineum in its present form. Due to the inherent uncertainty in the path forward for Vicineum at this time, we reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success (POS); we expect delays in the start of commercialization and estimate lower POS as a direct result of the CRL. We anticipate needing to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. We have assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, we now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. We participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expect to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss the clinical issues raised in the CRL. Both meetings are intended to help us determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates as a result of these meetings, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The milestone payments constitute debt-like obligations, and the high-yield debt index rate applied to the milestones in order to determine the estimated fair value decreased from 14.5% as of June 30, 2020, to 11.8% as of September&#160;30, 2020 and from 6.6% as of June 30, 2021 to 7.5% as of September&#160;30, 2021. The discount rate applied to the 2% earnout payment due on forecasted Vicineum revenues is derived from our estimated weighted-average cost of capital ("WACC"), and this WACC-derived discount rate decreased from 13.2% as of June 30, 2020 to 9.4% as of September&#160;30, 2020 and increased from 6.8% as of June 30, 2021 to 8.Hi Nora6% as of September&#160;30, 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The change in the fair value of contingent consideration was an $18.4 million loss for the three months ended September&#160;30, 2020. This was primarily attributable to lower discount rates, based on prevailing market conditions as of September 30, 2020, and to a lesser extent by refinement of timelines in certain OUS markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net was de minimis during the three months ended September&#160;30, 2020 and September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit (Provision) from Income Taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three months ended September 30, 2021, we recorded a benefit from income taxes of  $8.6 million. In the third quarter of 2021, we determined that the fair value of the Vicineum United States rights were zero, which resulted in an impairment charge of $31.7 million. In connection with this impairment charge, in the third quarter of 2021, we wrote-down the associated deferred tax liability by $8.6 million as a benefit. Please refer to Note 6, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the three months ended September 30, 2020, we recorded a provision for income taxes of $1.1 million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the License Agreement with Qilu.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months ended September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and 2020 </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,451)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,057)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,553)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,256)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,405&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss and Comprehensive Loss After Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,388)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,892)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Related Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the nine months ended September 30, 2021 was $6.5 million, which was due to achieving the IND milestone in China pursuant to the Qilu License Agreement, clinical supply revenue resulting from the delivery of drug product to our OUS partner for Greater China,</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and license revenue for additional purchase price due to the recovery of VAT by our OUS business development partner for Greater China. Revenue for the nine months ended September 30, 2020 was $11.2 million, which was due to the recognition of revenue pursuant to the license agreement with our OUS business development partner for Greater China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expense was $18.3 million for the nine months ended September 30, 2021 compared to $23.6 million for the nine months ended September 30, 2020. The decrease of $5.3 million was primarily due to lower costs associated with technology transfer and manufacturing costs ($9.7 million). This was partially offset by increases in regulatory consulting fees ($1.8 million), employee-related compensation driven by the anticipated commercial launch ($0.9 million), license fees related to a milestone payment to Amgen triggered by filing of the MAA ($0.6 million), and a milestone payment to the University of Zurich triggered by the receipt of the CRL ($0.5 million), and withdrawal of our MAA to the EMA for Vysyneum ($0.3 million). We anticipate that  R&amp;D expenses may increase beginning in 2022 due to additional clinical trial activity costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $20.8 million for the nine months ended September 30, 2021 compared to $10.9 million for the nine months ended September 30, 2020. The increase of $9.9 million was primarily due to increases in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing and commercial expenses of $4.0 million in preparation for the commercial launch, prior to the issuance of the CRL in August 2021. Additionally, increases in employee compensation and benefits ($3.4 million), legal expense ($1.6 million), professional fee ($0.3 million), insurance expense ($0.3 million) and other expenses ($0.3 million) contributed to the increase. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charge</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructurin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g expenses were $5.5 million for the nine months ended September 30, 2021 compared to no restructuring expenses for the nine months ended September 30, 2020. The increase of $5.5 million was due to one-time costs associated with the Restructuring Plan of approximately $2.7 million associated with the termination of certain contracts and severance and other employee-related costs of approximately $2.8 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles Impairment Charge</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles impairment charge was $31.7 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to no impairment for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2021, we received a CRL from the FDA regarding our BLA for Vicineum for the treatment of NMIBC, our lead product candidate, in which the FDA determined that it could not approve the BLA for Vicineum in its present form. The $31.7 million of impairment charges for the period ended September 30, 2021 are due to expected delays in the start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market at this time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The non-cash change in fair value of contingent consideration was income of $52.2 million for the nine months ended September 30, 2021, compared to income of $16.8&#160;million for the nine months ended September 30, 2020. The decrease in the fair value of contingent consideration of $52.2 million for the nine months ended September 30, 2021 was driven by the receipt of a CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form. Due to the inherent uncertainty in the path forward for Vicineum at this time, we reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success (POS); we expect delays in the start of commercialization and estimates lower POS as a direct result of the CRL. We anticipate needing to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. We have assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, we now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. We participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expect to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss the clinical issues raised in the CRL. Both meetings are intended to help us determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates as a result of these meetings, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The milestone payments constitute debt-like obligations, and the high-yield debt index rate applied to the milestones in order to determine the estimated fair value remained 11.8% as of December 31, 2019 and September&#160;30, 2020 and decreased from 8.4% as of December&#160;31, 2020 to 7.5% as of September&#160;30, 2021. The discount rate applied to the 2% earnout payment due on forecasted Vicineum revenues is derived from our estimated WACC, and this WACC-derived discount rate fluctuated from 5.6% as of December 31, 2019 to 9.4% as of September&#160;30, 2020 and from 8.8% as of December&#160;31, 2020 to 8.6% as of September&#160;30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was income of $16.8 million for the nine months ended September 30, 2020.  This was primarily attributable to significantly higher discount rates as a result of financial market conditions as of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020, offset by changes to the competitive landscape.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net was de minimis for the nine months ended September 30, 2021, compared to $0.2&#160;million for the nine months ended September 30, 2020. The decrease of $0.2 million was due primarily to lower interest income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit (Provision) from Income Taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, we recorded a benefit from income taxes of $8.3 million. In the third quarter of 2021, we determined that the fair value of the Vicineum United States rights were zero, which resulted in an impairment charge of $31.7 million. In connection with this impairment charge, in the third quarter of 2021, we wrote-down the associated deferred tax liability by $8.6 million as a benefit. Please refer to Note 6, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the nine months ended September 30, 2020, we recorded a provision for income taxes of $1.1 million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the License Agreement with Qilu. </span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_88"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September&#160;30, 2021, we had cash and cash equivalents of $175.2 million, net working capital of $187.9 million and an accumulated deficit of $325.2 million. We incurred negative cash flows from operating activities of $30.8&#160;million for the year ended December&#160;31, 2020 and $56.3 million for the nine months ended September 30, 2021. We believe that our cash and cash equivalents of $175.2 million as of September&#160;30, 2021, are sufficient to fund our operating plan through 2023. Since our inception, we have received no revenue from sales of our products, and we anticipate that operating losses will continue for the foreseeable future as we seek to address the issues raised in the CRL we received for our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete the follow-up stage of our ongoing Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, complete any additional clinical trials for Vicineum, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our IPO, follow-on public offerings, sales effected in ATM offerings, our OUS business development partnerships and license agreements and, to a lesser extent, from a collaboration. In November 2019, we entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which we may issue and sell shares of our common stock, par value $0.001 per share from time to time for an aggregate sales price of up to $35 million through Jefferies (the "ATM Offering"). In October 2020 and February 2021, we entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No.2 modified the Sale Agreement to reflect that we may issue and sell shares of our common stock from time to time for an aggregate sales price of up to an additional $50.0 million and $34.5 million, respectively. In June 2021, we entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, we filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of our common stock pursuant to the Sale Agreement. Sale of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule&#160;415(a)(4)&#160;of the Securities Act of 1933, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. We may sell shares of our common stock efficiently from time to time, but have no obligation to sell any of our common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon our instructions, which include a prohibition on sales below a minimum price set by us from time to time. We have provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. We raised $175.0 million of net proceeds from the sale of 56.9 million shares of common stock at a weighted-average price of $3.17 per share during the nine months ended September 30, 2021, including $38.2 million of net proceeds from the sale of 9.8&#160;million shares of common stock at a weighted-average price of $4.01 per share during the three months ended September 30, 2021. We raised $16.2 million of net proceeds from the sale of 16.8 million shares of common stock at a weighted-average price of $0.99 per share during the nine months ended September 30, 2020, including $8.2 million of net proceeds from the sale of 7 million shares of common stock at a weighted-average price of $1.21 per share during the three months ended September 30, 2020.  Share issue costs, including sales agent commissions, related to the ATM Offering totaled $1.2 million and $5.4 million for the three and nine months ended September 30, 2021 compared to $0.3 million and $0.5 million for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the effect of the outbreak of COVID-19. We are proactively executing risk mitigation strategies to attenuate the impact of COVID-19 on us, and at this time, we have not yet experienced any business disruptions as a result of the pandemic. We are continually assessing the effect of the COVID-19 pandemic on our operations and we are monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on our ability to develop, and if approved, commercialize our product candidates, including Vicineum for the treatment of BCG-unresponsive NMIBC, and ultimately upon our ability to attain profitable operations. In order to commercialize our product candidates, including Vicineum for the treatment of BCG-unresponsive NMIBC, we need to complete clinical development and comply with comprehensive regulatory requirements. We are subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of our product candidates, raising additional capital, development and commercialization by our competitors of new technological innovations, protection of proprietary technology and market acceptance of our products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of BCG-unresponsive NMIBC, requires substantial working capital, and we expect to seek additional funds through equity or debt financings or through additional OUS business development partnerships, collaborations, licensing transactions or other sources. We may be unable to obtain equity or debt financings or enter into additional OUS business development partnerships, collaborations or licensing transactions at favorable terms, or at all, and, if necessary, we may be required to implement cost reduction strategies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incur substantial expenses if and as we:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">address the issues identified in the CRL we received from the FDA for our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, which we expect will include the completion of an additional clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for Vicineum for the treatment of BCG-unresponsive NMIBC;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities (including completing the manufacturing process and technology transfer to any third-party manufacturers) to commercialize Vicineum for the treatment of BCG-unresponsive NMIBC, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add equipment and physical infrastructure to support our research and development;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory, quality control, scientific and management personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operational, financial and management systems and personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct research and pre-clinical and clinical development of Vicineum for the treatment of BCG-unresponsive NMIBC, less-than-adequate BCG and our other product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to discover and develop additional product candidates; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire the rights to other products, product candidates or technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, initiation, progress, timing, costs and results of pre-clinical development and laboratory testing and clinical trials for Vicineum for the treatment of BCG-unresponsive NMIBC and our other product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing COVID-19 pandemic and its impact on our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional OUS business development partnerships, collaborations or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities, including those associated with the manufacturing process and technology transfer to third-party manufacturers to facilitate such commercial-scale manufacturing of Vicineum;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of BCG-unresponsive NMIBC, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty and other payments to third-party licensors under our licensing agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory review by the FDA, EMA and comparable foreign regulatory authorities for Vicineum for the treatment of BCG-unresponsive NMIBC, including the potential for the FDA, EMA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect to perform;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain future regulatory, development and commercialization milestones under our out-license and OUS business development partnership agreements </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of Vicineum for the treatment of BCG-unresponsive NMIBC, if approved.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues from commercial sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic collaborations, OUS business development partnership agreements, partnerships, alliances, and licensing arrangements. We do not have any committed external source of funds other than the amounts payable under the License Agreement with Roche and the License Agreement with Qilu. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, strategic OUS business development partnerships, collaborations, alliances or licensing arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on our operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect our ability to raise additional capital in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the nine months ended September 30, 2021 and 2020 (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Operating Activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,278)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,328)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119,847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,152)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $56.3 million for the nine months ended September 30, 2021 and consisted primarily of a net loss of $9.3 million, which includes $6.5 million of revenue recognized pursuant to our license agreements, adjusted for non-cash items, including share-based compensation of $3.4 million, a decrease in the fair value of contingent consideration of $52.2 million, increase in impairment charge of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and a net decrease in operating assets and liabilities of $29.9 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $22.3 million for the nine months ended September 30, 2020 and consisted primarily of net loss of $7.4 million, which includes $11.2 million of revenue recognized pursuant to the License Agreement with Qilu, adjusted for non-cash items, including share-based compensation of $1.4 million, a decrease in the fair value of contingent consideration of $16.8 million and a net increase in operating assets and liabilities of $0.4 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was de minimis during the nine months ended September&#160;30, 2020 and September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $176.1 million and $16.2 million for the nine months ended September 30, 2021 and September&#160;30, 2020, respectively, and consisted, primarily, of net proceeds from the sale of common stock under the ATM Offering and, with respect to the nine months ended September 30, 2020, sales of common stock under our 2014 ESPP. </span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_91"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in accordance with United States generally accepted accounting principles and the rules and regulations of the SEC require the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. Management has determined that our most critical accounting policies are those relating to the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development costs; revenue recognition and going concern considerations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC is not obtained, we will immediately expense the related capitalized cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In August 2021, we received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, our lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. We participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expect to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss the clinical issues raised in the CRL. Both meetings are intended to help us determine the appropriate path forward for Vicineum. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, an impairment analysis was conducted, which concluded that the carrying value of our intangible assets of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges for the period ended September&#160;30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market as of September 30, 2021. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of our intangible assets of Vicineum E.U. rights, this asset was not impaired as of September 30, 2021. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the EU asset is burdened with significantly less expense than the US asset, as our strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with our earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Goodwill on our condensed consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. We recognize a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. We have only one reporting unit. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, an impairment analysis was conducted. While an impairment was recognized in one of our intangible assets, Vicineum U.S. Rights, we concluded that the carrying value of our goodwill of $13.1 million was not impaired as of September 30, 2021.  We believe we have sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. We project future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. We will continue to evaluate our timelines for commercialization and probability of success of development of Vicineum for the treatment of NMIBC. We have requested two separate Type A meetings with the FDA. The CMC Type A Meeting was held on October 29, 2021. The clinical Type A Meeting is expected to occur later this year. As a result of the CMC Type A Meeting, we do not believe any changes to the key assumptions are required and therefore management determined there is no impact to the evaluation of goodwill impairment. We also expect to assess the outcome of the Clinical Type A Meeting to determine if further impairment testing is required. Further reductions to estimated probabilities of success, additional development delays or increases in underlying discount rates have the potential to result in future goodwill impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration on our condensed consolidated balance sheet is the result of our acquisition of Viventia in September 2016 and represents the discounted present value of future launch milestones and net sales royalties due to the former shareholders of Viventia pursuant to the Share Purchase Agreement. For additional information, see "Item 1. Financial Statements - Notes to Condensed Consolidated Financial Statements - Note 1. Description of Business" of this Quarterly Report on Form 10-Q. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are unpredictable and inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of September&#160;30, 2021, we reduced our deferred tax liabilities by $8.6 million as a result of intangibles impairment charge, driven by the CRL.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. We recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. We recognize accrued interest and penalties related to uncertain tax positions as income tax expense in our consolidated statements of operations. As of September&#160;30, 2021 and December&#160;31, 2020, we did not have any uncertain tax positions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenue from our out-license agreements and OUS business development partnership agreements, including the License Agreement with Roche and our OUS partnerships. Under each of these agreements, we granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether our out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which we adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as we fulfill our obligations under these agreements, we perform the following steps:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1) Identification of the contract&#894;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)  Determination of whether the promised goods or services are performance obligations including whether they are distinct in &#160;&#160;&#160;&#160;   the context of the contract&#894;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)  Measurement of the transaction price, including the constraint on variable consideration&#894;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)  Allocation of the transaction price to the performance obligations&#894;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)  Recognition of revenue when or as the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, we evaluate whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, we will note recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we are required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued accounting standards are discussed in &#8220;Item 1. Financial Statements - Notes to Condensed Consolidated Financial Statements - Note 4. Recent Accounting Pronouncements&#8221; of this Quarterly Report on Form 10-Q.</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_94"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_97"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information under this item is not required to be provided by smaller reporting companies.</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_100"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as defined in Exchange Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rules 13a-15(e) and 15d-15(e), that are designed to ensure information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principle financial officer, to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as the end of the period covered by this Quarterly Report on Form 10-Q. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September&#160;30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore, the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with the policies and procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of controls, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our system of controls to enhance, where necessary, our control policies and procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, there were no changes in our internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f), which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_106"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 19, 2021, August 31, 2021 and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the U.S. District Court for the Southern District of New York. The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH, and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dresaj collectively as the &#8220;lead plaintiff&#8221; under the Private Securities Litigation Reform Act.  On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff.  The court has not ruled on those motions at this time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">D&#8217;Arcy v. Sesen Bio, Inc., et. al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, Case No. 1:21-cv-11577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> were filed against the Company's board of directors and certain of its officers in the U.S. District Court for the District of Massachusetts, with the Company named as nominal defendant. The two derivative complaints allege breach of fiduciary duties, waste of corporate assets and violations of federal securities laws, based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">D&#8217;Arcy </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The two derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages, and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, other than as set forth below, there were no material changes to the "Risk Factors" included in our Annual Report on Form 10-K for the year ended December 31, 2020. You should carefully consider the information described therein and in this Quarterly Report on Form 10-Q, which could materially affect our business condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Approval of Vicineum</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our lead product candidate, Vicineum for the treatment of BCG-unresponsive NMIBC. If we are unable to obtain marketing approval for or successfully commercialize our lead product candidate, either alone or through an out-license or a commercialization partnership, or experience significant delays in doing so, our business could be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently have no products approved for sale and have invested a significant portion of our efforts and financial resources in the development of Vicineum for the treatment of BCG-unresponsive NMIBC. On August 13, 2021, we received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA determined that it could not approve the BLA for Vicineum in its present form, and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On October 29, 2021, the Company participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL (the &#8220;CMC Type A Meeting&#8221;). During the CMC Type A Meeting, the Company and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. The Company is preparing for a separate Type A Meeting to discuss the recommendations specific to additional clinical/statistical data and analyses that the FDA raised in the CRL, which the Company expects to occur later this year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of Quality, Good Clinical Practice, Efficacy and Safety. We may be unable to address the issues identified in the CRL from the FDA or resubmit our BLA for Vicineum, or address the concerns identified in the EMA Withdrawal Assessment Report or resubmit our MAA for Vysyneum, including because of a lack of capital or otherwise. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the issues identified in the CRL or the concerns identified in the EMA Withdrawal Assessment Report are resolved to the satisfaction of the FDA or the EMA, respectively, the FDA and the European Commission retain the right not to approve the BLA or MAA, respectively, or to require additional information, or to raise additional issues with regard to regulatory approval, which could further delay or prevent its approval or limit product labelling claims.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prospects are substantially dependent on our ability and the ability of our out-licensing and commercialization partners to obtain marketing approval for and successfully commercialize Vicineum for the treatment of BCG-unresponsive NMIBC. In addition, either the substance of the issues identified by the FDA in the CRL, or the CRL itself, or the concerns identified in the EMA Withdrawal Assessment Report could have an adverse impact on future efforts to obtain marketing authorization for Vicineum from other foreign regulatory authorities, or on our future efforts to commercialize Vicineum and gain acceptance of Vicineum from third party payors. The success of Vicineum will depend on several factors, including the following:</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">addressing the issues identified in the CRL we received from the FDA and the concerns identified in the EMA Withdrawal Assessment Report, including conducting any additional clinical trials and the outcome of any such clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from the FDA, the European Commission or comparable foreign regulatory authorities, including our ability to address the issues identified by the FDA in the CRL or the EMA Withdrawal Assessment Report;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining the commercial manufacturing supply and distribution chain for Vicineum;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of current and our future out-licensing or commercialization partners, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protection of our rights in our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launch of commercial sales, if and when marketing approval is received;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of an acceptable safety profile prior to and following any marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketplace acceptance, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining pricing sufficient to realize a meaningful return on our investment; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with other therapies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our commercialization partners are unable to develop, receive marketing approval for, or successfully commercialize Vicineum for the treatment of BCG-unresponsive NMIBC or experience delays as a result of any of these factors or otherwise, our business could be materially harmed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC are required and such trials fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other foreign regulatory authorities or do not otherwise produce favorable results, we will be unable to complete, the development and potential commercialization of Vicineum for the treatment of BCG-unresponsive NMIBC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of Vicineum for the treatment of BCG-unresponsive NMIBC, we must complete pre-clinical development and conduct extensive clinical trials to demonstrate the safety and efficacy of Vicineum in humans. In order to address the issues identified in the CRL we received from the FDA for our BLA for Vicineum and the concerns identified in the EMA Withdrawal Assessment Report, we expect that we will need to complete one or more additional clinical trials. Such trials will require us to incur substantial additional costs and will delay the potential commercialization of Vicineum for the treatment of BCG-unresponsive NMIBC. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of pre-clinical studies and early clinical trials may not be predictive of the success of later clinical trials, and preliminary results of a clinical trial do not necessarily predict final results. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. If we are unable to demonstrate safety and efficacy of Vicineum for the treatment of BCG-unresponsive NMIBC to the satisfaction of the FDA, the EMA or other foreign regulatory authorities, we will not be able to obtain the required regulatory approvals which would prevent us from commercializing Vicineum and our ability to generate revenues in the future would be materially impaired.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial results may fail to support approval of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to address the issues identified in the CRL we received from the FDA for our BLA for Vicineum and the concerns identified in the EMA Withdrawal Assessment Report for our MAA for Vysyneum, we expect that we will need to complete one or more additional clinical trials. Even if such clinical trials are successfully completed as planned, the results may not support approval of Vicineum for the treatment of BCG-unresponsive NMIBC under the laws and regulations of the FDA, the European Commission or comparable foreign regulatory authorities. We cannot be certain that additional clinical data will demonstrate Vicineum is both safe and effective for its intended uses to satisfaction of the FDA, the EMA or comparable foreign regulatory authorities. Pre-clinical and clinical data and analyses are often able to be interpreted in different ways. Even if we view our results favorably, if a regulatory authority has a different view, we may still fail to obtain regulatory approval of Vicineum. This, in turn, would significantly adversely affect our business prospects. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United States would not assure approval of product candidates in foreign jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to market and sell any product candidate that we may develop outside of the United States, we or our third-party licensees or commercialization partners must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States it is required that the product be approved for reimbursement before the product can be sold in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. For example, on March 5, 2021, we submitted our MAA to the EMA for Vicineum for the treatment of BCG-unresponsive NMIBC under the EMA&#8217;s centralized procedure. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC. Given in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on the next steps for Vicineum in the United States. Additionally, on October 20, 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of Quality, Good Clinical Practice, Efficacy and Safety. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of our product candidates by regulatory authorities in other jurisdictions, the commercial prospects of our product candidates may be significantly diminished, and our business prospects could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business and Operations  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring plan and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The restructuring plan includes a reduction in our workforce by 18 positions (approximately 35%) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum. Restructuring expenses in the third quarter of 2021 were approximately $5.5 million, consisting primarily of severance and other employee-related costs of $2.8 million and contract termination costs of $2.7 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. Furthermore, our restructuring plan may be disruptive to our operations. For example, our headcount reductions could yield unanticipated consequences, such as increased difficulties in implementing our business strategy, including retention of our remaining employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and certain of our officers have been named as defendants in three pending securities class action lawsuits and two related shareholder derivative lawsuits have been filed. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend and are uncertain in their outcome.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 19, 2021, August 31, 2021 and October 7,2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against us and certain of our officers in the U.S. District </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Court for the Southern District of New York.  The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by us concerning our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH, and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dresaj collectively as the &#8220;lead plaintiff&#8221; under the Private Securities Litigation Reform Act.  On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff.  The court has not ruled on those motions at this time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against our board of directors and certain of our officers in the U.S. District Court for the District of Massachusetts, with Sesen Bio, Inc. named as a nominal defendant. The two derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by us concerning our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The two derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these lawsuits are without merit and intend to vigorously defend against these actions. However, whether or not the claims are successful, litigation is often expensive and can divert management&#8217;s attention and resources from other business concerns, which could adversely affect our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are not able to estimate the possible cost to us from these actions, as the pending lawsuits are currently at an early stage, and we cannot be certain how long it may take to resolve the pending lawsuits or the possible amount of any damages that we may be required to pay. If we are ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be the target of similar litigation in the future. The market price of our common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation. Any future litigation could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. We maintain liability insurance; however, if any costs or expenses associated with the pending lawsuits or any other litigation exceed our insurance coverage, we may be forced to bear some or all costs and expenses directly, which could adversely affect our business, financial condition, results of operations or stock price.</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_1153"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any unregistered equity securities during the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</span></div><div id="i0b6b8a80699f4ebca69187de21a4e617_112"></div><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514056904/d679756dex31.htm">Restated Certificate of Incorporation of Eleven Biotherapeutics, Inc. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 18, 2014 (File No. 001-36296).</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit31-ebioxcertificate.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000103/ex33-certificateofamendm.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q filed on May 10, 2021 (File No. 001-36296).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit32-elevenbiotherape.htm">Amended and Restated By-laws. Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex41.htm">Specimen Stock Certificate evidencing the shares of common stock. Incorporated by reference to Exhibit 4.1 to our Registration Statement on&#160;Form S-1/A&#160;filed on January 23, 2014 (Reg. No. 333-193131).</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514448885/d704357dex1023.htm">Form of Warrant issued to Silicon Valley Bank and Life Science Loans, LLC dated November 25, 2014. Incorporated by reference to Exhibit 10.23 to our Registration Statement on&#160;Form S-1&#160;filed with the SEC on December 19, 2014 (Reg. No. 333-201176).</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500317000132/ex41ebiopre-fundedwarrant1.htm">Form of Common Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on&#160;Form 8-K&#160;filed with the SEC on November 3, 2017 (File. No. 001-36296).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit41.htm">Form of Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on&#160;Form 8-K&#160;filed with the SEC on March 23, 2018 (File. No. 001-36296).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2017warrantamendmenta.htm">Form of 2017 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed October 29, 2019 (File No. 001-36296).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2018warrantamendmenta.htm">Form of 2018 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed October 29, 2019 (File No. 001-36296).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-09302021x10qex311.htm">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-09302021x10qex312.htm">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-09302021x10qex321.htm">Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-09302021x10qex322.htm">Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data File (Form 10-Q for the Quarterly Period ended September&#160;30, 2021 filed in XBRL). The financial information contained in the XBRL-related documents is "unaudited" and "unreviewed." The instance document does not appear in the interactive file because its XBRL tags are embedded within the Inline XBRL document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive File (embedded within the Inline XBRL document and included in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i0b6b8a80699f4ebca69187de21a4e617_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SESEN BIO, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Thomas R. Cannell, D.V.M.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sesn-09302021x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibef0217f268c43cbb2416b730014c88c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas R. Cannell, D.V.M., certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended September&#160;30, 2021 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.<br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sesn-09302021x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icaec6dc937194b4fb8814ec88da606a3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Monica Forbes, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended September&#160;30, 2021 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.<br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Monica Forbes&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sesn-09302021x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icab2b306b6074782a02da20eb974f618_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>sesn-09302021x10qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3ae232321b4c474e873dbe5caba36ed3_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Monica Forbes&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sesn-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:43f34410-0797-4c9d-95d4-0172445a49a1,g:6be5cc14-c349-4e45-a047-13acab623f46-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sesn="http://www.sesenbio.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sesenbio.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sesenbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION">
        <link:definition>2103102 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS">
        <link:definition>2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables">
        <link:definition>2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails">
        <link:definition>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>2112106 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>2313302 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails">
        <link:definition>2414405 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.sesenbio.com/role/LEASES">
        <link:definition>2115107 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails">
        <link:definition>2416406 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES">
        <link:definition>2117108 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2318303 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESCompositionofAccruedExpensesDetails" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails">
        <link:definition>2419407 - Disclosure - ACCRUED EXPENSES - Composition of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT">
        <link:definition>2120109 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITTables" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables">
        <link:definition>2321304 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails">
        <link:definition>2422408 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Equity Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails">
        <link:definition>2423409 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITCommonStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails">
        <link:definition>2424410 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails">
        <link:definition>2425411 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Summary of Common Stock Issued and Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITWarrantsDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails">
        <link:definition>2426412 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2127110 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2328305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREScheduleofEPSDetails" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails">
        <link:definition>2429413 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>2430414 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2131111 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2332306 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
        <link:definition>2433415 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2434416 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>2435417 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
        <link:definition>2436418 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2137112 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>2438419 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sesenbio.com/role/INCOMETAXES">
        <link:definition>2139113 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.sesenbio.com/role/INCOMETAXESTables">
        <link:definition>2340307 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails">
        <link:definition>2441420 - Disclosure - INCOME TAXES - Components of Earnings from Continuing Operations before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESCurrentTaxBenefitProvisionDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails">
        <link:definition>2442421 - Disclosure - INCOME TAXES - Current Tax Benefit (Provision) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDeferredTaxLiabilitiesDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails">
        <link:definition>2443422 - Disclosure - INCOME TAXES - Deferred Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESAdditionalInformationDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESAdditionalInformationDetails">
        <link:definition>2444423 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTS" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS">
        <link:definition>2145114 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTSDetails" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails">
        <link:definition>2446424 - Disclosure - LICENSE AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIES" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES">
        <link:definition>2147115 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESTables" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables">
        <link:definition>2348308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails">
        <link:definition>2449425 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails">
        <link:definition>2450426 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2151116 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS">
        <link:definition>2152117 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails">
        <link:definition>2453427 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedMay2015Member" abstract="true" name="WarrantsExpiringNovember2024IssuedMay2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" abstract="false" name="LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_UniversityOfZurichMember" abstract="true" name="UniversityOfZurichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_StockIncentivePlan2009Member" abstract="true" name="StockIncentivePlan2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_XOMAIrelandLimitedMember" abstract="true" name="XOMAIrelandLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_DebtInstrumentIndexRateHighYield" abstract="false" name="DebtInstrumentIndexRateHighYield" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_OperatingLeaseOtherMonthlyOperatingExpenses" abstract="false" name="OperatingLeaseOtherMonthlyOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" abstract="true" name="WarrantsExpiringNovember2024IssuedNovember2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" abstract="false" name="LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_QiluPharmaceuticalCoLtdMember" abstract="true" name="QiluPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_WarrantsExpiringMarch2023Member" abstract="true" name="WarrantsExpiringMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" abstract="false" name="SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" abstract="false" name="SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_SharesOfCommonStockReservedForIssuanceAbstract" abstract="true" name="SharesOfCommonStockReservedForIssuanceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_IL6Member" abstract="true" name="IL6Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" abstract="false" name="SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_WarrantOrRightOutstandingRollForward" abstract="true" name="WarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationLineItems" abstract="true" name="OrganizationAndBasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" abstract="false" name="DeferredTaxLiabilitiesInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CommonStockSharesIssuedAndReservedForFuture" abstract="false" name="CommonStockSharesIssuedAndReservedForFuture" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchievementExpense" abstract="false" name="LicenseAgreementMilestoneAchievementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_BusinessCombinationMilestonePayments" abstract="false" name="BusinessCombinationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SaleOfStockCommissionFixedRate" abstract="false" name="SaleOfStockCommissionFixedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_SaleOfStockAdditionalSharesAuthorizedForSale" abstract="false" name="SaleOfStockAdditionalSharesAuthorizedForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_EBI031Member" abstract="true" name="EBI031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ViciniumMember" abstract="true" name="ViciniumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ATMFacilityMember" abstract="true" name="ATMFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ViventiaBioIncMember" abstract="true" name="ViventiaBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SecondIndicationMember" abstract="true" name="SecondIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" abstract="false" name="BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyRate" abstract="false" name="LicenseAgreementRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_WeightedAverageCostOfCapital" abstract="false" name="WeightedAverageCostOfCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_AccruedRestructuringChargesRelatedCurrent" abstract="false" name="AccruedRestructuringChargesRelatedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" abstract="false" name="ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseMaintenanceFees" abstract="false" name="LicenseMaintenanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementOptionPeriods" abstract="false" name="LicenseAgreementOptionPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" abstract="false" name="StockIssuedDuringPeriodNewIssuesIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" abstract="false" name="LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_LicenseAgreementUpfrontFee" abstract="false" name="LicenseAgreementUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2022Member" abstract="true" name="WarrantsExpiringNovember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_DeferredTaxLiabilityImpairmentWriteDown" abstract="false" name="DeferredTaxLiabilityImpairmentWriteDown" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OtherDividendAndAdjustments" abstract="false" name="OtherDividendAndAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OperatingLeaseMonthlyRent" abstract="false" name="OperatingLeaseMonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_MicrometAGMember" abstract="true" name="MicrometAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NoncashFinancingItemsAbstract" abstract="true" name="NoncashFinancingItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" abstract="false" name="SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_MENALicenseAgreementMember" abstract="true" name="MENALicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" abstract="false" name="SaleOfStockMaximumAggregateSalesPriceInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_A2014EmployeeStockPurchasePlanMember" abstract="true" name="A2014EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementAdditionalUpFrontFee" abstract="false" name="LicenseAgreementAdditionalUpFrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_StockIncentivePlanTwoThousandFourteenMember" abstract="true" name="StockIncentivePlanTwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" abstract="false" name="LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_RoyaltyRevenuePercentage" abstract="false" name="RoyaltyRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_LicenseAgreementTextBlock" abstract="false" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sesn_OperatingLeasesAreaOfOfficeSpace" abstract="false" name="OperatingLeasesAreaOfOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightIssuedDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" abstract="true" name="EczacibasiPharmaceuticalsMarketingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_BusinessCombinationRoyaltyPaymentPercent" abstract="false" name="BusinessCombinationRoyaltyPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_FirstIndicationMember" abstract="true" name="FirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" abstract="false" name="DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" abstract="false" name="LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationTable" abstract="true" name="OrganizationAndBasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" abstract="false" name="StockIssuedDuringPeriodExerciseOfWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementAccountsReceivable" abstract="false" name="LicenseAgreementAccountsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>sesn-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:43f34410-0797-4c9d-95d4-0172445a49a1,g:6be5cc14-c349-4e45-a047-13acab623f46-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_93ab66ad-3ac7-460c-bc30-9836f0d81f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_59d5e128-4282-4ed0-8d13-ff38551a1923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_93ab66ad-3ac7-460c-bc30-9836f0d81f52" xlink:to="loc_us-gaap_AccountsPayableCurrent_59d5e128-4282-4ed0-8d13-ff38551a1923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1233114b-59b4-4274-972d-ea6d964e4cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_93ab66ad-3ac7-460c-bc30-9836f0d81f52" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1233114b-59b4-4274-972d-ea6d964e4cf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_77dd33e0-e0c2-4ea2-b71c-6332f1aca0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_93ab66ad-3ac7-460c-bc30-9836f0d81f52" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_77dd33e0-e0c2-4ea2-b71c-6332f1aca0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f3762b48-cd91-484c-baf8-99633715c962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_93ab66ad-3ac7-460c-bc30-9836f0d81f52" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f3762b48-cd91-484c-baf8-99633715c962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_08f27f05-013b-43ea-b117-49b03c6e3f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_93ab66ad-3ac7-460c-bc30-9836f0d81f52" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_08f27f05-013b-43ea-b117-49b03c6e3f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dab38510-f5e5-4754-8853-094c77c946ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3250e6f7-c6d2-4cb6-9be5-a754f21a1827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dab38510-f5e5-4754-8853-094c77c946ef" xlink:to="loc_us-gaap_PreferredStockValue_3250e6f7-c6d2-4cb6-9be5-a754f21a1827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9058526e-799b-454a-8943-ecce1bcdb22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dab38510-f5e5-4754-8853-094c77c946ef" xlink:to="loc_us-gaap_CommonStockValue_9058526e-799b-454a-8943-ecce1bcdb22a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e2202450-9860-491b-b4f7-9b5d7c50cc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dab38510-f5e5-4754-8853-094c77c946ef" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e2202450-9860-491b-b4f7-9b5d7c50cc95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4626db4a-4be3-4b4b-97f1-85ed07a3864d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dab38510-f5e5-4754-8853-094c77c946ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4626db4a-4be3-4b4b-97f1-85ed07a3864d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1271e1dc-7942-4b0d-aae4-011c0d972beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_901e5ea4-9be9-476f-898c-c93591a30007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1271e1dc-7942-4b0d-aae4-011c0d972beb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_901e5ea4-9be9-476f-898c-c93591a30007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bb38b6ce-d182-4455-8258-72b6a45cbe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1271e1dc-7942-4b0d-aae4-011c0d972beb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bb38b6ce-d182-4455-8258-72b6a45cbe2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_9bd6b402-5769-4dde-8097-02712e58d10f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1271e1dc-7942-4b0d-aae4-011c0d972beb" xlink:to="loc_us-gaap_RestrictedCashCurrent_9bd6b402-5769-4dde-8097-02712e58d10f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_66d59144-7c92-494f-8ad5-3c29d5c60910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1271e1dc-7942-4b0d-aae4-011c0d972beb" xlink:to="loc_us-gaap_ReceivablesNetCurrent_66d59144-7c92-494f-8ad5-3c29d5c60910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_26727879-4604-4d6a-ab7b-d56e0bb5e6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b3c679b-902a-47f9-9463-adf9a292358d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_26727879-4604-4d6a-ab7b-d56e0bb5e6f8" xlink:to="loc_us-gaap_StockholdersEquity_3b3c679b-902a-47f9-9463-adf9a292358d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e2b8a78d-f2e7-4ff1-8187-e56d96f49aab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_26727879-4604-4d6a-ab7b-d56e0bb5e6f8" xlink:to="loc_us-gaap_Liabilities_e2b8a78d-f2e7-4ff1-8187-e56d96f49aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1778f324-08fc-4a7e-84d0-10ff60fa00e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_825e9866-84e8-483d-9985-e2a71c0ee8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1778f324-08fc-4a7e-84d0-10ff60fa00e5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_825e9866-84e8-483d-9985-e2a71c0ee8de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e63e3036-694b-4a0d-94e9-16e1ae8109cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1778f324-08fc-4a7e-84d0-10ff60fa00e5" xlink:to="loc_us-gaap_Goodwill_e63e3036-694b-4a0d-94e9-16e1ae8109cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5aee2070-90f7-4a11-ba9d-e94dad3d2c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1778f324-08fc-4a7e-84d0-10ff60fa00e5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5aee2070-90f7-4a11-ba9d-e94dad3d2c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a8c4120a-84a1-4d25-a466-c43e8bcffb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1778f324-08fc-4a7e-84d0-10ff60fa00e5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a8c4120a-84a1-4d25-a466-c43e8bcffb6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31a662c2-b4a8-4e9d-b998-c11b523e94c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1778f324-08fc-4a7e-84d0-10ff60fa00e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31a662c2-b4a8-4e9d-b998-c11b523e94c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_2df0f496-008a-4ace-96af-5c2229fb1d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1778f324-08fc-4a7e-84d0-10ff60fa00e5" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_2df0f496-008a-4ace-96af-5c2229fb1d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dd91e61b-1e30-4b07-abdc-23700a40ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f421534d-d281-4348-9533-82c588ba0e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd91e61b-1e30-4b07-abdc-23700a40ae95" xlink:to="loc_us-gaap_AssetsCurrent_f421534d-d281-4348-9533-82c588ba0e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1b8914c6-f7c9-48d6-8d73-e802b2571e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd91e61b-1e30-4b07-abdc-23700a40ae95" xlink:to="loc_us-gaap_AssetsNoncurrent_1b8914c6-f7c9-48d6-8d73-e802b2571e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_603a8152-3a7a-400f-ad0c-a673c7e1cdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f725964e-eecc-4048-9561-b5ef69e12e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_603a8152-3a7a-400f-ad0c-a673c7e1cdb2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f725964e-eecc-4048-9561-b5ef69e12e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1eb3d20f-7eff-498c-828e-a56b424b43fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_603a8152-3a7a-400f-ad0c-a673c7e1cdb2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1eb3d20f-7eff-498c-828e-a56b424b43fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2feb4853-d01e-4bc0-9bef-1f7d1f75b44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_603a8152-3a7a-400f-ad0c-a673c7e1cdb2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2feb4853-d01e-4bc0-9bef-1f7d1f75b44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9664d166-964b-469a-8839-02312c4ca929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_603a8152-3a7a-400f-ad0c-a673c7e1cdb2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9664d166-964b-469a-8839-02312c4ca929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b0d7c2fa-17bf-4634-945d-106016f4f40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c45b0cb7-12ae-4a65-8ae9-4cf4c7fdb87c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0d7c2fa-17bf-4634-945d-106016f4f40b" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c45b0cb7-12ae-4a65-8ae9-4cf4c7fdb87c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d2096e1-7da8-4ac1-89fa-9590e8ca17e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b0d7c2fa-17bf-4634-945d-106016f4f40b" xlink:to="loc_us-gaap_LiabilitiesCurrent_5d2096e1-7da8-4ac1-89fa-9590e8ca17e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_30e09465-e76b-499d-8903-03d454b68c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_61021551-bee1-46e5-90cd-00b7a8bfa911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_30e09465-e76b-499d-8903-03d454b68c46" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_61021551-bee1-46e5-90cd-00b7a8bfa911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6e2f244a-f299-4082-90f2-39aee5e083c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_30e09465-e76b-499d-8903-03d454b68c46" xlink:to="loc_us-gaap_OperatingIncomeLoss_6e2f244a-f299-4082-90f2-39aee5e083c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e2b72e08-836c-4f5b-b934-1375259cd167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6ac74d1d-6d1b-4b0d-ac56-3cd3a0d5b18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e2b72e08-836c-4f5b-b934-1375259cd167" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6ac74d1d-6d1b-4b0d-ac56-3cd3a0d5b18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_40aa25de-e7f9-4ca5-bb5b-f7f553b2a2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e2b72e08-836c-4f5b-b934-1375259cd167" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_40aa25de-e7f9-4ca5-bb5b-f7f553b2a2e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ecf8c424-f4d1-4d4e-9d90-72b726fcfa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e2b72e08-836c-4f5b-b934-1375259cd167" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ecf8c424-f4d1-4d4e-9d90-72b726fcfa4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_872145c0-5d6d-4ee1-b571-74d2cde3086b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e2b72e08-836c-4f5b-b934-1375259cd167" xlink:to="loc_us-gaap_RestructuringCharges_872145c0-5d6d-4ee1-b571-74d2cde3086b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_618355b7-863c-44c2-bd4e-7577fd7683a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e2b72e08-836c-4f5b-b934-1375259cd167" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_618355b7-863c-44c2-bd4e-7577fd7683a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48192201-06b9-455d-9812-9df1ef61fcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_50b31a5b-d836-4171-91a2-94fec2bd18ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_48192201-06b9-455d-9812-9df1ef61fcc1" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_50b31a5b-d836-4171-91a2-94fec2bd18ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8638831c-207b-4990-a87b-2cf237e8aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_48192201-06b9-455d-9812-9df1ef61fcc1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8638831c-207b-4990-a87b-2cf237e8aa86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_033487cf-95a1-4b41-b1f7-4a61db9382ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_651f515b-242f-4c0d-9a2f-69abd1197a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_033487cf-95a1-4b41-b1f7-4a61db9382ac" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_651f515b-242f-4c0d-9a2f-69abd1197a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a216c9cf-f4a7-488b-b717-1b8d1b624934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_033487cf-95a1-4b41-b1f7-4a61db9382ac" xlink:to="loc_us-gaap_OperatingExpenses_a216c9cf-f4a7-488b-b717-1b8d1b624934" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33477151-056c-43be-90d5-a026e875f342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_22f87854-0e21-4dc7-8fc6-7695a4892248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33477151-056c-43be-90d5-a026e875f342" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_22f87854-0e21-4dc7-8fc6-7695a4892248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a852e997-556b-4222-b26c-3b48fc0c03a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_NetIncomeLoss_a852e997-556b-4222-b26c-3b48fc0c03a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_beb44ce7-f8a1-48c5-940b-72fdf82c3326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_DepreciationAndAmortization_beb44ce7-f8a1-48c5-940b-72fdf82c3326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_76af06f8-3fe3-4594-b7d1-05e7f836095b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_ShareBasedCompensation_76af06f8-3fe3-4594-b7d1-05e7f836095b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_46c467c8-abf6-4ffa-a8b2-df64dbf97256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_46c467c8-abf6-4ffa-a8b2-df64dbf97256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6f9223ca-2fb8-4804-91e5-3d68d51e08c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6f9223ca-2fb8-4804-91e5-3d68d51e08c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d955d9e3-432c-4c8b-b881-df58291f6ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d955d9e3-432c-4c8b-b881-df58291f6ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a6dfceca-ab3e-44ed-a6fd-7849c7b5ef23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a6dfceca-ab3e-44ed-a6fd-7849c7b5ef23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_946cecf3-b794-485f-8ac1-aa37f6afccd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_946cecf3-b794-485f-8ac1-aa37f6afccd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_04c30c2e-53fb-4ebf-a03f-97d3ae34b39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_04c30c2e-53fb-4ebf-a03f-97d3ae34b39b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ccbd5aff-453b-4314-a877-571216aebf54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2709cdb-35d4-40a0-997d-54b3c5251ce0" xlink:to="loc_us-gaap_AssetImpairmentCharges_ccbd5aff-453b-4314-a877-571216aebf54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff21e27f-400d-4c7a-b118-59bbd80e1d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_60f3baf0-04e7-4567-9b78-8c2829fbd9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff21e27f-400d-4c7a-b118-59bbd80e1d65" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_60f3baf0-04e7-4567-9b78-8c2829fbd9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_79f08985-2363-41d6-a11c-5fe523034e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff21e27f-400d-4c7a-b118-59bbd80e1d65" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_79f08985-2363-41d6-a11c-5fe523034e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9ca950d-985a-4264-b4bf-2cf9a69105b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff21e27f-400d-4c7a-b118-59bbd80e1d65" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9ca950d-985a-4264-b4bf-2cf9a69105b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_934cefed-6df7-4319-a420-74ee191e1870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01333daf-0dd5-4bc5-854b-4d2599b021b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_934cefed-6df7-4319-a420-74ee191e1870" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01333daf-0dd5-4bc5-854b-4d2599b021b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee035c42-baf5-4ffb-898e-77cd3dcd7183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_934cefed-6df7-4319-a420-74ee191e1870" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee035c42-baf5-4ffb-898e-77cd3dcd7183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355f1586-f814-4584-928b-bc8c8e2d6220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_934cefed-6df7-4319-a420-74ee191e1870" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_355f1586-f814-4584-928b-bc8c8e2d6220" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#ACCRUEDEXPENSESCompositionofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0f773cbc-f6a4-420d-a1c3-893df5cbca07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_0361aab2-7165-4d6c-930b-6315e1ef8f12" xlink:href="sesn-20210930.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0f773cbc-f6a4-420d-a1c3-893df5cbca07" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_0361aab2-7165-4d6c-930b-6315e1ef8f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba151bb4-b021-4b2d-abcb-096e5c9e7256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0f773cbc-f6a4-420d-a1c3-893df5cbca07" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba151bb4-b021-4b2d-abcb-096e5c9e7256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2152cc1c-3d5c-42f8-b4f0-35be8b2212e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0f773cbc-f6a4-420d-a1c3-893df5cbca07" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2152cc1c-3d5c-42f8-b4f0-35be8b2212e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a4668a4-a7c6-4ad3-aa21-ba81e34e83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0f773cbc-f6a4-420d-a1c3-893df5cbca07" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a4668a4-a7c6-4ad3-aa21-ba81e34e83d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_8c37de46-9f82-4c20-9050-c8ece51c1d01" xlink:href="sesn-20210930.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0f773cbc-f6a4-420d-a1c3-893df5cbca07" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_8c37de46-9f82-4c20-9050-c8ece51c1d01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_7740b292-2cb9-4297-99e8-a342bd6ef1f8" xlink:href="sesn-20210930.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_da5342c8-d957-41d4-9e66-77737cd34a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_7740b292-2cb9-4297-99e8-a342bd6ef1f8" xlink:to="loc_us-gaap_CommonStockSharesIssued_da5342c8-d957-41d4-9e66-77737cd34a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_665cd6f6-3b72-4826-a02e-ceff24bfdd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_7740b292-2cb9-4297-99e8-a342bd6ef1f8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_665cd6f6-3b72-4826-a02e-ceff24bfdd10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#EARNINGSLOSSPERSHAREScheduleofEPSDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_30e4cf06-81f2-4919-8a66-b080b3db7dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_ee011c64-7885-4036-a11d-37e2f634b491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_30e4cf06-81f2-4919-8a66-b080b3db7dee" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_ee011c64-7885-4036-a11d-37e2f634b491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_66a3196e-90e8-4e18-92af-aa468a828cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_30e4cf06-81f2-4919-8a66-b080b3db7dee" xlink:to="loc_us-gaap_NetIncomeLoss_66a3196e-90e8-4e18-92af-aa468a828cc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_ee58cbdd-ead5-4b57-8b82-8ab8ee3e4be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_30e4cf06-81f2-4919-8a66-b080b3db7dee" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_ee58cbdd-ead5-4b57-8b82-8ab8ee3e4be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_42f7d640-9307-4fb2-b32a-5e399ea75546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_555a47c8-5e18-4cbb-bff4-241f3154c191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_42f7d640-9307-4fb2-b32a-5e399ea75546" xlink:to="loc_us-gaap_NetIncomeLoss_555a47c8-5e18-4cbb-bff4-241f3154c191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_3697ddd9-6e5a-4f21-9149-f18e6093c703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_42f7d640-9307-4fb2-b32a-5e399ea75546" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_3697ddd9-6e5a-4f21-9149-f18e6093c703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_aa880326-134c-4656-ac72-63e7c0e5434b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_42f7d640-9307-4fb2-b32a-5e399ea75546" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_aa880326-134c-4656-ac72-63e7c0e5434b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cd8e1d7-38c7-4aea-8f0d-45620f8265cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_501ccf09-ab94-439e-9cdb-e1fd30b1e602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cd8e1d7-38c7-4aea-8f0d-45620f8265cf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_501ccf09-ab94-439e-9cdb-e1fd30b1e602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3befb729-8f3d-4b11-ab0f-849323541bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cd8e1d7-38c7-4aea-8f0d-45620f8265cf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3befb729-8f3d-4b11-ab0f-849323541bbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXESCurrentTaxBenefitProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6c02eca5-675c-4e6a-9c81-ad7da619c362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d093a997-a118-42fb-ac1f-517188fb66a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6c02eca5-675c-4e6a-9c81-ad7da619c362" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d093a997-a118-42fb-ac1f-517188fb66a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_dd463ca0-29d4-488d-af85-4b090d0c1470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6c02eca5-675c-4e6a-9c81-ad7da619c362" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_dd463ca0-29d4-488d-af85-4b090d0c1470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_91aa543e-aa2a-4fb9-baab-49fee1bc7299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6c02eca5-675c-4e6a-9c81-ad7da619c362" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_91aa543e-aa2a-4fb9-baab-49fee1bc7299" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXESDeferredTaxLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5baf2c20-cb92-4ec4-a426-355c7fba570a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_c9b9f0c7-7aa9-4bd5-befc-73c109f1957a" xlink:href="sesn-20210930.xsd#sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5baf2c20-cb92-4ec4-a426-355c7fba570a" xlink:to="loc_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_c9b9f0c7-7aa9-4bd5-befc-73c109f1957a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1fbaf81d-b869-4bdc-856d-571894cb40a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5baf2c20-cb92-4ec4-a426-355c7fba570a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1fbaf81d-b869-4bdc-856d-571894cb40a9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>sesn-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:43f34410-0797-4c9d-95d4-0172445a49a1,g:6be5cc14-c349-4e45-a047-13acab623f46-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i80e81323650240a49fa23a18d6e8734e_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8152a21e-5c73-43fb-866d-694998e76657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8152a21e-5c73-43fb-866d-694998e76657" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8a15c72a-85c4-4e8e-b3fa-0029c149bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_SharesOutstanding_8a15c72a-85c4-4e8e-b3fa-0029c149bf3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3eeab604-3d84-4fb3-9c75-d9f09038fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockholdersEquity_3eeab604-3d84-4fb3-9c75-d9f09038fb23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89874128-c5c5-4c25-a78e-fa6e238b64af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_NetIncomeLoss_89874128-c5c5-4c25-a78e-fa6e238b64af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d45293ec-53f5-46e3-a3a2-d1aa8294c0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d45293ec-53f5-46e3-a3a2-d1aa8294c0f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bccccde1-2419-4553-a396-774985d57b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bccccde1-2419-4553-a396-774985d57b04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_376f0a37-04b4-4486-9130-39ef9b03bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_376f0a37-04b4-4486-9130-39ef9b03bbb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1fa83978-5c24-4778-b0cc-8514152c99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1fa83978-5c24-4778-b0cc-8514152c99d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5582c1a9-7864-45f1-ba3e-4d9bb5eab910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5582c1a9-7864-45f1-ba3e-4d9bb5eab910" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_2f102b27-db0f-45bc-8ede-1e1939187a39" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_2f102b27-db0f-45bc-8ede-1e1939187a39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_0d4fda40-9c2d-4929-8a7e-bcc75f018b56" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_0d4fda40-9c2d-4929-8a7e-bcc75f018b56" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1266e0b9-c84d-4325-b1c0-23283d198152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1266e0b9-c84d-4325-b1c0-23283d198152" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_26831a9a-ab84-47d4-8d37-0d2803bf4a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_26831a9a-ab84-47d4-8d37-0d2803bf4a9d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8afded34-d12c-4201-89ab-22b518f4753d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ece02fe3-c040-4b92-8cfc-e0cdd6c8c093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8152a21e-5c73-43fb-866d-694998e76657" xlink:to="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_736cd3d8-8853-4e03-9a09-9efa8b64911d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_736cd3d8-8853-4e03-9a09-9efa8b64911d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_736cd3d8-8853-4e03-9a09-9efa8b64911d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_736cd3d8-8853-4e03-9a09-9efa8b64911d" xlink:to="loc_us-gaap_EquityComponentDomain_736cd3d8-8853-4e03-9a09-9efa8b64911d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_736cd3d8-8853-4e03-9a09-9efa8b64911d" xlink:to="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3a6ea69f-d25a-47dc-9dc8-86cb7c8bf06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:to="loc_us-gaap_CommonStockMember_3a6ea69f-d25a-47dc-9dc8-86cb7c8bf06d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_61599230-cd23-43c0-b1e6-8c9178397eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_61599230-cd23-43c0-b1e6-8c9178397eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3bbfe3b4-0d16-453d-9488-fea379219cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:to="loc_us-gaap_RetainedEarningsMember_3bbfe3b4-0d16-453d-9488-fea379219cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_beb66a63-f4d7-4601-b229-d352e19e5dcd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:to="loc_srt_CounterpartyNameAxis_beb66a63-f4d7-4601-b229-d352e19e5dcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_beb66a63-f4d7-4601-b229-d352e19e5dcd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_beb66a63-f4d7-4601-b229-d352e19e5dcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_beb66a63-f4d7-4601-b229-d352e19e5dcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6796dd82-bc21-415b-92b5-8af1212d9a8e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_beb66a63-f4d7-4601-b229-d352e19e5dcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6796dd82-bc21-415b-92b5-8af1212d9a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_118cf87c-245f-4f2d-b1a7-2972293b139c" xlink:href="sesn-20210930.xsd#sesn_UniversityOfZurichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6796dd82-bc21-415b-92b5-8af1212d9a8e" xlink:to="loc_sesn_UniversityOfZurichMember_118cf87c-245f-4f2d-b1a7-2972293b139c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="ie41247b293d2435b8a093243c4547c43_DESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9799b302-d215-40bd-b5e3-2e25d02a641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9799b302-d215-40bd-b5e3-2e25d02a641b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare_2d61fd8b-25ec-4987-af9a-49d58ba9681c" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare_2d61fd8b-25ec-4987-af9a-49d58ba9681c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b821061a-096e-4c4d-a6b3-d99b9dbd4709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b821061a-096e-4c4d-a6b3-d99b9dbd4709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct_a96e9c86-5dce-42b5-8511-1dec895807c8" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct_a96e9c86-5dce-42b5-8511-1dec895807c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods_9f4c9259-82d0-4929-a4a0-ba03312d62fa" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods_9f4c9259-82d0-4929-a4a0-ba03312d62fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales_5382faec-9054-47c4-ac42-c5309a0445e9" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales_5382faec-9054-47c4-ac42-c5309a0445e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations_2e211a86-0870-4dd2-bfcc-a0330f5f8f34" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations_2e211a86-0870-4dd2-bfcc-a0330f5f8f34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_490e13ac-3599-4615-b0ce-654593d88b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_490e13ac-3599-4615-b0ce-654593d88b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490e13ac-3599-4615-b0ce-654593d88b92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_490e13ac-3599-4615-b0ce-654593d88b92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_490e13ac-3599-4615-b0ce-654593d88b92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bba630fa-4a73-4c61-90c6-c5ebcf98ff9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_490e13ac-3599-4615-b0ce-654593d88b92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bba630fa-4a73-4c61-90c6-c5ebcf98ff9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioIncMember_1c67daa2-e373-469d-a494-5b99e8aaed22" xlink:href="sesn-20210930.xsd#sesn_ViventiaBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bba630fa-4a73-4c61-90c6-c5ebcf98ff9f" xlink:to="loc_sesn_ViventiaBioIncMember_1c67daa2-e373-469d-a494-5b99e8aaed22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_srt_ProductOrServiceAxis_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69" xlink:to="loc_srt_ProductsAndServicesDomain_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2326dddf-3d25-4b64-8dad-6d743a8e7c16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69" xlink:to="loc_srt_ProductsAndServicesDomain_2326dddf-3d25-4b64-8dad-6d743a8e7c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_db58d4c2-e078-47fd-8834-d4f7cb09c474" xlink:href="sesn-20210930.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2326dddf-3d25-4b64-8dad-6d743a8e7c16" xlink:to="loc_sesn_ViciniumMember_db58d4c2-e078-47fd-8834-d4f7cb09c474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dade8bb1-f017-42f0-b196-e5fe381f83de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_srt_StatementGeographicalAxis_dade8bb1-f017-42f0-b196-e5fe381f83de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dade8bb1-f017-42f0-b196-e5fe381f83de_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dade8bb1-f017-42f0-b196-e5fe381f83de" xlink:to="loc_srt_SegmentGeographicalDomain_dade8bb1-f017-42f0-b196-e5fe381f83de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8b5c1f1-eb96-4fb2-8665-b90c2fbeabd5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dade8bb1-f017-42f0-b196-e5fe381f83de" xlink:to="loc_srt_SegmentGeographicalDomain_e8b5c1f1-eb96-4fb2-8665-b90c2fbeabd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_f1d20705-7bc7-4aad-8620-cedaed2d73a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8b5c1f1-eb96-4fb2-8665-b90c2fbeabd5" xlink:to="loc_srt_EuropeMember_f1d20705-7bc7-4aad-8620-cedaed2d73a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_4fd7750f-788b-4ab1-ac68-2bdaf862b922" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8b5c1f1-eb96-4fb2-8665-b90c2fbeabd5" xlink:to="loc_country_JP_4fd7750f-788b-4ab1-ac68-2bdaf862b922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3a54debf-06c8-4656-88ec-ff2e89c5f94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3a54debf-06c8-4656-88ec-ff2e89c5f94c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a54debf-06c8-4656-88ec-ff2e89c5f94c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a54debf-06c8-4656-88ec-ff2e89c5f94c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a54debf-06c8-4656-88ec-ff2e89c5f94c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b711a7c-0589-4b4d-819c-33c21bf6ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a54debf-06c8-4656-88ec-ff2e89c5f94c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b711a7c-0589-4b4d-819c-33c21bf6ecab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember_45611770-96c9-4c7c-af7d-62a71c7575ef" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b711a7c-0589-4b4d-819c-33c21bf6ecab" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember_45611770-96c9-4c7c-af7d-62a71c7575ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="sesn-20210930.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="i9b7d2180d3464afc98b321af6804aa07_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bb4357-d72f-4257-9d17-7afae04e5564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6acc0bb7-1aff-4e80-b1fb-a770dbbde3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bb4357-d72f-4257-9d17-7afae04e5564" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6acc0bb7-1aff-4e80-b1fb-a770dbbde3cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c3548f57-823e-494a-88e1-1983eb681003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6acc0bb7-1aff-4e80-b1fb-a770dbbde3cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c3548f57-823e-494a-88e1-1983eb681003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8e49ca81-883a-45f1-950b-567c6e873921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bb4357-d72f-4257-9d17-7afae04e5564" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8e49ca81-883a-45f1-950b-567c6e873921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2b2a2a55-a79a-4b8d-af43-cebfa23a0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8e49ca81-883a-45f1-950b-567c6e873921" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2b2a2a55-a79a-4b8d-af43-cebfa23a0f8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3196ee76-f522-4128-9e1b-9adfa82a9975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8e49ca81-883a-45f1-950b-567c6e873921" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3196ee76-f522-4128-9e1b-9adfa82a9975" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bb4357-d72f-4257-9d17-7afae04e5564" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fa9bc530-2c3b-4615-acc3-a4171dfaae1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fa9bc530-2c3b-4615-acc3-a4171dfaae1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa9bc530-2c3b-4615-acc3-a4171dfaae1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fa9bc530-2c3b-4615-acc3-a4171dfaae1d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa9bc530-2c3b-4615-acc3-a4171dfaae1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a3b1999c-cd66-4208-b42d-0ba52d9948ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fa9bc530-2c3b-4615-acc3-a4171dfaae1d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a3b1999c-cd66-4208-b42d-0ba52d9948ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76b5dc5e-66d1-4d13-9d05-4644cf6bae73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a3b1999c-cd66-4208-b42d-0ba52d9948ca" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76b5dc5e-66d1-4d13-9d05-4644cf6bae73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_05a39c7e-4400-4746-8360-7a9d9d64f40d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76b5dc5e-66d1-4d13-9d05-4644cf6bae73" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_05a39c7e-4400-4746-8360-7a9d9d64f40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1a6095f3-155b-4b1d-bcea-4de300ae0881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76b5dc5e-66d1-4d13-9d05-4644cf6bae73" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1a6095f3-155b-4b1d-bcea-4de300ae0881" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ca62032-1dea-452f-af1f-a9e71e3fde86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ca62032-1dea-452f-af1f-a9e71e3fde86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ca62032-1dea-452f-af1f-a9e71e3fde86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ca62032-1dea-452f-af1f-a9e71e3fde86" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4ca62032-1dea-452f-af1f-a9e71e3fde86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d87f252-d9e6-4d05-aebe-04c7828aaf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ca62032-1dea-452f-af1f-a9e71e3fde86" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d87f252-d9e6-4d05-aebe-04c7828aaf1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_485ede97-106f-4d00-8b5e-642af719ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d87f252-d9e6-4d05-aebe-04c7828aaf1d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_485ede97-106f-4d00-8b5e-642af719ef6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_017ce333-655f-4039-aa4f-897fecd11b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_017ce333-655f-4039-aa4f-897fecd11b24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_017ce333-655f-4039-aa4f-897fecd11b24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_017ce333-655f-4039-aa4f-897fecd11b24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_017ce333-655f-4039-aa4f-897fecd11b24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_017ce333-655f-4039-aa4f-897fecd11b24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ab47e923-0813-4955-9e56-0eaa45b8364a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ab47e923-0813-4955-9e56-0eaa45b8364a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0ef30605-afd3-4ca4-b759-19522567ff36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0ef30605-afd3-4ca4-b759-19522567ff36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ef857bf0-209d-47a4-bc02-233580c1d22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ef857bf0-209d-47a4-bc02-233580c1d22b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="i2db6f966c06b4f43847392dd6e88b51d_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_31c1156d-290a-4a82-97cc-0da49c0a50d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_31c1156d-290a-4a82-97cc-0da49c0a50d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_a30d559e-1b2e-42c4-88c4-b248a80bc13a" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_a30d559e-1b2e-42c4-88c4-b248a80bc13a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_f5a24468-3d60-4383-a1ee-54ee55c20c5a" xlink:href="sesn-20210930.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_sesn_WeightedAverageCostOfCapital_f5a24468-3d60-4383-a1ee-54ee55c20c5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DebtInstrumentIndexRateHighYield_dbf76201-49d5-4cde-be07-ce96f9261819" xlink:href="sesn-20210930.xsd#sesn_DebtInstrumentIndexRateHighYield"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_sesn_DebtInstrumentIndexRateHighYield_dbf76201-49d5-4cde-be07-ce96f9261819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_20cad16f-910e-494a-bd6d-cd63ecb46ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_20cad16f-910e-494a-bd6d-cd63ecb46ee1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_8f4fc3e7-38a9-425a-9d72-23ced6b83a89" xlink:href="sesn-20210930.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_8f4fc3e7-38a9-425a-9d72-23ced6b83a89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9eb437a7-c259-48ef-9027-c3400974d122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9eb437a7-c259-48ef-9027-c3400974d122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9eb437a7-c259-48ef-9027-c3400974d122_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9eb437a7-c259-48ef-9027-c3400974d122" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9eb437a7-c259-48ef-9027-c3400974d122_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6993dd09-a36b-4042-9411-a34f409d62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9eb437a7-c259-48ef-9027-c3400974d122" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6993dd09-a36b-4042-9411-a34f409d62d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_fdb9a94d-8528-47a7-84ce-112ce8ac1285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6993dd09-a36b-4042-9411-a34f409d62d9" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_fdb9a94d-8528-47a7-84ce-112ce8ac1285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_26a22979-1b49-4a17-a539-11fa1c0264d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:to="loc_srt_RangeAxis_26a22979-1b49-4a17-a539-11fa1c0264d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26a22979-1b49-4a17-a539-11fa1c0264d2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_26a22979-1b49-4a17-a539-11fa1c0264d2" xlink:to="loc_srt_RangeMember_26a22979-1b49-4a17-a539-11fa1c0264d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f954e913-0ed1-4b7d-9905-c66c3832681e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_26a22979-1b49-4a17-a539-11fa1c0264d2" xlink:to="loc_srt_RangeMember_f954e913-0ed1-4b7d-9905-c66c3832681e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_91bb28e0-bd2a-4c65-b85c-32f04d0e80c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f954e913-0ed1-4b7d-9905-c66c3832681e" xlink:to="loc_srt_MinimumMember_91bb28e0-bd2a-4c65-b85c-32f04d0e80c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aff4d425-7ec1-4f48-aca4-604f5db3dcb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f954e913-0ed1-4b7d-9905-c66c3832681e" xlink:to="loc_srt_MaximumMember_aff4d425-7ec1-4f48-aca4-604f5db3dcb3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" xlink:type="extended" id="if49e2fcf28564cbdb54024056c9a186a_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2a7cdb40-355c-4d12-9617-da891edda7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2a7cdb40-355c-4d12-9617-da891edda7ef" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_923296d4-fe17-4dff-9bec-85f43a36359d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_923296d4-fe17-4dff-9bec-85f43a36359d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_1d6d8692-2bc6-4146-8141-2bc296957244" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_1d6d8692-2bc6-4146-8141-2bc296957244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_2e4693ce-f7a9-49d0-b7de-c2144bfc1b3a" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_2e4693ce-f7a9-49d0-b7de-c2144bfc1b3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e0dce4c6-d674-4f31-8dd2-8421c68aaa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2a7cdb40-355c-4d12-9617-da891edda7ef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9e13c8ca-c3fb-446c-8e38-aea767c80c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9e13c8ca-c3fb-446c-8e38-aea767c80c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9e13c8ca-c3fb-446c-8e38-aea767c80c97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9e13c8ca-c3fb-446c-8e38-aea767c80c97" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9e13c8ca-c3fb-446c-8e38-aea767c80c97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2284fb1b-62a1-4c67-8b57-74186891f3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9e13c8ca-c3fb-446c-8e38-aea767c80c97" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2284fb1b-62a1-4c67-8b57-74186891f3c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9bd55b84-6081-4ba2-8836-56ef6ada4691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2284fb1b-62a1-4c67-8b57-74186891f3c0" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9bd55b84-6081-4ba2-8836-56ef6ada4691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0d21f15-c700-499b-a983-03ea891ad941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0d21f15-c700-499b-a983-03ea891ad941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0d21f15-c700-499b-a983-03ea891ad941_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0d21f15-c700-499b-a983-03ea891ad941" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0d21f15-c700-499b-a983-03ea891ad941_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5191164-85fc-4755-b961-0aa4cead16b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0d21f15-c700-499b-a983-03ea891ad941" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5191164-85fc-4755-b961-0aa4cead16b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4ae6ddc7-6a6e-4487-885a-f9dec045004b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5191164-85fc-4755-b961-0aa4cead16b6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4ae6ddc7-6a6e-4487-885a-f9dec045004b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INTANGIBLEASSETSANDGOODWILLDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails" xlink:type="extended" id="i920c867459f645da88796d01823a5182_INTANGIBLEASSETSANDGOODWILLDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_cb26b922-2cb8-4b83-88e9-8845e6ae479d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_cb26b922-2cb8-4b83-88e9-8845e6ae479d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3f31efc1-be0e-448d-98ad-5715cf1a29d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_Goodwill_3f31efc1-be0e-448d-98ad-5715cf1a29d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_242df80c-04c9-4cb4-b904-3463d760f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_242df80c-04c9-4cb4-b904-3463d760f2e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9e9bb5c5-58be-414b-87b9-d395fef42002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9e9bb5c5-58be-414b-87b9-d395fef42002" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_252c60ed-b843-4941-ba82-1e4d13af8892" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_srt_ProductOrServiceAxis_252c60ed-b843-4941-ba82-1e4d13af8892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_252c60ed-b843-4941-ba82-1e4d13af8892_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_252c60ed-b843-4941-ba82-1e4d13af8892" xlink:to="loc_srt_ProductsAndServicesDomain_252c60ed-b843-4941-ba82-1e4d13af8892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88bdb96b-f44a-48e4-b4f8-debc6400f768" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_252c60ed-b843-4941-ba82-1e4d13af8892" xlink:to="loc_srt_ProductsAndServicesDomain_88bdb96b-f44a-48e4-b4f8-debc6400f768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_42cafb6d-7008-47f7-9513-717265d4850c" xlink:href="sesn-20210930.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_88bdb96b-f44a-48e4-b4f8-debc6400f768" xlink:to="loc_sesn_ViciniumMember_42cafb6d-7008-47f7-9513-717265d4850c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6c010ab-bb04-48e9-ac21-cda4d2716d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6c010ab-bb04-48e9-ac21-cda4d2716d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6c010ab-bb04-48e9-ac21-cda4d2716d0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6c010ab-bb04-48e9-ac21-cda4d2716d0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6c010ab-bb04-48e9-ac21-cda4d2716d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b744aa46-885f-413b-a938-e8558e4baa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6c010ab-bb04-48e9-ac21-cda4d2716d0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b744aa46-885f-413b-a938-e8558e4baa5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c163e8b0-c9d4-482e-8813-b78520a8a591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b744aa46-885f-413b-a938-e8558e4baa5c" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c163e8b0-c9d4-482e-8813-b78520a8a591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f1393e10-7fa5-47f8-8785-ce713d27eb75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_srt_StatementGeographicalAxis_f1393e10-7fa5-47f8-8785-ce713d27eb75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f1393e10-7fa5-47f8-8785-ce713d27eb75_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f1393e10-7fa5-47f8-8785-ce713d27eb75" xlink:to="loc_srt_SegmentGeographicalDomain_f1393e10-7fa5-47f8-8785-ce713d27eb75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b8a68a5d-d3ae-475b-9da5-d9f92345ccbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f1393e10-7fa5-47f8-8785-ce713d27eb75" xlink:to="loc_srt_SegmentGeographicalDomain_b8a68a5d-d3ae-475b-9da5-d9f92345ccbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_40361aaf-1f6b-4a5d-ae72-0f79635e4a85" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b8a68a5d-d3ae-475b-9da5-d9f92345ccbb" xlink:to="loc_country_US_40361aaf-1f6b-4a5d-ae72-0f79635e4a85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_3f978520-e92a-4852-a683-963710c9262e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b8a68a5d-d3ae-475b-9da5-d9f92345ccbb" xlink:to="loc_srt_EuropeMember_3f978520-e92a-4852-a683-963710c9262e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_27296245-ab89-4335-8339-1791819b7209" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_srt_RangeAxis_27296245-ab89-4335-8339-1791819b7209" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27296245-ab89-4335-8339-1791819b7209_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_27296245-ab89-4335-8339-1791819b7209" xlink:to="loc_srt_RangeMember_27296245-ab89-4335-8339-1791819b7209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0681974a-3775-470c-86b5-01ac8d520fbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_27296245-ab89-4335-8339-1791819b7209" xlink:to="loc_srt_RangeMember_0681974a-3775-470c-86b5-01ac8d520fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_04fd9777-51c9-4dec-9f2e-438ab2d3773b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0681974a-3775-470c-86b5-01ac8d520fbf" xlink:to="loc_srt_MinimumMember_04fd9777-51c9-4dec-9f2e-438ab2d3773b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6e3f5436-3ba9-414d-9406-1a7a62a26c52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0681974a-3775-470c-86b5-01ac8d520fbf" xlink:to="loc_srt_MaximumMember_6e3f5436-3ba9-414d-9406-1a7a62a26c52" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="extended" id="i38621abfd8b9493293e2626be948c832_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_8df3f4bb-1c08-4c42-813f-5e227e071b9d" xlink:href="sesn-20210930.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_8df3f4bb-1c08-4c42-813f-5e227e071b9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5c1cbc92-a02c-43ef-bdc9-d478d91c3ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5c1cbc92-a02c-43ef-bdc9-d478d91c3ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_3c9173d5-db2f-4ed5-8507-20a59ce2572f" xlink:href="sesn-20210930.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_3c9173d5-db2f-4ed5-8507-20a59ce2572f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_10094ecd-4fbc-462d-a6ba-9e4b18177ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_10094ecd-4fbc-462d-a6ba-9e4b18177ee4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_0d52cad8-4279-4d69-a77e-9efb5d26549a" xlink:href="sesn-20210930.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_0d52cad8-4279-4d69-a77e-9efb5d26549a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_0c2374f8-c5c6-492f-9be9-016c012a96fe" xlink:href="sesn-20210930.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_0c2374f8-c5c6-492f-9be9-016c012a96fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3883be1a-12a5-4c90-8971-ccc16eb8122a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_OperatingLeaseCost_3883be1a-12a5-4c90-8971-ccc16eb8122a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e7b0042f-01e6-4958-bc2c-1ffabb9468ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_OperatingLeaseExpense_e7b0042f-01e6-4958-bc2c-1ffabb9468ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f2ce8455-a176-46e7-8ed2-08c52fce8939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f2ce8455-a176-46e7-8ed2-08c52fce8939" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f2ce8455-a176-46e7-8ed2-08c52fce8939" xlink:to="loc_srt_StatementGeographicalAxis_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092" xlink:to="loc_srt_SegmentGeographicalDomain_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092" xlink:to="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_c4bb1dc3-69ea-4cdc-84ef-230d011cf2fd" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:to="loc_country_CA_c4bb1dc3-69ea-4cdc-84ef-230d011cf2fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_9eb4eac5-2f47-4302-99dc-3365e1fc386f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:to="loc_stpr_MA_9eb4eac5-2f47-4302-99dc-3365e1fc386f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_f943056b-ae22-4f87-b277-9b8972d7c75a" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:to="loc_stpr_PA_f943056b-ae22-4f87-b277-9b8972d7c75a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="extended" id="i9ac6a63766544fe494479bc0269ae612_STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ca923050-62dc-4226-83d1-94f39e0ae9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ca923050-62dc-4226-83d1-94f39e0ae9a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_c589c105-2700-450b-be29-24626ae8a3d1" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_c589c105-2700-450b-be29-24626ae8a3d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_44e35c6c-d232-41b0-877e-2a8067df0d62" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_44e35c6c-d232-41b0-877e-2a8067df0d62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_0dcdf831-2d9e-4935-b0b2-0a990efc12c6" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_0dcdf831-2d9e-4935-b0b2-0a990efc12c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aada6af4-1bae-48a7-9d89-4ab6dfae7f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aada6af4-1bae-48a7-9d89-4ab6dfae7f94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bd733ec5-9096-480c-b78d-f2a00afdddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bd733ec5-9096-480c-b78d-f2a00afdddb7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_ff290b82-2358-4d49-9b44-fa67245fdbad" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_ff290b82-2358-4d49-9b44-fa67245fdbad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_3d228512-138f-4ea9-9e95-7909e1f56213" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_3d228512-138f-4ea9-9e95-7909e1f56213" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7ebc6925-e87a-4bb5-880b-c0727d56d562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:to="loc_us-gaap_CreditFacilityAxis_7ebc6925-e87a-4bb5-880b-c0727d56d562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7ebc6925-e87a-4bb5-880b-c0727d56d562_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7ebc6925-e87a-4bb5-880b-c0727d56d562" xlink:to="loc_us-gaap_CreditFacilityDomain_7ebc6925-e87a-4bb5-880b-c0727d56d562_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3ca45314-c60a-4e81-8214-e5e77cc54674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7ebc6925-e87a-4bb5-880b-c0727d56d562" xlink:to="loc_us-gaap_CreditFacilityDomain_3ca45314-c60a-4e81-8214-e5e77cc54674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_1c3d59f6-6e7b-4441-9843-e830b487e34f" xlink:href="sesn-20210930.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3ca45314-c60a-4e81-8214-e5e77cc54674" xlink:to="loc_sesn_ATMFacilityMember_1c3d59f6-6e7b-4441-9843-e830b487e34f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_53f0b130-a3ce-4f89-81c6-41326611bfee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:to="loc_srt_StatementScenarioAxis_53f0b130-a3ce-4f89-81c6-41326611bfee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_53f0b130-a3ce-4f89-81c6-41326611bfee_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_53f0b130-a3ce-4f89-81c6-41326611bfee" xlink:to="loc_srt_ScenarioUnspecifiedDomain_53f0b130-a3ce-4f89-81c6-41326611bfee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0df5ec38-6a5f-444f-a014-ff0cf9c2ac08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_53f0b130-a3ce-4f89-81c6-41326611bfee" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0df5ec38-6a5f-444f-a014-ff0cf9c2ac08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_656a95d5-b9bf-4c2c-a6ad-5218586a74e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0df5ec38-6a5f-444f-a014-ff0cf9c2ac08" xlink:to="loc_srt_ScenarioForecastMember_656a95d5-b9bf-4c2c-a6ad-5218586a74e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended" id="i9b0088fbbb164e199430a96c2ef1e219_STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_c7868df9-9db2-44f4-abb3-f8b72139683e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_658c7f0c-550a-4246-9584-fa60f9594775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c7868df9-9db2-44f4-abb3-f8b72139683e" xlink:to="loc_us-gaap_CommonStockSharesIssued_658c7f0c-550a-4246-9584-fa60f9594775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_b8216252-ae1e-41c7-a87f-839ac7cc515a" xlink:href="sesn-20210930.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c7868df9-9db2-44f4-abb3-f8b72139683e" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_b8216252-ae1e-41c7-a87f-839ac7cc515a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6c7ad504-644b-4436-b3f2-693ec3d8fb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_b8216252-ae1e-41c7-a87f-839ac7cc515a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6c7ad504-644b-4436-b3f2-693ec3d8fb0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_079794c9-3fc9-4e6d-9e61-d8821b541f37" xlink:href="sesn-20210930.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_b8216252-ae1e-41c7-a87f-839ac7cc515a" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_079794c9-3fc9-4e6d-9e61-d8821b541f37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c7868df9-9db2-44f4-abb3-f8b72139683e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e049ca4-bc6a-4515-9e70-6ebb4537db10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:to="loc_us-gaap_AwardTypeAxis_4e049ca4-bc6a-4515-9e70-6ebb4537db10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e049ca4-bc6a-4515-9e70-6ebb4537db10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4e049ca4-bc6a-4515-9e70-6ebb4537db10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e049ca4-bc6a-4515-9e70-6ebb4537db10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4e049ca4-bc6a-4515-9e70-6ebb4537db10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5fab9ec0-a2de-465a-9446-f517e4164d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:to="loc_us-gaap_WarrantMember_5fab9ec0-a2de-465a-9446-f517e4164d7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a916d15-77bd-4cd9-8c2e-c0ceecdad2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a916d15-77bd-4cd9-8c2e-c0ceecdad2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_dfd54d8c-fab3-4f84-b65e-2ba70b1a2d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:to="loc_us-gaap_StockCompensationPlanMember_dfd54d8c-fab3-4f84-b65e-2ba70b1a2d84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_01e75fbe-e724-49e1-89a5-c211b39d5599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:to="loc_us-gaap_PlanNameAxis_01e75fbe-e724-49e1-89a5-c211b39d5599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_01e75fbe-e724-49e1-89a5-c211b39d5599_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_01e75fbe-e724-49e1-89a5-c211b39d5599" xlink:to="loc_us-gaap_PlanNameDomain_01e75fbe-e724-49e1-89a5-c211b39d5599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4f317f24-947c-45b4-b050-3d647491f6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_01e75fbe-e724-49e1-89a5-c211b39d5599" xlink:to="loc_us-gaap_PlanNameDomain_4f317f24-947c-45b4-b050-3d647491f6a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_23e8367e-351b-4a93-9d8a-3dd1367ea81e" xlink:href="sesn-20210930.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4f317f24-947c-45b4-b050-3d647491f6a7" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_23e8367e-351b-4a93-9d8a-3dd1367ea81e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_6d221f76-7547-4e8c-874c-4d4ba6897167" xlink:href="sesn-20210930.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4f317f24-947c-45b4-b050-3d647491f6a7" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_6d221f76-7547-4e8c-874c-4d4ba6897167" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="extended" id="i32e563bf004e4c8f80b3036187ca870b_STOCKHOLDERSEQUITYDEFICITWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3f8216fc-05ed-4e45-839e-d2c7d422f4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:href="sesn-20210930.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3f8216fc-05ed-4e45-839e-d2c7d422f4f0" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2a407d23-cc0e-4749-97c4-e8e8d497a10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2a407d23-cc0e-4749-97c4-e8e8d497a10d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_56b0c5b3-2463-4188-8be4-f286f0e0f997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_56b0c5b3-2463-4188-8be4-f286f0e0f997" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_97c39bcf-12d6-4e4f-b122-555514ed7afb" xlink:href="sesn-20210930.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_97c39bcf-12d6-4e4f-b122-555514ed7afb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1d101955-ce0c-46f8-aeaa-584fc918bc50" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1d101955-ce0c-46f8-aeaa-584fc918bc50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_3600c3c4-3708-4d76-8b54-f00242187a34" xlink:href="sesn-20210930.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_3600c3c4-3708-4d76-8b54-f00242187a34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3ed658a8-4879-445a-9f3e-7d1c92068724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_af019925-15e7-413c-9641-6cd4a682da9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3f8216fc-05ed-4e45-839e-d2c7d422f4f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_af019925-15e7-413c-9641-6cd4a682da9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_81468e28-3061-4807-b9cd-8494a7494996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_af019925-15e7-413c-9641-6cd4a682da9d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_81468e28-3061-4807-b9cd-8494a7494996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_81468e28-3061-4807-b9cd-8494a7494996_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81468e28-3061-4807-b9cd-8494a7494996" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_81468e28-3061-4807-b9cd-8494a7494996_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81468e28-3061-4807-b9cd-8494a7494996" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_9f3c443c-1767-4037-80f1-0cd63c564556" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_9f3c443c-1767-4037-80f1-0cd63c564556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_385c4580-2509-4cab-bbd7-45248af47f8d" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_385c4580-2509-4cab-bbd7-45248af47f8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_6600e65c-28d1-41de-be0d-5780ae798c4c" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_6600e65c-28d1-41de-be0d-5780ae798c4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_a3f2991e-630a-4443-b03e-e3228b44a425" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_a3f2991e-630a-4443-b03e-e3228b44a425" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#EARNINGSLOSSPERSHAREScheduleofEPSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails" xlink:type="extended" id="i99f74da6d94e4da5a31547a4036cb59b_EARNINGSLOSSPERSHAREScheduleofEPSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_42ddb1de-cde0-40b1-91d2-f7a82bd45beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_42ddb1de-cde0-40b1-91d2-f7a82bd45beb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_42ddb1de-cde0-40b1-91d2-f7a82bd45beb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8e177e53-4364-4818-9a8e-e9ba469ab77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:to="loc_us-gaap_NetIncomeLoss_8e177e53-4364-4818-9a8e-e9ba469ab77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9a5c3ea5-bc85-472f-ac48-ce3f2a91123f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9a5c3ea5-bc85-472f-ac48-ce3f2a91123f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e40839c2-6db4-40d0-8066-2eb07a3cb4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e40839c2-6db4-40d0-8066-2eb07a3cb4e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_760b9117-6322-4af8-abf7-582c55d8cc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_760b9117-6322-4af8-abf7-582c55d8cc5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_86521645-ff82-4a4f-bf29-853c4933fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_42ddb1de-cde0-40b1-91d2-f7a82bd45beb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_86521645-ff82-4a4f-bf29-853c4933fe83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a023476-f16a-47ad-9f6e-b21ea0c7f5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_86521645-ff82-4a4f-bf29-853c4933fe83" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a023476-f16a-47ad-9f6e-b21ea0c7f5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ad905931-7718-4571-a297-68f5a8d221b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_86521645-ff82-4a4f-bf29-853c4933fe83" xlink:to="loc_us-gaap_EarningsPerShareBasic_ad905931-7718-4571-a297-68f5a8d221b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_9c1007a8-00cd-4a46-9b6a-9d56d096320b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_9c1007a8-00cd-4a46-9b6a-9d56d096320b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_e4dd88f6-8e75-42eb-9110-9fe9942d740a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_9c1007a8-00cd-4a46-9b6a-9d56d096320b" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_e4dd88f6-8e75-42eb-9110-9fe9942d740a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9d900ab-1a75-4407-aeb8-9851d6d7181a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_9c1007a8-00cd-4a46-9b6a-9d56d096320b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9d900ab-1a75-4407-aeb8-9851d6d7181a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bfd088e1-e9de-4164-ae12-f4bcb18e28ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bfd088e1-e9de-4164-ae12-f4bcb18e28ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_063512e1-8587-4eb4-9b28-61268cb79cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_063512e1-8587-4eb4-9b28-61268cb79cc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9af8c042-7331-470d-a586-4653dc3efac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9af8c042-7331-470d-a586-4653dc3efac2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_f3b5720e-127d-474f-bd06-2a96890f9679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_f3b5720e-127d-474f-bd06-2a96890f9679" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3bda8786-0838-4b49-9624-0f6e89765a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_f3b5720e-127d-474f-bd06-2a96890f9679" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3bda8786-0838-4b49-9624-0f6e89765a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_987e3b21-98c8-4c2f-846a-7eb59f8c03de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_987e3b21-98c8-4c2f-846a-7eb59f8c03de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7facf6-38d1-4456-b971-c040acb56fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_987e3b21-98c8-4c2f-846a-7eb59f8c03de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7facf6-38d1-4456-b971-c040acb56fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7facf6-38d1-4456-b971-c040acb56fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7facf6-38d1-4456-b971-c040acb56fd3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7facf6-38d1-4456-b971-c040acb56fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50c9c66c-4637-4c9c-b988-ca3215ddbe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7facf6-38d1-4456-b971-c040acb56fd3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50c9c66c-4637-4c9c-b988-ca3215ddbe7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ab23095b-cb23-458e-8942-ef77e73f2c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50c9c66c-4637-4c9c-b988-ca3215ddbe7c" xlink:to="loc_us-gaap_WarrantMember_ab23095b-cb23-458e-8942-ef77e73f2c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_528a799f-e802-47f1-b142-31b576839f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50c9c66c-4637-4c9c-b988-ca3215ddbe7c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_528a799f-e802-47f1-b142-31b576839f72" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended" id="i684b489855554c1b877cffcd6cd9baab_EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b54ef73c-8f53-472f-a73e-9fc9fa7c2633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2f6d02d0-344b-4256-906c-5cf5ba7cda47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b54ef73c-8f53-472f-a73e-9fc9fa7c2633" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2f6d02d0-344b-4256-906c-5cf5ba7cda47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc2ad77-40f6-4e00-9754-a4c4261ef2da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b54ef73c-8f53-472f-a73e-9fc9fa7c2633" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc2ad77-40f6-4e00-9754-a4c4261ef2da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a152946-3569-4a20-971d-a7a3c46fdfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc2ad77-40f6-4e00-9754-a4c4261ef2da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a152946-3569-4a20-971d-a7a3c46fdfa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6a152946-3569-4a20-971d-a7a3c46fdfa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a152946-3569-4a20-971d-a7a3c46fdfa1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6a152946-3569-4a20-971d-a7a3c46fdfa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_efbb4493-8c3b-4574-a6f6-e556bfa06734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a152946-3569-4a20-971d-a7a3c46fdfa1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_efbb4493-8c3b-4574-a6f6-e556bfa06734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_42a135e5-8e6e-4e76-864d-8c3abfd9a3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_efbb4493-8c3b-4574-a6f6-e556bfa06734" xlink:to="loc_us-gaap_WarrantMember_42a135e5-8e6e-4e76-864d-8c3abfd9a3df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8852a36c-8d5b-4442-a9db-9751d2dd8777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_efbb4493-8c3b-4574-a6f6-e556bfa06734" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8852a36c-8d5b-4442-a9db-9751d2dd8777" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended" id="i96eaab98a03f47d09d5208df28f355a6_SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82fd84ba-84d5-49b4-ab7d-86338fff9963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_68a78cad-1538-44ef-823e-32a8a6a65781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82fd84ba-84d5-49b4-ab7d-86338fff9963" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_68a78cad-1538-44ef-823e-32a8a6a65781" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8050342e-3e17-40be-b913-3156b75b28f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82fd84ba-84d5-49b4-ab7d-86338fff9963" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8050342e-3e17-40be-b913-3156b75b28f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3eaf9709-7bf0-46a0-a145-abf78d5c68ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8050342e-3e17-40be-b913-3156b75b28f5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3eaf9709-7bf0-46a0-a145-abf78d5c68ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3eaf9709-7bf0-46a0-a145-abf78d5c68ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eaf9709-7bf0-46a0-a145-abf78d5c68ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3eaf9709-7bf0-46a0-a145-abf78d5c68ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51fb91ed-5274-407c-a728-38066a8ffcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eaf9709-7bf0-46a0-a145-abf78d5c68ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51fb91ed-5274-407c-a728-38066a8ffcc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22869715-bb94-4a89-bbc6-cfcaae65a88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51fb91ed-5274-407c-a728-38066a8ffcc7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22869715-bb94-4a89-bbc6-cfcaae65a88e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a8491e92-83e1-4400-913f-75099a00ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51fb91ed-5274-407c-a728-38066a8ffcc7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a8491e92-83e1-4400-913f-75099a00ca5c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i215cd9fb932149259b3a8abe88f6503b_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_e84df59c-9aee-4734-98a3-494248cd0e77" xlink:href="sesn-20210930.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_e84df59c-9aee-4734-98a3-494248cd0e77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3848e9d9-fb86-437c-8a79-cbf82d7b6b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3848e9d9-fb86-437c-8a79-cbf82d7b6b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1d6a6d6-89ea-45d1-bcb6-1e64a20be147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1d6a6d6-89ea-45d1-bcb6-1e64a20be147" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ed584040-1225-4644-aca5-aedd0137b6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ed584040-1225-4644-aca5-aedd0137b6c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b3892f1-ecf7-4b4e-81d7-0a3361dcadae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b3892f1-ecf7-4b4e-81d7-0a3361dcadae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7bf952f8-6035-40e9-9265-7997ffc1f78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7bf952f8-6035-40e9-9265-7997ffc1f78c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_a7b8da00-c0e3-4a01-a613-8825d3f0bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_a7b8da00-c0e3-4a01-a613-8825d3f0bc12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8c8d2eb1-8f08-4fa6-bd13-5c893854c5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8c8d2eb1-8f08-4fa6-bd13-5c893854c5fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d9869b4-895e-402d-8b26-e92ab2ead884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d9869b4-895e-402d-8b26-e92ab2ead884" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_801bd1b4-fc00-4578-969c-043e6eb2dff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_801bd1b4-fc00-4578-969c-043e6eb2dff3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0eeffb3-0611-481c-9c25-b073f9f85bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0eeffb3-0611-481c-9c25-b073f9f85bd8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e1003ab6-a811-4acf-95eb-2cff461d02de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_VestingAxis_e1003ab6-a811-4acf-95eb-2cff461d02de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e1003ab6-a811-4acf-95eb-2cff461d02de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_e1003ab6-a811-4acf-95eb-2cff461d02de" xlink:to="loc_us-gaap_VestingDomain_e1003ab6-a811-4acf-95eb-2cff461d02de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a0330a9f-8139-408b-b71d-b2bb425f4d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_e1003ab6-a811-4acf-95eb-2cff461d02de" xlink:to="loc_us-gaap_VestingDomain_a0330a9f-8139-408b-b71d-b2bb425f4d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_43076ffd-2ade-4b62-b6f9-771ae54df6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a0330a9f-8139-408b-b71d-b2bb425f4d50" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_43076ffd-2ade-4b62-b6f9-771ae54df6d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_19b7f6e5-8e58-4d90-84b2-52f8144bcc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a0330a9f-8139-408b-b71d-b2bb425f4d50" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_19b7f6e5-8e58-4d90-84b2-52f8144bcc9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_PlanNameAxis_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f" xlink:to="loc_us-gaap_PlanNameDomain_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a7d96eb2-ce06-46f4-91e0-b76647d3aca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f" xlink:to="loc_us-gaap_PlanNameDomain_a7d96eb2-ce06-46f4-91e0-b76647d3aca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_348f96cf-d387-4f70-bf98-ae180d893c1d" xlink:href="sesn-20210930.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a7d96eb2-ce06-46f4-91e0-b76647d3aca8" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_348f96cf-d387-4f70-bf98-ae180d893c1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_7362c8e9-46d6-4162-8dc6-8e7ae51b6267" xlink:href="sesn-20210930.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a7d96eb2-ce06-46f4-91e0-b76647d3aca8" xlink:to="loc_sesn_StockIncentivePlan2009Member_7362c8e9-46d6-4162-8dc6-8e7ae51b6267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e820aee1-5b6d-49f2-a82a-f8b4ed69309f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_AwardTypeAxis_e820aee1-5b6d-49f2-a82a-f8b4ed69309f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e820aee1-5b6d-49f2-a82a-f8b4ed69309f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e820aee1-5b6d-49f2-a82a-f8b4ed69309f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e820aee1-5b6d-49f2-a82a-f8b4ed69309f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f20eec08-3a60-4ec5-ab16-dc94683e4ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e820aee1-5b6d-49f2-a82a-f8b4ed69309f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f20eec08-3a60-4ec5-ab16-dc94683e4ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b5a7489c-7634-41c2-9609-7e55a070b962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f20eec08-3a60-4ec5-ab16-dc94683e4ab8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b5a7489c-7634-41c2-9609-7e55a070b962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_21c53ba2-f51b-4423-a047-7b1b5e935e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_GranteeStatusAxis_21c53ba2-f51b-4423-a047-7b1b5e935e7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_21c53ba2-f51b-4423-a047-7b1b5e935e7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_21c53ba2-f51b-4423-a047-7b1b5e935e7d" xlink:to="loc_us-gaap_GranteeStatusDomain_21c53ba2-f51b-4423-a047-7b1b5e935e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_b5bba3e1-bf8a-4d7b-b6c8-83b94001584f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_21c53ba2-f51b-4423-a047-7b1b5e935e7d" xlink:to="loc_us-gaap_GranteeStatusDomain_b5bba3e1-bf8a-4d7b-b6c8-83b94001584f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_25abc82b-b348-4dd2-b3bd-227a8e20ee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_b5bba3e1-bf8a-4d7b-b6c8-83b94001584f" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_25abc82b-b348-4dd2-b3bd-227a8e20ee6c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="ieb4cb2a394c94891a20cbfce51e82cd8_EMPLOYEEBENEFITPLANSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_110cc856-66fe-4bf2-b44e-33aa0d922d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_110cc856-66fe-4bf2-b44e-33aa0d922d13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fabbce30-930e-4716-809e-3ad664eedf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fabbce30-930e-4716-809e-3ad664eedf40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_d6259f77-5027-4f12-81d9-4967ec32f86e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_d6259f77-5027-4f12-81d9-4967ec32f86e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eef9b96a-d876-41fc-878d-6acb9abe9150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eef9b96a-d876-41fc-878d-6acb9abe9150" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_cfb5bf61-b2f3-4f22-82eb-9338fc2c1e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_cfb5bf61-b2f3-4f22-82eb-9338fc2c1e06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_b4ab8cc7-f0ef-45af-bc30-8a52e414cd58" xlink:href="sesn-20210930.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_b4ab8cc7-f0ef-45af-bc30-8a52e414cd58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_56df5a7e-66a0-4ea7-8889-452b0504ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_56df5a7e-66a0-4ea7-8889-452b0504ac40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_304fd755-6e6d-4fa6-b3d0-a3bb514a4436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_304fd755-6e6d-4fa6-b3d0-a3bb514a4436" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b66c7b82-e6c7-4f03-87ea-df558acbbfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_304fd755-6e6d-4fa6-b3d0-a3bb514a4436" xlink:to="loc_us-gaap_PlanNameAxis_b66c7b82-e6c7-4f03-87ea-df558acbbfc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b66c7b82-e6c7-4f03-87ea-df558acbbfc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b66c7b82-e6c7-4f03-87ea-df558acbbfc8" xlink:to="loc_us-gaap_PlanNameDomain_b66c7b82-e6c7-4f03-87ea-df558acbbfc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b697346f-e5d6-4684-a2ea-6aea5f9a08af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b66c7b82-e6c7-4f03-87ea-df558acbbfc8" xlink:to="loc_us-gaap_PlanNameDomain_b697346f-e5d6-4684-a2ea-6aea5f9a08af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_1bd2ca7a-a32a-4fc2-8dba-6fd87590ec4b" xlink:href="sesn-20210930.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b697346f-e5d6-4684-a2ea-6aea5f9a08af" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_1bd2ca7a-a32a-4fc2-8dba-6fd87590ec4b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#LICENSEAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended" id="ifd082011fd694e159ae02b58af9c3ad5_LICENSEAGREEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:href="sesn-20210930.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_fc32d933-dc53-4ab8-9f05-d0cc04431b66" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_fc32d933-dc53-4ab8-9f05-d0cc04431b66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_98a831e5-8f4b-48e4-a45a-d8239a030d28" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_98a831e5-8f4b-48e4-a45a-d8239a030d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_4985f9b7-ed56-4c24-a626-cfe6f7ad9e55" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_4985f9b7-ed56-4c24-a626-cfe6f7ad9e55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_47e6f1d4-0616-4963-be12-a0e04a85c875" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_47e6f1d4-0616-4963-be12-a0e04a85c875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_a7122ed1-c4ff-4ee5-9a50-9dc93aa34ff3" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_a7122ed1-c4ff-4ee5-9a50-9dc93aa34ff3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_8dbaaa89-4c32-4c37-b264-0e409778d665" xlink:href="sesn-20210930.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_8dbaaa89-4c32-4c37-b264-0e409778d665" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_cf4430b5-06d1-48ca-ae3e-9ffb40850ba3" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_cf4430b5-06d1-48ca-ae3e-9ffb40850ba3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_94899250-dc5a-4628-978b-d882608cbe1d" xlink:href="sesn-20210930.xsd#sesn_LicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseMaintenanceFees_94899250-dc5a-4628-978b-d882608cbe1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_c0dca754-d1fa-4a06-9762-766424e39b19" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_c0dca754-d1fa-4a06-9762-766424e39b19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_45bd2bfb-9bdd-4c23-88e5-951032806e01" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_45bd2bfb-9bdd-4c23-88e5-951032806e01" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_91fd4fc3-27c9-4e11-8684-a1879619504a" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_91fd4fc3-27c9-4e11-8684-a1879619504a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_3c137b56-cfdc-40e8-88d1-8f04ea51d9d5" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_3c137b56-cfdc-40e8-88d1-8f04ea51d9d5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_9aa67200-3b1b-4f28-8825-bdc25be754d5" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_9aa67200-3b1b-4f28-8825-bdc25be754d5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_f0ad18ae-5c65-45fd-b4b8-1d4b3e2d1d70" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_f0ad18ae-5c65-45fd-b4b8-1d4b3e2d1d70" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_11c018aa-81ad-445b-a1db-4452a3a5708d" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_11c018aa-81ad-445b-a1db-4452a3a5708d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_91a26e8f-c4e7-4ea9-9f84-d95ac9246947" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_91a26e8f-c4e7-4ea9-9f84-d95ac9246947" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_f6bcc8f4-ea28-47fb-83dd-11f4fb1bc83d" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_f6bcc8f4-ea28-47fb-83dd-11f4fb1bc83d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_1a09ab16-93de-4d18-9711-93a922bf62ac" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_1a09ab16-93de-4d18-9711-93a922bf62ac" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b2c05221-951d-4ff8-a42e-f6264f8e7c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b2c05221-951d-4ff8-a42e-f6264f8e7c1e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_436f8fb8-6ba9-4d65-9723-aedcb5f49532" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_436f8fb8-6ba9-4d65-9723-aedcb5f49532" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAccountsReceivable_32d8f720-f80f-474a-92b1-10b28ed130f7" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementAccountsReceivable_32d8f720-f80f-474a-92b1-10b28ed130f7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f4b46b90-12bf-426a-b85b-d22576ccf669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f4b46b90-12bf-426a-b85b-d22576ccf669" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ae3a815-c10a-48de-ac83-b937a0a84cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ae3a815-c10a-48de-ac83-b937a0a84cf9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0ae73638-258c-46c6-91d4-a31c77f409fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0ae73638-258c-46c6-91d4-a31c77f409fd" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_d3d17ad1-3a82-43f8-8f61-cd8dfb7b1e1d" xlink:href="sesn-20210930.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_RoyaltyRevenuePercentage_d3d17ad1-3a82-43f8-8f61-cd8dfb7b1e1d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:href="sesn-20210930.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27597b1c-8dd3-4d97-acf1-88d6713f9a16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_srt_CounterpartyNameAxis_27597b1c-8dd3-4d97-acf1-88d6713f9a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27597b1c-8dd3-4d97-acf1-88d6713f9a16_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_27597b1c-8dd3-4d97-acf1-88d6713f9a16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27597b1c-8dd3-4d97-acf1-88d6713f9a16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_27597b1c-8dd3-4d97-acf1-88d6713f9a16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_827043b1-26a7-4bf6-9de2-ef0aef042270" xlink:href="sesn-20210930.xsd#sesn_UniversityOfZurichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_UniversityOfZurichMember_827043b1-26a7-4bf6-9de2-ef0aef042270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_afdb46b2-fa57-4eb2-b8cb-5565879c8f44" xlink:href="sesn-20210930.xsd#sesn_MicrometAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_MicrometAGMember_afdb46b2-fa57-4eb2-b8cb-5565879c8f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_592a2cbe-47eb-4952-936b-841f5f25c741" xlink:href="sesn-20210930.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_XOMAIrelandLimitedMember_592a2cbe-47eb-4952-936b-841f5f25c741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_26930510-9f17-49be-a5e6-57efbcf00442" xlink:href="sesn-20210930.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_RocheMember_26930510-9f17-49be-a5e6-57efbcf00442" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_b505cd07-b146-4a5a-933c-93578c62c42b" xlink:href="sesn-20210930.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_b505cd07-b146-4a5a-933c-93578c62c42b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_1c56d4b2-9023-4196-82d5-fcd517b652ea" xlink:href="sesn-20210930.xsd#sesn_MENALicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_MENALicenseAgreementMember_1c56d4b2-9023-4196-82d5-fcd517b652ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_c0d57d8d-35d9-4eeb-947f-e5f99ad67451" xlink:href="sesn-20210930.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_c0d57d8d-35d9-4eeb-947f-e5f99ad67451" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d308a09-48ed-477c-bee0-3dc0045537eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_srt_ProductOrServiceAxis_4d308a09-48ed-477c-bee0-3dc0045537eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d308a09-48ed-477c-bee0-3dc0045537eb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4d308a09-48ed-477c-bee0-3dc0045537eb" xlink:to="loc_srt_ProductsAndServicesDomain_4d308a09-48ed-477c-bee0-3dc0045537eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_683bd49b-9b0a-4c42-baac-4439c47df2c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4d308a09-48ed-477c-bee0-3dc0045537eb" xlink:to="loc_srt_ProductsAndServicesDomain_683bd49b-9b0a-4c42-baac-4439c47df2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_3dc7c580-eec9-4a0b-93bc-30f52940b55d" xlink:href="sesn-20210930.xsd#sesn_EBI031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_683bd49b-9b0a-4c42-baac-4439c47df2c5" xlink:to="loc_sesn_EBI031Member_3dc7c580-eec9-4a0b-93bc-30f52940b55d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member_e9d57d5b-effe-4a2e-b990-3d6ddcb00b26" xlink:href="sesn-20210930.xsd#sesn_IL6Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_683bd49b-9b0a-4c42-baac-4439c47df2c5" xlink:to="loc_sesn_IL6Member_e9d57d5b-effe-4a2e-b990-3d6ddcb00b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d3c015a-8425-439b-bc1f-3c2d57d2d430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d3c015a-8425-439b-bc1f-3c2d57d2d430" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c015a-8425-439b-bc1f-3c2d57d2d430_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d3c015a-8425-439b-bc1f-3c2d57d2d430" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c015a-8425-439b-bc1f-3c2d57d2d430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d3c015a-8425-439b-bc1f-3c2d57d2d430" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_28513929-de49-49db-be9a-36e20ac2519b" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_28513929-de49-49db-be9a-36e20ac2519b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_38f16505-7d16-4565-b4be-ea629bfed3bb" xlink:href="sesn-20210930.xsd#sesn_FirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_FirstIndicationMember_38f16505-7d16-4565-b4be-ea629bfed3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_f935e1f6-c7f5-4d1b-9a2c-28073f69b97e" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_f935e1f6-c7f5-4d1b-9a2c-28073f69b97e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_1e76b781-63dc-4c0d-8141-b1919462e5de" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_1e76b781-63dc-4c0d-8141-b1919462e5de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_f0a6a539-f5da-4c8c-aa73-3365a2bc718d" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_f0a6a539-f5da-4c8c-aa73-3365a2bc718d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_1ea3c5eb-d870-46f3-a7e1-ff6e7290e1da" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_1ea3c5eb-d870-46f3-a7e1-ff6e7290e1da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_3a2cd7d0-8917-4161-ab28-e24552f7e25c" xlink:href="sesn-20210930.xsd#sesn_SecondIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_SecondIndicationMember_3a2cd7d0-8917-4161-ab28-e24552f7e25c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ed60935-ea76-4e71-ae4e-9bfe999482df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_srt_RangeAxis_6ed60935-ea76-4e71-ae4e-9bfe999482df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ed60935-ea76-4e71-ae4e-9bfe999482df_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6ed60935-ea76-4e71-ae4e-9bfe999482df" xlink:to="loc_srt_RangeMember_6ed60935-ea76-4e71-ae4e-9bfe999482df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48522218-a933-47c5-8af9-95b8afa520f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6ed60935-ea76-4e71-ae4e-9bfe999482df" xlink:to="loc_srt_RangeMember_48522218-a933-47c5-8af9-95b8afa520f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8aeba303-3228-4c07-b23b-d51799b6dbe1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_48522218-a933-47c5-8af9-95b8afa520f2" xlink:to="loc_srt_MinimumMember_8aeba303-3228-4c07-b23b-d51799b6dbe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_850a1220-cb38-4484-81e2-3f3d7a79122f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_48522218-a933-47c5-8af9-95b8afa520f2" xlink:to="loc_srt_MaximumMember_850a1220-cb38-4484-81e2-3f3d7a79122f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fe86b7d-c360-42c1-9a6d-672bf06adf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fe86b7d-c360-42c1-9a6d-672bf06adf75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_e9f52f1b-6785-496e-88a1-a97e65f66455" xlink:href="sesn-20210930.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fe86b7d-c360-42c1-9a6d-672bf06adf75" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_e9f52f1b-6785-496e-88a1-a97e65f66455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ddadd1-bacb-407d-a2f2-52f8c95eb624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ddadd1-bacb-407d-a2f2-52f8c95eb624" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1ddadd1-bacb-407d-a2f2-52f8c95eb624_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ddadd1-bacb-407d-a2f2-52f8c95eb624" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1ddadd1-bacb-407d-a2f2-52f8c95eb624_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03b16412-d530-4b84-b76b-174834225a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ddadd1-bacb-407d-a2f2-52f8c95eb624" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03b16412-d530-4b84-b76b-174834225a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_51cb6fef-4549-4b60-8c30-cbd97189a4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03b16412-d530-4b84-b76b-174834225a45" xlink:to="loc_us-gaap_LicensingAgreementsMember_51cb6fef-4549-4b60-8c30-cbd97189a4b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_edafe90b-6100-4554-8241-292753b39e39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_srt_StatementGeographicalAxis_edafe90b-6100-4554-8241-292753b39e39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_edafe90b-6100-4554-8241-292753b39e39_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_edafe90b-6100-4554-8241-292753b39e39" xlink:to="loc_srt_SegmentGeographicalDomain_edafe90b-6100-4554-8241-292753b39e39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d2df6263-9a96-47d0-b242-ca98fede35dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_edafe90b-6100-4554-8241-292753b39e39" xlink:to="loc_srt_SegmentGeographicalDomain_d2df6263-9a96-47d0-b242-ca98fede35dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_dca05775-8874-46aa-9d43-4065f45f9f38" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d2df6263-9a96-47d0-b242-ca98fede35dd" xlink:to="loc_country_TR_dca05775-8874-46aa-9d43-4065f45f9f38" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#RESTRUCTURINGANDRELATEDACTIVITIESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="extended" id="i6646f09fa7b34c09962faf426d001f28_RESTRUCTURINGANDRELATEDACTIVITIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_573bce67-1013-4a87-bce3-ffe498a29445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:to="loc_us-gaap_RestructuringCharges_573bce67-1013-4a87-bce3-ffe498a29445" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_d8051aa4-bea0-4dd2-b2b0-b795a9c98c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:to="loc_us-gaap_PaymentsForRestructuring_d8051aa4-bea0-4dd2-b2b0-b795a9c98c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_805a3e47-8667-4b34-899d-f2d34c4eb0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:to="loc_us-gaap_RestructuringReserve_805a3e47-8667-4b34-899d-f2d34c4eb0a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fb836918-14c2-4e0e-bb66-2cc61e79207e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fb836918-14c2-4e0e-bb66-2cc61e79207e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b4c47703-70d9-43e6-bca6-3c258f594422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fb836918-14c2-4e0e-bb66-2cc61e79207e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b4c47703-70d9-43e6-bca6-3c258f594422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b4c47703-70d9-43e6-bca6-3c258f594422_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b4c47703-70d9-43e6-bca6-3c258f594422" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b4c47703-70d9-43e6-bca6-3c258f594422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b4c47703-70d9-43e6-bca6-3c258f594422" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_21417c79-fc27-4772-b512-66ef46a4ec48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:to="loc_us-gaap_EmployeeSeveranceMember_21417c79-fc27-4772-b512-66ef46a4ec48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_c03a4140-58e9-4e3e-b26f-ba0fb2f1b01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractTerminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:to="loc_us-gaap_ContractTerminationMember_c03a4140-58e9-4e3e-b26f-ba0fb2f1b01f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_58cc218d-414e-4fb3-9f92-cde92629e562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:to="loc_us-gaap_OtherRestructuringMember_58cc218d-414e-4fb3-9f92-cde92629e562" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended" id="i1f04fc8bee3a4996908c18179997c299_SUBSEQUENTEVENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_72242d75-9c1c-4cfe-97df-1e810b173675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_d43ec636-1b8d-4fb0-a570-f327d6a5ad1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_72242d75-9c1c-4cfe-97df-1e810b173675" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_d43ec636-1b8d-4fb0-a570-f327d6a5ad1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_72242d75-9c1c-4cfe-97df-1e810b173675" xlink:to="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b671e43a-fd98-4986-a340-b5c08b926a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b671e43a-fd98-4986-a340-b5c08b926a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b671e43a-fd98-4986-a340-b5c08b926a0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b671e43a-fd98-4986-a340-b5c08b926a0e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b671e43a-fd98-4986-a340-b5c08b926a0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c59ef07f-06c7-4661-986c-f5a8985df658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b671e43a-fd98-4986-a340-b5c08b926a0e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c59ef07f-06c7-4661-986c-f5a8985df658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c940ca7c-0a7a-4496-9f07-c488946cee95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c59ef07f-06c7-4661-986c-f5a8985df658" xlink:to="loc_us-gaap_SubsequentEventMember_c940ca7c-0a7a-4496-9f07-c488946cee95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_15b731e3-244f-4deb-a367-8639054599c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:to="loc_srt_TitleOfIndividualAxis_15b731e3-244f-4deb-a367-8639054599c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15b731e3-244f-4deb-a367-8639054599c4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_15b731e3-244f-4deb-a367-8639054599c4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15b731e3-244f-4deb-a367-8639054599c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e9015ea-5761-48eb-8f74-673f119f8d3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_15b731e3-244f-4deb-a367-8639054599c4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e9015ea-5761-48eb-8f74-673f119f8d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_6168a4cf-e3c8-4b8e-967e-d398d438656f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e9015ea-5761-48eb-8f74-673f119f8d3b" xlink:to="loc_srt_ExecutiveOfficerMember_6168a4cf-e3c8-4b8e-967e-d398d438656f" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>sesn-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:43f34410-0797-4c9d-95d4-0172445a49a1,g:6be5cc14-c349-4e45-a047-13acab623f46-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_18926630-1712-44b9-9b9f-6d481a0a8cd3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DebtInstrumentIndexRateHighYield_5eebb9cf-93a8-4ded-905d-d55f3b4838a2_terseLabel_en-US" xlink:label="lab_sesn_DebtInstrumentIndexRateHighYield" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Index Rate, High-Yield</link:label>
    <link:label id="lab_sesn_DebtInstrumentIndexRateHighYield_label_en-US" xlink:label="lab_sesn_DebtInstrumentIndexRateHighYield" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Index Rate, High-Yield</link:label>
    <link:label id="lab_sesn_DebtInstrumentIndexRateHighYield_documentation_en-US" xlink:label="lab_sesn_DebtInstrumentIndexRateHighYield" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Index Rate, High-Yield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DebtInstrumentIndexRateHighYield" xlink:href="sesn-20210930.xsd#sesn_DebtInstrumentIndexRateHighYield"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DebtInstrumentIndexRateHighYield" xlink:to="lab_sesn_DebtInstrumentIndexRateHighYield" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_1bd4867e-11ea-43c5-866e-9fede87dc382_terseLabel_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_label_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_documentation_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember" xlink:href="sesn-20210930.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_XOMAIrelandLimitedMember" xlink:to="lab_sesn_XOMAIrelandLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2c477480-637c-47c7-a9ad-91da6570b688_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0063270-352c-4074-aeec-cc1385cd1027_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_85b231fb-f775-49a2-be77-c599627e2855_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) and Comprehensive Income (Loss) After Taxes</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4810ba9e-4c72-4c30-8a76-5d8c84cc9d92_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fd8b470b-fa3b-402a-ba3a-59e924a88e96_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3ff3f116-7b4c-4a2c-a643-5ca0b2446760_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations_d453e74b-c4ae-44c0-804b-72d6e47d91db_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" xlink:to="lab_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9cb67826-1909-41e2-88f9-53f3d0b62101_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f2932426-57ca-4c5d-a846-8836585ecb02_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_af2609b5-abeb-48f4-9875-f5e54e809225_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8b4a9216-bc5c-4907-8fe6-4ab8f86c1eee_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_72fa4600-f325-47d3-a044-3e4070edfe1c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_bea9203a-cb3f-4233-8eca-28107c414005_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_50a6c205-1c47-4a62-83ff-8563134c0a33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price, discount rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_10e1f9d1-d195-4ea9-9d82-703980c423b2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_dd0bb0bd-60d9-4255-adab-36a92eec39d8_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_8d06d262-46ce-49f1-8553-f19acf19cdf1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cc23bc68-ec89-4f77-8a0a-1759db02ff47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_11a3a788-6cac-4555-aef0-c507a227eb4c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5fa40f8d-841b-488b-b062-a43aa3eda9c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_783d35e6-8f0e-4df1-97fc-a5c10b37befe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractTerminationMember_2d575fad-75f5-4a43-9580-91f1fa1d4da1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Termination</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractTerminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember" xlink:to="lab_us-gaap_ContractTerminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a586319-b4d7-469c-a828-c78bfa07170b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for sale (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bf2b7ef1-57a3-41be-9b85-e3e9a34a7005_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_bced053c-5898-43a5-9421-503579f3a37a_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_7ab175db-c599-42a9-8ca1-47d292f5a925_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D intangible assets</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_372afe45-4139-4af2-b52d-01bf03aff8b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2027b06e-35ab-41f5-b485-50f5c14e9935_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_8291810c-740d-43f6-aaf1-4bc5b3a3b982_terseLabel_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_label_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_documentation_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage" xlink:href="sesn-20210930.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RoyaltyRevenuePercentage" xlink:to="lab_sesn_RoyaltyRevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_51462cff-ade6-410f-af17-132bed62c721_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f2d0f36b-8df0-4b19-a4ec-e0093b870a35_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_aa9e7e8b-f458-406d-b6a8-809f10e6c46e_terseLabel_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal option</link:label>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_label_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</link:label>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_documentation_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:href="sesn-20210930.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:to="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_7df914e7-3816-4a88-a6b7-6a4dbe7d0786_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front license fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementUpfrontFee" xlink:to="lab_sesn_LicenseAgreementUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c8490fb2-1284-4421-aeed-71316df4a821_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_837f09cc-1ff8-4d65-bc17-190da802d91b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_bf5eccd1-3568-46f7-bd02-67abc9003e8a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50c11cdd-d761-421a-9e41-87e650695b03_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_df5d0d6f-c245-4949-9fe4-ea8b823e8332_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty on net product sales, minimum</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e9659525-5a63-4b67-803d-2d0be0515168_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4bbf0b69-e2a9-4de5-9984-ec8190a666cf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7e8a3a59-44f3-484f-9d26-8ba9bf0d61ab_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_5cd9598d-da13-4884-9b72-c3870dc2e6b0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c4df4b1a-5511-4052-9e0a-5ede92c51206_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_49c3f062-0f9b-412d-b044-7e4f5467a4bc_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_a9217401-035b-4bdf-a56a-69238bb9638e_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space (in square feet)</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_label_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_documentation_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:href="sesn-20210930.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:to="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3780e37-234c-43b0-bbd0-684e3f542672_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6968078c-63ec-45a0-afaa-0d09005d1348_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_9a7981b8-9da1-459e-bfa8-0014e5f39d19_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_46e4e4a6-db7d-4182-b9d8-f9ee6af35363_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_919b871d-9706-4fc4-bcc7-16ff3c787930_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f7de8d02-9082-4fb1-b4fd-680813c37544_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8c46f22d-6a89-4f82-953c-57244fc25320_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ed7143bc-6555-4ba1-887e-b11d0eb04714_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at September&#160;30, 2021 and December&#160;31, 2020; no shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fb9f079-e64f-43c5-b211-0615e93d8b1d_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b20675d7-ddcb-4692-ad9b-bed88f5849ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9aee87a0-23a1-472c-a146-43cf9d48714c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b0f94d2f-646e-4ef4-9d3b-c7b3257e6216_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_92c17d61-4b38-4202-86f2-a5c7a75858e7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8e7201e8-1307-469a-bd3b-c55c7570560e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_cc0cbcee-eed3-4b6a-af3e-37d963471926_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8958c2dc-7df1-44fe-9885-4232f7312b87_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae49b49a-74e1-40b0-b0b1-bb0db4558a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_e1bbe227-b769-4a9f-bb22-16423dc74fc7_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, rate requiring reduction in the amount of royalties owed</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:to="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_830ff174-c7f3-49e7-a827-264629fa4a4c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability measurements used</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_906c7ed8-c311-4410-bff1-faf0d79931cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6ceb79bb-628f-4257-b41a-64f4d229cdc2_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_97b5b336-2d44-420a-bb37-9fe836c07411_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2c26b2f9-7f63-4db3-b467-f9ff0941735c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_697f2471-d985-4a51-a52b-64a3433717d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, vesting rate</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_d7d040b2-742c-4b0e-8c3a-a9fff46d729b_terseLabel_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achieving clinical and regulatory milestones</link:label>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_label_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Achieving Clinical and Regulatory Milestones, Percentage</link:label>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_documentation_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Achieving Clinical and Regulatory Milestones, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:href="sesn-20210930.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:to="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9e941ab0-91c4-420b-a729-2be7d450c710_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_8f22229e-3714-4278-bd6f-14925198dbb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8f9e3e62-e1a5-445f-9405-ac14a5b1ffa4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4b256b9e-ab9e-4777-9a42-d9970b4cb1af_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_40eed79d-db76-4823-aae1-461469650267_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_01a729fe-5f74-4c4e-8eb2-062474d0eea3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration - short term</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_2d29d09c-99e0-4877-b927-cc3f494dbba6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_a86f33c9-b6c3-4225-a949-4f3a6ec95737_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment based on annual net sales</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_label_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:to="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4a601e96-1f4b-492b-94af-f292139f1d10_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_99dc7695-1a2d-474f-8ae1-8953bd00f748_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_1bf033a2-8289-4d6e-bb0c-93a99c658559_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Earnings (Loss) Per Share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5ab36eb6-9a0d-4a1e-8f17-e8b78d014740_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f9f9d6a4-aba3-4234-8b71-642f7256bac0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_df2ddf56-6d1f-46ca-836b-c80ab1ce954c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b1efdbb0-b400-4793-a7b5-8aabe7b857de_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_FirstIndicationMember_17c8aef3-efaf-4b60-8e59-9839d415bc02_terseLabel_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_label_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_documentation_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember" xlink:href="sesn-20210930.xsd#sesn_FirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_FirstIndicationMember" xlink:to="lab_sesn_FirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_05f11093-441e-487f-ae53-3ac7e8f5e1dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_b49cbd9a-050e-47a0-90ab-1aa856393aea_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_b2bffb6a-875d-4840-8e30-6fe4857bd846_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_5bdccb56-a688-422a-8eb2-d61297b0f249_terseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2009 Stock Incentive Plan</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_label_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009 [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member" xlink:href="sesn-20210930.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlan2009Member" xlink:to="lab_sesn_StockIncentivePlan2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember_e2d7e659-1626-4d9c-96ad-c71b431ea86d_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5b74a9ae-2451-4886-adbd-5ffbe161b250_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_8de0aad6-e362-417f-aa85-2c9052bf8b3c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bd2ba444-aa59-4290-a8c1-1746d2f6dffb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de284d45-eb54-493f-aeff-e8a81ac0dc80_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d7352a3f-2b0d-4782-aee2-0d0ce5d8f30b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_551bf85b-c72a-48c3-bea3-5ddae19c07ce_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0ae2ec16-c9c4-4526-9b20-4992f585efe8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_15070733-fa33-4eea-857d-7d26f92fc22f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ba13c3f2-8b54-4156-b5b1-8e20ddea6f3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting on the First Anniversary of Date of Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_483e2bd5-f3f1-4344-ae39-a2136c40a331_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_eca3d1d3-af1e-47da-981f-ad2ba1362e2c_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_dcf1d2a2-4b15-498d-907b-e84ba29442a5_terseLabel_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary match per participating employee, maximum</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_label_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_documentation_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:href="sesn-20210930.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:to="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_944bd779-2c28-460d-99d0-efbee7bf2b03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_cbb97ac2-5da6-4cd4-8024-3e0a89caefe3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_4efde1c3-2bc5-4524-b594-164cd99bded4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7da5a4c0-03bf-4058-81dd-e7c71daab53d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7015af2f-0d51-4e84-86ef-a7fe18a1c799_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_65ea7246-f816-4c30-9c33-6ff2fbd87867_terseLabel_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 ESPP</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_f22d1df5-b294-4d18-8369-0e60d3ed8894_verboseLabel_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:href="sesn-20210930.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:to="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_81bd88aa-bf7a-468a-9f59-2c11c28284a3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3ad43ee6-aac8-485f-af09-334fe8e6d080_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2469baa1-a4f7-4eab-bec5-d6883c304126_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3466afab-22a3-416a-bd4f-c330b621ea4a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_48282484-1b38-4b50-b8c3-a4437cbf9b7b_terseLabel_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend on adjustment of exercise price on certain warrants</link:label>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_label_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Dividend And Adjustments</link:label>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_documentation_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Dividend And Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherDividendAndAdjustments" xlink:href="sesn-20210930.xsd#sesn_OtherDividendAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OtherDividendAndAdjustments" xlink:to="lab_sesn_OtherDividendAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cd4a6af2-e0f5-4b1c-ad6b-78947f8dc861_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5f5b41c8-5086-49e4-b66a-b6c9ca756552_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_47b7996a-6f88-47a9-a95e-4907169800c4_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sales price</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_label_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_documentation_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:to="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_9d6dc9ad-db6f-4abe-ae0c-529e90351634_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_3676abe4-d398-4bf7-8dd1-e8271d3174ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ba63701f-4dbc-4cea-bca9-8808fab549f9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7994a545-ff34-4d12-a689-13fa0fc9c79e_netLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_60f0bfe3-1792-423d-a2b9-e7edf38946aa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_fde96421-6aef-48c9-8e0e-f8ea17d32777_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, option periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_label_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementOptionPeriods" xlink:to="lab_sesn_LicenseAgreementOptionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_407e9a38-6d0d-456f-9bf2-737dd3c7e458_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IL6Member_16390e6b-0d50-46cc-9e22-b8d302872c39_terseLabel_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6</link:label>
    <link:label id="lab_sesn_IL6Member_label_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6 [Member]</link:label>
    <link:label id="lab_sesn_IL6Member_documentation_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member" xlink:href="sesn-20210930.xsd#sesn_IL6Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IL6Member" xlink:to="lab_sesn_IL6Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3941c0ce-8528-4051-8a5d-d66a2cbd7c9d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b95b5b50-3692-4c58-859f-55d3f1ecf4b9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_0a972ef4-2d30-4d28-bac7-2b14340648eb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7a63b17b-34a7-41cf-9ddf-1e712cee9b9c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_96daf45f-d112-4c9c-9df3-784cf9364d08_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_85115034-8a1f-4921-9cab-55c6260a4c7a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under ATM offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_10766b10-3cd6-431f-bbc1-60aa14b7262b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_167751d5-b376-4dfb-87e8-28122f5bdd82_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:href="sesn-20210930.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_de84c807-dcc0-404e-8f4f-f5f5458ab274_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_92c377a6-c3f5-4f45-9dff-e68a145c7c34_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d732c57c-fa95-4596-94b5-be32f31e5ecc_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_4ba766d2-b7a3-48d7-a5df-e609c2dab844_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8d4b1e75-19d7-40a1-b19d-3e1116901391_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f175868e-4e25-4ad9-854d-f3eb309cc920_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d2eeb079-ab01-43f9-9711-7eb5ea0f226b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c92e0fad-dfb7-4f60-be98-bbeee2e04273_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5853d2bd-b843-4ff5-b09d-f70c28602b95_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_eca5ef43-568f-4d6d-8056-f2be75112f44_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5a410d88-550c-4247-942a-d27f96010671_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct_a9844e49-32ff-40ef-89fa-5ac5fee7f629_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time milestone payment upon first sale of product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" xlink:to="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ae742127-946c-45fb-b582-65fd39f2a5c3_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8544abce-bbb6-4dc4-bf03-89fc2a6e12b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under ATM offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_e64217b5-618a-49ee-a0b6-ff92b13a5075_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration - long term</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:to="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_43435508-483f-4dc7-98bf-bb5fb7a6583e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods_79a2192d-d971-4aa1-9912-f5e73d855260_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales of quarterly earn-out payments during earn-out periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:to="lab_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_969869d8-98af-4103-a0d1-044c77a9e512_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_034b9ab8-6abc-43f2-8f0c-aefb1a15d80e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 400,000,000 and 200,000,000 shares authorized at September&#160;30, 2021 and December&#160;31, 2020, respectively; 199,463,645 and 140,449,647 shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_44bc6976-cd63-453a-add1-42f728451a47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Deemed Dividend</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fa8147f2-f2ac-4c8a-a112-57b95aab28e9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a27045dd-b9e5-485d-839c-c7e0270728ea_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Financial Statements</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_4c702075-e27f-4e18-badd-c604297d12fc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_f13a1516-f1f2-4c49-869e-944a50c7010a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_55ef0c3d-c9ac-4d52-8f8d-f56bb2d6d738_negatedTerseLabel_en-US" xlink:label="lab_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, in Process Research and Development</link:label>
    <link:label id="lab_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:href="sesn-20210930.xsd#sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:to="lab_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_dcb4b82f-5b17-4f5e-80b7-707f890f9397_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_aca26d71-bfeb-456a-8dc4-79dd57171f58_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fixed rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_label_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_documentation_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockCommissionFixedRate" xlink:to="lab_sesn_SaleOfStockCommissionFixedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1b7c5a1d-dab6-4062-867e-c817ebcf657c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d4ff5a05-26be-4c06-9f09-3e716b63a0e7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_205d88cc-effd-4ffb-b8fd-1237f2000504_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8540210b-37bc-4417-bc19-640da2634bd9_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_053d6a52-a3af-4a14-ab94-827fcd6f010e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_01b21e58-5862-494e-aafc-4de560f7c120_terseLabel_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_label_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_documentation_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:href="sesn-20210930.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:to="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_7806cf33-3c89-4435-965b-0c38b9e04b82_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1394d6d4-c29f-4d26-a760-b9a0468e8999_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_10a24b66-fbfc-4d0a-9bc4-1feeb481a7fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6c2cf7e0-2eb8-4a7b-aa48-42516e83d7ca_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b6212a5-c2ba-4313-bfa3-0fd0b26710a0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3a632d67-be0e-41f4-ba50-5663b03fbbe2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f7de44f0-0af6-45f9-8912-4dc01a1fa644_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_ae9d8c42-8e84-4671-b9d9-8182de5bb55b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ff26409c-b591-494a-9e46-a6ab92187bc5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_a3e87a34-4877-4e95-bf96-bcf22eaef848_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, period to pay buyout option once exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_label_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:to="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_9bc10687-fb22-4c6b-acc5-d45af98f4bd8_totalLabel_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock issued and reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_label_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_documentation_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:href="sesn-20210930.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:to="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0723ff7-6fa5-4e33-a048-231819968f06_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Tax Benefit (Provision):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_882a6848-a9b6-491a-bc32-9f3ef69ab3be_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_92faceba-f06f-4d02-b7ed-3d75d192e824_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_118acee8-bd7b-4855-ba16-82f848ed2865_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1154051-8e86-422a-a186-e92e59045b92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_83847e23-e213-4f12-b31a-310fcaab0c45_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_47c6066a-bf66-4fd5-ac29-50c33745561b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f3c55653-25d7-4ee0-88e7-acb40ac60927_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ef6e8a49-4f40-4be2-9a75-599794937b59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_47e8c927-3594-4aa8-8c54-5c6f12ddbc7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_5950f281-7dce-464f-82bc-bb3249be376a_verboseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_label_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent" xlink:href="sesn-20210930.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseMonthlyRent" xlink:to="lab_sesn_OperatingLeaseMonthlyRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a382400d-fb6d-469c-823a-2f23e9c08010_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d359fe5d-f4fd-49e1-a45b-46a1451c48f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bc176cf2-e3f1-4cc8-92f0-7ac0130386cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0371818e-19cb-4e39-9303-623c190cef7a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING AND RELATED ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_754ae392-b351-4a6c-81c1-7a3343c0e1e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b606d1c6-359c-4149-b16d-e7398c89f1ef_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_0c5e37a0-99e4-425b-9d3a-9aeee13a7950_terseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:href="sesn-20210930.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_e5384d04-d8d6-4e68-bb2c-b2210f861e1f_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_375934b6-8ef5-4f88-a506-61dd0ad66b49_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_f60fd48d-2509-4994-a036-63265cfe3395_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyRate" xlink:to="lab_sesn_LicenseAgreementRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_a1762389-4bd2-418a-937f-6b3f394231a0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_23b89a46-1e2a-4964-ade6-252f90eee2eb_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under second option period, upon non-issuance of patent rights or licensed product</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_563df121-c5e1-402a-9e84-f05c55f45ab2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_e202c4c1-cdb0-4c7b-a430-a43565978685_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_6d2f918e-8c2d-4944-9313-facea06ecaf9_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringMarch2023Member" xlink:to="lab_sesn_WarrantsExpiringMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e93f9897-894f-4d17-a54f-716af460f384_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d86ce5fa-03bf-4c74-882b-a77206c691c2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c7072f3e-0c1d-48f6-aec3-264d65e07a40_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bf5c28ef-c846-4377-b1e3-f7f2e7c41bec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_02f69e19-2474-474d-a839-508869b84a3c_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2a94298b-4bf0-4e9b-a646-cb7e9d6fb928_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60706a67-40da-432f-ab5a-7b4030d72ce5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ATMFacilityMember_fe4e49c0-7a6a-4ca1-b988-f3c9193f2214_terseLabel_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_label_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_documentation_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember" xlink:href="sesn-20210930.xsd#sesn_ATMFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ATMFacilityMember" xlink:to="lab_sesn_ATMFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9a34fa17-4490-45ca-920c-a4d581478aea_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_43c2171f-a0ee-43ab-ae03-f8515be59fb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_547795f3-4a98-4dc4-8461-75bc7acf3573_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare_89a94930-e76f-4436-82b9-05713568536d_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued to the selling shareholders (in shares)</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare_label_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" xlink:to="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8d499ab3-dee6-42fe-8d78-8b3d2b561bde_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d0a8cb2d-e698-41ce-b9c3-221eada9b151_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_52d56fdf-c7dd-4306-8fd0-0b1c57d57825_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_966c3891-7a6a-4a18-a215-8ff6014be195_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_aedffc06-c2ec-46e1-ab23-e6cba3a5a1b8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1e9e8844-d741-44bb-a7ca-1c2f98615cad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NoncashFinancingItemsAbstract_885d9aa4-936f-49b7-bb69-99ab3558a8bd_terseLabel_en-US" xlink:label="lab_sesn_NoncashFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_sesn_NoncashFinancingItemsAbstract_label_en-US" xlink:label="lab_sesn_NoncashFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Financing Items [Abstract]</link:label>
    <link:label id="lab_sesn_NoncashFinancingItemsAbstract_documentation_en-US" xlink:label="lab_sesn_NoncashFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Financing Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NoncashFinancingItemsAbstract" xlink:href="sesn-20210930.xsd#sesn_NoncashFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NoncashFinancingItemsAbstract" xlink:to="lab_sesn_NoncashFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_40092b2a-6d3d-48a1-aa15-997d47f5f168_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity (Deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_b76452ff-4fd6-41c8-bec1-ecb41916898e_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2e9ef081-f411-4d7b-8b9c-7be9a7ca759a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_be9d2cd0-98ad-4ded-9c65-80c58e066920_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Benefit (Provision)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_3d0dbd5b-9be8-4f21-a561-0fa5393dbb41_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_356900b6-9876-490b-a9c6-caeeacb45f67_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_62a80d99-6900-4396-b0e3-ef832aa8b9f8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViventiaBioIncMember_a7c36e9a-205e-4350-ad98-85388afd8599_terseLabel_en-US" xlink:label="lab_sesn_ViventiaBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc.</link:label>
    <link:label id="lab_sesn_ViventiaBioIncMember_label_en-US" xlink:label="lab_sesn_ViventiaBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc. [Member]</link:label>
    <link:label id="lab_sesn_ViventiaBioIncMember_documentation_en-US" xlink:label="lab_sesn_ViventiaBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioIncMember" xlink:href="sesn-20210930.xsd#sesn_ViventiaBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViventiaBioIncMember" xlink:to="lab_sesn_ViventiaBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_96a3cf2f-de34-4990-96ea-116e971cbc12_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_39246ce5-40f1-40cb-b3d6-c02f1b04859c_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_4a1447e0-a0bc-4736-90db-660e5cfc9085_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_2dedcf47-7944-406d-867d-de438405c7d7_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:to="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_92e339f9-435a-4cdc-b737-5b92e08478b1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period exercisable from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_64def5b4-7282-4733-b56b-2a033efb5537_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1c44bc87-5d35-4fb4-870a-ebe7ec837edd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6587744a-20d0-4b4d-8dee-1f137c0baa65_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of common stock under 2014 ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_96ce6e86-8b94-461d-92c7-7868d98c393b_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value (in dollars per share)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:href="sesn-20210930.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_b7f20e92-aed9-4ebe-b8ea-1ff335eb359f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0ce4400a-0d7c-416a-9bc3-752341bb35af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0b1843f4-f5df-48f4-8f5f-0e79e3466e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting at End of Each Successive Three-Month Period Thereafter</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e1296fdb-2c53-42e7-a699-98fe6fd6325f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5de0f618-334a-4f67-a419-ce8bd0c19c31_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f3853dee-a696-4d3d-82d5-1d595ca97dcc_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_32bc4f38-3ca8-44c9-8db6-c16ae6454bf3_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration - short term</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:to="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6f502c8d-a147-413d-a57e-621478f96705_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_afaca358-b2dd-4265-967a-6215c41f2161_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b25aaa11-b967-4905-9004-9db3ce16df27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5f900183-882d-4159-a9ea-dd438785a4fd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e6852b80-c69a-42f9-907b-9ac7689ad73c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c6765e81-8d75-4248-9d3f-71790e36bc50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_64b7f50b-dd3a-4858-baab-84274c7f7623_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_fd2ef821-1439-4651-b5a3-059915d8d283_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c448adc8-ade6-415b-8aea-6f54eeff81f2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0dbcbcba-a434-4ce4-a28b-d0c6df7b4687_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c2a0c13-1d11-451e-a995-33b6fbbe1888_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_1735f004-26b8-40c6-9761-321c9bb726ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c50b4f6b-cd2c-40d4-8fcf-ea38be9c083a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_921a0957-322d-4680-96d9-b4314ce37897_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:href="sesn-20210930.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015d5f6b-1ae3-472c-83a6-0c41a15932f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_c1380801-a009-443a-ac9d-85b81b78a3a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_25f290f9-a4db-4648-b85c-52c037566e46_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_f21c9fc1-ae40-4206-b340-41d1d262d093_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income attributable to participating securities - basic</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DeferredTaxLiabilityImpairmentWriteDown_cf8a93d0-b6ee-46ff-be2a-54b4d7da8b9f_terseLabel_en-US" xlink:label="lab_sesn_DeferredTaxLiabilityImpairmentWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, impairment write down</link:label>
    <link:label id="lab_sesn_DeferredTaxLiabilityImpairmentWriteDown_label_en-US" xlink:label="lab_sesn_DeferredTaxLiabilityImpairmentWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Impairment Write Down</link:label>
    <link:label id="lab_sesn_DeferredTaxLiabilityImpairmentWriteDown_documentation_en-US" xlink:label="lab_sesn_DeferredTaxLiabilityImpairmentWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Impairment Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxLiabilityImpairmentWriteDown" xlink:href="sesn-20210930.xsd#sesn_DeferredTaxLiabilityImpairmentWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DeferredTaxLiabilityImpairmentWriteDown" xlink:to="lab_sesn_DeferredTaxLiabilityImpairmentWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d8175664-4a80-4501-a0ef-334f9ff8e16f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, net of current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_caeb6f5a-a4d4-46e6-bc6e-d3a140383621_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration - long term</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_faef30a9-1273-4011-80dd-a6d6b414ec15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7c6c8f9f-c99b-4ee2-96e2-f1f580cc0d8f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1490ae27-5a63-4d71-8263-0f8bc7964b48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrants Outstanding and Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e5f43f88-2c59-4a42-b7d6-d7569821abd1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7ef053af-f544-469e-a3de-5a0d1fd0ca6d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_e094b76d-60e6-4604-9e5f-6597df4c20c4_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_8b8bad14-9ce6-422b-a0f8-2633e976d2f3_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8fb500fd-f4e6-49a4-ae93-2e32e3c426a4_netLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9a4fa91a-d2f5-417c-aec2-a8fe8008d352_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_68e2a682-7634-47ae-881b-674697f3ab7c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_2422855c-3665-4355-827f-c433e46736ad_negatedTerseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:href="sesn-20210930.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78542a17-b66b-4128-a5ab-1a04330b2a0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_c2953d6b-3875-447a-8d90-01e77f4fbf88_terseLabel_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge related</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_label_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:href="sesn-20210930.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:to="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1e497c83-8661-46c1-8b47-d357493d9ab5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_756bf6e9-d591-4dc2-985f-64f1d78916d8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_3265ec22-196d-4b87-bc72-0d4e3e8fdf81_terseLabel_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance for:</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_label_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_documentation_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:href="sesn-20210930.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:to="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_895bcf43-de22-4659-a1d2-32b34747840c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c1669081-b090-4756-8298-040c4b7887c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_e2cf703e-b855-4f62-a91c-54de94026c96_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_1a17738b-90b1-4049-8021-73b53b9e20a2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1c41f1ea-b282-465e-976b-b136ad73500e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Exercise Price per Option</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_3a9daf73-7373-4e76-8840-e24cd124bff6_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair value in excess of carrying amount</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0873abc7-d775-4600-89c1-c4094b664b83_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SecondIndicationMember_f4fae656-d4d9-4d11-9c7f-f18f74dd1d81_terseLabel_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_label_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_documentation_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember" xlink:href="sesn-20210930.xsd#sesn_SecondIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SecondIndicationMember" xlink:to="lab_sesn_SecondIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_ba85e1d0-a73d-43cd-b67a-1299ce92bf0f_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_label_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationMilestonePayments" xlink:to="lab_sesn_BusinessCombinationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_da2d2b10-3eea-45dd-b808-ad832c6fb5d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a51f5a8-bd68-486a-8e56-256f96b46143_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Loss before Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4c19d718-f4e1-4dac-847e-b84ef6efa030_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_8ae6db14-707c-480a-986d-8926f91bc26d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_b474b74c-d516-4ca9-84dd-bbf60ea22813_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EBI031Member_04a0a42d-75a9-4a2d-bcc4-3815c08a9482_terseLabel_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031</link:label>
    <link:label id="lab_sesn_EBI031Member_label_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:label id="lab_sesn_EBI031Member_documentation_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member" xlink:href="sesn-20210930.xsd#sesn_EBI031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EBI031Member" xlink:to="lab_sesn_EBI031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_abfbeea1-81d3-463d-8fb1-0377588f0726_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_108cf2b6-2f98-4a4a-8984-ec3b955e745b_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_aa881e11-7a71-4dd1-8de3-b3f34cce6ef0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_3a5a8600-02ab-4bdd-9ff7-b77c06fc7dd5_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Turkey</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fabbe941-d9c1-4a30-9059-1ac541759b31_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_92a10d2e-3d2a-4413-af5a-5f464f236c8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_12d42191-79ba-4e0c-8545-45339cb6abf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5a89da9b-dce1-4af9-914f-8f0af91a0118_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8745e848-77d4-4af3-b577-bb759d564fea_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e41d9fcd-5ff6-4bd8-9fe3-c935a54f41e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_af75d725-3c71-45a9-bb70-aae1479ef46f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_dd2fa221-e7d7-45a1-958a-d9c3f00cbd0e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_15057bce-9a78-4d1e-885a-104ad354b825_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_11c70fc4-46ac-4b6e-afec-e19995579f84_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d24e9729-0666-42f5-811b-600961dcc879_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_25d68831-2a8a-429b-b4e1-b8383282c45e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5e11f88b-5363-43ef-81c2-a29c15587916_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c2f8c54b-a805-4462-9819-086e47be0d61_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3a8e3d45-8856-4c73-955e-e62e086a9b1f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fb5aff38-72e7-4502-8a49-bd05fa25d326_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_d6fd9e46-2969-416a-a436-d2fca08a83fd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0d46975b-2d1e-4ca6-a519-9b4497af239b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6d6e7729-80b1-4c4b-ad5a-ad323a41dd1c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales_0159366a-fdfd-4f39-8029-ef0fc1871f52_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which quarterly earn-outs are payable after date of net sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" xlink:to="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_88fee2a0-f85f-43ad-884d-e689a8967f9d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fcdca574-e1dc-460a-9ef7-07f3deb15b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_2413dace-3224-4dfe-946d-38b28930be54_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_d498ce91-0c7b-4945-a60f-bf2337fa5a37_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6bb57064-7919-4cc8-b0be-665311bee86b_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f585d160-0a78-4781-b98b-530ea3566959_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_e9809935-36ef-4d81-b159-c247329a2e92_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4c04602-f025-4072-8fb2-8817f2359288_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_06b9c275-3900-46e5-a979-3e1dfb59dbf6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e56e6396-4ec5-4001-976f-fe273312c9d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e79e572-4dc7-4e5f-82bc-6651780dbc50_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_27156325-fe8c-4dc3-82be-1ad3549347e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dfc9d29d-2f8e-45af-8264-4cc9a985db19_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_013c357f-76f4-4c54-be60-6aa31b40d92b_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of common stock warrants (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1b71e805-2a41-420e-8949-d70f7f0917cb_negatedLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_49ce54ad-0536-4ab7-9de7-e75b58833313_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_3ac3c847-e22c-4f8c-83fe-762e1ba3ed58_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings (Loss) Per Share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_451cdf75-046c-429d-860f-d738479f8a95_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f4b7b83-4165-40dc-9f3b-7b92eba0d358_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_87e81548-b74d-476b-9cb1-ebbfb90f1f59_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_92ad723e-a378-4015-87bf-eaa56a6f95cf_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_f24764de-f95e-4c95-ba24-c03bf80172b9_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_a304564a-efe9-4370-9eed-be48782ec68a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_9ff91fdb-1ce6-45b0-b686-3a042bbfd198_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance costs</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:to="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d680b8ee-648d-4666-8853-3e8bc8057c24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5409630f-0d31-4e4f-9b15-c99dd96f7281_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_e1a96b07-01e8-47cf-8054-0416d8634de4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_2f53687e-6c53-40b4-af00-3e02bcdcd865_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ea0d567-3b78-4ae4-9d46-df17b02816cc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_7e5bf383-19d6-4a67-851b-008e3848806d_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_label_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Shares Authorized For Sale</link:label>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_documentation_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Shares Authorized For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:to="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_530b3824-2253-4478-9225-b2e0239c2c71_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated, period percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cadd1442-6ec3-4bd4-9880-9e5631c1b6dc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_d58d8843-b7cc-4506-bbd3-615d28451947_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5374feb7-354b-4fe1-96fd-f06d5e644c5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_6d91737c-37e0-4b32-a0a8-5d094aa5f485_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c2d4208b-83f8-42c6-98d7-320dbf6b4658_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_b9f6caed-6b54-4992-b520-e10bb73711df_terseLabel_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIP Agreement</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_label_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement [Member]</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_documentation_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:href="sesn-20210930.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:to="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c2f855ae-5a8e-4797-b0a4-a11c1dfd5f87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_3c246456-466a-417c-aa20-57d57472e1ac_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_30669c12-c026-4351-b50c-60d7c565fb20_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_dd6afdf5-85ec-4cea-899c-29fb31fb3054_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4777d291-2e00-4f35-adb5-3bf482ba4cad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9024078d-e449-473e-97ea-7728287e7df9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_928526e9-d332-47fe-ae02-dc5882d289e9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsCurrent" xlink:to="lab_us-gaap_IntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_c7137668-39a3-4cf8-9f61-5bdb6823e0e2_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to achievement of development milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:to="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_94691f56-7f0b-473c-a780-0d7792e828c1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_UniversityOfZurichMember_b9a2169a-75f1-4c4f-a624-b8b6ea7804e4_terseLabel_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_label_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich [Member]</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_documentation_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember" xlink:href="sesn-20210930.xsd#sesn_UniversityOfZurichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_UniversityOfZurichMember" xlink:to="lab_sesn_UniversityOfZurichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c9256f4-ef50-49be-b205-6a194923f76e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares under Option (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_af283f9a-eefa-4c15-af29-5d78307a1b79_terseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Stock Incentive Plan</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_label_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:href="sesn-20210930.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:to="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d1e12815-eec7-4eac-b7bd-40468d632410_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c89870dd-8a8e-4e55-b1d7-d9caf5a73c44_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1505e9e6-5fe3-4022-88bf-7c26c8dc06a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_77b7f946-f101-4a4b-9a40-2d0897715bbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income attributable to participating securities - diluted</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_34f8e5a5-5e73-4015-82b9-9dda1f13094b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RocheMember_3f571aea-2db7-454a-9c93-7ea652f082eb_terseLabel_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_sesn_RocheMember_label_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_sesn_RocheMember_documentation_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember" xlink:href="sesn-20210930.xsd#sesn_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RocheMember" xlink:to="lab_sesn_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1dc0362b-3d7d-416f-b96c-a4eb4d035b13_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_a452a061-150e-4326-b535-eac0a8c233b1_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of common stock warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:to="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0c6088e6-341a-4e9f-92a3-217b03d08835_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3898e55b-15d6-4875-bbd1-b7260f77e342_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_a4794e9d-3053-4b45-b18b-ec548db8ce87_terseLabel_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:href="sesn-20210930.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:to="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_83ba20f5-86e9-4f81-a9e1-798e3025a791_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_852134ea-d9fb-4a0c-a103-f73709960d68_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5c312ee7-8987-4be3-ac6c-a2f16f58a04b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_120d5cb7-5500-439a-9fa9-0da6ead7fdbd_terseLabel_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average cost of capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_label_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital" xlink:href="sesn-20210930.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WeightedAverageCostOfCapital" xlink:to="lab_sesn_WeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAccountsReceivable_f90d4b8c-ade4-49d9-84d7-a67416fdb609_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding payments</link:label>
    <link:label id="lab_sesn_LicenseAgreementAccountsReceivable_label_en-US" xlink:label="lab_sesn_LicenseAgreementAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Accounts Receivable</link:label>
    <link:label id="lab_sesn_LicenseAgreementAccountsReceivable_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAccountsReceivable" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAccountsReceivable" xlink:to="lab_sesn_LicenseAgreementAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1b8c5df7-e00b-4e70-98fc-41729fef3854_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_cd8b902d-a801-40f9-97e3-4fb96cb0d484_terseLabel_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:href="sesn-20210930.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:to="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d447ff6-4c05-45a1-8b6c-903738e97cdc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c9638ea-e194-4d46-b9cd-8841c04f4b29_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_e6ff0997-d059-4c3e-8827-e2fc80cb1cba_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_2abee2fb-5bd2-4f84-b14b-a1fb423eeb74_netLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_42ac2287-8b93-4f17-bb57-9ec96dc241a5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_18b7e533-c376-4a8f-8eff-aea357084fdf_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty on net product sales, percentage</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_240c1770-f261-4a79-87c2-f6dd1daabafa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_7822b274-7b04-4a36-823b-ffc6c6a96d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a9fd9852-5834-458e-803b-d3d931acd410_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_84318d0b-31c0-407d-9bd4-517b4c7ced66_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_cdf98444-8c87-4f3b-9fa5-bbbe58e68ba8_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseMaintenanceFees_533fe6da-3d52-4650-a10c-b3c297a7255f_terseLabel_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License maintenance fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_label_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_documentation_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees" xlink:href="sesn-20210930.xsd#sesn_LicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseMaintenanceFees" xlink:to="lab_sesn_LicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7757777e-5d33-4301-83a3-dd58a13d2bbc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_61e12cb6-433e-4b8c-9e02-9f37f5b26306_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_5eed70e7-8a80-4eb8-a658-650fcdcfa5c1_terseLabel_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="sesn-20210930.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_4757d90d-e890-4d97-b7ea-d1f037fed216_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7e63dbab-e460-480e-befc-75a5f7b93a2d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_5715d272-3821-47da-afca-b3551faf72eb_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_316a7e46-2284-4798-b866-05b0f8ce59a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5167e744-54a3-448e-a9d9-4ac77e637f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0e5fc18-533f-4d43-a514-2251c1cce998_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ed45ba2-1bb5-466d-ab6b-6f5e0dd41f66_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1750a3b3-34e2-459a-aceb-ec8bd916966c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_457d64fc-cfcb-42fe-8b04-25034b05dce1_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5669575e-137a-4ece-8430-f6f5bf6a84cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_b7b7769c-17de-4830-af13-cee699f7a5f5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_6e798cac-4d40-4412-84d1-9c1a78743248_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_bd9a75f9-c365-425b-b2d1-9c83f46ada01_terseLabel_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_label_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_documentation_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:href="sesn-20210930.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:to="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2712b64a-cc70-440a-baf6-1e74680b5506_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac9a7198-2d4d-434b-bc51-ef29ccaa60f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_63ff8645-a2b4-4e2b-a2c7-8904cc62c4d0_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_293c87c2-790d-4e63-b79c-d7bfe8deeb9c_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2022Member" xlink:to="lab_sesn_WarrantsExpiringNovember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cbdfc950-dbce-48f8-a998-9b9a83d423a2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b06a652c-118d-46e3-8d97-827b3208b4c9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_80ebcdd2-9f69-4933-a323-c4b40d5247e4_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds (cash equivalents)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6cd24037-5333-49e0-a630-29952f83dfae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_962a3bcc-7c6e-4567-8dde-344c371554fd_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_3248945c-ae41-4978-ab62-ea802927f5f3_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under first option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_96b11cfe-3f6f-465a-b090-e325b4afeb61_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding for diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_79a27b33-65f4-4617-9c09-dff9f2a3dc05_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_44dcf6e8-d28e-4705-a206-cd3190604608_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_3eefada4-f2a9-4cf9-b1c4-29399af06360_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_label_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementTextBlock" xlink:to="lab_sesn_LicenseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_48564b70-b354-4d84-bf2b-0ba015e13358_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2c377d53-b779-46f9-b2b2-ca8d7502761f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9605a14c-10ca-4909-b996-377fc92fec51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9c176580-14dd-403f-9c4e-36f8b0b9a4bf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_f48d54de-5d2b-466d-8b42-059b91b1bacb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_32deb1f5-da0f-415e-a50c-d3113a1f5a3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Excluded from Diluted Loss Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_77b3cdad-8908-4e77-99cf-ec2366266d6c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_2187575a-5a39-4cea-92cc-bde037d80c64_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d58b5770-9883-4292-bb7e-fa847deff79a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1c4e060-61d5-4d19-83d3-4bb0df44634b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_50bbb18d-9f30-492c-abe4-21234968e94d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_ae7fc97b-94e1-4710-ad2b-b41da1c9426e_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d6df2c16-6d16-461d-919a-40a21dd15478_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0710c4f0-71d5-40e9-8f79-ea0f0f4a9ce9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of common stock under 2014 ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_bf8724f6-ef5d-443d-99e7-5512c2735057_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price per share (in dollars per share)</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d35a9a1-eb1b-47f7-8609-0d36108242fe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_fa7f6210-5901-42df-8898-9243bc427e02_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_18e9d36d-4b51-4c51-aeb0-afc746c4c0aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_49bfd5c4-f2f6-4b60-894e-8a335a0783f8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f15d5eb9-34e6-4aad-8582-1b7a765d2386_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_d5cb48f3-8635-4e68-88ce-22ba0462e367_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MicrometAGMember_66e0f5c8-732a-4ecf-98d5-89c8e350515f_terseLabel_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG</link:label>
    <link:label id="lab_sesn_MicrometAGMember_label_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG [Member]</link:label>
    <link:label id="lab_sesn_MicrometAGMember_documentation_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember" xlink:href="sesn-20210930.xsd#sesn_MicrometAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MicrometAGMember" xlink:to="lab_sesn_MicrometAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4e0f5926-96d7-455e-808d-fde517ce7ab0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_962f57ee-d4df-48cc-bdda-676939afb4f7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' eligible compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bb937543-7222-4ecc-9d14-d71f6e5a1fb0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2f681148-39af-4778-a224-58ec198b6454_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_51c5b0cf-4284-4dce-82e9-d1059f6cc400_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_e3591c65-8734-4ab9-a134-b942fe2f894b_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, amount payable upon achievement of specified milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_label_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:to="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViciniumMember_828b5d81-a422-466f-8b71-c44eb7e14dd9_terseLabel_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium</link:label>
    <link:label id="lab_sesn_ViciniumMember_label_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:label id="lab_sesn_ViciniumMember_documentation_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember" xlink:href="sesn-20210930.xsd#sesn_ViciniumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViciniumMember" xlink:to="lab_sesn_ViciniumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f28cfcb9-4be3-4af3-81f2-9a90d301d31b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_83b0273f-991a-4a20-8a80-1e7c04e97378_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, royalty payment, reduction, conditions not met</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:to="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f2dd5995-9b17-43eb-8c63-61ed213513a8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8c5340b6-ab84-4a4e-8cef-53ab8ace0bb6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_749fc727-dedc-42f2-81b0-65af3afe0667_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_d19a4b62-6b75-4d47-82f7-181ebba79cc0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_58eff4dd-d8d4-4ecc-9c62-1141d4e99402_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5d7613af-71c3-4c9c-b105-526fb7580ad1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MENALicenseAgreementMember_6e3e848a-3986-41fe-9e94-d17f23b26ef6_terseLabel_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_label_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement [Member]</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_documentation_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember" xlink:href="sesn-20210930.xsd#sesn_MENALicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MENALicenseAgreementMember" xlink:to="lab_sesn_MENALicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_8dd97498-758d-4e47-b552-dbf639c178c3_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_5e57207a-3362-4d32-847b-881b94afdbc3_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_16f7781e-3600-4187-8580-07f24d96bfe1_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ea211f15-7791-4fa5-b0a3-595e8c6f15e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_20e2e7d3-96f3-4ee4-97c0-7b8069a1b2c2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_a0902144-48ec-4943-ace8-7d840d665bc6_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_label_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:to="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_1bb8d4e5-d316-4f7f-86da-129fbcaaf964_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost, including related operating cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_5533fc0d-42c2-4508-9ff7-248113d3ce76_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_41e379dd-57c5-4fc6-91ff-e3f9b494cc1b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_fe7af06e-dd66-4398-a6d5-aa5bc50332b9_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_940e1e3a-b324-4a82-b4a2-f26d80214de1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution retirement plan, maximum employee contribution deferred</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e41e45b5-26b4-46a2-b19d-09ec0e25874f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_7f63a6b3-71f2-41b4-8d99-da980a7771ee_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related operating expenses, per month</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_label_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:href="sesn-20210930.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:to="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>sesn-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:43f34410-0797-4c9d-95d4-0172445a49a1,g:6be5cc14-c349-4e45-a047-13acab623f46-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/Cover" xlink:type="simple" xlink:href="sesn-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_53d2ec59-871a-4449-af88-6a90ad68c176" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_DocumentType_53d2ec59-871a-4449-af88-6a90ad68c176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a43832c0-37a8-4293-bb66-5a39d45a901f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_DocumentQuarterlyReport_a43832c0-37a8-4293-bb66-5a39d45a901f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5deaf06a-eab8-4fdd-9b84-b6f45acfb40f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_DocumentPeriodEndDate_5deaf06a-eab8-4fdd-9b84-b6f45acfb40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_734ea5c3-1af8-4fb5-8fd2-e2e920b49a23" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_DocumentTransitionReport_734ea5c3-1af8-4fb5-8fd2-e2e920b49a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_be405b71-3855-4a03-8bed-49c35c0d0a84" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityFileNumber_be405b71-3855-4a03-8bed-49c35c0d0a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9f109030-3fbb-4bdf-9c10-b9e9e55b781f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityRegistrantName_9f109030-3fbb-4bdf-9c10-b9e9e55b781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b44e9544-f6ed-4af2-8703-545b138b35a0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b44e9544-f6ed-4af2-8703-545b138b35a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_35dad2c5-ec2f-4c15-bcc7-8259191ad10b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityTaxIdentificationNumber_35dad2c5-ec2f-4c15-bcc7-8259191ad10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5a3cd5ba-61d9-4f1f-90d9-b78035f85354" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityAddressAddressLine1_5a3cd5ba-61d9-4f1f-90d9-b78035f85354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e198dbb1-5ee0-4f81-9ada-32b826b88997" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityAddressAddressLine2_e198dbb1-5ee0-4f81-9ada-32b826b88997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c746e209-d9f2-4027-acbc-d40fe10cf995" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityAddressCityOrTown_c746e209-d9f2-4027-acbc-d40fe10cf995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6e619484-d62d-412d-b21a-94d47a7d4a2f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityAddressStateOrProvince_6e619484-d62d-412d-b21a-94d47a7d4a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fdde90fe-1a1c-4d3d-a206-09fcc8b661d7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityAddressPostalZipCode_fdde90fe-1a1c-4d3d-a206-09fcc8b661d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_05f9b0f5-da1a-4559-a94e-ea8b4e27f8bc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_CityAreaCode_05f9b0f5-da1a-4559-a94e-ea8b4e27f8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1fe9d260-a38e-4e1b-b053-bce7e69fed38" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_LocalPhoneNumber_1fe9d260-a38e-4e1b-b053-bce7e69fed38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c741f05c-0ff4-467f-99df-e1d14c2f7614" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_Security12bTitle_c741f05c-0ff4-467f-99df-e1d14c2f7614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d01367d9-ed47-4b98-ac5a-107f18e10239" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_TradingSymbol_d01367d9-ed47-4b98-ac5a-107f18e10239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0bad7eec-bc59-4e5e-881b-c32ca40aaf53" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_SecurityExchangeName_0bad7eec-bc59-4e5e-881b-c32ca40aaf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3b7863af-a06f-4904-b16a-9621d05760e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityCurrentReportingStatus_3b7863af-a06f-4904-b16a-9621d05760e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ce008dea-1183-45db-b6c9-7f6ac1158e32" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityInteractiveDataCurrent_ce008dea-1183-45db-b6c9-7f6ac1158e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e0bb02d0-8feb-49df-9faa-3d6e8e0b40af" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityFilerCategory_e0bb02d0-8feb-49df-9faa-3d6e8e0b40af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6645a6bb-755b-4f18-9041-5e6305519580" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntitySmallBusiness_6645a6bb-755b-4f18-9041-5e6305519580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3224027d-0c0b-4a8a-8009-db8a1fb9bc6e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityEmergingGrowthCompany_3224027d-0c0b-4a8a-8009-db8a1fb9bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2363ba0e-8b20-4377-beb0-cad228890c03" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityShellCompany_2363ba0e-8b20-4377-beb0-cad228890c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_24340f7f-7f7e-4413-b9b8-3e2551f28323" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_24340f7f-7f7e-4413-b9b8-3e2551f28323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_35656d63-66a8-4448-b138-53565d91b3a9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_EntityCentralIndexKey_35656d63-66a8-4448-b138-53565d91b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3ab4c747-534d-4c3c-9184-b99b62b4d099" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_CurrentFiscalYearEndDate_3ab4c747-534d-4c3c-9184-b99b62b4d099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9b0e6456-0175-45e1-9559-5f99c9466738" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_DocumentFiscalYearFocus_9b0e6456-0175-45e1-9559-5f99c9466738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_23651280-5559-4cd6-8622-368b72a7b145" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_DocumentFiscalPeriodFocus_23651280-5559-4cd6-8622-368b72a7b145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_074619c2-59a2-4942-aa10-6a8c68de1129" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_013865a9-accc-4e98-a821-7af389ce15fd" xlink:to="loc_dei_AmendmentFlag_074619c2-59a2-4942-aa10-6a8c68de1129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ff37e0c2-ae7b-4889-858b-9ef9bc97f78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c2615c19-8a18-4ae9-9f14-76615980413b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ff37e0c2-ae7b-4889-858b-9ef9bc97f78a" xlink:to="loc_us-gaap_AssetsAbstract_c2615c19-8a18-4ae9-9f14-76615980413b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5c567431-4ef7-461c-a72f-5405f1309c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c2615c19-8a18-4ae9-9f14-76615980413b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5c567431-4ef7-461c-a72f-5405f1309c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a25c06cd-7e9d-456d-a93e-ca63d0688f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c567431-4ef7-461c-a72f-5405f1309c8d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a25c06cd-7e9d-456d-a93e-ca63d0688f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e06c1366-04b0-41f2-abb9-841881ae0e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c567431-4ef7-461c-a72f-5405f1309c8d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e06c1366-04b0-41f2-abb9-841881ae0e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b9e294f-2f35-4aea-8be8-0ef7cbfb346e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c567431-4ef7-461c-a72f-5405f1309c8d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b9e294f-2f35-4aea-8be8-0ef7cbfb346e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7697a114-bd3a-4d90-b604-7c6be38a3dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c567431-4ef7-461c-a72f-5405f1309c8d" xlink:to="loc_us-gaap_RestrictedCashCurrent_7697a114-bd3a-4d90-b604-7c6be38a3dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_37188aa4-de0d-4e36-807a-6d258393da94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c567431-4ef7-461c-a72f-5405f1309c8d" xlink:to="loc_us-gaap_AssetsCurrent_37188aa4-de0d-4e36-807a-6d258393da94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c2615c19-8a18-4ae9-9f14-76615980413b" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_00baf994-ea6a-42e0-82a3-6f5b85fc84c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_00baf994-ea6a-42e0-82a3-6f5b85fc84c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8733a90f-b1ae-431e-81bf-17786f30e92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8733a90f-b1ae-431e-81bf-17786f30e92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0d0413a9-f459-40b5-b96c-31126dcea3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0d0413a9-f459-40b5-b96c-31126dcea3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c7fe68da-c454-4d37-9239-e6e1b161baf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:to="loc_us-gaap_Goodwill_c7fe68da-c454-4d37-9239-e6e1b161baf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_4ff9a6df-5f7e-4a63-8ce4-6923ac8de268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_4ff9a6df-5f7e-4a63-8ce4-6923ac8de268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ba5617ab-d09e-4b2e-a20f-505d911f3920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ba5617ab-d09e-4b2e-a20f-505d911f3920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_934f6ae9-2c75-4aa8-83ba-113909f4a680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1e3f3a2e-3ba0-437b-8718-8e629bcfb72e" xlink:to="loc_us-gaap_AssetsNoncurrent_934f6ae9-2c75-4aa8-83ba-113909f4a680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_598ee224-e9e0-4ec6-bc29-1690ac600e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c2615c19-8a18-4ae9-9f14-76615980413b" xlink:to="loc_us-gaap_Assets_598ee224-e9e0-4ec6-bc29-1690ac600e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25a4738c-83a2-4245-a1ab-940eac1e3e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ff37e0c2-ae7b-4889-858b-9ef9bc97f78a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25a4738c-83a2-4245-a1ab-940eac1e3e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26dc3812-396f-4698-badd-a0b113e88fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25a4738c-83a2-4245-a1ab-940eac1e3e5b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26dc3812-396f-4698-badd-a0b113e88fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c9e563c9-0316-4bd6-b2a0-5daa074e38af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26dc3812-396f-4698-badd-a0b113e88fc0" xlink:to="loc_us-gaap_AccountsPayableCurrent_c9e563c9-0316-4bd6-b2a0-5daa074e38af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_30c24ac9-e9d2-49a1-aead-b8da20e92458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26dc3812-396f-4698-badd-a0b113e88fc0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_30c24ac9-e9d2-49a1-aead-b8da20e92458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a4a72c05-d431-4af3-9db1-a2d6e218d783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26dc3812-396f-4698-badd-a0b113e88fc0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a4a72c05-d431-4af3-9db1-a2d6e218d783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2c413ae6-9899-4aaf-9697-0acf244b8cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26dc3812-396f-4698-badd-a0b113e88fc0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2c413ae6-9899-4aaf-9697-0acf244b8cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6709988b-0ba4-440a-af74-4f17c30101bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26dc3812-396f-4698-badd-a0b113e88fc0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6709988b-0ba4-440a-af74-4f17c30101bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_858518a8-ffdb-4d9d-8fe0-1892360c1e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26dc3812-396f-4698-badd-a0b113e88fc0" xlink:to="loc_us-gaap_LiabilitiesCurrent_858518a8-ffdb-4d9d-8fe0-1892360c1e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_6f5670df-9fd7-4f4f-a935-1f8dcbe236b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25a4738c-83a2-4245-a1ab-940eac1e3e5b" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_6f5670df-9fd7-4f4f-a935-1f8dcbe236b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8c33fec7-8a48-43cc-b95d-9b4b94cf2bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6f5670df-9fd7-4f4f-a935-1f8dcbe236b3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8c33fec7-8a48-43cc-b95d-9b4b94cf2bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d87aa7ca-6693-4d6f-9995-f08a9b9e19d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6f5670df-9fd7-4f4f-a935-1f8dcbe236b3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d87aa7ca-6693-4d6f-9995-f08a9b9e19d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a16fe0ba-255a-4fa4-9ea2-ff81f84666a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6f5670df-9fd7-4f4f-a935-1f8dcbe236b3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a16fe0ba-255a-4fa4-9ea2-ff81f84666a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2c652e69-9ed3-4624-b459-9d55dbdb8292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6f5670df-9fd7-4f4f-a935-1f8dcbe236b3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2c652e69-9ed3-4624-b459-9d55dbdb8292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_0ee891bf-4002-45eb-a8a2-c16705bb3fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6f5670df-9fd7-4f4f-a935-1f8dcbe236b3" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_0ee891bf-4002-45eb-a8a2-c16705bb3fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f7bab2c5-ad4e-4a65-a531-60cfab0df74f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25a4738c-83a2-4245-a1ab-940eac1e3e5b" xlink:to="loc_us-gaap_Liabilities_f7bab2c5-ad4e-4a65-a531-60cfab0df74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_22ede5ef-88b0-4774-8bf0-e4a2c78db35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25a4738c-83a2-4245-a1ab-940eac1e3e5b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_22ede5ef-88b0-4774-8bf0-e4a2c78db35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a6b9b7bb-0115-419f-a8d5-5c328b0f08c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22ede5ef-88b0-4774-8bf0-e4a2c78db35a" xlink:to="loc_us-gaap_PreferredStockValue_a6b9b7bb-0115-419f-a8d5-5c328b0f08c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_61281ea6-06fa-4431-a500-641f9cab53e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22ede5ef-88b0-4774-8bf0-e4a2c78db35a" xlink:to="loc_us-gaap_CommonStockValue_61281ea6-06fa-4431-a500-641f9cab53e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_03cfa90e-a5ac-4a82-bd59-8ef47c1a5853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22ede5ef-88b0-4774-8bf0-e4a2c78db35a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_03cfa90e-a5ac-4a82-bd59-8ef47c1a5853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf70339c-a7f1-4e87-be27-f6ff0df27142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22ede5ef-88b0-4774-8bf0-e4a2c78db35a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf70339c-a7f1-4e87-be27-f6ff0df27142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ce998e0-e3f6-4380-9653-36ece81814ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22ede5ef-88b0-4774-8bf0-e4a2c78db35a" xlink:to="loc_us-gaap_StockholdersEquity_8ce998e0-e3f6-4380-9653-36ece81814ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5fdf04a-22a3-40a7-9a1b-86f66386d758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25a4738c-83a2-4245-a1ab-940eac1e3e5b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5fdf04a-22a3-40a7-9a1b-86f66386d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_790ef0c2-619f-4169-b142-e25508f2ec04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_790ef0c2-619f-4169-b142-e25508f2ec04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fe1e3eef-7a4d-42af-b6ea-5cef3aa8b191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fe1e3eef-7a4d-42af-b6ea-5cef3aa8b191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d191e2f5-4e5c-4756-a68b-7c3c6717a91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d191e2f5-4e5c-4756-a68b-7c3c6717a91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d57b50a4-dbea-4e59-a489-ef50e80b3b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d57b50a4-dbea-4e59-a489-ef50e80b3b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a36ad46a-fb82-48c9-aac3-edfeff0404d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a36ad46a-fb82-48c9-aac3-edfeff0404d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_88ffde9d-7326-4ece-ae9c-2c1bdaa902e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_88ffde9d-7326-4ece-ae9c-2c1bdaa902e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2ffd08ba-18b1-4f9c-a3c2-f2b10008886f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:to="loc_us-gaap_CommonStockSharesIssued_2ffd08ba-18b1-4f9c-a3c2-f2b10008886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2f22c272-42b2-4574-9bc4-b1a4fffd6eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2da00a07-74fe-4b53-ace0-c627bd2ecd8d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2f22c272-42b2-4574-9bc4-b1a4fffd6eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5e58985b-2781-4b67-983b-147dc2703ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5e58985b-2781-4b67-983b-147dc2703ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_549fe599-67e6-43bc-85f3-438f8d3a89e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_OperatingExpensesAbstract_549fe599-67e6-43bc-85f3-438f8d3a89e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_69de5a67-bac7-4a28-ab9d-2a2edddaf0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_549fe599-67e6-43bc-85f3-438f8d3a89e0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_69de5a67-bac7-4a28-ab9d-2a2edddaf0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_063fcd58-2cc1-42f5-81aa-df75ce68d1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_549fe599-67e6-43bc-85f3-438f8d3a89e0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_063fcd58-2cc1-42f5-81aa-df75ce68d1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_431b376a-9da9-44bc-bd01-51c9a8f54801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_549fe599-67e6-43bc-85f3-438f8d3a89e0" xlink:to="loc_us-gaap_RestructuringCharges_431b376a-9da9-44bc-bd01-51c9a8f54801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_de0c887f-67c1-4f06-a7c7-24278e121006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_549fe599-67e6-43bc-85f3-438f8d3a89e0" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_de0c887f-67c1-4f06-a7c7-24278e121006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76b29ead-7630-45b3-998e-be3d3aa0a307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_549fe599-67e6-43bc-85f3-438f8d3a89e0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76b29ead-7630-45b3-998e-be3d3aa0a307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_44b611a1-ad60-43b6-9ae8-7530ec3894d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_549fe599-67e6-43bc-85f3-438f8d3a89e0" xlink:to="loc_us-gaap_OperatingExpenses_44b611a1-ad60-43b6-9ae8-7530ec3894d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f7b512eb-b4df-4c91-bec4-f32873023758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_OperatingIncomeLoss_f7b512eb-b4df-4c91-bec4-f32873023758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3c497997-00bc-427a-b660-ab712a744f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3c497997-00bc-427a-b660-ab712a744f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_c1197b97-ce9a-4e08-9926-65608385032d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_c1197b97-ce9a-4e08-9926-65608385032d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_198e1e0e-3d11-495d-976e-43ec7d5b1f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_198e1e0e-3d11-495d-976e-43ec7d5b1f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59e07d4e-fb86-46f8-b898-5e3507bba7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_NetIncomeLoss_59e07d4e-fb86-46f8-b898-5e3507bba7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_90f75186-af8e-4b43-9df9-c7c580d8cd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_90f75186-af8e-4b43-9df9-c7c580d8cd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8c729235-6908-48a1-bbef-702b34bedc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8c729235-6908-48a1-bbef-702b34bedc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6bfec6d6-47d7-4ec4-9110-3384d37e0e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_EarningsPerShareBasic_6bfec6d6-47d7-4ec4-9110-3384d37e0e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4d51da92-28b1-4174-a3ec-5ea4851419a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4d51da92-28b1-4174-a3ec-5ea4851419a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_498963b5-513a-4716-892a-92d4ed82baef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_498963b5-513a-4716-892a-92d4ed82baef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8827dfc3-6b91-4d6a-bb82-e03bc4b40c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8927143c-d575-4c53-8d74-cd46cf1f2601" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8827dfc3-6b91-4d6a-bb82-e03bc4b40c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cae5fc69-1be2-448f-9be0-db521a37d02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cae5fc69-1be2-448f-9be0-db521a37d02a" xlink:to="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_736cd3d8-8853-4e03-9a09-9efa8b64911d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_736cd3d8-8853-4e03-9a09-9efa8b64911d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_736cd3d8-8853-4e03-9a09-9efa8b64911d" xlink:to="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3a6ea69f-d25a-47dc-9dc8-86cb7c8bf06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:to="loc_us-gaap_CommonStockMember_3a6ea69f-d25a-47dc-9dc8-86cb7c8bf06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_61599230-cd23-43c0-b1e6-8c9178397eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_61599230-cd23-43c0-b1e6-8c9178397eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3bbfe3b4-0d16-453d-9488-fea379219cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_97080eb9-6c8e-4741-9c14-5df8e25707a6" xlink:to="loc_us-gaap_RetainedEarningsMember_3bbfe3b4-0d16-453d-9488-fea379219cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_beb66a63-f4d7-4601-b229-d352e19e5dcd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:to="loc_srt_CounterpartyNameAxis_beb66a63-f4d7-4601-b229-d352e19e5dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6796dd82-bc21-415b-92b5-8af1212d9a8e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_beb66a63-f4d7-4601-b229-d352e19e5dcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6796dd82-bc21-415b-92b5-8af1212d9a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_118cf87c-245f-4f2d-b1a7-2972293b139c" xlink:href="sesn-20210930.xsd#sesn_UniversityOfZurichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6796dd82-bc21-415b-92b5-8af1212d9a8e" xlink:to="loc_sesn_UniversityOfZurichMember_118cf87c-245f-4f2d-b1a7-2972293b139c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8152a21e-5c73-43fb-866d-694998e76657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8346a418-880a-4522-ae44-636c9297ecde" xlink:to="loc_us-gaap_StatementLineItems_8152a21e-5c73-43fb-866d-694998e76657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8152a21e-5c73-43fb-866d-694998e76657" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8a15c72a-85c4-4e8e-b3fa-0029c149bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_SharesOutstanding_8a15c72a-85c4-4e8e-b3fa-0029c149bf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3eeab604-3d84-4fb3-9c75-d9f09038fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockholdersEquity_3eeab604-3d84-4fb3-9c75-d9f09038fb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89874128-c5c5-4c25-a78e-fa6e238b64af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_NetIncomeLoss_89874128-c5c5-4c25-a78e-fa6e238b64af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d45293ec-53f5-46e3-a3a2-d1aa8294c0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d45293ec-53f5-46e3-a3a2-d1aa8294c0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bccccde1-2419-4553-a396-774985d57b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bccccde1-2419-4553-a396-774985d57b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_376f0a37-04b4-4486-9130-39ef9b03bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_376f0a37-04b4-4486-9130-39ef9b03bbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1fa83978-5c24-4778-b0cc-8514152c99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1fa83978-5c24-4778-b0cc-8514152c99d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5582c1a9-7864-45f1-ba3e-4d9bb5eab910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5582c1a9-7864-45f1-ba3e-4d9bb5eab910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_2f102b27-db0f-45bc-8ede-1e1939187a39" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_2f102b27-db0f-45bc-8ede-1e1939187a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_0d4fda40-9c2d-4929-8a7e-bcc75f018b56" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_0d4fda40-9c2d-4929-8a7e-bcc75f018b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1266e0b9-c84d-4325-b1c0-23283d198152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1266e0b9-c84d-4325-b1c0-23283d198152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_26831a9a-ab84-47d4-8d37-0d2803bf4a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_26831a9a-ab84-47d4-8d37-0d2803bf4a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8afded34-d12c-4201-89ab-22b518f4753d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_SharesOutstanding_8afded34-d12c-4201-89ab-22b518f4753d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ece02fe3-c040-4b92-8cfc-e0cdd6c8c093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f97c79bf-81ef-488c-9cfe-2389fd7a0ae8" xlink:to="loc_us-gaap_StockholdersEquity_ece02fe3-c040-4b92-8cfc-e0cdd6c8c093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f87fc0a0-10a2-4b79-8b60-6fa44a5c640c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_01cf0ffa-b5a7-4df6-bbee-73e16b552237" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f87fc0a0-10a2-4b79-8b60-6fa44a5c640c" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_01cf0ffa-b5a7-4df6-bbee-73e16b552237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cffa4ac-2f3d-4b11-b54a-6c6107e27146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cffa4ac-2f3d-4b11-b54a-6c6107e27146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_614c3b66-8304-4124-93b5-5735e513ea0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cffa4ac-2f3d-4b11-b54a-6c6107e27146" xlink:to="loc_us-gaap_NetIncomeLoss_614c3b66-8304-4124-93b5-5735e513ea0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55a5ac79-50e3-4cba-bda3-af8bdebcfbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cffa4ac-2f3d-4b11-b54a-6c6107e27146" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55a5ac79-50e3-4cba-bda3-af8bdebcfbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_efc3f06b-ebdb-48dd-8002-faaf3bc16a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55a5ac79-50e3-4cba-bda3-af8bdebcfbc3" xlink:to="loc_us-gaap_DepreciationAndAmortization_efc3f06b-ebdb-48dd-8002-faaf3bc16a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_504ed3b8-3172-4016-a4f3-4dafc7fe0cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55a5ac79-50e3-4cba-bda3-af8bdebcfbc3" xlink:to="loc_us-gaap_ShareBasedCompensation_504ed3b8-3172-4016-a4f3-4dafc7fe0cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_945f2205-80ec-4363-a37c-17072d58aecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55a5ac79-50e3-4cba-bda3-af8bdebcfbc3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_945f2205-80ec-4363-a37c-17072d58aecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a29eae5f-668a-4c64-a9d0-0d15be50dc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55a5ac79-50e3-4cba-bda3-af8bdebcfbc3" xlink:to="loc_us-gaap_AssetImpairmentCharges_a29eae5f-668a-4c64-a9d0-0d15be50dc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8398984-bd9e-4d3e-8be0-d1d3731d92f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55a5ac79-50e3-4cba-bda3-af8bdebcfbc3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8398984-bd9e-4d3e-8be0-d1d3731d92f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d251d675-59c6-4b3b-9abc-e92ee20f3f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8398984-bd9e-4d3e-8be0-d1d3731d92f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d251d675-59c6-4b3b-9abc-e92ee20f3f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d6ec9e4d-885c-45ed-b86f-831dc30b760f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8398984-bd9e-4d3e-8be0-d1d3731d92f1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d6ec9e4d-885c-45ed-b86f-831dc30b760f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6054a6d6-d68d-4d9e-895b-1edf2b27b0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8398984-bd9e-4d3e-8be0-d1d3731d92f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6054a6d6-d68d-4d9e-895b-1edf2b27b0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_58a0a555-57ba-4095-a202-7e85e2d2b0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8398984-bd9e-4d3e-8be0-d1d3731d92f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_58a0a555-57ba-4095-a202-7e85e2d2b0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_dc420717-bc6c-49aa-aa77-49fef2adef4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8398984-bd9e-4d3e-8be0-d1d3731d92f1" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_dc420717-bc6c-49aa-aa77-49fef2adef4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8541c48e-c1e7-4fe4-b1da-81b1d82c3fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cffa4ac-2f3d-4b11-b54a-6c6107e27146" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8541c48e-c1e7-4fe4-b1da-81b1d82c3fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6067e782-0619-4886-b3fc-6ec5f96480bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6067e782-0619-4886-b3fc-6ec5f96480bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_a7d2bea3-2022-45f1-b7c9-c714a5b906be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6067e782-0619-4886-b3fc-6ec5f96480bf" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_a7d2bea3-2022-45f1-b7c9-c714a5b906be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b44e389-5d7a-418f-a2ef-64575fb46303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6067e782-0619-4886-b3fc-6ec5f96480bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b44e389-5d7a-418f-a2ef-64575fb46303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3da7bc9a-c3ce-4a1e-a97a-8dc67d4b1029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3da7bc9a-c3ce-4a1e-a97a-8dc67d4b1029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9b0f4db2-b188-45a4-8cf3-2a9b6c9dc300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3da7bc9a-c3ce-4a1e-a97a-8dc67d4b1029" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9b0f4db2-b188-45a4-8cf3-2a9b6c9dc300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_91a885f0-e5b2-4d00-8b57-b449ead98a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3da7bc9a-c3ce-4a1e-a97a-8dc67d4b1029" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_91a885f0-e5b2-4d00-8b57-b449ead98a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_9c930e8c-57eb-4e1f-9007-d242b97e33bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3da7bc9a-c3ce-4a1e-a97a-8dc67d4b1029" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_9c930e8c-57eb-4e1f-9007-d242b97e33bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e228ce5-306c-4140-bbb0-6e158f5ade46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3da7bc9a-c3ce-4a1e-a97a-8dc67d4b1029" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e228ce5-306c-4140-bbb0-6e158f5ade46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbf63649-621f-4460-8194-6ccfe9b670b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbf63649-621f-4460-8194-6ccfe9b670b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d173fc2-904f-4164-9461-18df5558784c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d173fc2-904f-4164-9461-18df5558784c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2837f295-ba28-448e-b36f-a09dbd8662fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2837f295-ba28-448e-b36f-a09dbd8662fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bb47187a-6fd8-4c5e-a743-fe5a595f0b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bb47187a-6fd8-4c5e-a743-fe5a595f0b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_15b35c35-e15e-4181-b4a3-c8275a48860b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bb47187a-6fd8-4c5e-a743-fe5a595f0b53" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_15b35c35-e15e-4181-b4a3-c8275a48860b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_49b0f257-f240-44b1-ad9d-2b343e0e20bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bb47187a-6fd8-4c5e-a743-fe5a595f0b53" xlink:to="loc_us-gaap_OperatingLeasePayments_49b0f257-f240-44b1-ad9d-2b343e0e20bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NoncashFinancingItemsAbstract_adec9ae2-e232-4713-99ca-e2c8e9691231" xlink:href="sesn-20210930.xsd#sesn_NoncashFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0aa09642-b3a3-4492-ae1e-c226ee713c26" xlink:to="loc_sesn_NoncashFinancingItemsAbstract_adec9ae2-e232-4713-99ca-e2c8e9691231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherDividendAndAdjustments_426cb438-d52f-4c7b-aa63-d86d844d3785" xlink:href="sesn-20210930.xsd#sesn_OtherDividendAndAdjustments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_NoncashFinancingItemsAbstract_adec9ae2-e232-4713-99ca-e2c8e9691231" xlink:to="loc_sesn_OtherDividendAndAdjustments_426cb438-d52f-4c7b-aa63-d86d844d3785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="sesn-20210930.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_515dfe8f-9519-486e-b841-57e3492cd3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_14ff3780-f17b-4a6a-8f01-2198706cb50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_515dfe8f-9519-486e-b841-57e3492cd3e4" xlink:to="loc_us-gaap_NatureOfOperations_14ff3780-f17b-4a6a-8f01-2198706cb50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3576df86-d0f0-4c50-b357-e1c16a5196d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3576df86-d0f0-4c50-b357-e1c16a5196d3" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_490e13ac-3599-4615-b0ce-654593d88b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_490e13ac-3599-4615-b0ce-654593d88b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bba630fa-4a73-4c61-90c6-c5ebcf98ff9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_490e13ac-3599-4615-b0ce-654593d88b92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bba630fa-4a73-4c61-90c6-c5ebcf98ff9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioIncMember_1c67daa2-e373-469d-a494-5b99e8aaed22" xlink:href="sesn-20210930.xsd#sesn_ViventiaBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bba630fa-4a73-4c61-90c6-c5ebcf98ff9f" xlink:to="loc_sesn_ViventiaBioIncMember_1c67daa2-e373-469d-a494-5b99e8aaed22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_srt_ProductOrServiceAxis_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2326dddf-3d25-4b64-8dad-6d743a8e7c16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8b89ccfc-a5c4-45f2-b8da-d78ab6caff69" xlink:to="loc_srt_ProductsAndServicesDomain_2326dddf-3d25-4b64-8dad-6d743a8e7c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_db58d4c2-e078-47fd-8834-d4f7cb09c474" xlink:href="sesn-20210930.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2326dddf-3d25-4b64-8dad-6d743a8e7c16" xlink:to="loc_sesn_ViciniumMember_db58d4c2-e078-47fd-8834-d4f7cb09c474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dade8bb1-f017-42f0-b196-e5fe381f83de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_srt_StatementGeographicalAxis_dade8bb1-f017-42f0-b196-e5fe381f83de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8b5c1f1-eb96-4fb2-8665-b90c2fbeabd5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dade8bb1-f017-42f0-b196-e5fe381f83de" xlink:to="loc_srt_SegmentGeographicalDomain_e8b5c1f1-eb96-4fb2-8665-b90c2fbeabd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_f1d20705-7bc7-4aad-8620-cedaed2d73a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8b5c1f1-eb96-4fb2-8665-b90c2fbeabd5" xlink:to="loc_srt_EuropeMember_f1d20705-7bc7-4aad-8620-cedaed2d73a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_4fd7750f-788b-4ab1-ac68-2bdaf862b922" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8b5c1f1-eb96-4fb2-8665-b90c2fbeabd5" xlink:to="loc_country_JP_4fd7750f-788b-4ab1-ac68-2bdaf862b922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3a54debf-06c8-4656-88ec-ff2e89c5f94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3a54debf-06c8-4656-88ec-ff2e89c5f94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b711a7c-0589-4b4d-819c-33c21bf6ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a54debf-06c8-4656-88ec-ff2e89c5f94c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b711a7c-0589-4b4d-819c-33c21bf6ecab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember_45611770-96c9-4c7c-af7d-62a71c7575ef" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b711a7c-0589-4b4d-819c-33c21bf6ecab" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember_45611770-96c9-4c7c-af7d-62a71c7575ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_8e227739-a5bf-41d6-bae7-884806d9912b" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9799b302-d215-40bd-b5e3-2e25d02a641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9799b302-d215-40bd-b5e3-2e25d02a641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare_2d61fd8b-25ec-4987-af9a-49d58ba9681c" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare_2d61fd8b-25ec-4987-af9a-49d58ba9681c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b821061a-096e-4c4d-a6b3-d99b9dbd4709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b821061a-096e-4c4d-a6b3-d99b9dbd4709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct_a96e9c86-5dce-42b5-8511-1dec895807c8" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct_a96e9c86-5dce-42b5-8511-1dec895807c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods_9f4c9259-82d0-4929-a4a0-ba03312d62fa" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods_9f4c9259-82d0-4929-a4a0-ba03312d62fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales_5382faec-9054-47c4-ac42-c5309a0445e9" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales_5382faec-9054-47c4-ac42-c5309a0445e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations_2e211a86-0870-4dd2-bfcc-a0330f5f8f34" xlink:href="sesn-20210930.xsd#sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_277427f3-a1b6-4513-8d66-e40844a21705" xlink:to="loc_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations_2e211a86-0870-4dd2-bfcc-a0330f5f8f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="sesn-20210930.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ab3c17ef-e06d-4f63-bc80-6aba31bb5be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_904ebfd1-a866-4c42-85db-2e98e6cfe184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab3c17ef-e06d-4f63-bc80-6aba31bb5be7" xlink:to="loc_us-gaap_BasisOfAccounting_904ebfd1-a866-4c42-85db-2e98e6cfe184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sesn-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4972a9ec-b233-462c-8eb5-86ac79e2f487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a8acf954-a64a-424e-85e0-2e623c928acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4972a9ec-b233-462c-8eb5-86ac79e2f487" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a8acf954-a64a-424e-85e0-2e623c928acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sesn-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1ac4089c-a998-4f34-a91c-811339e349aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_70b691f6-0831-4b15-9974-bacd3ef98584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ac4089c-a998-4f34-a91c-811339e349aa" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_70b691f6-0831-4b15-9974-bacd3ef98584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_bc03af7e-2644-4457-a53d-a750d92ed2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ac4089c-a998-4f34-a91c-811339e349aa" xlink:to="loc_us-gaap_UseOfEstimates_bc03af7e-2644-4457-a53d-a750d92ed2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_5c11c328-8b3b-4cc6-acc2-525553cf7a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ac4089c-a998-4f34-a91c-811339e349aa" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_5c11c328-8b3b-4cc6-acc2-525553cf7a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d13afc41-03af-4027-8156-540f6d107016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ac4089c-a998-4f34-a91c-811339e349aa" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d13afc41-03af-4027-8156-540f6d107016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a5afd175-ea8d-4050-b718-6608200179a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ac4089c-a998-4f34-a91c-811339e349aa" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a5afd175-ea8d-4050-b718-6608200179a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_31656bc9-dfd6-40cb-aadb-6efb4e0ba5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ac4089c-a998-4f34-a91c-811339e349aa" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_31656bc9-dfd6-40cb-aadb-6efb4e0ba5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="sesn-20210930.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_449a840c-c1ec-4a2c-82ef-71c330b636ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_39a1a2f2-2b36-464e-bbdd-dac21a8331c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_449a840c-c1ec-4a2c-82ef-71c330b636ee" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_39a1a2f2-2b36-464e-bbdd-dac21a8331c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="sesn-20210930.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a57dc45a-7e3a-4cca-b248-84cb82d0cd83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b184c7d7-0fa9-444c-aaad-d3554af781e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a57dc45a-7e3a-4cca-b248-84cb82d0cd83" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b184c7d7-0fa9-444c-aaad-d3554af781e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="sesn-20210930.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8b13457b-a0c5-4cb2-93eb-fc17d19c8b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_74834319-7bc1-417c-b600-4c8faf7573a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8b13457b-a0c5-4cb2-93eb-fc17d19c8b2c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_74834319-7bc1-417c-b600-4c8faf7573a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_c6d41fd8-559d-43dd-ae8c-285cb22b7b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8b13457b-a0c5-4cb2-93eb-fc17d19c8b2c" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_c6d41fd8-559d-43dd-ae8c-285cb22b7b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="sesn-20210930.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3721189e-52ac-478d-b073-43550f1b115c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3721189e-52ac-478d-b073-43550f1b115c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fa9bc530-2c3b-4615-acc3-a4171dfaae1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fa9bc530-2c3b-4615-acc3-a4171dfaae1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a3b1999c-cd66-4208-b42d-0ba52d9948ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fa9bc530-2c3b-4615-acc3-a4171dfaae1d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a3b1999c-cd66-4208-b42d-0ba52d9948ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76b5dc5e-66d1-4d13-9d05-4644cf6bae73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a3b1999c-cd66-4208-b42d-0ba52d9948ca" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76b5dc5e-66d1-4d13-9d05-4644cf6bae73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_05a39c7e-4400-4746-8360-7a9d9d64f40d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76b5dc5e-66d1-4d13-9d05-4644cf6bae73" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_05a39c7e-4400-4746-8360-7a9d9d64f40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1a6095f3-155b-4b1d-bcea-4de300ae0881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76b5dc5e-66d1-4d13-9d05-4644cf6bae73" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1a6095f3-155b-4b1d-bcea-4de300ae0881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ca62032-1dea-452f-af1f-a9e71e3fde86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ca62032-1dea-452f-af1f-a9e71e3fde86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d87f252-d9e6-4d05-aebe-04c7828aaf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4ca62032-1dea-452f-af1f-a9e71e3fde86" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d87f252-d9e6-4d05-aebe-04c7828aaf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_485ede97-106f-4d00-8b5e-642af719ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d87f252-d9e6-4d05-aebe-04c7828aaf1d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_485ede97-106f-4d00-8b5e-642af719ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_017ce333-655f-4039-aa4f-897fecd11b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_017ce333-655f-4039-aa4f-897fecd11b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_017ce333-655f-4039-aa4f-897fecd11b24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ab47e923-0813-4955-9e56-0eaa45b8364a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ab47e923-0813-4955-9e56-0eaa45b8364a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0ef30605-afd3-4ca4-b759-19522567ff36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0ef30605-afd3-4ca4-b759-19522567ff36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ef857bf0-209d-47a4-bc02-233580c1d22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89b1be4c-5b26-4326-bc56-39835ef1e828" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ef857bf0-209d-47a4-bc02-233580c1d22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bb4357-d72f-4257-9d17-7afae04e5564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e8b1ed9-b0f3-45ed-988a-187e4e5beadd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bb4357-d72f-4257-9d17-7afae04e5564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6acc0bb7-1aff-4e80-b1fb-a770dbbde3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bb4357-d72f-4257-9d17-7afae04e5564" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6acc0bb7-1aff-4e80-b1fb-a770dbbde3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c3548f57-823e-494a-88e1-1983eb681003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6acc0bb7-1aff-4e80-b1fb-a770dbbde3cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c3548f57-823e-494a-88e1-1983eb681003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8e49ca81-883a-45f1-950b-567c6e873921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8bb4357-d72f-4257-9d17-7afae04e5564" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8e49ca81-883a-45f1-950b-567c6e873921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2b2a2a55-a79a-4b8d-af43-cebfa23a0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8e49ca81-883a-45f1-950b-567c6e873921" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2b2a2a55-a79a-4b8d-af43-cebfa23a0f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3196ee76-f522-4128-9e1b-9adfa82a9975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8e49ca81-883a-45f1-950b-567c6e873921" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3196ee76-f522-4128-9e1b-9adfa82a9975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c5cc207f-557a-486c-8b19-647952c5db38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c5cc207f-557a-486c-8b19-647952c5db38" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9eb437a7-c259-48ef-9027-c3400974d122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9eb437a7-c259-48ef-9027-c3400974d122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6993dd09-a36b-4042-9411-a34f409d62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9eb437a7-c259-48ef-9027-c3400974d122" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6993dd09-a36b-4042-9411-a34f409d62d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_fdb9a94d-8528-47a7-84ce-112ce8ac1285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6993dd09-a36b-4042-9411-a34f409d62d9" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_fdb9a94d-8528-47a7-84ce-112ce8ac1285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_26a22979-1b49-4a17-a539-11fa1c0264d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:to="loc_srt_RangeAxis_26a22979-1b49-4a17-a539-11fa1c0264d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f954e913-0ed1-4b7d-9905-c66c3832681e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_26a22979-1b49-4a17-a539-11fa1c0264d2" xlink:to="loc_srt_RangeMember_f954e913-0ed1-4b7d-9905-c66c3832681e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_91bb28e0-bd2a-4c65-b85c-32f04d0e80c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f954e913-0ed1-4b7d-9905-c66c3832681e" xlink:to="loc_srt_MinimumMember_91bb28e0-bd2a-4c65-b85c-32f04d0e80c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aff4d425-7ec1-4f48-aca4-604f5db3dcb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f954e913-0ed1-4b7d-9905-c66c3832681e" xlink:to="loc_srt_MaximumMember_aff4d425-7ec1-4f48-aca4-604f5db3dcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6ae5d7e9-afb9-49d5-a776-bdaef6691dd5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_31c1156d-290a-4a82-97cc-0da49c0a50d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_31c1156d-290a-4a82-97cc-0da49c0a50d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_a30d559e-1b2e-42c4-88c4-b248a80bc13a" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_a30d559e-1b2e-42c4-88c4-b248a80bc13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_f5a24468-3d60-4383-a1ee-54ee55c20c5a" xlink:href="sesn-20210930.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_sesn_WeightedAverageCostOfCapital_f5a24468-3d60-4383-a1ee-54ee55c20c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DebtInstrumentIndexRateHighYield_dbf76201-49d5-4cde-be07-ce96f9261819" xlink:href="sesn-20210930.xsd#sesn_DebtInstrumentIndexRateHighYield"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_sesn_DebtInstrumentIndexRateHighYield_dbf76201-49d5-4cde-be07-ce96f9261819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_20cad16f-910e-494a-bd6d-cd63ecb46ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_20cad16f-910e-494a-bd6d-cd63ecb46ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_8f4fc3e7-38a9-425a-9d72-23ced6b83a89" xlink:href="sesn-20210930.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_842da132-dddd-4ea7-891d-75967014b0aa" xlink:to="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_8f4fc3e7-38a9-425a-9d72-23ced6b83a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63668e15-a113-4e0f-9d5f-9effd2838c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63668e15-a113-4e0f-9d5f-9effd2838c25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9e13c8ca-c3fb-446c-8e38-aea767c80c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9e13c8ca-c3fb-446c-8e38-aea767c80c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2284fb1b-62a1-4c67-8b57-74186891f3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9e13c8ca-c3fb-446c-8e38-aea767c80c97" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2284fb1b-62a1-4c67-8b57-74186891f3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9bd55b84-6081-4ba2-8836-56ef6ada4691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2284fb1b-62a1-4c67-8b57-74186891f3c0" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9bd55b84-6081-4ba2-8836-56ef6ada4691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0d21f15-c700-499b-a983-03ea891ad941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0d21f15-c700-499b-a983-03ea891ad941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5191164-85fc-4755-b961-0aa4cead16b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0d21f15-c700-499b-a983-03ea891ad941" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5191164-85fc-4755-b961-0aa4cead16b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4ae6ddc7-6a6e-4487-885a-f9dec045004b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5191164-85fc-4755-b961-0aa4cead16b6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4ae6ddc7-6a6e-4487-885a-f9dec045004b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2a7cdb40-355c-4d12-9617-da891edda7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d107f813-7306-48e9-b451-051bb5cf3035" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2a7cdb40-355c-4d12-9617-da891edda7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2a7cdb40-355c-4d12-9617-da891edda7ef" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_923296d4-fe17-4dff-9bec-85f43a36359d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_923296d4-fe17-4dff-9bec-85f43a36359d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_1d6d8692-2bc6-4146-8141-2bc296957244" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent_1d6d8692-2bc6-4146-8141-2bc296957244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_2e4693ce-f7a9-49d0-b7de-c2144bfc1b3a" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_2e4693ce-f7a9-49d0-b7de-c2144bfc1b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e0dce4c6-d674-4f31-8dd2-8421c68aaa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_770f7694-dbc6-49b4-8727-72ccc6735091" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e0dce4c6-d674-4f31-8dd2-8421c68aaa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="sesn-20210930.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_038ddaae-4556-454d-9fc4-8c32ca04de2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ce6dee0c-d05c-4ed5-84ae-9a1ba62431ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_038ddaae-4556-454d-9fc4-8c32ca04de2d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ce6dee0c-d05c-4ed5-84ae-9a1ba62431ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="sesn-20210930.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c477c7cc-e97b-4504-bdb7-0ce4d4e4dc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_4be1816b-3c33-47a0-a021-8f53d5738682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c477c7cc-e97b-4504-bdb7-0ce4d4e4dc76" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_4be1816b-3c33-47a0-a021-8f53d5738682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INTANGIBLEASSETSANDGOODWILLDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43051937-e9e3-4e46-b949-5e0f2c1dfbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43051937-e9e3-4e46-b949-5e0f2c1dfbfa" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_252c60ed-b843-4941-ba82-1e4d13af8892" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_srt_ProductOrServiceAxis_252c60ed-b843-4941-ba82-1e4d13af8892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88bdb96b-f44a-48e4-b4f8-debc6400f768" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_252c60ed-b843-4941-ba82-1e4d13af8892" xlink:to="loc_srt_ProductsAndServicesDomain_88bdb96b-f44a-48e4-b4f8-debc6400f768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_42cafb6d-7008-47f7-9513-717265d4850c" xlink:href="sesn-20210930.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_88bdb96b-f44a-48e4-b4f8-debc6400f768" xlink:to="loc_sesn_ViciniumMember_42cafb6d-7008-47f7-9513-717265d4850c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6c010ab-bb04-48e9-ac21-cda4d2716d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6c010ab-bb04-48e9-ac21-cda4d2716d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b744aa46-885f-413b-a938-e8558e4baa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6c010ab-bb04-48e9-ac21-cda4d2716d0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b744aa46-885f-413b-a938-e8558e4baa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c163e8b0-c9d4-482e-8813-b78520a8a591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b744aa46-885f-413b-a938-e8558e4baa5c" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c163e8b0-c9d4-482e-8813-b78520a8a591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f1393e10-7fa5-47f8-8785-ce713d27eb75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_srt_StatementGeographicalAxis_f1393e10-7fa5-47f8-8785-ce713d27eb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b8a68a5d-d3ae-475b-9da5-d9f92345ccbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f1393e10-7fa5-47f8-8785-ce713d27eb75" xlink:to="loc_srt_SegmentGeographicalDomain_b8a68a5d-d3ae-475b-9da5-d9f92345ccbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_40361aaf-1f6b-4a5d-ae72-0f79635e4a85" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b8a68a5d-d3ae-475b-9da5-d9f92345ccbb" xlink:to="loc_country_US_40361aaf-1f6b-4a5d-ae72-0f79635e4a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_3f978520-e92a-4852-a683-963710c9262e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b8a68a5d-d3ae-475b-9da5-d9f92345ccbb" xlink:to="loc_srt_EuropeMember_3f978520-e92a-4852-a683-963710c9262e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_27296245-ab89-4335-8339-1791819b7209" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_srt_RangeAxis_27296245-ab89-4335-8339-1791819b7209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0681974a-3775-470c-86b5-01ac8d520fbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_27296245-ab89-4335-8339-1791819b7209" xlink:to="loc_srt_RangeMember_0681974a-3775-470c-86b5-01ac8d520fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_04fd9777-51c9-4dec-9f2e-438ab2d3773b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0681974a-3775-470c-86b5-01ac8d520fbf" xlink:to="loc_srt_MinimumMember_04fd9777-51c9-4dec-9f2e-438ab2d3773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6e3f5436-3ba9-414d-9406-1a7a62a26c52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0681974a-3775-470c-86b5-01ac8d520fbf" xlink:to="loc_srt_MaximumMember_6e3f5436-3ba9-414d-9406-1a7a62a26c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c9b8f0ae-feb6-46b9-aaec-f2d48cdb16c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_cb26b922-2cb8-4b83-88e9-8845e6ae479d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_cb26b922-2cb8-4b83-88e9-8845e6ae479d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3f31efc1-be0e-448d-98ad-5715cf1a29d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_Goodwill_3f31efc1-be0e-448d-98ad-5715cf1a29d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_242df80c-04c9-4cb4-b904-3463d760f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_242df80c-04c9-4cb4-b904-3463d760f2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9e9bb5c5-58be-414b-87b9-d395fef42002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_04aedac2-1929-46d7-875c-bce2c4e3d140" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9e9bb5c5-58be-414b-87b9-d395fef42002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASES" xlink:type="simple" xlink:href="sesn-20210930.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9bf73c43-575e-4d44-aa15-316ad1cdf75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0bcba69a-41dc-4625-9a47-3422493dcb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9bf73c43-575e-4d44-aa15-316ad1cdf75c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0bcba69a-41dc-4625-9a47-3422493dcb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c4c35240-a8b9-4556-8e66-b0ab0a36955b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f2ce8455-a176-46e7-8ed2-08c52fce8939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4c35240-a8b9-4556-8e66-b0ab0a36955b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f2ce8455-a176-46e7-8ed2-08c52fce8939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f2ce8455-a176-46e7-8ed2-08c52fce8939" xlink:to="loc_srt_StatementGeographicalAxis_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0cfa1ecf-ea5f-469c-8dde-ec64ef1ee092" xlink:to="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_c4bb1dc3-69ea-4cdc-84ef-230d011cf2fd" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:to="loc_country_CA_c4bb1dc3-69ea-4cdc-84ef-230d011cf2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_9eb4eac5-2f47-4302-99dc-3365e1fc386f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:to="loc_stpr_MA_9eb4eac5-2f47-4302-99dc-3365e1fc386f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_f943056b-ae22-4f87-b277-9b8972d7c75a" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d4298e6f-b050-432a-9ed8-b40ea32b219e" xlink:to="loc_stpr_PA_f943056b-ae22-4f87-b277-9b8972d7c75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f2ce8455-a176-46e7-8ed2-08c52fce8939" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_8df3f4bb-1c08-4c42-813f-5e227e071b9d" xlink:href="sesn-20210930.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_8df3f4bb-1c08-4c42-813f-5e227e071b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5c1cbc92-a02c-43ef-bdc9-d478d91c3ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5c1cbc92-a02c-43ef-bdc9-d478d91c3ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_3c9173d5-db2f-4ed5-8507-20a59ce2572f" xlink:href="sesn-20210930.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_3c9173d5-db2f-4ed5-8507-20a59ce2572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_10094ecd-4fbc-462d-a6ba-9e4b18177ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_10094ecd-4fbc-462d-a6ba-9e4b18177ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_0d52cad8-4279-4d69-a77e-9efb5d26549a" xlink:href="sesn-20210930.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_0d52cad8-4279-4d69-a77e-9efb5d26549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_0c2374f8-c5c6-492f-9be9-016c012a96fe" xlink:href="sesn-20210930.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_0c2374f8-c5c6-492f-9be9-016c012a96fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3883be1a-12a5-4c90-8971-ccc16eb8122a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_OperatingLeaseCost_3883be1a-12a5-4c90-8971-ccc16eb8122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e7b0042f-01e6-4958-bc2c-1ffabb9468ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9c681-c294-4e72-bdf9-c213191cf1a4" xlink:to="loc_us-gaap_OperatingLeaseExpense_e7b0042f-01e6-4958-bc2c-1ffabb9468ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="sesn-20210930.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a127253a-5dcc-4b1b-8f86-7c038626f1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_70e01828-a4c2-4799-bc73-dd97d9ccf7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a127253a-5dcc-4b1b-8f86-7c038626f1d4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_70e01828-a4c2-4799-bc73-dd97d9ccf7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="sesn-20210930.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_deed37ca-6d32-4a64-8177-e1d5b549610f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fead8848-bf6f-4aff-a9c8-475e2315fa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_deed37ca-6d32-4a64-8177-e1d5b549610f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fead8848-bf6f-4aff-a9c8-475e2315fa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#ACCRUEDEXPENSESCompositionofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_82ed857f-0b17-430f-84a0-58736ba4676d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_e121e0d1-ff75-4272-872b-5194f902a1ab" xlink:href="sesn-20210930.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_82ed857f-0b17-430f-84a0-58736ba4676d" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_e121e0d1-ff75-4272-872b-5194f902a1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8bc6c75c-c957-4a94-80d9-ad6f2fc729a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_82ed857f-0b17-430f-84a0-58736ba4676d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8bc6c75c-c957-4a94-80d9-ad6f2fc729a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_dc3f5156-6257-41e8-a492-d0bcfbafd8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_82ed857f-0b17-430f-84a0-58736ba4676d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_dc3f5156-6257-41e8-a492-d0bcfbafd8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_d1b63c7a-c4a8-4b75-a399-d7c6b3410e90" xlink:href="sesn-20210930.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_82ed857f-0b17-430f-84a0-58736ba4676d" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_d1b63c7a-c4a8-4b75-a399-d7c6b3410e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_74a924f5-8811-48f7-a3ea-5106658b0eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_82ed857f-0b17-430f-84a0-58736ba4676d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_74a924f5-8811-48f7-a3ea-5106658b0eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4c5da6c7-33c2-414b-9b3e-3e183b7f0daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_82ed857f-0b17-430f-84a0-58736ba4676d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4c5da6c7-33c2-414b-9b3e-3e183b7f0daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b5152e25-3609-4802-af61-922518aa02e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cc545dfd-d675-4195-a1bf-2fbd3dab32d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b5152e25-3609-4802-af61-922518aa02e5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cc545dfd-d675-4195-a1bf-2fbd3dab32d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_76815d10-4b2a-419d-83fc-c7ef7c69ac2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_23348956-5d1a-46c1-93b7-ca606585e3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76815d10-4b2a-419d-83fc-c7ef7c69ac2b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_23348956-5d1a-46c1-93b7-ca606585e3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_08e85884-3b95-48c8-a9b4-b35026284e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76815d10-4b2a-419d-83fc-c7ef7c69ac2b" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_08e85884-3b95-48c8-a9b4-b35026284e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_052246f9-b513-47d8-b4a2-6762d62b2b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_052246f9-b513-47d8-b4a2-6762d62b2b80" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7ebc6925-e87a-4bb5-880b-c0727d56d562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:to="loc_us-gaap_CreditFacilityAxis_7ebc6925-e87a-4bb5-880b-c0727d56d562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3ca45314-c60a-4e81-8214-e5e77cc54674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7ebc6925-e87a-4bb5-880b-c0727d56d562" xlink:to="loc_us-gaap_CreditFacilityDomain_3ca45314-c60a-4e81-8214-e5e77cc54674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_1c3d59f6-6e7b-4441-9843-e830b487e34f" xlink:href="sesn-20210930.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3ca45314-c60a-4e81-8214-e5e77cc54674" xlink:to="loc_sesn_ATMFacilityMember_1c3d59f6-6e7b-4441-9843-e830b487e34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_53f0b130-a3ce-4f89-81c6-41326611bfee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:to="loc_srt_StatementScenarioAxis_53f0b130-a3ce-4f89-81c6-41326611bfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0df5ec38-6a5f-444f-a014-ff0cf9c2ac08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_53f0b130-a3ce-4f89-81c6-41326611bfee" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0df5ec38-6a5f-444f-a014-ff0cf9c2ac08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_656a95d5-b9bf-4c2c-a6ad-5218586a74e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0df5ec38-6a5f-444f-a014-ff0cf9c2ac08" xlink:to="loc_srt_ScenarioForecastMember_656a95d5-b9bf-4c2c-a6ad-5218586a74e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_df7a3dc7-3a16-4622-a6b6-32b0dc410e15" xlink:to="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ca923050-62dc-4226-83d1-94f39e0ae9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ca923050-62dc-4226-83d1-94f39e0ae9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_c589c105-2700-450b-be29-24626ae8a3d1" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_c589c105-2700-450b-be29-24626ae8a3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_44e35c6c-d232-41b0-877e-2a8067df0d62" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_44e35c6c-d232-41b0-877e-2a8067df0d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_0dcdf831-2d9e-4935-b0b2-0a990efc12c6" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_0dcdf831-2d9e-4935-b0b2-0a990efc12c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aada6af4-1bae-48a7-9d89-4ab6dfae7f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aada6af4-1bae-48a7-9d89-4ab6dfae7f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bd733ec5-9096-480c-b78d-f2a00afdddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bd733ec5-9096-480c-b78d-f2a00afdddb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_ff290b82-2358-4d49-9b44-fa67245fdbad" xlink:href="sesn-20210930.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_ff290b82-2358-4d49-9b44-fa67245fdbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_3d228512-138f-4ea9-9e95-7909e1f56213" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0d404e7f-fe2b-4eda-be54-40a0530e29d1" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_3d228512-138f-4ea9-9e95-7909e1f56213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1387edfe-c9c4-45ba-b529-b34f70ba9124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cb9aed65-ff1b-4f72-87c8-d77ae61d37bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1387edfe-c9c4-45ba-b529-b34f70ba9124" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cb9aed65-ff1b-4f72-87c8-d77ae61d37bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6e6daca2-f573-455d-beda-c4bf0ea685da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1387edfe-c9c4-45ba-b529-b34f70ba9124" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6e6daca2-f573-455d-beda-c4bf0ea685da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_21c09a4a-a201-4216-bd80-6ce3229fe36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1387edfe-c9c4-45ba-b529-b34f70ba9124" xlink:to="loc_us-gaap_PreferredStockSharesIssued_21c09a4a-a201-4216-bd80-6ce3229fe36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e388d466-5a74-4d47-a8ee-4fac5fc5853a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1387edfe-c9c4-45ba-b529-b34f70ba9124" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e388d466-5a74-4d47-a8ee-4fac5fc5853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2187ae54-eb31-458e-acc4-addd587f6236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_eaff486c-ab46-480a-93d4-a779387984b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2187ae54-eb31-458e-acc4-addd587f6236" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_eaff486c-ab46-480a-93d4-a779387984b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a513f0a6-3c9d-421c-aef0-05758be87b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2187ae54-eb31-458e-acc4-addd587f6236" xlink:to="loc_us-gaap_CommonStockSharesIssued_a513f0a6-3c9d-421c-aef0-05758be87b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_225234de-c7c1-43dd-bc4c-d263d8948a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2187ae54-eb31-458e-acc4-addd587f6236" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_225234de-c7c1-43dd-bc4c-d263d8948a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0e62a6c1-7332-4a45-960a-70ee079c0dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0e62a6c1-7332-4a45-960a-70ee079c0dbc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e049ca4-bc6a-4515-9e70-6ebb4537db10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:to="loc_us-gaap_AwardTypeAxis_4e049ca4-bc6a-4515-9e70-6ebb4537db10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4e049ca4-bc6a-4515-9e70-6ebb4537db10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5fab9ec0-a2de-465a-9446-f517e4164d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:to="loc_us-gaap_WarrantMember_5fab9ec0-a2de-465a-9446-f517e4164d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a916d15-77bd-4cd9-8c2e-c0ceecdad2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a916d15-77bd-4cd9-8c2e-c0ceecdad2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_dfd54d8c-fab3-4f84-b65e-2ba70b1a2d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76140dc8-4043-42c2-b0e2-19775e2c43ab" xlink:to="loc_us-gaap_StockCompensationPlanMember_dfd54d8c-fab3-4f84-b65e-2ba70b1a2d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_01e75fbe-e724-49e1-89a5-c211b39d5599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:to="loc_us-gaap_PlanNameAxis_01e75fbe-e724-49e1-89a5-c211b39d5599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4f317f24-947c-45b4-b050-3d647491f6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_01e75fbe-e724-49e1-89a5-c211b39d5599" xlink:to="loc_us-gaap_PlanNameDomain_4f317f24-947c-45b4-b050-3d647491f6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_23e8367e-351b-4a93-9d8a-3dd1367ea81e" xlink:href="sesn-20210930.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4f317f24-947c-45b4-b050-3d647491f6a7" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_23e8367e-351b-4a93-9d8a-3dd1367ea81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_6d221f76-7547-4e8c-874c-4d4ba6897167" xlink:href="sesn-20210930.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4f317f24-947c-45b4-b050-3d647491f6a7" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_6d221f76-7547-4e8c-874c-4d4ba6897167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_c7868df9-9db2-44f4-abb3-f8b72139683e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_33e75c51-a686-4a41-b00a-e580411c37f7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_c7868df9-9db2-44f4-abb3-f8b72139683e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_658c7f0c-550a-4246-9584-fa60f9594775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c7868df9-9db2-44f4-abb3-f8b72139683e" xlink:to="loc_us-gaap_CommonStockSharesIssued_658c7f0c-550a-4246-9584-fa60f9594775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_b8216252-ae1e-41c7-a87f-839ac7cc515a" xlink:href="sesn-20210930.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c7868df9-9db2-44f4-abb3-f8b72139683e" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_b8216252-ae1e-41c7-a87f-839ac7cc515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6c7ad504-644b-4436-b3f2-693ec3d8fb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_b8216252-ae1e-41c7-a87f-839ac7cc515a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6c7ad504-644b-4436-b3f2-693ec3d8fb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_079794c9-3fc9-4e6d-9e61-d8821b541f37" xlink:href="sesn-20210930.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_b8216252-ae1e-41c7-a87f-839ac7cc515a" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_079794c9-3fc9-4e6d-9e61-d8821b541f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_99e550f1-055a-413f-9bc6-9ce2095a76b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_af019925-15e7-413c-9641-6cd4a682da9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_99e550f1-055a-413f-9bc6-9ce2095a76b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_af019925-15e7-413c-9641-6cd4a682da9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_81468e28-3061-4807-b9cd-8494a7494996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_af019925-15e7-413c-9641-6cd4a682da9d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_81468e28-3061-4807-b9cd-8494a7494996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81468e28-3061-4807-b9cd-8494a7494996" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_9f3c443c-1767-4037-80f1-0cd63c564556" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_9f3c443c-1767-4037-80f1-0cd63c564556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_385c4580-2509-4cab-bbd7-45248af47f8d" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_385c4580-2509-4cab-bbd7-45248af47f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_6600e65c-28d1-41de-be0d-5780ae798c4c" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_6600e65c-28d1-41de-be0d-5780ae798c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_a3f2991e-630a-4443-b03e-e3228b44a425" xlink:href="sesn-20210930.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f5cd9f07-88fa-46a7-9d6f-1f150a300343" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_a3f2991e-630a-4443-b03e-e3228b44a425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3f8216fc-05ed-4e45-839e-d2c7d422f4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_af019925-15e7-413c-9641-6cd4a682da9d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_3f8216fc-05ed-4e45-839e-d2c7d422f4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:href="sesn-20210930.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3f8216fc-05ed-4e45-839e-d2c7d422f4f0" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2a407d23-cc0e-4749-97c4-e8e8d497a10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2a407d23-cc0e-4749-97c4-e8e8d497a10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_56b0c5b3-2463-4188-8be4-f286f0e0f997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_56b0c5b3-2463-4188-8be4-f286f0e0f997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_97c39bcf-12d6-4e4f-b122-555514ed7afb" xlink:href="sesn-20210930.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_97c39bcf-12d6-4e4f-b122-555514ed7afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1d101955-ce0c-46f8-aeaa-584fc918bc50" xlink:href="sesn-20210930.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1d101955-ce0c-46f8-aeaa-584fc918bc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_3600c3c4-3708-4d76-8b54-f00242187a34" xlink:href="sesn-20210930.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_3600c3c4-3708-4d76-8b54-f00242187a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3ed658a8-4879-445a-9f3e-7d1c92068724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_dc27ccf6-5fc1-4b0d-ab5f-6d1292ff5b10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3ed658a8-4879-445a-9f3e-7d1c92068724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="sesn-20210930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0ad2144d-bcf4-433f-94ac-7be8a08264a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7e090af6-07ed-462d-8d33-efe73f0a800c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ad2144d-bcf4-433f-94ac-7be8a08264a1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7e090af6-07ed-462d-8d33-efe73f0a800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="sesn-20210930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_98c7ae21-ba35-4758-93fd-86e09896145f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1629246f-b505-4d25-9bd6-e5b99dde71ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98c7ae21-ba35-4758-93fd-86e09896145f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1629246f-b505-4d25-9bd6-e5b99dde71ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e6fb65b7-a123-46aa-acee-e73836c8aba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98c7ae21-ba35-4758-93fd-86e09896145f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e6fb65b7-a123-46aa-acee-e73836c8aba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#EARNINGSLOSSPERSHAREScheduleofEPSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d83beb82-a82f-4330-a78f-caec3638da76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_987e3b21-98c8-4c2f-846a-7eb59f8c03de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d83beb82-a82f-4330-a78f-caec3638da76" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_987e3b21-98c8-4c2f-846a-7eb59f8c03de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7facf6-38d1-4456-b971-c040acb56fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_987e3b21-98c8-4c2f-846a-7eb59f8c03de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7facf6-38d1-4456-b971-c040acb56fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50c9c66c-4637-4c9c-b988-ca3215ddbe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7facf6-38d1-4456-b971-c040acb56fd3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50c9c66c-4637-4c9c-b988-ca3215ddbe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ab23095b-cb23-458e-8942-ef77e73f2c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50c9c66c-4637-4c9c-b988-ca3215ddbe7c" xlink:to="loc_us-gaap_WarrantMember_ab23095b-cb23-458e-8942-ef77e73f2c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_528a799f-e802-47f1-b142-31b576839f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50c9c66c-4637-4c9c-b988-ca3215ddbe7c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_528a799f-e802-47f1-b142-31b576839f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_987e3b21-98c8-4c2f-846a-7eb59f8c03de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_42ddb1de-cde0-40b1-91d2-f7a82bd45beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_42ddb1de-cde0-40b1-91d2-f7a82bd45beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_42ddb1de-cde0-40b1-91d2-f7a82bd45beb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8e177e53-4364-4818-9a8e-e9ba469ab77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:to="loc_us-gaap_NetIncomeLoss_8e177e53-4364-4818-9a8e-e9ba469ab77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9a5c3ea5-bc85-472f-ac48-ce3f2a91123f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9a5c3ea5-bc85-472f-ac48-ce3f2a91123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e40839c2-6db4-40d0-8066-2eb07a3cb4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e40839c2-6db4-40d0-8066-2eb07a3cb4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_760b9117-6322-4af8-abf7-582c55d8cc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7422b71a-dc1b-406c-a183-c0f0f57cda7f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_760b9117-6322-4af8-abf7-582c55d8cc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_86521645-ff82-4a4f-bf29-853c4933fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_42ddb1de-cde0-40b1-91d2-f7a82bd45beb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_86521645-ff82-4a4f-bf29-853c4933fe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a023476-f16a-47ad-9f6e-b21ea0c7f5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_86521645-ff82-4a4f-bf29-853c4933fe83" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a023476-f16a-47ad-9f6e-b21ea0c7f5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ad905931-7718-4571-a297-68f5a8d221b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_86521645-ff82-4a4f-bf29-853c4933fe83" xlink:to="loc_us-gaap_EarningsPerShareBasic_ad905931-7718-4571-a297-68f5a8d221b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_9c1007a8-00cd-4a46-9b6a-9d56d096320b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_9c1007a8-00cd-4a46-9b6a-9d56d096320b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_e4dd88f6-8e75-42eb-9110-9fe9942d740a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_9c1007a8-00cd-4a46-9b6a-9d56d096320b" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_e4dd88f6-8e75-42eb-9110-9fe9942d740a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9d900ab-1a75-4407-aeb8-9851d6d7181a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_9c1007a8-00cd-4a46-9b6a-9d56d096320b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9d900ab-1a75-4407-aeb8-9851d6d7181a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bfd088e1-e9de-4164-ae12-f4bcb18e28ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bfd088e1-e9de-4164-ae12-f4bcb18e28ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_063512e1-8587-4eb4-9b28-61268cb79cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_063512e1-8587-4eb4-9b28-61268cb79cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9af8c042-7331-470d-a586-4653dc3efac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9f5d837-e8d7-4adb-96f3-9ac0a6236474" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9af8c042-7331-470d-a586-4653dc3efac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_f3b5720e-127d-474f-bd06-2a96890f9679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b7a39f3-a067-4afb-98df-4d3914135f43" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_f3b5720e-127d-474f-bd06-2a96890f9679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3bda8786-0838-4b49-9624-0f6e89765a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_f3b5720e-127d-474f-bd06-2a96890f9679" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3bda8786-0838-4b49-9624-0f6e89765a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_472f1ce5-1f5b-4519-b0d9-de6c671fde21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc2ad77-40f6-4e00-9754-a4c4261ef2da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_472f1ce5-1f5b-4519-b0d9-de6c671fde21" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc2ad77-40f6-4e00-9754-a4c4261ef2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a152946-3569-4a20-971d-a7a3c46fdfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc2ad77-40f6-4e00-9754-a4c4261ef2da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a152946-3569-4a20-971d-a7a3c46fdfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_efbb4493-8c3b-4574-a6f6-e556bfa06734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a152946-3569-4a20-971d-a7a3c46fdfa1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_efbb4493-8c3b-4574-a6f6-e556bfa06734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_42a135e5-8e6e-4e76-864d-8c3abfd9a3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_efbb4493-8c3b-4574-a6f6-e556bfa06734" xlink:to="loc_us-gaap_WarrantMember_42a135e5-8e6e-4e76-864d-8c3abfd9a3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8852a36c-8d5b-4442-a9db-9751d2dd8777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_efbb4493-8c3b-4574-a6f6-e556bfa06734" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8852a36c-8d5b-4442-a9db-9751d2dd8777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b54ef73c-8f53-472f-a73e-9fc9fa7c2633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abc2ad77-40f6-4e00-9754-a4c4261ef2da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b54ef73c-8f53-472f-a73e-9fc9fa7c2633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2f6d02d0-344b-4256-906c-5cf5ba7cda47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b54ef73c-8f53-472f-a73e-9fc9fa7c2633" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2f6d02d0-344b-4256-906c-5cf5ba7cda47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sesn-20210930.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e5fc3f9-3e9c-474f-9205-99ea02b0fe9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7631fee7-bdfe-4293-b939-f244f1ce6ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e5fc3f9-3e9c-474f-9205-99ea02b0fe9a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7631fee7-bdfe-4293-b939-f244f1ce6ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sesn-20210930.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2002eee0-d538-4939-8e1f-a677a61e8711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fede2d28-a491-43b9-b2a1-00e53d9d3cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2002eee0-d538-4939-8e1f-a677a61e8711" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fede2d28-a491-43b9-b2a1-00e53d9d3cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4dc8ef6b-80a6-4bf0-86bc-e1143b4b85e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2002eee0-d538-4939-8e1f-a677a61e8711" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4dc8ef6b-80a6-4bf0-86bc-e1143b4b85e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5fcc0765-645d-4320-b372-72f4f476d1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2002eee0-d538-4939-8e1f-a677a61e8711" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5fcc0765-645d-4320-b372-72f4f476d1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6280b9a-6c7f-4355-93ae-9ab36c24614c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8050342e-3e17-40be-b913-3156b75b28f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6280b9a-6c7f-4355-93ae-9ab36c24614c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8050342e-3e17-40be-b913-3156b75b28f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3eaf9709-7bf0-46a0-a145-abf78d5c68ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8050342e-3e17-40be-b913-3156b75b28f5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3eaf9709-7bf0-46a0-a145-abf78d5c68ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51fb91ed-5274-407c-a728-38066a8ffcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eaf9709-7bf0-46a0-a145-abf78d5c68ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51fb91ed-5274-407c-a728-38066a8ffcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22869715-bb94-4a89-bbc6-cfcaae65a88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51fb91ed-5274-407c-a728-38066a8ffcc7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22869715-bb94-4a89-bbc6-cfcaae65a88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a8491e92-83e1-4400-913f-75099a00ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51fb91ed-5274-407c-a728-38066a8ffcc7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a8491e92-83e1-4400-913f-75099a00ca5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82fd84ba-84d5-49b4-ab7d-86338fff9963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8050342e-3e17-40be-b913-3156b75b28f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82fd84ba-84d5-49b4-ab7d-86338fff9963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_68a78cad-1538-44ef-823e-32a8a6a65781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82fd84ba-84d5-49b4-ab7d-86338fff9963" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_68a78cad-1538-44ef-823e-32a8a6a65781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a0da0f9-7f2c-4368-809e-0dd8ce4077d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a0da0f9-7f2c-4368-809e-0dd8ce4077d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e1003ab6-a811-4acf-95eb-2cff461d02de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_VestingAxis_e1003ab6-a811-4acf-95eb-2cff461d02de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a0330a9f-8139-408b-b71d-b2bb425f4d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_e1003ab6-a811-4acf-95eb-2cff461d02de" xlink:to="loc_us-gaap_VestingDomain_a0330a9f-8139-408b-b71d-b2bb425f4d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_43076ffd-2ade-4b62-b6f9-771ae54df6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a0330a9f-8139-408b-b71d-b2bb425f4d50" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_43076ffd-2ade-4b62-b6f9-771ae54df6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_19b7f6e5-8e58-4d90-84b2-52f8144bcc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a0330a9f-8139-408b-b71d-b2bb425f4d50" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_19b7f6e5-8e58-4d90-84b2-52f8144bcc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_PlanNameAxis_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a7d96eb2-ce06-46f4-91e0-b76647d3aca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_78a52c26-6ee6-4a06-9e8d-803bb7a1e78f" xlink:to="loc_us-gaap_PlanNameDomain_a7d96eb2-ce06-46f4-91e0-b76647d3aca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_348f96cf-d387-4f70-bf98-ae180d893c1d" xlink:href="sesn-20210930.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a7d96eb2-ce06-46f4-91e0-b76647d3aca8" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_348f96cf-d387-4f70-bf98-ae180d893c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_7362c8e9-46d6-4162-8dc6-8e7ae51b6267" xlink:href="sesn-20210930.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a7d96eb2-ce06-46f4-91e0-b76647d3aca8" xlink:to="loc_sesn_StockIncentivePlan2009Member_7362c8e9-46d6-4162-8dc6-8e7ae51b6267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e820aee1-5b6d-49f2-a82a-f8b4ed69309f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_AwardTypeAxis_e820aee1-5b6d-49f2-a82a-f8b4ed69309f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f20eec08-3a60-4ec5-ab16-dc94683e4ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e820aee1-5b6d-49f2-a82a-f8b4ed69309f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f20eec08-3a60-4ec5-ab16-dc94683e4ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b5a7489c-7634-41c2-9609-7e55a070b962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f20eec08-3a60-4ec5-ab16-dc94683e4ab8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b5a7489c-7634-41c2-9609-7e55a070b962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_21c53ba2-f51b-4423-a047-7b1b5e935e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_GranteeStatusAxis_21c53ba2-f51b-4423-a047-7b1b5e935e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_b5bba3e1-bf8a-4d7b-b6c8-83b94001584f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_21c53ba2-f51b-4423-a047-7b1b5e935e7d" xlink:to="loc_us-gaap_GranteeStatusDomain_b5bba3e1-bf8a-4d7b-b6c8-83b94001584f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_25abc82b-b348-4dd2-b3bd-227a8e20ee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_b5bba3e1-bf8a-4d7b-b6c8-83b94001584f" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_25abc82b-b348-4dd2-b3bd-227a8e20ee6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03266028-6d3c-4200-a983-50f989e29fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_e84df59c-9aee-4734-98a3-494248cd0e77" xlink:href="sesn-20210930.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_e84df59c-9aee-4734-98a3-494248cd0e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3848e9d9-fb86-437c-8a79-cbf82d7b6b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3848e9d9-fb86-437c-8a79-cbf82d7b6b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1d6a6d6-89ea-45d1-bcb6-1e64a20be147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1d6a6d6-89ea-45d1-bcb6-1e64a20be147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ed584040-1225-4644-aca5-aedd0137b6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ed584040-1225-4644-aca5-aedd0137b6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b3892f1-ecf7-4b4e-81d7-0a3361dcadae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b3892f1-ecf7-4b4e-81d7-0a3361dcadae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7bf952f8-6035-40e9-9265-7997ffc1f78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7bf952f8-6035-40e9-9265-7997ffc1f78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_a7b8da00-c0e3-4a01-a613-8825d3f0bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_a7b8da00-c0e3-4a01-a613-8825d3f0bc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8c8d2eb1-8f08-4fa6-bd13-5c893854c5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8c8d2eb1-8f08-4fa6-bd13-5c893854c5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d9869b4-895e-402d-8b26-e92ab2ead884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d9869b4-895e-402d-8b26-e92ab2ead884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_801bd1b4-fc00-4578-969c-043e6eb2dff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_801bd1b4-fc00-4578-969c-043e6eb2dff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0eeffb3-0611-481c-9c25-b073f9f85bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_501ad23d-290f-4829-b2ff-5126e9ead37e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0eeffb3-0611-481c-9c25-b073f9f85bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da655f99-2c6d-4b3b-9a1f-b6c395f69358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aef7334d-b4d6-4603-93ed-16d5c7daa4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da655f99-2c6d-4b3b-9a1f-b6c395f69358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aef7334d-b4d6-4603-93ed-16d5c7daa4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e2fe3b39-9ea0-4c8d-b00a-a4631ce4186d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aef7334d-b4d6-4603-93ed-16d5c7daa4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e2fe3b39-9ea0-4c8d-b00a-a4631ce4186d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea55823e-3c17-4a8f-ad07-e12330586b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aef7334d-b4d6-4603-93ed-16d5c7daa4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea55823e-3c17-4a8f-ad07-e12330586b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13d24e7c-e942-4b8a-b39e-88841ed6377f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aef7334d-b4d6-4603-93ed-16d5c7daa4de" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13d24e7c-e942-4b8a-b39e-88841ed6377f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b2130980-2888-498d-8fd7-4d9130312bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aef7334d-b4d6-4603-93ed-16d5c7daa4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b2130980-2888-498d-8fd7-4d9130312bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29411c80-bdbe-404b-83c6-458917cad429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aef7334d-b4d6-4603-93ed-16d5c7daa4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29411c80-bdbe-404b-83c6-458917cad429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e0b47a47-8681-4d39-9d62-d61a960fd80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aef7334d-b4d6-4603-93ed-16d5c7daa4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e0b47a47-8681-4d39-9d62-d61a960fd80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b67bf1e-9e66-4cbf-9648-0d5a5bdb9383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da655f99-2c6d-4b3b-9a1f-b6c395f69358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b67bf1e-9e66-4cbf-9648-0d5a5bdb9383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ebf4adcb-6091-4ccc-9845-45e2356be270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b67bf1e-9e66-4cbf-9648-0d5a5bdb9383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ebf4adcb-6091-4ccc-9845-45e2356be270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5c33dfa-2a3b-4f38-88c3-cd9b91e0db4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b67bf1e-9e66-4cbf-9648-0d5a5bdb9383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5c33dfa-2a3b-4f38-88c3-cd9b91e0db4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_09ba7a03-2beb-40bf-b178-68fd0ce92243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b67bf1e-9e66-4cbf-9648-0d5a5bdb9383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_09ba7a03-2beb-40bf-b178-68fd0ce92243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53594382-9f5b-4bf0-bc88-b2ed161dc377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b67bf1e-9e66-4cbf-9648-0d5a5bdb9383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53594382-9f5b-4bf0-bc88-b2ed161dc377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_82096cf1-b809-4d3a-a8a5-9186300c306f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b67bf1e-9e66-4cbf-9648-0d5a5bdb9383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_82096cf1-b809-4d3a-a8a5-9186300c306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d2837d76-351e-4960-8aaf-a81a805f24fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b67bf1e-9e66-4cbf-9648-0d5a5bdb9383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d2837d76-351e-4960-8aaf-a81a805f24fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5b279aac-80a6-40a6-b461-36ad1f3cc0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da655f99-2c6d-4b3b-9a1f-b6c395f69358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5b279aac-80a6-40a6-b461-36ad1f3cc0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0aad5b1c-221a-41bf-816e-94ce39f9ede9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5b279aac-80a6-40a6-b461-36ad1f3cc0bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0aad5b1c-221a-41bf-816e-94ce39f9ede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_712e875b-fc57-4c37-879a-06c6aaa77dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5b279aac-80a6-40a6-b461-36ad1f3cc0bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_712e875b-fc57-4c37-879a-06c6aaa77dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d91a802-289d-4a9a-b34c-216b470f64df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5b279aac-80a6-40a6-b461-36ad1f3cc0bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d91a802-289d-4a9a-b34c-216b470f64df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cd8bc53d-772c-469e-880d-b1c55dcc4d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5b279aac-80a6-40a6-b461-36ad1f3cc0bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cd8bc53d-772c-469e-880d-b1c55dcc4d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a86b0842-793f-4679-b6f8-faa81f6e8714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_b0f6d120-6049-44fb-9f94-e7108cf567fa" xlink:href="sesn-20210930.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a86b0842-793f-4679-b6f8-faa81f6e8714" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_b0f6d120-6049-44fb-9f94-e7108cf567fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0a669671-a1b6-4e33-8e60-3bfb786986fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a86b0842-793f-4679-b6f8-faa81f6e8714" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0a669671-a1b6-4e33-8e60-3bfb786986fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_23d082db-041c-41c8-bc00-45f80cf7e22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a86b0842-793f-4679-b6f8-faa81f6e8714" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_23d082db-041c-41c8-bc00-45f80cf7e22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33c06c55-deba-4775-9e64-eec5edeb1804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a86b0842-793f-4679-b6f8-faa81f6e8714" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33c06c55-deba-4775-9e64-eec5edeb1804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15dbb8d2-7fb9-461f-b420-d03e38793dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a86b0842-793f-4679-b6f8-faa81f6e8714" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15dbb8d2-7fb9-461f-b420-d03e38793dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_97a3598c-c726-4520-bcf5-14e4ebacf588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a86b0842-793f-4679-b6f8-faa81f6e8714" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_97a3598c-c726-4520-bcf5-14e4ebacf588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="sesn-20210930.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_408428ce-7bc4-4edf-8446-d4169912e1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_853a142b-6233-4442-be6e-b44706f0eba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_408428ce-7bc4-4edf-8446-d4169912e1ed" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_853a142b-6233-4442-be6e-b44706f0eba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01d46e69-8f7e-489a-999f-059c6dcff915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_304fd755-6e6d-4fa6-b3d0-a3bb514a4436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01d46e69-8f7e-489a-999f-059c6dcff915" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_304fd755-6e6d-4fa6-b3d0-a3bb514a4436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b66c7b82-e6c7-4f03-87ea-df558acbbfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_304fd755-6e6d-4fa6-b3d0-a3bb514a4436" xlink:to="loc_us-gaap_PlanNameAxis_b66c7b82-e6c7-4f03-87ea-df558acbbfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b697346f-e5d6-4684-a2ea-6aea5f9a08af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b66c7b82-e6c7-4f03-87ea-df558acbbfc8" xlink:to="loc_us-gaap_PlanNameDomain_b697346f-e5d6-4684-a2ea-6aea5f9a08af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_1bd2ca7a-a32a-4fc2-8dba-6fd87590ec4b" xlink:href="sesn-20210930.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b697346f-e5d6-4684-a2ea-6aea5f9a08af" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_1bd2ca7a-a32a-4fc2-8dba-6fd87590ec4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_304fd755-6e6d-4fa6-b3d0-a3bb514a4436" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_110cc856-66fe-4bf2-b44e-33aa0d922d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_110cc856-66fe-4bf2-b44e-33aa0d922d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fabbce30-930e-4716-809e-3ad664eedf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fabbce30-930e-4716-809e-3ad664eedf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_d6259f77-5027-4f12-81d9-4967ec32f86e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_d6259f77-5027-4f12-81d9-4967ec32f86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eef9b96a-d876-41fc-878d-6acb9abe9150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eef9b96a-d876-41fc-878d-6acb9abe9150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_cfb5bf61-b2f3-4f22-82eb-9338fc2c1e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_cfb5bf61-b2f3-4f22-82eb-9338fc2c1e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_b4ab8cc7-f0ef-45af-bc30-8a52e414cd58" xlink:href="sesn-20210930.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_b4ab8cc7-f0ef-45af-bc30-8a52e414cd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_56df5a7e-66a0-4ea7-8889-452b0504ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f44db19c-ce97-4a61-b380-f3cbb973ee53" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_56df5a7e-66a0-4ea7-8889-452b0504ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d96e4f20-d93a-4b2a-b95d-2edec2c19d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a8685cc6-a95c-439e-9617-af81fcabcb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d96e4f20-d93a-4b2a-b95d-2edec2c19d52" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a8685cc6-a95c-439e-9617-af81fcabcb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_185cda6c-f244-47a4-85dc-08dc65f8deb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_ee3f208a-4de3-4eb6-8b1c-81ff5b1d2ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_185cda6c-f244-47a4-85dc-08dc65f8deb1" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_ee3f208a-4de3-4eb6-8b1c-81ff5b1d2ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_21389489-1855-4b5e-b75a-4e0fa77849d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_185cda6c-f244-47a4-85dc-08dc65f8deb1" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_21389489-1855-4b5e-b75a-4e0fa77849d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6beec172-1c92-42d9-910f-e5535138cf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_185cda6c-f244-47a4-85dc-08dc65f8deb1" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6beec172-1c92-42d9-910f-e5535138cf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6005e943-5c90-4ae7-91fc-f7d03b645a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bdf55120-8644-4005-8b66-5aa19da9d892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6005e943-5c90-4ae7-91fc-f7d03b645a7f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bdf55120-8644-4005-8b66-5aa19da9d892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8fc06309-d02c-477d-aa85-de0b71a02b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6005e943-5c90-4ae7-91fc-f7d03b645a7f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8fc06309-d02c-477d-aa85-de0b71a02b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_36a9b27c-2b8f-420b-88d0-83e19f44d154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6005e943-5c90-4ae7-91fc-f7d03b645a7f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_36a9b27c-2b8f-420b-88d0-83e19f44d154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXESCurrentTaxBenefitProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8b291bdf-ba22-4c5f-aa2b-78a1954a85f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_24975116-5abd-438e-b871-47136a41f62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b291bdf-ba22-4c5f-aa2b-78a1954a85f0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_24975116-5abd-438e-b871-47136a41f62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d84bb214-1f34-46a9-83a5-ca31512954cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_24975116-5abd-438e-b871-47136a41f62e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d84bb214-1f34-46a9-83a5-ca31512954cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e8058f75-7279-4ee6-90c4-88544485ad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_24975116-5abd-438e-b871-47136a41f62e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e8058f75-7279-4ee6-90c4-88544485ad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_8c8a6c5e-29b1-427d-965b-2f94510a9cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_24975116-5abd-438e-b871-47136a41f62e" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_8c8a6c5e-29b1-427d-965b-2f94510a9cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2f064947-0ab7-4b78-957f-04c129f04fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_24975116-5abd-438e-b871-47136a41f62e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2f064947-0ab7-4b78-957f-04c129f04fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXESDeferredTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2fc7f8bc-eb17-47cb-a5e4-ddaf9e26aa03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_62455cfd-f51e-4476-89f3-3866bb1f3d3d" xlink:href="sesn-20210930.xsd#sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2fc7f8bc-eb17-47cb-a5e4-ddaf9e26aa03" xlink:to="loc_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_62455cfd-f51e-4476-89f3-3866bb1f3d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_aaf8506d-1459-476e-8024-29450765cb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2fc7f8bc-eb17-47cb-a5e4-ddaf9e26aa03" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_aaf8506d-1459-476e-8024-29450765cb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_96a74c3f-f016-4647-a8cb-c2b63499ac2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2fc7f8bc-eb17-47cb-a5e4-ddaf9e26aa03" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_96a74c3f-f016-4647-a8cb-c2b63499ac2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a00952cb-4bf1-44bf-aa25-e3a77b6ec0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eb38c905-6b67-4740-b7cf-59a747d3c737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a00952cb-4bf1-44bf-aa25-e3a77b6ec0c6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eb38c905-6b67-4740-b7cf-59a747d3c737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ab6e3b60-ac56-4262-950a-1ad571a128c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a00952cb-4bf1-44bf-aa25-e3a77b6ec0c6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ab6e3b60-ac56-4262-950a-1ad571a128c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxLiabilityImpairmentWriteDown_47932a17-bc18-4de0-aa29-cb808ac91116" xlink:href="sesn-20210930.xsd#sesn_DeferredTaxLiabilityImpairmentWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a00952cb-4bf1-44bf-aa25-e3a77b6ec0c6" xlink:to="loc_sesn_DeferredTaxLiabilityImpairmentWriteDown_47932a17-bc18-4de0-aa29-cb808ac91116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="simple" xlink:href="sesn-20210930.xsd#LICENSEAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01db39fa-09b2-46d3-ac88-b610259502e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock_bdadf8fb-052d-41cb-8add-4173736aeaca" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01db39fa-09b2-46d3-ac88-b610259502e9" xlink:to="loc_sesn_LicenseAgreementTextBlock_bdadf8fb-052d-41cb-8add-4173736aeaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#LICENSEAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20fa37c5-7e08-4431-846d-7ae810b3249e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:href="sesn-20210930.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20fa37c5-7e08-4431-846d-7ae810b3249e" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27597b1c-8dd3-4d97-acf1-88d6713f9a16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_srt_CounterpartyNameAxis_27597b1c-8dd3-4d97-acf1-88d6713f9a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_27597b1c-8dd3-4d97-acf1-88d6713f9a16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_827043b1-26a7-4bf6-9de2-ef0aef042270" xlink:href="sesn-20210930.xsd#sesn_UniversityOfZurichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_UniversityOfZurichMember_827043b1-26a7-4bf6-9de2-ef0aef042270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_afdb46b2-fa57-4eb2-b8cb-5565879c8f44" xlink:href="sesn-20210930.xsd#sesn_MicrometAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_MicrometAGMember_afdb46b2-fa57-4eb2-b8cb-5565879c8f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_592a2cbe-47eb-4952-936b-841f5f25c741" xlink:href="sesn-20210930.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_XOMAIrelandLimitedMember_592a2cbe-47eb-4952-936b-841f5f25c741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_26930510-9f17-49be-a5e6-57efbcf00442" xlink:href="sesn-20210930.xsd#sesn_RocheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_RocheMember_26930510-9f17-49be-a5e6-57efbcf00442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_b505cd07-b146-4a5a-933c-93578c62c42b" xlink:href="sesn-20210930.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_b505cd07-b146-4a5a-933c-93578c62c42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_1c56d4b2-9023-4196-82d5-fcd517b652ea" xlink:href="sesn-20210930.xsd#sesn_MENALicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_MENALicenseAgreementMember_1c56d4b2-9023-4196-82d5-fcd517b652ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_c0d57d8d-35d9-4eeb-947f-e5f99ad67451" xlink:href="sesn-20210930.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efd16754-65d2-4d28-98ec-7622f9a3f3b5" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_c0d57d8d-35d9-4eeb-947f-e5f99ad67451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d308a09-48ed-477c-bee0-3dc0045537eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_srt_ProductOrServiceAxis_4d308a09-48ed-477c-bee0-3dc0045537eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_683bd49b-9b0a-4c42-baac-4439c47df2c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4d308a09-48ed-477c-bee0-3dc0045537eb" xlink:to="loc_srt_ProductsAndServicesDomain_683bd49b-9b0a-4c42-baac-4439c47df2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_3dc7c580-eec9-4a0b-93bc-30f52940b55d" xlink:href="sesn-20210930.xsd#sesn_EBI031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_683bd49b-9b0a-4c42-baac-4439c47df2c5" xlink:to="loc_sesn_EBI031Member_3dc7c580-eec9-4a0b-93bc-30f52940b55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member_e9d57d5b-effe-4a2e-b990-3d6ddcb00b26" xlink:href="sesn-20210930.xsd#sesn_IL6Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_683bd49b-9b0a-4c42-baac-4439c47df2c5" xlink:to="loc_sesn_IL6Member_e9d57d5b-effe-4a2e-b990-3d6ddcb00b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d3c015a-8425-439b-bc1f-3c2d57d2d430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d3c015a-8425-439b-bc1f-3c2d57d2d430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d3c015a-8425-439b-bc1f-3c2d57d2d430" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_28513929-de49-49db-be9a-36e20ac2519b" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_28513929-de49-49db-be9a-36e20ac2519b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_38f16505-7d16-4565-b4be-ea629bfed3bb" xlink:href="sesn-20210930.xsd#sesn_FirstIndicationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_FirstIndicationMember_38f16505-7d16-4565-b4be-ea629bfed3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_f935e1f6-c7f5-4d1b-9a2c-28073f69b97e" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_f935e1f6-c7f5-4d1b-9a2c-28073f69b97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_1e76b781-63dc-4c0d-8141-b1919462e5de" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_1e76b781-63dc-4c0d-8141-b1919462e5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_f0a6a539-f5da-4c8c-aa73-3365a2bc718d" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_f0a6a539-f5da-4c8c-aa73-3365a2bc718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_1ea3c5eb-d870-46f3-a7e1-ff6e7290e1da" xlink:href="sesn-20210930.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_1ea3c5eb-d870-46f3-a7e1-ff6e7290e1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_3a2cd7d0-8917-4161-ab28-e24552f7e25c" xlink:href="sesn-20210930.xsd#sesn_SecondIndicationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a0b17c9-aca7-4088-b69b-077eb0a12ec2" xlink:to="loc_sesn_SecondIndicationMember_3a2cd7d0-8917-4161-ab28-e24552f7e25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ed60935-ea76-4e71-ae4e-9bfe999482df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_srt_RangeAxis_6ed60935-ea76-4e71-ae4e-9bfe999482df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48522218-a933-47c5-8af9-95b8afa520f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6ed60935-ea76-4e71-ae4e-9bfe999482df" xlink:to="loc_srt_RangeMember_48522218-a933-47c5-8af9-95b8afa520f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8aeba303-3228-4c07-b23b-d51799b6dbe1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_48522218-a933-47c5-8af9-95b8afa520f2" xlink:to="loc_srt_MinimumMember_8aeba303-3228-4c07-b23b-d51799b6dbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_850a1220-cb38-4484-81e2-3f3d7a79122f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_48522218-a933-47c5-8af9-95b8afa520f2" xlink:to="loc_srt_MaximumMember_850a1220-cb38-4484-81e2-3f3d7a79122f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fe86b7d-c360-42c1-9a6d-672bf06adf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf04385b-30c4-4e57-a9ae-c3a8f7bacc2a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fe86b7d-c360-42c1-9a6d-672bf06adf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_e9f52f1b-6785-496e-88a1-a97e65f66455" xlink:href="sesn-20210930.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fe86b7d-c360-42c1-9a6d-672bf06adf75" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_e9f52f1b-6785-496e-88a1-a97e65f66455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ddadd1-bacb-407d-a2f2-52f8c95eb624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ddadd1-bacb-407d-a2f2-52f8c95eb624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03b16412-d530-4b84-b76b-174834225a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ddadd1-bacb-407d-a2f2-52f8c95eb624" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03b16412-d530-4b84-b76b-174834225a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_51cb6fef-4549-4b60-8c30-cbd97189a4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03b16412-d530-4b84-b76b-174834225a45" xlink:to="loc_us-gaap_LicensingAgreementsMember_51cb6fef-4549-4b60-8c30-cbd97189a4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_edafe90b-6100-4554-8241-292753b39e39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_srt_StatementGeographicalAxis_edafe90b-6100-4554-8241-292753b39e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d2df6263-9a96-47d0-b242-ca98fede35dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_edafe90b-6100-4554-8241-292753b39e39" xlink:to="loc_srt_SegmentGeographicalDomain_d2df6263-9a96-47d0-b242-ca98fede35dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_dca05775-8874-46aa-9d43-4065f45f9f38" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d2df6263-9a96-47d0-b242-ca98fede35dd" xlink:to="loc_country_TR_dca05775-8874-46aa-9d43-4065f45f9f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:href="sesn-20210930.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_7e951afb-c590-433b-ae42-634a731b632d" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_fc32d933-dc53-4ab8-9f05-d0cc04431b66" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_fc32d933-dc53-4ab8-9f05-d0cc04431b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_98a831e5-8f4b-48e4-a45a-d8239a030d28" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_98a831e5-8f4b-48e4-a45a-d8239a030d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_4985f9b7-ed56-4c24-a626-cfe6f7ad9e55" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_4985f9b7-ed56-4c24-a626-cfe6f7ad9e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_47e6f1d4-0616-4963-be12-a0e04a85c875" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_47e6f1d4-0616-4963-be12-a0e04a85c875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_a7122ed1-c4ff-4ee5-9a50-9dc93aa34ff3" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_a7122ed1-c4ff-4ee5-9a50-9dc93aa34ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_8dbaaa89-4c32-4c37-b264-0e409778d665" xlink:href="sesn-20210930.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_8dbaaa89-4c32-4c37-b264-0e409778d665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_cf4430b5-06d1-48ca-ae3e-9ffb40850ba3" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_cf4430b5-06d1-48ca-ae3e-9ffb40850ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_94899250-dc5a-4628-978b-d882608cbe1d" xlink:href="sesn-20210930.xsd#sesn_LicenseMaintenanceFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseMaintenanceFees_94899250-dc5a-4628-978b-d882608cbe1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_c0dca754-d1fa-4a06-9762-766424e39b19" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_c0dca754-d1fa-4a06-9762-766424e39b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_45bd2bfb-9bdd-4c23-88e5-951032806e01" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_45bd2bfb-9bdd-4c23-88e5-951032806e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_91fd4fc3-27c9-4e11-8684-a1879619504a" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_91fd4fc3-27c9-4e11-8684-a1879619504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_3c137b56-cfdc-40e8-88d1-8f04ea51d9d5" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_3c137b56-cfdc-40e8-88d1-8f04ea51d9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_9aa67200-3b1b-4f28-8825-bdc25be754d5" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_9aa67200-3b1b-4f28-8825-bdc25be754d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_f0ad18ae-5c65-45fd-b4b8-1d4b3e2d1d70" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_f0ad18ae-5c65-45fd-b4b8-1d4b3e2d1d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_11c018aa-81ad-445b-a1db-4452a3a5708d" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_11c018aa-81ad-445b-a1db-4452a3a5708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_91a26e8f-c4e7-4ea9-9f84-d95ac9246947" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_91a26e8f-c4e7-4ea9-9f84-d95ac9246947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_f6bcc8f4-ea28-47fb-83dd-11f4fb1bc83d" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_f6bcc8f4-ea28-47fb-83dd-11f4fb1bc83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_1a09ab16-93de-4d18-9711-93a922bf62ac" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_1a09ab16-93de-4d18-9711-93a922bf62ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b2c05221-951d-4ff8-a42e-f6264f8e7c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b2c05221-951d-4ff8-a42e-f6264f8e7c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_436f8fb8-6ba9-4d65-9723-aedcb5f49532" xlink:href="sesn-20210930.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_436f8fb8-6ba9-4d65-9723-aedcb5f49532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAccountsReceivable_32d8f720-f80f-474a-92b1-10b28ed130f7" xlink:href="sesn-20210930.xsd#sesn_LicenseAgreementAccountsReceivable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_LicenseAgreementAccountsReceivable_32d8f720-f80f-474a-92b1-10b28ed130f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f4b46b90-12bf-426a-b85b-d22576ccf669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f4b46b90-12bf-426a-b85b-d22576ccf669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ae3a815-c10a-48de-ac83-b937a0a84cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ae3a815-c10a-48de-ac83-b937a0a84cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0ae73638-258c-46c6-91d4-a31c77f409fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0ae73638-258c-46c6-91d4-a31c77f409fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_d3d17ad1-3a82-43f8-8f61-cd8dfb7b1e1d" xlink:href="sesn-20210930.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_abb38080-03e5-467c-b035-640839c558b0" xlink:to="loc_sesn_RoyaltyRevenuePercentage_d3d17ad1-3a82-43f8-8f61-cd8dfb7b1e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="simple" xlink:href="sesn-20210930.xsd#RESTRUCTURINGANDRELATEDACTIVITIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b90c6b5b-5082-4dce-928e-4c4a7fc6990b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a78ea105-38cf-4b6d-9b5d-0687e64cf1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b90c6b5b-5082-4dce-928e-4c4a7fc6990b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a78ea105-38cf-4b6d-9b5d-0687e64cf1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="simple" xlink:href="sesn-20210930.xsd#RESTRUCTURINGANDRELATEDACTIVITIESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8f4185b6-3587-4a8c-b4da-69aff7dea7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_9818048c-281a-40e2-86ec-3b9367960300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8f4185b6-3587-4a8c-b4da-69aff7dea7b9" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_9818048c-281a-40e2-86ec-3b9367960300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#RESTRUCTURINGANDRELATEDACTIVITIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_88f4c36f-d201-434b-8180-47ef702144a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fb836918-14c2-4e0e-bb66-2cc61e79207e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_88f4c36f-d201-434b-8180-47ef702144a9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fb836918-14c2-4e0e-bb66-2cc61e79207e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b4c47703-70d9-43e6-bca6-3c258f594422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fb836918-14c2-4e0e-bb66-2cc61e79207e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b4c47703-70d9-43e6-bca6-3c258f594422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b4c47703-70d9-43e6-bca6-3c258f594422" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_21417c79-fc27-4772-b512-66ef46a4ec48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:to="loc_us-gaap_EmployeeSeveranceMember_21417c79-fc27-4772-b512-66ef46a4ec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_c03a4140-58e9-4e3e-b26f-ba0fb2f1b01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractTerminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:to="loc_us-gaap_ContractTerminationMember_c03a4140-58e9-4e3e-b26f-ba0fb2f1b01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_58cc218d-414e-4fb3-9f92-cde92629e562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6364696e-4c26-4980-a392-eb4386a1e937" xlink:to="loc_us-gaap_OtherRestructuringMember_58cc218d-414e-4fb3-9f92-cde92629e562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fb836918-14c2-4e0e-bb66-2cc61e79207e" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_573bce67-1013-4a87-bce3-ffe498a29445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:to="loc_us-gaap_RestructuringCharges_573bce67-1013-4a87-bce3-ffe498a29445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_d8051aa4-bea0-4dd2-b2b0-b795a9c98c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:to="loc_us-gaap_PaymentsForRestructuring_d8051aa4-bea0-4dd2-b2b0-b795a9c98c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_805a3e47-8667-4b34-899d-f2d34c4eb0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8ca6d04a-dac6-4dfb-9ccf-ba1ae104885f" xlink:to="loc_us-gaap_RestructuringReserve_805a3e47-8667-4b34-899d-f2d34c4eb0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3a105569-1249-4ddb-af63-2a7baca9310d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_86f8ec0b-8599-4f8a-ac60-3812d33ba8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3a105569-1249-4ddb-af63-2a7baca9310d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_86f8ec0b-8599-4f8a-ac60-3812d33ba8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_62fd8aa7-35e0-4926-af22-5df3cbb9cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3a105569-1249-4ddb-af63-2a7baca9310d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_62fd8aa7-35e0-4926-af22-5df3cbb9cc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sesn-20210930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_790fc765-5560-43c4-8fc7-d237ecdfe573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65de29b5-cd17-42b4-857d-735ea5916f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_790fc765-5560-43c4-8fc7-d237ecdfe573" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65de29b5-cd17-42b4-857d-735ea5916f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sesn-20210930.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ce7c3470-4dfe-4e3a-95ec-f8d85b7727e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ab31d384-f43a-4095-b09c-f405c34aabf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ce7c3470-4dfe-4e3a-95ec-f8d85b7727e8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ab31d384-f43a-4095-b09c-f405c34aabf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20210930.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_83e2c254-1c8a-49bd-b1b9-41048f6d5ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_83e2c254-1c8a-49bd-b1b9-41048f6d5ad2" xlink:to="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b671e43a-fd98-4986-a340-b5c08b926a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b671e43a-fd98-4986-a340-b5c08b926a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c59ef07f-06c7-4661-986c-f5a8985df658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b671e43a-fd98-4986-a340-b5c08b926a0e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c59ef07f-06c7-4661-986c-f5a8985df658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c940ca7c-0a7a-4496-9f07-c488946cee95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c59ef07f-06c7-4661-986c-f5a8985df658" xlink:to="loc_us-gaap_SubsequentEventMember_c940ca7c-0a7a-4496-9f07-c488946cee95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_15b731e3-244f-4deb-a367-8639054599c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:to="loc_srt_TitleOfIndividualAxis_15b731e3-244f-4deb-a367-8639054599c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e9015ea-5761-48eb-8f74-673f119f8d3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_15b731e3-244f-4deb-a367-8639054599c4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e9015ea-5761-48eb-8f74-673f119f8d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_6168a4cf-e3c8-4b8e-967e-d398d438656f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e9015ea-5761-48eb-8f74-673f119f8d3b" xlink:to="loc_srt_ExecutiveOfficerMember_6168a4cf-e3c8-4b8e-967e-d398d438656f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_72242d75-9c1c-4cfe-97df-1e810b173675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_41e9050c-9302-4a9e-a40c-0c204c8a210d" xlink:to="loc_us-gaap_SubsequentEventLineItems_72242d75-9c1c-4cfe-97df-1e810b173675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_d43ec636-1b8d-4fb0-a570-f327d6a5ad1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_72242d75-9c1c-4cfe-97df-1e810b173675" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_d43ec636-1b8d-4fb0-a570-f327d6a5ad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>sesn-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sesn="http://www.sesenbio.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sesn-20210930.xsd" xlink:type="simple"/>
    <context id="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia74a1039ca8c4ff2869659d992be7a2e_I20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="i342f8c81e3cd4634b8691627803c791d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94658670cd664227afb5198f212af78d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id546f5275111478eae55ae8b7ddd61d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1bdbafc64bc4e6f927a8c8b89d17e1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb42dcf497cf4db4bb42c8d89c51f961_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic41f4d8f7f114855a616af3e79f0b5f1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7f203500303a43978dd153bf5525882b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia736239317b24101bef5d62a00a3d7c9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iac80310a46fa497792ae2b23f361970b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3172bc731cc8465ca35ef631d4862d13_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8d261af049ab482490810fd8b8e53435_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i504486b9de8f4cd5ab2cc5ddda4d7df6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieb4562dea9ab4a92a5891acdb449c85e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iac6b4e3f3ab049039f1f5a6789966e1c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dbf1c141a0c4eb483ea692aec134f4b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i45ac0ee18ade4af8b7b471481a04a2c3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifd658161e2c94d2a852bd1a21e30693d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2075535641a548e287b521ae3d4bbb18_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia5c7eda9e3954ea795f7fc70c0134b09_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ba9eed293fb489583e83d76334fb473_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3e794ca5abe9423b8fcb06f2a3b212a6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9d9e1dcf0f804b12800ee77146e934bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia345782a36b04632a22dcefbffbf2122_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a6721966bda4737b5d6c09a51510e67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i30cab611aee04f429c25aa68fcb3a66d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i746ad97c6cd749bea3090dff8cc5d3c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c0f30e637a74e7bbfde72ce37739632_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i95480a6da5214cc3867f93de1459e972_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieafcf2967a0e4400ba5e2ef91b2c4e95_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i153d728efff347759e0394fab9944503_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if8a154a5219c4779983d780486eecb41_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if14f953deda7433f98e5de86c3866f7a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i64611da1b2004612b9b69bfe30c13dc8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id7e08a33ca6d4f589a32a804b0218dab_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4502189f31a9474283888eeb7a770696_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i002e2f171b10423aa884ac9b368e3eb8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i54dfac6708f940ae8d7d54eb45c4cdf6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i069fefbb34c949ec9377080da376e4fb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibe33102ebcf8432bb484924b03e689bd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idf4b71ad2308422da8c65596d76c09fd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9fee51ba1523446dac271d22281350e4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaf3a7c87f6d1422aa77aa5b7f9f2ecb0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5245ae5196f44ba6949d51a19c7f5a0f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief9d18a3e43644049cf7c9dd882573e0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i255ec6c67daf44f3b60c0bef3b4adc4d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if0f99021539f4ebcb94f4695fa55a58b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iad4cdeca849b4134b8aa1380f258de14_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i566ffe1fbdb6406dbcda243abb86908b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="idc9920534e564063b17cf3276820d0f3_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="i04d84ce34ad9409399002fee7af82ae3_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i07f5c65b436140d38150a47e9b6c1c36_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="icd5b45b654db4116bd06d251988b14f4_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="ia797d1ca4fc645e8b395e6d9263565df_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3bcc2b9836694810a0403c78508eec6f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia45b2253ea0241f883b480c50a91e7ee_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifb8cfcaa24fb4ed5a8ee17f30da2aecb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5ad64fc04cf04fd8be661f0721499ef2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6b740de8bf63490bb488468c1c7ef16b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72e931e5abe8401e88a126d64a293b20_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i956068aabeb24f898f4ef28b58b5d3e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e4934a8dc9143cca95a8e41327cd312_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54798f9a263e4006acf115b512314f6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c50f17d10a14d9eabcc22c8f3758312_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i084a1ef5b7d84536a0488186c21a7485_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ac34a0eb6d444668cb6a7cfe8729dcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41191996f8d5431abab1f677026cf472_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic84c83bbc78b4c12a4fe38ef570304f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ed5df0fffaa498399f610dcc2d9649d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e86bda1e5244696a1806edda33f2bfb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib1415d97efbe429391dd2e7d1b088f99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6825967355184d4db34915ea37cd569f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i555450de9c964d30965deb1462b538f4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1d44b389ccbd43a2bbfcdc75634eaab2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i09310b7c37a84f11878085deb559133d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id7b6d5d2caa648dcb555f0031c4766b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib081c37a1b7148fabc6bbbdd4c81cd6d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifd9a1851f4b84938b499fb6f2ec592fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3daf5ae769a4d4691f5323122b152a4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3748dd3582454f23a8200a59516d8d6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1c35ca8bc59451b99b15883438c09e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd7692a883ce45169ba52f34b1597844_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i52acd18eaeab4bbeb00da4524f747aa3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i18ebb0e11dab4338ba1489efd21f78a5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2bd4a05fa0ad4322ae22d1c69ac3251a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a7fddfe10f34cafa6c5a4a5879fe96b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i68276962a8f74cf19dd3fffa8b75f81a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39f8f4fa4924486482fcd1b7ca9c6d9d_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="idd5ea54630c14b3b8074d7e574a485d1_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i67a67d24259846938c78c4e27aa8ba68_D20201001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i5526ac0da03b4995acfde7f67df66fdc_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ia14f2b1575414e92a7e8692a1656ed6e_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="ib12fdfe409da499985845294be59cd32_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23e8f40d129643c4955e53934f43c919_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if89a1bed4d6e4801a7b55c57bb01b6a0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id978bed0cf5c4d5fbab94cd056d775b8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie7579e0e22c047768232e96e33209c00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d4b935d6b414f729cd483380a572798_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8591390616e24942a1790a6fef158000_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fcaf5bf73c144fb87d727c536f11433_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9742c1fa4df446ea92bcdc4006e5dac4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i980c30d4b2e5432f83166c9129e01ffa_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i716f44ff8fdb4ed68f03fe519e006002_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52d9dcbb55e2474ea2ed0ba322bad3ac_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57e070c6f5694cc184d3ff043754818a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6379246986547cc9a88c6f8b29535d6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcd1ce8b4f094a86aaf1094f5ade0c3a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1e16f0e7c69a48b793e80ba1cbd35337_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a98b848353a4028b0c3659a7cc0fc8d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if30380f6c6c241cca4d331347c506d7b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4e50b89a5f094c2485a5ef23806abe14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ac338c8a528448585157860bb14aae6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ideefad39445444f5978ed30df0f8d67d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1595e3478bb64207a037de6271baebed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i044c60384a9e4cc8afe4aaa8645c9ef6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia92cad4084294782890738c13756e328_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib500bf44eae5476d9fdf2b96b6e0d1d7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87670fceac7f42239018c3f8b55269ad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23062afacb1848248023392b8378bd19_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i079b1e485a6a4b42a083e958ffce61c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c43cdc3ac654396a4484ffac139d4b2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9fb6380fa09c4290abc4c61a23509a0c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23f2a7e233df4d15a0180432313c57a9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7ed6768ea3b4560b2c82d895f9ea130_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e8e8e954db04e80ad3a16adadbfc86f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic81f556c7f3c49bd8d272a05a36ddb60_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d48ee562070454db26870e4c0814801_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba8f1e5ffe2b4317a81ef1b3efe55cdb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98c2750e9d614718ab26e1de3cd36e4b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac03a2fc4741476e8ed3f485593ae492_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12438f69900b46c898f17d03af72571f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99f44079082f4029859d1879bcb92442_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib66fca9e5de8456b900bc5c4eff17509_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="if6ccec642f85408396200523b237087c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a6396e7d05347c98d3c1b2c891d6ee3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c4abb48a5d14a81b4f1e923deb97260_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide409042192a4d70ab470516112033d4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2c7f2bf3ddf5406f8bc9acdceac07628_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4063b8153be44ce181d918f92b6ef50e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id8d3a64a89d7413aa462e07545736067_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ac93b032a464cdd8545afbe5796bd81_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="i4cb66b6b5cfd47af8f6c6a3efea03f81_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i3fffc682fabb44acb6f7a3985fe6f99d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4100955bccbe4c1ca4b78e3cf52bfe56_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc91c1e2691446ca8ae6ebaf034e2270_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b253e391e304883b5148ddaac3a9fd8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16e23dc0be574c6988f056e62ef032cd_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b9fbfe5c81f499888ab93c21e589337_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd6eb0c1e7e34af989c1740d371026c8_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf84269345dc45a9bd019d1e9ba53cbf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic42971e76e3e4c0d9a0e368891e0d42c_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="id1d3fa03486b42c3b433ce8bdf6e4808_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="id3ed448b11a8424c96a6b8d0eb2a1783_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i30b08122198e489bbce9b4354ecc6c61_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i0fb8cc9e9e234566a44813522f65ed55_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="ie0859c061dad4634bd9bf31be447575b_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="ibc6ff2c6504a4ed1b6cfa6a5cbdb6eb9_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i15b167efec9143cf989e99b7088a541a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i045d66e15494473e88b935c50abb8750_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i63e6b449973d4c2792e479ee587c6018_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia7693b351b0846618d4fcdce51f3fe9e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:IL6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="id7df092ca1e64946a1a0ac3ea4c32c84_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="ife38f0f87de845fe90d0a4d078d250cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3fe2301ff7fd49808ebec14107299e1c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i610ca7a4385742b085d50632419fb7f8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib78e2ef0bd77468a99078bdc44ca15ac_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibc185febf435474dabf49a740bcc7f59_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e4a691bd7f24cc8a757bf6eb9a87a8e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a6554c571ca414ea564532ae47c5f15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia96662f1953a42bc873ffe3a7870d8b6_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="i136787f1fdff4cf289282d421587f27f_D20210805-20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="i23457221904940608ad590d221ec55f2_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="i3294967843ca408b88c9279ce575d789_D20210830-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie0910e0e2e544c658b3c5f01387c4bf7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i31980ac255374540a2c360974effe9e9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7eb45047e6e3464eb0f8a32d0685227a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07777b364f564270bb6efdada23c4efe_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>sesn:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="term">
        <measure>sesn:term</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="option">
        <measure>sesn:option</measure>
    </unit>
    <unit id="position">
        <measure>sesn:position</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl80LTEtMS0xLTkwMTI_e09d608e-6e23-4cfc-9949-e601ee4832b6">0001485003</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl81LTEtMS0xLTkwMTI_3075cd22-4486-4601-acc7-1f23686cabdf">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl83LTEtMS0xLTkwMTI_573f1815-62a5-4d98-a867-795a8ef00227">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl84LTEtMS0xLTkwMTI_574c5619-2549-4a47-9370-f6ea39691363">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180L2ZyYWc6ZDg0MzZlNDJiOWFiNGViZGFjNzM3ZmQzMTg5YjY4N2EvdGFibGU6ODY0MDBjNzRlMzI5NDgxN2E2Njc4OWNjYzBiZjIyNmYvdGFibGVyYW5nZTo4NjQwMGM3NGUzMjk0ODE3YTY2Nzg5Y2NjMGJmMjI2Zl85LTEtMS0xLTkwMTI_fe79f694-51ea-46ef-8e76-639154bcab3e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY184Ng_1586bc7a-df49-4637-9c9b-e188ca359c93">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MTY4N2Y0NjNiNTk4NDEzZTg4ZTI1M2I1MjE0MjU1MmMvdGFibGVyYW5nZToxNjg3ZjQ2M2I1OTg0MTNlODhlMjUzYjUyMTQyNTUyY18wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpmMjgzZmMwYTNmZDE0YTMxYWYyNzRhNDllMzBhZTY2M180_a876f458-0b12-459f-9122-e55354c2f849">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18xMzQ_376060f4-0cce-4543-9d2d-44fc5fb72508">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6ZDZkZmQzYWMxMTNjNDcwOWE0ZDc5MmNjZjBjMmI1ZmMvdGFibGVyYW5nZTpkNmRmZDNhYzExM2M0NzA5YTRkNzkyY2NmMGMyYjVmY18wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpkYThmMmFkMmZkMTE0NDIyYjI3NGEyMGNkY2Q4MzNlZV80_b9d0c27a-e056-4bc8-a207-ded5eb2efc01">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18yMTY_4348198b-849f-42d5-b7eb-4aa583e5d321">001-36296</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18yMjE_29cfb2c6-0f57-4875-bde1-c09a7b880a3d">Sesen Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MmQ2ZjNkNmMyZDNiNDYxMzkxNTZkMDMzOGQyZWY1YzkvdGFibGVyYW5nZToyZDZmM2Q2YzJkM2I0NjEzOTE1NmQwMzM4ZDJlZjVjOV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjo1M2E3MjYwYTg5MzE0ZDRiOTQ1ZTFhMGZiOTRkZGY1Zl80_38914a6e-dca5-4072-aa94-664e23c32b6d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MmQ2ZjNkNmMyZDNiNDYxMzkxNTZkMDMzOGQyZWY1YzkvdGFibGVyYW5nZToyZDZmM2Q2YzJkM2I0NjEzOTE1NmQwMzM4ZDJlZjVjOV8wLTEtMS0xLTkwMTIvdGV4dHJlZ2lvbjo2NmFhZWE2NGY3NDI0ODg2OWZiZjg1NTJmMGVmMjEzNV80_fb202a54-a5a3-45bc-86bd-287769d1fbbb">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpiNDczZTc2Yjk4NjI0OTBmOWY4ODlkZGNmN2Y2NTI2Nl80_f683634a-9509-42ce-82c0-dceaa1eb72a8">245 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpiNDczZTc2Yjk4NjI0OTBmOWY4ODlkZGNmN2Y2NTI2Nl84_3ac032d1-cf87-44f1-8c72-903f21a16696">Suite 1800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpiNDczZTc2Yjk4NjI0OTBmOWY4ODlkZGNmN2Y2NTI2Nl8xMQ_b3d25e9b-acbd-4eb8-8083-77d20935af66">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTAtMS0xLTkwMTIvdGV4dHJlZ2lvbjpiNDczZTc2Yjk4NjI0OTBmOWY4ODlkZGNmN2Y2NTI2Nl8xNQ_efeb908c-0b69-4d9f-93c7-8d4eb1e8e263">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6MzBlNDc1ZDc4MDFkNDEzMTgwOGVkMjEzNTZlNzM2OTEvdGFibGVyYW5nZTozMGU0NzVkNzgwMWQ0MTMxODA4ZWQyMTM1NmU3MzY5MV8wLTEtMS0xLTkwMTIvdGV4dHJlZ2lvbjo5ZmRhM2VlNzEyMGE0NzQzYjg4YzdmNWVhMDU0ODA2OV80_60c4600b-8e1e-4336-97a3-49ed2002527f">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18yODY_40189021-0a10-4429-a4b8-17b0f3e93419">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18yOTA_e676d7af-b1ed-407d-9094-8e2acaa7e7a6">444-8550</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6YTdlMWRkYjMwZTRjNDI1MGE5MGUzMmU5ZDE2NGRjMzUvdGFibGVyYW5nZTphN2UxZGRiMzBlNGM0MjUwYTkwZTMyZTlkMTY0ZGMzNV8xLTAtMS0xLTkwMTI_c48600f1-15e9-43a5-8f8c-f7bd6d796e18">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6YTdlMWRkYjMwZTRjNDI1MGE5MGUzMmU5ZDE2NGRjMzUvdGFibGVyYW5nZTphN2UxZGRiMzBlNGM0MjUwYTkwZTMyZTlkMTY0ZGMzNV8xLTEtMS0xLTkwMTI_46f36cad-60a6-41f8-8fd0-ce4a36d4f160">SESN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6YTdlMWRkYjMwZTRjNDI1MGE5MGUzMmU5ZDE2NGRjMzUvdGFibGVyYW5nZTphN2UxZGRiMzBlNGM0MjUwYTkwZTMyZTlkMTY0ZGMzNV8xLTItMS0xLTkwMTI_392c6783-e14d-4f69-9f55-ed840242f430">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY184NTg_f644ac4a-2c0c-4567-846f-936c7504f77d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18xMTU1_d2c9adbd-5a9a-4971-855e-3c09138ce87c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6NDJkMmNmYWZhMTU5NGVlNmFhYjYwNjYyOWM4YzBiNzEvdGFibGVyYW5nZTo0MmQyY2ZhZmExNTk0ZWU2YWFiNjA2NjI5YzhjMGI3MV8wLTMtMS0xLTkwMTIvdGV4dHJlZ2lvbjo5MzcwM2VlZjNhYzg0NWZiODBiYmJlNWZhMmJmOTdhYl80_e308816d-6b57-41be-bab1-73d0c269a9d8">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6NDJkMmNmYWZhMTU5NGVlNmFhYjYwNjYyOWM4YzBiNzEvdGFibGVyYW5nZTo0MmQyY2ZhZmExNTk0ZWU2YWFiNjA2NjI5YzhjMGI3MV8xLTMtMS0xLTkwMTIvdGV4dHJlZ2lvbjo2NjlkMWI4YzRjMWU0MzA1YjYzODJlYmJmMDI4NzBjYV80_35a0b04e-2221-40f1-b2ee-b752174f3a47">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGFibGU6NDJkMmNmYWZhMTU5NGVlNmFhYjYwNjYyOWM4YzBiNzEvdGFibGVyYW5nZTo0MmQyY2ZhZmExNTk0ZWU2YWFiNjA2NjI5YzhjMGI3MV8yLTAtMS0xLTkwMTI_dbfaba67-6325-43ae-95e0-cbfe1e9e3d01">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityShellCompany
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18xODg3_b51f89a5-cf78-427f-a63f-10349c7ed312">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia74a1039ca8c4ff2869659d992be7a2e_I20211101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xL2ZyYWc6MWVmMjM4ZDA1OTU0NDViNGE0MTlkNDI5NTI4ZDkzZWMvdGV4dHJlZ2lvbjoxZWYyMzhkMDU5NTQ0NWI0YTQxOWQ0Mjk1MjhkOTNlY18xOTEw_416a7e0e-079b-4ea0-8112-754db0770ba5"
      unitRef="shares">199463645</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMy0xLTEtMS05MDEy_df006554-39fc-48b4-a608-eba3b24704ca"
      unitRef="usd">175236000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMy0zLTEtMS05MDEy_85c751ea-ef18-4490-bbe4-e66150a30a30"
      unitRef="usd">52389000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNC0xLTEtMS05MDEy_cb6ffd7f-3025-4bc0-8aad-96576a7a73ec"
      unitRef="usd">1107000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNC0zLTEtMS05MDEy_7fe90166-dfff-4739-8299-7ad02f1c1ac4"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNS0xLTEtMS05MDEy_60d9b9b1-4f53-4f6c-8290-b793908373dd"
      unitRef="usd">24137000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNS0zLTEtMS05MDEy_3aa18e09-eca0-41e8-9926-3334a79c8935"
      unitRef="usd">7478000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNi0xLTEtMS05MDEy_a779a811-f19a-47a6-904f-77d21eb6ecc7"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNi0zLTEtMS05MDEy_bce1c45b-96dc-487c-bc78-5a7a9d0ee122"
      unitRef="usd">3000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNy0xLTEtMS05MDEy_18da26f9-7a25-4a8d-a243-9d5f5212acfc"
      unitRef="usd">200480000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNy0zLTEtMS05MDEy_28e89c49-d6bf-48c4-9249-f1ee0b48d088"
      unitRef="usd">62867000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTAtMS0xLTEtOTAxMg_81ebb001-dfba-43f7-9ec6-adc2c70b823c"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTAtMy0xLTEtOTAxMg_e6951901-a26b-4f55-aee0-88ccd58a0a78"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTEtMS0xLTEtOTAxMg_c1b747a3-6baa-49d8-b8eb-f84dc76f3718"
      unitRef="usd">53000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTEtMy0xLTEtOTAxMg_99722407-d852-4b3f-be8d-c62a98ebf864"
      unitRef="usd">123000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTItMS0xLTEtOTAxMg_1ecb79aa-23f9-417b-ae16-ca50e2616a5b"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTItMy0xLTEtOTAxMg_33acb1b5-922c-45e1-bae0-565917ad2d31"
      unitRef="usd">46400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTMtMS0xLTEtOTAxMg_c825e174-2d6b-4782-afb7-67b918e73938"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTMtMy0xLTEtOTAxMg_069a0782-dcb0-4759-8682-7dc6b24c8542"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTQtMS0xLTEtOTAxMg_055c33e1-048f-415f-8054-7faea3aff142"
      unitRef="usd">7192000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTQtMy0xLTEtOTAxMg_2fe2f63a-4ecc-4d76-98b8-1c2734efc178"
      unitRef="usd">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTUtMS0xLTEtOTAxMg_19bf954f-6f82-4355-a00c-8106212d0e94"
      unitRef="usd">162000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTUtMy0xLTEtOTAxMg_440d155c-3113-4a62-a554-285da6bda0c1"
      unitRef="usd">349000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTYtMS0xLTEtOTAxMg_f503b61f-ef92-422e-bad3-22008a6bc6e9"
      unitRef="usd">35191000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTYtMy0xLTEtOTAxMg_86b0c38a-6ff8-40d6-b825-06a9788a1ad9"
      unitRef="usd">59956000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTctMS0xLTEtOTAxMg_ee42bae3-2c97-4a40-8322-de71a9c10fd7"
      unitRef="usd">235671000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMTctMy0xLTEtOTAxMg_76f9fc8d-8f83-495b-a838-0ef24758830a"
      unitRef="usd">122823000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjEtMS0xLTEtOTAxMg_8bc6f263-e12b-4cc1-b214-09c5c5779c47"
      unitRef="usd">3909000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjEtMy0xLTEtOTAxMg_b2caa210-260c-442a-b53c-8f1ae4e0a260"
      unitRef="usd">3102000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjItMS0xLTEtOTAxMg_0cf0adf1-59d6-44a8-89e8-a76a20f4672d"
      unitRef="usd">8186000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjItMy0xLTEtOTAxMg_62ddddfd-a729-457d-9212-c97ea2d41e87"
      unitRef="usd">3973000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjMtMS0xLTEtOTAxMg_f6c09103-baeb-4f22-86f3-0c9ac9a4c8c5"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjMtMy0xLTEtOTAxMg_c3836784-9ee9-4a34-a944-37d8eb3aab21"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjQtMS0xLTEtOTAxMg_0f5767ad-c681-4472-beef-6332f69dd45f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjQtMy0xLTEtOTAxMg_53205f28-98be-4c9b-90ad-047d02f156d1"
      unitRef="usd">8985000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjUtMS0xLTEtOTAxMg_d36a7e41-353a-4fde-8f67-ef7f37fbfe4d"
      unitRef="usd">499000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjUtMy0xLTEtOTAxMg_f37ab62c-3bea-45bd-ae37-5077a3366486"
      unitRef="usd">489000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjYtMS0xLTEtOTAxMg_b84b56a9-d156-44e2-b854-bde87835aafa"
      unitRef="usd">12594000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjYtMy0xLTEtOTAxMg_32594926-5775-4486-bc0f-ec359e36fe71"
      unitRef="usd">18049000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjktMS0xLTEtOTAxMg_fce812ac-548b-42d1-8d5d-1b5804284bec"
      unitRef="usd">56600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMjktMy0xLTEtOTAxMg_18a12625-c7f1-4248-9432-c23b1b7f60e3"
      unitRef="usd">99855000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzAtMS0xLTEtOTAxMg_2850e566-682e-4bbf-8cea-2d2087efea28"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzAtMy0xLTEtOTAxMg_7c8ec831-93f9-432d-943a-0e2f62bdee55"
      unitRef="usd">12528000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzEtMS0xLTEtOTAxMg_0597326e-d958-4cda-a1c1-009bd4750d91"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzEtMy0xLTEtOTAxMg_a239f186-7f2d-4d60-bf72-66fed5bbfd0d"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzItMS0xLTEtOTAxMg_607fb631-475d-441d-a6fb-0665ac533fbb"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzItMy0xLTEtOTAxMg_e4a1ceb3-cb03-4792-8df1-dcac611b2554"
      unitRef="usd">118000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzMtMS0xLTEtOTAxMg_dcc6fd05-a518-4680-ab41-73d58eea5ec7"
      unitRef="usd">62069000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzMtMy0xLTEtOTAxMg_dcdb29ba-3876-4967-a2cb-3627c5a072b2"
      unitRef="usd">114001000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzQtMS0xLTEtOTAxMg_29bdd823-4624-4d95-be20-23375e6fdc7c"
      unitRef="usd">74663000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzQtMy0xLTEtOTAxMg_2c4e7321-4a0d-4525-a0d7-47f977f7cc22"
      unitRef="usd">132050000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzIx_120ac6c1-0b66-4f93-8c97-4d68225ec2d7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzIx_b7358a26-9532-437b-aa83-e1b213b2e226"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzQ1_bc576579-6e75-4ffe-bcf7-ce921032cd6c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzQ1_d25bad4e-3d06-46a3-a52e-d330a8bd9fd2"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzEwNg_006793d7-1abb-42bf-8bdf-c8bab813b78a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzEwNg_0d03d9b1-1aee-449e-ae97-57ac598d0b5c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzEwNg_40fdbfe9-e1b6-4609-91f6-2128e9cced92"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmNmOWNiYmU3N2NmMTRkYjc4MTNiYWQwNDBjMjJjMmUxXzEwNg_77692980-2470-4176-9f7b-357b5e5dc765"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMS0xLTEtOTAxMg_66c1ec53-c194-4b57-bebc-be58a3d05b7c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzgtMy0xLTEtOTAxMg_174624c3-da58-404d-b234-7a9c60a31fcd"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzE4_6a73a4f1-f446-4b69-864f-8decb5523923"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzE4_e5ee92cd-77c7-41d7-bd85-e4bcbb5be003"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzQy_709eecbe-9f28-4356-bd53-52c0a4859d0a"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzQ5_afbb4c46-b7b5-4e0a-892a-0936e2adb9d0"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzEyNA_9d4a88a4-55a5-4548-a09a-f249a9ce2f86"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzEyNA_c3d78f1f-3e56-4f00-b990-184ec215f932"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzEzMQ_6c520777-a6ed-4080-b8f5-58360afb5400"
      unitRef="shares">140449647</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjk1NTBkOWRkMTFjYzRlOTI5MTMzMWI1NWNjZGJlNDg2XzEzMQ_ef91ad3d-eaae-4771-82f4-71c06f55e746"
      unitRef="shares">140449647</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMS0xLTEtOTAxMg_3e133af7-562e-497a-8ab2-d735062db4dc"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfMzktMy0xLTEtOTAxMg_3ef025fe-29d6-4171-9508-d3a7ab7b14f1"
      unitRef="usd">140000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDAtMS0xLTEtOTAxMg_d6cdb563-cd68-4f37-bece-76faf7a52d09"
      unitRef="usd">486010000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDAtMy0xLTEtOTAxMg_e34dd971-2863-41ee-b26e-4f80e1d496cc"
      unitRef="usd">306554000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDEtMS0xLTEtOTAxMg_c6c3a9df-989f-4e3d-8772-36a78bd99db6"
      unitRef="usd">-325201000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDEtMy0xLTEtOTAxMg_3533fba3-14bf-4501-a516-cbc99f736a14"
      unitRef="usd">-315921000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDItMS0xLTEtOTAxMg_857645b4-cfbb-4d38-be12-ca20a454599d"
      unitRef="usd">161008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDItMy0xLTEtOTAxMg_4c8a6ef8-1543-456c-b01c-cbb56624a7e3"
      unitRef="usd">-9227000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDMtMS0xLTEtOTAxMg_e9689010-33be-4e3d-a231-56356fa4826a"
      unitRef="usd">235671000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xNi9mcmFnOjFiMWNmMzljZThhNTQ5MGE5M2M5MjAwZTNmYmRjNTQ1L3RhYmxlOjlmNDdmMTVkNzRlNDRhOGViZjhhY2EyMjc5MTg3NmQyL3RhYmxlcmFuZ2U6OWY0N2YxNWQ3NGU0NGE4ZWJmOGFjYTIyNzkxODc2ZDJfNDMtMy0xLTEtOTAxMg_63e00a4c-3c94-4f70-b9c0-0efe67ff7157"
      unitRef="usd">122823000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi0xLTEtMS05MDEy_16b8e6c9-893c-45dd-8d15-8b313987704c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi0zLTEtMS05MDEy_7dad26a6-9566-46e4-a1f0-eeb3cdf67645"
      unitRef="usd">11236000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi01LTEtMS05MDEy_848a5c50-13f4-4407-8df7-802a5005740b"
      unitRef="usd">6544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi01LTEtMS05MDEy_e66a903f-68ac-47b9-af46-4bc215b8b85b"
      unitRef="usd">6544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi03LTEtMS05MDEy_354ff255-2f3f-400b-9fd4-aac7e0e1582f"
      unitRef="usd">11236000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMi03LTEtMS05MDEy_7fb951d5-b424-43c3-b1ea-27ed11ff956d"
      unitRef="usd">11236000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNS0xLTEtMS05MDEy_8b86c125-30ca-4000-8022-946103af8fc7"
      unitRef="usd">4967000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNS0zLTEtMS05MDEy_764fea54-c5e2-410c-a419-6b5e09908161"
      unitRef="usd">10196000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNS01LTEtMS05MDEy_7c35c8ba-5ae1-4444-abb5-a99ae384cb69"
      unitRef="usd">18273000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNS03LTEtMS05MDEy_c5dba97f-2578-45d7-930b-0af54d6aebed"
      unitRef="usd">23625000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNi0xLTEtMS05MDEy_276044d4-45d5-47e7-b336-f73cd3cf4e51"
      unitRef="usd">8699000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNi0zLTEtMS05MDEy_8df6f61e-d81f-4d4d-a48e-5591d00474f1"
      unitRef="usd">4115000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNi01LTEtMS05MDEy_110f9e8e-a29d-4969-864e-31be4f6c4ea7"
      unitRef="usd">20797000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNi03LTEtMS05MDEy_fd6d993c-9621-4f17-b1c1-c123bc805642"
      unitRef="usd">10882000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy0xLTEtMS0yMDM3Mw_e96e3f93-97d0-438d-a7a9-1bfbf49b7c63"
      unitRef="usd">5522000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy0zLTEtMS0yMDM4Mw_bcb64857-d9fe-4fd5-8498-7e4205de058d"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy01LTEtMS0yMDM5MA_6f46690c-d1e9-4aab-bfec-4626bf41f9f2"
      unitRef="usd">5522000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy03LTEtMS0yMDM5Nw_19e8ff22-c86b-41dc-a096-10a8856b7a15"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC0xLTEtMS0yMDM3Mw_3c65ddb9-5362-482e-a3a0-5acad000eda9"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC0zLTEtMS0yMDM4Mw_27c251b5-cf36-4bd0-873a-fc27fbbc02e8"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC01LTEtMS0yMDM5MA_fc16b759-753a-4105-8973-c51f7e0d725c"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC03LTEtMS0yMDM5Nw_90cd370e-08c0-4005-8dee-6201043e8af8"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy0xLTEtMS05MDEy_97c1ab7e-6b6f-4cb0-ab2f-af1099ced6fb"
      unitRef="usd">-114000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy0zLTEtMS05MDEy_4197a5b1-fef0-47fd-944c-ba70516ef57f"
      unitRef="usd">18400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy01LTEtMS05MDEy_cd9199b3-a347-4665-81b6-15ed83cccaa6"
      unitRef="usd">-52240000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfNy03LTEtMS05MDEy_16df4903-3883-4252-a1a1-e6bcf5ead42a"
      unitRef="usd">-16820000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC0xLTEtMS05MDEy_638fe0f0-5058-4c08-a496-d3c127546395"
      unitRef="usd">-63112000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC0zLTEtMS05MDEy_9f54c8d5-9b35-48b5-a6fd-2c983bd1c17f"
      unitRef="usd">32711000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC01LTEtMS05MDEy_085e4d02-29bf-4048-98c4-9d2de6995c97"
      unitRef="usd">24052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC01LTEtMS05MDEy_55e9a84b-977a-4455-8fc6-d264b93be1e3"
      unitRef="usd">24052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC03LTEtMS05MDEy_09a9ca57-38e5-4f66-a375-16eb0a2171ad"
      unitRef="usd">17687000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfOC03LTEtMS05MDEy_248881b8-cc85-4d13-82fb-c078276a02c0"
      unitRef="usd">17687000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTAtMS0xLTEtOTAxMg_1458cc70-6932-43a1-a377-bf51b45c96b4"
      unitRef="usd">63112000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTAtMy0xLTEtOTAxMg_62b58c8c-98f9-4e8c-8840-c48ed8e64bff"
      unitRef="usd">-21475000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTAtNS0xLTEtOTAxMg_0bba6a75-c595-4ed9-a4f0-d8af8a562a48"
      unitRef="usd">-17508000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTAtNy0xLTEtOTAxMg_01c85714-7fd2-45d4-a82f-84d6f5ab6951"
      unitRef="usd">-6451000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTEtMS0xLTEtOTAxMg_94b4d3c5-4b65-4200-9948-035d1235a4c6"
      unitRef="usd">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTEtMy0xLTEtOTAxMg_09a4632f-1695-428b-ae3b-961e8e8a2c08"
      unitRef="usd">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTEtNS0xLTEtOTAxMg_9cf03b19-6788-4977-b4f1-5eaef78d1bb3"
      unitRef="usd">-45000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTEtNy0xLTEtOTAxMg_05104e8c-151d-4d16-a5fc-cdfcf0779646"
      unitRef="usd">195000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTItMS0xLTEtOTAxMg_780db623-8f65-4b61-8c42-15b894acf042"
      unitRef="usd">63113000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTItMy0xLTEtOTAxMg_cbc7e897-be88-462b-aa21-59925b1fe181"
      unitRef="usd">-21476000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTItNS0xLTEtOTAxMg_bf8cc452-3939-45ad-9dfd-9cc65842bb20"
      unitRef="usd">-17553000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTItNy0xLTEtOTAxMg_96920a7e-e8d7-4c22-9929-ba63f6257c2f"
      unitRef="usd">-6256000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTMtMS0xLTEtOTAxMg_08c5e228-3d07-4714-8a94-1c915e74037f"
      unitRef="usd">-8561000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTMtMy0xLTEtOTAxMg_7771854a-da8d-46f3-a0c8-2a08401424e7"
      unitRef="usd">1132000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTMtNS0xLTEtOTAxMg_9022cab7-9bb7-48ac-b56d-27e752261e83"
      unitRef="usd">-8273000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTMtNy0xLTEtOTAxMg_8416f036-37dd-4984-99b2-90973adee74f"
      unitRef="usd">1132000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTQtMS0xLTEtOTAxMg_6b5e45b6-344c-4ba6-b618-c2b2b6df2261"
      unitRef="usd">71674000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTQtMy0xLTEtOTAxMg_769123d9-f212-4041-ab32-513bf244e20e"
      unitRef="usd">-22608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTQtNS0xLTEtOTAxMg_9fb15208-20f9-4d7e-8e11-409feec84b43"
      unitRef="usd">-9280000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTQtNy0xLTEtOTAxMg_590175f4-6957-4a60-ab34-4bcb44e1cb76"
      unitRef="usd">-7388000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTgtMS0xLTEtOTAxMg_0cabd591-a301-4b4a-89bc-322810ace8b4"
      unitRef="usd">71622000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTgtMy0xLTEtOTAxMg_79e9941d-624c-408e-b6f0-d94aa8780171"
      unitRef="usd">-22608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTgtNS0xLTEtOTAxMg_69747083-2be7-45e7-a5ac-f964f385e6ae"
      unitRef="usd">-9280000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTgtNy0xLTEtOTAxMg_bc286e27-04a0-40eb-8a8f-9ff423ca7599"
      unitRef="usd">-7535000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTktMS0xLTEtOTAxMg_a7fc125b-acfa-4092-aa0f-72496c375bd1"
      unitRef="usd">71623000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTktMy0xLTEtOTAxMg_50534143-b78f-47f5-b759-576de9b914cd"
      unitRef="usd">-22608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTktNS0xLTEtOTAxMg_56607b45-db50-48f3-95ad-77817378238d"
      unitRef="usd">-9280000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMTktNy0xLTEtOTAxMg_e69b3128-91ee-46f5-bd97-4672f2858dec"
      unitRef="usd">-7535000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtMS0xLTEtMjU3MzI_170d987f-3a59-4d2e-b885-ab52c4da81c9"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtMy0xLTEtMjU3MzI_d8b24b25-ebbe-4161-a200-39f95cbdbf4f"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtNS0xLTEtMjU3MzI_63ca0587-c9eb-49cc-9d89-f38bfc89e589"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtNy0xLTEtMjU3MzI_20494a06-c8ba-42d7-b7fa-97d2e9d6c518"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtMS0xLTEtOTAxMg_b67d7d02-510e-4862-80e6-f0bf9f19a231"
      unitRef="shares">196778000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtMy0xLTEtOTAxMg_51c9e48f-4e07-499d-8f80-da43c76f395c"
      unitRef="shares">117886000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtNS0xLTEtOTAxMg_10b11a01-a77e-49e7-be1a-0311ad0c339c"
      unitRef="shares">176547000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjEtNy0xLTEtOTAxMg_04a88dea-581e-4058-8594-7e5666f5acf2"
      unitRef="shares">113437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjItMS0xLTEtOTAxMg_55303c59-49fe-45f8-b7ef-5650c65f5862"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjItMy0xLTEtOTAxMg_e08eb5d1-5a08-4373-8d95-6fe7d49a26b8"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjItNS0xLTEtOTAxMg_38859e16-f59a-4bff-83ad-8bedac2ab8fe"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjItNy0xLTEtOTAxMg_c9d170ec-7cec-4332-accb-364debff9652"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjUtMS0xLTEtMjU3MzI_19852ea4-d591-4bd4-8072-cb7d75ef7384"
      unitRef="shares">201017000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjUtMy0xLTEtMjU3MzI_bf733197-552f-46cf-96e2-fb3bedeb6380"
      unitRef="shares">117886000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjUtNS0xLTEtMjU3MzI_5552b0c9-ce89-4ef5-9efb-c73e0e4d6de6"
      unitRef="shares">176547000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xOS9mcmFnOjY0NTU5MDIxZmVmNjRiMDFhZTQ2MDdjNzQ1MTAwYWJjL3RhYmxlOjczNjg4NTE1NjZjYzQ5MjU4YzE5YzM1MTY0NGNkY2RiL3RhYmxlcmFuZ2U6NzM2ODg1MTU2NmNjNDkyNThjMTljMzUxNjQ0Y2RjZGJfMjUtNy0xLTEtMjU3MzI_759381d0-5fb0-4e6b-a628-cce1a71b4025"
      unitRef="shares">113437000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="id546f5275111478eae55ae8b7ddd61d8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi0xLTEtMS05MDEy_bd0dd0f7-8762-4166-8499-843aaf1ea9e7"
      unitRef="shares">140449647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id546f5275111478eae55ae8b7ddd61d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi0zLTEtMS05MDEy_6090e364-c4a9-4a61-9ea4-fad0531fe180"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1bdbafc64bc4e6f927a8c8b89d17e1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi01LTEtMS05MDEy_09d40c2b-193b-4538-bf17-b01dbe6ece4b"
      unitRef="usd">306554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb42dcf497cf4db4bb42c8d89c51f961_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi03LTEtMS05MDEy_8bdd4b43-ec03-4279-87d3-53c851d37858"
      unitRef="usd">-315921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMi05LTEtMS05MDEy_1a45aa5d-4afb-46c5-9672-5f724384d585"
      unitRef="usd">-9227000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic41f4d8f7f114855a616af3e79f0b5f1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMy03LTEtMS05MDEy_70cfeaba-a4d6-4dfd-ad48-01cb8ef4e14d"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMy05LTEtMS05MDEy_7c7e5728-f6f6-4b57-b491-77a7cc73b35c"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7f203500303a43978dd153bf5525882b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNC01LTEtMS05MDEy_37afb932-8e8c-4a58-8e64-f31f8bb84669"
      unitRef="usd">958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNC05LTEtMS05MDEy_b57a55d4-e644-4625-a052-13388e1ff8b0"
      unitRef="usd">958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNS0xLTEtMS05MDEy_66cbe24a-b6f4-4bc7-8743-cd1380aa064e"
      unitRef="shares">30610</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7f203500303a43978dd153bf5525882b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNS01LTEtMS05MDEy_27095072-ebfa-40aa-b349-c7bfe7285c4d"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNS05LTEtMS05MDEy_521120df-3d63-4217-ad8c-9cea6a0f36df"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNi0xLTEtMS05MDEy_77a3f5ba-f1c8-48e8-b228-318eadc315f6"
      unitRef="shares">852840</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNi0zLTEtMS05MDEy_a3f7523c-1b41-47ca-bfa8-6e205783a2f7"
      unitRef="usd">1000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i7f203500303a43978dd153bf5525882b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNi01LTEtMS05MDEy_75629a31-5f4d-4e84-bb12-07a106ed2a12"
      unitRef="usd">468000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNi05LTEtMS05MDEy_48cb91cd-4c54-478b-9f38-7b2f397b573e"
      unitRef="usd">469000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy0wLTEtMS05MDEyL3RleHRyZWdpb246YTI1ZDNmYmFhMmU2NDA1Y2I0NTIzNzhjOTk0MjVlNjZfNzQ_572ad8d6-14d5-4901-a7f7-ce6be6035027"
      unitRef="usd">2200000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy0xLTEtMS05MDEy_d2c97003-8e36-4b6d-9914-84acf1af7543"
      unitRef="shares">30645702</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i96c62b120a0a46508b25feecc0559b1b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy0zLTEtMS05MDEy_bd075b4b-402d-4b36-b2dc-14558724d402"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7f203500303a43978dd153bf5525882b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy01LTEtMS05MDEy_75b1f0b0-2592-4b71-975a-ca08b473b873"
      unitRef="usd">72512000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8ace1193a362420e9982d3d254289d5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfNy05LTEtMS05MDEy_c0e325cf-340e-4588-aa94-dd756af0fb92"
      unitRef="usd">72543000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="ia736239317b24101bef5d62a00a3d7c9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC0xLTEtMS05MDEy_0a1647e3-220f-457a-b4cf-2eb1fbe519d8"
      unitRef="shares">171978799</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia736239317b24101bef5d62a00a3d7c9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC0zLTEtMS05MDEy_83b88357-7ac6-4b9a-a66a-1e01e181b619"
      unitRef="usd">172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac80310a46fa497792ae2b23f361970b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC01LTEtMS05MDEy_f12b2c0a-6f21-4892-899d-edc350d4042a"
      unitRef="usd">380531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3172bc731cc8465ca35ef631d4862d13_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC03LTEtMS05MDEy_e4ff2044-1c97-48bb-85e9-a693fdc49cf8"
      unitRef="usd">-371433000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d261af049ab482490810fd8b8e53435_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfOC05LTEtMS05MDEy_775010e0-a52c-40ea-b0a1-bfe137070599"
      unitRef="usd">9270000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i504486b9de8f4cd5ab2cc5ddda4d7df6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTAtNy0xLTEtOTAxMg_256bab5a-3c5e-4079-b723-d40340f85f0e"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTAtOS0xLTEtOTAxMg_9fccd568-122f-457c-94ad-afcce2ac22c5"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieb4562dea9ab4a92a5891acdb449c85e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTEtNS0xLTEtOTAxMg_52872494-c80f-4af9-b801-8c2267d1231c"
      unitRef="usd">1260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTEtOS0xLTEtOTAxMg_96272cf6-3f8c-431d-84d8-dfc0c3375ef3"
      unitRef="usd">1260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOmQ4OGFkZTkxZTM1NDQ5ZThhOTUyZGJkNWI4ZTU0NGFkXzc1_6a5cc844-bc7e-414a-bd95-aa1bdc0e6f1a"
      unitRef="usd">2000000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iac6b4e3f3ab049039f1f5a6789966e1c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtMS0xLTEtOTAxMg_669170fa-7df7-438d-8668-e132283185fa"
      unitRef="shares">16482152</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iac6b4e3f3ab049039f1f5a6789966e1c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtMy0xLTEtOTAxMg_d9b41ede-f2b9-459e-87e7-f5083e06cc6b"
      unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ieb4562dea9ab4a92a5891acdb449c85e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtNS0xLTEtOTAxMg_b8702bbf-68ee-44b9-aa85-4020b0c1390c"
      unitRef="usd">64245000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0dabf277cd58429499eaacf07849e5e3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTQtOS0xLTEtOTAxMg_4253ba3e-c046-41a6-b4d1-ffe3b15d7735"
      unitRef="usd">64261000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i5dbf1c141a0c4eb483ea692aec134f4b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtMS0xLTEtOTAxMg_d3744109-2faa-411f-aea8-6b4fd34fbded"
      unitRef="shares">188460951</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5dbf1c141a0c4eb483ea692aec134f4b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtMy0xLTEtOTAxMg_1fb8d183-2c4a-4aa1-97fd-6f852ca98473"
      unitRef="usd">188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45ac0ee18ade4af8b7b471481a04a2c3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtNS0xLTEtOTAxMg_7e0c9ea4-d5e9-4a5a-a63f-c97b75815907"
      unitRef="usd">446036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd658161e2c94d2a852bd1a21e30693d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtNy0xLTEtOTAxMg_fa6ee3d4-3a38-4059-92eb-afff8e1da6a1"
      unitRef="usd">-396875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2075535641a548e287b521ae3d4bbb18_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTUtOS0xLTEtOTAxMg_2de72a3f-ddd8-45e7-a9e4-a2702402456f"
      unitRef="usd">49349000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia5c7eda9e3954ea795f7fc70c0134b09_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTctNy0xLTEtOTQzNQ_63bd3922-e3dc-4965-bc77-aabeae83c5d8"
      unitRef="usd">71674000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTctOS0xLTEtOTQzNQ_3e534b2e-631c-4322-b712-aa9b10726f32"
      unitRef="usd">71674000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTgtNS0xLTEtOTQzNQ_edac3937-f5b5-4921-a249-5d2379053156"
      unitRef="usd">1168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTgtOS0xLTEtOTQzNQ_24ec20ff-47cd-4e17-8304-652999400668"
      unitRef="usd">1168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTktMS0xLTEtOTQzNQ_9be4ecd2-3161-402b-b1ba-55ce91755635"
      unitRef="shares">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTktNS0xLTEtOTQzNQ_dd3799e5-90f1-466b-9726-3c90c2ccc580"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMTktOS0xLTEtOTQzNQ_9deb6022-8400-4842-87e0-2f157627f89f"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjAtMS0xLTEtOTQzNQ_e831799b-3d1a-484d-b369-9220b91744ac"
      unitRef="shares">1195219</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjAtMy0xLTEtOTQzNQ_43abc68a-aefc-48cf-bc38-9a30ee7f0084"
      unitRef="usd">1000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjAtNS0xLTEtOTQzNQ_1d6ab790-bddf-4dc0-bb10-3384b6418e01"
      unitRef="usd">656000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjAtOS0xLTEtOTQzNQ_dd918873-c3ba-47e9-ad8b-b18582aa2841"
      unitRef="usd">657000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtMC0xLTEtOTM0Ny90ZXh0cmVnaW9uOmNlYWI3NDZmMjI0YTQzZGZiYTUwMWIxOGU0NjM4YzFjXzQzOTgwNDY1MTEyMDM_21cd5a79-f8dc-4701-9728-4be19b4f76a7"
      unitRef="usd">1200000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtMS0xLTEtOTQzNQ_ca0faa23-52b1-4a0c-b183-5de98f67a6ee"
      unitRef="shares">9804475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5a9f89455db04e19ad8a0ea9889880cb_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtMy0xLTEtOTQzNQ_e5b3fe51-45a0-4675-b6cf-d9569d1ebccf"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia7b3b560c2844d2896278dddbab1efe9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtNS0xLTEtOTQzNQ_831e4f58-48e0-4284-82f6-60545e7b1f04"
      unitRef="usd">38147000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjEtOS0xLTEtOTQzNQ_8270d9f1-57bb-49bb-817b-724184e925e3"
      unitRef="usd">38157000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i2ba9eed293fb489583e83d76334fb473_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItMS0xLTEtMTk5Mjc_8aa33315-6e98-4217-88a3-5ca9d8c943fb"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2ba9eed293fb489583e83d76334fb473_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItMy0xLTEtMTk5Mjc_091b03a4-3ca0-479b-8343-a164723caa1d"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e794ca5abe9423b8fcb06f2a3b212a6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItNS0xLTEtMTk5Mjc_41c6ab20-ed48-4cc2-88ea-dc1b42d00d59"
      unitRef="usd">486010000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d9e1dcf0f804b12800ee77146e934bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItNy0xLTEtMTk5Mjc_cd861de7-11a3-4c8b-b462-81e164bf80e4"
      unitRef="usd">-325201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOjMxM2U4NWEwYTVlNzQxNGRhZTkyOWZjMTE0NzhlNTQzL3RhYmxlcmFuZ2U6MzEzZTg1YTBhNWU3NDE0ZGFlOTI5ZmMxMTQ3OGU1NDNfMjItOS0xLTEtMTk5Mjc_69113b2d-58d9-4f7f-b082-12ce5d16ce9e"
      unitRef="usd">161008000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ia345782a36b04632a22dcefbffbf2122_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi0xLTEtMS05MDEy_1ead621f-0535-42bc-8f8b-842f0ba07c4b"
      unitRef="shares">106801409</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia345782a36b04632a22dcefbffbf2122_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi0zLTEtMS05MDEy_25a89862-c345-462e-920e-1e477287a016"
      unitRef="usd">107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a6721966bda4737b5d6c09a51510e67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi01LTEtMS05MDEy_815a5948-a16c-41d1-8afb-df16c02cb056"
      unitRef="usd">266717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30cab611aee04f429c25aa68fcb3a66d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi03LTEtMS05MDEy_a5064421-6755-4395-8896-86efcdb0cd26"
      unitRef="usd">-293524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i746ad97c6cd749bea3090dff8cc5d3c8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMi05LTEtMS05MDEy_1823f9fa-1a48-4e31-b562-dc8614585d05"
      unitRef="usd">-26700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4c0f30e637a74e7bbfde72ce37739632_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMy03LTEtMS05MDEy_4639690a-abf1-4ccf-9272-1f40164afa85"
      unitRef="usd">41564000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMy05LTEtMS05MDEy_3a99c3f2-f1c2-4b4b-97fd-13781ad6f37d"
      unitRef="usd">41564000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i95480a6da5214cc3867f93de1459e972_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNC01LTEtMS05MDEy_c0677471-0592-49b5-aa89-0765711c678a"
      unitRef="usd">407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNC05LTEtMS05MDEy_350d736c-53b5-45a7-9e2a-5dd2f75c697c"
      unitRef="usd">407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ieafcf2967a0e4400ba5e2ef91b2c4e95_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNS0xLTEtMS05MDEy_0dabba62-6371-4f25-b669-805d227b96a8"
      unitRef="shares">2785</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i95480a6da5214cc3867f93de1459e972_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNS01LTEtMS05MDEy_bf602756-8f35-4f86-901a-63e9186b98a5"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNS05LTEtMS05MDEy_24d22ff2-cf31-4f08-a32e-6bc67ffa4c6e"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi0wLTEtMS05MDEyL3RleHRyZWdpb246MDBmMDk4OTQ2OTljNDEzMDhkMWM2NDI2NDFhYzc1ZTBfNzQ_6b3f921c-c73c-4c56-a840-9929b9af3ffa"
      unitRef="usd">100000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ieafcf2967a0e4400ba5e2ef91b2c4e95_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi0xLTEtMS05MDEy_08aff9b9-44d8-4689-b0ff-4b1494e45055"
      unitRef="shares">3187359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ieafcf2967a0e4400ba5e2ef91b2c4e95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi0zLTEtMS05MDEy_745d2229-94d9-4b12-a05d-8f0f72f8be97"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i95480a6da5214cc3867f93de1459e972_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi01LTEtMS05MDEy_433a8387-d4e1-4db2-8ee7-5a0d61fc6654"
      unitRef="usd">3176000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icb61538a0325426c82471f96c7d8f85d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNi05LTEtMS05MDEy_f2fa35d1-507d-43a2-8f17-ac6db7ca5024"
      unitRef="usd">3179000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i153d728efff347759e0394fab9944503_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy0xLTEtMS05MDEy_78dbe9d3-27eb-432c-a664-44dc22971f2e"
      unitRef="shares">109991553</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i153d728efff347759e0394fab9944503_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy0zLTEtMS05MDEy_b241df34-3cb9-470a-8563-928dfc58f52b"
      unitRef="usd">110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8a154a5219c4779983d780486eecb41_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy01LTEtMS05MDEy_6b997623-5611-4747-8613-1576b3d99c36"
      unitRef="usd">270301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if14f953deda7433f98e5de86c3866f7a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy03LTEtMS05MDEy_7913dd55-22cc-4bcd-9827-43d66ad19b29"
      unitRef="usd">-251960000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i64611da1b2004612b9b69bfe30c13dc8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfNy05LTEtMS05MDEy_f54981e7-7355-4704-9b64-c349de436bcb"
      unitRef="usd">18451000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id7e08a33ca6d4f589a32a804b0218dab_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfOS03LTEtMS05MDEy_a6ac1532-5694-4050-9ab4-1fd693c938ce"
      unitRef="usd">-26344000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4502189f31a9474283888eeb7a770696_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfOS05LTEtMS05MDEy_c6683111-06fc-4e0a-8ef8-de8fb4e9abc6"
      unitRef="usd">-26344000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i002e2f171b10423aa884ac9b368e3eb8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTAtNS0xLTEtOTAxMg_5411ff6d-3ce9-45bd-a25c-6ad9a93c7ea8"
      unitRef="usd">491000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4502189f31a9474283888eeb7a770696_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTAtOS0xLTEtOTAxMg_1bf5ad96-a5b0-4afe-84e0-24ae57f1baf3"
      unitRef="usd">491000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i4502189f31a9474283888eeb7a770696_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtMC0xLTEtOTAxMi90ZXh0cmVnaW9uOjg2MTM5MWZkMjlmODQ3ZDI4NmI3NTYzNjk0YjU4YjBlXzgx_22e2dcfa-3a17-44bc-ac1b-4cd394cd6a04"
      unitRef="usd">100000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i54dfac6708f940ae8d7d54eb45c4cdf6_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtMS0xLTEtOTAxMg_3963cca8-2ca1-4850-a874-eead81e6f8b5"
      unitRef="shares">6636100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i54dfac6708f940ae8d7d54eb45c4cdf6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtMy0xLTEtOTAxMg_5202ce60-fb36-483d-9d3d-b0df1b0827e4"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i002e2f171b10423aa884ac9b368e3eb8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtNS0xLTEtOTAxMg_12860074-bc35-4825-bfe8-bab0b25d3ee4"
      unitRef="usd">4768000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4502189f31a9474283888eeb7a770696_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTEtOS0xLTEtOTAxMg_5e900866-5813-40c1-9f24-5217b82d01e2"
      unitRef="usd">4774000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i069fefbb34c949ec9377080da376e4fb_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItMS0xLTEtOTAxMg_e0f9ae60-5124-498f-8583-c7dab3900397"
      unitRef="shares">116627653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i069fefbb34c949ec9377080da376e4fb_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItMy0xLTEtOTAxMg_78e01faa-4277-4651-9089-e2da8a86c0d1"
      unitRef="usd">116000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe33102ebcf8432bb484924b03e689bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItNS0xLTEtOTAxMg_d2e596f5-72cf-483d-8c54-b3db00df683e"
      unitRef="usd">275560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf4b71ad2308422da8c65596d76c09fd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItNy0xLTEtOTAxMg_8a80d3c9-3a0b-40c6-b8a2-ca0d9a3cdf4c"
      unitRef="usd">-278304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9fee51ba1523446dac271d22281350e4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTItOS0xLTEtOTAxMg_bba69e89-1a27-4d28-adf0-ff292248ffdc"
      unitRef="usd">-2628000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iaf3a7c87f6d1422aa77aa5b7f9f2ecb0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTQtNy0xLTEtOTgwMg_6fed6bb5-4db2-4d9b-a556-cbdccc8fc84e"
      unitRef="usd">-22608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTQtOS0xLTEtOTgwMg_ce2b5961-2daa-4dc9-96f3-9c502688810d"
      unitRef="usd">-22608000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5245ae5196f44ba6949d51a19c7f5a0f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTUtNS0xLTEtOTgwMg_f3ddb0ce-85f4-444c-9ac2-b6851422f3a8"
      unitRef="usd">453000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTUtOS0xLTEtOTgwMg_4fedc4d0-6c03-4e12-af2f-726eea388dd7"
      unitRef="usd">453000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ief9d18a3e43644049cf7c9dd882573e0_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTYtMS0xLTEtOTgwMg_12efb218-befd-4a60-b668-1e025634a5a6"
      unitRef="shares">25401</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5245ae5196f44ba6949d51a19c7f5a0f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTYtNS0xLTEtOTgwMg_5ebd0b4f-4003-45d3-b3a1-65eb29944143"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTYtOS0xLTEtOTgwMg_db6ccec4-8be3-4e1d-a1d2-7c49d334b86b"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctMC0xLTEtOTc1NC90ZXh0cmVnaW9uOjYwOGI5ZTM1ZDI0ODQyODA5NTA1MTk5N2VlMDNjODE2XzQzOTgwNDY1MTEyMDI_ef31f59d-ac7c-4b26-8aca-4bd7c7f95bdc"
      unitRef="usd">300000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ief9d18a3e43644049cf7c9dd882573e0_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctMS0xLTEtOTgwMg_33ddd41a-91e5-42a7-98fa-fd562b8040a2"
      unitRef="shares">6991953</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ief9d18a3e43644049cf7c9dd882573e0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctMy0xLTEtOTgwMg_9b92b167-b1c9-41dd-b966-d49648485b94"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5245ae5196f44ba6949d51a19c7f5a0f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctNS0xLTEtOTgwMg_414ae9b8-e1f7-4c3f-8cf2-57568805cbb4"
      unitRef="usd">8214000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTctOS0xLTEtOTgwMg_ed0447e1-9871-4c60-8c55-eba60ddb488c"
      unitRef="usd">8221000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i255ec6c67daf44f3b60c0bef3b4adc4d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtMS0xLTEtMTk5NDE_5185d158-0d49-4bc4-a0c5-e39f41861123"
      unitRef="shares">123645007</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i255ec6c67daf44f3b60c0bef3b4adc4d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtMy0xLTEtMTk5NDE_345fec8f-e9dc-4c79-91df-6f618fb16ba9"
      unitRef="usd">123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0f99021539f4ebcb94f4695fa55a58b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtNS0xLTEtMTk5NDE_d769b947-6da2-4703-a85f-3d5528ab0030"
      unitRef="usd">284236000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad4cdeca849b4134b8aa1380f258de14_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtNy0xLTEtMTk5NDE_0b9ae290-730c-4291-84bd-ba8eb29da00a"
      unitRef="usd">-300912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yMi9mcmFnOjlkMTQ1ZGZkZDk0MjQ3YmNhZWIzODVjOGMwMzMxNDVhL3RhYmxlOmM3NTg0ZmVlZjA0YjRmYjZiMTczMzJmOWEwNWM1YWVhL3RhYmxlcmFuZ2U6Yzc1ODRmZWVmMDRiNGZiNmIxNzMzMmY5YTA1YzVhZWFfMTgtOS0xLTEtMTk5NDE_18c24c45-4573-4ec9-aaf2-d930ec6f797e"
      unitRef="usd">-16553000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMy0xLTEtMS05MDEy_9fb15208-20f9-4d7e-8e11-409feec84b43"
      unitRef="usd">-9280000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMy0zLTEtMS05MDEy_590175f4-6957-4a60-ab34-4bcb44e1cb76"
      unitRef="usd">-7388000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNS0xLTEtMS05MDEy_b58f348f-437b-4e86-b1ed-6945a4ccf40c"
      unitRef="usd">74000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNS0zLTEtMS05MDEy_1f3073de-d7c0-48a9-94d1-e507049d9829"
      unitRef="usd">92000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNi0xLTEtMS05MDEy_12c2a7fd-260b-4dc6-b292-9c8eda720e28"
      unitRef="usd">3386000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNi0zLTEtMS05MDEy_880ce9f0-1a50-4c31-a5e1-423685345576"
      unitRef="usd">1351000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNy0xLTEtMS05MDEy_cd9199b3-a347-4665-81b6-15ed83cccaa6"
      unitRef="usd">-52240000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfNy0zLTEtMS05MDEy_16df4903-3883-4252-a1a1-e6bcf5ead42a"
      unitRef="usd">-16820000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AssetImpairmentCharges
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfOC0xLTEtMS0yMjIzNg_7b70c202-6815-4cc6-a0ae-457931367c72"
      unitRef="usd">31700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfOC0zLTEtMS0yMjIyOQ_af934467-5152-4d9b-8c91-6bfa81cb5b4b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfOS0xLTEtMS05MDEy_0f070e35-50af-4739-a978-f9a28352bcb6"
      unitRef="usd">1107000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfOS0zLTEtMS05MDEy_352d822e-0742-4d5f-ac5d-a6ced93ccdaf"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTAtMS0xLTEtOTAxMg_fcd3aaf2-4644-4a83-8fa3-590ac3b0bc66"
      unitRef="usd">23665000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTAtMy0xLTEtOTAxMg_de2838c8-bb88-404f-add3-e87e6e28646c"
      unitRef="usd">899000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTEtMS0xLTEtOTAxMg_671243cc-4153-4ee1-93ef-eefa051f2a10"
      unitRef="usd">807000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTEtMy0xLTEtOTAxMg_60c05ac1-d18d-4fc9-9dc5-02af4c69c4fc"
      unitRef="usd">-378000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTItMS0xLTEtOTAxMg_e58370bc-0dd2-4133-afea-18b6ef138148"
      unitRef="usd">-4453000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTItMy0xLTEtOTAxMg_0f181cdd-bd24-4887-a1e4-97ae8fc3d907"
      unitRef="usd">1714000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTMtMS0xLTEtOTAxMg_f0441605-4bcb-4400-9a93-ecd355a347ce"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTMtMy0xLTEtOTAxMg_ef6e1bc8-441a-49a3-acc3-f68220f1b0f2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTQtMS0xLTEtOTAxMg_5624ed41-bfdc-4c01-80d4-96b4d918eb63"
      unitRef="usd">-56278000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTQtMy0xLTEtOTAxMg_c9230a91-ffe8-4fb2-9b03-f1eee560c5a2"
      unitRef="usd">-22328000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTYtMS0xLTEtOTAxMg_88c95616-4490-446f-a6f2-f824c3aa93b4"
      unitRef="usd">4000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTYtMy0xLTEtOTAxMg_09fcb2b7-34c4-44e2-b4ab-cc32c1f075e7"
      unitRef="usd">8000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTctMS0xLTEtOTAxMg_b8469b8e-3bd2-4fa9-86fc-2466d528865e"
      unitRef="usd">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTctMy0xLTEtOTAxMg_b481b4fc-6086-4622-b926-64fc33a7f542"
      unitRef="usd">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTktMS0xLTEtOTAxMg_6aef8029-cfd4-4383-a3e7-f1c17c030994"
      unitRef="usd">174961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMTktMy0xLTEtOTAxMg_c3ec0a3f-c4b8-4b31-84b2-b6e8bc51458a"
      unitRef="usd">16174000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjAtMS0xLTEtOTAxMg_50d20518-35d5-487f-ad6d-658e45ec36d8"
      unitRef="usd">42000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjAtMy0xLTEtOTAxMg_36df4ea3-d326-4a4a-a0ea-24d7037cb4ca"
      unitRef="usd">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjEtMS0xLTEtOTAxMg_4984ecc0-01ef-4093-bac7-0b62449136ca"
      unitRef="usd">1126000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjEtMy0xLTEtOTAxMg_b1bdc33d-7a47-47bc-b6f5-10223979c28a"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjQtMS0xLTEtOTAxMg_4dc19f98-44de-4ad0-abc7-77efca51fc47"
      unitRef="usd">176129000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjQtMy0xLTEtOTAxMg_b9b9cac0-d22d-4264-b528-3254c91657be"
      unitRef="usd">16184000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjUtMS0xLTEtOTAxMg_50225eb1-7dcb-4319-b024-d0ca884a70b6"
      unitRef="usd">119847000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjUtMy0xLTEtOTAxMg_2eb6bf7f-278d-4c92-bd58-49a52200ac2a"
      unitRef="usd">-6152000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjYtMS0xLTEtOTAxMg_ae25cca5-eb6f-448c-a7af-c50fc9d51231"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i746ad97c6cd749bea3090dff8cc5d3c8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjYtMy0xLTEtOTAxMg_e020044e-7848-4064-99c6-80ae135d688a"
      unitRef="usd">48141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjctMS0xLTEtOTAxMg_54e1fbad-5095-4909-b8f6-09201df89c81"
      unitRef="usd">175256000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMjctMy0xLTEtOTAxMg_741a5539-a50e-4ca0-bca2-b243afa2e15d"
      unitRef="usd">41989000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzAtMS0xLTEtMjAwMTk_e041a4ca-0c80-435e-9933-b2192f58e1d1"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzAtMy0xLTEtMTk5ODk_78eeff60-aa0f-4135-b12e-6481f237475e"
      unitRef="usd">290000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzAtMS0xLTEtOTAxMg_3b10d3c9-3a28-4c82-b2fd-982364968c9b"
      unitRef="usd">131000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzAtMy0xLTEtOTAxMg_65c49cb8-317b-4357-8b0b-753187a5d041"
      unitRef="usd">113000</us-gaap:OperatingLeasePayments>
    <sesn:OtherDividendAndAdjustments
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzQtMS0xLTEtOTAxMg_72965146-943d-46b3-8c5e-aab1fd21e9e0"
      unitRef="usd">0</sesn:OtherDividendAndAdjustments>
    <sesn:OtherDividendAndAdjustments
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18yNS9mcmFnOmM4NTBhYTgzMTkzYzQyMGE5N2Y0N2EyOGJiNDEyZDJhL3RhYmxlOjUyZTczZGZhOGJjZTQ1NzQ4ZGFhNjg5YzExOTcyZThkL3RhYmxlcmFuZ2U6NTJlNzNkZmE4YmNlNDU3NDhkYWE2ODljMTE5NzJlOGRfMzQtMy0xLTEtOTAxMg_41874779-f7c5-46c3-9eea-48900168b86e"
      unitRef="usd">147000</sesn:OtherDividendAndAdjustments>
    <us-gaap:NatureOfOperations
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfMTIxNTE_ba7304e4-e3df-403d-b26f-7ed1954c12a5">DESCRIPTION OF BUSINESS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Sesen Bio, Inc. ("Sesen" or the &#x201c;Company&#x201d;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#x2019;s most advanced product candidate, VicineumTM, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus Calmette-Gu&#xe9;rin ("BCG")-unresponsive non-muscle invasive bladder cancer ("NMIBC"). The Company has an ongoing single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On July 13, 2021, the Company participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, the Company and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to chemistry, manufacturing and controls (&#x201c;CMC&#x201d;), and a timeline to submit additional supporting information was agreed upon. On August 13, 2021, the Company received a complete response letter (&#x201c;CRL&#x201d;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On October 29, 2021, the Company participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL (the "CMC Type A Meeting"). During the CMC Type A Meeting, the Company and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any potential future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. The Company is preparing for a separate Type A Meeting to discuss the recommendations specific to additional clinical/statistical data and analyses that the FDA raised in the CRL (the &#x201c;Clinical Type A Meeting&#x201d;), which the Company expects to occur later this year. The Company operates in one segment under the direction of its Chief Executive Officer (chief operating decision maker). The Company was formerly known as Eleven Biotherapeutics, Inc. until its name changed in May 2018.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Viventia Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#x201c;Selling Shareholders&#x201d;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#x201c;Clairmark&#x201d;) (the &#x201c;Share Purchase Agreement&#x201d;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#x201c;Viventia Acquisition&#x201d;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0&#160;million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, who served as a director of the Company until his retirement in July 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5&#160;million payable upon the first sale of Vicineum (the &#x201c;Purchased Product&#x201d;) in the United States; (ii) a one-time milestone payment of $7&#160;million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3&#160;million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033 and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country (collectively, the "Contingent Consideration"). Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts for the first seven years following the closing of the Viventia Acquisition, to achieve marketing &lt;/span&gt;&lt;/div&gt;authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors, however as of September&#160;30, 2021, none of these individuals are employees or members of the Company's board of directors.</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfMjQxOA_a752229e-f6c6-4b5f-a141-4f5a0044f5c0"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare
      contextRef="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfMzM3Nw_e654b78e-ca60-49af-b5a8-92d383a30a3b"
      unitRef="shares">4000000</sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="idc9920534e564063b17cf3276820d0f3_I20160930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfMzQ4MQ_2bac8133-4aec-42e2-af49-773fed1d8c09"
      unitRef="number">0.199</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct
      contextRef="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDA1OQ_9a617dad-c388-4d10-99d4-6737860cb698"
      unitRef="usd">12500000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct
      contextRef="i04d84ce34ad9409399002fee7af82ae3_D20160901-20160930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDE4Nw_f57626b1-e731-470c-962a-94cbe23efb36"
      unitRef="usd">7000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct
      contextRef="i07f5c65b436140d38150a47e9b6c1c36_D20160901-20160930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDMzMw_24eeca64-6c8b-4354-bc0b-48df18af0cf6"
      unitRef="usd">3000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct>
    <sesn:SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods
      contextRef="icd5b45b654db4116bd06d251988b14f4_D20160901-20160930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDQ0NQ_860b1dfd-4223-4d20-9657-2ec78b0ad63c"
      unitRef="number">0.02</sesn:SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods>
    <sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales
      contextRef="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNDcxMQ_cf62a3f9-fb78-4d88-869b-d2bea4f884bd">P15Y</sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales>
    <sesn:SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations
      contextRef="iefd253ff4a8542ada923e3344c5c59ea_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zMS9mcmFnOjE2Y2QwZDU5NjVhMTRkOTc4ODBlMDU5ZTIwYTA2NmJjL3RleHRyZWdpb246MTZjZDBkNTk2NWExNGQ5Nzg4MGUwNTllMjBhMDY2YmNfNTA3Mg_d8f22075-2ac8-4b3a-8342-82726ec49331">P7Y</sesn:SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations>
    <us-gaap:BasisOfAccounting
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2NA_78fd89a5-fc33-4e93-b2d0-c7a5aa896ef3">BASIS OF PRESENTATION&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates (&#x201c;ASUs&#x201d;), promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interim Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#x2019; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on March 15, 2021, wherein a more complete discussion of significant accounting policies and certain other information can be found.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; revenue recognition and going concern considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the U.S. dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2NQ_0e2441f5-acc8-4f99-89b1-f42343013808">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interim Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#x2019; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on March 15, 2021, wherein a more complete discussion of significant accounting policies and certain other information can be found.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2Ng_7deea7dc-47c3-4597-8faf-7db2303a7071">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; revenue recognition and going concern considerations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2Nw_b5ea9c49-be56-4f1b-a6ae-cb99176a31a8">Principles of ConsolidationThe Company&#x2019;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNC9mcmFnOjNjZjk2YzAyY2RkNjQwM2NiZDE0ZGZhNTYzZTAxZDQzL3RleHRyZWdpb246M2NmOTZjMDJjZGQ2NDAzY2JkMTRkZmE1NjNlMDFkNDNfMzg2OA_67f0ff54-9a14-4bbb-9cfb-369c16b29ac2">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the U.S. dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18zNy9mcmFnOjdkMjhlMDc2ZTkyYzQxZGJhNTY4MzQyMTc1ZTczZGZmL3RleHRyZWdpb246N2QyOGUwNzZlOTJjNDFkYmE1NjgzNDIxNzVlNzNkZmZfMzY4_de370e33-0525-473d-9196-a4c6428b7f83">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2020.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180MC9mcmFnOjE4MjUyYjRhYzhkYjRiMzRiODgyOWQ4ZmM2ZTg3NzFiL3RleHRyZWdpb246MTgyNTJiNGFjOGRiNGIzNGI4ODI5ZDhmYzZlODc3MWJfOTM2_efd1a5d1-3b31-4418-831c-3a91e5fc6a72">RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP &lt;/span&gt;&lt;/div&gt;for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180MC9mcmFnOjE4MjUyYjRhYzhkYjRiMzRiODgyOWQ4ZmM2ZTg3NzFiL3RleHRyZWdpb246MTgyNTJiNGFjOGRiNGIzNGI4ODI5ZDhmYzZlODc3MWJfOTM3_34130b83-d43f-4438-b898-f13f42156ca7">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP &lt;/span&gt;&lt;/div&gt;for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNTI5MA_3765bd69-5c86-40d0-8143-7b87f760d293">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of September&#160;30, 2021 and December&#160;31, 2020 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs.  The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - short term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - short term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s contingent consideration was determined using probabilities of successful achievement of clinical and regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2024 to 2033, the level of commercial sales of Vicineum forecasted for the United States, Europe, Japan, China and other potential markets and discount rates ranging from 7.5% to 8.6%  as of September&#160;30, 2021 and 8.4% to 8.8% as of December 31, 2020. There have been no changes to the valuation methods utilized during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the nine months ended September 30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108,840&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - short term &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the Company&#x2019;s contingent consideration is determined based on the present value of projected future cash flows associated with sales based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of&lt;/span&gt;&lt;span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2%&lt;/span&gt;&lt;span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#x2019;s estimated weighted-average cost of capital (&#x201c;WACC&#x201d;), which has fluctuated from 8.8% as of December 31, 2020 to 8.6% as of September&#160;30, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December 31, 2020 to  7.5% as of September&#160;30, 2021. The decrease in the fair value of contingent consideration of  $52.2 million for the nine months ended September 30, 2021 was driven by the receipt of the CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form. Due to the inherent uncertainty in the path forward for Vicineum at this time, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success (POS); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company anticipates needing to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#x2019;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA later this year to discuss questions related to clinical matters raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates as a result of these meetings, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNTI4Nw_a54599c4-25b9-44c3-bb73-bcb44540412b">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of September&#160;30, 2021 and December&#160;31, 2020 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs.  The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNTI3Mw_b9282bfa-ba7a-4b2f-a905-cd97a32f0e36">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - short term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - short term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia797d1ca4fc645e8b395e6d9263565df_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC0xLTEtMS05MDEy_0a5d5bca-dc00-4cd9-8e03-c47213a2c7ba"
      unitRef="usd">16380000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3bcc2b9836694810a0403c78508eec6f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC0zLTEtMS05MDEy_048ba4d6-9104-41a6-a63b-a6984965da28"
      unitRef="usd">16380000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia45b2253ea0241f883b480c50a91e7ee_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC01LTEtMS05MDEy_829f73f1-efaf-448c-9331-ae55588ad9ba"
      unitRef="usd">16380000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifb8cfcaa24fb4ed5a8ee17f30da2aecb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC03LTEtMS05MDEy_0be23201-5fb2-4030-923e-33f9c5a3dd58"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5ad64fc04cf04fd8be661f0721499ef2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNC05LTEtMS05MDEy_b97f964c-ea4f-47bd-ab39-47ef4f9a8348"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ia797d1ca4fc645e8b395e6d9263565df_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi0xLTEtMS05MDEy_2990c186-8bcb-40c5-9238-8d495822926f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i3bcc2b9836694810a0403c78508eec6f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi0zLTEtMS05MDEy_2a20a632-f7d1-4837-8573-2eb1191254ac"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ia45b2253ea0241f883b480c50a91e7ee_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi01LTEtMS05MDEy_dd43f09c-2933-47a8-86fc-aedb41d570f6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ifb8cfcaa24fb4ed5a8ee17f30da2aecb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi03LTEtMS05MDEy_d389fd0a-99f3-417a-9439-744851f05f16"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5ad64fc04cf04fd8be661f0721499ef2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNi05LTEtMS05MDEy_89252b17-f2c0-46e3-8376-b15878590979"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia797d1ca4fc645e8b395e6d9263565df_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy0xLTEtMS05MDEy_d4c368b8-d89b-459c-9abc-9b04f4fb7550"
      unitRef="usd">56600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3bcc2b9836694810a0403c78508eec6f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy0zLTEtMS05MDEy_8147c9ef-2c1c-4808-b345-b85525aeca02"
      unitRef="usd">56600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia45b2253ea0241f883b480c50a91e7ee_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy01LTEtMS05MDEy_0b550ca0-5e83-40da-8ee2-f83f412e9d27"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ifb8cfcaa24fb4ed5a8ee17f30da2aecb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy03LTEtMS05MDEy_28e1cb81-f21e-44ec-b460-863b56aedf91"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5ad64fc04cf04fd8be661f0721499ef2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjZkZWE0ODFjYjFjZTQ0Mzc5ZWQ4OWIyMDU4YWYwZTQyL3RhYmxlcmFuZ2U6NmRlYTQ4MWNiMWNlNDQzNzllZDg5YjIwNThhZjBlNDJfNy05LTEtMS05MDEy_16c3be8e-e905-47af-b57a-787f1dd62db1"
      unitRef="usd">56600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6b740de8bf63490bb488468c1c7ef16b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC0xLTEtMS05MDEy_2150906d-7456-4636-8f93-01b362f495c6"
      unitRef="usd">16374000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i72e931e5abe8401e88a126d64a293b20_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC0zLTEtMS05MDEy_8f555c9e-ac41-4465-a8d7-5768fcdd121f"
      unitRef="usd">16374000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i956068aabeb24f898f4ef28b58b5d3e3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC01LTEtMS05MDEy_d443559e-92c1-47bd-8473-0f887da8e4e0"
      unitRef="usd">16374000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1e4934a8dc9143cca95a8e41327cd312_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC03LTEtMS05MDEy_fe3e1a6a-8d88-436f-b441-82c54beabd9f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i54798f9a263e4006acf115b512314f6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNC05LTEtMS05MDEy_f5419af1-a2f1-41f2-a09a-20b411bcf472"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i6b740de8bf63490bb488468c1c7ef16b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi0xLTEtMS05MDEy_e6f6eacd-3bac-4d9f-b010-15da9191844d"
      unitRef="usd">8985000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i72e931e5abe8401e88a126d64a293b20_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi0zLTEtMS05MDEy_7031942f-e118-42bb-98d5-8ae30a4e64c4"
      unitRef="usd">8985000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i956068aabeb24f898f4ef28b58b5d3e3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi01LTEtMS05MDEy_b1713848-4005-476b-8609-7ba992bb893e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i1e4934a8dc9143cca95a8e41327cd312_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi03LTEtMS05MDEy_2ad1b067-4e5c-4895-8f51-9806063938c6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i54798f9a263e4006acf115b512314f6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNi05LTEtMS05MDEy_35ce1c82-14a0-4c68-a236-ab16dc010d29"
      unitRef="usd">8985000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6b740de8bf63490bb488468c1c7ef16b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy0xLTEtMS05MDEy_42a5d091-57e3-4cee-893b-73cafd4f6a5c"
      unitRef="usd">99855000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i72e931e5abe8401e88a126d64a293b20_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy0zLTEtMS05MDEy_c07bd829-90f4-4086-98d3-498cb1949418"
      unitRef="usd">99855000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i956068aabeb24f898f4ef28b58b5d3e3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy01LTEtMS05MDEy_d6511a2d-b783-4730-9a49-cb1cd386f6ae"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i1e4934a8dc9143cca95a8e41327cd312_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy03LTEtMS05MDEy_acb9b006-8e55-4027-b60d-8e8a9f2b07db"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i54798f9a263e4006acf115b512314f6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOjhmZjZlOTc3MGQ4ZDQ1ZDg4Y2ZhYTMwZmRmNmUxN2QzL3RhYmxlcmFuZ2U6OGZmNmU5NzcwZDhkNDVkODhjZmFhMzBmZGY2ZTE3ZDNfNy05LTEtMS05MDEy_96a8cdde-3a58-4f43-8c22-acd2b9ea000c"
      unitRef="usd">99855000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6c50f17d10a14d9eabcc22c8f3758312_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDM5ODA0NjUxOTYyNQ_0136e45f-c501-4b97-8e12-bb6458ffadbe"
      unitRef="number">0.075</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i084a1ef5b7d84536a0488186c21a7485_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMjc0ODc3OTA4NDYyMA_c4ad2738-4eee-45b8-ac75-36bbd1de1a0c"
      unitRef="number">0.086</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i4ac34a0eb6d444668cb6a7cfe8729dcc_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMzU5NA_181dc2c2-1157-4a12-8ca5-bd9cef9a6cf6"
      unitRef="number">0.084</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i41191996f8d5431abab1f677026cf472_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMzYwMA_74e37d53-f769-47e6-b8be-8ba2b9e2e59d"
      unitRef="number">0.088</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNTI4MA_1534c68d-626c-4288-8d1a-86fb72aa1f3e">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the nine months ended September 30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108,840&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - short term &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic84c83bbc78b4c12a4fe38ef570304f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOmJlYWQxNWYyOTg1MzQ1YWU4YTE3NjAzYjM3ODA4M2IxL3RhYmxlcmFuZ2U6YmVhZDE1ZjI5ODUzNDVhZThhMTc2MDNiMzc4MDgzYjFfMC0xLTEtMS05MDEy_5284ec9a-f17c-417b-989f-707b462fa169"
      unitRef="usd">108840000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent
      contextRef="i8ed5df0fffaa498399f610dcc2d9649d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOmJlYWQxNWYyOTg1MzQ1YWU4YTE3NjAzYjM3ODA4M2IxL3RhYmxlcmFuZ2U6YmVhZDE1ZjI5ODUzNDVhZThhMTc2MDNiMzc4MDgzYjFfMS0xLTEtMS05MDEy_59f348f1-0605-4740-968b-4ea4a95c9e68"
      unitRef="usd">-8985000</sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent>
    <sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent
      contextRef="i8ed5df0fffaa498399f610dcc2d9649d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOmJlYWQxNWYyOTg1MzQ1YWU4YTE3NjAzYjM3ODA4M2IxL3RhYmxlcmFuZ2U6YmVhZDE1ZjI5ODUzNDVhZThhMTc2MDNiMzc4MDgzYjFfMi0xLTEtMS05MDEy_aa326154-e286-4043-85d9-8d15c4d4d4b8"
      unitRef="usd">-43255000</sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6e86bda1e5244696a1806edda33f2bfb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RhYmxlOmJlYWQxNWYyOTg1MzQ1YWU4YTE3NjAzYjM3ODA4M2IxL3RhYmxlcmFuZ2U6YmVhZDE1ZjI5ODUzNDVhZThhMTc2MDNiMzc4MDgzYjFfMy0xLTEtMS05MDEy_d2e02c83-06d0-437b-a73d-4ab379231a85"
      unitRef="usd">56600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDI2Mg_968458d3-0516-4d29-9b25-d7e7c2460baf"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDM2MQ_2c2523f5-7369-4988-8120-e70473b85abb"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="ib1415d97efbe429391dd2e7d1b088f99_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDQ4MQ_7bf88e50-b45d-4418-a16c-3746e25a94da"
      unitRef="number">0.088</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i6825967355184d4db34915ea37cd569f_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDM5ODA0NjUxODM2MA_bca8da15-c0c2-4281-b067-b2f75eafffed"
      unitRef="number">8.6</sesn:WeightedAverageCostOfCapital>
    <sesn:DebtInstrumentIndexRateHighYield
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDcyNg_69ce82b1-d4f0-4f48-8fa2-e74121707e9a"
      unitRef="number">0.084</sesn:DebtInstrumentIndexRateHighYield>
    <sesn:DebtInstrumentIndexRateHighYield
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfNDM5ODA0NjUxODM2Ng_0a94000f-34ee-4fdb-b266-d1ec61263432"
      unitRef="number">0.075</sesn:DebtInstrumentIndexRateHighYield>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMTY0OTI2NzQ0OTEyMw_cdced075-0aee-411b-ab05-379bc1cb1dce"
      unitRef="usd">-52200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage
      contextRef="i555450de9c964d30965deb1462b538f4_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMjE5OTAyMzI2ODc5OQ_849e4b15-ffdb-49ac-af82-abb0eb04c8a4"
      unitRef="number">0.45</sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage>
    <sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage
      contextRef="i1d44b389ccbd43a2bbfcdc75634eaab2_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180My9mcmFnOmZjNzIyNTdlYzZhNjQ3NDFhNGJhMzNkZWFkMDMyMzcyL3RleHRyZWdpb246ZmM3MjI1N2VjNmE2NDc0MWE0YmEzM2RlYWQwMzIzNzJfMTY0OTI2NzQ1NTAwMw_bc9fa622-90a3-4240-a458-939d29b516a5"
      unitRef="number">0.55</sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDc5_9fa5dc01-0927-4007-95f4-c861340fd7e7">INTANGIBLE ASSETS AND GOODWILLIntangible Assets &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum United States rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The fair value of the acquired intangible asset for the U.S. and E.U. rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, the Company&#x2019;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss the clinical issues raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, an impairment analysis was conducted, which concluded that the carrying value of our intangible assets of Vicineum United States rights was fully impaired as of September 30, 2021. However, while similar delays in timelines and reduced probabilities of success also affected the carrying value of our intangible assets of Vicineum E.U. rights, this asset was not impaired as of September 30, 2021. The $31.7 million of impairment charges for the period ended September&#160;30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market as of September 30, 2021. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of our intangible assets of Vicineum E.U. rights, this asset was not impaired as of September 30, 2021. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the EU asset is burdened with significantly less expense than the US asset, as our strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with the Company earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $13.1 million as of September&#160;30, 2021 and December&#160;31, 2020. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, a quantitative impairment analysis was conducted during the quarter, in advance of the Company's typical annual assessment date of October 1. While an impairment was recognized in one of its intangible assets, Vicineum U.S. Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September 30, 2021, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately 45%. The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#x2019;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in our current development profile (ranging from 45% to 55% globally) also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of BCG-unresponsive NMIBC. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss questions related to clinical matters raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum, and will assess the outcome of those meetings, and other information obtained, to determine if further impairment testing is required. Further reductions to probabilities of success, additional development and commercial launch delays, or increases in underlying discount rates have the potential to result in future goodwill impairment.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDgw_606ebb5a-c531-4dd9-ab52-c3258f5fb1cf">The following table sets forth the composition of intangible assets as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum United States rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i09310b7c37a84f11878085deb559133d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfMi0xLTEtMS05MDEy_ea2d633b-ac40-44b4-9859-986f16053795"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="id7b6d5d2caa648dcb555f0031c4766b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfMi0zLTEtMS05MDEy_5de45dbd-07fc-4986-ac8d-6e4ea00a4f6b"
      unitRef="usd">31700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ib081c37a1b7148fabc6bbbdd4c81cd6d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfMy0xLTEtMS05MDEy_ec2fab0f-1389-4bca-98fa-f928a7737be1"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ifd9a1851f4b84938b499fb6f2ec592fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfMy0zLTEtMS05MDEy_d76e50af-e6e4-4175-a287-2204f68c9975"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ib3daf5ae769a4d4691f5323122b152a4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfNC0xLTEtMS05MDEy_ecf86472-c18e-4c5f-9ce8-87c82dcccabd"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i3748dd3582454f23a8200a59516d8d6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RhYmxlOmZhN2M2NWU3MjkxZDRmNjc5ODE5OTBhZWRhMGQ1YmRhL3RhYmxlcmFuZ2U6ZmE3YzY1ZTcyOTFkNGY2Nzk4MTk5MGFlZGEwZDViZGFfNC0zLTEtMS05MDEy_22b08188-825c-4324-a4a6-dba56dee5b17"
      unitRef="usd">46400000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="id1c35ca8bc59451b99b15883438c09e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfMjc0ODc3OTA3NzU4OQ_d118f3a5-1d6d-4772-9ff7-c27378682d3d"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDYw_4d38d096-6b32-48c4-bfc5-c97ac2d5f200"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDYw_ec6b4bde-3b22-49c2-a2cb-ecef409e7259"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDM5ODA0NjUyOTQ1Ng_8c5db6e0-9d9d-4590-8eb5-2d36f258942e"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfMTY0OTI2NzQ3NDEyOQ_acb0a40d-0e03-4860-9f3a-e3bc4df34c55"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i555450de9c964d30965deb1462b538f4_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfMTY0OTI2NzQ3NDExOQ_f5a3deef-b03c-4fc3-b1e2-07fd67280ce0"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i1d44b389ccbd43a2bbfcdc75634eaab2_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180Ni9mcmFnOjE5ZGZhZTZjYTAzMTQ0Y2Y5YjlkNWEzM2RmZDRkOTZiL3RleHRyZWdpb246MTlkZmFlNmNhMDMxNDRjZjliOWQ1YTMzZGZkNGQ5NmJfNDM5ODA0NjU1NTQ3MQ_24533f43-0611-4ec2-9b37-200897f7baa9"
      unitRef="number">0.55</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMjE4Ng_b3c7b457-b180-4b3d-8771-8b316009e322">LEASES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for operating leases under ASC Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022, with a right to extend the lease for one subsequent three year term. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,300 at exchange rates in effect on September 30, 2021). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,300 at exchange rates in effect on September 30, 2021). Operating lease cost under this lease, including the related operating costs, were $79,000 and $245,000 for the three and nine months ended September 30, 2021 and $75,000 and $223,000 for the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The asset component of the Company&#x2019;s operating leases is recorded as operating lease right-of-use assets and reported within other assets on the Company's condensed consolidated balance sheets. The short-term lease liability is recorded in other current liabilities and the long-term lease liability is recorded in other liabilities on the Company&#x2019;s condensed consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every three months to six months and currently extend through June 2022 and November 2021, respectively. The minimum monthly rent for these office spaces is $2,100 and $18,000, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases. The Company recorded $63,000 and $201,000 in rent expense for the three and nine months ended September 30, 2021 and $64,000 and $195,000 for the three and nine months ended September 30, 2020, respectively. The Company's accounting policy election was disclosed in "Item 15. Exhibits and Financial Statement Schedules - Note. 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sesn:OperatingLeasesAreaOfOfficeSpace
      contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTEz_83106b93-a4a4-4c08-8c51-1831497dc5cb"
      unitRef="sqft">31100</sesn:OperatingLeasesAreaOfOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ifd7692a883ce45169ba52f34b1597844_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMjE4OA_dec24413-2169-4743-8181-c244c6445d9d">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption
      contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMzky_f33ea8c1-c19c-425b-bb38-df9ce99421fe"
      unitRef="term">1</sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ifd7692a883ce45169ba52f34b1597844_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMjE4NQ_5ea273b0-5c07-44b8-a610-12696850e29f">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfNDY5_9d32420b-1c70-4d0d-ab38-4e403acb6eac"
      unitRef="cad">18100</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfNDk3_07781f4f-f820-4a7e-93bb-171b30437c1f"
      unitRef="usd">14300</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfNjA5_d5f20611-a43f-43c1-b5e9-d4598cac5700"
      unitRef="cad">18200</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfNjY3_aa9d5288-747e-418a-b6c1-6c01c1498371"
      unitRef="usd">14300</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <us-gaap:OperatingLeaseCost
      contextRef="i52acd18eaeab4bbeb00da4524f747aa3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfODAw_83efc213-3d42-4166-b711-8a6935eb5b0b"
      unitRef="usd">79000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ibf462f249d974be4bac9cacfe8c03ea2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfODA3_28680885-1489-41aa-b349-9dd5be67128e"
      unitRef="usd">245000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i18ebb0e11dab4338ba1489efd21f78a5_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfODI1_128d74eb-c595-4a46-99e4-aaaf6a91f096"
      unitRef="usd">75000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2bd4a05fa0ad4322ae22d1c69ac3251a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfODMy_475c5f27-6381-48ac-8682-dfa0110ff4d7"
      unitRef="usd">223000</us-gaap:OperatingLeaseCost>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i5a7fddfe10f34cafa6c5a4a5879fe96b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTA5OTUxMTYzMDIwMQ_fabd13e2-38ff-4751-9b02-0236a902cd3f"
      unitRef="usd">2100</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i68276962a8f74cf19dd3fffa8b75f81a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTY5NQ_194a707e-7782-48c7-9191-4227005106e3"
      unitRef="usd">18000</sesn:OperatingLeaseMonthlyRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTgyNw_32803834-80d8-4e63-b22c-c8f9233a568b"
      unitRef="usd">63000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTgzNA_898c6307-02d4-49a6-8859-ce536991436e"
      unitRef="usd">201000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTg2OA_4d005c47-e868-4917-8329-efa71ed7a28f"
      unitRef="usd">64000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN180OS9mcmFnOjcxMmVmZGNiNjU2ZjRhNmNiODkwNzMzODg3ODU4YTQ5L3RleHRyZWdpb246NzEyZWZkY2I2NTZmNGE2Y2I4OTA3MzM4ODc4NThhNDlfMTg3NQ_5a0f8757-522b-4a13-89ae-0d6e7dfdae92"
      unitRef="usd">195000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RleHRyZWdpb246ZTBlM2Q4OTZjZTVkNGYyODgyOWZmYTJmNDgxNzkyYzhfMTMw_90168b0f-577a-4595-9437-ce903bada001">ACCRUED EXPENSES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,973&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RleHRyZWdpb246ZTBlM2Q4OTZjZTVkNGYyODgyOWZmYTJmNDgxNzkyYzhfMTMz_1c6b0888-8495-40cb-8300-0a829a282d83">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,973&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfMS0xLTEtMS05MDEy_59fc32cc-1063-4c56-997b-d16e62c79ebe"
      unitRef="usd">2148000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfMS0zLTEtMS05MDEy_e223e342-e1a8-40e8-bab9-044fcc18c4e9"
      unitRef="usd">1372000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfMi0xLTEtMS05MDEy_3cdb04c5-3e17-4fb1-a013-c963cf94b683"
      unitRef="usd">1628000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfMi0zLTEtMS05MDEy_d874025e-ffe3-4a71-8110-a45dadeab8b9"
      unitRef="usd">1892000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNC0xLTEtMS05MDEy_afa64678-98a7-4123-b2c0-beee5d4bd373"
      unitRef="usd">2089000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNC0zLTEtMS05MDEy_fdbd51a1-c110-4d78-88a2-b3bdb7d4590b"
      unitRef="usd">684000</us-gaap:AccruedProfessionalFeesCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNS0xLTEtMS05MDEy_94624a5d-3d57-4366-b534-7b110c0de49e"
      unitRef="usd">2237000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNS0zLTEtMS05MDEy_9b79eeea-b141-4f40-be62-d8d6ab39cb51"
      unitRef="usd">0</sesn:AccruedRestructuringChargesRelatedCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNi0xLTEtMS05MDEy_1f64eadb-2258-40fc-9499-39c48f088ede"
      unitRef="usd">84000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNi0zLTEtMS05MDEy_9e58f2e2-4600-4d1b-a7d7-cb7139a205e9"
      unitRef="usd">25000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNy0xLTEtMS05MDEy_8740d818-0ae0-4351-8fcf-003eb303afc1"
      unitRef="usd">8186000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181NS9mcmFnOmUwZTNkODk2Y2U1ZDRmMjg4MjlmZmEyZjQ4MTc5MmM4L3RhYmxlOjlmNjU4ZDBmNWY2YjRiNDQ5ZDZmN2QxNjU2M2I3ZDJmL3RhYmxlcmFuZ2U6OWY2NThkMGY1ZjZiNGI0NDlkNmY3ZDE2NTYzYjdkMmZfNy0zLTEtMS05MDEy_f7f12a37-37e9-4f76-9c8b-d96082a2f2cb"
      unitRef="usd">3973000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNjEyMg_fa11db4c-abd0-440f-b673-45368b71654a">STOCKHOLDERS' EQUITY (DEFICIT)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company entered into an Open Market Sale Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time for an aggregate sales price of up to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $35&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through Jefferies (the "ATM Offering"). In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively.  Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $50&#160;million and $34.5&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement.  Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. The Company may sell shares of its common stock efficiently from time to time, but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#x2019;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $38.2&#160;million of net proceeds from the sale of 9.8&#160;million shares of common stock at a weighted-average price of $4.01 per share during the three months ended September 30, 2021, compared to $8.2 million of net proceeds from the sale of&lt;/span&gt;&lt;span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0 million shares of common stock at a weighted-average price of $1.21 per share during the three months ended September 30, 2020. The Company raised $175.0&#160;million of net proceeds from the sale of 56.9&#160;million shares of common stock at a weighted-average price of $3.17 per share during the nine months ended September 30, 2021, compared to $16.2 million of net proceeds from the sale of 16.8 million shares of common stock at a weighted-average price of $0.99 per share during the nine months ended September 30, 2020. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $1.2&#160;million and $5.4&#160;million during the three and nine months ended September 30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to its Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following approval by the Company&#x2019;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200 million to 400 million, of which 199 million and 140 million shares were issued and outstanding as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;September&#160;30, 2021 and December&#160;31, 2020, respectively. In addition, the Company had reserved for issuance the following number of shares of common stock for the purposes described below as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#x2019;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s outstanding warrants are non-tradeable and permanently classified as equity because they meet the derivative scope exception under ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC 815-40")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's warrant activity for the nine months ended September 30, 2021 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year-to-Date Warrant Activity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Expired)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification (ii) subject to further adjustment based on down round provision added by amendment described in "Item 15. Exhibits and Financial Statement Schedules - Note. 10 Stockholders' (Deficit) Equity" in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i39f8f4fa4924486482fcd1b7ca9c6d9d_I20191130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjg0_20e7f3b3-37a7-4482-a7de-c8ebf362cf04"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="idd5ea54630c14b3b8074d7e574a485d1_D20191101-20191130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzU0_9c312feb-81dc-4cd0-b2b6-9101f4089285"
      unitRef="usd">35000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockAdditionalSharesAuthorizedForSale
      contextRef="i67a67d24259846938c78c4e27aa8ba68_D20201001-20211031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNzIx_df5cad38-4e4f-4330-b75d-e75de10b9e7f"
      unitRef="usd">50000000</sesn:SaleOfStockAdditionalSharesAuthorizedForSale>
    <sesn:SaleOfStockAdditionalSharesAuthorizedForSale
      contextRef="i5526ac0da03b4995acfde7f67df66fdc_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNzI4_07ca67e1-dddd-47aa-98b7-be3a78554099"
      unitRef="usd">34500000</sesn:SaleOfStockAdditionalSharesAuthorizedForSale>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="ia14f2b1575414e92a7e8692a1656ed6e_D20210601-20210601"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA2Mg_3a8b8f01-cd81-4690-aa85-5d4ce6ee2601"
      unitRef="usd">200000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockCommissionFixedRate
      contextRef="idd5ea54630c14b3b8074d7e574a485d1_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjA5OQ_ba3eac08-2fa3-4160-9a30-02af757a7688"
      unitRef="number">0.030</sesn:SaleOfStockCommissionFixedRate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ib12fdfe409da499985845294be59cd32_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjQ3NA_cffd002c-716c-44a9-929d-b38520eafa4c"
      unitRef="usd">38200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib12fdfe409da499985845294be59cd32_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjUxMA_2ebf1950-0e67-49d7-855f-6db52e2e5932"
      unitRef="shares">9800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="ib12fdfe409da499985845294be59cd32_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjU2Nw_28b10857-f220-4b94-b8ed-6ad1e1c66ea5"
      unitRef="usdPerShare">4.01</sesn:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i23e8f40d129643c4955e53934f43c919_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzMzk1MA_c4e12246-ff29-4e98-876e-25ac3985bebe"
      unitRef="usd">8200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i23e8f40d129643c4955e53934f43c919_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzMzk1NQ_809c2980-0976-4716-a47e-26a709014482"
      unitRef="shares">7000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="i23e8f40d129643c4955e53934f43c919_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzMzk2MQ_b57d4b31-1aa6-45b2-bdb3-fc344c76d60b"
      unitRef="usdPerShare">1.21</sesn:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDM3Mg_84c05c40-ecd2-44b2-8ad4-2168d16ef5ee"
      unitRef="usd">175000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDQwOQ_d90ea873-2134-46a8-acf4-35c647e5b02c"
      unitRef="shares">56900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDQ2OA_a90985c9-3adb-4d48-ad76-0009d6d061af"
      unitRef="usdPerShare">3.17</sesn:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="if89a1bed4d6e4801a7b55c57bb01b6a0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDUxMA_4b958da0-dccf-4ada-afb4-8c89197fcc03"
      unitRef="usd">16200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if89a1bed4d6e4801a7b55c57bb01b6a0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDU0Nw_a4d3b533-a0c4-455a-a0aa-c2f869387e2d"
      unitRef="shares">16800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="if89a1bed4d6e4801a7b55c57bb01b6a0_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMTA5OTUxMTYzNDYzOA_7228b135-7b4b-4cf3-b74b-3b9ee115eccf"
      unitRef="usdPerShare">0.99</sesn:SaleOfStockWeightedAveragePricePerShare>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="ib12fdfe409da499985845294be59cd32_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjgxOA_9e7caae2-5c09-4469-8014-fe99c6fa0cac"
      unitRef="usd">1200000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i7aab58b73c4b445cbccf5ca7c6a0d8b9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjgyNQ_b55d1b9c-db8a-4e04-bf49-f50ce80df904"
      unitRef="usd">5400000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzAyNg_bc576579-6e75-4ffe-bcf7-ce921032cd6c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzAyNg_d25bad4e-3d06-46a3-a52e-d330a8bd9fd2"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzA3MA_120ac6c1-0b66-4f93-8c97-4d68225ec2d7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzA3MA_b7358a26-9532-437b-aa83-e1b213b2e226"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzUxNA_2cb99a36-97f7-41f5-9d13-8f60ae654b5c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzUxNA_38d87f44-06f9-4fe3-89db-7a053c33571f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzUxNA_80684d5d-88f6-4983-ba89-d266ae6ff7ef"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzUxNA_8c5c3e40-4003-4b2b-8f70-3e91b2500040"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMjE5OTAyMzI2MzQ5MQ_afbb4c46-b7b5-4e0a-892a-0936e2adb9d0"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzY2Nw_709eecbe-9f28-4356-bd53-52c0a4859d0a"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzcxMA_7a8e0f7b-742a-49e7-86a5-f0fda7a1e569"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzcxMA_97be4b97-3d06-44c2-97d3-f71269c04263"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzcxNw_4e65743a-0a3d-43f5-bbc8-48c651dcbd2a"
      unitRef="shares">140000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfMzcxNw_6ed12997-f41e-4803-8937-1b205b99ddb8"
      unitRef="shares">140000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNjExNg_f38e3bf8-7981-40d8-b941-6a9493314d60">In addition, the Company had reserved for issuance the following number of shares of common stock for the purposes described below as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfMS0xLTEtMS05MDEy_e9d914a8-6bd9-42a4-9650-4ff3fc032d6a"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfMS0zLTEtMS05MDEy_ecd0cc19-49c9-476e-979d-eefd9d4ee605"
      unitRef="shares">140450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id978bed0cf5c4d5fbab94cd056d775b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfMy0xLTEtMS05MDEy_eea58201-3598-423d-acea-bc9141e9bb84"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie7579e0e22c047768232e96e33209c00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfMy0zLTEtMS05MDEy_c47900cb-7909-480a-b174-62ada3d6995b"
      unitRef="shares">2247000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1d4b935d6b414f729cd483380a572798_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNC0xLTEtMS05MDEy_b6f46fe8-93c8-4c4a-866f-36504926384f"
      unitRef="shares">15511000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8591390616e24942a1790a6fef158000_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNC0zLTEtMS05MDEy_e2d50a73-bc1b-4d16-874a-b8e077b6e8d1"
      unitRef="shares">10147000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9fcaf5bf73c144fb87d727c536f11433_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNS0xLTEtMS05MDEy_5243a917-d16a-4861-8b11-4713c224303f"
      unitRef="shares">11983000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9742c1fa4df446ea92bcdc4006e5dac4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNS0zLTEtMS05MDEy_8079278f-ee05-4d17-96a1-d05068c77d48"
      unitRef="shares">4863000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i980c30d4b2e5432f83166c9129e01ffa_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNi0xLTEtMS05MDEy_af6bf17e-3633-4c85-bfe2-bd853846be39"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i716f44ff8fdb4ed68f03fe519e006002_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNi0zLTEtMS05MDEy_14e56ddb-93c2-4750-add2-c497c21aaa3b"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNy0xLTEtMS05MDEy_82962f50-dba7-406f-88e0-529edbfc8d30"
      unitRef="shares">229457000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOjFmYzFmMzM3N2Q3YTRkMTA5ZjQzNWMzYWMwMTUxZDE2L3RhYmxlcmFuZ2U6MWZjMWYzMzc3ZDdhNGQxMDlmNDM1YzNhYzAxNTFkMTZfNy0zLTEtMS05MDEy_b71924c8-793d-4895-8d0c-620325f9ecaf"
      unitRef="shares">157707000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RleHRyZWdpb246ZTIzMzgyZTE1MGMwNDQwNmIzOTE3YzdkMWY0NTcyNjBfNjEyNA_5c477d2e-2a31-43dd-aac9-d14c6757daf9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's warrant activity for the nine months ended September 30, 2021 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year-to-Date Warrant Activity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Expired)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification (ii) subject to further adjustment based on down round provision added by amendment described in "Item 15. Exhibits and Financial Statement Schedules - Note. 10 Stockholders' (Deficit) Equity" in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i52d9dcbb55e2474ea2ed0ba322bad3ac_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy0yLTEtMS05MDEy_e2a22303-4d17-488f-b9a0-70987d3c12d9"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i57e070c6f5694cc184d3ff043754818a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy02LTEtMS05MDEy_872670d0-343f-4433-b657-63fdcabb2c6b"
      unitRef="shares">1705000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="ic6379246986547cc9a88c6f8b29535d6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy04LTEtMS05MDEy_c2f7f656-596e-45fa-b7f8-bc626218dbdb"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ic6379246986547cc9a88c6f8b29535d6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy0xMC0xLTEtOTAxMg_354a47b0-3858-407c-8ddb-0275431d5ded"
      unitRef="shares">1573000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="ic6379246986547cc9a88c6f8b29535d6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy0xMi0xLTEtOTAxMg_e602dd8a-4f12-4d73-a1c4-dc27e8b453a6"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i52d9dcbb55e2474ea2ed0ba322bad3ac_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfMy0xNC0xLTEtOTAxMg_32818989-7ee5-4194-8818-756ba8c999df"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idcd1ce8b4f094a86aaf1094f5ade0c3a_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC0yLTEtMS05MDEy_04139728-38a7-4dc7-bb12-d967e75aecb7"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1e16f0e7c69a48b793e80ba1cbd35337_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC02LTEtMS05MDEy_d4180d10-472c-4b86-9fea-12382428a180"
      unitRef="shares">487000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i7a98b848353a4028b0c3659a7cc0fc8d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC04LTEtMS05MDEy_bd4ca023-c234-4897-987b-2e33b768d404"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i7a98b848353a4028b0c3659a7cc0fc8d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC0xMC0xLTEtOTAxMg_878dcc13-0bf9-4d63-a962-c728c16b5d69"
      unitRef="shares">475000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i7a98b848353a4028b0c3659a7cc0fc8d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC0xMi0xLTEtOTAxMg_c1a03426-c579-4347-b497-dffbb0cad755"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="idcd1ce8b4f094a86aaf1094f5ade0c3a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNC0xNC0xLTEtOTAxMg_ac520164-f102-4a7c-861f-1580667a9eeb"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if30380f6c6c241cca4d331347c506d7b_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS0yLTEtMS05MDEy_cf8a943e-1f95-420e-84bc-d4a5b8d7ecd1"
      unitRef="usdPerShare">11.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4e50b89a5f094c2485a5ef23806abe14_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS02LTEtMS05MDEy_2d0381b8-0d99-4f7a-9df5-275cce90b2c5"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i5ac338c8a528448585157860bb14aae6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS04LTEtMS05MDEy_8ab83454-cb1a-4fe9-b2bb-0456af4e8f54"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i5ac338c8a528448585157860bb14aae6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS0xMC0xLTEtOTAxMg_4f16ab42-d4f2-478c-9bb3-6a65cb441cc0"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i5ac338c8a528448585157860bb14aae6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS0xMi0xLTEtOTAxMg_60f82121-d1c8-4dca-ba4b-d75eb7434b14"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if30380f6c6c241cca4d331347c506d7b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNS0xNC0xLTEtOTAxMg_f203ca26-8a2f-4dfb-8cf6-952e332e918d"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ideefad39445444f5978ed30df0f8d67d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi0yLTEtMS05MDEy_ba28c8ac-c5eb-4016-8f58-d025bb6d0934"
      unitRef="usdPerShare">11.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1595e3478bb64207a037de6271baebed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi02LTEtMS05MDEy_fe2358aa-345a-4dee-94d0-a3fe4264132f"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i044c60384a9e4cc8afe4aaa8645c9ef6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi04LTEtMS05MDEy_8f1be93a-8533-4f80-bc0a-fad370438c1e"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i044c60384a9e4cc8afe4aaa8645c9ef6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi0xMC0xLTEtOTAxMg_e1fa335e-c797-43e7-a82f-2c76a4f27a67"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i044c60384a9e4cc8afe4aaa8645c9ef6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi0xMi0xLTEtOTAxMg_1c23b19c-0212-4e39-ada7-a8b87740898e"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ideefad39445444f5978ed30df0f8d67d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNi0xNC0xLTEtOTAxMg_a70c56a8-2ed7-475e-8b79-2d1e51831185"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy02LTEtMS05MDEy_daa11037-493c-48a5-bcbd-99eb13d4b168"
      unitRef="shares">2247000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy04LTEtMS05MDEy_969bbe84-602e-4831-98d4-eace817b8d7c"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy0xMC0xLTEtOTAxMg_34fc7823-973d-4931-925b-f369f2309381"
      unitRef="shares">2048000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy0xMi0xLTEtOTAxMg_f071429f-5d1a-4487-aee6-bc6167fe24de"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN181OC9mcmFnOmUyMzM4MmUxNTBjMDQ0MDZiMzkxN2M3ZDFmNDU3MjYwL3RhYmxlOmVlMzQwOTYxZWU5MzRiYWFhMDkzOWZiNjhkZWQxZWUyL3RhYmxlcmFuZ2U6ZWUzNDA5NjFlZTkzNGJhYWEwOTM5ZmI2OGRlZDFlZTJfNy0xNC0xLTEtOTAxMg_b6922ab2-a82e-4669-8fc3-96f653c86355"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RleHRyZWdpb246NzBhNzkwM2E2ODVhNGM4NTk3ZjA5NmVjMDFiZDgzZmJfMjg0NA_9e57437e-0b0a-4a4e-9edc-5eceaae6c31e">EARNINGS (LOSS) PER SHARE&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A net loss cannot be diluted.  Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#x2019;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income.  During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, the Company applied the two-class method to calculate basic and diluted net earnings per share of common stock for the three months ended September 30, 2021. The two-class method was not applied for the nine months ended September 30, 2021 and for the three and nine months ended September 30, 2020 as the Company&#x2019;s participating securities do not have any obligation to absorb net losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the determination of earnings (loss) per share for each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic Earnings (Loss) Per Share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Deemed Dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to participating securities - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,886&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,437&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share applicable to common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Dilutive Earnings (Loss) Per Share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Deemed Dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to participating securities - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)  attributable to common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive impact from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding &lt;br/&gt;- diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share applicable to common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of September&#160;30, 2021 and 2020 have been excluded from the denominator of the diluted income (loss) per share of common stock outstanding calculation as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months ended&lt;br/&gt;&#160;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RleHRyZWdpb246NzBhNzkwM2E2ODVhNGM4NTk3ZjA5NmVjMDFiZDgzZmJfNDM5ODA0NjUxNTQxMw_64397b1a-2296-49cd-ab4e-161f09c0b5bc">The following table illustrates the determination of earnings (loss) per share for each period presented:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic Earnings (Loss) Per Share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Deemed Dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to participating securities - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,886&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,437&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share applicable to common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Dilutive Earnings (Loss) Per Share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Deemed Dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income attributable to participating securities - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)  attributable to common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive impact from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding &lt;br/&gt;- diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share applicable to common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNS0xLTEtMS0yNTU4MA_6b5e45b6-344c-4ba6-b618-c2b2b6df2261"
      unitRef="usd">71674000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNS0zLTEtMS0yNTU4MA_ed406716-c5ce-4215-8de7-8fc47fbef877"
      unitRef="usd">-22608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNS01LTEtMS0yNTU4MA_9fb15208-20f9-4d7e-8e11-409feec84b43"
      unitRef="usd">-9280000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNS03LTEtMS0yNTU4MA_d1055552-0618-46c6-a553-d32dc9a63a5c"
      unitRef="usd">-7388000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNi0xLTEtMS0yNTU4MA_1d1c87ee-d1f5-4e12-b8a2-5b6ead0b2445"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNi0zLTEtMS0yNTU4MA_9411a073-5f32-4554-b26d-bf2987ad5c49"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNi01LTEtMS0yNTU4MA_bbdcc0dc-6a1d-4971-a918-b6e3caad3c7e"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNi03LTEtMS0yNTU4MA_8f1a2721-57d4-4b15-9f8c-eaa58a21590d"
      unitRef="usd">147000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNy0xLTEtMS0yNTU4MA_48abda6a-f91e-4974-a85c-bb380ee9ac85"
      unitRef="usd">52000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNy0zLTEtMS0yNTU4MA_83c4976c-367e-47d0-93c3-83a095fcfbc5"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNy01LTEtMS0yNTU4MA_ea1089e8-d6ad-4d98-9f39-c20459281f08"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfNy03LTEtMS0yNTU4MA_c688cd9b-c752-4572-a30d-41aac849088c"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfOC0xLTEtMS0yNjAyMA_50b572ec-ab7d-4b5e-adb6-c8adb13f4936"
      unitRef="usd">71622000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfOC0zLTEtMS0yNjAyMA_2de1c770-f62e-4ef6-a85d-2f628607ef15"
      unitRef="usd">-22608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfOC01LTEtMS0yNjAyMA_a2f4e613-a2be-473c-8515-53dfaf707642"
      unitRef="usd">-9280000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfOC03LTEtMS0yNjAyMA_3ad098a9-74cb-4149-b3bf-f612ac60fce3"
      unitRef="usd">-7535000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTEtMS0xLTEtMjU1ODY_f5eb7ac4-9239-41c3-a0a9-9623646e6cdf"
      unitRef="shares">196778000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTEtMy0xLTEtMjU1ODY_61523968-dae8-4e1e-b98f-983ef033538b"
      unitRef="shares">117886000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTEtNS0xLTEtMjU1ODY_46d791d0-3ee7-448d-829d-93519627a9f7"
      unitRef="shares">176547000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTEtNy0xLTEtMjU1ODY_70158be9-2a36-4732-889e-dfb10ab9b66d"
      unitRef="shares">113437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTItMS0xLTEtMjYwMjA_0491aa71-54bc-4b66-9bec-f2b64c2840ba"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTItMy0xLTEtMjYwMjA_83142186-22ee-4fcb-a4dc-07ccfe713c47"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTItNS0xLTEtMjYwMjA_d690b649-b547-45ab-94b9-8802576ec7b5"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTItNy0xLTEtMjYwMjA_77f19f48-27e6-44b5-8fcc-1562367a81e2"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTYtMS0xLTEtMjU1OTE_28ec05a8-089a-40de-b321-eb1587af3d66"
      unitRef="usd">71674000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTYtMy0xLTEtMjU1OTE_d140548e-96b9-43cb-bfcc-76b3f452821e"
      unitRef="usd">-22608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTYtNS0xLTEtMjU1OTE_e80dcbff-66c7-475d-b405-e827d9b90771"
      unitRef="usd">-9280000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTYtNy0xLTEtMjU1OTE_980e528e-ca88-439f-abdd-ae19ecf55ea2"
      unitRef="usd">-7388000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTctMS0xLTEtMjU1OTE_1ac000c4-a5bb-468f-80bb-145313086f51"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTctMy0xLTEtMjU1OTE_0de94fb5-157d-454e-bf6b-fccf79a7a63b"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTctNS0xLTEtMjU1OTE_6e11f28a-de1e-4544-8779-9b9d609fbb9c"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTctNy0xLTEtMjU1OTE_eb5815bb-d833-48cc-9da8-8fb8c1ad9168"
      unitRef="usd">147000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTgtMS0xLTEtMjU1OTE_a57413fa-88af-446c-8b45-ac79d64526ae"
      unitRef="usd">51000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTgtMy0xLTEtMjU1OTE_9c60bb4e-cb83-4a62-a756-74bfef371894"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTgtNS0xLTEtMjU1OTE_cad5cc6c-2167-4239-9e28-062e2dbbd888"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTgtNy0xLTEtMjYwMjA_e119ba09-1316-4674-b2ce-4bcc08abdeec"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTktMS0xLTEtMjYwMjA_45c8ce52-a5b6-45d2-a22d-f0f0bfb0a329"
      unitRef="usd">71623000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTktMy0xLTEtMjYwMjA_bd083888-02c1-45e6-b900-c79eb823337d"
      unitRef="usd">-22608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTktNS0xLTEtMjYwMjA_72769564-f19c-43cf-bfb2-ffe6e385ddc9"
      unitRef="usd">-9280000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMTktNy0xLTEtMjYwMjA_95d5d59c-c08f-4aed-8ebb-ab9b136d8cd3"
      unitRef="usd">-7535000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjItMS0xLTEtMjU2MDI_48178140-134b-4351-b024-7a5aa8403c67"
      unitRef="shares">196778000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjItMy0xLTEtMjU2MDI_370bc635-e711-4dce-bf5d-f1b983b748b4"
      unitRef="shares">117886000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjItNS0xLTEtMjU2MDI_bd49ee3d-c84a-4259-8173-87fcbd235a75"
      unitRef="shares">176547000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjItNy0xLTEtMjU2MDI_05ef5c81-1e7f-44b7-a1bb-e4f01b6a8a44"
      unitRef="shares">113437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjUtMS0xLTEtMjU3NjA_1d42b603-ba84-4e9d-bd80-8609af65c245"
      unitRef="shares">4239000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjUtMy0xLTEtMjU3NjA_76f92937-76e2-42c2-b684-b546068821c6"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjUtNS0xLTEtMjU3NjA_acbfad74-bd76-4d39-b8d4-ae82ef4f0710"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjUtNy0xLTEtMjU3NjA_cbfb22de-950f-4789-8a57-45d692e2abb8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjYtMS0xLTEtMjYwMjA_391a675f-c148-446a-b8d6-c19f37b24f25"
      unitRef="shares">201017000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjYtMy0xLTEtMjYwMjA_46262594-4aad-44bf-abfe-022b5a90846d"
      unitRef="shares">117886000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjYtNS0xLTEtMjYwMjA_931d1137-120a-4253-826e-bfdc68e75a8c"
      unitRef="shares">176547000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjYtNy0xLTEtMjYwMjA_11ea2f15-6a73-437c-9dc8-1fd4e8f53563"
      unitRef="shares">113437000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjctMS0xLTEtMjYwMjA_a33f4001-1930-4af7-b501-a747c211a654"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjctMy0xLTEtMjYwMjA_b204da15-7d4b-4f43-a18b-df9561472bd3"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjctNS0xLTEtMjYwMjA_c3583037-be32-4f39-bebe-64df042d8cde"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOjZiNjdhNTI5MTM5YTRjNTQ4MWE4MTA0ZjdkMzg0MDRiL3RhYmxlcmFuZ2U6NmI2N2E1MjkxMzlhNGM1NDgxYTgxMDRmN2QzODQwNGJfMjctNy0xLTEtMjYwMjA_d0d9d805-ee30-4278-bf39-3dacb989b069"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RleHRyZWdpb246NzBhNzkwM2E2ODVhNGM4NTk3ZjA5NmVjMDFiZDgzZmJfMjg0Mw_617baf07-fd44-49a5-b4b7-ecda497c95a7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of September&#160;30, 2021 and 2020 have been excluded from the denominator of the diluted income (loss) per share of common stock outstanding calculation as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months ended&lt;br/&gt;&#160;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia92cad4084294782890738c13756e328_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMi0xLTEtMS05MDEy_d77f9ece-dc21-4adc-8c80-b20d1c50b9d7"
      unitRef="shares">55000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib500bf44eae5476d9fdf2b96b6e0d1d7_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMi0zLTEtMS05MDEy_205ac309-3248-4855-a80f-58662a9ef91e"
      unitRef="shares">2485000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i87670fceac7f42239018c3f8b55269ad_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMi01LTEtMS05MDEy_95dd5bbc-b942-41ef-a5fb-f9f1cde0cda0"
      unitRef="shares">199000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i23062afacb1848248023392b8378bd19_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMi03LTEtMS05MDEy_194d9312-bd54-4ae4-bcf1-206e94ed85df"
      unitRef="shares">2485000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i079b1e485a6a4b42a083e958ffce61c2_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMy0xLTEtMS05MDEy_39515396-b843-497e-b632-39b384d45f6d"
      unitRef="shares">11273000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7c43cdc3ac654396a4484ffac139d4b2_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMy0zLTEtMS05MDEy_a46f9128-e8fc-412d-862d-cfaae09c39ec"
      unitRef="shares">10227000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9fb6380fa09c4290abc4c61a23509a0c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMy01LTEtMS05MDEy_1b51aa5c-58f0-49e6-a18b-a79531299782"
      unitRef="shares">15511000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i23f2a7e233df4d15a0180432313c57a9_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfMy03LTEtMS05MDEy_2cb76f46-221c-4050-898d-cfae441de306"
      unitRef="shares">10227000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfNC0xLTEtMS05MDEy_c700f073-c46d-4373-ba48-fb22903707bd"
      unitRef="shares">11328000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfNC0zLTEtMS05MDEy_4bd413ac-e39a-4390-a56c-bfc2cddc7d1e"
      unitRef="shares">12712000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfNC01LTEtMS05MDEy_31afb673-d5f3-409c-9729-b7eac4779681"
      unitRef="shares">15710000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182MS9mcmFnOjcwYTc5MDNhNjg1YTRjODU5N2YwOTZlYzAxYmQ4M2ZiL3RhYmxlOmU3ZmY5ZTQ0YWNkZjRlOTNhMGI0ZjViMGRkNWU1NzJhL3RhYmxlcmFuZ2U6ZTdmZjllNDRhY2RmNGU5M2EwYjRmNWIwZGQ1ZTU3MmFfNC03LTEtMS05MDEy_15d30504-18d3-491a-8f65-72cf64c417f5"
      unitRef="shares">12712000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDgxNg_d7e7d33b-8b88-4752-af33-8de33f44f54f">SHARE-BASED COMPENSATION&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its condensed consolidated statements of income (operations) and comprehensive income (loss) for the three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months ended&lt;br/&gt;&#160;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Stock Incentive Plan, as amended ("2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#x201c;evergreen&#x201d; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#x2019;s stockholders in May 2021, the Company&#x2019;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 12.0&#160;million shares of common stock available for issuance under the 2014 Plan as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 12.7 million stock options outstanding under the 2014 Plan as of September&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#x201c;Retention Program&#x201d;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#x201c;RSU&#x201d;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#x201c;PSU&#x201d;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2009 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 2009 Stock Incentive Plan, as amended and restated ("2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-of-Plan Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;here were approximately 2.6 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average Exercise Price per Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average Remaining Contractual Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense related to stock options of $1.2 million and $3.4&#160;million for the three and nine months ended September 30, 2021, respectively and $0.5 million and $1.4&#160;million for the&lt;/span&gt;&lt;span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and nine months ended September 30, 2020, respectively. As of September&#160;30, 2021, there was $11.5 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 2.83 years. The weighted-average grant-date fair value of stock options granted was $2.20 per option for the nine months ended September 30, 2021 and $0.56 per option for the nine months ended September 30, 2020. The total intrinsic value of stock options exercised during the nine months ended September 30, 2021 was de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDgxOA_10c7b3b2-6467-4c64-9132-d62aa68129b1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its condensed consolidated statements of income (operations) and comprehensive income (loss) for the three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months ended&lt;br/&gt;&#160;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7ed6768ea3b4560b2c82d895f9ea130_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMi0xLTEtMS05MDEy_5a434e1c-28ab-471e-a003-73e7b7c5fe4c"
      unitRef="usd">152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e8e8e954db04e80ad3a16adadbfc86f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMi0zLTEtMS05MDEy_19fdb9b1-351a-4db8-9321-82cce3e7f4ef"
      unitRef="usd">95000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic81f556c7f3c49bd8d272a05a36ddb60_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMi01LTEtMS05MDEy_404e2d05-0a0c-43cb-888e-15bd516d3a59"
      unitRef="usd">536000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d48ee562070454db26870e4c0814801_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMi03LTEtMS05MDEy_d4497392-97c7-4751-99bd-eb8877923e94"
      unitRef="usd">266000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba8f1e5ffe2b4317a81ef1b3efe55cdb_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMy0xLTEtMS05MDEy_161ab03f-0999-45da-b1a2-48f0455cd43e"
      unitRef="usd">1016000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98c2750e9d614718ab26e1de3cd36e4b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMy0zLTEtMS05MDEy_d32dc1c9-1e20-457a-a6dc-758a80345f55"
      unitRef="usd">358000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac03a2fc4741476e8ed3f485593ae492_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMy01LTEtMS05MDEy_abd5d39a-00cc-47a0-8b46-2b24da89d00e"
      unitRef="usd">2849000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12438f69900b46c898f17d03af72571f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfMy03LTEtMS05MDEy_3e15d7c1-91e5-4391-b157-2f354e729865"
      unitRef="usd">1085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfNC0xLTEtMS05MDEy_d0f38a63-f571-4ff1-aa98-9b3a09f12780"
      unitRef="usd">1168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfNC0zLTEtMS05MDEy_9f4af30e-6a5e-4348-96c2-f97a015bc50b"
      unitRef="usd">453000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfNC01LTEtMS05MDEy_5d3546db-3bb7-4b22-8bee-6de1f66a20ce"
      unitRef="usd">3385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk1NGYxMmU1NGIzZjQxMjRhZmU1NjBhNWFmNWQyYWQ0L3RhYmxlcmFuZ2U6OTU0ZjEyZTU0YjNmNDEyNGFmZTU2MGE1YWY1ZDJhZDRfNC03LTEtMS05MDEy_91688025-841e-4cf3-9dcf-2a13385afa86"
      unitRef="usd">1351000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="i99f44079082f4029859d1879bcb92442_D20190601-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTU4Mw_e61dcd1c-cdb0-44a1-9c36-ba9e39b76af2"
      unitRef="shares">7900000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="ib66fca9e5de8456b900bc5c4eff17509_D20210501-20210531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMjA1Mg_3e39e358-6c80-4e63-a7d5-f53ffe882c03"
      unitRef="shares">12000000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if6ccec642f85408396200523b237087c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMjE2MA_4b58f7c4-24f6-434e-93e4-1f15d2bb7d6a"
      unitRef="shares">12000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3a6396e7d05347c98d3c1b2c891d6ee3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDM5ODA0NjU1MDU5Ng_8f1ba1d8-2273-4c8a-9bef-dcff562bf580">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i3c4abb48a5d14a81b4f1e923deb97260_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NDU2MQ_c6b8e37e-87a0-4e03-8884-e0212e06b8c7"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ide409042192a4d70ab470516112033d4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NzI1OA_4ed6d963-7808-4c5c-b1a0-0e730c02cdb1"
      unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3a6396e7d05347c98d3c1b2c891d6ee3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NDYyMg_2991dba5-06f2-4213-ba99-930345db1d59">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if6ccec642f85408396200523b237087c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NDU4Nw_710284d9-a301-4e06-88aa-3bb07176c222"
      unitRef="shares">12700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i2c7f2bf3ddf5406f8bc9acdceac07628_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMzE2OA_5d85fe3e-4aee-468c-9aa7-44b292d69976">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i2c7f2bf3ddf5406f8bc9acdceac07628_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMzIyMA_7f9b31d3-8a53-480a-af15-b94f3ebe4842"
      unitRef="shares">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4063b8153be44ce181d918f92b6ef50e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMzcyNw_f973dbf7-c9aa-4e21-a8c9-4b04886fe46a"
      unitRef="shares">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDgyMw_1ab7dcf4-5ac8-49d5-8b5f-daa0c271847c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average Exercise Price per Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average Remaining Contractual Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMS0xLTEtMS05MDEy_628fba90-f178-4d5f-9b5e-68700b1f258f"
      unitRef="shares">10147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMS0zLTEtMS05MDEy_3a199556-d015-494b-ac2e-381db5e122c6"
      unitRef="usdPerShare">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id8d3a64a89d7413aa462e07545736067_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMS01LTEtMS05MDEy_120e68c6-8905-4466-8b21-f8e68a6a2f24">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMS03LTEtMS05MDEy_eb614063-6d2e-4405-a9a5-66205f77777f"
      unitRef="usd">3160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMi0xLTEtMS05MDEy_bf4c2a4e-526d-45ec-b0bd-a6c318db7240"
      unitRef="shares">8026000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMi0zLTEtMS05MDEy_e63bdd43-ffb3-40e9-ad97-f1dde22a22a5"
      unitRef="usdPerShare">3.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMy0xLTEtMS05MDEy_c4ae705a-c31d-448d-af31-de2703948c90"
      unitRef="shares">34000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfMy0zLTEtMS05MDEy_b0def66e-2b7c-4f5d-897b-7c35908bc351"
      unitRef="usdPerShare">1.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNC0xLTEtMS05MDEy_25fecbd7-be45-4ec7-a7f1-f81cbd8de554"
      unitRef="shares">2628000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNC0zLTEtMS05MDEy_7a583e50-faae-4a78-93a1-7a11e4378456"
      unitRef="usdPerShare">3.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNS0xLTEtMS05MDEy_76c8eef8-4bf9-427b-a002-ae08fd6f7ebe"
      unitRef="shares">15511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNS0zLTEtMS05MDEy_db073b9d-52aa-4aaa-a9e8-ef62b56b9206"
      unitRef="usdPerShare">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNS01LTEtMS05MDEy_a68cd6e0-c9de-4962-9420-ab6221a3cfc2">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNS03LTEtMS05MDEy_ad71ae70-4a80-4cab-b73d-dc8d159af003"
      unitRef="usd">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNi0xLTEtMS05MDEy_90739fa7-2178-4eaa-8513-43a4dd80f383"
      unitRef="shares">6706000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNi0zLTEtMS05MDEy_c2f820bc-66e5-4ddd-ad01-e1ac17f1ae11"
      unitRef="usdPerShare">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNi01LTEtMS05MDEy_d4bca69a-450b-4a1b-b5d7-0e5b9c0c0a75">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOjk4OGIyMjRlNzk4ZDRkM2M4ODc5MGRhNmQwOTI2NzA4L3RhYmxlcmFuZ2U6OTg4YjIyNGU3OThkNGQzYzg4NzkwZGE2ZDA5MjY3MDhfNi03LTEtMS05MDEy_5ae2b426-3a4b-4f60-b509-759bd5722f3c"
      unitRef="usd">49000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDE2Nw_ad2d6fd3-943c-4a6e-a8fb-0ba817ae4a14"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDE3NA_1fadff09-a28c-4ac1-b7d1-e81486f386e4"
      unitRef="usd">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba80f4ec43df4c62bd79b9a57a9ef51f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDIwNg_6cadb380-87b2-4eb3-95a1-fe4f5d21ec94"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDIxMw_8dddc798-3660-4eae-ae53-c6bc4d8242bb"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDI2Mg_b4089faa-75ab-4ef3-8307-ccb88a495cd8"
      unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDQxNA_a1207ade-e482-4e0f-a1a0-4c452487087f">P2Y9M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDQ5Ng_2682ad9c-f7f6-4b7a-8234-782708896bc5"
      unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfMTA5OTUxMTY2NzI2Mg_2950f479-ebc3-4acf-b03b-a00f8d0ec22f"
      unitRef="usdPerShare">0.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RleHRyZWdpb246Mjg5ZGJkYTJkZGYxNDY4MzkyYmQ0ZGU0MjA0NjQzZmZfNDgxOQ_52f54050-127a-4094-a117-07361fcca52e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMS0xLTEtMS05MDEy_df187fb6-1400-452f-82e4-85da4dc9e479"
      unitRef="usdPerShare">3.40</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMS0yLTEtMS05MDEy_c0487f3d-ed53-42b1-aa15-14c6f249cc92"
      unitRef="usdPerShare">0.87</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMi0xLTEtMS05MDEy_d89fce2d-fde3-49b7-a2bf-ab11d599d321"
      unitRef="usdPerShare">3.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMi0yLTEtMS05MDEy_09ede7c3-c1c0-4a81-90c8-5afc313ddd58"
      unitRef="usdPerShare">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMy0xLTEtMS05MDEy_0e86cb95-8643-4f36-85b4-fad41d7e0227">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfMy0yLTEtMS05MDEy_863c2eb9-ac9e-4693-9fc4-78abc3b55c34">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNC0xLTEtMS05MDEy_ffea81f8-b161-4123-b019-3c9151c8cad2"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNC0yLTEtMS05MDEy_8ae47c6d-0b4d-4926-9bd6-6df7104e982f"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNS0xLTEtMS05MDEy_b862b9d3-3a8c-43d3-bba3-d17fa3d597c6"
      unitRef="number">0.746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNS0yLTEtMS05MDEy_5f516acb-f925-4386-bce3-44ccba74f959"
      unitRef="number">0.715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNi0xLTEtMS05MDEy_10984c1f-0f0a-47a6-9fec-471cc077fa08"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182NC9mcmFnOjI4OWRiZGEyZGRmMTQ2ODM5MmJkNGRlNDIwNDY0M2ZmL3RhYmxlOmNlMjkzYzAyYmMwMzRiODliMDI3YTE3YWE0NjZkNjFlL3RhYmxlcmFuZ2U6Y2UyOTNjMDJiYzAzNGI4OWIwMjdhMTdhYTQ2NmQ2MWVfNi0yLTEtMS05MDEy_02b9df70-9975-4b40-b3e0-b064f7bc4352"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMjQ0MA_cb730b22-dd48-4f8f-bd78-40556fa7cd24">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2 million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of September&#160;30, 2021, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States - 401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 401(k) defined contribution retirement plan which covers all of its U.S. employees. Employees are eligible to participate immediately upon their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum $4,000 per year. The expenses incurred for the periods presented were de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canada - Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8ac93b032a464cdd8545afbe5796bd81_I20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMzg2_eecaa350-e088-468e-a171-b39246dc3b6d"
      unitRef="shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i4cb66b6b5cfd47af8f6c6a3efea03f81_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfNjE2_93090480-c7e3-424b-aab3-5b52d81a7a18"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i3fffc682fabb44acb6f7a3985fe6f99d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfOTYz_82c68667-70ce-4c22-a09a-5d1ece01ce15"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4100955bccbe4c1ca4b78e3cf52bfe56_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMTM3Ng_9e63cd70-bda6-4f38-a8c2-5e802d2143ed"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMTc0Ng_f02a0a07-8916-4ef8-8919-f7169d3966a2"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMTk0Mg_55e7038a-c5b5-4119-99be-179fcea3947a"
      unitRef="usd">4000</sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN182Ny9mcmFnOmRhYWI3YjFkODNlNjQwOGQ4MGRiYWZmMWZmNDQ1OTZlL3RleHRyZWdpb246ZGFhYjdiMWQ4M2U2NDA4ZDgwZGJhZmYxZmY0NDU5NmVfMjI5MQ_e066478d-444d-4d9f-b939-04419e8cf433"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl80Mzk4MDQ2NTE0NDYw_b724ef26-2f1b-4d42-9ae2-a5954733dead">INCOME TAXES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Loss before Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Tax Benefit (Provision):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Current Benefit (Provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred tax liability is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021, the Company recorded a benefit from income taxes of $8.3&#160;million.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2021, the Company determined that the fair value of the Vicineum United States rights was zero, which resulted in an impairment charge of $31.7&#160;million. In connection with this impairment charge, in the third quarter of 2021, the Company wrote-down the associated deferred tax liability by $8.6&#160;million as a benefit. Please refer to Note 6, "Intangible Assets and &lt;/span&gt;&lt;/div&gt;Goodwill," for further information regarding the impairment charge. For the nine months ended September 30, 2020, the Company recorded a provision for income taxes of $1.1&#160;million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the License Agreement with Qilu.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl80Mzk4MDQ2NTE1MTA1_260f0b37-25fb-4ca2-9111-609c5a45c3d4">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Loss before Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl8zLTEtMS0xLTI0NjQ5_953896b8-6e3d-4fb3-9b7e-a867b5cebc4d"
      unitRef="usd">-38864000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl8zLTMtMS0xLTI0NjQ5_a711bcbb-d8c4-4276-b5e3-4339c415fc53"
      unitRef="usd">-18838000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl80LTEtMS0xLTI0NjQ5_5349558d-65ee-4a76-8446-3fbc4b9d84e0"
      unitRef="usd">21311000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl80LTMtMS0xLTI0NjQ5_fac3d362-d2ea-46a0-8c7a-660e9071e5fd"
      unitRef="usd">12582000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl81LTEtMS0xLTI1NDI5_0bdc7881-7b7b-43b0-8d46-e7fdd6f260b9"
      unitRef="usd">-17553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6MzM4OGFmMDkwNzg4NDY0NWE2ZjU4M2ExMDc4NzY3YmYvdGFibGVyYW5nZTozMzg4YWYwOTA3ODg0NjQ1YTZmNTgzYTEwNzg3NjdiZl81LTMtMS0xLTI1NDI5_0c748119-c6ab-43c3-9b28-0c3ed2d5dc9f"
      unitRef="usd">-6256000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl80Mzk4MDQ2NTE1MTA4_0b87aa4c-defb-4310-b0d2-2bac9c470690">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Tax Benefit (Provision):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Current Benefit (Provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV8zLTEtMS0xLTI1MDU5_b2e2d84b-d568-4a9d-abdd-7b90f3692ad1"
      unitRef="usd">8559000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV8zLTMtMS0xLTI1MDU5_47299229-1f01-4bc7-99d8-4efe2e7da9fd"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV80LTEtMS0xLTI1MDU5_59af3eda-0666-4f12-9e1b-7ec0fd5c970e"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV80LTMtMS0xLTI1MDU5_90edf4b0-94b6-48fb-874d-d59472257354"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV81LTEtMS0xLTI1MDU5_8a298082-5c8d-4966-8bc6-64388ab0104d"
      unitRef="usd">-286000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV81LTMtMS0xLTI1MDU5_36d5de92-35e3-4e72-96a6-9f4020f2d518"
      unitRef="usd">-1132000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV82LTEtMS0xLTI1MDU5_d42248c9-e6ca-4de3-a38b-d51aeb53e2cf"
      unitRef="usd">8273000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6ZjI0ZDdlYWY5MmQxNDJkZGFlYzY0Y2Y5YTA3NTIzMzkvdGFibGVyYW5nZTpmMjRkN2VhZjkyZDE0MmRkYWVjNjRjZjlhMDc1MjMzOV82LTMtMS0xLTI1MDU5_0e7a81ba-0100-496c-9af6-6593703c847b"
      unitRef="usd">-1132000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl80Mzk4MDQ2NTE1MTA5_ed2794af-085f-4703-8e70-5632b219112b">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred tax liability is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <sesn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8zLTEtMS0xLTI0OTAy_55bb7240-13dd-486c-9a6b-cf3d1fd303e2"
      unitRef="usd">3969000</sesn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <sesn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8xMC0zLTEtMS0yNDgwOQ_3bd56da5-6687-4ec7-bf10-1fc2a90cc9cf"
      unitRef="usd">12528000</sesn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8zLTEtMS0xLTI1NDQy_e1dc4790-b402-41a2-944d-66ef1882f5e3"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8xMS0zLTEtMS0yNDgwOQ_fab3c77a-2855-4b67-b82b-dae5f1b45f76"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF80LTEtMS0xLTI1NDQy_43a9e9f9-a4ef-4348-8ab9-5f407a065506"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGFibGU6NjBkNGE3ZmQ0ZDk4NGY0ZTk5MTM2ZjVlOTFhNjY5NjgvdGFibGVyYW5nZTo2MGQ0YTdmZDRkOTg0ZjRlOTkxMzZmNWU5MWE2Njk2OF8xMi0zLTEtMS0yNDgwOQ_24f9d774-c522-4a80-ac7d-16b5a73f8031"
      unitRef="usd">12528000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl8xNjQ5MjY3NDQ2OTQ2_43bc89a7-1857-41e2-a501-e9d2b36a329a"
      unitRef="usd">8300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl8xNjQ5MjY3NDQ3MDQ2_6fd529e8-d144-4c78-aca9-17023216b167"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <sesn:DeferredTaxLiabilityImpairmentWriteDown
      contextRef="i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl8xNjQ5MjY3NDQ3MDMy_6dd8e36a-78ef-4643-b8e3-48a821496c6c"
      unitRef="usd">8600000</sesn:DeferredTaxLiabilityImpairmentWriteDown>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i94658670cd664227afb5198f212af78d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTM3L2ZyYWc6M2Q2M2Q2Mzg1MDY5NGNkZWEyZjVlNThjMTFjMmY4MDYvdGV4dHJlZ2lvbjozZDYzZDYzODUwNjk0Y2RlYTJmNWU1OGMxMWMyZjgwNl8xNjQ5MjY3NDQ2OTU0_15216db2-eaf0-40d4-af49-7bea1aa7255e"
      unitRef="usd">-1100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <sesn:LicenseAgreementTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTgzNjY_69acee52-4ce8-49a0-815f-dbdadbcf047e">LICENSE AGREEMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Zurich&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has a License Agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same. These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $0.5&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million related to achievement of a development milestone, (the submission of the Company&#x2019;s BLA with the FDA in December 2020), in the three months ended December 31, 2020 and a regulatory milestone, (the Company&#x2019;s receipt of the CRL from the FDA in August 2021), in the three months ended September&#160;30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Micromet&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents cover some key aspects of Vicineum. Under the terms of the License Agreement with Micromet, as of September&#160;30, 2021, the Company may be obligated to pay up to &#x20ac;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.8&#160;million at exchange rates in effect on September 30, 2021). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#x20ac;50,000 (approximately $57,965 at exchange rates in effect as of September 30, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of  &#x20ac;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ecember 2020. The Company recorded an expense of &#x20ac;0.5&#160;million (approximately $0.6&#160;million) related to the submission of the Marketing Authorization Application ("MAA") to the European Medicines Agency (&#x201c;EMA&#x201d;) for Vysyneum&#x2122; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with XOMA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a License Agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. Under the terms of the License Agreement with XOMA, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#x2019;s clinical development pathway. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#x2019;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Roche License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into the License Agreement with F. Hoffmann-LA Roche Ltd and Hoffman-La Roche Inc. (collectively, "Roche"), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#x2019;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal&#160;antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the License Agreement with Roche, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#x201c;Roche Licensed Product&#x201d;) and pursue ongoing patent prosecution, at its cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received from Roche an upfront license fee of $7.5 million in August 2016 upon the effectiveness of the License Agreement with Roche following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5 million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5 million in development milestones, the next of which is $20.0&#160;million for initiation of the first Phase II study, (ii) $50 million in regulatory milestones and (iii) $75 million in commercialization milestones. In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. Additional amounts of up to $65 million are payable upon the achievement of specified development and regulatory milestones in a second indication. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Buy-Out Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The License Agreement with Roche provides for two &#x201c;option periods&#x201d; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#x201c;Initiation&#x201d;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a  Roche Licensed Product in either the United States or in the E.U., in which case Roche is required to pay the Company, within 30 days after Roche&#x2019;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#x2019;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the E.U.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Either the Company or Roche may each terminate the License Agreement with Roche if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the License Agreement with Roche following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the License Agreement with Roche if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OUS Business Development Partnership Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qilu License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#x201c;Qilu&#x201d;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to develop, manufacture and commercialize&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Vicineum (the &#x201c;Licensed Product&#x201d;) for the treatment of NMIBC and other types of cancer (the &#x201c;Field&#x201d;) in China, Hong Kong, Macau and Taiwan ("Greater China&#x201d;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Licensed Product in the Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#x201d;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Licensed Products in Greater China. The royalties are payable on a Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Licensed Product in such region (collectively, the &#x201c;Royalty Terms&#x201d;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Licensed Product in a particular region or no data or regulatory exclusivity of a Licensed Product in a particular region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Licensed Product necessary for Qilu to develop and commercialize the Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Licensed Product has been obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The License Agreement with Qilu will expire on a Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the License Agreement with Qilu for the other party&#x2019;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the License Agreement with Qilu is terminated under certain circumstances.  The License Agreement with Qilu includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The License Agreement with Qilu is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606"), which was adopted effective January 1, 2018. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the License Agreement with Qilu represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million dollar milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company recorded the outstanding $2.8&#160;million to accounts receivables as of March 31, 2021 and received the payment as of June 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;MENA License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("the MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The Company also concluded that its agreements under &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered.  As of September&#160;30, 2021,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;EIP License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 5, 2021, we entered into an exclusive license agreement with Eczacibasi Pharmaceuticals Marketing (&#x201c;EIP&#x201d;) pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the licensing agreement, we are entitled to receive an upfront payment of $1.5&#160;million, are eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and are also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The EIP License Agreement is subject to the provisions of ASC 606 and as of September&#160;30, 2021, none of these amounts have been received by the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No initial transaction price was estimated by management as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September&#160;30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; as the upfront payment is subject to a refund if certain regulatory approvals in the US are not obtained. The Company also concluded that its promises under this license agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September&#160;30, 2021,&lt;/span&gt; none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</sesn:LicenseAgreementTextBlock>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ibc91c1e2691446ca8ae6ebaf034e2270_D20210101-20210930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNTM2_bf467bf8-43f3-4390-89b0-d35c5b5ceb56"
      unitRef="usd">500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i6b253e391e304883b5148ddaac3a9fd8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODU4_a1624b8a-0a0e-48f7-87d6-3fa59cf51f75"
      unitRef="number">0.04</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="i6b253e391e304883b5148ddaac3a9fd8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTEyOQ_3db67aeb-04cf-41e3-9df7-9db6e0f60201"
      unitRef="number">0.10</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="i6b253e391e304883b5148ddaac3a9fd8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTIwNg_25331ca7-3838-459a-8689-58415a096ecd"
      unitRef="number">0.02</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i16e23dc0be574c6988f056e62ef032cd_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTU5OA_30d5bac9-010c-42a0-8524-4ba19d530f65"
      unitRef="usd">300000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i9b9fbfe5c81f499888ab93c21e589337_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTA5OTUxMTY0NjU3NQ_82a08939-7cb5-47fb-ab9f-5a0f7b4459e7"
      unitRef="usd">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMjIyMw_caf986e6-519e-4575-b8f5-115e0d447f89"
      unitRef="eur">2400000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMjM3MA_433274e9-c145-4dad-9f65-6839adf11534"
      unitRef="usd">2800000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMjYxNQ_604798b4-2f98-48be-bfba-a55bdbfc9e57"
      unitRef="number">0.035</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent
      contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMjc4NA_3977103f-792d-4529-a7b7-3b8f3cf5a238"
      unitRef="number">0.015</sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent>
    <sesn:LicenseMaintenanceFees
      contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzE3Nw_d56373ca-76e8-4753-8ab0-6a9b8492c426"
      unitRef="eur">50000</sesn:LicenseMaintenanceFees>
    <sesn:LicenseMaintenanceFees
      contextRef="i57c19b37fa334157888bbd6e15f8fd6d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzE5NQ_c1f8c839-8c90-4832-84d1-3eb77440948d"
      unitRef="usd">57965</sesn:LicenseMaintenanceFees>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="idd6eb0c1e7e34af989c1740d371026c8_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzM2NA_b55a4131-a61a-4899-a732-eaa6a07dff49"
      unitRef="eur">700000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="idd6eb0c1e7e34af989c1740d371026c8_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzM2OA_506b0981-ffae-4169-b51a-1e6a253a7f29"
      unitRef="usd">900000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="idf84269345dc45a9bd019d1e9ba53cbf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzU4OA_e0a39b8e-3a06-4ad4-a14a-a9667c7541c4"
      unitRef="eur">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="idf84269345dc45a9bd019d1e9ba53cbf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMzYwNg_43f69617-d745-4f7f-b698-a760705b4b62"
      unitRef="usd">600000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDIzMw_6f82d11a-9743-4bad-88e9-a0b22de82a6f"
      unitRef="usd">250000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDU2Mw_5ff7a0e6-20c6-4dd8-8416-7869bccb60b2"
      unitRef="number">0.025</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDg4MQ_6bd1c7bb-efde-4df1-9807-e7d1b7bdcaa1"
      unitRef="number">0.0175</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="i7db91ec35a34434abd7ab8cc49d8ba3a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDk1NA_3243ed0a-da3d-4d90-9876-feb4c95f515e"
      unitRef="number">0.50</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementUpfrontFee
      contextRef="ic42971e76e3e4c0d9a0e368891e0d42c_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjIxNg_9054da59-a266-4ba1-a4d2-e053e9c16469"
      unitRef="usd">7500000</sesn:LicenseAgreementUpfrontFee>
    <sesn:LicenseAgreementAdditionalUpFrontFee
      contextRef="ic42971e76e3e4c0d9a0e368891e0d42c_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjM4Nw_cb402c49-aa8e-45db-baae-572a0845fb00"
      unitRef="usd">262500000</sesn:LicenseAgreementAdditionalUpFrontFee>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="id1d3fa03486b42c3b433ce8bdf6e4808_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjU3Mw_de03c635-8b3e-4917-b9f6-b5b9cfaa76c0"
      unitRef="usd">197500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="id3ed448b11a8424c96a6b8d0eb2a1783_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjcwMg_af4e5ac5-beb1-451c-8f02-e919a282a702"
      unitRef="usd">72500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i30b08122198e489bbce9b4354ecc6c61_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjc1Mw_db250387-eb77-45e6-8249-f13cee6194c2"
      unitRef="usd">20000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i0fb8cc9e9e234566a44813522f65ed55_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjgwNQ_9c6c3118-a94b-4499-ab10-384ed2249c9f"
      unitRef="usd">50000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ie0859c061dad4634bd9bf31be447575b_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjg0Mw_ab6eaaa2-259c-449b-955f-eb7beec405d4"
      unitRef="usd">75000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ibc6ff2c6504a4ed1b6cfa6a5cbdb6eb9_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNjk1Ng_bbe35f89-b9e1-4059-a318-7d5853967d9a"
      unitRef="usd">22500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i15b167efec9143cf989e99b7088a541a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzEwNw_134653e4-e9ae-46cd-9340-696088be02b3"
      unitRef="usd">65000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i045d66e15494473e88b935c50abb8750_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzM1Ng_4739cd77-6a82-45ab-92be-66bcc4703781"
      unitRef="number">0.075</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i63e6b449973d4c2792e479ee587c6018_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzM2Mg_cbfdafbd-bc22-4b21-ac18-605817fb9ccc"
      unitRef="number">0.15</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="ia7693b351b0846618d4fcdce51f3fe9e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzQzNg_7b00978d-783d-420a-a0b7-904758faeee4"
      unitRef="number">0.50</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementOptionPeriods
      contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNzcwNQ_bbe3288c-70d8-404d-9fba-f753203ca87e"
      unitRef="option">2</sesn:LicenseAgreementOptionPeriods>
    <sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod
      contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODE5OA_3c572e6c-c887-4313-bf7c-9e902d468136"
      unitRef="usd">135000000</sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODIwOA_47f520dd-784e-4d51-b5ae-32e8c47f7dc2">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODcxMg_13fd7a3b-ce8a-4906-bb4e-af6130895231">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod
      contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODgwNQ_48c5c88d-b2e0-4874-bb52-56d2c9bd1182"
      unitRef="usd">265000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct
      contextRef="i4795cc728a1144a0804eeca13972e3a5_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfODg0Mg_0c846f2a-b5b9-43ce-908b-32efa3eb8ae1"
      unitRef="usd">220000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id7df092ca1e64946a1a0ac3ea4c32c84_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTExMTI_89858895-07f0-411d-a1f1-a40d81230a63"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount
      contextRef="id7df092ca1e64946a1a0ac3ea4c32c84_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTExNTQ_979d846d-2dcc-421d-ab2a-10a0ebd53f1b"
      unitRef="usd">23000000</sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount>
    <sesn:BusinessCombinationRoyaltyPaymentPercent
      contextRef="id7df092ca1e64946a1a0ac3ea4c32c84_D20200730-20200730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTE0NTc_3ee0e869-2892-4a20-a457-7977546b89d6"
      unitRef="number">0.12</sesn:BusinessCombinationRoyaltyPaymentPercent>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ0NTY_b4a1e2a1-202d-4ca5-bfb0-00f1ee5eebc9"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ife38f0f87de845fe90d0a4d078d250cd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ1MTI_92dbdb8b-4877-4341-8dfb-226a79c76819"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ3MzA_25ef3b34-4ba9-46fa-aa7b-0cd59f12d309"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i566ffe1fbdb6406dbcda243abb86908b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ3NDY_80165365-a409-4b08-bf3f-6f2f30b6975e"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3fe2301ff7fd49808ebec14107299e1c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTQ4MTQ_fa49730e-1ff5-4af5-b70f-658754151291"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:BusinessCombinationMilestonePayments
      contextRef="i610ca7a4385742b085d50632419fb7f8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTUwODc_82ffc158-d507-43d9-8926-49de1da79947"
      unitRef="usd">3000000</sesn:BusinessCombinationMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i610ca7a4385742b085d50632419fb7f8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTUxNjU_b63d8070-66a9-49c5-bd1e-19a9099c7b3b"
      unitRef="usd">23000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i610ca7a4385742b085d50632419fb7f8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTUyMjI_db47d39f-ec44-4e50-b5df-37b3e76f05a2"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:LicenseAgreementAccountsReceivable
      contextRef="ib78e2ef0bd77468a99078bdc44ca15ac_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTUzNDY_e9d2a27b-89e0-40f9-95a3-56e40e33b772"
      unitRef="usd">2800000</sesn:LicenseAgreementAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibc185febf435474dabf49a740bcc7f59_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTU3MjE_b6dfeec6-d3c1-46a9-950b-d3a1632c489f"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7e4a691bd7f24cc8a757bf6eb9a87a8e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTY2NDc_ceafb377-28ef-4720-856b-13efc0a9f3ee"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4a6554c571ca414ea564532ae47c5f15_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTcwODQ_665fb962-3856-4f6f-82ae-bc7927fc888b"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i4a6554c571ca414ea564532ae47c5f15_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTcxMjg_caa50bb3-a7bf-46d9-a1bd-79daee52df0a"
      unitRef="number">0.50</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7e4a691bd7f24cc8a757bf6eb9a87a8e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfMTc3ODQ_a5e7464c-8ee0-4d23-8229-2fc66d92c5fe"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia96662f1953a42bc873ffe3a7870d8b6_I20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDM5ODA0NjUzMTUxMg_0615a3c8-1f39-48c0-9c62-03e281b41e5b"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i136787f1fdff4cf289282d421587f27f_D20210805-20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDM5ODA0NjUzNjA2Mw_18f47ebe-a294-40ba-a019-bec350fd8263"
      unitRef="usd">2000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i23457221904940608ad590d221ec55f2_I20210805"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183MC9mcmFnOjQwN2FlYzVhOWYyYjRjY2NiNTI1MGFkMzk4OTkwNDVjL3RleHRyZWdpb246NDA3YWVjNWE5ZjJiNGNjY2I1MjUwYWQzOTg5OTA0NWNfNDM5ODA0NjUzMTUyNg_a68a7b18-245e-48cb-a463-823d7825e6b6"
      unitRef="number">0.30</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGV4dHJlZ2lvbjpjNzYwZTYwMjg2YTM0MGYzYWJlZTcyZjRjZjdhYjdmY180Mzk4MDQ2NTEzNTg0_541e6947-f291-40c0-90a2-b9f5d330875b">RESTRUCTURING AND RELATED ACTIVITIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#x201c;Restructuring Plan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Restructuring Plan included a reduction in the Company&#x2019;s workforce by 18 positions (or approximately 35% of the Company&#x2019;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the Restructuring Plan:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.130%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and benefits costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,730&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company&#x2019;s Condensed Consolidated Statements of Income (Operations) and Comprehensive Income (Loss) in the three months ended September 30, 2021. The Company expects that substantially all of the accrued restructuring costs as of September 30, 2021 will be paid in cash by the end&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; of September 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="i3294967843ca408b88c9279ce575d789_D20210830-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGV4dHJlZ2lvbjpjNzYwZTYwMjg2YTM0MGYzYWJlZTcyZjRjZjdhYjdmY180Mzk4MDQ2NTEzODMz_19382e21-99a2-4eaa-88fa-a12a6b403cf3"
      unitRef="position">18</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i3294967843ca408b88c9279ce575d789_D20210830-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGV4dHJlZ2lvbjpjNzYwZTYwMjg2YTM0MGYzYWJlZTcyZjRjZjdhYjdmY180Mzk4MDQ2NTEzODM3_cc2370aa-0def-4fea-9d70-a250a7d2cf13"
      unitRef="number">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGV4dHJlZ2lvbjpjNzYwZTYwMjg2YTM0MGYzYWJlZTcyZjRjZjdhYjdmY180Mzk4MDQ2NTEzNTg1_6543dccb-046b-4f23-b802-0d9b0b8f3fa6">The following is a summary of accrued restructuring costs related to the Restructuring Plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.130%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and benefits costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,730&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ie0910e0e2e544c658b3c5f01387c4bf7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml8yLTEtMS0xLTIwMDM3_0a13cd4e-ddf0-431d-8a00-6cb21f1af522"
      unitRef="usd">2792000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i31980ac255374540a2c360974effe9e9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml8zLTEtMS0xLTIwMDM3_886e7c16-3a80-41f7-bcb7-7ab53db61109"
      unitRef="usd">2730000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7eb45047e6e3464eb0f8a32d0685227a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml80LTEtMS0xLTIwMDM3_b839e3f4-835b-4e3d-8e0f-e0d3688cb542"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml81LTEtMS0xLTIwMDM3_7b162756-1a59-486d-8f90-82b69e2904ab"
      unitRef="usd">5522000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml82LTEtMS0xLTIwMDQz_deb1cc10-1825-4d70-aeca-460c8b8dbc67"
      unitRef="usd">856000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i342f8c81e3cd4634b8691627803c791d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTE4L2ZyYWc6Yzc2MGU2MDI4NmEzNDBmM2FiZWU3MmY0Y2Y3YWI3ZmMvdGFibGU6ZGU3NGZhZjhmNzM5NDU2OGEwYTIxM2MyNWVlNzY0NjIvdGFibGVyYW5nZTpkZTc0ZmFmOGY3Mzk0NTY4YTBhMjEzYzI1ZWU3NjQ2Ml83LTEtMS0xLTIwMDQ3_bc7d9aff-ba52-45d8-bedd-9fc22594ec4a"
      unitRef="usd">4666000</us-gaap:RestructuringReserve>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN18xMTI0L2ZyYWc6NzBiNmEwNWYyMDVjNGFiMmJmNjJmODNiZTczMDZjYzQvdGV4dHJlZ2lvbjo3MGI2YTA1ZjIwNWM0YWIyYmY2MmY4M2JlNzMwNmNjNF80Mzk4MDQ2NTMzMzg3_a9f5ff65-fd04-4d2a-a083-bacf06b26c87">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#x2019;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 19, 2021, August 31, 2021 and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the U.S. District Court for the Southern District of New York.  The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#x2019; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH, and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dresaj collectively as the &#x201c;lead plaintiff&#x201d; under the Private Securities Litigation Reform Act.  On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff.  The court has not ruled on those motions at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#x2019;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#x2019;s board of directors and certain of its officers in the U.S. District Court for the District of Massachusetts, with the Company named as a nominal defendant. The two derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#x2019;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The two derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#x2019; fees. On October 18, 2021, the court consolidated the two cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538.&lt;/span&gt;&lt;/div&gt;The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183My9mcmFnOjAzMGU1Y2MxMWRlNDQzMWViNWNlNmQ4Nzg5NGJiZWJmL3RleHRyZWdpb246MDMwZTVjYzExZGU0NDMxZWI1Y2U2ZDg3ODk0YmJlYmZfMjEzMQ_d6c7c933-be07-4e8a-bfc3-18272d044267">SUBSEQUENT EVENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the Retention Program described in Note 11 above, and effective as of October 1, 2021, the Company&#x2019;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#x201c;RSU&#x201d;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock. Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#x201c;PSU&#x201d;) award equal to the value of approximately 50% of current base salary. Each PSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;October 29, 2021, the Company participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL. During the CMC Type A Meeting, the Company and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any potential future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. The Company is preparing for a separate Clinical Type A Meeting, which the Company expects to occur later this year.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i07777b364f564270bb6efdada23c4efe_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiNmI4YTgwNjk5ZjRlYmNhNjkxODdkZTIxYTRlNjE3L3NlYzowYjZiOGE4MDY5OWY0ZWJjYTY5MTg3ZGUyMWE0ZTYxN183My9mcmFnOjAzMGU1Y2MxMWRlNDQzMWViNWNlNmQ4Nzg5NGJiZWJmL3RleHRyZWdpb246MDMwZTVjYzExZGU0NDMxZWI1Y2U2ZDg3ODk0YmJlYmZfNDM5ODA0NjUyMzcxNA_fe183808-192f-4293-859e-518dcbf813c6"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072618392088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sesen Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">444-8550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SESN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072617901928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 175,236<span></span>
</td>
<td class="nump">$ 52,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,107<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">24,137<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">200,480<span></span>
</td>
<td class="nump">62,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">14,700<span></span>
</td>
<td class="nump">46,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,064<span></span>
</td>
<td class="nump">13,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">7,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">35,191<span></span>
</td>
<td class="nump">59,956<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">235,671<span></span>
</td>
<td class="nump">122,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,909<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,186<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,594<span></span>
</td>
<td class="nump">18,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="nump">56,600<span></span>
</td>
<td class="nump">99,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,969<span></span>
</td>
<td class="nump">12,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">62,069<span></span>
</td>
<td class="nump">114,001<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">74,663<span></span>
</td>
<td class="nump">132,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at September&#160;30, 2021 and December&#160;31, 2020; no shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 400,000,000 and 200,000,000 shares authorized at September&#160;30, 2021 and December&#160;31, 2020, respectively; 199,463,645 and 140,449,647 shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">486,010<span></span>
</td>
<td class="nump">306,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(325,201)<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">161,008<span></span>
</td>
<td class="num">(9,227)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 235,671<span></span>
</td>
<td class="nump">$ 122,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072541584200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072537685768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,236<span></span>
</td>
<td class="nump">$ 6,544<span></span>
</td>
<td class="nump">$ 11,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,967<span></span>
</td>
<td class="nump">10,196<span></span>
</td>
<td class="nump">18,273<span></span>
</td>
<td class="nump">23,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,699<span></span>
</td>
<td class="nump">4,115<span></span>
</td>
<td class="nump">20,797<span></span>
</td>
<td class="nump">10,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">5,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(114,000)<span></span>
</td>
<td class="nump">18,400<span></span>
</td>
<td class="num">(52,240)<span></span>
</td>
<td class="num">(16,820)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(63,112)<span></span>
</td>
<td class="nump">32,711<span></span>
</td>
<td class="nump">24,052<span></span>
</td>
<td class="nump">17,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from Operations</a></td>
<td class="nump">63,112<span></span>
</td>
<td class="num">(21,475)<span></span>
</td>
<td class="num">(17,508)<span></span>
</td>
<td class="num">(6,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income (Loss) Before Taxes</a></td>
<td class="nump">63,113<span></span>
</td>
<td class="num">(21,476)<span></span>
</td>
<td class="num">(17,553)<span></span>
</td>
<td class="num">(6,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">8,561<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
<td class="nump">8,273<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) and Comprehensive Income (Loss) After Taxes</a></td>
<td class="nump">71,674<span></span>
</td>
<td class="num">(22,608)<span></span>
</td>
<td class="num">(9,280)<span></span>
</td>
<td class="num">(7,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders - basic</a></td>
<td class="nump">71,622<span></span>
</td>
<td class="num">(22,608)<span></span>
</td>
<td class="num">(9,280)<span></span>
</td>
<td class="num">(7,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) attributable to common stockholders - diluted</a></td>
<td class="nump">$ 71,623<span></span>
</td>
<td class="num">$ (22,608)<span></span>
</td>
<td class="num">$ (9,280)<span></span>
</td>
<td class="num">$ (7,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) per common share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per common share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">196,778<span></span>
</td>
<td class="nump">117,886<span></span>
</td>
<td class="nump">176,547<span></span>
</td>
<td class="nump">113,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding for diluted (in shares)</a></td>
<td class="nump">201,017<span></span>
</td>
<td class="nump">117,886<span></span>
</td>
<td class="nump">176,547<span></span>
</td>
<td class="nump">113,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072618874392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,801,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (26,700)<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 266,717<span></span>
</td>
<td class="num">$ (293,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">41,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Sales of common stock under 2014 ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Sales of common stock under 2014 ESPP</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs</a></td>
<td class="nump">3,179<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,991,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">18,451<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">270,301<span></span>
</td>
<td class="num">(251,960)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">(26,700)<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">266,717<span></span>
</td>
<td class="num">(293,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(7,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,645,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="num">(16,553)<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">284,236<span></span>
</td>
<td class="num">(300,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,991,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">18,451<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">270,301<span></span>
</td>
<td class="num">(251,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(26,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,636,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs</a></td>
<td class="nump">4,774<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,627,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="num">(2,628)<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">275,560<span></span>
</td>
<td class="num">(278,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,627,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(22,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Sales of common stock under 2014 ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Sales of common stock under 2014 ESPP</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,991,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs</a></td>
<td class="nump">8,221<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">8,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,645,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="num">(16,553)<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">284,236<span></span>
</td>
<td class="num">(300,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,645,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(9,227)<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">306,554<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(55,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercises of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercises of common stock warrants</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,645,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs</a></td>
<td class="nump">72,543<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">72,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,978,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">9,270<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">380,531<span></span>
</td>
<td class="num">(371,433)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(9,227)<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">306,554<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (9,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercises of common stock warrants (in shares)</a></td>
<td class="nump">2,048,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 161,008<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">486,010<span></span>
</td>
<td class="num">(325,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,978,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">9,270<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">380,531<span></span>
</td>
<td class="num">(371,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(25,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,482,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs</a></td>
<td class="nump">64,261<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">64,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,460,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">49,349<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">446,036<span></span>
</td>
<td class="num">(396,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,460,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">71,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercises of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercises of common stock warrants</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,804,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under ATM offering, net of issuance costs</a></td>
<td class="nump">38,157<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">38,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 161,008<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 486,010<span></span>
</td>
<td class="num">$ (325,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Exercise Of Warrants, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072617917176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Issues, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072537961272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,280)<span></span>
</td>
<td class="num">$ (7,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,386<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(52,240)<span></span>
</td>
<td class="num">(16,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Intangibles impairment charge</a></td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable (net)</a></td>
<td class="num">(1,107)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(23,665)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">807<span></span>
</td>
<td class="num">(378)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(4,453)<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(56,278)<span></span>
</td>
<td class="num">(22,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</a></td>
<td class="nump">174,961<span></span>
</td>
<td class="nump">16,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of common stock warrants</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">176,129<span></span>
</td>
<td class="nump">16,184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">119,847<span></span>
</td>
<td class="num">(6,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of period</a></td>
<td class="nump">55,409<span></span>
</td>
<td class="nump">48,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end of period</a></td>
<td class="nump">175,256<span></span>
</td>
<td class="nump">41,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NoncashFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OtherDividendAndAdjustments', window );">Deemed Dividend on adjustment of exercise price on certain warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NoncashFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Financing Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NoncashFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OtherDividendAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Dividend And Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OtherDividendAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536760120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, VicineumTM, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus Calmette-Gu&#233;rin ("BCG")-unresponsive non-muscle invasive bladder cancer ("NMIBC"). The Company has an ongoing single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On July 13, 2021, the Company participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, the Company and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to chemistry, manufacturing and controls (&#8220;CMC&#8221;), and a timeline to submit additional supporting information was agreed upon. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On October 29, 2021, the Company participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL (the "CMC Type A Meeting"). During the CMC Type A Meeting, the Company and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any potential future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. The Company is preparing for a separate Type A Meeting to discuss the recommendations specific to additional clinical/statistical data and analyses that the FDA raised in the CRL (the &#8220;Clinical Type A Meeting&#8221;), which the Company expects to occur later this year. The Company operates in one segment under the direction of its Chief Executive Officer (chief operating decision maker). The Company was formerly known as Eleven Biotherapeutics, Inc. until its name changed in May 2018.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0&#160;million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, who served as a director of the Company until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5&#160;million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;) in the United States; (ii) a one-time milestone payment of $7&#160;million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3&#160;million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033 and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country (collectively, the "Contingent Consideration"). Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts for the first seven years following the closing of the Viventia Acquisition, to achieve marketing </span></div>authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors, however as of September&#160;30, 2021, none of these individuals are employees or members of the Company's board of directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072625908728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASUs&#8221;), promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on March 15, 2021, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; revenue recognition and going concern considerations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the U.S. dollar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536158360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072534660856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2021</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP </span></div>for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536763512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September&#160;30, 2021 and December&#160;31, 2020 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs.  The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:35.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:35.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of clinical and regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2024 to 2033, the level of commercial sales of Vicineum forecasted for the United States, Europe, Japan, China and other potential markets and discount rates ranging from 7.5% to 8.6%  as of September&#160;30, 2021 and 8.4% to 8.8% as of December 31, 2020. There have been no changes to the valuation methods utilized during the nine months ended September 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the nine months ended September 30, 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.643%"><tr><td style="width:1.0%"/><td style="width:78.187%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108,840</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - short term </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2%</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s estimated weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from 8.8% as of December 31, 2020 to 8.6% as of September&#160;30, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December 31, 2020 to  7.5% as of September&#160;30, 2021. The decrease in the fair value of contingent consideration of  $52.2 million for the nine months ended September 30, 2021 was driven by the receipt of the CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form. Due to the inherent uncertainty in the path forward for Vicineum at this time, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success (POS); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company anticipates needing to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA later this year to discuss questions related to clinical matters raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates as a result of these meetings, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536288328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILLIntangible Assets <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The fair value of the acquired intangible asset for the U.S. and E.U. rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, the Company&#8217;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss the clinical issues raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, an impairment analysis was conducted, which concluded that the carrying value of our intangible assets of Vicineum United States rights was fully impaired as of September 30, 2021. However, while similar delays in timelines and reduced probabilities of success also affected the carrying value of our intangible assets of Vicineum E.U. rights, this asset was not impaired as of September 30, 2021. The $31.7 million of impairment charges for the period ended September&#160;30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market as of September 30, 2021. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of our intangible assets of Vicineum E.U. rights, this asset was not impaired as of September 30, 2021. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the EU asset is burdened with significantly less expense than the US asset, as our strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with the Company earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div>Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $13.1 million as of September&#160;30, 2021 and December&#160;31, 2020. Given the inherent uncertainty at this time in the development plans for Vicineum as a result of the CRL, a quantitative impairment analysis was conducted during the quarter, in advance of the Company's typical annual assessment date of October 1. While an impairment was recognized in one of its intangible assets, Vicineum U.S. Rights, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of September 30, 2021, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately 45%. The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in our current development profile (ranging from 45% to 55% globally) also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of BCG-unresponsive NMIBC. The Company participated in a Type A Meeting with the FDA on October 29, 2021 to discuss questions related to CMC raised in the CRL, and expects to engage in a Type A meeting with the FDA in the fourth quarter of 2021 to discuss questions related to clinical matters raised in the CRL. Both meetings are intended to help the Company determine the appropriate path forward for Vicineum, and will assess the outcome of those meetings, and other information obtained, to determine if further impairment testing is required. Further reductions to probabilities of success, additional development and commercial launch delays, or increases in underlying discount rates have the potential to result in future goodwill impairment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536147048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022, with a right to extend the lease for one subsequent three year term. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,300 at exchange rates in effect on September 30, 2021). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,300 at exchange rates in effect on September 30, 2021). Operating lease cost under this lease, including the related operating costs, were $79,000 and $245,000 for the three and nine months ended September 30, 2021 and $75,000 and $223,000 for the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within other assets on the Company's condensed consolidated balance sheets. The short-term lease liability is recorded in other current liabilities and the long-term lease liability is recorded in other liabilities on the Company&#8217;s condensed consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every three months to six months and currently extend through June 2022 and November 2021, respectively. The minimum monthly rent for these office spaces is $2,100 and $18,000, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases. The Company recorded $63,000 and $201,000 in rent expense for the three and nine months ended September 30, 2021 and $64,000 and $195,000 for the three and nine months ended September 30, 2020, respectively. The Company's accounting policy election was disclosed in "Item 15. Exhibits and Financial Statement Schedules - Note. 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536177640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands): </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:59.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.065%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.066%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536606024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="text">STOCKHOLDERS' EQUITY (DEFICIT)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time for an aggregate sales price of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $35&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through Jefferies (the "ATM Offering"). In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively.  Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $50&#160;million and $34.5&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement.  Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. The Company may sell shares of its common stock efficiently from time to time, but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $38.2&#160;million of net proceeds from the sale of 9.8&#160;million shares of common stock at a weighted-average price of $4.01 per share during the three months ended September 30, 2021, compared to $8.2 million of net proceeds from the sale of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 million shares of common stock at a weighted-average price of $1.21 per share during the three months ended September 30, 2020. The Company raised $175.0&#160;million of net proceeds from the sale of 56.9&#160;million shares of common stock at a weighted-average price of $3.17 per share during the nine months ended September 30, 2021, compared to $16.2 million of net proceeds from the sale of 16.8 million shares of common stock at a weighted-average price of $0.99 per share during the nine months ended September 30, 2020. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $1.2&#160;million and $5.4&#160;million during the three and nine months ended September 30, 2021, respectively. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200 million to 400 million, of which 199 million and 140 million shares were issued and outstanding as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September&#160;30, 2021 and December&#160;31, 2020, respectively. In addition, the Company had reserved for issuance the following number of shares of common stock for the purposes described below as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,450&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,457</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and permanently classified as equity because they meet the derivative scope exception under ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 815-40")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's warrant activity for the nine months ended September 30, 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:8.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year-to-Date Warrant Activity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Expired)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,573)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,048)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification (ii) subject to further adjustment based on down round provision added by amendment described in "Item 15. Exhibits and Financial Statement Schedules - Note. 10 Stockholders' (Deficit) Equity" in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072647380808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted.  Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income.  During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Company applied the two-class method to calculate basic and diluted net earnings per share of common stock for the three months ended September 30, 2021. The two-class method was not applied for the nine months ended September 30, 2021 and for the three and nine months ended September 30, 2020 as the Company&#8217;s participating securities do not have any obligation to absorb net losses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the determination of earnings (loss) per share for each period presented:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic Earnings (Loss) Per Share:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Deemed Dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income attributable to participating securities - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders - basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,608)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,535)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,886</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,547</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,437</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share applicable to common stockholders - basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dilutive Earnings (Loss) Per Share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Deemed Dividend</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income attributable to participating securities - diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)  attributable to common stockholders - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,535)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive impact from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding <br/>- diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,017&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share applicable to common stockholders - diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of September&#160;30, 2021 and 2020 have been excluded from the denominator of the diluted income (loss) per share of common stock outstanding calculation as their effect is anti-dilutive.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,710</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536606024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its condensed consolidated statements of income (operations) and comprehensive income (loss) for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended ("2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 12.0&#160;million shares of common stock available for issuance under the 2014 Plan as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 12.7 million stock options outstanding under the 2014 Plan as of September&#160;30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated ("2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately 2.6 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of September&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the nine months ended September 30, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Exercise Price per Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Remaining Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,628)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense related to stock options of $1.2 million and $3.4&#160;million for the three and nine months ended September 30, 2021, respectively and $0.5 million and $1.4&#160;million for the</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2020, respectively. As of September&#160;30, 2021, there was $11.5 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 2.83 years. The weighted-average grant-date fair value of stock options granted was $2.20 per option for the nine months ended September 30, 2021 and $0.56 per option for the nine months ended September 30, 2020. The total intrinsic value of stock options exercised during the nine months ended September 30, 2021 was de minimis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.40</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072537676328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2 million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of September&#160;30, 2021, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its U.S. employees. Employees are eligible to participate immediately upon their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum $4,000 per year. The expenses incurred for the periods presented were de minimis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536210712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:63.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,553)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,256)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:63.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Benefit (Provision):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Benefit (Provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Deferred Tax Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, the Company recorded a benefit from income taxes of $8.3&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021, the Company determined that the fair value of the Vicineum United States rights was zero, which resulted in an impairment charge of $31.7&#160;million. In connection with this impairment charge, in the third quarter of 2021, the Company wrote-down the associated deferred tax liability by $8.6&#160;million as a benefit. Please refer to Note 6, "Intangible Assets and </span></div>Goodwill," for further information regarding the impairment charge. For the nine months ended September 30, 2020, the Company recorded a provision for income taxes of $1.1&#160;million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the License Agreement with Qilu.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072534390056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text">LICENSE AGREEMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a License Agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same. These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $0.5&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million related to achievement of a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the three months ended December 31, 2020 and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the three months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents cover some key aspects of Vicineum. Under the terms of the License Agreement with Micromet, as of September&#160;30, 2021, the Company may be obligated to pay up to &#8364;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.8&#160;million at exchange rates in effect on September 30, 2021). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;50,000 (approximately $57,965 at exchange rates in effect as of September 30, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of  &#8364;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ecember 2020. The Company recorded an expense of &#8364;0.5&#160;million (approximately $0.6&#160;million) related to the submission of the Marketing Authorization Application ("MAA") to the European Medicines Agency (&#8220;EMA&#8221;) for Vysyneum&#8482; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. Under the terms of the License Agreement with XOMA, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#8217;s clinical development pathway. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the License Agreement with F. Hoffmann-LA Roche Ltd and Hoffman-La Roche Inc. (collectively, "Roche"), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal&#160;antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the License Agreement with Roche, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $7.5 million in August 2016 upon the effectiveness of the License Agreement with Roche following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5 million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5 million in development milestones, the next of which is $20.0&#160;million for initiation of the first Phase II study, (ii) $50 million in regulatory milestones and (iii) $75 million in commercialization milestones. In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. Additional amounts of up to $65 million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement with Roche provides for two &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a  Roche Licensed Product in either the United States or in the E.U., in which case Roche is required to pay the Company, within 30 days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the E.U.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the License Agreement with Roche if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the License Agreement with Roche following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the License Agreement with Roche if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Licensed Product in the Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Licensed Products in Greater China. The royalties are payable on a Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Licensed Product in a particular region or no data or regulatory exclusivity of a Licensed Product in a particular region.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Licensed Product necessary for Qilu to develop and commercialize the Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Licensed Product has been obtained.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement with Qilu will expire on a Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the License Agreement with Qilu for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the License Agreement with Qilu is terminated under certain circumstances.  The License Agreement with Qilu includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The License Agreement with Qilu is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606"), which was adopted effective January 1, 2018. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the License Agreement with Qilu represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million dollar milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company recorded the outstanding $2.8&#160;million to accounts receivables as of March 31, 2021 and received the payment as of June 30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("the MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The Company also concluded that its agreements under </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered.  As of September&#160;30, 2021,</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 5, 2021, we entered into an exclusive license agreement with Eczacibasi Pharmaceuticals Marketing (&#8220;EIP&#8221;) pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the licensing agreement, we are entitled to receive an upfront payment of $1.5&#160;million, are eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and are also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The EIP License Agreement is subject to the provisions of ASC 606 and as of September&#160;30, 2021, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No initial transaction price was estimated by management as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as the upfront payment is subject to a refund if certain regulatory approvals in the US are not obtained. The Company also concluded that its promises under this license agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2021,</span> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536755096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING AND RELATED ACTIVITIES</a></td>
<td class="text">RESTRUCTURING AND RELATED ACTIVITIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Restructuring Plan included a reduction in the Company&#8217;s workforce by 18 positions (or approximately 35% of the Company&#8217;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the Restructuring Plan:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.130%"><tr><td style="width:1.0%"/><td style="width:82.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company&#8217;s Condensed Consolidated Statements of Income (Operations) and Comprehensive Income (Loss) in the three months ended September 30, 2021. The Company expects that substantially all of the accrued restructuring costs as of September 30, 2021 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> of September 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072534673800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Legal Proceedings </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 19, 2021, August 31, 2021 and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the U.S. District Court for the Southern District of New York.  The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH, and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dresaj collectively as the &#8220;lead plaintiff&#8221; under the Private Securities Litigation Reform Act.  On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff.  The court has not ruled on those motions at this time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the U.S. District Court for the District of Massachusetts, with the Company named as a nominal defendant. The two derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The two derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538.</span></div>The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536002936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Retention Program described in Note 11 above, and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately 50% of current base salary. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 29, 2021, the Company participated in a Type A meeting with the FDA to discuss questions related to CMC raised in the CRL. During the CMC Type A Meeting, the Company and the FDA reviewed issues related to CMC to be further discussed during the review of the BLA for Vicineum upon potential resubmission. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of the BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any potential future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues. The Company is preparing for a separate Clinical Type A Meeting, which the Company expects to occur later this year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072534532680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Interim Financial Statements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on March 15, 2021, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; revenue recognition and going concern considerations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the U.S. dollar.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2021</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP </span></div>for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September&#160;30, 2021 and December&#160;31, 2020 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs.  The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div>Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072625912568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:35.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:35.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Summary of Contingent Consideration Liability</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the nine months ended September 30, 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.643%"><tr><td style="width:1.0%"/><td style="width:78.187%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108,840</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - short term </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536705304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">The following table sets forth the composition of intangible assets as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536172264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands): </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:59.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.065%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.066%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,973</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072535931704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Common Stock</a></td>
<td class="text">In addition, the Company had reserved for issuance the following number of shares of common stock for the purposes described below as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,450&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,457</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Outstanding and Warrant Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's warrant activity for the nine months ended September 30, 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:8.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year-to-Date Warrant Activity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Expired)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,573)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,048)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification (ii) subject to further adjustment based on down round provision added by amendment described in "Item 15. Exhibits and Financial Statement Schedules - Note. 10 Stockholders' (Deficit) Equity" in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072535953976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Diluted Loss Calculation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of September&#160;30, 2021 and 2020 have been excluded from the denominator of the diluted income (loss) per share of common stock outstanding calculation as their effect is anti-dilutive.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,710</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings (Loss) Per Share</a></td>
<td class="text">The following table illustrates the determination of earnings (loss) per share for each period presented:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic Earnings (Loss) Per Share:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Deemed Dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income attributable to participating securities - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders - basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,608)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,535)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,886</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,547</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,437</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share applicable to common stockholders - basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dilutive Earnings (Loss) Per Share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Deemed Dividend</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income attributable to participating securities - diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)  attributable to common stockholders - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,280)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,535)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive impact from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding <br/>- diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,017&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share applicable to common stockholders - diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072532892632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its condensed consolidated statements of income (operations) and comprehensive income (loss) for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months ended<br/>&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the nine months ended September 30, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Exercise Price per Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average Remaining Contractual Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,628)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.40</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536246616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:63.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,553)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,256)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:63.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Benefit (Provision):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Benefit (Provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Deferred Tax Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072534594728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text">The following is a summary of accrued restructuring costs related to the Restructuring Plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.130%"><tr><td style="width:1.0%"/><td style="width:82.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072618457016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioIncMember', window );">Viventia Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare', window );">Shares of common stock issued to the selling shareholders (in shares) | shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired (as a percent)</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales', window );">Period during which quarterly earn-outs are payable after date of net sales</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations', window );">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioIncMember', window );">Viventia Bio, Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods', window );">Percentage of net sales of quarterly earn-out payments during earn-out periods</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioIncMember', window );">Viventia Bio, Inc. | Vicinium | Europe | Collaborative Arrangement, Revenue based on Specified Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioIncMember', window );">Viventia Bio, Inc. | Vicinium | Japan | Collaborative Arrangement, Revenue based on Specified Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072617862664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">56,600<span></span>
</td>
<td class="nump">99,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,380<span></span>
</td>
<td class="nump">16,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">56,600<span></span>
</td>
<td class="nump">99,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,380<span></span>
</td>
<td class="nump">16,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">56,600<span></span>
</td>
<td class="nump">99,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,380<span></span>
</td>
<td class="nump">16,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration - short term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">$ 56,600<span></span>
</td>
<td class="nump">$ 99,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072618124808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DebtInstrumentIndexRateHighYield', window );">Debt Instrument, Index Rate, High-Yield</a></td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">$ (114,000)<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="num">$ (52,240)<span></span>
</td>
<td class="num">$ (16,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage', window );">Probability of achieving clinical and regulatory milestones</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage', window );">Probability of achieving clinical and regulatory milestones</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WeightedAverageCostOfCapital', window );">Weighted-average cost of capital</a></td>
<td class="nump">860.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurements used</a></td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability measurements used</a></td>
<td class="nump">0.086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DebtInstrumentIndexRateHighYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Index Rate, High-Yield</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DebtInstrumentIndexRateHighYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Probability of Achieving Clinical and Regulatory Milestones, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Cost of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072541252840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details) - Unobservable Inputs (Level&#160;3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 108,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent', window );">Change in fair value of contingent consideration - short term</a></td>
<td class="num">(8,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent', window );">Change in fair value of contingent consideration - long term</a></td>
<td class="num">(43,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 56,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072537439208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 13,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | IPR&amp;D intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | IPR&amp;D intangible assets | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | IPR&amp;D intangible assets | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072537255256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CAD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeasesAreaOfOfficeSpace', window );">Office space (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption', window );">Renewal option | term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100<span></span>
</td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses', window );">Related operating expenses, per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost, including related operating cost</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="nump">$ 223,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Other Monthly Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseOtherMonthlyOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeasesAreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Area Of Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeasesAreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536943640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Composition of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 2,148<span></span>
</td>
<td class="nump">$ 1,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll-related expenses</a></td>
<td class="nump">1,628<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">2,089<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedRestructuringChargesRelatedCurrent', window );">Restructuring charge related</a></td>
<td class="nump">2,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 8,186<span></span>
</td>
<td class="nump">$ 3,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedRestructuringChargesRelatedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Restructuring Charges Related, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedRestructuringChargesRelatedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072541507160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) - Equity Financing (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockAdditionalSharesAuthorizedForSale', window );">Additional shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockCommissionFixedRate', window );">Commission fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockWeightedAveragePricePerShare', window );">Stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember', window );">ATM Facility | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockAdditionalSharesAuthorizedForSale', window );">Additional shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockAdditionalSharesAuthorizedForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Additional Shares Authorized For Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockAdditionalSharesAuthorizedForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockCommissionFixedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Fixed Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockCommissionFixedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Sales Price In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Issues, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072541172424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072540498520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072618163496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockSharesIssuedAndReservedForFuture', window );">Total shares of common stock issued and reserved for issuance (in shares)</a></td>
<td class="nump">229,457,000<span></span>
</td>
<td class="nump">157,707,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember', window );">2014 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">2,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="nump">15,511,000<span></span>
</td>
<td class="nump">10,147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-based payment arrangement | 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="nump">11,983,000<span></span>
</td>
<td class="nump">4,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-based payment arrangement | 2014 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockSharesIssuedAndReservedForFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Issued And Reserved For Future</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockSharesIssuedAndReservedForFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Of Common Stock Reserved For Issuance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharesOfCommonStockReservedForIssuanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072537907704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) - Warrants (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="num">(2,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">Warrants, Expiring March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="num">(1,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">Warrants, Expiring November 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member', window );">Warrants, Expiring November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member', window );">Warrants, Expiring November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued During The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Number Of Expirations During The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072541439240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Schedule of EPS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 71,674<span></span>
</td>
<td class="num">$ (25,442)<span></span>
</td>
<td class="num">$ (55,512)<span></span>
</td>
<td class="num">$ (22,608)<span></span>
</td>
<td class="num">$ (26,344)<span></span>
</td>
<td class="nump">$ 41,564<span></span>
</td>
<td class="num">$ (9,280)<span></span>
</td>
<td class="num">$ (7,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Deemed Dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Income attributable to participating securities - basic</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Income (Loss) Available to Common Stockholders, Basic, Total</a></td>
<td class="nump">$ 71,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,280)<span></span>
</td>
<td class="num">$ (7,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">196,778,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,547,000<span></span>
</td>
<td class="nump">113,437,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) per common share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Dilutive Earnings (Loss) Per Share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Less: Income attributable to participating securities - diluted</a></td>
<td class="num">$ (51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) attributable to common stockholders - diluted</a></td>
<td class="nump">$ 71,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,280)<span></span>
</td>
<td class="num">$ (7,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan (in shares)</a></td>
<td class="nump">4,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding for diluted (in shares)</a></td>
<td class="nump">201,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,547,000<span></span>
</td>
<td class="nump">113,437,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per common share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Potentially dilutive securities outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">11,328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,710,000<span></span>
</td>
<td class="nump">12,712,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Potentially dilutive securities outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">2,485,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Potentially dilutive securities outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">11,273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,511,000<span></span>
</td>
<td class="nump">10,227,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2740-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072623558648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">11,328,000<span></span>
</td>
<td class="nump">12,712,000<span></span>
</td>
<td class="nump">15,710,000<span></span>
</td>
<td class="nump">12,712,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">2,485,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">2,485,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">11,273,000<span></span>
</td>
<td class="nump">10,227,000<span></span>
</td>
<td class="nump">15,511,000<span></span>
</td>
<td class="nump">10,227,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072623605736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="nump">$ 453<span></span>
</td>
<td class="nump">$ 3,385<span></span>
</td>
<td class="nump">$ 1,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,016<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 2,849<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072618779144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="nump">$ 453<span></span>
</td>
<td class="nump">$ 3,385<span></span>
</td>
<td class="nump">$ 1,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember', window );">2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Period exercisable from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member', window );">2009 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Period exercisable from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting on the First Anniversary of Date of Grant | 2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based compensation, vesting rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting at End of Each Successive Three-Month Period Thereafter | 2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based compensation, vesting rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072532750984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares under Option (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">10,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">8,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled or forfeited (in shares) | shares</a></td>
<td class="num">(2,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">15,511<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">6,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average Exercise Price per Option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled or forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">1.95<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Life (in years), Outstanding</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Life (in years), Exercisable</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 3,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072618599128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue', window );">Fair market value (in dollars per share)</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 10 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">74.60%<span></span>
</td>
<td class="nump">71.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072618791624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution retirement plan, maximum employee contribution deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee', window );">Discretionary match per participating employee, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Common stock purchase price, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for sale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072541141688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Earnings from Continuing Operations before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (38,864)<span></span>
</td>
<td class="num">$ (18,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Canada</a></td>
<td class="nump">21,311<span></span>
</td>
<td class="nump">12,582<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total Loss before Income Taxes</a></td>
<td class="num">$ (17,553)<span></span>
</td>
<td class="num">$ (6,256)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072541278840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Current Tax Benefit (Provision) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Tax Benefit (Provision):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 8,559<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current Benefit (Provision)</a></td>
<td class="num">$ (8,273)<span></span>
</td>
<td class="nump">$ 1,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536257112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred Tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="num">$ (3,969)<span></span>
</td>
<td class="num">$ (12,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">$ (3,969)<span></span>
</td>
<td class="num">$ (12,528)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, in Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072540457944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">$ 8,561<span></span>
</td>
<td class="num">$ (1,132)<span></span>
</td>
<td class="nump">$ 8,273<span></span>
</td>
<td class="num">$ (1,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DeferredTaxLiabilityImpairmentWriteDown', window );">Deferred tax liability, impairment write down</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DeferredTaxLiabilityImpairmentWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Impairment Write Down</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DeferredTaxLiabilityImpairmentWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072524678536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,236,000<span></span>
</td>
<td class="nump">$ 6,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,561,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,000<span></span>
</td>
<td class="num">$ (8,273,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationRoyaltyPaymentPercent', window );">Royalty payment based on annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationMilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAccountsReceivable', window );">Outstanding payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">License agreement, royalty on net product sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">License agreement, rate requiring reduction in the amount of royalties owed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">License agreement, royalty on net product sales, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember', window );">Micromet AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">License agreement, royalty on net product sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent', window );">License Agreement, royalty payment, reduction, conditions not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,965<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember', window );">XOMA Ireland Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">License agreement, royalty on net product sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">License agreement, rate requiring reduction in the amount of royalties owed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">License agreement, royalty on net product sales, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementUpfrontFee', window );">Up-front license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAdditionalUpFrontFee', window );">Additional up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementOptionPeriods', window );">License agreement, option periods | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod', window );">License agreement, buyout amount under first option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised', window );">License agreement, period to pay buyout option once exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod', window );">License agreement, buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct', window );">License agreement, buyout amount under second option period, upon non-issuance of patent rights or licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | First Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative Arrangement, Revenue Based on Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative Arrangement, Revenue Based on Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative Arrangement, Revenue Based on Commercialization Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Second Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Collaborative Arrangement, Revenue Based on Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | IL-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember', window );">MENA License Agreement | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Percentage of upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">EIP Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">EIP Agreement | Turkey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Percentage of upfront payment</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Long-term Purchase Commitment, Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationRoyaltyPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Royalty Payment Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationRoyaltyPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAdditionalUpFrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Additional Up-Front Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAdditionalUpFrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Amount Payable Upon Achievement of Specified Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under First Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchievementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achievement Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchievementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementOptionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Option Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementOptionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty On Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty on Net Product Sales, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Period to Pay Buyout Option Once Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Up-front Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Basis Of Presentation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RoyaltyRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Revenue, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RoyaltyRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MicrometAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_EBI031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_EBI031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_IL6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_IL6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072541695544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">$ 5,522<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,522<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
<td class="nump">$ 4,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536183784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>position</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of positions eliminated</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, period percent</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140072536273512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MQD#]_L"Y?+MIWK+T;]5._P)02P,$%     @ %T!H4Z/X"MSM @  R0D  !@
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M?##XCBX'VJX7L#91#JP,[13E44CXN(6Q6*+DJ=D)SX:U6N=NXFSF4ZIS-V%
MW-5G/@*COA?X+<S9GCE[YP.HZNW)C2C+4[(L1$;JF@&3 *7/C(Z@[$W8&:..
MKR]P&([ZKA7H_!&<Y[BTA?_>;E"[D_],KG@!7\-.A7K<3S^3G*/5K,YV- PZ
M<Q-R9@PZ@G%<G3+2UJ"ECM&] Z+=%NAXP*\Y[!@Y>8Q>6R:[@XZVK7,V8=5H
MZQ4<P\%HNWH-QW!0PUO,$-V[(>IVDK^&,KY,)#E9%V*;J"UK/>?K"2!;=7#-
MDNYZQM";*%@7;::K@"0S?<R[R8XUV'LWVFW>[K@DQY- F9JQR-8%7ZE]_)9K
M[T=+"=](^QPQ'9=//=_1Q3%A9XQY^I<^P7 #%ABU ('Y=A"TR+,W>K3;Z2EY
MWI:#=">/E$7RM)$1N 0B!93'+!,Y@0WVXN=*I% H2]BS/D5ELD#E,=T9R&,X
M) 2&RX/@,'D0F._:;<O'WA32;E?XI_+$2;J1Z';[NF[1TP0RUA@3A@N$X#"!
M$%B'0'M#2;L=I1*H5@;J:*.&.LEXFR7D!-Q7+-(T FD4J'I[BFJS:RPX=(#G
M^OYRC*#.K',ZT)5!8991=W 8N-/#?RV5E^V-*.LVH@="U1,*T:N>-K^A6-WJ
M.XHA*$PQ'&8HU@+[H&)[E\JZ7>J/ZNR2QV?1%AP:F/A#L4HB-K*$W4RL#.SA
M3-N]QL5"7"7LSOU EPO!43\(]/J.X7S/=?0-*YK/=NP6.\OV=I9UV]G?D B,
MS]'TZI+)-)_,HA;5CS$0'"X3@D-EPO(A,O4/3G$S#CM7=7Q> O=-+G=';\W3
MYHA^5!U,:\^OZ<68(L\G]"+<'<#OT^_^'G +&^4D+TG*E]"4=>Y#9XO=$?ON
M1HIU=8;\)*04676YXA%4!06 ]TLAY-N-:J#Y0\?P/U!+ P04    "  70&A3
MJ^CY&(<)  !+/@  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;,6;:V_;
M.!:&_XH0##!38%R+=VJ0!(@OW69VFF3J=!>+Q7Y0;241*DL92VXZ_WXI6S$M
M\I"R&Z?^TMKQX>'+P\O#0TJG3\7B2_F0)%7P;9[EY=G)0U4]_M;OE].'9!Z7
M;XO')%>_W!6+>5RIKXO[?OFX2.+9JM \Z^,PY/UYG.8GYZ>KO]TLSD^+996E
M>7*S",KE?!XO_AXD6?%T=H).GO_P,;U_J.H_],]/'^/[9))4GQYO%NI;?^-E
MELZ3O$R+/%@D=V<G%^BWL:1U@97%O]+DJ=SZ'-1-^5P47^HOE[.SD[!6E&3)
MM*I=Q.J_K\DPR;+:D]+Q5^/T9%-G77#[\[/W=ZO&J\9\CLMD6&3_3F?5P]F)
M/ EFR5V\S*J/Q=/[I&D0J_U-BZQ<_1L\-;;A23!=EE4Q;PHK!?,T7_\??VL"
ML54 $4<!W!3 NQ8@30%B%,#"48 V!:A9P-4&UA18-;V_;OLJ<*.XBL]/%\53
ML*BME;?ZPRKZJ](J7FE>#Y1)M5"_IJI<=3Z\OAJ-KR;C4: ^3:[_N!Q=W*HO
MDUOUWX?QU>TDN'X7#-]?7/UC/ DNK]0/U\-_OK_^8S3^./DY&/_YZ?+V/\$O
MH_&[R^'E[9N@%WR:C()??GH3_!2D>7#[4"S+.)^5I_U*B:VK[$\;88.U,.P0
M=EM4<084&_J+#8OY7(V_255,OP"E1_[2%[-96H_?. MNXG364TT8QH\IK&3<
MX6LZ7<Z765PELV"4W*73M&H[Z:NNVO07WO077GDE#J^7^52M!V6B8IZL/[VI
M [UJ[T.1S9)%J;KEKV5:_1W\]V.198&:3T_Q8O8_3^5D4SE954X=E0^2^S3/
MT_Q>S<TLSJ=*A:J[?(@72?D&ZJNU.[9R5R]97\]1R&6(:!B=]K\"2NA&"=U3
M25RI*$_?!@3]&N 01="(6_OD6W)ZF(LPW&A9J[;-4"C:-B/;!G,ND&$VAFJ,
M",,4;C[;-)_]^%' -Y5S;^RO%+[2?%K,5?5948(]/^!6SU/$.#7"TV75TB<V
M^H17WZ0>C[V:'K- J51(+>-Z4D,RA2W ZFJ_34NBW$B4?HEQEI1!<5?KJY>K
MLNZX8)FKCJL'+PW&DYN;KLDE+5U82 8+BS;"HI<+@P(9V3/="*//HJ45A9I=
MH5?M95DN5Y,?%GQQ^T']<I<LU#KQ:Y"K8:OLTN<RTZ*LRJX8-P*V51,D!6&.
M]0MM<1>]LG:0J0C0*R)C@6NLMI<E8O06[(@[6JWIA;"WU>-\YL!'O8!_B!?/
M"S@.P>[  %"B*$*,$8<TS3;DAYLA;0<Y P3P35*&S' 3&R@H- -N^\(B)*'A
M; S8]3!#$0\= =!(1:_!U,8IZX(JVH6J@#,0JV"E'JXB#59T!+(BC59T +8B
M&YL]0:1TM%US$_G!Z9^<D^11C830,SEM4"),.&6A"Y=(\Q+Y@6E/SBXY V3S
ML8?X]D+1R);VP,36<@C 5E+5.G-@ I62,(P0=D1 @QE%/WY@8HU:[$?MWEM_
M;).S8ZG&FIW8STYPI>I<K;&--&BUQC8<[=4:\ 6NUH"==[7&6WG@$1)!K&F)
M_;3<::'"$*LXH68:T&W75JF1AOU(VR<5P#93:&1N8CN,VC(U=# [\CZV$;"M
MFW/"4>@:AYI8V$^LU]G'8B S%(*:4Y5;4Y6;'08YX@Y48HU*_!)4_K[,_:C$
M "H1YUAPY^*H48GW1667G $&J(4YEF:X 5(B*^!06LH8#\TY#]4I) E=DUZ3
M$A^!E$23DAR8E 0@I7\P$$U*XB?E3LLT@2"%>6CT_[C;KJU2LXSXL\)]EFEB
MIX#4W-.-.HS:,K=./_W,.\BI#0'R/$9#!T.(1AWI0-WWGMP0&VF1&4Z?25NO
M9AXY-O,(P#RU_XR< T$SCQR#><1&E<38W)X2FWEF%@TZ0HYUE6CFD5=-#\G>
MZ2'1S",'3P_)CNDAV24]!)R!Z2%4J2\])!IZY C0HQIZ],#0HP#T_*.!:NC1
M?=/#+C% 9DA#2B-.76(TVZB?;5VG:O#HI#; >A'&QDP?-F:\+=R\JK)]D5"-
M=#,+@^HDB$78P2:JP4G)$0;GUEVA'XT[;8(H<*3(&-N:F4V4.NW:*C40J1^(
M^VR"J(VVB$FSW_U&;9F:?=3/OO&W9#%-RQ7[UM K'FN9G3BF-I74,$2.!)1J
M+-$.+#6"2DL1&#F;0L3<[OAMVC(UHF@'HK9EMC8-:J OXKQ[/T-M>$BF,..*
MH&8']5_Z=4L#(VE?Z%%NWC0U1JT%RHPVY,<Q3)D&$COVU2 #K@9#!3 1.I8"
MI@'&CG$WR&S*"95ZF!L>!EP.FGT&NW*M@4S#DAWJ>A"!70)<#PH4"2DBQ_QE
MFF'L)=>#D)P!LU.]" OS8HP!MX,"FP&W71$9,K-CQH!=CPA$B2/G81JB[&6W
M@_ ^A@&T!/8Q#+@<M/8Q@"]P'P/5Z=O'L*VG;HYP.<@T>MD!+@>9G1^JB$L'
M))C&+-L-L_MR?\  FM+0=?#,-%#9*P-UP("L+:32K4T3E740=>=4&5['@&=E
MHHCR.C^"I7$-1NX'HS]5!M>QQF-K=M97!^;Y,&07F9LK;F.32AZ:-VQCP*Y'
M,,.NDS*NZ<K1CY_%7#..[YL0=FPT^-Y4XYIJ?-\G.G<!&]\);'P7L &N0+ !
M=EZP<0TV3H\P'#13N#_MV^UI2CN5ZZFM&S63TVZ[MLJM1S[]Z-DG.>5VHH>P
M>?\SZK)J"]68XGY,O?Z^GP/GF)Q*C)@KRAIIW(^TU]GW<QMSG&)N'BQSX*#3
MO-R#73FAI'G)7\++[?M+D)<<X*64E(<1<]!":%Z*?7G9)6<@ ,1%A)JYL0!P
M*<U#',B7:IAUL@S8]4C$I7#TC="X%$? I="X% ?&I0!PV3$8-"[% 9YZ$3:J
M!.+FPPOC3K.V1LTS<;AG7H2=*B'$K3'88=46JLDG_.3[[I-$85...#?M0C-.
M[':RN=M!H@".,\VX^4S:(K?>;=CCM/.[CA$%].Q)Q#!R;":%QI=X:48&!A)@
M"C,/" 0 )S/:D!_' ^M"DTGXR?3Z^PEAPRN2(:6NE5MJ=,G7/@.%^DL"YYX2
M63TF ;J9>T#8E>O.36ID2?_YZ0O3;PE<!_K3;ZEQ)O<ZX=PE_9; )1^4?D-V
M5OH-&('I-V#G3;^E9J@\PF6@U'B4^YYC=KUF!=#/,1KZ6^_AUJ]9JT1:558&
M67*GRH9O:W MUF\NK[]4Q>/JU=S/1545\]7'AR16(:@-U.]W15$]?ZG?]MV\
M/W[^?U!+ P04    "  70&A3$0(7J-8"  "W!P  &    'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;(V5;6_:,!#'OXH555HK=20DE&X5( $)+5MY6$,W3=->
MF,00JTY,;:>TWWYG)V24 N(-\</]_G=GF[O6FHLGF1"BT&O*,MFV$J56-[8M
MHX2D6-;XBF2PL^ BQ0JF8FG+E2 X-E#*;-=QFG:*:69U6F9M*CHMGBM&,S(5
M2.9IBL5;CS"^;EMU:[/P0)>)T@MVI[7"2Q(2];B:"IC9E4I,4Y))RC,DR*)M
M=>LWMPUM;PQ^4K*66V.D,YES_J0GP[AM.3H@PDBDM *&SPOI$\:T$(3Q7&I:
ME4L-;H\WZ@.3.^0RQY+T.?M%8Y6TK2\6BLD"YTP]\/4=*?.YTGH19]+\HG5I
MZU@HRJ7B:0E#!"G-BB]^+<]A"P"=_8!; NXNT#@ >"7@G0HT2J!Q*G!5 E>G
M LT2:)X*7)? M;FLXG3-U?A8X4Y+\#42VAK4],#<KZ'A1FBF7V*H!.Q2X%2G
M/QG[P3@,? 2C<'(_]+LSF(0S^(R"\2Q$DP'JWW7'MT&(AF/8F/2_WTWN_> A
M_(2"'X_#V6]T[@>#87\XNT#G4RQ(IA*B:(39!?J,'D,?G9]=H#-$,S2BC,$#
ME"U;0>PZ CLJX^P5<;H'XO30B(.N1$$6D_@];T/.5>+N)O&>>U0P)*L:\IQ+
MY#IN?4\\_>/XMSP[BOO'\1$6@-</XL'IP3M[\,'IP>_#;T\/WCER%5[U!CVC
MYQW*1F%%H+HIQ!<H5#QZ2CB+B9#PP)YSJM[0G^Y<*@%EZ^\1=XW*7<.X:QQP
M-Y0RQUE$M+>(IRD41*F=7B*ZV8FX5'L?::'\U2CK(O_2J=?<EOVR_7 *F^:6
MS8Z%_U'%W54)/MHX->^]S6"?3?V]S>UQF^( [:WZD1*Q-*U!PBGDF2K^4=5J
MU7VZINCNK/>@*Q5-Y+],T=+@S2QI)A$C"Y!T:M=0*$71)HJ)XBM3I>9<0<TS
MPP0Z*Q': /87G*O-1#NH>G7G'U!+ P04    "  70&A3A%44OF4&  #@%P
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M]Y"6<HB=<MZ#AE;> .\%YX5*2=,!W_<)!V/2/6L:I(8,:#F)G)YIRJK+I#C
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MT#KLUQ;)7XFT9^>^V@&CT+YH*NH]!7F(IB1F&ER 3&,[RHLJ<4O[RH5?[&2
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MNKO=!ZI%^B[3'T]?M\!E-AKI,&H-T=GD^W<C@ 9_,4H7T57\E6;E8G0E_RR
MQ<K3 3PG;M5>D('NL]W5?P%02P,$%     @ %T!H4R:]*,RR @  YP4  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULM53?;],P$/Y73D&"%VC2M!MC
MM)72;AT1M*N:#800#VYR::PE=K =NOWWG)TV*]*V)WB)?]Q]WW=W\=UH)]6=
M+A -W%>ET&.O,*8^]WV=%E@QW9,U"K+D4E7,T%%M?5TK9)D#5:4?!L&I7S$N
MO,G(W:W49"0;4W*!*P6ZJ2JF'J98RMW8ZWN'BS7?%L9>^)-1S;:8H+FM5XI.
M?L>2\0J%YE* PGSL1?WSZ=#Z.X>O''?Z: \VDXV4=_809V,OL %AB:FQ#(R6
MWSC#LK1$%,:O/:?725K@\?[ /G>Y4RX;IG$FRV\\,\78._,@PYPUI5G+W2?<
MYW-B^5)9:O>%7>L[''B0-MK(:@^F""HNVI7=[^MP!#@+G@&$>T#HXFZ%7)07
MS+#)2,D=*.M-;';C4G5H"HX+^U,2H\C*"6<FR>UB$:V_P_4<DOAJ&<_C6;2\
M@6@VN[Y=WL3+*UA=?XEG\64R\@WI692?[KFG+7?X#/<'6$AA"@V7(L/L;[Q/
M<7;!AH=@I^&+A G6/1@$;R$,POX+?(,N^8'C&SS#%Z6I;(3A8@LK6?*4HX8?
MT48;18_EYPL"PTY@Z 2&_Z6Z_XK[ID"8R:IFXN&-AI1V)1H\]"'('#3?"I[S
ME E#?=(5I3X4A0RP0<C)D $7X,4&*^B?].#RON ;;C0PLLRY8"+EK(3$,/)
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M0X9PPSO8\MY2GL]11Q<+?-\ PTU4HPFVA1<9X*TIJ+:>TH3AX.0D[!+:Z5@
M4R4"YDYQ\+IH,8+,&0O%YU+3QUM/T-X35[4%KO3$/R1,VQ-C9*E,HJW%^[;9
MH[%,.RY 4)+J0T?5I_VSAZ3J>?_)P_WMQ7G_-,X\;V9N$-:&S"SD'?5AX"A@
M-$V$Q\*SAHU"(6>S)+)_F;YL:=,$5_?0ILGF9K<)R:"*V(2VC5[-&P\K[@S9
MACD@4=I"M[UCVUGA&@__S$DW.KG+>/,$\9M=PX/CP7GO_'2 \&B.^Y-HT*'=
MCYA1/_YOI*RI]J/3D][P#%(2C;><K^V!/NWSRX^A1'>0I',M$(O>6C 0YO>0
MRPT4$XN8T040P;!!DM(@%Y>0JT'>/6P@;#1UJ XEL#]B!4:@S$+).\V,H"+?
M$EZ5]_.1"$N$T?MAN2MZ^N*JV95 :0,\9=FHQ7LP@7S( 9KG*02M]4UAJ*'Q
M;601CH5DZZA.%YXHR%F3V=BBV97]$"Z2&&:V.7%=.Y;\387*#@$;%H4-*KJ
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MZ"?4I@D8GQETA_$#;=#^S.;5?P!02P,$%     @ %T!H4UP!EH5(!P  %1(
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M!&%H =[3P:Z](0?=E][UOU!+ P04    "  70&A3S2$*>\("  #1!0  &0
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M&(%#(<H]AF2"'0V&*M7P!2,>K?CG/PZ'P\$K8(1= &URO@Y?"="3)0HX @%
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ME!M<1JJ<));"R1206SGHXH<Y2)3+"NX)5MQ<1G5(@]M>IP?MV$1$%H.AU1(
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M(&#Y@"<H]#H2OW-+>-[%[Z(]>AWYCG<@PD$0C@_$B[ _G(K#_H3/C,/IP.,
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M!OA^KG7M_L -_(^<OOD?4$L#!!0    ( != :%-;RJ5;4@0  .$)   9
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M;,#[W(+.[D$"]/]ZCO\&4$L#!!0    ( != :%/OF%:P[ D  )H:   9
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M(F-O#?YF=*UVQF!.LA#BT4RFR<CQC"":T5@;!H)_3_2:9IDA0AF_:DZG<6F
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M-DI2)1)\J'=<RSO7S(-K5,/&\BIW9[EQ8"@1%LLU1:W+!M"^&X10<))>(U:
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MILV#55!S;44F:@H]I6>GHE^Y%XP0#1,V>M; UT >Z]\MS$+)'/6#ZA8T8P=
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MM3M ^QM%_<IVX@ST?UR6?P)02P,$%     @ %T!H4[))80T]!0  %0P  !D
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M(J\#U/L94QO[_$8?HQ7'IMW_ 5!+ P04    "  70&A3_I+0$ED$  ![$@
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MBH464.LKQN3+@]X@O6_J_@]02P,$%     @ %T!H4]3+%K_] @  ^ 8  !D
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M)O.$.+ZFT3<2BLW Z!D@Q"N41N*>[O[ 14(=Y2^@$<]^P2ZW]3P#!"D7-"[
M,H*8)/D_>BD*L0>0?IH!=@&PWP+<(P"G #AM&=P"X+9EZ!2 3EN 5P"\K/9Y
ML;)*^TB@89_1'6#*6GI3%UF[,K0L,$G4REH*)N\2B1/#V=W#Z.YF-IY/P&BY
MG#PLP>C.!S=?OOC?9O,Y^.AC@4C$/X'/X''I@X\?/H$/@"3@84-3CI*0]TTA
MPU#.S*"@'.>4]A%*!]S21&PXF"0A#AOPOAY_J<&;,OVR!O9K#<:VUN$2;R^
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MW& 48J8,Y/T5I>)UH C*SS##?P%02P,$%     @ %T!H4V7I;,'K P  ^P\
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M@(L; &X&<"\%>!G >PL8- "Z&:![*<#/ /ZE+O4R0,_$/@V6B?2<2#(9<79
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M3.68!J8*9'Y%J=@&:A)T@S_\!U!+ P04    "  70&A3CO>W7<,#   5$
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M[DLE]--0X]1D^?!Q^N?[CQ]FM_?+/\#MI\_SA[_!J]GMW7PZ?W@-WH)EMB
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MO2!81#1IXZ_T/M3O3K72)9'?H6K^I1:9:35I43HK>H&UOC5[YS5(Z4^]IU?
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MSN7XI9E_?=09<1V'M&$S .:Z+N[ YI WXEF3-NP=!/-LIQ/;?1_F8-?KH!:
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MQ</X<LZHQX0F@.=3SM7V1BO(/O!T_P=02P,$%     @ %T!H4\3\/+Z!!
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MD;B ,[!!K#$G F@"+PF5XK+2\6/-4H&34'6>?6@/;:F M5D[R.%N,SBW 6X
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MC'7C$>V:,@;6YH[,<+^Z<M=-!Q*Y);![=%@XA2K3CMP*EG?=<$)1&;J1]X5
M<0J7=\BEW.4U@)5!'K5'^>;@<0IDI\YYO6X#9!GI47NH_\]P<@IKM\ZA@^ZG
M\)(/.W*7EGD#'94X3( Y=0)^#9F/&LC*9()ZK?'%W"VN]-4ZA F+5;TAL+E@
MC+DZ62NB:@ 5!G90'3?#.],]WF(>7N[OG)<P#D.J7W$$4RJ"B(E4WUO^'"^$
MY*H"^*LM1)6Y!K4GFX.(^$QT :0WRT1='[6A5!'\09>9KW=$>?I"89:[JM:_
M[5;[F1[P(,[NJ*@/(=[57A^/5.7GJMJ\4F8PU)["3O5*96?6>J7=:B^?2F_O
M%;_&*1^O[F7F<YU6W>/5BI,5E@3N%3]5I6@ /W&4D@]+J<]-'7BNW*^F8^_3
M8:\9XR'?J3]2;IE#W?8<V@)>C0--X.@ JC/XA&17*LB8\)4IK 4$+$UD5DP6
MO47Q/C8EJUT.SRK_!\Q5BA<0D:42=53TMH!GQ736D&QCZM$%DZJZ-:]K@E4E
MH@>H[TO&Y+ZA#11_:8S^!5!+ P04    "  70&A3<!.ZJR,#   S"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6R55DUOVS@0_2L#81=H@;4D2_XL
M; .RX[8YI#7B=G,H>F"LL4V$$E62MN-_WR'E:)U$UJ87B:3F/;['$3D<':1Z
MT%M$ X^9R/78VQI3? @"O=IBQK0O"\SIRUJJC!GJJDV@"X4L=:!,!%$8]H*,
M\=R;C-S80DU&<F<$SW&A0.^RC*GC%(4\C+VV]S1PRS=;8P>"R:A@&URB^5XL
M%/6"BB7E&>::RQP4KL=>TOXP&]IX%_ OQX,^:X-U<B_E@^U<IV,OM()0X,I8
M!D:O/<Y0"$M$,GZ=.+UJ2@L\;S^Q?W3>R<L]TSB3XHZG9COV!AZDN&8[86[E
MX3.>_'0MWTH*[9YP.,6&'JQVVLCL!"8%&<_+-WL\K<,9H-V[ (A.@.@%((HO
M .(3('9&2V7.UA4S;#)2\@#*1A.;;;BU<6ARPW.;Q:51])43SDR6GY/;>6N:
M+.=7,/MZLYA_62;?KK]^@1;<N27 M)7L45%&X3HO=D8#RU-(-*6]L(G0\.X*
M#>-"OR?,7Q" WC*%>A08DF<G"58G*=-22G1!RA!N9&ZV&N9YBNES?$"V*F_1
MD[=IU$BXQ,*'./P'HC!JU^B9O1T>-LB)JZ6.'5]\B<^N2\O^<RDLV)&V@H%$
M*99OT+5_)/?:*/JO?S9,UJDFZ[C).A<F^\BXHO]$/=!!L&=BA_".YY!*(9C2
M4* JT_2^+DTE\\ QVU-@/XG]SBC8GR_=ZYC0'_2KH&>:NY7F;J/F3[06!O 1
MU8IKA$+QU9_([KY!]NN8R[)[E>Q>H^SY8T%G$B75H,J<WB.2VEJ-S4R]$@GM
M$%)VK-M"LS<20&:W$O1J>)YY[%<>^XW$MUP_M-8*$7A.-E$;4,Q@G<5FHM ?
MAG_7&6N&M?WX)>R9CT'E8_"V7.VE8(8+;HYU'II)^AV_5V_B?W!MO]OH8EBY
M&#827?$]3Y&.X2-'D=89:,:'?EBO_X]AI?S@K/YDJ#:N+&M8R5UNRN.Z&JTJ
M?^(*WHOQ*=T(R@+^'TUYG;AA:L.IV A<$V7H]VDGJ[)$EQTC"U?E[J6AFNF:
M6[K5H+(!]'TMI7GJV FJ>]+D-U!+ P04    "  70&A3192"=9T#  #("@
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MX$IW]7*8ZIL=A G0[Q/.U79B!)K_"L/?4$L#!!0    ( != :%,,FO/ 0 H
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MCRR8E'+**3_,?OJ>O8GI.OW][1.-8^JG+U?$F9.0#V#?+RA;A/D;_I/>S7]
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M[)'T,):-,C*U03Y?4BH>)DJ@;KV'OP%02P,$%     @ %T!H4WB 6#E6 @
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M^1[<>1_YZ_>4O_G_YN@74$L#!!0    ( != :%.7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ %T!H4\VSZX42!0
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M@=J7E%&5KX_?K1V_N?O\'U!+ P04    "  70&A3F!M:GOL!  #+(P  &@
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MHM[M3^I=IL]#+M>>KS5>_R>IGL[GYNOE+\NOG7B_:"\X)_AWY_$O4$L#!!0
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M              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ %T!H4VC1KE@^!0  [A4  !@              ("!# @  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( != :%.)>XT@908  &$;   8
M              " @8 -  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  70&A3H_@*W.T"  #)"0  &               @($;%   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ %T!H4T-#VD S!@
M]!@  !@              ("!/A<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( != :%.KZ/D8APD  $L^   8              " @:<=
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  70&A3$0(7
MJ-8"  "W!P  &               @(%D)P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ %T!H4X15%+YE!@  X!<  !@
M ("!<"H  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !=
M:%/]ZO8P\ L  # >   8              " @0LQ  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  70&A37N*,3^P'  #"$P  &
M        @($Q/0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ %T!H4R:]*,RR @  YP4  !D              ("!4T4  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  70&A3NJCGU]0"   O!@
M&0              @($\2   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( != :%-OTI\D\PL  '(C   9              " @4=+  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ %T!H4UP!EH5(
M!P  %1(  !D              ("!<5<  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  70&A35RT&D*(%  #U#0  &0
M@('P7@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !=
M:%/-(0I[P@(  -$%   9              " @<ED  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ %T!H4YDP&AH)#   UR$  !D
M         ("!PF<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  70&A3V:#R<,D'  #W%@  &0              @($"=   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( != :%-IO_H'? L  !PB
M   9              " @0)\  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ %T!H4V]A^!*^!0  ^0T  !D              ("!M8<
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  70&A3@NVC
MAR0$  "%"0  &0              @(&JC0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( != :%,U*\R 51@  /!4   9
M  " @062  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M%T!H4UO*I5M2!   X0D  !D              ("!D:H  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  70&A3MH^)3H,'  "%$@  &0
M            @($:KP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( != :%,8-S]'= 4   $-   9              " @=2V  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ %T!H4^^85K#L"0
MFAH  !D              ("!?[P  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    "  70&A3Y%./K@$$  !3"P  &0              @(&B
MQ@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( != :%/1
M>!E(N0(  -4%   9              " @=K*  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ %T!H4QM.IEK/ @  U04  !D
M     ("!RLT  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( != :%.)7A*2R@(  .$%   9              "
M@=?C  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ %T!H
M4Y[YUJ--!   Y X  !D              ("!V.8  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    "  70&A3EKA%$G$$  !"%0  &0
M        @(%<ZP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( != :%/^DM 2600  'L2   9              " @03P  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ %T!H4]3+%K_] @  ^ 8
M !D              ("!E/0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    "  70&A3 ]CDE?H#  "2$0  &0              @('(]P
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( != :%-EZ6S!
MZP,  /L/   9              " @?G[  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ %T!H4PI.4??, @  HP<  !D
M ("!&P ! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  7
M0&A3XQ%_**,$  "C$P  &0              @($> P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( != :%/AIL\[=@(  + &   9
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M970T-BYX;6Q02P$"% ,4    "  70&A3W9)**SD#  "?"P  &0
M    @('Y&P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M != :%,%:^*C)P,  +<*   9              " @6D? 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ %T!H4X^X;XBD!0  [!D  !D
M             ("!QR(! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    "  70&A3Q/P\OH$$  #>$   &0              @(&B* $ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( != :%-P$[JK(P,
M #,)   9              " @5HM 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ %T!H4T64@G6= P  R H  !D              ("!
MM# ! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  70&A3
MMP**JZH"  ",!@  &0              @(&(- $ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( != :%,JA8LVB@(  .8&   9
M      " @6DW 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ %T!H4]G\_GE8 @  O@4  !D              ("!*CH! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  70&A3'*VYE.<"   W"
M&0              @(&Y/ $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( != :%,,FO/ 0 H  (Q    9              " @=<_ 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ %T!H4ZGB4Y0T
M P  A@L  !D              ("!3DH! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    "  70&A3>(!8.58"   W!0  &0
M@(&Y30$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !=
M:%-6#C-? @(  $@$   9              " @490 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ %T!H4_I%B$Q* P  [!0   T
M         ( !?U(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  70&A3EXJ[
M',     3 @  "P              @ 'T50$ 7W)E;',O+G)E;'-02P$"% ,4
M    "  70&A3S;/KA1(%  #W)P  #P              @ '=5@$ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ %T!H4Y@;6I[[ 0  RR,  !H
M     ( !'%P! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ %T!H4W32QF+> 0  6B,  !,              ( !3UX! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     $0 1 "3$@  7F !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>193</ContextCount>
  <ElementCount>342</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112106 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2115107 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2117108 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2120109 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2127110 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131111 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2137112 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2139113 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2145114 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTS</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2147115 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2151116 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2152117 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INCOMETAXES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419407 - Disclosure - ACCRUED EXPENSES - Composition of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES - Composition of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2422408 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Equity Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) - Equity Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Summary of Common Stock Issued and Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) - Summary of Common Stock Issued and Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Schedule of EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441420 - Disclosure - INCOME TAXES - Components of Earnings from Continuing Operations before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Components of Earnings from Continuing Operations before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - INCOME TAXES - Current Tax Benefit (Provision) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails</Role>
      <ShortName>INCOME TAXES - Current Tax Benefit (Provision) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - INCOME TAXES - Deferred Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Deferred Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - LICENSE AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails</Role>
      <ShortName>LICENSE AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/LICENSEAGREEMENTS</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sesn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2453427 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sesn-20210930.htm">sesn-20210930.htm</File>
    <File>sesn-09302021x10qex311.htm</File>
    <File>sesn-09302021x10qex312.htm</File>
    <File>sesn-09302021x10qex321.htm</File>
    <File>sesn-09302021x10qex322.htm</File>
    <File>sesn-20210930.xsd</File>
    <File>sesn-20210930_cal.xml</File>
    <File>sesn-20210930_def.xml</File>
    <File>sesn-20210930_lab.xml</File>
    <File>sesn-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sesn-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 193,
   "dts": {
    "calculationLink": {
     "local": [
      "sesn-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sesn-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sesn-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sesn-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sesn-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sesn-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 464,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 54,
   "keyStandard": 288,
   "memberCustom": 27,
   "memberStandard": 35,
   "nsprefix": "sesn",
   "nsuri": "http://www.sesenbio.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sesenbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112106 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115107 - Disclosure - LEASES",
     "role": "http://www.sesenbio.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117108 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120109 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127110 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131111 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137112 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139113 - Disclosure - INCOME TAXES",
     "role": "http://www.sesenbio.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145114 - Disclosure - LICENSE AGREEMENTS",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTS",
     "shortName": "LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147115 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151116 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152117 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "ia45b2253ea0241f883b480c50a91e7ee_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementRoyaltyRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231",
      "decimals": "3",
      "lang": "en-US",
      "name": "sesn:DebtInstrumentIndexRateHighYield",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "ic84c83bbc78b4c12a4fe38ef570304f9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "ic84c83bbc78b4c12a4fe38ef570304f9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i3748dd3582454f23a8200a59516d8d6f_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) AND COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) AND COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419407 - Disclosure - ACCRUED EXPENSES - Composition of Accrued Expenses (Details)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES - Composition of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422408 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Equity Financing (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Equity Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "ia14f2b1575414e92a7e8692a1656ed6e_D20210601-20210601",
      "decimals": "-6",
      "lang": "en-US",
      "name": "sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "sesn:CommonStockSharesIssuedAndReservedForFuture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) - Warrants (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of EPS (Details)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Schedule of EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockDividendsAndOtherAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "id7ed6768ea3b4560b2c82d895f9ea130_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "ia345782a36b04632a22dcefbffbf2122_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "ia345782a36b04632a22dcefbffbf2122_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i7d30b6f1274e4165b26ffc39fdf1ac9c_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441420 - Disclosure - INCOME TAXES - Components of Earnings from Continuing Operations before Income Taxes (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Components of Earnings from Continuing Operations before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - INCOME TAXES - Current Tax Benefit (Provision) (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails",
     "shortName": "INCOME TAXES - Current Tax Benefit (Provision) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - INCOME TAXES - Deferred Tax Liabilities (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails",
     "shortName": "INCOME TAXES - Deferred Tax Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - INCOME TAXES - Additional Information (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESAdditionalInformationDetails",
     "shortName": "INCOME TAXES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sesn:DeferredTaxLiabilityImpairmentWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i342f8c81e3cd4634b8691627803c791d_I20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementRoyaltyRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - LICENSE AGREEMENTS (Details)",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
     "shortName": "LICENSE AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i610ca7a4385742b085d50632419fb7f8_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i3294967843ca408b88c9279ce575d789_D20210830-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Additional Information (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i3294967843ca408b88c9279ce575d789_D20210830-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i8bfcc5a738c340a29fa96c583d8ea8b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i07777b364f564270bb6efdada23c4efe_I20211001",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453427 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails",
     "shortName": "SUBSEQUENT EVENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "i07777b364f564270bb6efdada23c4efe_I20211001",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://www.sesenbio.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20210930.htm",
      "contextRef": "icb8c5622b4bd4021a7288a030cc8e8fd_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_TR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TURKEY",
        "terseLabel": "Turkey"
       }
      }
     },
     "localname": "TR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sesn_A2014EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2014 Employee Stock Purchase Plan [Member]",
        "label": "2014 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 ESPP",
        "verboseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2014EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ATMFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Facility",
        "label": "ATM Facility [Member]",
        "terseLabel": "ATM Facility"
       }
      }
     },
     "localname": "ATMFacilityMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedRestructuringChargesRelatedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Restructuring Charges Related, Current",
        "label": "Accrued Restructuring Charges Related, Current",
        "terseLabel": "Restructuring charge related"
       }
      }
     },
     "localname": "AccruedRestructuringChargesRelatedCurrent",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "terseLabel": "Shares of common stock issued to the selling shareholders (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Current",
        "terseLabel": "Change in fair value of contingent consideration - short term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Change in fair value of contingent consideration - long term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "label": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "terseLabel": "Total milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Milestone Payments",
        "label": "Business Combination, Milestone Payments",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationRoyaltyPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Royalty Payment Percent",
        "label": "Business Combination, Royalty Payment Percent",
        "terseLabel": "Royalty payment based on annual net sales"
       }
      }
     },
     "localname": "BusinessCombinationRoyaltyPaymentPercent",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ClassOfWarrantOrRightIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued During The Period",
        "label": "Class Of Warrant Or Right, Issued During The Period",
        "terseLabel": "Warrants Issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "label": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "negatedTerseLabel": "Warrants Expired (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone",
        "label": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue based on Specified Milestone",
        "label": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue based on Specified Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnSpecifiedMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Commercialization Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Development Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Regulatory Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedforFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CommonStockSharesIssuedAndReservedForFuture": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Issued And Reserved For Future",
        "label": "Common Stock Shares Issued And Reserved For Future",
        "totalLabel": "Total shares of common stock issued and reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssuedAndReservedForFuture",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_DebtInstrumentIndexRateHighYield": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Index Rate, High-Yield",
        "label": "Debt Instrument, Index Rate, High-Yield",
        "terseLabel": "Debt Instrument, Index Rate, High-Yield"
       }
      }
     },
     "localname": "DebtInstrumentIndexRateHighYield",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sesn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, in Process Research and Development",
        "label": "Deferred Tax Liabilities, in Process Research and Development",
        "negatedTerseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInProcessResearchAndDevelopment",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_DeferredTaxLiabilityImpairmentWriteDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability, Impairment Write Down",
        "label": "Deferred Tax Liability, Impairment Write Down",
        "terseLabel": "Deferred tax liability, impairment write down"
       }
      }
     },
     "localname": "DeferredTaxLiabilityImpairmentWriteDown",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "label": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "terseLabel": "Discretionary match per participating employee, maximum"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_EBI031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EBI-031 [Member]",
        "label": "EBI-031 [Member]",
        "terseLabel": "EBI-031"
       }
      }
     },
     "localname": "EBI031Member",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_EczacibasiPharmaceuticalsMarketingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eczacibasi Pharmaceuticals Marketing Agreement",
        "label": "Eczacibasi Pharmaceuticals Marketing Agreement [Member]",
        "terseLabel": "EIP Agreement"
       }
      }
     },
     "localname": "EczacibasiPharmaceuticalsMarketingAgreementMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_FirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Indication [Member]",
        "label": "First Indication [Member]",
        "terseLabel": "First Indication"
       }
      }
     },
     "localname": "FirstIndicationMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_IL6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IL-6 [Member]",
        "label": "IL-6 [Member]",
        "terseLabel": "IL-6"
       }
      }
     },
     "localname": "IL6Member",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option",
        "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option",
        "terseLabel": "Renewal option"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_LicenseAgreementAccountsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Accounts Receivable",
        "label": "License Agreement, Accounts Receivable",
        "terseLabel": "Outstanding payments"
       }
      }
     },
     "localname": "LicenseAgreementAccountsReceivable",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAdditionalUpFrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Additional Up-Front Fee",
        "label": "License Agreement, Additional Up-Front Fee",
        "terseLabel": "Additional up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalUpFrontFee",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "label": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "terseLabel": "License agreement, amount payable upon achievement of specified milestone"
       }
      }
     },
     "localname": "LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under First Option Period",
        "label": "License Agreement, Buyout Amount Under First Option Period",
        "terseLabel": "License agreement, buyout amount under first option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderFirstOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period",
        "label": "License Agreement, Buyout Amount Under Second Option Period",
        "terseLabel": "License agreement, buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "label": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "terseLabel": "License agreement, buyout amount under second option period, upon non-issuance of patent rights or licensed product"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchievementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achievement Expense",
        "label": "License Agreement, Milestone Achievement Expense",
        "terseLabel": "Expenses related to achievement of development milestone"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchievementExpense",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementOptionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Option Periods",
        "label": "License Agreement, Option Periods",
        "terseLabel": "License agreement, option periods"
       }
      }
     },
     "localname": "LicenseAgreementOptionPeriods",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty On Net Product Sales",
        "label": "License Agreement, Percentage of Royalty On Net Product Sales",
        "terseLabel": "License agreement, royalty on net product sales, percentage"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSales",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "label": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "terseLabel": "License agreement, royalty on net product sales, minimum"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "label": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "terseLabel": "License agreement, rate requiring reduction in the amount of royalties owed"
       }
      }
     },
     "localname": "LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "label": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "terseLabel": "License agreement, period to pay buyout option once exercised"
       }
      }
     },
     "localname": "LicenseAgreementPeriodToPayBuyoutOptionOnceExercised",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "label": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "terseLabel": "License Agreement, royalty payment, reduction, conditions not met"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Rate",
        "label": "License Agreement, Royalty Rate",
        "terseLabel": "Royalty rate"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyRate",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Text Block]",
        "label": "License Agreement [Text Block]",
        "terseLabel": "LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sesn_LicenseAgreementUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Up-front Fee",
        "label": "License Agreement, Up-front Fee",
        "terseLabel": "Up-front license fee"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontFee",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Maintenance Fees",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_MENALicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MENA License Agreement",
        "label": "MENA License Agreement [Member]",
        "terseLabel": "MENA License Agreement"
       }
      }
     },
     "localname": "MENALicenseAgreementMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MicrometAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Micromet AG",
        "label": "Micromet AG [Member]",
        "terseLabel": "Micromet AG"
       }
      }
     },
     "localname": "MicrometAGMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NoncashFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Financing Items",
        "label": "Noncash Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "NoncashFinancingItemsAbstract",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Rent",
        "label": "Operating Lease, Monthly Rent",
        "verboseLabel": "Monthly rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyRent",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeaseOtherMonthlyOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Other Monthly Operating Expenses",
        "label": "Operating Lease, Other Monthly Operating Expenses",
        "terseLabel": "Related operating expenses, per month"
       }
      }
     },
     "localname": "OperatingLeaseOtherMonthlyOperatingExpenses",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeasesAreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Area Of Office Space",
        "label": "Operating Leases Area Of Office Space",
        "terseLabel": "Office space (in square feet)"
       }
      }
     },
     "localname": "OperatingLeasesAreaOfOfficeSpace",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Line Items]",
        "label": "Organization And Basis Of Presentation [Line Items]",
        "terseLabel": "Organization And Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationLineItems",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Table]",
        "label": "Organization And Basis Of Presentation [Table]",
        "terseLabel": "Organization And Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationTable",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OtherDividendAndAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Dividend And Adjustments",
        "label": "Other Dividend And Adjustments",
        "terseLabel": "Deemed Dividend on adjustment of exercise price on certain warrants"
       }
      }
     },
     "localname": "OtherDividendAndAdjustments",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probability of Achieving Clinical and Regulatory Milestones, Percentage",
        "label": "Probability of Achieving Clinical and Regulatory Milestones, Percentage",
        "terseLabel": "Probability of achieving clinical and regulatory milestones"
       }
      }
     },
     "localname": "ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_QiluPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu Pharmaceutical Co., Ltd.",
        "label": "Qilu Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Qilu Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "QiluPharmaceuticalCoLtdMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "label": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RoyaltyRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Revenue, Percentage",
        "label": "Royalty Revenue, Percentage",
        "terseLabel": "Percentage of upfront payment"
       }
      }
     },
     "localname": "RoyaltyRevenuePercentage",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sesn_SaleOfStockAdditionalSharesAuthorizedForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Additional Shares Authorized For Sale",
        "label": "Sale Of Stock, Additional Shares Authorized For Sale",
        "terseLabel": "Additional shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "SaleOfStockAdditionalSharesAuthorizedForSale",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockCommissionFixedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Fixed Rate",
        "label": "Sale Of Stock, Commission Fixed Rate",
        "terseLabel": "Commission fixed rate"
       }
      }
     },
     "localname": "SaleOfStockCommissionFixedRate",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "label": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "terseLabel": "Aggregate sales price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateSalesPriceInTransaction",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Weighted-Average Price Per Share",
        "label": "Sale of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_SecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Indication [Member]",
        "label": "Second Indication [Member]",
        "terseLabel": "Second Indication"
       }
      }
     },
     "localname": "SecondIndicationMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "terseLabel": "Fair market value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "label": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "terseLabel": "One-time milestone payment upon first sale of product"
       }
      }
     },
     "localname": "SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleOfProduct",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "label": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "terseLabel": "Percentage of net sales of quarterly earn-out payments during earn-out periods"
       }
      }
     },
     "localname": "SharePurchaseAgreementPercentageOfNetSalesOfQuarterlyEarnOutPaymentsDuringEarnOutPeriods",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "label": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "terseLabel": "Period during which quarterly earn-outs are payable after date of net sales"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsArePayableAfterDateOfNetSales",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "label": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "terseLabel": "Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodInWhichAcquireeIsToUseCommerciallyReasonableEffortsToAchieveMarketingAuthorizations",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharesOfCommonStockReservedForIssuanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "label": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "terseLabel": "Shares of common stock reserved for issuance for:"
       }
      }
     },
     "localname": "SharesOfCommonStockReservedForIssuanceAbstract",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_StockIncentivePlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2009",
        "label": "Stock Incentive Plan 2009 [Member]",
        "terseLabel": "2009 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2009Member",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIncentivePlanTwoThousandFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "label": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "terseLabel": "2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwoThousandFourteenMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Exercise Of Warrants, Value",
        "label": "Stock Issued During Period, Exercise Of Warrants, Value",
        "terseLabel": "Exercises of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfWarrantsValue",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, New Issues, Issuance Costs",
        "label": "Stock Issued During Period, New Issues, Issuance Costs",
        "terseLabel": "Issuance of common stock, issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewIssuesIssuanceCosts",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Exercise Of Warrants",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "negatedLabel": "Warrants Exercised (in shares)",
        "terseLabel": "Exercises of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_UniversityOfZurichMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Zurich",
        "label": "University of Zurich [Member]",
        "terseLabel": "University of Zurich"
       }
      }
     },
     "localname": "UniversityOfZurichMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViciniumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vicinium",
        "label": "Vicinium [Member]",
        "terseLabel": "Vicinium"
       }
      }
     },
     "localname": "ViciniumMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViventiaBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viventia Bio, Inc.",
        "label": "Viventia Bio, Inc. [Member]",
        "terseLabel": "Viventia Bio, Inc."
       }
      }
     },
     "localname": "ViventiaBioIncMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Or Right Outstanding [Roll Forward]",
        "label": "Warrant Or Right Outstanding [Roll Forward]",
        "terseLabel": "Warrant Or Right Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "WarrantOrRightOutstandingRollForward",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_WarrantsExpiringMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring March 2023 [Member]",
        "label": "Warrants, Expiring March 2023 [Member]",
        "terseLabel": "Warrants, Expiring March 2023"
       }
      }
     },
     "localname": "WarrantsExpiringMarch2023Member",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2022 [Member]",
        "label": "Warrants, Expiring November 2022 [Member]",
        "terseLabel": "Warrants, Expiring November 2022"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2022Member",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedMay2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "label": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "terseLabel": "Warrants, Expiring November 2024"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedMay2015Member",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedNovember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "label": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "terseLabel": "Warrants, Expiring November 2024"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedNovember2014Member",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Cost of Capital",
        "label": "Weighted Average Cost of Capital",
        "terseLabel": "Weighted-average cost of capital"
       }
      }
     },
     "localname": "WeightedAverageCostOfCapital",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_XOMAIrelandLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA Ireland Limited",
        "label": "XOMA Ireland Limited [Member]",
        "terseLabel": "XOMA Ireland Limited"
       }
      }
     },
     "localname": "XOMAIrelandLimitedMember",
     "nsuri": "http://www.sesenbio.com/20210930",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r52",
      "r54",
      "r87",
      "r88",
      "r223",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r222",
      "r233",
      "r281",
      "r284",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r464",
      "r467",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r222",
      "r233",
      "r281",
      "r284",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r464",
      "r467",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r261",
      "r263",
      "r437",
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r261",
      "r263",
      "r437",
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r222",
      "r233",
      "r271",
      "r281",
      "r284",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r464",
      "r467",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r222",
      "r233",
      "r271",
      "r281",
      "r284",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r464",
      "r467",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r53",
      "r54",
      "r87",
      "r88",
      "r223",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r102",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r102",
      "r107",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r261",
      "r264",
      "r466",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r261",
      "r264",
      "r466",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r102",
      "r107",
      "r209",
      "r282",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r168",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r421"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r32",
      "r320",
      "r421"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r316",
      "r317",
      "r318",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r287",
      "r290",
      "r323",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r290",
      "r312",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "netLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r74",
      "r188"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r82",
      "r153",
      "r156",
      "r162",
      "r172",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r365",
      "r368",
      "r395",
      "r419",
      "r421",
      "r445",
      "r454"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r51",
      "r82",
      "r172",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r365",
      "r368",
      "r395",
      "r419",
      "r421"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r82",
      "r172",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r365",
      "r368",
      "r395",
      "r419"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r291",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Interim Financial Statements"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r280",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r280",
      "r283",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired (as a percent)"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r73",
      "r363"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r358",
      "r359",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration - short term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "verboseLabel": "Contingent consideration liability measurements used"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, net of current portion",
        "verboseLabel": "Contingent consideration - long term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r40",
      "r76"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r76",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r399"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r255",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r255",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r210",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r421"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 400,000,000 and 200,000,000 shares authorized at September\u00a030, 2021 and December\u00a031, 2020, respectively; 199,463,645 and 140,449,647 shares issued and outstanding at September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractTerminationMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Contract Termination [Member]",
        "terseLabel": "Contract Termination"
       }
      }
     },
     "localname": "ContractTerminationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r257",
      "r258",
      "r262"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r257",
      "r258",
      "r262"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r337",
      "r346"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r337"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r337",
      "r346",
      "r347"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total Current Benefit (Provision)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current Tax Benefit (Provision):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r337",
      "r346"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESCurrentTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r26",
      "r27",
      "r332",
      "r446",
      "r453"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r327",
      "r328"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' eligible compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution retirement plan, maximum employee contribution deferred"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r74",
      "r189"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r62",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r110",
      "r113",
      "r125",
      "r128",
      "r129",
      "r134",
      "r135",
      "r377",
      "r378",
      "r450",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic Earnings (Loss) Per Share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r62",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r113",
      "r125",
      "r128",
      "r129",
      "r134",
      "r135",
      "r377",
      "r378",
      "r450",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net (loss) income per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Dilutive Earnings (Loss) Per Share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Potentially dilutive securities outstanding"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period to recognize non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "netLabel": "Stock options",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r59",
      "r90",
      "r91",
      "r92",
      "r96",
      "r104",
      "r106",
      "r137",
      "r173",
      "r247",
      "r254",
      "r316",
      "r317",
      "r318",
      "r339",
      "r340",
      "r376",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r468",
      "r469",
      "r470",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r380",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r379",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r379",
      "r380",
      "r383",
      "r384",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r224",
      "r272",
      "r273",
      "r278",
      "r279",
      "r380",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r272",
      "r273",
      "r278",
      "r279",
      "r380",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r380",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)",
        "verboseLabel": "Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r386",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r385",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Contingent Consideration Liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r184",
      "r185",
      "r438",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r180",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r176",
      "r177",
      "r421",
      "r444"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r286",
      "r288",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r74",
      "r186"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D intangible assets"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r59",
      "r64"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income (Loss) Before Taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r84",
      "r348"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r153",
      "r155",
      "r158",
      "r161",
      "r163",
      "r443",
      "r448",
      "r451",
      "r461"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total Loss before Income Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r84",
      "r348"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofEarningsfromContinuingOperationsbeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r191",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r330",
      "r331",
      "r334",
      "r344",
      "r349",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r105",
      "r106",
      "r152",
      "r329",
      "r345",
      "r350",
      "r462"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit (provision) from income taxes",
        "terseLabel": "Benefit (provision) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable (net)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options and employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Total Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r179",
      "r182"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r82",
      "r157",
      "r172",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r366",
      "r368",
      "r369",
      "r395",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r36",
      "r82",
      "r172",
      "r395",
      "r421",
      "r447",
      "r456"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r82",
      "r172",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r366",
      "r368",
      "r369",
      "r395",
      "r419",
      "r420",
      "r421"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r24",
      "r25",
      "r82",
      "r172",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r366",
      "r368",
      "r369",
      "r395",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate",
        "verboseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r140",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r55",
      "r56",
      "r59",
      "r61",
      "r75",
      "r82",
      "r95",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r106",
      "r122",
      "r153",
      "r155",
      "r158",
      "r161",
      "r163",
      "r172",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r378",
      "r395",
      "r449",
      "r459"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss) and Comprehensive Income (Loss) After Taxes",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r102",
      "r110",
      "r111",
      "r124",
      "r129",
      "r153",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income (loss) attributable to common stockholders - basic",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r112",
      "r117",
      "r118",
      "r119",
      "r120",
      "r124",
      "r129"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income (loss) attributable to common stockholders - diluted",
        "totalLabel": "Net income (loss) attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r93",
      "r94",
      "r97",
      "r98",
      "r107",
      "r108",
      "r109",
      "r170",
      "r171",
      "r174",
      "r175",
      "r265",
      "r266",
      "r267",
      "r268",
      "r319",
      "r341",
      "r342",
      "r343",
      "r375",
      "r396",
      "r397",
      "r398",
      "r417",
      "r439",
      "r440",
      "r441",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r153",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (Loss) from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r412",
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost, including related operating cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r409",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESCompositionofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r45",
      "r421"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other Restructuring"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r70",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r67",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedTerseLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r291",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r111",
      "r130"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedTerseLabel": "Less: Deemed Dividend"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "netLabel": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "netLabel": "Preferred stock, shares authorized (in shares)",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r29",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r29",
      "r421"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at September\u00a030, 2021 and December\u00a031, 2020; no shares issued and outstanding at September\u00a030, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under ATM Offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r315"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r190",
      "r421",
      "r452",
      "r458"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r31",
      "r37",
      "r421",
      "r457",
      "r476"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Percentage of fair value in excess of carrying amount"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r326",
      "r436",
      "r491"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r7",
      "r23",
      "r76",
      "r77",
      "r478"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r4",
      "r15",
      "r77"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r195",
      "r198",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING AND RELATED ACTIVITIES"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions eliminated, period percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r74",
      "r192",
      "r199",
      "r201"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charge"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r194",
      "r195",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r195",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Restructuring Reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r254",
      "r320",
      "r421",
      "r455",
      "r471",
      "r475"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r90",
      "r91",
      "r92",
      "r96",
      "r104",
      "r106",
      "r173",
      "r316",
      "r317",
      "r318",
      "r339",
      "r340",
      "r376",
      "r468",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r150",
      "r151",
      "r154",
      "r159",
      "r160",
      "r164",
      "r165",
      "r167",
      "r260",
      "r261",
      "r437"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "License and related revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Diluted Loss Calculation"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r290",
      "r311",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Carrying Amounts and Fair Values of Financial Instruments Measured"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r180",
      "r183",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r201",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r195",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r291",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r295",
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r80",
      "r138",
      "r139",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r240",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r228",
      "r229",
      "r230",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Summary of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r255",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrants Outstanding and Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Common stock purchase price, discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Grant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock available for sale (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r297",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "netLabel": "Stock options outstanding (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares under Option (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-average Exercise Price per Option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r289",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on the First Anniversary of Date of Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting at End of Each Successive Three-Month Period Thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r288",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Share-based compensation, vesting rate"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Period exercisable from date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r306",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Life (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average Remaining Contractual Life (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested stock options outstanding (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "terseLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r57",
      "r58",
      "r59",
      "r90",
      "r91",
      "r92",
      "r96",
      "r104",
      "r106",
      "r137",
      "r173",
      "r247",
      "r254",
      "r316",
      "r317",
      "r318",
      "r339",
      "r340",
      "r376",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r468",
      "r469",
      "r470",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r137",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share-based payment arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r29",
      "r30",
      "r247",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Sales of common stock under 2014 ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r247",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under ATM offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r247",
      "r254",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r29",
      "r30",
      "r247",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Sales of common stock under 2014 ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r247",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under ATM offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r50",
      "r247",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercises of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r34",
      "r35",
      "r82",
      "r169",
      "r172",
      "r395",
      "r421"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity (Deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r254",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r406",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r406",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r406",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r406",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r194",
      "r195",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r123",
      "r126",
      "r127"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedTerseLabel": "Less: Income attributable to participating securities - basic"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "auth_ref": [
      "r121",
      "r123",
      "r126",
      "r127"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "negatedTerseLabel": "Less: Income attributable to participating securities - diluted"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "netLabel": "Warrants",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r112",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding for diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r492": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r493": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r494": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r495": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r496": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r497": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001485003-21-000221-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001485003-21-000221-xbrl.zip
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M!$LW;)])T75<?Z[" V3&W*ZOLNZBY]KKNL6GOSSLKC&?_Q]02P,$%     @
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MS6O\^;#9O#8#TE-D1<1$LL"PX):(&!W5T4=LG';%#"!,Z)SQ$P*'/J,3X"?
M.WM)%"]?#_QJ&-;54PNM;7KMSB-9[];UZ<>-T&HW\]9=MQU705R[Q<OKH_\9
MYRL;G>-&4N4H0X;H:+1P7%&O@E$6#_6YG&]]+J>ASZ_-FS4*118<HSXR)XCU
M4EMMN#0Z1(YC,6]H-&]H'N<-C3]O:&+SIIG@X.D@YX5@X.68:#G6*A),3)3*
M#^<-S_>\C8L?)C=OGC,1.9$<;#J3()N!<Q.4E=Y[@;V:GGX>OG4X3"[#X*N'
MAYV=-G*7]ZJA:>$1/H>C@T628>#^U5X/7CU=L_E//X4)V\W3=@N^=M?/<@!'
MH]/@]V:[M==KNY/!O?Y\>><C+F?M<B13-!S72!.Q]=9$)P#KLR"B!JX&,&&5
M]E@&4 7+0IIU[_,42S>-]R;WVZTWYC3OF<:"D"E81KR+3$OXX\%_@>].>:4=
MJ&LM\-*0:3?T3-X*?M-T6GGKL+L@]'$, UU4E!&GN>-&8&$B3<XULCSBFYXE
M+0GU8)ST +^77J'J$^R6,BY@K*FA@C""@M:*>.H)9P3T(W<SH.I"S)N,!-'T
M!H@:1C4@(X\YM9%SPI4B=OFD86K69?;$!0\+/ 9,D$$&\#!2EO 8@G.(<VWQ
M$A+W65'=[ D*_K,@5%,L+6% -@L^H!?$(&2HETX/XT<E'1\0V**3@17&*41Q
MDK-H /M)34P@EM!(!=82V:4AS2S0^>3(!*)#K),4.Z= )3I#>8B"8L^4(![3
MI2'35-'YY.BC/!'81,2TL4P1II'"*'KP<@.GC/+IT6=6,\!12L:PV@<5F?/<
M6.(<]]X;YJ6/8FBTV<AHB^>/7"T\J]ZTW&Q\RRTF$U=#WMA(I 2"*D8TTSH8
MXR*2BNG  YT!51=BWH)E'!1S,$D?&#"J7&ELG+>,::=X6#YIF)E_,GWB&B<L
M"P"1C 6%CZB..'(CI-):B(#=\A%WJO[)] G*O8W8888-<@Q$5]%@1$+"#E,6
MV0@$EW1\ *P0DUEX9]PX% )6Q@=FHK+2,@D3"*1BACBZ-*29D7\R(3)%+[C"
M @?B-//$*$ZLQX;@0)'0U"\-F:;MGTR(/@1)SBD7H.(X4X$H:3G!)E#/K+58
M38\^LYH!PYT,WNA -6?!2,VCC$XBAT#'6Z1GD,FQ\*PZ^SP3(RVU7"!'% .]
MHW3*2@.GTQJ+0PQ+2-69X>SI$Y<;'95F'. 98@%KXY5!X%(I!?\B9Y>/N%/%
MV=,G*+&@?X,GFD8 V9H#SE;42T$!90.LH]/+(UUD.CY+@FM*)&#.<&.#9H1:
M%9U%(A)#;<H]$TM#FAGA[ F127L=L'<11868Q40A<(XD.$0B:( Q=FG(-&V<
M/2'Z&,JX5" U DR6H,00XEV(-L*_($<DT0?K)<BBFI*&PWIB"50I0D>P%L)Z
M [8&'" O'-*&8XY1$')I2#,##3=!,E&4RG)@\$T#8I$1[0@W1B1[1(T0?FG(
M-$T--T'Z2":,U]()YR73-AB*-/(QJK3:1YV:'GUF-0/,H4A!8U!I) O2VNB#
M)"Y0*:D&G7\S1[]<E'^@;_*P'003RE%RH'0X37LU4_*E<(HPF1*?G?0J*GYK
MY\5\+.7/?MXT9PH9X0TGF#E'E9!14Q\PXSIHN832,)L(S$R(&TQTD6@A#0J,
M(60-#R1$C2UQ+&B^?,2=7@1F)@0%%><E42'&2)F4(**(:A:-U9HQC@81F)*.
MX[N.:&()5%$9S%E2H]H!:;1.H3'P\I4(P5F&EX8TL]DG-3$R818U2%'P@/XH
MC5H%[H,2R?*)*,W2D&G*^Z0F11_!P'GT!BP40O"16&V%MC& 7XFI=VIZ])G5
M#'@9D#*4.D!E+'*E#24FA0L1P<H;.S3:;&2TRT7YAUON<7.4T,1RE, Z _ET
MI-AH)AE15"D5@@4G5"*AQ0RHNA#SAA ))&*)+4:,4&.48L9I2X4*-%BU?-(P
M,_]D^L3ES$?CA$0J:H9,4%YZGC+XN&-NE'2^5,2=JG\R VD5.H9H+65.,QV<
MIJ#=%/*&2A%8M$/K7=+Q ;!B0@E4-@!F F5J752,$FN98IH JJ!!*&W]TI!F
M1O[)A,CD([,2&T\H4HP0;Y03G&OA95KMBLM#IFG[)Q.B#^BWP+$%7Y]0QH0W
MCDCL"2$*4XX"FQY]9C4#)E(CG9)1> P<:@# &L.MC#J2X"R:06VHA6?5FY9[
M^I6K.&'< &=K$1FS1H#Y]AP;K)V,W*!95/Q:%CLQ>^*&J#U6A@9&!6.(:1>E
MT]XK1;BD80E%=JHX>_H$)9P')\!S\@;$-5(KD$,VP =FO&,CE%#2\0'F<4(I
M9!%%K1'!G XZT5C-(A.:1\.YX<HN#6EFA+,GE>GGF?/!&7""+$M;2)0QF"H4
M"5=I]7MIR#1MG#TA^G A8@PX6F\%0\);YPUAU-A4O!A-4XRF. /?:VH/IO]6
M%>A4]7Q$F]$]QBX#':(GG,;(C.*,&&\TH8&"%^.XXSJ8A *P0+I  >G#_/+^
MZWX7>+K;77? ^]U"#0VXOIB@3_G7] CS.F]OM]SSVG\L$L''LO^#4Y]<;[W5
M3P._I][Z*7Q\,&-XIS5!G++ DZQ1BZ6+E$BA"/(H%ED%)3^,E:8H)J8 $?.*
MN4 !T&D&<P^@ I$8@C11$3,HW;$@TIIZ@>W$]4['M X+BW6%-F_:C8:Q[8[I
M 9&NG+(;@&;]\-IT@]]I[9T&EP;AJWDC='M@YWY"Q9^.K=OIO7K?:?N^Z^UT
M]D+G:^["-99Q>2OO-R?QF$M#O17:AQUS>I0[TQ@^"PYO]COMTR>_SWQ(PDPT
MXW6QD9$[P2UXNI@A3Q7FR# 9M!4..RI*L7E.?A[V4WSU]_NYE\Q28(:)TQZ$
MA5O!4]5HC(7U@+9)JEJO+ ;7M1281; S)3>/"@IHZ;$S+!6LYT%9JGD07A-!
MN> ^SO\&R[<F[WPR#6#)\^H P*<;O.V$?_JAY<ZO._>7)U\YM;L;7+_3 5]_
M4DQU]Y! 9/*;T3K3Z9S#@W?#:;O3"WZ]F>S!Y>4;>=<UVNGZ!=D.2JUSQ&I%
MA=!,86002RV3@.8J!"=*;GI6;MKL]O(FZ(&=>'G)XK*2 1M+"*?!(,)P5(I:
MII #<*IQD"&4K/0T5KK\^&]X2=-Q1^?OP+(W[AG5=NNTW^L69^ %8:!HE8O.
M&))J;02?.JD&+"-%WJ1*=PM0.F!)&8@L" -QXP7 (L1<1"S5-@Y"X(@DP:DL
M;"0E \V(@>B",)"PDB$/F#H*RC1*&82*">6PDR&"XSC_+8;FFX$6 5M/KB&2
M)$%3'%+%(L40#DH93 2H*$,TM025W+3DV'IRK*2Y0$(9X"0+Z$AI%1G8,V4Y
M_.MIH"4K+26VGAP#X< T949YIS&CSAF=X#7#E$CG*28E RTEMIX< W$F0>MH
M0P0-#"%A7,286YY8AD7A2P9:2FP].082CJ.(I<?(8.9U,"GR2)R*5'(UTD!S
M[9Q=885B_M-BS'7ZW#PCX8R$87<!ATQBF64WK>E\7U>OYJV\^=.5E7EQKI!B
M!H?(K?2*<2H, N\**^$(-A*H53+ PQG G"T0 S#C (*@8(5GC GPJZTPTL6@
M)-'>N?DW(?/' %/0 ),S 0QCC;4647G.*#:I!GH44B(B7&1R 4#H_#' %#3
M!%M$*^84M=9)99G#Q+ 8J *;(!%%+.KY9X!?";&IX+F/*,9H#-.*:AT%1J"H
MB=>":7^SR^T<6^XY)=O-@O</:'P[H6P2$50J-XP#)V"2M3!8(1&\-Y1&8N-B
MK;G-$VF?!4%9S##W6H9H R.::NP]">!36:3 .5\ _?FL!G1>%*=0A&LA*>=8
M,<^\I4QC'@Q-72J%7H"DFCDFTP27BSEG'/F@'9@S3Y$6W <0,4$LIRJR^273
MPL<",'B EBKMG/6,&F)M=-Y)+B@+QM@Y#@8MO!<.DXJ1E8Y*HUC$6$F%5&)\
MSC6FEXWPYG#J+RTXL'HOO,N_!K_=@FDXS&TCK'>[H==]?5XUQ^W.FX;IWE@.
MW&Z][[1=Z'9W0S<D;+ .H"G9_O9I>OR")$&/N3GAX][<LZ&75H![09PQ@BGO
M@/UX!$;!CDDAK)A_*%.RX<S8<')0#8 S3JH0V]2S-1KKA+76>^;@=R]*;;C
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M>RO0 MG[N2?P3"PW]TR%P 4!(65)CHE0$@7FD,)I?^T"6>ZY)_!,;+ U*N+
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MCZN?/Z+JQ3J&,5SL;/P-<_5WL[JQS6H7KX_WTP8;R@VRB(6,@)N8L;1P;$D
M;2XYP9)%:IA\2,7?)5+DS[]258A!@?536..PW3F_JY)4843>#$\HY>-G\G%^
M,R/"VVBL$3(3E/"4$1$RS0/*G(T!!QT LN"4[WQ'X.<1Z\"+Q.&7^&SLM[J6
MVON 4Q^ZNG=_4OR,0Y#Q!]&^M.G@S@AE'N]:,"B6"8#36NUB.:S?'40*X56+
M)B1WE=IN=XIG-<[3P[_E\.@4@FS!N[53\.]KWBTXMV5:+C>-%%A,->?2R:F!
MJS<=WZVDHG6YOR]MF/YF?K\S %BI_&*AX^Y1:#0NP[R_ <&*&.Z@\.>/HZ6_
MOZCLP]AG#;#VTALL,JYZ_(K)SL8A_6(YCDH;GKDH5<:(C)D1-&884::=#)YB
M<B^VN5PK$>,7/9\-;]>!@T/E6_ISUP8G:]P)Z*E^RV?#$<7BGS^FO-?O;;&,
M!SJFW\H'0M ],IW07;DN&$8R P32SBC'8B1*:,&UUYK8( T9-0X'P5@!@71Y
MTS2Z?ZULU]Y>;W34ZC<SWRX*VZ=3[ECK+S(@B_24O6(<._U>H21!6X(M PL-
MIZ-?36SJF]^^,"R,#"AD2&J;L6!0IC FF>3,6R0ELH:OK&&M5YF@JX+QD>B,
M*+PVPW8&*VL#KAJIY>]:_7^[29FGK-=ND9/4_D[O5->Y'7\P:"&P#^H9!SW3
M&:NUOU[I7X5'[:MF-QLO9K.,5S8X_^&*[MJU'9&W+AN^"2,O9)KMT_8 N[[J
MA)2J\C6,]C8.YNG*A<,70]\O,19>HM^[?<G] [GZ-]V[4-O("JN,0D+KR()U
M1FBLI \ MU@06'Z1*Z-KCCK?_9?#D-E.,">9B?#VKTSCFSGOKKR\CG6!MVZ\
M\7WO=V4^B_S>^R%PC,\F5#]J\U(OI P4YIMDB%N][EU3.R[.G^FFY;W-O<U:
MY?7VSFIEN_;F_J2%^7V#RX:QE4$68MJUE+8V5U);Z\O,R.]GO;_2MK)R3R?"
M>>H\>/=;W\N!4]ZM*EX(_:C=JOH%PI-/C%#T!<'C[2I]6-=$)L;;6;L(T=SQ
MB@?=\-CF/'XWO7>:98WIN^JZ_<A.O3>I..+X.S8?$;2<MSTT=Y>^>[^^6Z]L
M5[+*V^W:>NW-]OH[,'=O=W:KZZDAX6/#N<_1&F064>UML($5_&+RLCZ[5WI[
M&=(M2G06VR2>[04?AP^>"[O^1"?\:>9F+)6C3HI@_>OG;@>F*VO@8)LG+* ^
M7*=5TG^IO(,+BN]Y*Y7Q?Y45K=;FAO$!#\*PTJH&?"H\VV)Q[K5IF%2O9^\H
MA%YW$+[YCGXKE\ W93UO!#?\=1#90*7<+*S<B%G)#5$_DQN] &+SW7@D>4D=
MJIJA\MO.:1C0I/M[(3!IQ:@3CN#ZM%?I\K1W[2Z<,/) ZT"T4)Q>@Z=7JH-=
M1C?<T.N"6,K>0LN>7EDCI>Q-2/;>%&O%W;247"Q!';4;0)+N_U8V_^GGO?/*
M;QLAYB[OE0+WRPH<(2MKM!2X20F<Z1Y5WC;:W[YO+[\M1Z.9GEE*[CB"/$=-
M"$MQ?H X\Y4U/FUQ?C#QA]</RM202V?QBMS/JJ1;NP<WZ[4K]TC[71&24F06
M7&34RIIXFLC,?62O"%:2I0I65DW+'!82>%F>>R/ONGZWF[*_DCU;;YG&>3<O
M#/-WP4V2/4AW3>?LAFZ_,;#=WQW4,N:YL,(L1>KI]RM(,UTJ:?Z04L3S7I'"
M4P@F_- 8?4]RW6AW^RGA;MVV^[UAI:_*;MX]*85U8855RY4U]D2T.O><70@K
M6RIA3>DS'1A_(:CO.VT7?)+-4A(75A+A1C\7Q1LIF)C_()OTJ3NY)I]0\!SI
M&=,0P?MS,P:).=LI0V.G_N_-W3([8ZFS,]Z%0W!?"G5;E-TK]>TBZ]O4&>N7
MB#K@]:62PN1R5-X:UVMW2@$L!7"^F74)PWX?6U=:4NV9QF /WG ]^TI]ZN2:
M?.P6V?Y#DUF*ZP*+*^84Y%7_"O*Z7(&]C1!-$6'_>)KJ2(=6WNY<D=-2)DN9
MG&\&7L+X736EI.R9&,!D7HFME[)8RN)\,VXABWRI9'&GJ RTW1I4%0'ZEU)8
M2N%\LVPAA>)%99G$<//L*+=YN=UMD:4/Z94UCLHUK 5CSH?NSWY.YGS@6!YD
M&E;6]K:W:NOUC[N;>_<PZ:1+70X+6RYO91V,RM(ZCRBM,R\%6<:L,/!0IJ K
MXXK$M%]XN"Q=N:_6XWU_?[PS_Z'S(WX^/W-3J6C<6DOS,MXW.[6-S=K>YD8%
M/NWMO-O>6*_#E]?K[X#!-RM[_][<K._-_5O\]K%E^C[O!?\'^*:5WE&[#[?S
MW=74YSZD\F^I_&&QR'(*[NO@FS<]\_N#7FW*A??4"Z3U8^HN";B2CU=X[T$=
MJ>@+S<FC;OOC8YR-5WCIP8.=2/NLVZ5BG0L!3.<#8.Z]]_A9&<-YR/$:IT+1
MC5UZ!6*Z6C#S,7-3SN_UE:GO%3M&TWM](_.#^7A8\GCV48_Q9F"]VPU7L.)#
MN&'XI@\O"OK(J7S*/1Y9N?0)"FQ^"']/ O>@OVW%% SP:M8ZY=GN,2$!+K:K
M8SW/!$W[SA,:<^E#:JC\U32N.8+7;?98;XXJ\\['__VDU_OCIE\_-^]U;RW[
M?M??*&1/&8G**1RH\TQ09A6X>X)(A:B3&OM!(?M!8X?OA>PS.E8=^WXW.S3F
M]%5BK_663__9_,Y;Z[TWIM-)34(^F48_7):SIS,N9U_+==,UW[9VCM_FU<^U
M9O6B<7Q0/SJJU3_PZM8FKY(JKQZO?SNHUYK[S=UC^!V_H[M'^\VSQLYQHUG;
M\,UJ_=-)[0+&L+%[M+/U*3\X/CK:)YOGU6-7/+/6_' ^N@:>U3\@'T4:5XW
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M3R,Y,B>#\/KJE]^N^@]UNM7SJ@_]=GGX7AX4F>7&C_$\X^'+EP2HY2O-6>;
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M(SER7/.$9J^1@8B1S_?Y3)*Q 57Y%#A6!<VKB>8%I7D6-,\ S:-G,R9.<4D
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MQ>,U_O$18],@DJ9Z[T?FN/X/KC8=78V;/_-H*UT:6V&545AH'2%89X0F2OI
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M\91II]/<<U\$!&?:0VUY,^++Q84BII42TU(4K D6N* ^F!S;,)H:KC0QSEL
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MJ)=(6\T%M$CS_J%"#?<R;5$1)R3:,9N=!^NQA8C2?D@J(O<,668($ND%JC4
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MG"IC,4X26Z<*FI2M4!.'0MZ%O%><O">JC^7!)<XU"K0%DI,/C2%,X4BY\H'
M_>Q=BOTNAL;']&]LM0E48R093OHWU00IL!Y9HW+*OC<8F[5UAG%3$SJS>K^%
M10N+%A;]D;0@1(R!1.NM "R\=4FG F:L54+CAW3@PJ(+8='=,668*$?! 4?
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M21K&KK#<^)E'6ZD\V J;FSL)/?1#&J&)DCY08B ((C]1OG;UH</KEB(GYG-
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M45:$2)@BH-;6H0E3]3\HCHLZV@SSO2Y5D#YOI(\J+3@219SWR'H*")22R)
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M^!\9LZ9IBAN5@*N[P0Z\X7NPRH?V.+,D9O?;GQWZ@F Q;U&+F>PO%&@//NZ
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MF=)>5.2X#$:NB;318;\0$<HLY')78(N&KK+S%=_K=B:W8OKR-P;76Q:#^:]
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MFC>@WK*L:+ZR946S1Z^6]@%]/VZ_<F!\"*>V*H71]@\J!F5^U%K_M([?UQO
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MC"UZE%).-&.&&.ESQKE*4JE?O$F7R--WA9A[Q?>N#_RA#ORJOG4B<VE2'F?
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MU/6PG<H#NE%%>19UXC@0:B1GGALAHF"&\01_&6*NJFU7FZA[R1U=U.+]]9T
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MMO^?,1SFX4)%G')\W@5[T7B3K<#%P.Z?P4?5N#Q2Z%X:_V(C#V\UL!N_K=;
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MB8B=(9IJ2U1B(B:M3KF@@+<VZ1R3Z"F'S-W!/[+HZ,C[#:I?-?OJ+BZ0>\J
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MS(\<T(^*8DH<E2!^$^F(8BD#W)'![:R)=&(QC'=#*\;BK&?IRH23*"N3L15
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ML.FRT#DJY=:'3BW2,!U3'^G8>A%[ .\LCC-I(^-2N#Y;F8+%<,??VP-XG%F
M0?:Z9$9*Y/<J2GSJ]YH/)*X1?5]!7IJ3V]ZO1,3XBBM8>LKX9.EIXR28&->\
M,>J!+UW __T<C510*,4>-%YM%#]L_%8Z8H[["F>SU8&-0P]&#A>#F5O<O7#B
M;([O'7Z!"B<?ZO)+F_C/,_4-?CA1<.V9LO#C$*Y&DR9WG4XC8-6&<?V! HO\
M7 60"AH0$$D?-JMAVX"I4 &6FJP^>P[ V@!A'*#Z[@ M^M++@MZCW?,WVTU
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M5$)&3SD?5JW/<R  V+Y2NF[6AQ//U(6Y1^:]FSEMU#P[3-XLZ>':,NVJ0&B
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M>NZ;00_MD71<DXN&WJ2YUK9( P8%@8/M#G7F2*=YWBB]3QUUD0]#2K0ZQU_
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M+F0]_HAM/TI)TG<]?]O^!]TR[)98&YMY%:IE,[B?VX/A"*T"5#_N]8]'G>5
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M-VYLB(.)6$KY6;\L+&^2&WH.5H68H.,4R-/6"9O3 1A>7C&_X,,?;U\==$[
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M';T-U;C& HYQ""86/HB1S.;EVT-456"]8?>IBE*0#TM56)NX,@I3!,JN*/M
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MZ"*-"L7$>+LF%'.>>$@1-PJIF2Q2D5HZ2,'XDPL5DALUUGN2#3B.F@8<N]"
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M51;^"R4IOIG5EQ^G]*\TR_VYI9A@3;#VQF00#D-@:4 \["<&ZX^M6GX<Y/3
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M*(:M!<!!N<I8!AGX=& 7>)Z<(6>AOD#K'S0U&?5?M,4<IC&X=2+"'WW$^$A
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MDI9O^)5HIAR=0UKP!'P/0.3= =M,KB0A%9[3@@(O?B:!(I\XTK"G[96K\8N
MK%6T;Z)_U;<)=XS1*:)7R>@+YHV%\NF2>:.P.<+6I9=Q\ITKJ HZ_ST(<^7#
MTU_?F!\:BTCY\_0U$Q&5K_'MK.*-EKDT#N,A8U%OK(*H=A0=_X(#*P-(%5W#
MMBCW\1F+!O"(?R+X]O><SQ_^=/ZKTP;XE4,F1>FT'39986QRETP-1ZW8;!,3
MA!>5L>]<8$1#-(]D 4XQ96'&U[1FH?"4+;&*/+G I,P2OS$!5MOVM!#5/0F^
MR\W"A#Z^#$!=#F4I2U7&1R0S>C]B:Q,ZOTH&KD%;;9!4F5?0)>85L?X59;8&
M));0\*U+^YC*I\R?[?TJ1R)(%W16$>A7$6MNH[%0S;1PI61A0UP&Y(#2Q1L+
M*_;GEYT^NFY07!#%R_]%ED%56RR65$52^BKW[OL)'X>S'LOQ=OLB [;U,6NK
MM7##M!?,/T[PAJM:L\A"X-);28,'C,=O?@V1*5'5Q@&#E:H%L?G&U\\@:5\B
M.2&$7W%A/[']1^#F2*X-W=>!UZZ(B?VFFI:>3<!8V@WL7N6MTM6!7MMR5JG8
M$>R]RTD,[N1!?(FZ%:5GX >@=EU@T@MB",Q3N&!]>RUW0?I'COSAA3D%MG0M
M0)754[:Y7;#=8:EWF=\"8L(? #4M:PG8HKZ71HO8;\,0^)#?*.@6=Q+/19C-
M#X:2TWQJ-ZZR #PNAB8#/L1JMIP%'A9Y@@ZAH\=)L3[ 2JV@BB/<RGXO0^%]
M'R=H\Q\H5([H?R_N"[%4I47<9T>(I*K)TZ(=%GS07E77"9%:M;@9Z+R4VP90
M5P%L*(F,Z3K_Q-;M_Q.C(CP7GLCIH2\BN!08]2IQ\=XS3@;;UQV9K!R<.+ Y
M99FOEXB+=UM-8F5J<C;&6\GV+!U(7?6C-^\'S_1Z5DEFL8Q*H2-.3*E,@DZN
MLKO S I]IGZ?&U%8+V(CXYQF23FOL;D%+O\^3H"[3T<)<#1&R"G0J-)DYZ_?
MGYHT&:$D3[##+?YU/X"]ENT\M2\5#$AU[GNQ9GWC#>^:OZ/GMN!!*D),Q1"!
MGSIM!UX=\J0;M(^U?;+<U-78\>^47#:FN2F*(%Y "9^%N@,<)SSRF6EO86H<
M?NKVS+NIX(/OWM&@!,W)FA$J(O7N$GU:6158%W ;1Q1'PCQGB 7&<'(P1&HI
M=K504"V7"!XBBI#C$2FI")<=QP7F16.95\%::*I1$7.RN UT.6UMNSR",W7V
MLH;YF.>I7A,)R5P8H>H1YAP4$QE %U"L*C)'F7*/-WH7M;OFU[G,R/BH_#$+
MBIE#_$98BR\+8R$4(-P+13"%Y2\D>]H)?Z+=$0I"<4(9UYB*C)J,J9$T=LL4
MNBE0?&[+SG6;59*G<L<6(6+=)\^!86U MVL6KL]8Z[8>?+:1ID,]1@R4TS<E
M/L%*4^.MREK*"Q(OG[*+7+HI>:E*'_F&410K##+JL-M<H<045LEY(J2F"S3)
M97  UD23)T 1EB3H4KV6@;D-ZR7:7EIG-T,O7RAZ;57X H/ATJ\P.J'JA56J
M[NW[5RH*:"!1Q%W!>-"Q0?)BR1JG']-*KVDDFLV))&R<]_J=YZINUUQ*/_6!
M!X,T2ZQ[G_KR.=?5\86><C!.ESGC+4ARJ55[ 0I6<-R<;Y0"!G\JU(81\RCJ
MN!(6@]IX(KM.9_EG<6X4OZV& KOJ<.FI5/="P#MY/CS8&OSMOSK]]@O]^#Z*
M:J2XTR_/4-UH!P:;0T6YM L@*:?&(U4QSQK$& ;#5<O] 6Z7.!]2R^DDM!4P
M7&U0$-D@H,<1=:, *OT\ 1*)J80JO@BH+>M+D-%@H0/ /WO4+8TMP\)4@$7V
MK']^49;#7LLYC2RODN_C8CL!# =S,3S:"A6/.NE$<)#1MG*PB<D/E'OXX07I
M#>0;>8"MRWSZ<G\/B +8$ _%G<A.4Q+\VC13--5NG91IBM1)-?GH^4],. 18
MY8YWB-6:8BV[6*O3%&L]4+'6@XL=>XA6#N*56ZYC&6:A6HSB^&]L"1<JK<H7
MK^?JG@CZ+U,X1^9(+$J@:R=9:GA:B7[2$I2+P-L^0VF;4/ UYC=5J'F]KMDQ
ML^0*.D,/?O=.1(%.4Z-6"G9N';?\9_!]*I:*!=Z].P/E0-^!>K#O _+OEW2C
M"8.LC6_RPP\<X*2K[JM"3Q0" J(P9G@1?+JSP!.MAB^E[C)TT=F7B=4Q%!?C
MI34@U5$4/+F#B1(*=#\689S/0'I@)PSF75>YZ_I:3!&,,-S-_J/EK5/+4,O5
M7P90$>J47'.*?U]!(P1,?=62Z .SGG3=3-\\Y-:DE%IQJTG3M1J\%%UQ1(XW
MLC0>+$]CN2T$&2+HWZ+]0@.I>!D+;WBPY_3W_X'%_9@.]ED ZIQ3K%81KO,O
MNFKM.N=Q$GM>[#JOQ_,9P/B='(H(/?'_R2]%P(1R&HZI+$RU>>47ZY<F4K=0
M$93WIW)&] 6H\CV/N$/.(M@I?E2U(Z8EWA3?0DKCJ;G22FUVS>2.B00\3SR,
MR:0XIVNZ  *5#*23T= OO(M'P[N<$-OCP5KX+QKN%:D0*0?=(GTWS')W+@7;
MH(5ZP6X4F55L7-W"PR8V.#2(A9!L:,#CT0Y&0-=:/10^KG5"42?O55&HW2IP
M:]7SVOM+>,%0I,&2_CDWG*UC[:_??MQ,Q\ /J]].L:)Q0#>2UN0?MNR$8X7\
M*54@D\@YF\^2'&REKZ8J!Z6C*?KC#9'8T@#A1&4B*\/4R[*<@^2M(QTBL.[4
M%<K ER/U=NLINERGS,4B=(J](Q!:[-FA$"[?YBQWGU\(K -!!JJ"PNRX,&WM
M2P4EH%=8EW2L;JL(_E/\9154P/#YV00&%]74.K3H:;D$H$35 BU"&"]PD_6-
M],20*D,)'UH'):N9.-]SE+I@LB@\5!><L:T%SI^H[!S*+/[KWX<)N'OU%'=;
M-GXV8;HSSG.^C6!_&3;EKNGY-BPWP^Y,55=%N)D!TNPGT/0424.ZM,M)BAB3
MEG=GGTY?%<E%0UBK8:<??'_VUCRF99EMNB[$GH$8AT&DPJ+XEE.,DOY;1M(3
MYJY=,)WB$;V)]+[KB9V38!A0 XD\P; 2]M[<JO-&L8E4WYSVC5%X$0ALMHO&
M_52":QP%*<?F/>W_^@$(@@Q,@>_HTZJ,N0<^@6I.@;VAT  13AASXXE1**:J
M.Z*NO*(8&XZ'R2EYY'PYH!6T.,TP4P"_#8,1M:/@2CL06B!U6&Y:KVTY+U6K
M*"UFE:UD#N"JK,-4S*D@L*CQXKO:<[!ZQW2M6G6WXE3%&,M3*E%5A0]=BSZ9
MSS!/CQ-P SUW ?-CA=0!0N'0-5_'["S4F)7&3? -IFHEF&%'!PK(L[G'3;I<
M/$/1M6@88,A2%?(G[(,LI0Z7#FC1ED7>W 9?$[DZ[ZI#I-A+)"IH0M)\"2_)
M@\SJ#'$[O>%N3TA?L=*3#)5V5X=*<;N!_X^]H#WL#P=BT.Z?G(P.Y= 3_9/.
MX-B7W8XXE/W.\?\-NGM-?/7:\555\'?G%%!M-YR5KG!\ "M5C_W!?\Y4R"2]
MBO_N_!!;FD,Z3H(BZI,*SGSBY,HNM8LIG44GAU37OM1.&%D9--N10Z_CP]?/
MSE"7V]I&BXH)I9-@5CA-J9Z]E:HV?5BB0B[7Z><SI]_NFV[-'-DFZPR5K^Y9
M:;:D>H_9^@<VG,\.2CX!V 45/DLY9,9M)2/5N,S$M+8\6"W[!&U)UJMLW3H>
M;2U-EPYBXP[=N@BOT2LJQ^S-E!N#T14;;C-*?3?\*TWQK?JBEF;.W<UXR/Y&
ML.&L\*8H+4V][%4C^3X'B=9@9.\Z_5TYH!=I)!*FB#;5-\0$CT\*I-4QBJ(E
M8-Y=2'T91/=L5"X ]UET%(&9BYLW::EH;K%BM$0F46JWGB_F'*QM"KO<(HH2
MEXK>[8O<2E*72SC++L!JZFS(\>;D* $-\5P60\VT4+0K[E*!';SQLR%HWE&
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MZ!M)UY^+P8"]MKORT,N8;..1]QX1?-[#)\O@86)8#:2G0_?%H90R1 L"SN2
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M9B>*<O0Z%BDN,)CU!B"^!9Y2BS]D<&<%.U=MZ<$QUWI02+TM63HNB&.VARX
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MY'0(/E2O[3K==K?C7(K4^:G?.G)@0V$01ZYS.0F\"7WNPV)9[ AO$L@+;#Z
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M6!).08J6F=(6,@="&R3=)-9$KP^=;#01?-4L((E,V$Q1%J@$!\7^)/X&=#@
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MKV@"G.?37HW?*$?I23.BG9AEI0SJ(E]%!#"G,J/-9:\+:^=')<7'Q1>"8R=
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M,"J'4D # 6N5;,N 7)/,$@B=/E&E#30RS=#O-0?I+3:<F:?W8D33STCU+=I
MN$J]MW;PBWR/@BA&A5H.: XR>0#KEN0D2H,J2.KQB5DYSS1G?'4V,=$4UYK7
MAU(FV'*Z6#MAIN[DMK',9U,<65M:=N[6;CUNC[6ZM4H/Q_H>[)TXL,;#T?D1
M(^&%UJ2,QQE3A,]!IY1KHCE$$U.]I8UNH>V4<0^,GN/@+J[:<'.!7PP^:;_9
M]-T 3V)UD^6N&*<Q3L4CS94*]M["%@,0HK^8TLD+6R>Z'WQ("Q9MY^:$S]T3
M7O(S?.IKE0^S>*9/]Y58V7LL@N!"_F7L]<^D__!"?T%CO=O9_U<[:+QW^.D4
M!$))0K4@!5JO:A/.%,DD!W(*\ <56YI]=@FZC28E.HLLP>)$GN0%JT/;N23-
M?F2E4* N#Y[B2(4TSY^Y'KNNG/W29!7(?K0);<P<-P);)ND 6.B*G-TXF8&Q
M%CQ]AR(SZ+O15^>Q8-AD6+TV?^8Z663!)QQ58(GKE<^B>H+=R:"_AE"X-RY4
MVTV&T+6G1(8=3_K24R7NUGEWE2^Y[POAB;7:P_BF/(W;V$EF@B).3;E[;55#
MUY0YZ\-P+ $Q+7);S)@7IH7.'61''N4 K0@PUP=SLD%Y4(3.<*( <(J?=Y4[
M;N5.?U>Y\\>JW.& 3TZZHI$A26&@6<&U\*(O<E>'ZIRCF7=+10SP-5LERQ4-
M<R.P;*2H*J#\EY<X6.0_W&+FB 24<L.PE!+;)I>R43KA7!)1:<KXJ9-Y)?]J
MM)<=<+*=?=4;E_B3S_,%VRJV<3LK2HZ=GA!4")*9D&R!D\>@]*?;'#27? 8:
M80M-(HMM1)G7T:T=?"%@_"'2%+KT%.(,"Q[XKB<KV4Q.[J5R:AIR;$#,:SJ2
M 6%+.J/@>7'F%L+CJ@;D%&J3VJ9KJ2*7+?:F7ABT/&0U4L^2KW]6QOCDU(5*
M9,P0_(I=43?J@'$MF3CV72PWNE:1!QB#(.' MH#H>#4%XQ1'9[AGBZ^N5%I(
M82#:BAG.WB@F2EN9)A)5TR94U\4>BJ2BA9F=Q NQ41LBUWU97*KBCF9C6XC.
MQ8E7G=5V,LD;,BE"<K(/G$J@--8D_D:Y,LPH4(H#7Y;C,9(1+XT<'%'E(/+B
MGLGIEXEAH-1)UE+TQPVP^A4V4L3'92'H,'K/=0\09/:3D_:1[?WU@THVC)PO
M5OVT@BBC.+D,:<92K4<GK+XF'IUHR06'G:B1A#C%2W8^U:9C3O/XR*-W/LT4
M"*!$IIM1>(>O3R45HFR0-GDE]T6U#[P>4WN_L!1..&'&M)G\GE[2;##)_AYV
M_O3,AOR]9^GYBSG<#9D'03E+F;_4]W J51RZT12L9T7)+GX0CM.C$-T4KJ0P
M(6'W!>W@8R&SWEH8,M2[\]B6!4+E,LSQ>0+-^)WXH@F5I!7FH7(-2-G5_?,)
MQ>.44^@#A7)1,QGO&8T-\L)83)F(I9.:' ZSDAM0:*XEQZ=!BG"(Q"FR--YA
MA8AX<*.^45WK$R>+S:)./RS&@HQ06R$0:$FOU=#]J*O[W#%"'$?^I-*&E?X4
MQM5G[B3=QITL%55"=%ED>F$I?+ P.]R.';W!&/%J5=?*,;/X>GR'.[FS'7PE
M(X]38'I8J_L2H#F:'BGUB&P?9CPO%$Y6?8<U4$N?WE5E%*2;%)*N>!M@E]^8
M4FH2)/[)H-^!U%W.]JD*S;QGI%2^.,+=R:796)$M4*.HJ.#^U'V.CW"_4RUQ
M>WQJ$X<;+Y09W"XE2IUWD ]!S"$5G5V<!T>=(QU^PDFI4<K@"B3[_A$F)=J>
M)-BZ)YH(S<_BQ*Q94[=;),Z6O8L696U5K7-H1/:HG(PH"X[;'<!EB%UI')M%
M6M?5'!PGUZ/G\D+-\A>/[NZ[SX*W4EHQ]"9Q(E-E8#O_U_\Y.3UXV;BOK=E(
M[UD 2E&/PY6-:&(F%P'D*S4C8/(M9U\ENXJU4R.WRA/.'4*P$M1YV)S+WLEE
M'%)BC_7PXO\&@3E-.*G'>KA].-SW3G9 6X$@]7,>6\VEDE6%@^8.?"E."EU^
M0=ZG%QUZ+&=P &=P!MSNL\G"$9A9NO7T]%AV>PB[_>R@<SB2E.KTT-5E#_L\
M!5\2K$Q$Q\M':"23I5"__Y^A"_]UQ9[X;.V)]WZ2E?RBX),8!MM_Z6>%E,DA
MSI'<.E89V9'LE0B+J_CK;*5K98N!7%E<^[N\BI[!B3].!AAO#DS5R,/F8=W/
M^MZT_G )G'CEBSS*,3/J+D#<'7&MY2$Z:OE6N]]F';3YT.](,4@V6$@)?O*U
M:6JD4I^6#HYJ+(_Z(^,8>IRO7CM&")<=NBPRXSB%9&3%]2RR=!)(8%7L.O7G
M7'_2PL3J.*!*Q 4<#S1\Y9E+;T@2K1;I!$.)YB$ZRDL-J5P;8-;MEA1P94*E
M9&&QET1C@228[+<^O+X3"[:2EP,.'1<&<RY<\"SXPG(I6; T+R5B:2(=.W3:
M]=*=;[M"T0Z &*L/A3UU19PIB<G:VVAX+O4%/>T^DY!,-B43V=Y]W>E(J,(T
MP]("*F_#WST%PTG6A?=7>^:Q+2Y;OE!3".YEC!4ATF!D-'3TY^ WCJ*W@'(X
MMU133FF8W-UO=6E$7M^E7IZNNX OA!,\FEQ-)H+3-C1U9[*)K?34-HY_.-D%
M5S*<8R?4-FYPJ0;ZW)0L<5 N=0HB<3J+)?ZOFS[;0>.#3+^H@T<UP)9D79 B
M;=+R']10YLIOHFFD9<S,#IWLCEE@R]:"-NT DTDFLBH@3K9&TPV/U+?7R^*6
MP*SQWCS$93BC/$T2)9ORL([#"7P-EVZBLQ3F:(! ;F'WH\XZ3*@LLF46LZ]C
MI,CT8Q42%JC3(5_MX=-G561Q:)8&A%1BAV6IL3\ETZT=)XR>BO?6\L(]SG?]
M.VQF]C]D\<G!KOCD%HM/MDZ.ODUL'X';&D0VDU<03OALWS#\=D7*W-J1:0!F
M5(3->IB,7XR:<!&8))<,RHC?CTTU IS^:!165C!2OP09H95%DPU=7:"N&*"L
M;9@S-F<<N>EEHR;(9^5V2WK9G')(E,4SG4*X.?,]WBZE4'2NCXW6+5:I31;"
MD,L9WR(D1^1" %^0G91%C]%.D$W%O"D',#77F](Q.@0G8<)$L[+7>7F'%<<'
M:'D0*HR+M)RE28I)./HJ+:+[<LT"Y!N#41]L+1CUQ]%H_Y74Q5]07?R9XVP]
M.E+\M9)Q7:BX-M!%NC#/=O$(1L5D3C]M4;8VA>/QVP9<7Y1<00)+M+)V%>#T
MS8GH>&N)B'BXWVZ,NS_D5)F'75/]>?W+:?@G4OF7TXG\VD!^Y\'9("V+X#V7
MF'Z.\V_K:KP'!'YWFDI,X@YC:4@CL4:OL_;.0'FC%/(IN'/4-::;,884TD:#
MY*:< Z;O=K/.03/K-/WO.8<)!2P'09HCI)BMH8_ZW;[Q&B@LI0<-V[DU_?/@
M4[9^Q8A:S*41#JC_T-WWS.R[JEC>?)=2S+-A43M%[-Y,/=)NW7ZXWSU\JI[1
MLKN'$?]7RX:[(X5Q>>FV26BKKERH"  Y$)8 A%X@_,]5 =BAC[Y..9@B.HBI
M<O9.Q:D:;06"6H[_FI=3C+K\1Q(59L:!TQY%8 /:/) 0K57HH+/_G#MJ'7>A
M2Y"QYK0D6&Z[-^P0&(*_5'+@1=?4E$D\U-5J-&/ Q%?=V ]^(E,L,!CU70U+
M4@HIMO'#MIE,9,J%4^$HG[>HOABK(+C5&]NYAG$ND(0:7M*<OB7$[2P_6PEL
M[QZBB6];2$=G,,3Y.%8CH!A]H!^= ^7/K"?Q41^F3I<)M!L54&-=KO3#4_WO
M2E[6J5F51-H,E "IKM2F*M_5W8^O*/3'Y:+X==O_W;KI%JL(%6ONZ!I;TLUQ
M:-1ZB\I#/2T9&<T3ZD8,EY50;C7MU>NQ=_&4S#4R[4$\5RGCKM79O>6@3:(R
MG^=P=U12#'(.*WW'(&2N%:--:%!;)'&JG$7)BY@88MIQ";4+VT3861*@;3GT
M8JJF34HJ]^ITS%*D_X43G 9MH"49;=0^TL/@_VI:4OVR[@6'-5^"2L[1)LV!
M^H=NF8P%R&.$AI9;+Y[K)BNZ9_U8;P@01ZPE61=G&@^O!@)GXM"30 /R>KVW
MT.FKA1Y46H![V/I<G6,-!14$3T+08+F_5J,488MZ%I81SY%(YBVM($,QP.=.
M_ V+_1@^A\L_&_9!DD6+!DE0T/W:%C>J'&0-A9%/LO=A)P-LRRTGQ=SJ68I\
M1^EUPGMEZ Z=K*2;SF,<XA&H+ -C >'.XAQ["-K!F>G6PS8W[\CPRBBZ>44A
M =UP@6A'<)0E3?_AJ^;>$LK:8&9FCG/#L9)6JH^N4X.P-E/IC"T6OV\/I7U&
MS&#OC2OQ'7K%VAVF5/=V8X$:Y>P/'!KJ.%8%.K+LM1&2V\C)5;<*7^+ W(KM
M$+<^BB2M<B*N1U9'P67J]N8E6) <9 8JG\=R/BPL8!,-:<XB;^CFQS3AR\A?
MRF@4PBJUC!3.\5:Y'RJ,P%+!A+-SSR[.EGF6KJ.(%%:'"K[H;!+;,6(, ^(,
M67/4&;6-8[5BC$D())BAH/<AO5RN9E?B['VK$!=OL%7;^P84ZK0=".*#H5_B
M1UH<$SNN&O]+.I8L$WY<TPZIV.5:7*PCE@D%4=\W2S,KH*EK0S"U+-ZA%53&
M6*JA;/(/QO@.K#Y&6DP4FNYA-F]YE3(-E[?E#N^YI5:3*!;C(/B(Y&]-LL\Z
MXO'HK(37-LA:C)'_5@RR;(G4(3,29([#TH*PIE/%4B2%!V7YQX2&EGK)GJ<Z
M\CS5T3,+M*#;GPV*,R%E<C9+V&)NNKW2Q1^T-EOR+O'M);X/FQ/?FX3W^GN[
M=/EMILOOB2CJ1>:GL\]?@K=O@_W@XY>_O_D<O/WPR\?/[\^^O/WXX>8!X*/5
M >#M\2YU2G33F/ [=0FRYA-/]D7PAD=>X-WM89C'#%'IGFKU(7^01DONP=1
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M]P>"5 2>E5A,82$+X4Y.MAYRY?0VQ,J:'I4KRI?&/YNWA85/>L+8(,QC*<5
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MPYMF$8Y=\Q491_?)L!>P5MU4%6.%"J;97B*_LF!G8#V=+<N<7&RE=+")@YW
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M+%$S$ZCB<"P[K&5Q3<.:T Y9)ZZO;>].,2\INZZL^EXPBFJ16+8%N.BP<RO
M1=W#'7#1#P,7;0T>S\7;OWTX^_+U\YN+1P=-YL9J6"K;J?5K:Y6*.$<LW:@$
M]4>^;<1*,6-52#"JA'7,#2/H^ X4J).1AG G\I OR#@4'(^%SY-QO/\!Q_N'
M#OK>/9&3P_Y-/)'#]O')[4,:]>&QI[</P'0WBSTX:?<.;L5M^E&EZG[UZ!$"
M"H&8>G/QYD/PZNW'5O#VP_F-')$_PN'5^P1//QL!]^RA[;L[M!IO'[_L(2[K
M-5CS+V[?(WW0/9E^"IE)\I-M[]7\9[NPY_ES3D]\&</#\N!S.S@/DT1-)JW@
M=?O?[?</)H$?YWE^ &]^'1JYS:CA@VYX1S>W<XQQ,?GIM,&G3.4T^9:"A0UE
M,=M#)S\923W]E,4)#CV?U-0BT00^=%?/C+NJ/ZNQ'!]MF&YK(G+=YHC<\T$:
MS>$?XV(Z^>O_!U!+ P04    "  70&A3Y89'EU(4  !LS   $0   '-E<VXM
M,C R,3 Y,S N>'-D[5UM<^*XLOZ^OT(W7^YLU66"P4DFJ9TYY8#)N"Y@%LC,
M[/ER2M@"?,?(K%^2<'[]U8L-!MNR#63&<YRJJ=U@2T^WU*U6M]22__C'R\H&
M3\CU+ =_O)#>-R\ PH9C6GCQ\>)QVFM\N/C'I]]^^^._&HUO]^,^Z#I&L$+8
M!QT701^9X-GRE^"KB;SO8.XZ*_#5<;];3[#1^,0J=9SUQK462Q^TFBWI\*U[
M)[?G;5F6FHWFS>U-0S9NS<;ME2DWFM)-2Y:OH'P+I?]9W%W/T)5A2'+#:,NW
M#1G)5PW8E&\:4AL:<';=:L_E:P;ZXMUYQA*M(" -P][=B_?Q8NG[Z[O+R^?G
MY_?/[?>.N[AL-9O2Y;=!?\**7H1E;0M_WRO],G/MJ'S[DKZ>00]%Q3WDX;WB
MY '",\MY;SBK2]K<YFV[&96F6)8 W<*>#[&Q13=]M^%OULA+KT->7]+7E [I
M/*G1DN*43'];+4[FZI*_O #0]UUK%OBHY[BK+IK#P"95 OQW &UK;B&3Z(&-
MJ*3W"L1>^]!=('\(5\A;0P,5Z(E/OP% !62MUH[K YRH.H?>C+'JN3ZK1AO6
M)@WC(NT[!O29GM+R7M2V1*U+9/L>_=788;Q_\<R+R^(<!%YC >'Z""[B-3DG
MX9/RW,0T5KJ]O;U\H2J8SD>J3K'R#?IG0VJ5(YNEG,5IDU^-J-XY>-@-OW(\
M1/5.Y"%UP&5I1%Y-]MLKR$;Z "[8"5$%VOJK,@0]9+Q?.$^7AA-@W]TP=<X9
M FE5HA],^8^A;R*K#.VH./WC:)J>OW;+$-V69W^ED(48.SY#H$_"9^NUA><.
M?T >43V]BY1UC.:1-4_,2BD6@?WO#KJ&Z]@YYN-R[3IKY/H6\N(S&@-8NFC^
M\8+.:XW(:/_+AK/WA).H2(+ _HBCKR])%63W=RV)ZE*E)_!$!C;B?5/EAJ]=
M5+;AI J9][B@?_GV&] NVWY2Q0CL_XSFFVA>MOFDBH6M(UI/:T_)>V"9'R\Z
M#G''+P!]]CC6LMTJ1I(7CM BO!TCGYK$TR7_0&/GN3< J_7'Y6'9 Y3 0Z:.
M/[&_#S4[K!P6$50\4(G"]?;[,K5:^##J/%&7ZL.N.IRH7?+'1.]K766J=N^5
MOC+LJ)//JCJ=%.[O?"2!,"0FC!:1P(1T)8JD$6&"."@(40&'?9-6K(]'T"7-
M6R+?(@R?3W3[L&(YTE%_C!S!NSTJO]==KI,I^>] '4XG>D\;=O2!JH_4L3+5
M2!EE2(H.1F/U,ZFF?5'Y^[X^.6VX'DE2K _M9E,NI@\[\D#O 4X O-NQ\#L@
M3( ]+K:E*"-O*A.37^>S,GQ0)]IP,M4[__M9[W?5\43]\U&;_M55>UI'FYY-
M50J0$JN(3"*P8U0D)$R4 ,1)_S?@Q,&[D/R;8I22UODFD5/HBE7FJMF\?E65
M>9N.!*)4)I][??WK^6:;':)8[-?-YLU18B?X@!&HD1R[ZJ0SUD9T[M1[]X]D
MZ*G%'83TR@+ID.A0DG@\97F&[7B!B^B/'0X51(14=S%TD0\MVSM)&A&&2"AR
MD_PK*A1B_3ADG:S=O3+1B 4B/N6$6 OF:1:52EI5\0AI2RS(W1,&0Z%BB./4
M2 "3Q\% &?^E]R;:PU CLZ]"^J#3T1^'4VWX,"(6O:.IA>U6032QF&2)Q;![
M8@J!J:!BT&"'#2+P-]D=]/;(L2W#0H6M74E4D2Q;S:M6TOX5ER5Q T,R=;*)
M8[6C[G7YF,P[C\,.=ZB*BC$'13P$KR6V;+ G-@ZX)Z8]R!I)J*=HXR]*_Y$T
M7)D\CEG[E6&WIPV584=3^C3,&C^6$E<92+'L;B06S^_)CJ(#!@]B^&Q%9TL!
MQ$B\R3*MXZ=P9A>WH^6!17)M-S^TDZ:TK%S!.TZJ3N:TA!PFP6H%W8TS5SP/
M^1[$9M^",\NVZ/;< $':ZR;T>]!ROT [0 X>(R-P70LO[J%G>=R!?P4%.1-C
MXECE5DZZQZ45C$SOG%?@S 'G%A!V08Q?$#$,H \HRX#Q#!P,MEP#QG84$KVI
M:ZI6#*'K$FZ?4,EX]A020A4B7D/2=3]"A;94:QD3'V,7.DN(%\BS\,X$S#L.
M]LE0(AU!_O(L$[FL8:^G+*=P(]8K24[ZHZ>9II!%8.$]$T1>;/D$>XS64A4U
M*NL'[;Y/.GBB3ND^Y(.N=[]J_7Y1_1%!"!U9B<8AAT+?H0$.Q^0= ;Y)AO9"
M.3<U'TCHEDKM=M)K$$NICDZHH)=+VN,"2&);*LO)^#!/8#4T?;1_BR]\AJ7%
M!NU*8OMG>SW/*]:N7X]U73-JBS7^6DY.)!RH]KZFTNF,']6N^FU$=W$+J_MA
M-;'>WTC-#X?]'R* "**^?5YNNDZO+)ZB/[234=EA_]=Q4C[HRXZS6CL> W?F
MBF&X 3+5ES7"1 HES=01R&(3=BLGIXZ$"&D&]9806W_AI$!$JY8F[N04O*,2
MZUI2JRDU;Q-[7V^9<CE2*6<.\V"$AK$EM9/+"GF):?4SDYE]K/X=6/ZF9V&(
M#0LO2MK(LK!" ]EJR4D?(T>4#< I@2VI-_NXEQ'JHCER761.?,?X?B[IIJ.*
MA=N6RUI24F!+"#!*;[*-2X$X"BL'GU6P*9!BJ=+[%4I+E5-Y$VFR_W>K[SM!
M:)Y'_#^(S3%ILON$S+GCTF?T\/NYY'XL7;%R7,E2,G$H3SGBZ_MQ/>'LL'W(
MB"% . (12V^*%!?H5[HB@OVR,4]A/+'@KV4IL9Z<*_B(1"T%J2KCH39\F-!3
M6"/20Y^5L5I4:*EUQ6'-C90TVQ%,>!0,$"C L&HNAG+!C !!',=\:">7]#-%
M4L<0)JUGZ25+9F C9ZZ.RIX(*(PGMG6WLI18F,N6&[&#(0DZP1$B;]8NT?4*
M]BW3L@.ZH#^AR40LX^BLTA63$ J\W92EQ()#48''Z8(=X5HJ >N?>X6=:1O0
MU<]2)T<R:@NGO;8DI3BD%*C!D$ <JO:2*+F()\(0SGSM5CNYM9<EE3I.?.E=
M.UE"%]U#@DDW#!#V&)?A+D%9M_]X"F);V9:EA%.3*5KRBE)L,)(@3C/:_'BS
MD]O>.G;SO2":6*RR+!4?L77?GL\87'110U]3&J6#],* 8BE>R5)B/U(T.-DR
M3$CA39+;KOF*Z!VTR%2>D L72,/K@&7W*YX7K,XHX!)TQ'*_EJ7D-DNVW".Z
MC9 PX)392ER,=BTU0AV,^OI?JGJO#M6>-AWUE6'A_)O4NF+_]49*KJM%,"#$
M 0RHYC(H&RP*(,1CZ8,L)7:UTB52R_'!+Y>:*M^*IZ7%JXA'PZV47'D);[-B
MU>O9SV4SQP\K"F,UN=E.YC#%^[R.\5FL#UGN%B9-\9RY"EULX85'KZ[G!U("
M\E-?AV=1O!F:.RZ9QHDLT!2^E%[A.C=9H:&3);F5V#'8$WR8N,:X8&N;(1_\
MZOX=)V#'"N"\ ,X,8-S4W4QV I=>FD7ZXAYA0L,?N<Z313^A<()ZY&**9=^2
M6XEELT/9<Q)4AB D MYMR?Q>=ZEVPS06TCVQ0[3'2U2,)Y9F6VZE'/;9DV8$
MS\09/_5;<S$JILE0H:UA8KE6QYS%+ HG%B(9E$+?AZ86;]%!#+Z6(NQK'9I=
MK3R,U7(7L"0K"EU2^4I*[@V%&& '4N>>+WM6**N^>'A<DSDK7PZU' MCE9ZF
M[DQ)WP\?E&%WK/;I=8]*9ZI]T:8E[@G+!Q*/E1LIN3>PA\G.+X:H8 ?[)JM=
M7Y0+]HK"B4/ #^UDEG81N=4Q-,SM\9+FL#">V#S>RJVCAMZ;P4SK\W-XA:<1
M$4K[JBFW$KMUA:3]YD/NW>D\&&A3YC>PF_S9]7GJL,S-FB((X5Q)W,KDAFL,
M+;S6/X97(\%,'N]IKC+I!_5+&=\^44\L GH&.GD+9@0!.$:-N_WHA(0\'+%Q
M:\NM?+'4*0?AC\O]#\#QWWL?B:.?B N_P,E$2;].]:\H_5Y]65OT]K:A\X16
M,^2VFBV9G[T8P$VK*5T-V.,+ &>>[T+#_WCANP&Z8!^^^WA1&@9;MDW]P@B&
M?<ST;HU<RS&G[,-69L#7BR^ %Q":EA_07P^N$ZP_7O#BEH]6%X!_!VO[==,[
MTUE!"VOD'07:?3(OT?8)M)$^9PD.![OL(]<RT BY+#,IWN8YM+UMHPO7?\7&
MKD,B!9K;)SQA#RD+%[$W8V<#;7\S@AOV"YF!08EV',QG?V_H^ /DDV:0>GYF
M+YP*^[J=0VD4Z)M';+%/%OL;??[/@$AO*=;W[/)54.R.0WEPN.53Z,A<<-&@
M)X0#GMQ'W<@G9#MK^F)@D0C-=S 2M_ITW"KT#C_FAJEFD&:,;(A;S>:MN.7B
M.E5HU3=]H&@NLMD%HRL"9HI;E%V^"JWIHIFO8<(W^\"@ADWT,H8^^DRL[%\6
MLLU,:Y1?,;]Y_!O#?L'6A?6#0C8X/;DV-I3N-[LBH0E5GJ%K;J]CC.5>T6<#
MZ'Y'/GN3/4^]*M%J3&[A]C)>]!%IA>XOD3MPL+^T-]LWT54JF?U4"J-,L_F[
M&;3IB57R LVL<MJU(B;4A^ZF0$?D>V*[)Y)\JE>7AE4%^U%DIM)39ZK1DKS3
MM-,GPD+P5>BK0P<N],R(&TLMYQC]'3#A;STY#4^72%G1KW#K<^[M6<C3GU&V
M53XGB4KXB]D-BOC=Z'B(:,H%;1*-%++MSG%@E>B'/RT[("KMKJ"! O;!MX[3
M]W-<CYQ*51@3AY:/S'C&DIB]=CF#F:A6A;:Q*744$,[@OM(1'C3\=4F"&<6@
M(Q(AS9LZCQZB-S(0E;"@;6_&9&YT,&V#.I\[KD]**,;2(J:.>P6DU4K@+QW7
M^C=/]Q*[)3^2C[-W/G\253JQZ[L!U1C6[#\#Z/K(M3<TFTX/?$\AM>"&\J[,
MR8LN,9KZG%@$L5UY)6H5Z49/CU];$ET.TMO=5J*$O9(9TY5$>:5V$W@BB0*M
MUOK78NL3*U!I.[.=W"*=TN>'.AA&(1Y7T^@A8_\(?3^98"7FVIB>[C;H.G!M
M^=#FNAR[LJ<7^#0B#94XL\M.PGRM <'H%I^D=7=,%U^IY2)ANTG]2.*>DR%,
M0]B<F3JG[L\>\N$MH%0&U)-0L!F+*<)8-,S!S11Q*8P2BR,'0:WA(O/UHMK[
MP+,P\CRBKS,+PW!!.>VK%+%HS.-?BM!P%$ED5(E273=#!QLYO?GC&:GJ0H/N
M+B .G2NB5.RK/_I\M+]AQI9NO*Q!6 KB9X_%].1K#9.HS" *D3Z^!.N41Z%5
M=7S&YA$^;?#E(65WC5POFC^*S$7Y&*^SBEMXZCD,V;?K.V$,$K.MA<-^(495
MK4"*/=RM=84^51ECFE+YA*:_KM+']G^I[EH>/?32LU[(9$M"IB+;QJG5*N%L
MQIC<.89\6$9A-1N/M%R1EA8 J:J*J_=:LRV)0Z_],E6(OKY8AH6M8"7F^[!4
M%3A7IH,>-)@?)&8^I6 5^/]B/=%M8GAO.1HV\OH_K6P56G$X.]T'&R?PN0/[
MB(G'.D&&@TU^,0@/E O/=(6P*FOVBVW^=&PRL QHOTZ613'\*N@1%ZU&8FN#
M3_#B/(N,TE5H28JWTG?P8HK<5;3HQ.9S?]^98UI>Q@4J 5K9,9*1%";TBX1U
MSNWO'^,3'23Y=1R/AO)\L2RS5>)*56C6V#&6.29IKT@5QN)N48OP8/ALT;9#
M',L%7;"TB<:8Q9?%<A&J&G2GKT7MEI.F9.KP^#(#_UR&AGU$?&]_%UFSQ5RZ
MAT:<$'\3#[O)-!SMOHFS8'\P%S][T7GD.K-PE4Z?\TB=:DXX&[/%B@5-_';<
MS=9<>[L]B,QN/!FW"J:DF.LR62/#FEO(/*M#E(U:!8,53FX#4MI'])LUJ(?R
M4T(2Q:L:(^=Z^#W+)1/?68*%%*A?Q@^*LUT\(>B@UBN90*IJ"^06SJ!F!IKO
MEW+6ANB9/?2B+4+J[ BV:\NA_"JJSULQ=49PPU672T\GG*@O-'O%*Y<H5P#L
MYV=D'/+]N)Z[#O:)T2K<U'B5RHYG049LZ^A<VE:5)JJ4C:F-MEI#RZ7EOKH$
MONL\XS(;6^GUJSJ>6=YWUWHB#BRFSJEB_E_@^>*-#&&=RC9T+]T]S'0?BV(F
M08VJ-G)@&:ZS0K[R(!Z>R7)5&(PT#P!ZR^U7#ME6>%Y>6TZEG[V/_F,R*/+"
M_Q_,156'1WK*G([1U%JAP[W8QS7=IR3.-]_7"]/12Z;CE<2NK"<0!I]C9#@+
M?F [%G?Z2\<<.3[;VK&+[X>?A%G9GAJH0R61ZR VQH(:53#+L7WM 7RQ5L%*
M61 ^%]!'++V4'?_6^,H7-#@O^5ODA:&J:DP4>@I,7:UM9X,0:U(T^NF!V9R]
MW$)UJR#\0\7<938\KGME@Y[TRI4=RL><5!I8F*KU64\_;3&KD2N3.!P^?7:F
M2R>@WVGH.8'K(Y2W[UD&HA*C@/A."-$X@!ZTB;E(^S&"-PPHST22"*-G://E
MBVQ=. WUIR^,15N6?!XOL.J?7>&G'E/OV-#S]/E^DGS4Z6P%@Y^IXNMVTR7*
M6=,]&N]G[_8<&J<I>O'O;3)6"YNS6(U7'+=^1*5TW$]/>T%]KL_GA/')&@H.
MB^17?,46$H'!8S4WOLA\I+)F0/QL_52-?T/#FA%[N7^@UML=@BSF<A\!5(5I
M*"6,W[]_:)1S>U%Q@$JX&BQ$+II,E5&X"G+KTFO.Z'TDV'>M&8.G3D\8 +CT
M7C<7,<?8W0R@;RSI7GBL<!0K81Q FZ_&$$%%\8-H<?I5R58U,CLB 9,NR P=
M'&W"Z?,1I&L/S!AZNALBFGF+0#^ \B\3+84*PX]6TU;&#GHX\V3^0O$HLC1P
M9?NLV!5C*;DPY[BY3 !;!:.9?UR.7;5]_&F[L/H9VFKZ=\L-G=:"&8LWCMPK
MR$@1X!EBT0;XUE4KG6J0C?.S_;H,AI.LYMS\51+F%S<+N_M!0C4_JW7(1Z^"
MD4C,#89!)P=OC QD/1W:!_&TDE+U^%S8\S@X[%Y;SUBB%?STV_\#4$L#!!0
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MZ]\_GA77CPE5TT4]([JL1#B?Y"_1(<RC^1#GG;6"1=2?6:02*/$6O^(Q<V'
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M.LDVH;Q[KG7G/R]_!-_!S]_]'U!+ P04    "  70&A3>H>XYE]/   &3@,
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MUB'[93=**<3 . J$>L0I*%<;ZQ"E3A"=N!*L$F>>OLLK<CD5?<0T188\AF.
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M#B^!)0I9P>"O)%GB,94\M+).6HV]N'GL3Q-DN*TR"H\P;$#,B=D&1O'Q1W<
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M=F!V;2;:DA.#'K:5;0%C;]ORKJ."56UY-Y!?Q;:\6,)#%;>(*96M >R1EDZ
M_*W7 ;:3Y%IUAG@9:FS7EK> %M<16]6VO)BG8)122)"<H15@2S$I3_IDVCH:
M !XK9]Z^D+:\:PE_95O>=217M2VOC"P)SB1B+O>3(3P@P[%$Q"HKJ:5P,I3+
M\7@A;7DW5N'&DNNF+6^N*SA\9EI\NWJ+%9]4H,:B#<8'=15,2TJL2T$[PPVC
MX$"".2E=-&"\:$9[*SYSNX#QAP@&5/P0[1@^<.Q'_:OY8N>)9"HFXX%(R%/#
M$<^NBPO)Y$9,C!B2DYYYFQ=G[5#Q,\"VR@8XOFH:(@V^-A\_/AA%>YR.4^K[
M>'IE?>SID%CBSB'B\\6WYQ1IPA(2D8+SCA5Q#^LH5N0'//>D[F/=)15^+W>@
MJ% K9!/,%GX?Y5D<7<[ZDHVLG_2$)]Z!%X<LIAX.J9A@[7!P!:YT@+4S'ULU
M;]^0[$]AVP^B5-)%Z6RAVZ7G7.D['>T></S3-(OP.)W$0?S#7APW$NHQ;XAB
M0:#@: +!P%=:8 6ZM\+X2(6BJ=7FL16,_2!,Q^JHD&JRC.IS@)GQ/8*QX=$'
MQ),#GDL:D)7.(A.Y U=)J1AK'K K@>T'?VIHH>3]VN.#\R-L@.<7UR>YIA"#
ME>YM@,.2JNP^29/G3$5 E9P(5 INVG507?F(_=!R03&6C.H]1G4\.8^C.;2;
MGQQ^OXH#^.4>]I2IG*?I1=.>E3;=LPV\NSF!A5HCT[,NS;H/W5L"E!/U8TIL
M/8K[/M2WP_&DQ[1F+A*+X.G@K7N#D38*I. ]D=%I0JFM<@X\QK(?G"@DZ\?:
MEV6U/^=D+RJ',0<B8A(S)85&SH/I2U*RSADNM6]U0[<E >9P]ID#FTC\,0U4
M&<OPX8)G5UDI#P;E0B!+5+[*B@KI&"C"V@N:X&>&U1GI^P2HK@H<Z]N!V\O\
M)10SKDX_P3Y9$GU"T>;\1&E\;D4>4?22QT1BQ 4K&E]<HEXQ';?*S%M'UITE
M9+4!]3HS\]925ZO,K$UDW1D1 J=&1YF0PP(CSFAV:<$3<AQ'RZBCQ)1+^_D1
M,O/*ZW\=$5?(S'M[T//<.1(\0]+$//PTP)I@,8@R'#"! Y&FI[H^K9>9]_;@
MI61TK27XX592*WDW/;D:]3X>]$QT/%HO$$U< 7I,D3& @3$I(DF>:?E44LA"
M:?GC9AK+7]VJ:_Z8'UE7FTBJY,::'__YH)<,/%)(AVRD%/&D%7)4*60<^(PT
M**_$4XYY*T5]_O$5M::D5D;:BZ8*G)X=O_T_?SW^\.[PY/3P/[\<G?WWN\/W
M1V^/S@[_.>U/KM_W!W;@P2W<(H=@W4<42"[8:E4/NSE:+ZUD2DK!>8K<<*Z,
MRX/3C8V2T-ZZ#]O.)VXJK8[3Z63H_W'K\>' ,?AY":5(7;["L<A% ;X?ME@P
M'*D)=>K5EL+9UN]_.[R\' Z:S_QL1\>CQE@)3:>FSW%T>FY'L>>M@7,(WD!)
M8:?CE$JD62#(\,1,Q#8:6Z??40MPW8>&MF?%PSA :1V4-!!R+/O4YHSG!M\\
M'>O@Z]=1_ HH\X_&GT=]'X\&9R,[&%O?W'-ZH8TG&([)IFNSP [$00VB7%)I
MH[;LX4NRXO9@_6?_R(SH0MRE\Q/NP#T(H1&UO6A(.SZ83LZ'H_Z_8G@_'.7?
MZW$>F?#2HT 9G,K$8:3S[1>U&DL5$@Z2KLN+9Y^Z3XPH*^+28SWO ,V;6G^<
MG>/W_>\QY*$D(  ?DF8$T6 BXH8)L.P<1=@:@W,K4^KENMI?\IQ]TO>V8JS1
M*?$NNCL#'4^BC[D>YOC>UF1ML-(FCHC+I4[:@@D><AJ^=3(D"^(Q=5)*UH+Y
M(U.FOEX*YB$L ;O(E)IM:$?C\3375-W%ZH)B+(+3;;#)\VNPS[T' DK48FQ3
M",'5:2.]#LH]HU!9K11,6WBX0_X]]K^>@[U\\ WX_C4VUM&-V9P2-=AIBB@3
M&O' #3*.<Y2L5)2+%)QMESO=\H$_,@FJ";9@UL(,8T8W8^2[:1YU!:CZP_ I
M_M%\LR&K'?@FO6+<8X%2+0A%A.F<<FD!:30"*:!M)$E(2E@["JSSV!^?"-6$
M7"%[X;8NMX']YKH1QGSX65+@_GB%F"7YEI7F,FDG$:,.#"E.<"2UNS4_ M55
M]D*%$Z*0I'>=LW CH5$$A^J]]<TH\N963N7&E(8*%+6RB#LGD-;@47NLJ I"
MPO_K=))_C&7W=>Y;:OEAI&L[:5?H478?T?S>H0VFJAT6EZ':31O%;37V) &V
M$'=75&#><L$(1UYBP!8U09K"7Z.(2GDON%1UW-?N*/!,<\,N&+".E$O'+P_.
M/B[0S*N,B6<A#Q1#,JH\M9D39'+?Z:@9=ERKR'B[FJE''[T#JW!K<0^+R:I6
M;\!3'P<6C-.&FX(E[ C#R#(?\[VO09KDM'K"J)2$N!0+)ADM@[ OAW89&9<,
M,6= <QQ?!N.KZ/NI#^[)C-1M0)5/,UP%9X=IAINK:EA+SJ53#%>"PR&)Z)E&
MLLFHXSPABV%G2PG[9#RU'I<;FM"Q\MND&%;6_3KBK:3S]\-1]':\Z$TKA;1&
MA#S;U0&B7#%A91Z"1XD66EH%CFYQA=_'T'&V5!GE+%'W%I+M9L[MRNR?T^GE
MI1U=#].=3(I9Z,H.0FYM//H60QJ.%C&K&AE6FV*HF8)51"X/<[0<QEHGYQR1
M/!*3T^RLD9[FA&5*S.H<K4W1%$GB^GON5#.8'(].<E#[-A;FE98Z%^R8X"B\
M-(DCZQQ#23M%"3-2LSJ%;D_C*IC6=?<"!UYJ[17L!TB(;/E3+I$1N@G;XV2$
MX:I=U^QM4KGN MI9F+P$'Y[(X]I8Z,5SMQH@QW??N<6K]O[V53MPXUFC$P=^
MH*2YDV@D>0@C> Q6JX0T,]9GUY \S"]>=5FRUG/W@@:UY5TCY'6+\JV]ZD\6
M645W(+^?3J:CN #>DU[9(#!'DO/L[S.)'$L42</ ]@AP,.!*^^6Z4#LTRVHK
M?O4^4T%KI>-K*W;%@]LS_P9O#RNC3)X\S%)NT1AE0"9*@H(&<3G!26*JU?:S
MQD/WCR=5Q5ZA*]'2O7@6MV(L*@&+S)VMP7&U>? ?AD,T"HTY(9ZI5"?S9S6F
MCN]NJQ@J903^4NYP#_ZPHW &O]Q$/7C$W'C+D?,2K"UX08#,"B,9G>."J>!(
MG4GS]V#L*@A<2K7#4B*N8+4T^]D;"_R"32YWS[ SR=[V8GMS??L[G^UU_EZS
M@MME#,+G"SNX,T:IS9JJWOG66-5N[HRW(,O#;).7HND?A<5*$HZ#UXCC/"B7
M>@KO>,R3U\''S-/6F6W5'7R/V?O,=?<+)^\Z"JY VOFY,@\1BV2=B1XC2P,8
MIU)89#B7* FB(B>2!U6';?=@=!\\V+UFAZ744J&W\>'EU<7P.L;&]YCU/5TD
M"UA#9(!W2"D7<I<#@[2G$7GL8_3!!AI:S9Y8FR\K(?WD3B%UU3@@Y_5/-T+*
MBYY#"RD('K1'0'66KS9AAY8B(NJLPHX \76EJJ+5H'YRJ9C**@09%JN<-=XA
MX HE\*BBHAQQ$PG2QHK<M8TX9H(0IDY'N[LH]LQ%W%C %96]N!EO@::J;_<2
MO++-];-"T5L(M\)I\=#)2XRH!( ,5QX,=\=G3618D%QQ0Y*T=0*'+\"%J:7I
M=61:O,M DRTP\'" ];_%#.SLC^'9^7 ZMH/P?C@=36)<G#241<VDBH@)DL=<
M&I9+6RW@#"1_WVK2KG7U&@_M_O#?1CF/"[W*2[;T3?8!Q83?,U8_3T?^'"R;
M.T:&#)22I"12(K?GBF!N:,5]+E!T<*89162["Z0V3_MQ=5Y<EMT,VUJ96C2W
M9<8U$KL>?G;-A*TGU_%P1!>-0C*7,.:1>YTT=BS/]]7*6PT6]>I$K(=/J9I@
MQ5*^P4P>81'!B8P\#U\T8*A2KP*G-/%4YSJF3H)5\_K<_\SCZ60\@;VR/_AZ
M,KRX>#\<9>>J%SQ5WB>)1/($<8<#LDXD!!XU-30E\>@>:L56U.9I+RZ!9AVU
MW]N:BLNV0H1KZ=H/OX,+UA_/ZN1O?CB>_W1,>M1RK )ER'N<AS[GDGGE.8HZ
MZL"-L@0_U1FU\)OP'-R.TR+*J[W-G7=1G=7(SUH&^HYP>D(Z[(5CN=,70YQH
MC;2+'"6J9<(1)V,ZS(^X@^Q5T&=3391NN[44W-W>#6?G<=:^H0?L9<;YA @-
M,N_+"3E"*1+P/\)C4#:Y5J=2^V?N"Q5JBKKT&*\5W3MFF6"+7>]VP^N10# Q
M0B ?<1XYEC2RT5HD-$_>$.V\:&>LK/G@O>)&3:&7'@6VE,>+GD^'WZ_ZL]YA
MXX>D9A)CS^ $9"K/30W@'FHG8)O#F'(*SH=E?//]XWD >T68+I1086#8LV<A
MBT$*;0&:SC/N>+Z 3BPB%8@W%$NM:*6F"6M9)44S56V"=SGW1" BJEQBZ9&1
MG"#I [=2TV ?3FE^+9FJF[B"A07^4C)5ERZG"=-KPJ6.5".&)<G-]!1RQ@>D
MN>$6W YNC.R./B_T>G(ME;=ATMJB[\K'FP=XVT"KVXAH-;@=]2,JH\8VY-A"
M!QW3) D?3 )@6B<+AF33RU6"XY&(P)9AS'B=4?&=T^.Y7D6=LV,=T9>^$UTX
M$HVE"-;-1_CH<] 4FU_@@,WE.8=-DB@)VR5F@!(GT*,/DGDAN1#MVFT_\Z 7
M$GS>1"-+(L]%Q%GZ\O,AMD_#;PTH@$?G\)@6G@N-$148C&YO'7(N %!!N;:)
MJZ3;M;I]_EE[JO MA5K[];X#C\^B#!_M-<5$+.YKP2N,4GA$=8 MCH2(7 1?
M5"B-;51&>^ZW)<"R!^\_&[86=^F [_-8;[]#^!RP98D:0R*2++<A@*T,.0Q>
M>624:L>YY504XL?CI[\:DFPI^)6!X**)%(<')Y^./OU^^N'X]/3SX<GI7P].
M#A?MXX;I\//I%HD4K3^[0"+%9NMXV-'&),6#E<'P"/\5EA'!E84#7GHGC.NU
M?LJ69:R#23_T+Z8Y#>LT^ND(!)+CQOYB"F#? \%S9O5TTL0$C].A'0V @>-%
M2_;;@ MURC*P5I#%V5"QR2&C0T(\,$/ :Q:IDCM0:@5;5Z \^. W=MSW-R7U
MG(;@\G;M0\1@QSF"# D4)64U=8$+%^M4+3T)J_L-<B=\>U1]4DQ5%?(\/L7)
MT0 VF_AA.!X??(-W/(>ASH9W>BN<#R_@6>/[L!6G(!-B4? Y31)+CRS1#'F<
M<!+*!ZOJU#EM"+A[[A54^[![G54([]R#W=.1*!4%0YQ)CK@F&AFKP6(PSG)I
MK%/JJ3&OA0C4/2TZ4=Y3A%E+\C6J&$"9<32*H5GKN_ZW?@!397PP",>3\S@Z
M"/\S'4^:RJZ>L<*S: 5R7@O$%4W(>JZ1CV!N6D,(974VF?887P>!*NFL0EG4
MET'HPX+[;CJ)8;$%-Y*Z:/YQ#&?#SW8TZ?O^%9SZ@Z^W9D$CKE[D6#/C*9+!
MY7DA 2.-I40T.@PV@'<\UDGFW1;YZV!BI_JM,%EP39GUE,0.7AH%CG6>\6US
M HU+"@E-O1!!>R_JW+FO"?1UL*^F]BI,('PPWNS^O+L[.2/OLHL4P[O^.&<*
MY*YZV>FYD9B6@A+)!4I)YU7D++]$#=*">6X82U'7<;;+X-\GTW\'&JUP2+==
MQ>PE(A93QI5$B>0&-<H&9)*,R%$2+?8JB5"GH>]:,+MGV2ZXL"$=UU=D!<=C
MZ5O9L\%@81A!2H$CQ(4BR%(#.[9.PNI<'^A:C5,H$RI[E2S:7C$5]JB'H.;K
MOUEP'D8/!J-&&/N0%RR1<4!KDX=#80,'/NXFQ/H V,\@Z];JJK#W;.&VS%<"
MCDL(6B>)=%3@6(._ F8#P;"%1F/ IE <UPF8;8]]]Q;85G0HYX)NHLO:D=@G
MW9@%X&!@-\;6(6(S8(X5LM%I>#\%"3+ #DTZB-:V@;I?7*NKJ1V:]C?2"0;,
M/LT4BCHG'=D KX*$,\!8CZVD++=YV*EU_\H/UJH*K4! >%U&346#O9B_) W2
M@\ELQYZ]/H\[QMUI*-=S*6"M(T'1Y.:28-;FUO3@H'/G'<DIMM97H>3VV%^N
M_[ 9/X8[56Z-[K++Q37?O1])K8<E$X3FCE9"YPXUCL/A0362A$KMG3+>=QK\
M6 5TSXE74VW=.:\]8Y/VF%.D&#C67.4R3I';($K!@F<Q65]G[OL*0'O.FA)J
MJ' 'M0)6<Y5[&]^YC>TDYH2B.")"5<@=0A)R 4M$K9':X&2DJM-*=$V@K]1"
MJZG."NS;4F8'E\/I8-)C+EBMX)W!FFG$7>Y:(RE'.,FHC9+"RCIAVR+P7XR3
M6H8D#R>I=*[A&JVY;T:-;[F<65VOR7/B'<VCXW/?:4\3TEQ:I*(3)I\&+-09
M*E=V'5W5V[^(C76'%'@IU?Q;+OS-]?(/:.I5HU=@Z"2)6%-=Q(5$SBB"P#+"
MUCLA4WB1.?Q/+6I7'05V2=6RNW\QRE0X$Y8CN].MM@V^JLT,GD.XHVE9+X42
MK:BZI3YWP3N!O?%2Y@Y;X*ER^ O@U!IYRR@1(;BHZD0L=\.WY^9;_:AT6T>-
MU2=?64<9-L(A#U\@+G1$VG"*8E(J*I:HYY4BC[N=?%562T].L5I'Q)U.L1)4
M6V5,0E%C"MY?(L@1 ,8(>(52@T&M*L4)7\X4JZH\*"/Z;EK2/UT;O%Q,U8JK
MGWY<]7KK-5;[H 1;:NZX-CJW1N6>.*V43\D'Z8-QUCY7@OWT@U](5;83'+8N
MYI%.N;RLJ?U1+"*3O$E6>2K9B_3H/I2JRBX3^:))!DP#1JP994_!QC"Y3$'X
M))S-%0J\3L?K'S2VN1/^U@EZKJ/Z"A9!X3""=9[:H'(GJ93;0V.,C!(<6>XY
ME20F&NIDC;WRH.<V/-XA!5Y#T%-:(JCAX#\*:1"W-,N#!-"/99Z#]Y@L>8E[
M^RL(>JY%U0Z#GNM09A?!IS;X?@8]=T>)=:-0F^AS)\'VY!SGAB'MF<L%0O"J
M2GASHQ#2I7S?][!/_P_-MQT&/:O2;1TU5@]Z<FH)$U$@'66$,R"/'9 \9&S6
MI6 LJS2^_:4'/=?2TI-!SW5$W&G04VM!+0-G2P?A<@]#BJS)Z7Y*D$!#T$K5
M<;M_I*#G-CPH(_J.YG#F\-N;@]/#=V^//WX^_'1Z<'9T_&GY-/K#[_G+N,UD
MSLV?5F)69Z&U/FPZ*:.USFB+6>(J8!,$Q3HDJA,3PLK>%L_=,LRQ]!%WR@3>
M7#\N(LAS<&Y=;$U3T-Q9I'D0B!L'[X%3L(N!:ZU32L;(.J'.[;%O;9@MRAR?
MU%1/:JNTMP$1D?/W>$Q(4Q81HU9;::50NI*GVPI?]WMKQZQ[9(B55UO5".2S
MXAJODM?,G==88,8I((\D^_0N(F<( [; 2:6$@VVHSOUUL25T%7?<,3%WH_*7
M$FR<E?>>@E_6?.Z'_ _RHK/?Q:)-1F&#E$LX]_#&R!(NFAY28"EYJ6.U0L15
MH'8?[.N4)8\+$(MHJX(CNP+:W&YO ZYJD.Y)>+N)T!539CN2;*&)SNDB2()W
M(@8DJ,I=$I5'5N710KE7HH4=W?LZOO .:/),8&TW+%E' 178<0).(GS@^<$@
MO(O?XL7P*F.<VXASIYU2+8TB CEG *+5!K[R$OGDK8U26*WKE+2T ->]=5]0
MG<.ZNJA@M?\>!W%D+P#A0;@$4><BLAQ"N@_2:@XR,!1I.'ES:Q*,X-Q-2 EL
MC,786U''G&D%;Y\H4UX?NXRZ?<KQXPR_>(3MT2=7BZ8]O88'D3-*FN$]SC!*
MN*'". ;.MXNY9138KFY%Y.S1,W8>)1.8V$!90-3@A+BFL"W1E) @5$83;6"J
M4M7CSJ)DLZG7M^V9#D)H2&0OWMJK_L1>S%H-Y$U]]"V&-!R]GTYR.\7Q>&H'
M/O8BN-!)&(^,C1%QQ3@RVC)PJCGEV@<<'UY#K!H_OCF('S(XM@[9[L\H[TA;
M%0[>.]"7 G[_"##37$<3#$HN=YQ@<*SDA'/D7=(T* <N<)W^]FM#?34D[$:9
M-6KD-Y57\\??XCAW1_P<1_UA(#U'@K0R2*1!3(B+0)#S3B(29<XX<)%4RGHN
MN8I7Q]F=4:!"UZ0&J'M^+>ZIM30S&'-:C<]MRK[""1&$YIAC1"@5B$O.D07+
M&MD8 B8,7E)?)TVIRG)>)\%W2HH*/7@V7E0S%+3YY=D[VV..:4,30=$GE;NT
M1*1)4 A;QB0)W@9;T<(OL82?C.Y$^17&FVPLQUGNT=UV;[,^<#WEDA$T:20Q
M@]<21X,,E0(I8U1*GB2EZT2HBB_E=;)Z9V1XS&ZQLSUZOJ!\],1PO\%ASRJG
M@\48>1S!2;7 1"L)0UI3$5C"SI,ZA=TU5O,Z.;Y+2CRFN>PHFTQ['6AT!.F$
M->+)2N0"H!1>&Z8%]R+5&;>QQ]EDVU"Q@MH>DTL52_:.HV]]'Y=C_30<?&M>
MC$8\X[/AK+OTS<_?#L>33\/)?\?)2?3#KX/^OW(+UV"TS&E.VH@(AP,-2#LJ
M4334.@JRT[J.5U=M2:^.PB^#'(]9KU\LZV=F__OA:/ZM_'NDIS&!=QI6FSR<
M(EPHC8PT'F'.HHR.AI3JI$)WN\Z?[\?+H='CE\;LVIG\/9<XC8_FKO&#-N/-
M#]_!<?G>]D=_LQ?3V LXQI0<0U@2DJ=P>V0\%<AAQ9))6KA0IX%QQPM]=:_-
M2R;2DCN@%Y2QCQF5$N<I"8%YQ"EL ]9H,!9Q,MI$:E*EN2NO,6-_*XKO1.4O
M)6-_'M.?M8,D&#/K)+(ZOWS6)P0FGT/4I\0ER;U\ZH2_[X#X\3/RUV+!L(PV
M*ER'SZ$L*F5;@*F:<7\/SFXR[#=6SG(E;R'9ZNJVF#%L34*:, ,^GW;(Y1X)
MCCK'J4@\B#IY-1VH^9D,^3I:7D>@W>6V-)L6[&NP]QT/%HFTG&$E4X*SU.:9
M8DY2Y&0R>7*QC8*')"MULE\#9/=V^!;J;&=2;ZV+&O6KST(]^V,XATJ,4TDV
MG3"$1CP8C#1W%.5+)\*Y\]YTFAV[#.1^TV8S7538;3Y?V$'NLM'LH4I;03V5
M2,8H\XV,1";J@#1FSBE+HM)UFM#<1?&ZK<J-]5$A+6V!9?Y&M$%3U:Z\CV<W
MAN7F^EFAZ"V$6W$[6&R"*I@< D4^XCPE,'%D2,2P$TK)56#6VSJQPBY4_8QQ
M64O3Z\BTH(:;@H,FQ?MHD),!^]]B!@8'T=GY<#JV@_!^.!U-8ERT1F)<)R/!
MC XL3Q)-"B#"_I6'UFH<M&&>A%;E(&L\M/M#?QOE##N0;$%+<05..)[,')AB
MDGH=P=S)N="<@ FK@Y=@FB@P80F8M+)=!=!33]DG'6\HNQI-*QOS WYYY@QK
MBFV,! DG ^(F47"+J45).QZ#!%V9.H;</1BOVY+;7".U\JXW$L3M,@;AP8O4
M9DU5#<(:J]I1S][-R;+N+6!7FMY%V=<F:TL4Q^BQ1LQ*C'CTN8L&D2AXPZ5F
MD5NWH_OP%\/>YSH OVSRKJ/@"J1=W7S4":NX-AXIR3B8#)XB(W-/ERB$Q0H[
M(_=^V-7N-=ZZ5^PZZJK1ZB1G8,2F:\=TUAV;$B^8LQ0EL"\1YS0/&^8**4><
MB(:)J$(5_CR"\KHMO>TT4Z$^Z1Z@^3O1!E)58VT)J-W86ENJZRGE;R'K"B?/
M,FA..&=SUQV7M$4\*(><]!IIY@S'F C-ZWB&G:G_&6.EOO;7$7%5(WFQR]UN
M@HO#;=&\2UCG-05\C.>[IT#A*Q<0I<KJF ]16;OJ\#F,W5LD6ZMTI4U;5!\K
M+8RR(S@_?OYP_-^'AV\./QV^/SK[_.'@T^DV(S:?^+@2(S3;HGW0]BHZ[AVU
MS' P$+4AEF+ODH^"@#/C@^X]]<$[[W65. ^.@%WJHU&(6PDT91JCQ+QS1K$8
MQ;YVA%^_<0TAV'LM))(RY2P-\$X=YQ$Q9BT.AM) Z@CK=70A6H>+VW<A6D>9
MW:7</"^O12'L;=.OV4H/II/SX:BIY$K6.1\91K!UYO9>X+UJ;&!I-DC)8PR)
MU\GJJ[BH5\?HET*0E]2!ZUU_[//$V3P8[*,=_2-./H_Z/GZ>COPY_&XN,>D%
M285)2H'W3?,%*:&YO8=!W$@5/:-)RQ?6O;'%JGZR?U<4J=6Q:YLW>_X^?P,3
M,L>?X&QK_(Y>C,DX(RT*6N5KY.215CH@:;TS@,.02MG<M5;TD_:[H$:%*^1W
M675Y48/)J.^F33>F"SOX:+_W+Z>7!X/!-!?@WOXP=QU;^+?S!F0]G\"33EF:
M-#%X:RF\M30Z.,.83IYZ$K&LPNX"X%\=D;M6>,% >).NLP+_'.(HGS*CV%A7
MH^N/=N+/^X.O=W_YWD(/+O.)=&>%/9=OD;Q7*.&8$!<V(>?!'LN9@I$3[H/0
MS\5#.L#Y:FC[TG1>H3/7,ZM;MJ#%BRAD2,*J"*ZRS5>B5B&M-=A+@CHL,+>^
MDC^Y.>97P]R.U5NAEU:Y>UB&>0I*""1CSAYI^C:Q@)%ES@G"+>>LCH7P&DOQ
MMS)S=Z+REU**?Z\XP$GIE=,41?@O+  S,,PCV.E)" W&N4N^;I7$?J1@K,6#
MI\JFUM%'_1J:-FA>5]G46OIYNIAF$^%VH7+8/+E,*(I<"R U1Y8"*FFC%<E8
MK&W=.LJ74C955-/M95JZ;.J 8L+O)08N8I&-0SPOY'6!>JLL[%?4PEI]+@!Q
M # %K83!T7/7RA]L\[2=%]&LI8YA35EVDPCQX>CMX:?3PX/?3PX//QY^.MLF
M"V+E9Q5(@6B'\T'^0PI8@UI("M+P2(2Q$5,';V@RGMD@>BL_=8N7ZGCTU0[Z
M_YH9"8, 1D%_?)P^C_*2)G:^\KFA:EVV2\$RQ2SFJ07*(Y=[8TN.-3,>-A.'
M6[U;:SQTJQWC0]_G-K0'7T>Q,7WFH01[G2V=+U?P<'#EXK?F9\-T>A5]/_5C
M^-B_B./)<!![R3,:#&,H>)&;(SN-3,("!>P]!DN(P-;::L7;(NENIZG*BGM[
M4*?:*5W!^1#\[7"/XW0RO+87D^OCP:=\9S8,4S\YM0"Z9[35C.0N$XD[Q'6$
M[9J+?)5 &6S6# ?:+EBYR=-? X6*:Z&T#;,:\(F=P$'XSVE_E ?&Q P79'0T
M.#N/LQ=CL:)^'!__$4./&PU'O%,H!@%GOZ>P#$GSS-<HD[+!1"&V)-.ZF%X7
MQ:IJK.!M^<9ORD=0W^7TLL<5X".!YQ:C,M_M,^0BH<CBB+G5PH,U6&W;FH-X
M7=0JJY."U]!+<=^<R'<.[,4$ *L(I3$0Y'E*B$>0D+$"(Q.\8=8R_J@[>$ON
M//'0U\"54C(O?=U[ E@&TWBGM?<-TH]Q<CX,GX>3W+G!7MQ\?QZ#'/>R<VGS
M['(.AEW^0R%')5 \<FR4TD'*=OO,%B#VD3M=Z:3@7>M2SL_WQ#FVFQ/W[7 P
MR\\<?QI.8$&W60_@ V G8(L,N3.VM\A&%L%'2 Y$)K"SFVT]Z^'81T9UJ)F"
M]Z1WH7\$00+I<P+[^YB= JZ-H;!)@B]I0104?$FE'3@%FDJL/1RN[?HL+?_\
M/2;!-I(L./-G*2^_7(%@!A/ U?,X>*L$1X$D.^\=IB1%N=T0Y9$91\Q&N\'M
M,_98R=M*M."8F^6QHYL4_2]7[Q< N7"!NN20<2%D?RM/-<O&D""848UEQ&2S
MZ-V2I[T&Y6\MY8*#6YXZA[)GWC,D!9X\0U1Y,%\B(4@W%R1$*R.)R?DXVQS_
M)YU6$^S\;%];IB6'C2P%-FL+,IN3,NXQG^<FBQQ-"3Z/Z]1 P]!,GN/1"A),
MV"Q(<>\QKT'AF\MUB<K+ADO?3*^'T_E%P9<!/.%]?S2^![AGK)4J-PYA+O<1
M2%0WHRR1"YX*%^&\VI 'SS_[-9"CL :6,*9XG!,PG0W!-9E!GT$]!FOU\#NX
M(_UQKN+#-A!M(Q)>@G1$"LAQIQ$)W+%( PFJW<7F)D]_#:PIKH4EO"D;TWS$
M\]/HP9N]1W1"/ ; %FEBP?(!0P@.PI";EPAJF14*Z[5\QG4>_AI84UH'2TBS
M7;!S \#Y7OO3<+ HG@<9VAQ[.\ECWL;'H_DGAGG(OY>[8,BH$_(\JIQ1;I!)
M8' %(ZPWE$O#V_4"K@[U)R%KZW<)?;>+K[Z9CD%&X_';X:7K#V9"&PZ^GL71
MY2(;+'>#Z$_N7S@TR^\EZ;S7B:-HX8#G"AQ S< !)"3Q! >_A[^U8N8V*/:1
M=)UI90F?M@NM+D%^/S"\B/\2BTW3"M*P/*0'3GUD%/B2AEE#J4N2/ISTV)X[
M2Y_X2GBRO;27<&+K*>SSZZ?<1Z IFK)^\O?^Y/SM%(A[&4=' W\Q#7F V!C6
M!7OCF?W><]1C02G)4:1<A9 TLIQ&!& E3SHJ3^KTGM@ [)Z1JRNU+:':=C'A
M)2_$X_M,SF32";P*Z>"LY0$\#:-RK\$8O!.)&\'HIEO/J[A,+B[E)3PH&Q0^
M\$T?D_%)]+'_;5;D1(-.BF*4=)Y^J[A%ACJ""'94QT 83IN9U8^?M8\<*"SA
M);EN6W<%6U#Q;'C@<XI>7/ VCG\?#<>YZM)QZ0Q&!(Y Q*FTR&GP'@.E0DGO
MDY2FR@GS'+(](TP5A2QAS-;58W"@P;D&I]@\C>I-'(#L)SUM([.:".0)MHAK
ML*$LF-'(&:8LMIK[5(<H*P#M*3]*B'\)+;;N,763/)5%!>8.6-5I.+ILG'MW
MT?_:B*"';51,,HVHT!Y6[L':SMF9EA&O5.+8I#I-X%O!VU/*E%?-$@)M%U9>
M7)[.D-XF^/8""T39 /JTFB+.P%+6N4./#SHDIQQIFV^TZ@E[IO-RTERBX^VB
MP,\O?599KR)X138YY 6<<IPQ!_8PIT@R;E4N5@*;J5#Y7"<M,+K3>PT)[[J'
MQ7@TZ;W-5G,<7=G1Y/JF6ILJ88"Q'ND06!Y%K.# 2R3?NDM%6#*6M.J] @^X
M<XS WQX>(:L0=-W#HIZ*AP5%7;(2#/"<Q*MY,/?&BWH(<3'&H@7(=3I7M.)%
M:WC=-K(HH\EA5VK8&6=B"D3FU$PI IR'(>?@ZIAG)E$*2%EB3NP+5U9TPM@A
M5=:1?ND"TR^#_K<X&O<GU\?I_TY'?7\^;^:@J<*<.8+ L5:Y2SN8P2%2%!,8
MR ES2EOFN*QZ0H<&9SUM#$N+LG3=^<<^B.@R3@Y^GX.Q*>2X"47)BGR##%\Y
M[1T20@JM3+X,Y*WT^O"3]TZ?6XFN]'OZ7\<?#XY&\<(.PH?^97\2PQR4,-12
M[W(S^>@0-X(BPZ1#FI,D$A5>\79)ZZN>L'=Z+2+*TO76)T-_?C-0*(_;% 0C
MDPCPS  B*Z)$0L7D?,*8\W9W3G<^=.^TN*G 2A<W_V?_8OKYW(XNK8_32=_G
M[LH?)@M*.8&%#U@A1[A$W J;FRA[^$,H[27UG+9K+_7D8_9.N>6$6KI>^>/A
MIX-'M=7S]E=>R,#A4#"8@J%(C$2:!H&2#X(H)P6-[0I(5C]C[Q1=2)RE*XD/
M_;^L[SL[[M]GX7@VV")G,3Q ZW$0*NB F,CS+&+NELY5;K26C+'@*7#1[AA>
M^]%[QXFZPB]9'PSRF"=F'H].X^@;$+EQ&7E@6%ML<K.@ -9$#ES&B!$+'LXB
M(1C8%\7<Z64(]C(DM[6H2]ILMWC&L-8YHL7@R3:@BH?@5L+I/N2VO:8>J[V0
MF N'V%:#DYJY *8H,B[?0X--@IRU'G'.C.<J).K+A=0ZUOT3(;2.5+^.=$N[
MXH=OCC C\Z,'EJ"\T!C%F"M<+<Y34IQ'#"=!#<=.B':7='<_M=LCO9"4AR5$
M5#K\=?1!SE%$DVT$X5!,>>JDI1$Y8S('90C>8>QHN]:<-Q_YPVMI,^%4:,1]
M!K]WG.[TG&]V#1V8QP2<.\VI #L!5N@\28AYFM'2P%F=X2=+X>R=255.^!7&
MEMV=/P +_Y1'_]Q\YPR^&MNF8]!X$6)O ;=JN_XU >^FGW\!50^[UU.%#6=M
MV'!HD=S"POI\@X.U1DX"=JS <L&6T.CI_M+JF=D!+X!5:ZBGM#7X=G@!WQJ.
M8#?^%N\ GR>=-5-3C@=OX=_F&,8[^.[%\.I>*=XBB*T%888:>(UYGH@:0&#1
M6,1DI-AZ*HAI%RHNA:C[:055]3[<M=)*V[9-)XVC00"(357-W-K6B4B!!5(A
M-WH54N2N"!%%*ZEQ*0;FVM%HZ<?O,2>V%^<NMI;AX EV)L-$)$DBKY+(E9S@
M(UCJ$=58L012,>K9L1=%D.PQ;3I54NE;YW;@3^+7Z47^F.N'V$E4TBE-P-'(
MS9X\#D@33I CAA@N:12A),%6 GGU_"JCHM)WX^VPY^X$N:>/O9A[NH_>$&RE
M%<R@)$(.<&B/++BUB#$I+'5>D99]<\K@>?5D*ZJPTA?T[4R[9?OQYWRK>71T
M\]Y8YD7,?6@51EPFAJR*!*4DHZ(&1Q+:W>87 O3*65=:9:4S!F:=?1Z;CW"2
M!Q4PTB9G)A%)D'54HTBY$#2I2$6[SB7+/W^/25% H(6O^D_R,IO8AHQ!@GH$
M> $*G(*H2 ZW1I0= F,,US2TFA39+EU^\=B]BT!O+M22A\8"Q)Q@;6"4+Y^Y
M!=#];?V&*GBHQ"WD5[KNY0X<K@6EE&AD\^ WKKQ >4 B,L+!?ZV@.+6*W+X,
M-3YQ\5Y6B^N(K;#VYA.+;LZ/Z"S#8#O2W*#,YZQ/"IM+S@$TQLG@(BFFOWN/
M[CBO;E/A#TM(KF1H,@.QW^\"$?F<IQAYQP (UQP\T$@12RPHJPS\K-QI>>_1
M/Z *-Y9<A5NR1<>5I@'+>":YO,'XA#G+K588]APV&*%@F38BSZQ.REGOJ6VC
MT+5OPU8 VCO#J*0""CHZ3\&:]>A9Y/ZV 5CU.OY9B+NY@"^BT!8DV5X;'6TG
M]X'R%+5T*@ R">\*]009*P.2BKJ$I0WIX>#('YLNSURL[X8MZRBA](W7TW4_
MT21P\8D#*%KD&981:6W!NC4J2I&DY"TGV+Z08JI*.FE?2+6.0 N:B(MUO\^2
MC1_ZWV(X@C-S\+4/!V9N#SH9O[G^:/]G.'I[84$LF?.6A&!#( CH[1#'( M+
M$T6 7WLCHI.45]D:U@"YMW9(+445#-"U@'H+]$Z54ANX52V5-0'OQFZI1H#V
M1"NFO0J6S;JP,7-$<D+!%V?P+CKPZYR2#A'%->.4"LOKV#DO@FS/6#TOE6OK
M**T"QV95LG>+'Q=7+()X)U-,B(N<@^; 0M">Y:!!,(IH8[FKDYRZ$E+W)E15
M90YK:*)PR.T4SOH&R^]Q^'5DK\ZSK=>\(S'8% T&(X]@6*H0'&G*":*&*L$<
M,Y&UZD?;*ORV$L;>V4;EA%YRJ&T&->LS>!?2HB*[!:CB5ULKX71_T55(7<-:
MLBY\D;(:7* A3UA@X$0:B7B^3G<4^.ZMT2F&R$1HU7WX)1+@B2NR+O6_CH@+
MZKWIJS^Z[IV=](*W6"@EP*57''%I+3*!,["2P+7G(IG$]!-*'D?_IZ_#;[_-
M/W&FY_E?&C4W"KY]7K=W+84$/]Q*:BN/\'__[8$0/L!?FQ\TW\^+/(GIE_S?
M+R='-P+YXX\_0.QP-KG^\$]^>/E;(XV3P].SDR]OS^ W/_U^\.G=R>&'@[/#
M=P=OSX[^=G1V='CZ+DYL_V)\']6X?WEU\6SN;>O/_NT6_?U5S1]P3[$EUQ&_
M3^(@1%!9/_SEU[Z47"9LDE6.<8^-D339Q*D,&)-$=:_U4[;M\CZ>C*9^,AV!
M'?AV.)Z >0'?BZ-O8(0N^A=K;P$7MRA8#U0,>>:U]PF<%6(CP5QKT>KB<X,F
M[\^CV[[/_=UGG-O1USCN"<6<CU(A@@F\,U8K!']G**7(C;;4\$J.[3(TW7LA
MQ5GQN(/]ED*O$,5=#.IX/QS=@]<+&H-5;<&SBA8.U1 H[,0.MF-EA#7>:/^P
M,V'AB2D/$>TA(8H(OT*TXAZ8^8I[ ,FRR!724N8^J RL+&,"2C3 9LYS/FB=
M0,4R-'M(AJV%7K"\:('IU)_',+V(Q^D>NF;I%V".ARR(\<P-3TXS:8A&A'N*
M>,01.2<EHMY+$I6A^&&Y6B%^K &R]I"$SLA22S&[GI/00H"-R^> _$IAAA3.
M/>-8E'!J6IGKTX5. @Y-VL%F]!A8UX&RZGQXTH393B_56M'< SEW+-L JWI3
MN!+:;NX$BRIR:4^:4EKHE":2@8N:,RG@U8 ]V6B,+#,41<>9EI9$P]0^T..9
M6[S=L&,=X5=@Q>'EU<7P.L;3^"V.\EBQ19<(PHGRRJ#DJ<K][\ 8%X0B*6/B
MTO+H^5.AN,TYL0)0][9O(94-R\N[@D>\&'^<1[ O1MXN&M4RRPG'2.B8&]4R
M.#BIS 8;3BYG8F%2)R*T$M*^4*&,S"OL"<>3\WC?-U]<%FOO*=$! 3A8<G(,
MF02K]2$:*JF)0M8Q0%<AVA<J%)'X2E>X:&S_],N;T\/__'+XZ>SP;_#'Z:=<
M3)NKH+>(Z3_[F05B^>OA?A##)PGSY+6+$5Y,8Z3!VA.=BY*,\M28WK.?OF5(
M8NK&\9]3\#$/O\$?M^ZTHI33H 0XT22WRD@1&142(E&37,7,9*7T\U6(M@Z^
MG-O1K'S^[? R3\F=94+<%FR_N;[]E7DH\> /.PKS,J2;\Q7P^5'_*O_K$_ %
M>P$,-@_O*"(NOT[)P>LI%$:)416D%394.L=JK:C[O:\("Q\%=5Z"PBM85 ^$
M-8M"<#@%L,!Y[@>FB%L3D>7P5^PIYEY;V!/KS%!>AJ:KN& =VFPKWI<2]'NX
M$/AG,V]3*A(YLR@%H[,Y(<&< )/0"8^U@\/?XDJ1Y>6 =A;DVUK1SS!G$X%7
M,+J7P%K$CUH JQK%6PEM-U&\(@I\GA1;2+]3>GAA8L(J(2R]0EQ*@@"D1TE8
M;;0(28HZD9J.:?%,]*Y;5JPC]/IL6(0-#.R!5L$V:)5%G!L)SB)6R'.M#9<^
M1M.),[ KW[R0NIXFP0:R+IPW?]:?Y#NOW&?J6S],Y_F@1#C%2&2(<IX0#]$!
MSV6^0V=P5')AC&]5;=@J078IA!_>0B@CW,(CFQX!^GM_<M[<;^:69>?]J[/A
MX6#2GUS/J=X&:O&,^35!=I]'7T"M3Y&D@DX*9]:O"]G ZT-$M$@HV"RY!L@Z
M*8ZD8HD0DW1@Y>;!O0CZ/)&%OUOVK*.*PJPY_![]-(<QCU/J^SA:-$PC4EOP
MUU%D7N=2-'#<I8+-FAD=<K1;R'+MD99CZ#9WOZK*AD7EO6Z&__S;^0]GQ_$_
M_NW_!U!+ P04    "  70&A3F1Q1$Y/;  "$-0D %0   '-E<VXM,C R,3 Y
M,S!?;&%B+GAM;-R]:7/<.)8N_'U^!6[UC7Y=$4(7%W!!]\S<D"VY1A&VI2NI
MNF>BXD8&5HG3J4PUF:FR^M>_ )?<E,D$F"#%FHEIEVR1Q#D/R <'!V?YU__S
M_6D*7D1>9//9O_W@_\G[ 8@9F_-L]O!O/_QR_QFF/_R??_^7?_G7_P7A?WZ\
M_0(NYFSY)&8+\"D79"$X^"U;/(*_<5'\'<A\_@3^-L__GKT0"/^]O.G3_/DU
MSQX>%R#P G_WM_F?42A#A'P/>@E.(&*80QQQ!#T_"1"*",+$/WOX<TQ%Q)B/
M( L1ADB@"!(/)= /"2,T#D*)XO*ATVSV]S_K/R@I!%#*S8KRK__VP^-B\?SG
MGW[Z[;??_O2=YM,_S?.'GP+/"W]JKOZAOOS[F^M_"\NK?8SQ3^5O5Y<6V;X+
MU6/]G_[SZY<[]BB>",QFQ8+,F!Z@R/Y<E/_X9<[(HL3\J%S@X!7Z;["Y#.I_
M@GX 0_]/WPO^P[__"P 5'/E\*FZ%!/J_O]Q>'1P2_Z2O^&DF'O3,WH@\F_.[
M!<D77P@54R5]^;3%Z[/XMQ^*[.EY*II_>\R%W/_8:9YO/55+B;64?JRE_,.A
MP7XZ07Q'\B[>RNI N%+=;ZYD;,/TFS-Q[Q4_B/X%WACF9)&K%^IRQH=Z=U=#
MG2QZ_Q*[>BWF"S(=X+58#[,A\E3_PQ?U4SV,?E +F9;CU-2](:KXOA S+BJV
MW'HTR/B__:!^FBP+^$#(\^0FGS,A>/%9K7)_(WE.9HO+[R)G62&*B9_B((Y#
M#_J)DA\ABB&F6,*8H]0G'DD9#R>+U?L]$3/XRUTC2CF>^6 _6&B\./#EYJ*8
M+W.V7O.>IOL6,K6&Z54O_6E&GD3Q3.H;E,3:/*B4^/=&UFK]7SP*(&I1P5P"
M-G]ZFL] L9BSOX/?*E6*?_UIK?B)R$\'Q7,Z))2UH& EZ4'8YFQ+I*DV+N;Y
M+AYS9H7'^L,ME"HE&)(4M-2F?LY/VJC[24P71?,O4/^+LMYJ*^0/1@/^].8=
M.,\;C4C.CDQ,?<5/;*YLK.<%W)HC#:2]ZHNY_>M30:^$^0',<RYR94WO46SU
M<JL[9Y,+01=7RCK,2YOZ2C'1]UM%>?^A#.;_RL243R(A*,5,0AR2%"+%5!![
M$8<\BF1(41JF)##A%:/1QD8L6EZP%O@,E"(#+?,9T%+#4FPS,C'#NYU-G*/8
M,YV\ X"\WA^6FYOA@-P:=KR &O.T%4 54>M;2O;U<.B5W&OVD$'(UTJ?AGWM
M;NI O_]Y_?7\*A=JBOF7["E3MN97\41%/O&ILMOB1$#?%P2BD$4PC6,!L11<
MI EG86I.NX=&&1O=:CE!+2BH);6@AH-@&G"J"XAZYM)]Z(!?*S'_GPN8+)C3
M!5P#,:;52V5'C\=0:*7%@S</1X?'Y-^BP:,7V]%?8]A^6N:Y>@GNU&L@SM6C
M%>+3>_+]\ONSF!7BHY@)F2TF 4-)@E(/QF'"($I8 @DFRA3U.8FCQ*-QFMKL
M;HU&'1L]EM+:;5S-T#7;P3K'K&>^K.4%I<"@_/JUR$#)#&JAP8=:[!_=;6RM
M8'*ZPS4;>="MKA48NWM>NYN[T<]GDN5_)=.E^"I(L<R%7I"*U3_^1R9R]<C'
MUXOY$\EF$^YY<1@D'@RC0-&0ER!(A&"0,3],(\9]+TAL:,AJ]+'1D983E(*"
ME:3E9_;M_*_@UTIF0[NDVVR8T59O&/=,7Z?!:TU;G6!R2E]V$@Q*8YW V:6S
M;@_I1FO?A-JHLOF3^#(OBDD:T2#T)84R22*(, D@%4D"681Q'"0B2*-HLE@=
M<AS]I+:>;D5+!\YK7'XW2CA020<^:/E^+#^:3_.GYUP\JH4C>Q$[OS^7BBZU
M6=#BWS9 &:6^1PD6$+$D4'^$'DQ)$L.(IRQ%C&&.@\F+R.G<='GHC//F*/TB
MG=5(3C62IZ G>4J1,N2A)"%52VM ("4A@1$6.$ D306.;9;6[N_H $NG1DXC
M=@I@9JM?9QAZ7MW>?J7GBT6>T>6"T*D BSFX(=KX<[? [47"Z0*V/<*@"]1>
MY787H/T7V2TP7&23R]DB6[Q>/HG\(9L]_)S/?UL\:GXEL]=)*&4H?3^&"47*
M0B;*3"8Q"F'$B$<#A.(D]DP^XR/CC.V#KD0%C:R@$A;4TII]YL>@;?_@'0+6
M\Z??$2OC#]X0B3V??B'8GQ[F+S^I)U1?O?JA_-C+S_S8<P?YX V5:SY]T\L[
M'%W</2J"OE$OQ2,IQ/E#+DJ#M@I%NIK][3%CC^?L'\M,_>*JN)__4@@UZ),^
MLB;3Z>NMLH'G,\WUEU+.\X6ZXIP]9N)%?"7YW\5"27J^7#S.\^R?I7^XF' 4
MA2)!%#)$E(V%F#*O//77)."Q0 G'/J?&)R(#"S\VNJH45<8;^$VK"DBM*\@*
MO?0N"U%&S33Z@GRE,!"5QOHR4ND,GAJE =G2VN),8NB7R>!$:,2O2,\$76H.
M&M7!2O<SL'YO2OW!^?9[HS  FR" -0K@<OW>U$" %1+@_/?RWE@<D8WX_1GH
MY&VT[Y'=*=\[363KX>'0,@UW)OE.:&\==;Z7#-U\?3?J11%Y+OB=CG M92^N
MEPN=\:&3:":8T3A)@QCZV,,0^2* :2HQC$(9<H_&ZMWR[2*#6\<;G:W3B%M%
M )^!HI08S-<B@P^*B:I_MO1A'</>S$GC$-&>38,UF'<5F)6P8$-:ER'"1K X
MCA)N'W/@0&$C -[&"IO=UHUN+I^>I_-7(6[%M,SDR C-IMDB$T5]7CN1 0X#
MI @G2AB!B$4<DA3%BG7".$HCP:AG%+MF/.+H*(>\JK&F,*\$!J(ZL;9T]QX'
MVHQ=G,+7MV^HEG4%W8:T9Z"6UQW#&$/CE&..CSHHRQB#L,LSYC=V8YK*65V&
M?VC[JTE8/?^>%1,B@]C#-(+J3@I1*A'$:1)!&8D(B=3#01#9<$S+6&-CE_K8
M9"4K:(0%OVIQ+4,NVD VXQ='T/7,+)U1LR85 SR<TDG;>(,2B8'BNQ1B<HNE
M;SI?3&[5Q(LZJ#FEB.# CR%E$8,(>PE,I8@A(C25:<Q\(821VWC[N6,C!0UA
M5BPR'>"X$5]B&8>U"]X1-VEW2/KV8'9%P]PSM%_WM@];W;+Q4:N_[7[0N\\<
MQNFR7Y&5/^3 K[N>&I]SKB:ZJ/_S)9L)?Y($DJ#8\Z ,@PBBA(>ZM :"H4!>
MX@DNA<_LSHSWC#*V#[8^!:U%/&M^ %I8<#TSC/-N!];TQ/A$N(8Y+[9'JL.)
M<0L2)YP7[WOJP*?%+8J]/2MNN]C=AQ],J%!+LQ<2R&@H(0K"$*:"$1BDOI<P
MY"//,S+B6T?Y77WX][_-3__P@Q,^?"NXWO/#;T/*R8<?]/+A!^__X0<V'W[0
M\<-O#/S2^_B1%(+KD!,Q*RK[7A<P>"AMLH^OZTMNR*O^I_/?2,XOLH+-E[.%
M+GA0G9O<Y!E;G<I<J!W#)/)(S (O@CY#B;+HXP"FH90PC>+0#Q'S2&A5\Z1/
M8<=&0Y\VJZ(\-V>TSUKL,\!K?4!NG7'6ZX2;.23&,HU];W*T#E 77JO"VQM%
MP8:F@+Z"S>MJ;4&I[AEH%*ZJO50J@YOJ'5B=VU^TO0/6WI$A)L>I>Z57@0?U
MSPP!_:Z#9Y QN]JDG[.IR#^I)SW,\]>)[PE?8NY#[F.U#56V*<0\#6#BA3CU
MF#)/J=&QU8'GCVT!J*VK4D;0"&EK?&XC:&IV=L9E&(/3$)(.5N9>Q4^P+[>?
M-[!EN5>9MS;E_LLZG@@]/9,LUQQQ+:]F"S5W&9V*\Z(0B^+R.YLN]?GVS_,Y
M_RV;3B><>Y1ZE,/8XUAM+Z,($DXH#&.U[12"A>KSMCHCLAE];)_[6N "9"M%
M@"+3_,'2Q+.;!<-#I+ZP[?M8:0WE7(*UY* 2'7Q8"0\:Z1W6&NB$FMO#)RL)
MACV.Z@+.FP.J3@_IQFZW0A>98HMEKI[Y:5XLSF=<_9O(7T1Y')MR+^:!VN2B
MF F(L/353C<*H?0Q8>H/QJ55(-^1\<;&8%OB@GOU_$X'WL=0-N,KA]CUS%#V
ML%G3D"$83HGGV)B#4HTA +OD8GK;P*ZWZ^<R+/GS/)<B4\*)XFI6!3]/&%.[
M(!:G4+!4F50R26!*/ +]),*<>H&4*)F\*:;=G\?FL*A&7Z!9D7&G;C==AG\J
MN)I)("NIU5\ZQQ_W,<<].]E.G++?C6^MUO,,;&BJ,UXJ74?@4#L^$>/PH[7(
M^?MPGQT'VIG7S&"HCG6RYKG('F958"=[O5>2%(25@ZE%J_SKM,IFN9E/,W6!
M^+[XJ-#[^\3W24B2-(4Q(PRB2._"A?0@B[R$!$$B*#**[CA9DK'9L[4BH-$$
M;,AN63:K\^28<?T@D/?,Z/O1KK4H2P1MZ@$J1<"O]7^U1J!4R67)K5-A=5M^
MJ[,TPY;B.A6T-V6Y3GY@-T:]7CR*O'(D?%.JURD=D23(DRF'*?)U7'M*(?74
MEI^@D)!0<(*9U1Y_[RAC8\)22$!**>V8;S^(9JQV,C0],U:%2B7@&5B+Z(Z
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M7;WBOD2U^>2&*7V\%3U-&GGUB0XHB/IA^ .=8[/=\ZF.PQD<_]%.I>S*&"W
M^=8;4&H\@@,>PSD9QRG/,6%_'T<]AI [.^\Q'6_@I6?5U>"\*)9/U9F4;MO"
M%H)?9"\9%S.N>^A-J QH(J0/HX2$$/E40$S3"(I08!(BDAAF  XF\=@,Y48V
M\&K>1W.XZ>UYT>ECTL:_^FPTAMG0^PPTFH/5.W$[CLP=VVD:QX)D+/7O8V6R
MG01G2Y3UP%V=*!M2Z3"Z1585_=")1-.Y+@%R3HMRAS:A3' O"AF,4IQ"%)((
M8J3>GL@+HP3+D(0)L7.K&(\]MO5C+2NH&ZH5X-=&6$M/M\T4F#IA>@&V9X[O
MB&D'OXPU.HX]->;C#^R[L0;FK3?'_A%=J]S=Y',FBD)'_NH.8&JX"_$BIO-G
M/5[MM$P(]9.(T[)G%T0!P3!EQ-?5<@(<R(A@VWIW!J..C:RN;F[_2)Z>_W(!
MLG6B39>P 3/,S3C*.9(]L]/5#-0"@T;B,OQI0^8>?,A6*#DNCV<R\L"%\BS
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M=H3&5D2QJV=V+3QX-5/K@EI1LQ=Q01;D4Y5\/\$"(Y]0#V*?E0>*%!*UL,&
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MXX/H/U"2)! 3%$".<>)1Q*A/I U![!UE=.0@%N##=%X4/Y9]NMC\Z6E>=[
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MZ!W\HG>+.?O[U4SGEBC)M'&N-]RU^RJBG#$:Q9#$::JS_$A5(8''?H 3ZLD
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MZE;\[P $IQ4"W'WH\$4!#ZBUMT#@H6L[=T*</XE[\KVS-Z'E"2-Z0RLIRPR
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M?9E8,E%V!^5)@F' @A2BV%-6">8>%)(*D5 94"]TX.KM2?RQ&2J-<!Q\R&:
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M.C!V86AS')T! V^S(US[WL641:=6B)[K_ZT%=826A3_9$6H#N9$[HF?G.3:
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M;]'D21BP*&%0$JS0C' ,,:+*^!9A($-?1(*Q2965=SGC R"Z/5:/,0NE9'U
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MS>6WN_/[J^MO=HO3J9-DMN@,"/V B\EJD=A81W[M91_A"#^GQ'ZJ3(,2MB,
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M>93XB2^CU#R7J'6LL3''6D0@M8Q 87^XU9\UL@96ICN\^MZZZJ*8U[()AMM
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M9SDQ";SO ^+!"^"]1 @*+'*(9(XA8PF'+-&#I7"N=[Q6!JI7J<:V5.SHM7N
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M8"X=,V"?0=EN,^0/N\"+<@5;6])-2H!:6)]9 :Q0\9L@H+O+87,%6*E_D#;
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M/^E1HTK+YV7%.3I&%ZT=ER(_X"IP)-;P"M2R RU\B,!#=]"&H.2C_8^!7+N
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M:O7OH(YQI.M*P=)T6"_ <UL?L-HZU$+ C$YNC'?QR-JQX2 #-0Q3[J@"&EW
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M11:K]?5<U/E</VZRTE&*<2SC&!:T,/>E0INM0J:0I2I%G,M<*J?[4IM.Q[;
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M9 P+;?^E49+1@C@ECCO5T=AX]%@^L//1"F[8VEEV/A +S*']P'(VV<XAX=5
M.]G9H.;8.97WC:^SSWNI,'<]%_I?EB^R7;5D&Z^QK2N$LR1.D:10$,4@HA&'
M-(Y2J(JTB C)(Y$[A47TE&-LY')]<_/E^^U[</O_/-Q^_GKK6"*[[V#8T<T
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M8FA!BR+'#,8%%Q"5BH^(C%/(A,@QE@7)I%'E$?,NQ\9)G85 FVA'.0;XYJ+
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MD0ZDCG+(>!KC*(]0'I4VQ&G2Z=@8<F.>'3L:X6M&@[Y1"\QWV\M +3?:6AE
M6\$&%J^$9=3QH,QD \4A!5E]UL/AZ4X!%"$DX01!M0;#$#&)(8T9@@E.,28R
MRM/<*#FCOYNQ\<G[A[O[CU_OP>UO7^[O/]Q_?#RO(V<#IL-)YABKBQP=E('?
M3<J%V"!UQ=FC$V*O=<1HAMQUQXAGZJ<8GA8.7.G$S(/>LS]?=4FV]4\V41;;
M+R@JLQS1(M*EYM1VE9<(4IE0&%$2Q9F(TS2S6G7U=38V=GSX>/?IPSUXO/VO
M'GU->TAM]IO7 S7,AE+9N1-MY7FVVT 28#=XIL-7V.[UNWYZ/W?A,_:1W*V$
MP#O5*)G^79#%_8R_)2LQ25A:%#S3V7"%6D+E>@F5T 0R4O(BBY(BCZ5I-/>Y
M3L9&$9V616,HT):">UWQWE@&KQ?2?JKP!51@BG#"R"K*^Q((3I'>9QL=+-K[
MDEN[$=\7G[VVKF1]AOZK#FO:C7[:#6^Y9:OJ9[5Z.:A)B/,H(S%B,(X8@0A'
MBA8PSJ$B"\EP(@7+K&X$KS=I;"2R6\6PMKZ[=>_,=RTBZ3QF9DN484<B,$N=
MC-O;AO9UT7LWFT$9J(+DM= &*B+I;-8KU9&\%L;SI22O;OF*2/8?\ZGZQ%*'
MS*]>/LY7XM1^ [.XR+,R@C'B'*(HE1 S)&":RY)&%!-$C=9EUCV/CF<?/]W]
M]=\_O7][_^7KG\']?WQ[>/P[>//V_MW#W<.C2Y"T$?R&7!H"U-"4N6/SGT%C
M-=!FA]\*6L/E/[;9J/?A0YIM0#D9R6S5P)7W?;^^[!ST*PZMEG6Y5HE*GB$N
M8,83VE0Z+"E*8)1ABF,:4V)72.-"?V/CJ5UM\-I(IVJXET"VO.^['KK ;&2-
MFOLE7S\68>[WSO3Y.E=[_0"<O=6[\+%KMZBWLU551U!6/T6; 5V)Y?T?;+KF
M@C=!#4_/Z^;RXY.\)PM=S'79U>+8N0Q,N*"QS" GD80HS@0D6<0@3^,X)>H7
M)+7B'_\FCHVR=K>P&Y'AZ4L34*E\!5MG0>=M$W[4AN@!'7<"[LB4K:>DMX[=
M4%\"VSWP:PQMZ 7>SJCNNG=^-'=<U!_JG-Q6*!IHU^Q[, +MHKV9^4J[:M\P
MG]]E>^_)===-5O7;ZY/4N>KOIO-_;D4JBX*FC!.N%3U+B$110(R9A((E:9XG
M:AEK61NVI[/1O0 Z6_6TKT49:G.=]3][@3;=4ON!+_@NVADYAVWS94@\[Y1[
M.AQX<WS9]>/]L,%G'.5TIF2Y;,N_OJ]FXD%UM)PD<5ED14:@6F'J*#1!($X8
M@Y2+*"UX&;$<6<FCG^IE;-11&[F]^_A=&PIJ2RTYXS2F9F1Q-5*A+U$=0++7
MMND#P:^.S<F>AM6LZ7/V2)^F]V%'"E@(7JW>$59-J]5+?2;#LY)F11%!7)8I
M1 E.(*6%@)*4J.!"R@(3J_E_U,7H)G]M(>A,=#KI.@&DX:2_"I[0,]X.&?O)
M?M9YOS/]N)MAI_E9-X_F^/DG'8^Y*YW0]E[M6/C#;*7&ME([WZ8.RP?RC_FB
M)A4MS?=V_D2JV40'G(LHCV >\PPB'F-8IESQ *41EPCE*;([]K;K?VS4T)@/
M:_O!U@'0U1&J?0#-BU%[ 7YO_+ ])[<<)<-S\W#8!^8=_[#;'[2[@>?WX-W2
MAF$/XMT .CJ8=VS&C0X_BI7>17U>S']67/!?7[XM=;\/LY\ZAW#VO0V3J,1R
MDD644JT)C&4:0:3V0% UB6 2)RG">2DPXI/5?$6F9DQHWK45"6X,"#<;E>6@
MU@M=Z\"D:J;^:VT&9&.T'>%9C(,9UX5!-S#-:6#KTY;.;"W>]N9;@_(O8&,\
MN+T,LS7!V2/FE=LLNA^4UNQA.60TAQ;<R.SS?*%/FF]7F\O-$V*E;68M$3K2
MM: 0(Q%#5,01)#JP@:*8DYAAE.16"J(6?8]M3=>:#LAJ5Z=WYU;8CLIL1L&,
MRP)A&YC,+L(:(.79 2FO)&;3_Z LY@#,(8VY-.&<_+?0Q;/>BN;_#[-6[F'V
MO:V1M[EUX3F7"8MSF'/U!U*;5(AC3""*2!)S'F>HL$T%-.QZ;"QV5XOJU^JM
M\\[DMMYO+4H^K0C5APCJ-6-9_]=B.,SX+ S(@>FL,QJ\Z<S^16.]L7Q3K#/$
M'9D]8KYS#DV['SH#T1*6$_F(MBUX%7FOZ?/^Z7DZ?Q&B?N:S^L+^4)9\5M^^
M2:3690S)"!;UZ5LD,"QE@:$@D8PD(I@)HV(T5UDQ-J;[2J8GJA,W KE)%"-P
M__7S9R_RXA=&Q_3*/S#FP6,!-+R- Z#QH)5>O>E4;#HWVHO SA&@/0DN(FX&
MY! ZXA<L&8.4N!E8AFKBAHTY:.+H*=[>;!ZH*'Y>5$QT$503*LLB03*'0F8<
M(I2JY1\6!<RR.&%)D6915A@KY!AV.CHZK.?<LS912X(W&JVU6BN?3Z=DL=S^
MU#"?R&H(^DDP%+"A.8_L9+[>@(UB;J?86MN]#2 - *N%"$\ > >2Y/$%LYU&
MCR5>O8H]IFT-I]]CZ=V>FH_M9[W>N6P6WMOST,V^,N-I1C")H: QA:B0!2SS
M",.(IWD<E0E*I-5II;T)8V/]G:#,.LA]NP_=VFZYSW<8EZON8CRA_;IW,J=P
M#W($X [B$-<T?6:,X;K& ";#:QN3EMQX\3<Q4TU/;V?\EC]5LTHWJE,+[O_0
M&?S=E8$DA<S5:PAF6(T.2KB$9:GK3"<HI0PEA8B,ZDQ;]3HV]FN-K@\VR9[9
M=I1G!KD9RWD',C"Q[6*X;S%H30YP06,%DE?B,NMY4*ZR N.0GNP^[!@-/)\M
MY].*U]N S^IO[&6;BQB7 JOEE]IVTTP1$5-_$$$C2"0K4,X0BXA=7'!/9V/C
M'[4<GK'JN3V'W+/<,DRX#V$SWO&%6V"ZV3/S!C2&@M_;_P=)O31!QF]<<5^'
MPT88&[A^%&ML\AG'VP^];:2'>D0[4E:_OFP?:96NZ@*5FROFV^5R_=25+'P6
M3&U-'\7B*9X@3"7/F!;)EKGBHCR")48"EB15>\:H*%-I=0,<SM2QD5AG'%"=
M/=4'AB^"+*PKLX8;6L/[E5$,6.@#R>LKO>X$X>PX? ,V7P/ML\?;FN##XO=*
M)YRYP][[!(?]Z'(H?(]N+YWWVXB75HET(N.,9X)BF"*A7A9$Y\5G90)C6I B
MSWB2EKE-#/=Q%U8D/T"L]J/N [!6[G8G",B.Y4]@:<;.UR$4F%5WC+L!K7G^
M&/"\ZUZ9ZT0W@S+.>3</F:+G2<> YX9-EH_S6_:_ZVHA?ETOJYE8+L7RM\5\
MJ7-7&46E3&&9IQE4<[Z$9<D$3!)*(I0G(LV-[H=-.QS;$J\^N'YNC+:,8KX$
MK=GT]PE88#+H3 6K.6B-!5MK;T!MK\=094-D_,8G7^ITV*!D0PB.(I%-/^<0
M>?*A4BX\B=7M;^WA;YZ+2&:LA$6:$$4A3$)<\DQM,EDI=(!)G!DIU9YL?6Q\
MT=D';G^SB&DXPJR?&ZY&(C 1[(!P^03<  V+4(YK4!DH9L/D*V(7CW'.Z=[
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MJ[_]Y4_=3]0?6B/O+W_Z/U!+ P04    "  70&A3PT;2(?V$   7Z 4 %0
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MK8GRPB6TEHZRW(ORGRV\$@YX^SC81IZ-0.(SS,;3=#!)'_#X':D$/E/M"?B
M#.2$QV>PD@2=D?R8@Z3] .+)LBO!0;0/A\UEV0@8SF9^,A\7P2\!;80$KR+Z
M 6C:D(>@B,V)$^#@. WH37'1S^GP;.65("';A\16$AT8%0>3Q7CQ]>/X$HYN
MK@+,1@$D5<$P(JQ21'KT#VV 1*2+0D6:J+=R*S0\7W$E%*AV4;"5!)O0_@F<
MCXL0)HLC?P4CE]$_IP(/N!P"D2%EXB)&6\&! X6<V2T=AM=670D%NG44;"')
M)I!PB&'\#$U8)_A3E#_L3V\FB]G7_6F"49 H#R4ER;K V6>.;C&B6TD54&Q!
M*$][ ,:[1*R$$],Z3OJ3<Q.P.?-_'"84WSB/;V\HEI90J.03CXI Y)G(R!0)
M,1IBN7+,,9\8#3T YHWE5X**;1TJ?<BV"9#LI80JF"__\VD\ 3;"F"DF%3S1
M+#ETE!@:2(I?H66D0F6KA.K#V7AEZ97 X5H'Q[8R;108? 3,V10"(PJ (A.6
M$>>3)X('RW6PUCE3!1A\M>LK^OTA8SVAMH2,??SR>'8V_7TRBD9JX-21Y/!4
ME)0;%$^()&&<#8S&[)SJ#Q</"Z^&BH9O-?L0:$N8Z)RFX]GGV?3+>!)AI$$S
M)ZTD27/TF1C^$3CSQ,DDC3=)>MY'T/+ZZJNAH^&[SMY$VQ)$/D_G"W_Y?\;7
MG5.=4P*'F";,,Q1-$HEX3C6A+L=H@\;3LL<3Y<G:J\&CX;O/GL0Z,#B*U=N;
M@>_HIBJ[0+,BR9>'':50*$X" 6^#!&ZR#7&[E[Q'JZT&@(9O.C<6W< J+R_F
MEY\OII.[NSF6P26N*?'" @J !1*H$A@Z@0'M,B1AMU+[\Q574WW#UYM;B7!@
M]9]"O)DA=!D/9^/%)11OAV6J(J$Y2R*UP=C(I4R )28QCC::;1=O/E]Q-?4W
M?*^YE0@'5O_9S)><I-.O5V%Z.4HH FTP$ 9T6X@,10)1><*HR<RBK\N%VTKW
M3Y9;3?$-7U1N+KQ&-OW!'_'"3\ZANXFGP2<#$-%*J9(+IH!8BY8K"AZ]I-YG
MM=T;YVNKKH:!AF\@MQ9E$^' _LVLB.OV;;9 &G5P,Q^)8*P6/A-/=2;244D"
MTQC6:,X25493Z.,UX_755X-&\_>//8BV"8@<3O#34!SC+_#!+_R2K5$$2FT"
M-'/,"O1T$[HZ.CIBLO:1,65!\!X@\OKJJ^5/-7\1V8-HFX!(>>"?[?L%G$]G
M7T= 0Z \46(S!$1X>=G-WA.1-%C\(=K!/JZ;GBRZ&B":OX/<7)!-X.#TRE]>
M_G0S'T]@/A]I+977(1"C5"B/+9:@M2LW[%I0I9A3MH]#Y,FBJ^&@^=O&S079
M! X.KF!VCD?>S[/I[XN+_>G5M9]\'0G.RQUZ(C129,-;3RPMM^O!>I:#"U%#
M#WAX=?'5<-'\->/V@FT"'Z<7<'EY1ST76@1/T5,.G!(IC"$! B71)\ZM=<C4
M=N''RS570T/#=XY;BK$)$"#A5R7!9QK_<7J!<IL?WRQ*74^)K$=<"DFSR>CS
M&"!2,D$0QY8(X&CP,K=BR[S;;].P&D@:OIWL6<QM@ 8E-_.7AY,$?_P;H.E3
M6NFD!=&Z%!Q(:4E) R.J_" Y%H3?[N+JU657@T;#-Y?;"W/H]ZK;4.GC>![]
MY7^"G]T5'0@?9#32(-$R$1E%)(Z5H@/G@N9!)NJV \1;*Z^&B88O-7L1:2-U
M' ],?,3OS$<N4$ G6I<R6(41-3#BRMN<RLY%)[4V6SYMO;'P:J!H^):S#X$V
MA8G;$J5;)M!E4HQ;2E0A7<:DB=6<$Z%M,-R;P.1V"5-O+KT:+AJ^XNQ'J ,C
M8P\Y2!T7E_Y\1(W4S$5.E/.<2"<Y\9Y1@F=AU#8!8WR[D^/)<JN5_#5\@[FY
M\'K3^C__^$)XG_ ;&Q?J'Q]].#@Z/?B 7YP>?SK\L'=V\.&GO4][1_L'IW\[
M.#@[?<K!BE7\W_[4?DK\UZ1^R_K_FSDY]_YZU"7$%1@<YX_CB9_$,9J#Z6W%
MWSW&<A8&**+#@PE$8C1*K+*!.,@N1(?!A_7O;*WLYZ&#PG+1V_T%EXOYW7<Z
MD>-9M.S5\#_7H6Y3"W*WQMY\#HOY/:^1:Z8B0PX]0R?:@R,N,TF,QN\[2S'&
M>J^N8W->G](Q3*>!:JBXLSP]"'W 0^<I]4N'^YX)%94V4C TPMD0M*>1>,,S
M49*JS 1UT;[70&-;Y#PC9U@ ;:/?5Z&RC; ;0,R^GU_L35+YS\%_W8R_^$MD
M9KZWV/>SV=?QY/SO_O(&1IZK2'5,Q(##2 V#>>*= !*]%HEJ:[-][X9]<P2M
M1%X+B-H*!M/:.FD :"<0 5D)ES _@L7=BS0@!TQH#/=DH$2RC$8[!-R.DEG+
M/%!P=0[P5\D9IGM*/2!M+_,&@/-Y!M=^G [^N(;)''!?'"\N,,QX+*R1#@ZX
MDYGP+$KU/_A2_6\)19G%D(.0[[X ;@ZC%8@;I@=+/5#UK8\&('8"*)=Q7$!G
M<^^8,-H9S] 9"$EX(I.C)&B*OD'4 83U(L7W$I&VL4VOD#-,WY::MFE;F3<
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M(TYXU(J#=DA_P@VDN22AI"&ZI%0**5CNZIRU;]/4S,5&S^#J20L-X.EU)BB
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M66"< 4V,Y%Q:!J!/44:W!:*8D]E1[ID/W\+6NHNV:[;6@<*3JZ9:(F_@JND
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M?_IP<')Z\.^_'I[]YX>#CX?[AV>;7"&\_6&]W!2L2&M/%P('_W4S7GR]AU!
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M9L%,1L*=-+&\TR+ 2Y&D2%H:Z5C6OL[-1DLN_^;Z? ,8&PBWC=3C241QC;]
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M'0@=!ZYD:CR-23A3BI16.)$C U%MP%G#02)3C4W,YDI-NOZ9QMP4O_72F)N
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MRW0 R35@E6^1^BB![Q\0R(TPR48+V9<Q<%P',$Y;"+C;,=SKE-=UZH<V7NK
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M!'G AQO]@65KS4&5]=.A^U>]: '/4NE;C3]_.YTLF7/I+L[3[#L;$>>B]#0
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M+S<=QVE^CTSE4PI4,Z#!,A L6K"4E*HIR26R(&12J;'B=@L>]KRJ/E#K2>\
M/,,;+9WF8S<K+5'G10@ENAY/+O';TQ]IMGSCW-_=@-(N'=GZ7D+?7FG_?-F#
M3ZL(D<D*#C)8 L(EC=C,J!XZ$NZ5D$[7L2S5P^4/T_G\_1/L?_. _6O/:.1+
M/7+IJ654L0_('?2 E +I'(:&SD9C:Z8/MEITN[[L)NAZ/-BN+\4&W((M2%W[
M[R.3 U&<6(BDM/?4.H)SIK0:(5Y31Y@7=4;2;;_F=KW8/<-U&QD>)EJ/?R&#
M4;+C<O*T3/=_FN*GDP4N[6+5 WK9+F?$E;.>Z0#,FXRN$O%@3$0]YHG:<D)
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M,O8)SB<7,FQWF\:PV8^X#@.:;Z??OZ=9*>!=QW@/M)$XY22WD&4L"0$3P&%
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MH5$TE2]GZ:H@5.1DE-<1*5#()!8H6*<B*,U\)LK%K#O5J_6"JSM+&_88KQ<
M= #5]M(8.J)]_AI"LAE#+.IQZ4:"L*4_J7'HO5F=E,Q*80C6*;#=_9['7C&R
M@SR[W_'8A+D-6*'WZ(\MTH?QS])P]&YKM3>_/[K_G,[>7CAD8]$O1V-T,5)
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MQ;LG%%<'$=01ZSQ58'E,I>UFR3=CB&^YLXSYK)CKUK6JZQN[8>R $_M56-_
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MNT50(6-)U-*L+WL5>O25M28<-(D6V984^.!4&9(N3996",;J*^3#A0T+NVJ
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M.S53V X]SR]NH*GV_<#@.5#U*).!X7;\*X7+$MB>YCP.:;8VJHHJXT3(D'C
M?=Z;!%;I!)%;$TLQKE2=#N,ZH>KQ-30$GC[%/>V5]^UY0Q^N:XTT8X)%+<$&
M&@ )0CITS$"3H<13C9JW%X?HPT:%R=7JLVH'9=LQO@4 ?4/^O7'S<I;\O72Y
M6XMDYB9?5T, ?M_\RKJH\>CO;A8_NE]EUOCU/23D1YB-EZ,!EG/&4%E24%P!
M]:7\/WL"9;0%9,YT5$ZZ6.G^3BV*FG+JM\3;?1"W(/SZ^?/U!^4?CY3\G__Q
M_P%02P$"% ,4    "  70&A3  53[E((  !L+0  &@              @ $
M    <V5S;BTP.3,P,C R,7@Q,'%E>#,Q,2YH=&U02P$"% ,4    "  70&A3
M0LSS24$(   A+0  &@              @ &*"   <V5S;BTP.3,P,C R,7@Q
M,'%E>#,Q,BYH=&U02P$"% ,4    "  70&A3GA9(B?@$  #A%P  &@
M        @ $#$0  <V5S;BTP.3,P,C R,7@Q,'%E>#,R,2YH=&U02P$"% ,4
M    "  70&A329,X?]D$  "]%P  &@              @ $S%@  <V5S;BTP
M.3,P,C R,7@Q,'%E>#,R,BYH=&U02P$"% ,4    "  70&A3;ZU48AE1 @!Z
MM18 $0              @ %$&P  <V5S;BTR,#(Q,#DS,"YH=&U02P$"% ,4
M    "  70&A3Y89'EU(4  !LS   $0              @ &,; ( <V5S;BTR
M,#(Q,#DS,"YX<V102P$"% ,4    "  70&A36-A+)L 6  "KT@  %0
M        @ $-@0( <V5S;BTR,#(Q,#DS,%]C86PN>&UL4$L! A0#%     @
M%T!H4WJ'N.9?3P  !DX# !4              ( ! )@" '-E<VXM,C R,3 Y
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( != :%.9'%$3D]L  (0U"0 5
M      "  9+G @!S97-N+3(P,C$P.3,P7VQA8BYX;6Q02P$"% ,4    "  7
M0&A3PT;2(?V$   7Z 4 %0              @ %8PP, <V5S;BTR,#(Q,#DS
?,%]P<F4N>&UL4$L%!@     *  H J@(  (A(!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
